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Autoimmune disease represents a group of more than 60 different chronic autoimmune 
diseases that affect approximately 6% of the population. Autoimmune diseases 
arise when ones immune system actively targets and destroys self tissue resulting in 
clinical disease with prime examples such as Lupus and Type 1 diabetes. The immune 
system is designed to protect us from foreign pathogens such as viruses and bacteria. 
However, during the process of generating immune cells for this purpose, as a negative 
consequence, self-reactive immune cells are also generated. This book aims to present 
the latest knowledge and insights regarding the different contributing factors and 
their interplay, discussions on several autoimmune diseases and their case studies, and 
therapeutic treatments, including stem cell, for autoimmune diseases.



















DISEASES – CONTRIBUTING  
FACTORS, SPECIFIC  
CASES OF AUTOIMMUNE  
DISEASES, AND STEM CELL  
AND OTHER THERAPIES 
 




DISEASES – CONTRIBUTING  
FACTORS, SPECIFIC  
CASES OF AUTOIMMUNE  
DISEASES, AND STEM CELL  
AND OTHER THERAPIES 
 
Edited by James Chan 
 
  
Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and 
Other Therapies
http://dx.doi.org/10.5772/2896
Edited by James Chan
Contributors
Daniel Getts, Stephen Miller, Marcus Müller, Katerina Chatzidionysiou, Bin Li, Dan Li, Miranda Piccioni, Andy Tsun, 
Ahmad Massoud, Amir Hossein Massoud, Jean Pierre Peron, Reginald Halaby, Samuel Huber, Nicola Gagliani, Eun 
Wha Choi, Alla Arefieva, Marco Wiltgen, Gernot Tilz, Jorge Kattah, Jennifer Manilay, Jesus Ciriza, Anna Pituch-
Noworolska, Katarzyna Zwonarz, Alexander Baranov, Jianxun Song, Rizwanul Haque, Fengyang Lei
© The Editor(s) and the Author(s) 2012
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2012 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other 
Therapies
Edited by James Chan
p. cm.
ISBN 978-953-51-0693-7
eBook (PDF) ISBN 978-953-51-7020-4
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,100+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Dr James Chan’s main research interests focus on toler-
ance induction, autoimmune diseases, gene therapy and 
stem cell therapy.  It is the aim of combining these areas 
of research that one day the fruits of this research can 
benefit patients at the clinic. He conducts his research 
using two autoimmune disease models, namely diabetes 
and experimental autoimmune encephalomyelitis (EAE), 
a model for the human disease multiple sclerosis. There are 2 main areas in 
his research namely 1) using gene therapy technique to genetically modify 
haematopoietic stem cells to induce immune tolerance for the treatment of 
autoimmune disease and 2) the use of stem cells from various tissues such 
as placental stem cells and bone marrow mesenchymal stem cells for the 
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Autoimmune disease represents a group of more than 60 different chronic autoimmune 
diseases that affect approximately 6% of the population. It is the third major category of 
illness in the United States and many industrialized countries, following heart disease 
and cancer. Autoimmune diseases arise when one’s immune system actively targets and 
destroys self tissue resulting in clinical disease. Common examples include Systemic 
Lupus Erythematosus, Type 1 Diabetes, Rheumatoid Arthritis and Multiple Sclerosis. 
While different in clinical features and may involve different organs, the underlying 
mechanism is the failure of immune tolerance of the adaptive immune system. 
The immune system is designed to protect us from foreign pathogens such as viruses 
and bacteria, and in particular the adaptive immune system mounts antigen specific 
attack on targets. The underlying mechanism that enables recognition and responses to 
unknown targets is the generation of antigen receptors on lymphocytes through the 
process of random gene recombination. A negative consequence of this process is the 
generation of self-reactive receptors capable of responding to self-antigens and causing 
pathology. Although a number of mechanisms such as clonal deletion and other immune 
regulations are in place to eliminate or counter the action of these self-reactive clones, a 
number of known factors can interfere and breakdown these regulatory mechanisms. 
This book entitled “Autoimmune Diseases - Contributing Factors, Specific Cases of 
Autoimmune Diseases, and Stem Cell and Other Therapies” aims to present the latest 
knowledge and insights regarding the different contributing factors and their 
interplay, discussions on several autoimmune diseases and their case studies, and 
therapeutic treatments, including stem cell, for autoimmune diseases. The quest in this 
field of research is to better understand the underlying factors and pathways leading 
to autoimmune diseases and derive proper treatment for each disease.  
I believe this book will provide an invaluable resource for researchers and students in 
the field of autoimmunity/immune tolerance, and also for a general readership to 
better understanding autoimmune diseases.   
 
James Chan Ph.D. 
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1. Introduction 
Multiple Sclerosis (MS) is a chronic, progressive, immune mediated central nervous system 
(CNS) disorder that affects both adults and children.  MS is characterized by the formation 
of multiple lesions along the nerve fibers in the brain, spinal cord and optic nerves (Bradl 
and Lassmann, 2009; Bruck, 2005; Bruck and Stadelmann, 2005; Chitnis et al., 2009; Hafler, 
2004; Holland, 2009; Mah and Thannhauser, 2010; Pohl et al., 2007).  The precise triggers of 
autoreactive T cell development remain to be fully understood, however, it is clear that 
myelin antigens are the major target (Grau-Lopez et al., 2009).  T cell activation results in 
cytokine release and recruitment of other immune cells that results in tissue damage not 
only to the myelin sheath but, over time and with repeated attacks, to the underlying axons 
as well.  Demyelination and axonal damage impairs or interrupts nerve transmission, giving 
rise to clinical signs and symptoms. 
Clinically, neurological symptoms in patients with MS vary from mild to severe and 
typically include one or more of the following:  sensory symptoms (numbness, tingling, 
other abnormal sensations, visual disturbances, dizziness), motor symptoms (weakness, 
difficulty walking, tremor, bowel/bladder problems, poor coordination, and stiffness), and 
other symptoms such as heat sensitivity, fatigue, emotional changes, cognitive changes and 
sexual symptoms (Bronner et al., 2010).  While some persons have a limited number of 
“attacks” or “relapses” and remain fairly healthy for decades, others may deteriorate rapidly 
from the time of diagnosis, with poor quality of life and shortened lifespan.  There is no way 
of knowing at the clinical onset what course the disease will take (Andersen, 2010; Bradl and 
Lassmann, 2009; Bruck, 2005). 
In this chapter how the autoimmune process is triggered as well as current clinical options 
to try and reduce disease symptoms are addressed.  While the induction of long-term 
durable antigen-specific T cell tolerance is the desired treatment option, such a therapy 
 The Author(s). Licens e InTech. This chapter is distributed under the terms of the Creative C mmons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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remains to be clinically developed. Instead, once a diagnosis of MS is made, immune based 
treatment is generally begun, with numerous therapies aimed primarily at inactivating T 
cells and other immune functions. 
2. Multiple Sclerosis triggers and animal models 
The ability for the immune system to differentiate between self and non-self is critical for 
host preservation. Deficits in self-non-self discrimination can result in opportunistic 
infections or immunological over-reactivity resulting in immunopathology and 
autoimmunity. It is therefore, not surprising that multiple genetic factors that influence the 
sensitivity of the immune system are known to trigger autoimmune mediated diseases. 
However it is hypothesized that clinical symptom development may only manifest after 
exposure to certain environmental factors, including viral infection. The interplay of 
genetics and the environment in regards to the development of MS, and other autoimmune 
diseases, has not been completely elucidated. No matter what the potential switch that 
causes MS initiation the activation, proliferation and effector functions of auto-reactive CD4+ 
T cells appears to be critical for disease development and progression (Goverman, 2009; 
Miller and Eagar, 2001; Miller et al., 2001).  
i. Predisposing genetic factors 
The significantly higher concordance rates of MS in monozygotic twins compared to 
dizygotic twins (Hansen et al., 2005; Islam et al., 2006; Willer et al., 2003), the 2-fold increased 
risk of disease development in siblings of affected individuals (Ebers et al., 2004) as well as 
the observed increased susceptibility in offspring from two affected parents, compared to 
those with only one affected parent (Ebers et al., 2000; Robertson et al., 1997) all point to a 
strong genetic component in the pathogenesis of MS. However, like many other complex 
autoimmune diseases, MS is not transferred from parent to offspring via classic Mendelian 
genetics and the disease trait involves a large number of genes (Hoffjan and Akkad, 2010). 
Until recently, most gene variations associated with increased or decreased susceptibility 
were thought to be within the human leukocyte antigen (HLA) loci (Ramagopalan et al., 
2009). However, recent studies have also identified risk-conferring alleles within several 
non-HLA genes (Nischwitz et al., 2011). Importantly, most of these genes are known to play 
important roles in T cell activation and function, which further supports the concept that a 
dysfunctional immune process is involved in the initiation and progression of MS 
(Nischwitz et al., 2011). 
ii. HLA genes 
Allelic variations within the major histocompatibility complex (MHC) exert the greatest 
individual effect on the risk of MS (Ramagopalan et al., 2009). Initial studies published in 
1972 identified the HLA Class I antigens HLA-A*03 and HLA-B*07 as risk-conferring alleles 
(Jersild et al., 1972; Naito et al., 1972). Between 1973 and 1976, several studies reported a 
significant link between the HLA Class II gene HLA-DR2 and MS (Jersild et al., 1973; 
Terasaki et al., 1976; Winchester et al., 1975). This has been further subtyped into a strong 
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and consistent association between the HLA-DRB5*0101, HLA-DRB1*1501, HLA-DQA1*0102 
and HLA-DQB1*0602 extended haplotype and disease (Fogdell et al., 1995). As these genes 
are tightly linked, early genetic studies failed to identify which of these alleles confers the 
greatest risk for MS (Hoppenbrouwers and Hintzen, 2011). However, statistically-powered 
studies conducted in the past decade, including several international genome-wide 
association studies (GWAS), have identified HLA-DRB1*1501 as the major risk conferring 
gene for the development of MS (2007; 2009; Hafler et al., 2007; Lincoln et al., 2005; 
Oksenberg et al., 2004; Sawcer et al., 2011).  
Other HLA-DR2 alleles that confer susceptibility in some populations include HLA-DRB1*17 
and HLA-DRB1*08, however the effects of these alleles are modest compared to HLA-
DRB1*1501 (Dyment et al., 2005; Modin et al., 2004). Some variants are also reported to 
confer protection from the development of MS, including HLA-DRB1*14, HLA-DRB1*01, 
HLA-DRB1*10 and HLA-DRB1*11 (Brynedal et al., 2007; Dyment et al., 2005; Ramagopalan et 
al., 2007). 
iii. Non-HLA genes 
Early gene linkage studies failed to validate associations between non-HLA genes and the 
development of MS, potentially due to the small individual contribution of each gene to 
disease (Nischwitz et al., 2011). However, in recent years, several GWAS have identified 
polymorphisms within a number of non-HLA genes that play an important role in the 
development of MS (Pravica et al., 2012). These include genes that are involved in cytokine 
pathways, such as those encoding the IL-2, IL-7, IL-12 and TNF receptors, which are 
important for T cell development, homeostasis, proliferation and differentiation (2009; 
Baranzini et al., 2009; Sawcer et al., 2011).  
Also, variations within genes coding for co-stimulatory molecules, such as CD40, CD58, 
CD80 and CD86, which promote the activation of T cells, were also implicated in 
susceptibility to MS (2009; Baranzini et al., 2009; Sawcer et al., 2011). Polymorphisms within 
genes encoding for molecules such as STAT3 and TYK2, which are involved in several 
signal transduction pathways including those that mediate T cell activation and Th17 
differentiation, were also linked with the development of MS (2009; Baranzini et al., 2009; 
Sawcer et al., 2011). 
Variations within other genes that can affect T cell functioning, including CD6, CLEC16A, 
and the vitamin D alpha hydroxylase gene CYP27B1 are also implicated in the pathogenesis 
of MS (2009; Baranzini et al., 2009; Sawcer et al., 2011).  Although the individual contribution 
of each gene to the development of MS is modest, the identification of such genes is critical, 
as they will provide novel targets or approaches for therapeutic intervention in MS 
(Nischwitz et al., 2011).  
There is clearly further research to be performed to better understand the role of genetics 
and MS development. However the data clearly show that genes associated with T cell 
activation and other immune functions certainly highlight the importance of targeting 
immune factors when treating disease.  
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3. Environmental factors 
Although it is clear that genetics play a key role in determining susceptibility to MS, 
concordance rates between monozygotic twins (i.e. with identical genomes) varies between 6 
and 30 percent (Dyment et al., 2004). This suggests that other non-inheritable factors play an 
important role in the initiation of the auto-reactive immune response. A number of 
infectious and non-infectious stimuli have been identified as key factors that increase the 
risk of MS development.  
i. Infectious factors 
For many years, underlying infections have been implicated in the induction of the 
autoreactive CD4+ T cell response that leads to MS (Kakalacheva and Lunemann, 2011). 
Roles for several pathogens, including Epstein Barr Virus (EBV), Human Herpes Virus-6 
(HHV-6) and Varicella Zoster Virus (VZV) have been investigated. There is considerable 
evidence that links EBV with the initiation and progression of MS (Ascherio and Munger, 
2007a, b; Dyment et al., 2004). EBV infects over 90% of the world population and causes 
infectious mononucleosis (IM) in a large proportion of individuals, which is characterized 
by glandular fever and the massive expansion of virus-specific T cells (Vetsika and Callan, 
2004). Pooled data from 18 clinical studies revealed a significant link between IM and an 
elevated risk of MS (Kakalacheva et al., 2011).  
Furthermore, in individuals that concurrently tested positive for IM and the HLA allele 
HLA-DRB1*1501, the risk of developing MS was increased by 7-fold (Kakalacheva and 
Lunemann, 2011). Also, an increased proportion of MS patients are seropositive for EBV, 
however, it is important to note that not all patients are seropositive which suggests that 
EBV infection is not critical for the development of disease (Kakalacheva and Lunemann, 
2011; Kakalacheva et al., 2011). Nevertheless, taken together these studies support the 
concept that EBV infection may at least increase the risk of MS development in genetically 
susceptible individuals. The mechanisms by which EBV infection trigger the autoreactive 
immune response are unclear, but some data suggest that CD4+ T cells in MS patients are 
specific for an increased range of EBV nuclear antigens, which frequently recognize myelin 
peptides (Lang et al., 2002; Olson et al., 2001). Further investigations into the role of infection 
in the development of disease are needed to show definitively the role of virus infection in 
the pathogenesis of MS.  
ii. Non-infectious factors 
Smoking and Vitamin D have been identified as the two primary non-infectious 
environmental factors that can contribute to MS susceptibility. Although the elevated risk of 
MS development in individuals who smoke was originally identified in a study in the 1960’s 
(reviewed in (Wingerchuk, 2012)), it has become more prominent in recent years. Smoking is 
argued to increase the chance of MS development by a factor of 1.5 (Wingerchuk, 2012). In 
addition, patients that smoke increase the potential for rapid MS development. In a recent 
Belgium study, patients that smoked were more likely to develop a score of 6 on the 
Extended Disability Status Scale. This represents an increased potential to develop 
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intermittent or unilateral constant assistance (cane, crutch or brace) required to walk 100 
meters without resting (D'Hooghe M et al., 2012). The amount or timing of cigarette 
exposure to enhance MS risk remains to be defined, with linkage between smoking and MS 
remaining a predominately epidemiological observation. Further research is required to 
better define the role and process of smoking exposure in MS development and progression.  
Vitamin D is a potent immunomodulatory molecule that has been shown to affect numbers 
and activity of regulatory T cells. Several epidemiological studies have identified a 
significant link between the incidence of MS and distance from the equator (Kurtzke et al., 
1979; Miller et al., 1990; Vukusic et al., 2007). Although MS occurred more frequently at high 
latitudes, this effect was negated in populations that consumed a vitamin D-rich diet 
(Agranoff and Goldberg, 1974; Swank et al., 1952; Westlund, 1970). These findings are 
supported by a large study in which high serum levels of the vitamin D metabolite 25(OH)D 
were shown to correspond with a significantly decreased risk of MS (Munger et al., 2006). In 
a separate study, low serum levels of 25(OH)D were associated with relapse and the degree 
of disability in MS patients (Smolders et al., 2008a). 
A possible explanation for these findings is the indirect immunomodulatory functions of 
vitamin D on T cells (Bartels et al., 2010; Smolders et al., 2008b). Also, T cells express vitamin 
D receptors (VDR), suggesting a direct vitamin D- T cell interaction resulting in T cell 
regulation (Cantorna, 2011). Indeed, a recent study using the EAE mouse model 
demonstrated that vitamin D could inhibit auto-reactive T cells, which express high levels of 
VDR, but did not affect numbers of regulatory T cells, which express low levels of VDR 
(Mayne et al., 2011). An earlier study also showed that survival of EAE-induced mice could 
be prolonged with vitamin D injection (Hayes, 2000). 
4. Epitope spreading and disease progression 
Multiple sclerosis is initiated by the activation of auto-reactive CD4+ T cells specific for a 
single or few myelin epitopes in the CNS (Vanderlugt and Miller, 2002). Inflammation 
caused by this initial response recruits and activates other CD4+ T cell clones specific for a 
range of other self-epitopes, a process which is referred to as “epitope spreading” (Lehmann 
et al., 1992). This process occurs, within experimental settings, in a hierarchical fashion, 
likely the result of differential antigen liberation, processing and presentation by various 
antigen-presenting cell (APC) populations. In addition the availability of self-reactive CD4+ 
T cell clones throughout the course of disease is also important. Epitope spreading was 
originally described and characterized in the Experimental Autoimmune Encephalomyelitis 
(EAE) model of MS, but also occurs in Theiler’s murine encephalomyelitis virus induced 
demeylinating disease (TMEV-IDD) (Lehmann et al., 1992; Miller et al., 2001; Miller et al., 
1997b; Vanderlugt et al., 2000). Evidence has also accumulated supporting the existence of 
epitope spreading within the human context.  
1. Epitope spreading in EAE 
Experimental autoimmune encephalomyelitis is induced in susceptible murine strains by 
immunization with myelin peptides in conjunction with adjuvant (Miller et al., 2010). This 
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3. Environmental factors 
Although it is clear that genetics play a key role in determining susceptibility to MS, 
concordance rates between monozygotic twins (i.e. with identical genomes) varies between 6 
and 30 percent (Dyment et al., 2004). This suggests that other non-inheritable factors play an 
important role in the initiation of the auto-reactive immune response. A number of 
infectious and non-infectious stimuli have been identified as key factors that increase the 
risk of MS development.  
i. Infectious factors 
For many years, underlying infections have been implicated in the induction of the 
autoreactive CD4+ T cell response that leads to MS (Kakalacheva and Lunemann, 2011). 
Roles for several pathogens, including Epstein Barr Virus (EBV), Human Herpes Virus-6 
(HHV-6) and Varicella Zoster Virus (VZV) have been investigated. There is considerable 
evidence that links EBV with the initiation and progression of MS (Ascherio and Munger, 
2007a, b; Dyment et al., 2004). EBV infects over 90% of the world population and causes 
infectious mononucleosis (IM) in a large proportion of individuals, which is characterized 
by glandular fever and the massive expansion of virus-specific T cells (Vetsika and Callan, 
2004). Pooled data from 18 clinical studies revealed a significant link between IM and an 
elevated risk of MS (Kakalacheva et al., 2011).  
Furthermore, in individuals that concurrently tested positive for IM and the HLA allele 
HLA-DRB1*1501, the risk of developing MS was increased by 7-fold (Kakalacheva and 
Lunemann, 2011). Also, an increased proportion of MS patients are seropositive for EBV, 
however, it is important to note that not all patients are seropositive which suggests that 
EBV infection is not critical for the development of disease (Kakalacheva and Lunemann, 
2011; Kakalacheva et al., 2011). Nevertheless, taken together these studies support the 
concept that EBV infection may at least increase the risk of MS development in genetically 
susceptible individuals. The mechanisms by which EBV infection trigger the autoreactive 
immune response are unclear, but some data suggest that CD4+ T cells in MS patients are 
specific for an increased range of EBV nuclear antigens, which frequently recognize myelin 
peptides (Lang et al., 2002; Olson et al., 2001). Further investigations into the role of infection 
in the development of disease are needed to show definitively the role of virus infection in 
the pathogenesis of MS.  
ii. Non-infectious factors 
Smoking and Vitamin D have been identified as the two primary non-infectious 
environmental factors that can contribute to MS susceptibility. Although the elevated risk of 
MS development in individuals who smoke was originally identified in a study in the 1960’s 
(reviewed in (Wingerchuk, 2012)), it has become more prominent in recent years. Smoking is 
argued to increase the chance of MS development by a factor of 1.5 (Wingerchuk, 2012). In 
addition, patients that smoke increase the potential for rapid MS development. In a recent 
Belgium study, patients that smoked were more likely to develop a score of 6 on the 
Extended Disability Status Scale. This represents an increased potential to develop 
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intermittent or unilateral constant assistance (cane, crutch or brace) required to walk 100 
meters without resting (D'Hooghe M et al., 2012). The amount or timing of cigarette 
exposure to enhance MS risk remains to be defined, with linkage between smoking and MS 
remaining a predominately epidemiological observation. Further research is required to 
better define the role and process of smoking exposure in MS development and progression.  
Vitamin D is a potent immunomodulatory molecule that has been shown to affect numbers 
and activity of regulatory T cells. Several epidemiological studies have identified a 
significant link between the incidence of MS and distance from the equator (Kurtzke et al., 
1979; Miller et al., 1990; Vukusic et al., 2007). Although MS occurred more frequently at high 
latitudes, this effect was negated in populations that consumed a vitamin D-rich diet 
(Agranoff and Goldberg, 1974; Swank et al., 1952; Westlund, 1970). These findings are 
supported by a large study in which high serum levels of the vitamin D metabolite 25(OH)D 
were shown to correspond with a significantly decreased risk of MS (Munger et al., 2006). In 
a separate study, low serum levels of 25(OH)D were associated with relapse and the degree 
of disability in MS patients (Smolders et al., 2008a). 
A possible explanation for these findings is the indirect immunomodulatory functions of 
vitamin D on T cells (Bartels et al., 2010; Smolders et al., 2008b). Also, T cells express vitamin 
D receptors (VDR), suggesting a direct vitamin D- T cell interaction resulting in T cell 
regulation (Cantorna, 2011). Indeed, a recent study using the EAE mouse model 
demonstrated that vitamin D could inhibit auto-reactive T cells, which express high levels of 
VDR, but did not affect numbers of regulatory T cells, which express low levels of VDR 
(Mayne et al., 2011). An earlier study also showed that survival of EAE-induced mice could 
be prolonged with vitamin D injection (Hayes, 2000). 
4. Epitope spreading and disease progression 
Multiple sclerosis is initiated by the activation of auto-reactive CD4+ T cells specific for a 
single or few myelin epitopes in the CNS (Vanderlugt and Miller, 2002). Inflammation 
caused by this initial response recruits and activates other CD4+ T cell clones specific for a 
range of other self-epitopes, a process which is referred to as “epitope spreading” (Lehmann 
et al., 1992). This process occurs, within experimental settings, in a hierarchical fashion, 
likely the result of differential antigen liberation, processing and presentation by various 
antigen-presenting cell (APC) populations. In addition the availability of self-reactive CD4+ 
T cell clones throughout the course of disease is also important. Epitope spreading was 
originally described and characterized in the Experimental Autoimmune Encephalomyelitis 
(EAE) model of MS, but also occurs in Theiler’s murine encephalomyelitis virus induced 
demeylinating disease (TMEV-IDD) (Lehmann et al., 1992; Miller et al., 2001; Miller et al., 
1997b; Vanderlugt et al., 2000). Evidence has also accumulated supporting the existence of 
epitope spreading within the human context.  
1. Epitope spreading in EAE 
Experimental autoimmune encephalomyelitis is induced in susceptible murine strains by 
immunization with myelin peptides in conjunction with adjuvant (Miller et al., 2010). This 
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disease initiation method, with a single and defined myelin peptide allows for the 
observation and measurement of changing T cell specificities over time (Vanderlugt and 
Miller, 2002). Using this model epitope spreading has been described as a hierarchical event, 
with a defined path through which T cells specific for certain epitopes emerge. Epitope 
spreading is a critical phenomenon in the SJL model of EAE, as it is responsible for the 
relapsing remitting pattern of disease (Vanderlugt and Miller, 2002).  
The first study to demonstrate epitope spreading was reported in 1992 by Lehmann and 
colleagues (Lehmann et al., 1992), in which susceptible (SJLxB10.PL)F1 mice were immunized 
with guinea-pig MBP. T cell responses in the draining lymph node and spleen were 
measured 9 days after immunization. At this time point, T cells only responded to MBPAc1-11, 
and not MBP35-47, MBP81-100 or MBP121-140. In comparison, T cells isolated from the spleen 40 
days after immunization responded to all of these peptides. These findings demonstrate that 
epitopes that are initially hidden or sequestered during the initial phase of disease can 
become liberated as disease progresses (Lehmann et al., 1992).  
Studies in our laboratory have also characterized epitope spreading in EAE induced by 
immunization of SJL mice with the immunodominant PLP epitope PLP139-151(Vanderlugt et 
al., 2000). In this model, T cell responses are initially specific for PLP139-151. However, the first 
relapse, which occurs within 30-40 days after immunization, coincides with T cell responses 
against PLP178-191. During the second relapse, which occurs between 50-70 days after 
immunization, T cells are also shown to respond to MBP84-104. Understanding of the epitope 
spreading hierarchy has allowed for epitope specific therapeutic targeting in EAE. The 
induction of tolerance against relapse-associated peptides blocks the progression of disease, 
even though PLP139-151 responses remain intact (Vanderlugt et al., 2000). These observations 
highlight the role of changing T cell specificities in mediating chronic disease as well as the 
need for therapeutic strategies that address these specific T cells populations (Vanderlugt 
and Miller, 2002).  
2. Epitope spreading in TMEV-IDD 
Theiler’s murine encephalomyelitis virus- induced demyelinating disease is induced by 
intracranial inoculation of SJL/J mice with TMEV, resulting in low-level chronic CNS 
infection that progresses into myelin-specific autoimmune disease (Getts et al., 2010). The 
initial CD4+ T cell-mediated immune response against chronic TMEV infection of the CNS 
causes significant damage to myelin, which in turn results in the activation of myelin-
specific T cell clones (Karpus et al., 1995; Miller et al., 1997a). Similar to EAE, this occurs in a 
hierarchical order, beginning with the immunodominant PLP139-151 epitope (Miller et al., 
1997b). Subsequent T cell reactivity against other peptides, including PLP178-191, PLP56-70 and 
MOG92-106 has been demonstrated as disease progresses (Miller et al., 2001).  
These findings correspond with antigen presentation by CNS APC. These cells present viral 
peptides but not myelin peptides up to day 40 post-immunization, at which time point there 
are still no clinical signs of disease and no evidence of myelin destruction (Katz-Levy et al., 
1999; Katz-Levy et al., 2000). However, by day 90 post-infection, microglia and macrophages 
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isolated from the CNS present both viral and myelin antigens to T cells in vitro (Katz-Levy et 
al., 1999; Katz-Levy et al., 2000).  
In further support of epitope spreading after TMEV inoculation, tolerance induction to 
multiple myelin epitopes using MP-4 during ongoing TMEV-IDD in SJL mice was shown to 
significantly attenuate disease progression, reduce demyelination and decrease CNS 
leukocyte infiltration (Neville et al., 2002).  
3. Epitope spreading in MS 
Evidence of epitope spreading in human MS patients is growing, with a number of small 
studies at least supporting a potential for epitope spreading in human disease. A study by 
Tuohy and colleagues conducted over several years followed peripheral T cell responses to 
myelin epitopes in three patients with isolated monosymptomatic demyelinating syndrome 
(IMDS) (Tuohy et al., 1997; Tuohy et al., 1999a; Tuohy et al., 1999b). T cell autoreactivity to 
several myelin epitopes was initially shown to be strong, waning with time. However, when 
two of these three patients progressed to clinically-defined MS, peripheral T cells isolated 
from these patients showed expanded reactivity to different myelin peptides than originally 
observed during the patients IMDS stage (Tuohy et al., 1997; Tuohy et al., 1999a; Tuohy et al., 
1999b). A separate study by Goebels and colleagues investigated MBP-specific responses of 
five MS patients over 6-7 years (Goebels et al., 2000). Two of these patients showed a focused 
T cell response that broadened over the course of 6 years, thus providing evidence of 
epitope spreading in human disease. The pattern was non-consistent, however, with two 
patients showing a broad epitope response that fluctuated over time, with the other patient 
exhibiting a very focused response to a cluster of MBP epitopes. Together the data suggest 
that unlike the EAE model, patient T cell epitopes exhibit strong heterogeneity with the 
precise epitope spreading hierarchy likely to be variable between patients. Not 
withstanding, the liberation of antigens and activation of novel T cell clones over time in MS 
patients supports the role of epitope spreading in human MS patients (Goebels et al., 2000). 
5. Current clinical strategies in Multiple Sclerosis to modify the course of 
disease 
The pathologic role of T cells in driving MS has resulted in numerous therapies aimed at 
inactivating T cells and/or the induction of T cell tolerance. Tolerance induction in 
autoimmune disease refers to a reinstatement of sustained, specific non-responsiveness of 
the native immune system to self-antigen. Manipulation of T cell activation and 
differentiation pathways has been at the center of current tolerance induction theory, and 
the basis of tolerance induction utilizing current immunosuppressive agents. Over recent 
years, experimental models have shown that it is possible to exploit the mechanisms that 
normally maintain immune homeostasis and tolerance to self-antigens, as well as to 
reintroduce tolerance to self-antigen in an autoimmune setting (Getts et al., 2011; Kohm et al., 
2005; Podojil et al., 2008; Turley and Miller, 2007).   However, in the clinical setting the 
utilization of co-stimulatory blockade, soluble peptide, altered peptide ligands among 
others have yielded disappointing results. As such while the induction of tolerance remains 
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disease initiation method, with a single and defined myelin peptide allows for the 
observation and measurement of changing T cell specificities over time (Vanderlugt and 
Miller, 2002). Using this model epitope spreading has been described as a hierarchical event, 
with a defined path through which T cells specific for certain epitopes emerge. Epitope 
spreading is a critical phenomenon in the SJL model of EAE, as it is responsible for the 
relapsing remitting pattern of disease (Vanderlugt and Miller, 2002).  
The first study to demonstrate epitope spreading was reported in 1992 by Lehmann and 
colleagues (Lehmann et al., 1992), in which susceptible (SJLxB10.PL)F1 mice were immunized 
with guinea-pig MBP. T cell responses in the draining lymph node and spleen were 
measured 9 days after immunization. At this time point, T cells only responded to MBPAc1-11, 
and not MBP35-47, MBP81-100 or MBP121-140. In comparison, T cells isolated from the spleen 40 
days after immunization responded to all of these peptides. These findings demonstrate that 
epitopes that are initially hidden or sequestered during the initial phase of disease can 
become liberated as disease progresses (Lehmann et al., 1992).  
Studies in our laboratory have also characterized epitope spreading in EAE induced by 
immunization of SJL mice with the immunodominant PLP epitope PLP139-151(Vanderlugt et 
al., 2000). In this model, T cell responses are initially specific for PLP139-151. However, the first 
relapse, which occurs within 30-40 days after immunization, coincides with T cell responses 
against PLP178-191. During the second relapse, which occurs between 50-70 days after 
immunization, T cells are also shown to respond to MBP84-104. Understanding of the epitope 
spreading hierarchy has allowed for epitope specific therapeutic targeting in EAE. The 
induction of tolerance against relapse-associated peptides blocks the progression of disease, 
even though PLP139-151 responses remain intact (Vanderlugt et al., 2000). These observations 
highlight the role of changing T cell specificities in mediating chronic disease as well as the 
need for therapeutic strategies that address these specific T cells populations (Vanderlugt 
and Miller, 2002).  
2. Epitope spreading in TMEV-IDD 
Theiler’s murine encephalomyelitis virus- induced demyelinating disease is induced by 
intracranial inoculation of SJL/J mice with TMEV, resulting in low-level chronic CNS 
infection that progresses into myelin-specific autoimmune disease (Getts et al., 2010). The 
initial CD4+ T cell-mediated immune response against chronic TMEV infection of the CNS 
causes significant damage to myelin, which in turn results in the activation of myelin-
specific T cell clones (Karpus et al., 1995; Miller et al., 1997a). Similar to EAE, this occurs in a 
hierarchical order, beginning with the immunodominant PLP139-151 epitope (Miller et al., 
1997b). Subsequent T cell reactivity against other peptides, including PLP178-191, PLP56-70 and 
MOG92-106 has been demonstrated as disease progresses (Miller et al., 2001).  
These findings correspond with antigen presentation by CNS APC. These cells present viral 
peptides but not myelin peptides up to day 40 post-immunization, at which time point there 
are still no clinical signs of disease and no evidence of myelin destruction (Katz-Levy et al., 
1999; Katz-Levy et al., 2000). However, by day 90 post-infection, microglia and macrophages 
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isolated from the CNS present both viral and myelin antigens to T cells in vitro (Katz-Levy et 
al., 1999; Katz-Levy et al., 2000).  
In further support of epitope spreading after TMEV inoculation, tolerance induction to 
multiple myelin epitopes using MP-4 during ongoing TMEV-IDD in SJL mice was shown to 
significantly attenuate disease progression, reduce demyelination and decrease CNS 
leukocyte infiltration (Neville et al., 2002).  
3. Epitope spreading in MS 
Evidence of epitope spreading in human MS patients is growing, with a number of small 
studies at least supporting a potential for epitope spreading in human disease. A study by 
Tuohy and colleagues conducted over several years followed peripheral T cell responses to 
myelin epitopes in three patients with isolated monosymptomatic demyelinating syndrome 
(IMDS) (Tuohy et al., 1997; Tuohy et al., 1999a; Tuohy et al., 1999b). T cell autoreactivity to 
several myelin epitopes was initially shown to be strong, waning with time. However, when 
two of these three patients progressed to clinically-defined MS, peripheral T cells isolated 
from these patients showed expanded reactivity to different myelin peptides than originally 
observed during the patients IMDS stage (Tuohy et al., 1997; Tuohy et al., 1999a; Tuohy et al., 
1999b). A separate study by Goebels and colleagues investigated MBP-specific responses of 
five MS patients over 6-7 years (Goebels et al., 2000). Two of these patients showed a focused 
T cell response that broadened over the course of 6 years, thus providing evidence of 
epitope spreading in human disease. The pattern was non-consistent, however, with two 
patients showing a broad epitope response that fluctuated over time, with the other patient 
exhibiting a very focused response to a cluster of MBP epitopes. Together the data suggest 
that unlike the EAE model, patient T cell epitopes exhibit strong heterogeneity with the 
precise epitope spreading hierarchy likely to be variable between patients. Not 
withstanding, the liberation of antigens and activation of novel T cell clones over time in MS 
patients supports the role of epitope spreading in human MS patients (Goebels et al., 2000). 
5. Current clinical strategies in Multiple Sclerosis to modify the course of 
disease 
The pathologic role of T cells in driving MS has resulted in numerous therapies aimed at 
inactivating T cells and/or the induction of T cell tolerance. Tolerance induction in 
autoimmune disease refers to a reinstatement of sustained, specific non-responsiveness of 
the native immune system to self-antigen. Manipulation of T cell activation and 
differentiation pathways has been at the center of current tolerance induction theory, and 
the basis of tolerance induction utilizing current immunosuppressive agents. Over recent 
years, experimental models have shown that it is possible to exploit the mechanisms that 
normally maintain immune homeostasis and tolerance to self-antigens, as well as to 
reintroduce tolerance to self-antigen in an autoimmune setting (Getts et al., 2011; Kohm et al., 
2005; Podojil et al., 2008; Turley and Miller, 2007).   However, in the clinical setting the 
utilization of co-stimulatory blockade, soluble peptide, altered peptide ligands among 
others have yielded disappointing results. As such while the induction of tolerance remains 
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the optimal future treatment for MS current therapies are focused on agents that are disease 
modifying.  
Over the last three decades a number of broad acting immune modifying therapeutic 
options have been developed and introduced to treat MS patients. None of these therapeutic 
options is a cure, currently available therapies aim instead to prevent or at least reduce the 
frequency of relapsing inflammatory events, with the idea of reducing impact of disease on 
overall quality of life over time (Miller and Rhoades, 2012; Rio et al., 2011). In addition to the 
clear efficacy requirement long-term safety is also paramount for any MS therapy, with 
typical MS patients requiring treatment for many decades. The available MS therapies may 
be divided based on function into “immune modulatory” or “disease modifying” drugs 
(DMFs) as well as classic immune suppressive substances. In addition, a third group has 
recently emerged, which includes monoclonal antibodies (biologics). These drugs act by 
direct interference with specific immune system functions or by broad immune subset 
depletion. DMFs are typically used early in the course of the disease, whereas immune 
suppressive drugs and biologics are mostly viewed as treatment options in those patients 
with abnormally high disease activity, a high risk of sustained disability and/or show poor 
response to the front line therapeutics (Table 1). 
The most widely used disease modifying drugs are Interferon- (IFN) and glatiramer 
acetate (GLAT) (Johnson, 2012). Both drugs were approved after large phase III studies, 
which were conducted in the 1990s. These studies proved the efficacy of these drugs in 
relapsing remitting MS. IFN- and GLAT reduce the relapse rate in relapsing remitting MS 
patients by up to 50% (Boster et al., 2011; Johnson, 2012; Limmroth et al., 2011). Furthermore, 
both agents significantly slowed the progression of disease and have an excellent safety 
profile allowing for long-term utilization. However, there remain a number of 
administration and efficacy issues with these drugs. Administration is required weekly at a 
minimum via subcutaneous or intramuscular injection, resulting in significant discomfort to 
patients. In addition, while IFN- and GLAT have relatively comparable efficacy, there is 
some patient to patient variability.  For example a patient that is not responsive to IFN- 
may be responsive to GLAT and vice versa. Unfortunately no marker exists that may predict 
those populations that should be prescribed IFN- over GLAT or GLAT over IFN-. 
Currently trial and error serve as the best strategy for physicians to use when determining 
the optimal treatment regimen.  
The exact mechanism(s) through which GLAT or IFN- modify disease progression in MS 
patients are not completely defined, with multiple mechanisms likely to be involved. There 
is evidence suggesting IFN- can inhibit T-cell co-stimulation and activation (Chen et al., 
2012). In an experimental setting, IFN- inhibits immune-cell migration by increasing 
soluble Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 
(VCAM-1), as well as by decreasing very late antigen-4 (VL4-4) on the cell surface of T cells. 
It has also been shown that IFN- can stabilize the blood brain barrier by reducing matrix 
metalloproteinase-9, an important tissue degradation enzyme.  
GLAT is a randomized mixture of synthetic polypeptides consisting of the amino acids l-
alanine, l-lysine, l-glutamic acid and l-tyrosine. GLAT was originally designed to induce CNS 
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inflammation in animals by stimulating the myelin auto-antigen MBP, however, subsequent 
studies showed that the product appeared to be a protective immunomodulator. The ability 
for this drug to prevent relapses and disease progression is supported by large clinical 
studies. Mechanistically, GLAT may compete with myelin peptides for access to peptide 
binding cleft in MHC complex (Racke and Lovett-Racke, 2011). In addition to MHC binding, 
GLAT may stimulate a TH2 environment through its ability to modulate APC such as 
dendritic cells and monocytes (Miller et al., 1998). Evidence for the ability of GLAT to induce 
a TH2 biased immune response includes the finding that GLAT promotes the expression of 
anti-inflammatory cytokines such as IL-10 and TGF- in the CNS of MS patients (Neuhaus et 
al., 2001). More recent studies revealed that GLAT elevates the levels of T-regulatory (Tregs) 
cells and reduces the levels of potentially harmful Th-17 cells (Lalive et al., 2011). 
It is difficult to establish the long-term efficacy of drugs in MS because the disease can be 
highly variable and unpredictable. Still, the available long-term observational data point 
toward a significant prevention and delay of disability in most MS patients treated with 
either GLAT or IFN- over a long time. Furthermore, there is sparse evidence that the early 
treatment reduces the long-term mortality of MS patients (Goodin et al., 2012). 
More recently, new disease-modifying drugs have become or are expected to soon be 
available (Buck and Hemmer, 2011; Fox and Rhoades, 2012) (Table 1). These drugs include 
more convenient agents that can be applied orally and may have enhanced efficacy in 
regards to reducing patient disease activity relative to GLAT or IFN-  (Killestein et al., 2011) 
(Hartung and Aktas, 2011). However, the long-term safety profiles of these substances 
remains questionable, with more time needed to adequately address the safety profile of 
these agents.  
If front line disease modifying therapies fail to provide sufficient relief, therapeutic 
escalation to include more effective therapies has to be considered (Repovic and Lublin, 
2011). The most effective currently available therapy for escalation is the monoclonal 
antibody Natalizumab (Tysabri®). Natalizumab acts via the blockade of the VLA-4 receptor, 
which plays a significant role in leukocyte migration into the brain parenchyma (Rudick and 
Sandrock, 2004). Clinical studies with Natalizumab have shown this drug to have high 
efficacy in terms of its ability to prevent disease relapses and progression (Chaudhuri and 
Behan, 2003; O'Connor et al., 2004). However, this efficacy comes at the cost of some 
significant safety issues. For example severe JC-Virus mediated encephalitis called 
“progressive multifocal leukencephalopathy” (PML) has been recorded in numerous 
patients receiving Natalizumab. This severe complication occurs in approximately 1:1000 
patients. PML is severe, not only because it can potentiate MS symptoms, but because it can 
cause death (Berger and Koralnik, 2005; Langer-Gould et al., 2005; Ransohoff, 2005). As a 
result of this treatment related risk, Natalizumab utilization is usually reserved for patients 
with highly active MS, who do not respond sufficiently to standard disease modifying 
therapies and subsequently likely to suffer rapid disease progression (Kappos et al., 2011a; 
Keegan, 2011). Finally, Natalizumab must be given chronically for it to maximize its clinical 
effect. Patients that stop taking Natalizumab usually relapse, with patients developing 
symptoms similar to those experienced before Natalizumab therapy was initiated   
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the optimal future treatment for MS current therapies are focused on agents that are disease 
modifying.  
Over the last three decades a number of broad acting immune modifying therapeutic 
options have been developed and introduced to treat MS patients. None of these therapeutic 
options is a cure, currently available therapies aim instead to prevent or at least reduce the 
frequency of relapsing inflammatory events, with the idea of reducing impact of disease on 
overall quality of life over time (Miller and Rhoades, 2012; Rio et al., 2011). In addition to the 
clear efficacy requirement long-term safety is also paramount for any MS therapy, with 
typical MS patients requiring treatment for many decades. The available MS therapies may 
be divided based on function into “immune modulatory” or “disease modifying” drugs 
(DMFs) as well as classic immune suppressive substances. In addition, a third group has 
recently emerged, which includes monoclonal antibodies (biologics). These drugs act by 
direct interference with specific immune system functions or by broad immune subset 
depletion. DMFs are typically used early in the course of the disease, whereas immune 
suppressive drugs and biologics are mostly viewed as treatment options in those patients 
with abnormally high disease activity, a high risk of sustained disability and/or show poor 
response to the front line therapeutics (Table 1). 
The most widely used disease modifying drugs are Interferon- (IFN) and glatiramer 
acetate (GLAT) (Johnson, 2012). Both drugs were approved after large phase III studies, 
which were conducted in the 1990s. These studies proved the efficacy of these drugs in 
relapsing remitting MS. IFN- and GLAT reduce the relapse rate in relapsing remitting MS 
patients by up to 50% (Boster et al., 2011; Johnson, 2012; Limmroth et al., 2011). Furthermore, 
both agents significantly slowed the progression of disease and have an excellent safety 
profile allowing for long-term utilization. However, there remain a number of 
administration and efficacy issues with these drugs. Administration is required weekly at a 
minimum via subcutaneous or intramuscular injection, resulting in significant discomfort to 
patients. In addition, while IFN- and GLAT have relatively comparable efficacy, there is 
some patient to patient variability.  For example a patient that is not responsive to IFN- 
may be responsive to GLAT and vice versa. Unfortunately no marker exists that may predict 
those populations that should be prescribed IFN- over GLAT or GLAT over IFN-. 
Currently trial and error serve as the best strategy for physicians to use when determining 
the optimal treatment regimen.  
The exact mechanism(s) through which GLAT or IFN- modify disease progression in MS 
patients are not completely defined, with multiple mechanisms likely to be involved. There 
is evidence suggesting IFN- can inhibit T-cell co-stimulation and activation (Chen et al., 
2012). In an experimental setting, IFN- inhibits immune-cell migration by increasing 
soluble Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 
(VCAM-1), as well as by decreasing very late antigen-4 (VL4-4) on the cell surface of T cells. 
It has also been shown that IFN- can stabilize the blood brain barrier by reducing matrix 
metalloproteinase-9, an important tissue degradation enzyme.  
GLAT is a randomized mixture of synthetic polypeptides consisting of the amino acids l-
alanine, l-lysine, l-glutamic acid and l-tyrosine. GLAT was originally designed to induce CNS 
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inflammation in animals by stimulating the myelin auto-antigen MBP, however, subsequent 
studies showed that the product appeared to be a protective immunomodulator. The ability 
for this drug to prevent relapses and disease progression is supported by large clinical 
studies. Mechanistically, GLAT may compete with myelin peptides for access to peptide 
binding cleft in MHC complex (Racke and Lovett-Racke, 2011). In addition to MHC binding, 
GLAT may stimulate a TH2 environment through its ability to modulate APC such as 
dendritic cells and monocytes (Miller et al., 1998). Evidence for the ability of GLAT to induce 
a TH2 biased immune response includes the finding that GLAT promotes the expression of 
anti-inflammatory cytokines such as IL-10 and TGF- in the CNS of MS patients (Neuhaus et 
al., 2001). More recent studies revealed that GLAT elevates the levels of T-regulatory (Tregs) 
cells and reduces the levels of potentially harmful Th-17 cells (Lalive et al., 2011). 
It is difficult to establish the long-term efficacy of drugs in MS because the disease can be 
highly variable and unpredictable. Still, the available long-term observational data point 
toward a significant prevention and delay of disability in most MS patients treated with 
either GLAT or IFN- over a long time. Furthermore, there is sparse evidence that the early 
treatment reduces the long-term mortality of MS patients (Goodin et al., 2012). 
More recently, new disease-modifying drugs have become or are expected to soon be 
available (Buck and Hemmer, 2011; Fox and Rhoades, 2012) (Table 1). These drugs include 
more convenient agents that can be applied orally and may have enhanced efficacy in 
regards to reducing patient disease activity relative to GLAT or IFN-  (Killestein et al., 2011) 
(Hartung and Aktas, 2011). However, the long-term safety profiles of these substances 
remains questionable, with more time needed to adequately address the safety profile of 
these agents.  
If front line disease modifying therapies fail to provide sufficient relief, therapeutic 
escalation to include more effective therapies has to be considered (Repovic and Lublin, 
2011). The most effective currently available therapy for escalation is the monoclonal 
antibody Natalizumab (Tysabri®). Natalizumab acts via the blockade of the VLA-4 receptor, 
which plays a significant role in leukocyte migration into the brain parenchyma (Rudick and 
Sandrock, 2004). Clinical studies with Natalizumab have shown this drug to have high 
efficacy in terms of its ability to prevent disease relapses and progression (Chaudhuri and 
Behan, 2003; O'Connor et al., 2004). However, this efficacy comes at the cost of some 
significant safety issues. For example severe JC-Virus mediated encephalitis called 
“progressive multifocal leukencephalopathy” (PML) has been recorded in numerous 
patients receiving Natalizumab. This severe complication occurs in approximately 1:1000 
patients. PML is severe, not only because it can potentiate MS symptoms, but because it can 
cause death (Berger and Koralnik, 2005; Langer-Gould et al., 2005; Ransohoff, 2005). As a 
result of this treatment related risk, Natalizumab utilization is usually reserved for patients 
with highly active MS, who do not respond sufficiently to standard disease modifying 
therapies and subsequently likely to suffer rapid disease progression (Kappos et al., 2011a; 
Keegan, 2011). Finally, Natalizumab must be given chronically for it to maximize its clinical 
effect. Patients that stop taking Natalizumab usually relapse, with patients developing 
symptoms similar to those experienced before Natalizumab therapy was initiated   
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Substance Indication Side-Effects Comments 
Interferon- Scheme 1. RR-MS, CIS Scheme 2. Flu-like 
symptoms 
Scheme 3. good safety 
profile, inconvenient 
administr., moderate efficacy  
(Sanford and Lyseng-
Williamson, 2011) 
Scheme 4. Glatirameracetate Scheme 5. RR-MS, CIS Scheme 6. Local 
irritation,  
Scheme 7. good safety 
profile, inconvenient 
administr., moderate efficacy  
(Lalive et al., 2011) 
Scheme 8. Fingolimod Scheme 9. RR-MS or 
escalation in RR-MS1 
 




Scheme 11. Increased relapse 
reduction compared to IFN- 
(Singh et al., 2011) (Jeffery et 
al., 2011) 
Scheme 12. Natalizumab Scheme 13. Escalation 
in RR-MS 
Scheme 14. Infections
, hepatopathy, allergic 
response, PML 
Scheme 15. Excellent 
efficacy, severe viral 
encephalitis as a dangerous 
side-effect 
(Keegan, 2011; Pucci et al., 
2011) 
Scheme 16. Mitoxantrone Scheme 17. Escalation 
in RR-MS, 







ve escalation option. Option 
in progressive MS courses 
(Rizvi et al., 2004; Stuve et al., 
2004) 
Scheme 20. Cyclophosphamide Scheme 21. Escalation 
in RR-MS, 




Scheme 23. Therapeutic 
option if other escalation 
therapies including 
mitoxantrone fail (Rinaldi et 
al., 2009; Weiner et al., 1984) 
Scheme 24. Teriflunomide Scheme 25. RR-MS?  
(phase-III trial 
ongoing) 
Scheme 26.  
lymphopenia, 
hepathopathy 
Scheme 27. (Warnke et al., 
2009; Wood, 2011) 
Scheme 28. BG-12 (fumaric acid) Scheme 29. RR-MS?  
(phase-III trial 
ongoing) 
Scheme 30.  
gastrointestinal 
complaints 
Scheme 31. (Kappos et al., 
2008; Papadopoulou et al., 
2010) 
Scheme 32. Laquinimode Scheme 33. RR-MS? 
(phase-III trial 
ongoing) 
Scheme 34.  
Hepatopathy, 
thrombosis? 
Scheme 35. (Thone and Gold, 
2011) 
Scheme 36. Ocrelizumab Scheme 37. Escalation 
therapy? 
(trials ongoing) 
Scheme 38. Severe 
infections and sepsis 
possible, allergic 
response 
Scheme 39. (Chaudhuri, 
2012; Kappos et al., 2011b) 
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Scheme 40. Daclizumab Scheme 41. RR-MS, 
escalatation? 
(trials ongoing) 
Scheme 42.  
Cutaneous rash, 
infections 
Scheme 43. Increased relapse 
reduction compared to IFN- 
likely (Stuve and Greenberg, 
2010) 
Scheme 44. Alemtuzumab Scheme 45. Escalation 
therapy? 
(trials ongoing) 
Scheme 46. Induction 
of autoimmune 
diseases, infections 
(Cossburn et al., 2011)
Scheme 47. Increased relapse 
reduction compared to IFN- 
(Coles et al., 2012; Klotz et al., 
2012) 
RR-MS: relapsing remitting Multiple sclerosis, CIS: clinical isolated syndrome, PP-MS: primary progressive Multiple 
Sclerosis, SP-MS: secondary progressive Multiple Sclerosis, 1: Fingolimod is recommended as a first-line treamtent in 
the US but as an escalation therapy in the EU  
Table 1.   
(O'Connor et al., 2011). The chronic treatment requirement increases patient risk and 
highlights the ongoing conundrum for all MS therapies, which is how to balance immune 
modulation efficacy with safety. The emergence of PML with Natalizumab is one striking 
example, however, more recent cardiac issues have been associated with the recently 
approved oral DMF, ingolomid (Gilyena), highlighting the point that all therapies focused 
on immune intervention require diligent safety studies.  
The need for safer therapies, combined with animal data showing the ability for short course 
immune induction therapy (SCIIT) to induce long term disease remission, has supported a 
new approach to treating MS. SCIIT is a therapeutic strategy employing rapid, specific, 
short-term modulation of the immune system usually using a biologic therapeutic to induce 
long term T cell non-responsiveness. Alemtuzumab clinical studies are leading the way in 
employing this therapeutic concept. In this example, a one week dosing regimen with 
Alemtuzumab has been in phase 2 and 3 studies shown to have a long term dramatic impact 
on disease, reducing disease relapses for over a year (Coles et al., 2008; Hauser, 2008; 
Moreau et al., 1996). The ability for long lasting relapse prevention even after the treatment 
is discontinued is the primary objective of SCIIT. Unfortunately, from an immunological 
perspective, tolerance is the result of a number of T cell reprogramming pathways, not 
induced by Alemtuzumab. Alemtuzumab functions through long term whole scale immune 
cell depletion. While this drug may have great efficacy it come has added consequences 
including the potential for JC-virus infection, cancer and up to 20% of patients may develop 
other autoimmune diseases (notably Thyroiditis). As such newer therapies are required that 
focus on immune reprogramming and less on immune depletion. Some potential candidates 
in development may include Daclizumab (Wynn et al., 2010), Ocrelizumab (Chaudhuri, 
2012; Kappos et al., 2011b) or the anti-alpha beta T cell receptor antibody, TOL101 (Table 1).  
In situations where all other avenues have been exhausted and disease continues to progress 
at an unusually rapid rate, physicians may prescribe the chemotherapy drugs mitoxantrone 
or cyclophosphamide (Neuhaus et al., 2006; Perini et al., 2006; Rinaldi et al., 2009; Stuve et al., 
2004; Theys et al., 1981). These drugs are often considered as final options due to their potent 
immunosuppressive and other serious effects. These drugs can suppress both cell-mediated 
and humoral immunity and often result in lymphopenia, increasing malignancy and 
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(O'Connor et al., 2011). The chronic treatment requirement increases patient risk and 
highlights the ongoing conundrum for all MS therapies, which is how to balance immune 
modulation efficacy with safety. The emergence of PML with Natalizumab is one striking 
example, however, more recent cardiac issues have been associated with the recently 
approved oral DMF, ingolomid (Gilyena), highlighting the point that all therapies focused 
on immune intervention require diligent safety studies.  
The need for safer therapies, combined with animal data showing the ability for short course 
immune induction therapy (SCIIT) to induce long term disease remission, has supported a 
new approach to treating MS. SCIIT is a therapeutic strategy employing rapid, specific, 
short-term modulation of the immune system usually using a biologic therapeutic to induce 
long term T cell non-responsiveness. Alemtuzumab clinical studies are leading the way in 
employing this therapeutic concept. In this example, a one week dosing regimen with 
Alemtuzumab has been in phase 2 and 3 studies shown to have a long term dramatic impact 
on disease, reducing disease relapses for over a year (Coles et al., 2008; Hauser, 2008; 
Moreau et al., 1996). The ability for long lasting relapse prevention even after the treatment 
is discontinued is the primary objective of SCIIT. Unfortunately, from an immunological 
perspective, tolerance is the result of a number of T cell reprogramming pathways, not 
induced by Alemtuzumab. Alemtuzumab functions through long term whole scale immune 
cell depletion. While this drug may have great efficacy it come has added consequences 
including the potential for JC-virus infection, cancer and up to 20% of patients may develop 
other autoimmune diseases (notably Thyroiditis). As such newer therapies are required that 
focus on immune reprogramming and less on immune depletion. Some potential candidates 
in development may include Daclizumab (Wynn et al., 2010), Ocrelizumab (Chaudhuri, 
2012; Kappos et al., 2011b) or the anti-alpha beta T cell receptor antibody, TOL101 (Table 1).  
In situations where all other avenues have been exhausted and disease continues to progress 
at an unusually rapid rate, physicians may prescribe the chemotherapy drugs mitoxantrone 
or cyclophosphamide (Neuhaus et al., 2006; Perini et al., 2006; Rinaldi et al., 2009; Stuve et al., 
2004; Theys et al., 1981). These drugs are often considered as final options due to their potent 
immunosuppressive and other serious effects. These drugs can suppress both cell-mediated 
and humoral immunity and often result in lymphopenia, increasing malignancy and 
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infection risk. Results from smaller clinical studies suggest, that treating with these 
immunosuppressive drugs at the very beginning of the disease and in addition to immune 
modulating drugs might have a beneficial impact on the course of the disease. However, the 
harmful side effects associated with these drugs means their use is usually restricted to 
patients that have failed other treatment options, such as Natalizumab. 
6. Summary 
Multiple Sclerosis (MS) is a chronic, progressive, immune mediated central nervous system 
disorder that affects both adults and children. The precise triggers of autoreactive T cell 
development remain to be fully understood, however, it appears that a host of genetic and 
environmental factors contribute to disease development. Disease initiation may be the 
result of a single myelin specific T cell clone being activated, however, animal models and 
preliminary human data suggest that epitope spreading which results in the activation of 
numerous myelin specific T cells is important for disease progression. Therapies capable of 
inducing T cell tolerance, thereby rendering these myelin specific T cells inactive remain to 
be developed for human use. Instead a number of disease modifying agents are available, 
with GLAT and IFN- being the primary front line MS treatments. In those patients 
refractory to these therapies or who show a rapid disease progression, escalation to more 
broad acting therapies, such as Natalizumab may be considered. Unfortunately, while 
escalating therapies may have enhanced efficacy this comes with increases in safety 
concerns. In progressive MS patients whereby all other therapies have failed or no longer 
show efficacy more toxic chemotherapeutic agents are usually the last resort.  
Currently within the field of MS treatment, reduction of relapse rates by around 50% is 
considered to be a success. As such even patients who are considered treatment successes 
suffer relapses. During these relapses CNS damage and epitope spreading continue to occur 
with further neurological impairment the result. Future therapies need to have a higher 
objective and bring the relapse rate down by 75-100%. This goal may not be out of reach 
with short course Alemtuzumab therapy shown to induce disease remission for an extended 
period of time. While the safety profile of this drug remains highly questionable, the 
observed efficacy certainly generates promise that safer more efficacious therapeutic options 
for MS treatment may soon be available. 
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1. Introduction 
Diabetes mellitus (DM) is a metabolic disorder resulting from a defect in insulin secretion, 
insulin action, or both (Kumar et al., 2002). In type 1 diabetes, the body does not produce 
insulin. Insulin is a hormone that is needed to convert sugar, starches and other food into 
energy needed for daily life. Insulin deficiency in turn leads to chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism (Kumar et al., 2002). As the 
disease progresses tissue or vascular damage ensues leading to severe diabetic 
complications such as retinopathy, neuropathy, nephropathy, cardiovascular complications 
and ulceration (Huang, Kim et al. 2002; Wallace, Reiber et al. 2002; Bearse, Han et al. 2004; 
Seki, Tanaka et al. 2004; Svensson, Eriksson et al. 2004). Thus, diabetes covers a wide range 
of heterogeneous diseases. Diabetes is the most common endocrine disorder and by the year 
2015, it is estimated that more than 200 million people worldwide will have DM and 300 
million will subsequently have the disease by 2025. Type 1 diabetes is usually diagnosed in 
children and young adults, and was previously known as juvenile diabetes.  
The diagnostic criteria and the classification of diabetes was first put forward by the World 
Health Organization (WHO) in 1965 then by the National Diabetes Data Group (NDDG) in 
1979, and the latest recommendations have been published by the American Diabetes 
Association (ADA) in 1997 and by the WHO in 1999(Genuth, Alberti et al. 2003). According 
to the ADA recommendation, the fasting glucose concentration should be used in routine 
screening for diabetes as well as epidemiological studies; the threshold for fasting glucose is 
fasting glucose = 7.0 mmol/L (126 mg/dl) and /or a 2-h glucose = 11.1 mmol/L (200 mg/dL). 
For the diagnosis of diabetes, at least one criteria must also apply: 
 Symptoms of diabetes (polyurea, polydipsia, unexplained weight loss, etc) as well as 
casual plasma glucose concentration = 11.1 mmol/L (200mg/dL). 
 Fasting plasma glucose = 7.0 mmol/L (126mg/dL), with no caloric intake for at least 8 h. 
 The Author(s). Licensee InT ch. This chapter  distribut d under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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Diabetes Mellitus may be categorized into several types but the two major types are type 1 
and type 2. The term type 1 and type 2 were widely used to describe Insulin-Dependent 
Diabetes Mellitus (IDDM) and Noninsulin-Dependent Diabetes Mellitus (NIDDM), 
respectively. On the basis of etiology, Type 1 (DM) is present in patients who have little or 
no endogenous insulin secretory capacity and who therefore require insulin therapy. The 
two main forms of clinical type 1 diabetes are type 1a (about 90% of type 1 cases) which is 
thought to be due to immunological destruction of pancreatic beta-cells resulting in insulin 
deficiency, and type 1b (idiopathic, about 10% of type 1 diabetes), in which there is no 
evidence of autoimmunity. Type 1a is characterized by the presence of islet cell antibody 
(ICA), anti-glutamic acid decarboxylate (anti-GAD), IA-2 or insulin antibodies that identify 
the autoimmune process with beta-cell destruction. Autoimmune diseases such as Grave’s 
disease, Hashimoto’s thyroiditis and Addison’s disease may be associated with Type 1 (DM) 
(Betterle, Zanette et al. 1984; Atkinson and Maclaren 1994). There is no known etiological 
basis for type 1b diabetes mellitus. Some of Type1b patients have permanent insulinopaenia 
and are prone to ketoacidosis, but have no evidence of autoimmunity. This form is more 
prevalent among individuals of African and Asian origins. 
Type 2 diabetes is the commonest form of DM and is characterized by disorders of insulin 
secretion and insulin resistance. 
Type 1 (DM) is a multifactorial disease characterized by the autoimmune destruction of 
insulin-secreting pancreatic beta-cells causing tissue damage. The peak age of onset is about 
12 years, and from then onwards daily injections of insulin are required by affected 
individuals. With a frequency of about 0.4% in Caucasians of European descent, Type 1 
(DM) is second to asthma as the most serious chronic childhood disease in the Western 
world (Wan, Yang et al. 2010). There is a marked geographic variation of Type 1 (DM), with 
a higher incidence in the European and North American than the Asian and south American 
countries. The current global increase in incidence of 3% per year is well reported. This 
rapid rise strongly suggests that the action of the environment on susceptibility genes 
contributes to the evolving epidemiology of this disease(Wan, Yang et al. 2010). 
Type 1 (DM) shows a complex mode of inheritance, with disease susceptibility caused both 
by genetic and by environmental components. The penetrance of disease genes being 
determined by unknown environmental factors. Identical twins of affected individuals have 
a risk of developing the disease of only 36% (Owerbach and Gabbay 1996), demonstrating 
the importance of the environmental factors. Nevertheless, genetic factors are essential, as 
measured by the quantity (i.e. the ratio of the risk to siblings of patients compared with the 
population prevalence). The disease is polygenic in humans and in mice, with a number of 
different susceptibility genes each accounting for a portion of the familial clustering of the 
disease (Pharoah, Dunning et al. 2004). Around the time of clinical presentation, insulitis, a 
chronic inflammatory infiltrate of the islets affecting primarily insulin containing islets, is 
present in the majority of cases. The mononuclear cell infiltrates in the islet, which results in 
the development of insulitis (a prerequisite step for the development of diabetes) are 
primarily composed of T cells. It is now well accepted that these T cells play important roles 
in initiating and propagating an autoimmune process, which in turn destroys insulin-
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producing islet beta-cells in the pancreas (Toyoda and Formby 1998). Understanding 
insights of the mechanism of immune-mediated islet cell destruction and the interaction 
between the immune system and pancreatic islets provide new therapeutic means of 
preventing this chronic debilitating disease. 
Before safe and rational therapies can be offered in a clinical setting, a detailed 
understanding of the immune-mediated process that results in Type 1 (DM) is required, as 
is the accurate identification of those at risk of the disease. The immunogenetics of type 1 
diabetes has become the model upon which other complex disorders are studied, and in this 
chapter we focus on the importance of recent insights into the pathogenesis and natural 
history of Type 1 (DM) with consideration to current therapeutic strategies, and future 
perspective for the efficient treatment. 
2. Diabetes mellitus clinical manifestation and diagnosis 
The symptoms of diabetes are more readily recognizable in children than in adults, so it is 
surprising that the diagnosis may sometimes be missed or delayed. Those families with a 
strong family history of diabetes should suspect diabetes, especially if there is one child in the 
family with diabetes. Main manifestations are: polyuria, polydipsia, polyphagia, progressive 
cachexia, glucosuria, hyperglycemia, increasing of specific gravity of urine, blurred vision, 
fatigue, cramps and candidiasis. Diabetic retinopathy is a major complication of diabetes 
(Bakker, Tushuizen et al. 2012). Diabetes causes high blood sugar levels, which can damage 
blood vessels. The damaged vessels around the retina can leak protein and fats, forming 
deposits that can interfere with vision. The damaged blood vessels are also not as effective at 
carrying oxygen to the retina, which can also cause damage (Bakker, Tushuizen et al. 2012). 
When blood glucose concentrations increase, more glucose is filtered by the glomeruli of the 
kidneys than can be reabsorbed by the kidney tubules, resulting in glucose excretion in the 
urine. High glucose concentrations in the urine create an osmotic effect that reduces the 
reabsorption of water by the kidneys, causing polyuria (excretion of large volumes of urine) 
(Katavetin 2009). The loss of water from the circulation stimulates thirst. Therefore, patients 
with moderate or severe hyperglycemia typically have polyuria and polydipsia (excessive 
thirst). The loss of glucose in the urine results in weakness, fatigue, weight loss, and 
increased appetite (polyphagia). Patients with hyperglycemia are prone to infections, 
particularly vaginal and urinary tract infections and an infection may be the presenting 
manifestation of diabetes (Katavetin 2009). 
There are two acute life-threatening complications of diabetes: hyperglycemia and acidosis 
(increased acidity of the blood), either of which may be the presenting manifestation of 
diabetes. In patients with Type 1 (DM), insulin deficiency, if not recognized and treated 
properly, leads to severe hyperglycemia and to a marked increase in lipolysis (the 
breakdown of lipids), with a greatly increased rate of release of fatty acids from adipose 
tissue (Wajchenberg 2007). In the liver, much of the excess fatty acid is converted to the keto 
acids beta-hydroxybutyric acid and acetoacetic acid. The increased release of fatty acids and 
keto acids from adipose, liver, and muscle tissues raises the acid content of the blood, 
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primarily composed of T cells. It is now well accepted that these T cells play important roles 
in initiating and propagating an autoimmune process, which in turn destroys insulin-
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producing islet beta-cells in the pancreas (Toyoda and Formby 1998). Understanding 
insights of the mechanism of immune-mediated islet cell destruction and the interaction 
between the immune system and pancreatic islets provide new therapeutic means of 
preventing this chronic debilitating disease. 
Before safe and rational therapies can be offered in a clinical setting, a detailed 
understanding of the immune-mediated process that results in Type 1 (DM) is required, as 
is the accurate identification of those at risk of the disease. The immunogenetics of type 1 
diabetes has become the model upon which other complex disorders are studied, and in this 
chapter we focus on the importance of recent insights into the pathogenesis and natural 
history of Type 1 (DM) with consideration to current therapeutic strategies, and future 
perspective for the efficient treatment. 
2. Diabetes mellitus clinical manifestation and diagnosis 
The symptoms of diabetes are more readily recognizable in children than in adults, so it is 
surprising that the diagnosis may sometimes be missed or delayed. Those families with a 
strong family history of diabetes should suspect diabetes, especially if there is one child in the 
family with diabetes. Main manifestations are: polyuria, polydipsia, polyphagia, progressive 
cachexia, glucosuria, hyperglycemia, increasing of specific gravity of urine, blurred vision, 
fatigue, cramps and candidiasis. Diabetic retinopathy is a major complication of diabetes 
(Bakker, Tushuizen et al. 2012). Diabetes causes high blood sugar levels, which can damage 
blood vessels. The damaged vessels around the retina can leak protein and fats, forming 
deposits that can interfere with vision. The damaged blood vessels are also not as effective at 
carrying oxygen to the retina, which can also cause damage (Bakker, Tushuizen et al. 2012). 
When blood glucose concentrations increase, more glucose is filtered by the glomeruli of the 
kidneys than can be reabsorbed by the kidney tubules, resulting in glucose excretion in the 
urine. High glucose concentrations in the urine create an osmotic effect that reduces the 
reabsorption of water by the kidneys, causing polyuria (excretion of large volumes of urine) 
(Katavetin 2009). The loss of water from the circulation stimulates thirst. Therefore, patients 
with moderate or severe hyperglycemia typically have polyuria and polydipsia (excessive 
thirst). The loss of glucose in the urine results in weakness, fatigue, weight loss, and 
increased appetite (polyphagia). Patients with hyperglycemia are prone to infections, 
particularly vaginal and urinary tract infections and an infection may be the presenting 
manifestation of diabetes (Katavetin 2009). 
There are two acute life-threatening complications of diabetes: hyperglycemia and acidosis 
(increased acidity of the blood), either of which may be the presenting manifestation of 
diabetes. In patients with Type 1 (DM), insulin deficiency, if not recognized and treated 
properly, leads to severe hyperglycemia and to a marked increase in lipolysis (the 
breakdown of lipids), with a greatly increased rate of release of fatty acids from adipose 
tissue (Wajchenberg 2007). In the liver, much of the excess fatty acid is converted to the keto 
acids beta-hydroxybutyric acid and acetoacetic acid. The increased release of fatty acids and 
keto acids from adipose, liver, and muscle tissues raises the acid content of the blood, 
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thereby lowering the pH of the blood. The combination of hyperglycemia and acidosis is 
called diabetic ketoacidosis and leads to hyperventilation and to impaired central nervous 
system function, culminating in coma and death.  
Many studies have also shown that hyperglycemia causes oxidative stress in tissues that are 
susceptible to complications of diabetes mellitus, including peripheral nerves (Ziegler, Sohr 
et al. 2004). The autonomic nervous system modulates the electrical and contractile activity 
of the myocardium via the interplay of sympathetic and parasympathetic activity (Lahiri, 
Kannankeril et al. 2008). An imbalance of autonomic control is implicated in the 
pathophysiology of Type 1 (DM). Cardiovascular autonomic neuropathy, a common form of 
autonomic dysfunction found in patients with diabetes mellitus (Maser and Lenhard 2005), 
as well, and causes abnormalities in heart rate control, as well as defects in central and 
peripheral vascular dynamics. 
Symptoms are similar in both types of diabetes but they vary in their intensity. 
Longstanding Type 1 (DM) patients are susceptible to microvascular complications; and 
macrovascular disease (coronary artery, heart, and peripheral vascular diseases) (Saely, 
Aczel et al. 2004; Svensson, Eriksson et al. 2004)and end stage renal disease. Ketoacidosis is 
usually not a problem in patients with type II diabetes because they secrete enough insulin 
to restrain lipolysis. 
Symptoms in type 2 DM are similar but usually milder and insidious in onset. Geographical 
differences exist in both the magnitude of these problems and their relative contributions to 
overall morbidity and mortality.  
3. Composition of the islet infiltrates and the mechanism of beta-cell 
destruction 
The histopathology of type 1 diabetes is defined by a decreased beta-cell mass in association 
with insulitis, a characteristic lymphocytic infiltration limited to the islets of Langerhans and 
prominent in early stage disease in children. It is considered to be pathognomonic for recent 
onset disease. The infiltrate consists predominantly of T cells, in which CD8+ lymphocytes 
dominate, but may also contain CD4+ lymphocytes, B-lymphocytes and macrophages 
(Willcox, Richardson et al. 2009).  
The cellular response is accompanied by a humoral response that includes autoantibodies 
against a wide array of beta-cell antigens (which will be discussed later). However, the 
precipitating (auto)antigen against which the inflammatory response is directed has not 
been identified, nor has it been established whether the humoral response that is considered 
to be part of our current diagnostic criteria is a cause or a consequence of the disease. 
Although animal models for the disease exist, like the spontaneously non-obese diabetic 
(NOD) mouse, they are found to differ from the human disease in many key aspects and it is 
an open question whether data derived from such models will be applicable to patients. In 
fact, even after a century of research we know very little about the etiology and 
histopathology of the human disease. 
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The pancreas is a difficult organ to biopsy and most of the material is therefore post-
mortem. The islets are scattered in a matrix of exocrine tissue and thus form only 1–2% of 
the parenchymal tissue. In addition the beta-cells are not homogeneously distributed 
throughout the gland and are often located within a few lobes. In a diabetic condition, the 
lesions are mainly found in islets in which beta-cells are still present and the lesions will 
largely disappear together with the beta-cells against which the reaction appears to be 
directed. In addition, the few cases that were brought to autopsy often died in ketoacidosis, 
they may thus represent a more fulminant version of the disease that is not necessarily 
characteristic for the disease process in the rest of the population. Lastly, and perhaps most 
importantly, the histopathological lesions that we observe in cases with recent onset disease 
will only show the final stages of a process that has been going on for a long period of time, 
and until recently, we had no material available of earlier stages of the disease. Identifying 
patients with pre-clinical disease and studying the immunological processes occurring at 
this stage may prove to be indispensable for a breakthrough in our quest for the etiology of 
the disease.  
3.1. A Brief history of insulitis 
Inflammatory infiltrates in the islets of Langerhans were first described in 1902 by the 
German pathologist Schmidt (Nagler and Taylor 1963), who found foci of small-cell 
infiltration in the periphery of islets of Langerhans from a 10 year old diabetic child with an 
unknown duration of disease. This islet-specific inflammation, later termed “insulitis” by 
the Swiss pathologist von Meyenburg, was long considered to be a rare event. Cecil (Cecil 
1909) described leucocytic infiltration associated with islets in 9 out of 90 patients with 
diabetes, but often under conditions in which a more generalized pancreatitis was present; 
he observed islet-specific inflammation in only a single case, involving a young adult patient 
with recent onset disease. In 1928 Stansfield and Warren were the first to draw attention to 
the association between insulitis and the age of the patient; they described insulitis in a six year 
old girl who died in a diabetic coma two months after onset of the disease, and in an 11 year 
old girl who died in a diabetic coma within four weeks after the initiation of symptoms. In 
their view, the striking lymphocytic infiltration in the islets of both cases suggested a causal 
relationship between the inflammation and the diabetic condition in these two young patients 
with recent onset fulminant disease. On the other hand, it was clear from their studies in larger 
groups of children that insulitis was not always observed. These observations were revisited in 
1958 by LeCompte (Lecompte 1958) who collected four cases with insulitis, all involving acute 
onset disease and short duration in children. He proposed four possible explanations for the 
presence of the cellular infiltrate: a direct invasion of the islets by an infectious agent, a 
manifestation of functional overstimulation or strain, a reaction to damage by some unknown 
nonbacterial agent and lastly an antigen-antibody reaction. 
Fifty years later one could still make the same list, as none of these possibilities has been 
excluded. In a 1965 landmark study, Willy Gepts (Gepts 1965) reported the presence of the 
lesion in 15/22 (68%) recent onset cases below the age of 40 and noted that it was not present 
in patients with a disease duration of more than a year. He also noted that beta-cell mass 
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onset disease and short duration in children. He proposed four possible explanations for the 
presence of the cellular infiltrate: a direct invasion of the islets by an infectious agent, a 
manifestation of functional overstimulation or strain, a reaction to damage by some unknown 
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appeared to be reduced to approximately 10% of that in non-diabetic controls. Other authors 
supported the findings as well. Foulis et al (Foulis, Liddle et al. 1986) using a 25-year 
computerized survey of deaths in the UK to identify 119 young patients who died in 
ketoacidosis before the age of 20, in combination with immunohistochemistry to identify islets 
and infiltrating leucocytes, confirmed that insulitis was present in 47 out of 60 (78%) of young 
patients with recent onset disease (<1 year). These investigators, however, also pointed out that 
certain heterogeneity seemed to exist in their patient population, as it is observed that young-
adult patients with a short duration of the disease showed no evidence of insulitis and in 
which all islets contained insulin. Together it appears that insulitis exist predominantly in (pre) 
diabetic patients in which it is limited to islets that were still insulin-containing. 
3.2. Pathogenic autoantigen in type 1 diabetes 
The major autoantigens in Type 1 (DM), identified by circulating autoantibodies, are 
glutamic acid decarboxylase (GAD), tyrosine phosphatase-like insulinoma antigen and (pro) 
insulin. It is not clear, however, which if any drive pathogenic T cells. So far, no antigen has 
emerged as dominant, although both glutamic acid decarboxylase and insulin have been 
postulated to be principal autoantigens (Pugliese, Brown et al. 2001). 
With the possible exception of rare self-antigen-expressing cells in lymphoid tissue 
(Pugliese, Brown et al. 2001), proinsulin is expressed uniquely in beta-cells. Investigation on 
humans (Kent, Chen et al. 2005), and murine model (Nakayama, Abiru et al. 2005), highlight 
the pancreatic beta-cell hormone insulin as a major target for T cell attack. If insulin, or 
peptides of the β chain of insulin, is given orally (Bergerot, Fabien et al. 1994) intranasally 
(Harrison, Dempsey-Collier et al. 1996) or subcutaneously(Hutchings and Cooke 1998), 
diabetes is suppressed. In addition, when proinsulin is expressed in the NOD mice under 
the control of a MHC class II promoter, such that it is expressed on antigen-presenting cells 
and in the thymus, the incidence of diabetes is decreased (French, Allison et al. 1997). There are 
some reports demonstrating that insulin gene polymorphism is associated with predisposition 
to Type 1 (DM) (which will be discussed later). In some studies specificity of the T cell 
response was confirmed by isolation of CD4+ and CD8+ T cell clones specific for the insulin 
epitopes. The most convincing evidence of a pathogenic role of insulin specific CD4+ T cells 
came from a study in which the insulin A1–15 specific T cells were expanded from pancreatic 
lymph nodes of deceased patients affected by Type 1 (DM) (Kent, Chen et al. 2005). 
Moreover, Multiple T-cell epitopes against GAD65 (glutamate decarboxylase 65) have been 
associated with Type 1 (DM). GAD65 is expressed in the endocrine cells of the islets of 
Langerhans and in the central nervous system (Karlsen, Hagopian et al. 1991). The major 
autoantigens, in which there are evidence that are associated to the pathogenesis of Type 1 
(DM) are listed below. 
3.3. Phenotyping insulitis 
Immunophenotyping of the infiltrate showed that most cells corresponded to T cells, with T 
cytotoxic/suppressor cells being most abundant, although helper CD4+ T cells and NK cells 
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were also present (In't Veld 2011). CD8+ T lymphocytes (T cytotoxic/suppressor) were the 
main infiltrating cell type. In addition to lymphocytes, macrophages were a prominent 
feature of the infiltrate; although it is controversial and in some studies macrophages were 
not found in insulitic lesions. The composition of the cellular infiltrate is stratified according 
to the percent beta-cells present in islets collected across patients (In't Veld 2011). The 
percent beta-cells would be a surrogate marker for the stages of advent of the insulitic 
lesion, with 50–69% insulin-positive area taken as starting point and 0% insulin-positive 
area as end-stage (In't Veld 2011). In all stages, CD8+ T cells are predominant, increasing in 
number with decreasing insulin-positive area, but disappearing when insulin-positivity is 
completely lost. CD20+ B-cells were found to be the second most prominent cell type, 
following the dynamics of CD8+ cells, while macrophages were present at relatively 
constant levels becoming the most prominent infiltrating cell type in insulin-deficient islets. 
 










Insulin β-cell, thymus secretory granule + + + + 
GAD 65 neuroendocrine synaptic-like microvesicles + + + + 
GAD 67 neuroendocrine cytosol + + + + 




granule  + + + 
IGRP β-cell 
endoplasmic 
reticulum + ? + + 
Chromogranin neuroendocrine
Secretory 
granule + ? ? ? 
ZnT8 β-cell secretory 
granule 
? + ? ? 
HSP-60 
HSP-70 
Ubiquitous mitochondria + + + ? 
Glima-38  
secretory 
granule ? + ? ? 
Amylin/IAPP  
secretory 
granule ? ? ? + 
CD38 Ubiquitous ? ? ± ? ? 
Table 1. Autoantigens defined as recognized by T cells in human and NOD mice type 1 (DM).  
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Phenotyping the infiltrating cells in insulitic lesions is only a first step in a process to 
identify the antigen against which the infiltrate is directed. The key step will be to analyze 
their specificity. Direct analysis of insulitic T cell specificity has been reported to date is 
limited, although some studies suggest that CD4+ T cells isolated from pancreases of Type 1 
(DM) patients are specific to some parts of the insulin molecule (Kent, Chen et al. 2005). 
Although the predominantly CD3+CD8+ phenotype of the infiltrating cells is compatible 
with a cytotoxic T cell mediated beta-cell destruction, it has not yet been proven that the 
cells in the insulitic lesion are the cells that are actually responsible for the destruction of the 
beta-cell component. However many studies suggest that a cytotoxic T cell mediated 
destruction of insulin-producing beta-cells is initiated by an unknown (auto)antigen, 
leading to the destruction of beta-cell mass. 
It is equally well possible that a large part of such infiltrates are the consequence of beta-cell 
destruction rather than its cause, at least at this relatively late time point in the progression 
of the disease. What we observe at clinical presentation is the final stage of a process that 
may have been going on for a long period of time. If the presence of circulating 
autoantibodies against islet cell antigens is considered as a surrogate marker for beta-cell 
destruction, then the process may take years before the clinical threshold is reached. 
Determining the incidence and time course of insulitis prior to diagnosis and correlating it 
to the presence, and persistence of circulating immune markers, will be crucial for our 
understanding of the disease and for the development of immune intervention strategies. It 
is important to correlate such information to the regenerative capacity of the beta-cell mass. 
Not all individuals who are autoantibody-positive progress to overt disease and the process 
may well involve episodes of fulminant destruction followed by episodes of repair and 
regeneration. 
Islets with insulitis contain replicating beta-cells, indicating that beta-cells retain a sub-
stantial capacity for growth that appears to be activated under conditions of inflammation. 
It cannot be excluded that such newly formed cells attract recurrent autoimmune attack and 
that islets with a low insulin-positive area represent islets with regeneration rather than 
islets in the last stages of beta-cell destruction.  
3.4. Mechanisms of beta-cell destruction and initiation of pathogenesis 
Although the pathogenesis of Type 1 (DM) has been extensively studied, the precise 
mechanisms involved in the initiation and progression of beta-cell destruction remain 
unclear. Animal models used in the study of Type 1 (DM), such as the (BB) rat and (NOD) 
mouse, have greatly enhanced our understanding of the pathogenic mechanisms involved 
in this disease. In these animals, macrophages and/or dendritic cells are the first cell types to 
infiltrate the pancreatic islets (Yoon and Jun 2005). Macrophages must be involved in the 
pathogenesis of Type 1 (DM) early on, since inactivation of macrophages results in the near-
complete prevention of insulitis and diabetes in both NOD mice and BB rats (Yoon and Jun 
2005). The activated macrophages secrete IL-12, which stimulates Th1 type CD4+ T cells. The 
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CD4+ T cells secrete IFN-γ and IL-2. IFN-γ activates other resting macrophages, which, in 
turn, release cytokines, such as IL-1β, TNF-α, and free radicals, which are toxic to beta-cells. 
During this process, IL-2 and other cytokines induce the migration of CD8+ peripheral T 
cells to the inflamed islets, perhaps by inducing the expression of a specific homing 
receptor. The precytotoxic CD8+ T cells that bear beta-cell-specific autoantigen receptors 
differentiate into cytotoxic effector T cells upon recognition of the beta-cell-specific peptide 
bound to MHC class I molecules in the presence of beta-cell-specific CD4+ T helper cells. The 
cytotoxic CD8+ T cells then affect beta-cell damage by releasing perforin and granzyme, and 
by Fas-mediated apoptosis. In this way, macrophages, CD4+ T cells, and CD8+ T cells 
synergistically destroy beta-cells, resulting in the onset of autoimmune Type 1 (DM). 
Both direct and indirect killing of beta-cells, mediated by CD8+cytotoxic T cells and 
CD4+helper T cells respectively, are thought to occur by apoptosis following activation of 
caspases, but necrosis also might play some role (Rasche, Busick et al. 2009). Based upon 
animal models, it is now generally believed that multiple effector molecules and pathways 
are involved in beta cell killing. In addition to apoptosis being the main mechanism by 
which beta-cells are destroyed, beta-cell apoptosis has been implicated in the initiation of 
Type 1 (DM) through antigen cross-presentation mechanisms that lead to beta-cell-specific T 
cell activation (The term cross-presentation denotes the ability of certain antigen-presenting 
cells to take up, process and present extracellular antigens with MHC class I molecules to 
CD8+cytotoxic T cells). In mammals, there are 14 caspases, of which many participate in the 
apoptotic pathways. Caspase-3 is the major effector caspase involved in apoptotic pathways. 
Caspase-3 knockout mice were protected from developing diabetes in autoimmune diabetes 
model. 
As explained before, autoantibodies have turned out to be excellent diagnostic and 
predictive markers for Type 1 (DM). However, it is generally thought that they play only a 
minor role, if any, in the actual pathogenesis of the disease. Instead, the cell-mediated 
immune response is believed to be responsible for beta-cell killing as explained above. 
Inflammatory cells are found in and around the pancreatic islets. However, human studies 
show that in some individuals these inflammatory cells are present for years without clinical 
symptoms. In fact, some individuals with autoantibodies and insulitis do not go on to 
develop clinical disease. The outcome appears to be related to the amount of beta-cell 
destruction. It is estimated from animal studies that between 80 and 90% of the beta-cells 
must be destroyed before the diabetes becomes clinically apparent. In humans, however, 
the temporal and quantitative relationships between inflammatory cells, beta-cell damage, 
and clinical diabetes have been difficult to determine because pancreatic biopsies are not 
easy to be performed. Finally, much of our information about cell-mediated immune 
pathogenesis and beta-cell killing comes from animal models. These animals 
spontaneously develop an autoimmune disease similar, although not identical, to human 
autoimmune Type 1 (DM). 
The possible dysregulation of Regulatory T cells (Treg) suppressor activity is shown to 
association to Type 1 (DM) as well. 
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Phenotyping the infiltrating cells in insulitic lesions is only a first step in a process to 
identify the antigen against which the infiltrate is directed. The key step will be to analyze 
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autoantibodies against islet cell antigens is considered as a surrogate marker for beta-cell 
destruction, then the process may take years before the clinical threshold is reached. 
Determining the incidence and time course of insulitis prior to diagnosis and correlating it 
to the presence, and persistence of circulating immune markers, will be crucial for our 
understanding of the disease and for the development of immune intervention strategies. It 
is important to correlate such information to the regenerative capacity of the beta-cell mass. 
Not all individuals who are autoantibody-positive progress to overt disease and the process 
may well involve episodes of fulminant destruction followed by episodes of repair and 
regeneration. 
Islets with insulitis contain replicating beta-cells, indicating that beta-cells retain a sub-
stantial capacity for growth that appears to be activated under conditions of inflammation. 
It cannot be excluded that such newly formed cells attract recurrent autoimmune attack and 
that islets with a low insulin-positive area represent islets with regeneration rather than 
islets in the last stages of beta-cell destruction.  
3.4. Mechanisms of beta-cell destruction and initiation of pathogenesis 
Although the pathogenesis of Type 1 (DM) has been extensively studied, the precise 
mechanisms involved in the initiation and progression of beta-cell destruction remain 
unclear. Animal models used in the study of Type 1 (DM), such as the (BB) rat and (NOD) 
mouse, have greatly enhanced our understanding of the pathogenic mechanisms involved 
in this disease. In these animals, macrophages and/or dendritic cells are the first cell types to 
infiltrate the pancreatic islets (Yoon and Jun 2005). Macrophages must be involved in the 
pathogenesis of Type 1 (DM) early on, since inactivation of macrophages results in the near-
complete prevention of insulitis and diabetes in both NOD mice and BB rats (Yoon and Jun 
2005). The activated macrophages secrete IL-12, which stimulates Th1 type CD4+ T cells. The 
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CD4+ T cells secrete IFN-γ and IL-2. IFN-γ activates other resting macrophages, which, in 
turn, release cytokines, such as IL-1β, TNF-α, and free radicals, which are toxic to beta-cells. 
During this process, IL-2 and other cytokines induce the migration of CD8+ peripheral T 
cells to the inflamed islets, perhaps by inducing the expression of a specific homing 
receptor. The precytotoxic CD8+ T cells that bear beta-cell-specific autoantigen receptors 
differentiate into cytotoxic effector T cells upon recognition of the beta-cell-specific peptide 
bound to MHC class I molecules in the presence of beta-cell-specific CD4+ T helper cells. The 
cytotoxic CD8+ T cells then affect beta-cell damage by releasing perforin and granzyme, and 
by Fas-mediated apoptosis. In this way, macrophages, CD4+ T cells, and CD8+ T cells 
synergistically destroy beta-cells, resulting in the onset of autoimmune Type 1 (DM). 
Both direct and indirect killing of beta-cells, mediated by CD8+cytotoxic T cells and 
CD4+helper T cells respectively, are thought to occur by apoptosis following activation of 
caspases, but necrosis also might play some role (Rasche, Busick et al. 2009). Based upon 
animal models, it is now generally believed that multiple effector molecules and pathways 
are involved in beta cell killing. In addition to apoptosis being the main mechanism by 
which beta-cells are destroyed, beta-cell apoptosis has been implicated in the initiation of 
Type 1 (DM) through antigen cross-presentation mechanisms that lead to beta-cell-specific T 
cell activation (The term cross-presentation denotes the ability of certain antigen-presenting 
cells to take up, process and present extracellular antigens with MHC class I molecules to 
CD8+cytotoxic T cells). In mammals, there are 14 caspases, of which many participate in the 
apoptotic pathways. Caspase-3 is the major effector caspase involved in apoptotic pathways. 
Caspase-3 knockout mice were protected from developing diabetes in autoimmune diabetes 
model. 
As explained before, autoantibodies have turned out to be excellent diagnostic and 
predictive markers for Type 1 (DM). However, it is generally thought that they play only a 
minor role, if any, in the actual pathogenesis of the disease. Instead, the cell-mediated 
immune response is believed to be responsible for beta-cell killing as explained above. 
Inflammatory cells are found in and around the pancreatic islets. However, human studies 
show that in some individuals these inflammatory cells are present for years without clinical 
symptoms. In fact, some individuals with autoantibodies and insulitis do not go on to 
develop clinical disease. The outcome appears to be related to the amount of beta-cell 
destruction. It is estimated from animal studies that between 80 and 90% of the beta-cells 
must be destroyed before the diabetes becomes clinically apparent. In humans, however, 
the temporal and quantitative relationships between inflammatory cells, beta-cell damage, 
and clinical diabetes have been difficult to determine because pancreatic biopsies are not 
easy to be performed. Finally, much of our information about cell-mediated immune 
pathogenesis and beta-cell killing comes from animal models. These animals 
spontaneously develop an autoimmune disease similar, although not identical, to human 
autoimmune Type 1 (DM). 
The possible dysregulation of Regulatory T cells (Treg) suppressor activity is shown to 
association to Type 1 (DM) as well. 
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3.5. Immunoregulatory problems underlie loss to beta-cell tolerance 
Regulatory CD4+ T-cells (Treg), whose development and function is dictated by the Foxp3 
gene in mice and humans have the primary function of pouring a cold shower on 
inflammatory responses. They suppress and regulate the function of various immune 
responses to microbes, tumors, allergens and transplants (Sakaguchi, Setoguchi et al. 2006). 
It is suspected that defects in Treg number and activity are causally related to the 
development of Type 1 (DM). It is likely, that certain genetic predispositions, coupled with 
the possible contribution of external environmental factors or infections, could potentially 
alter regulatory T-cell function in susceptible individuals and trigger a full-scale diabetic 
autoimmune reaction in the pancreas.  
Many studies have implicated Treg cells in the control of diabetes onset and progression, 
and that reduced Foxp3+ Treg cell frequencies or functions in NOD mice, represent a 
primary predisposing factor to diabetes. Whether thymic development of Treg cells is 
normal in NOD mice has been a contentious issue. Recent studies show that thymic 
development of Treg cells seems to be normal, as thymectomy in NOD mice up to 3 weeks 
of age results in exacerbated Type 1 (DM) due to a marked reduction in Treg cells 
(Dardenne, Lepault et al. 1989). Surprisingly, the NOD background proved superior in 
generating Treg cells in the thymus relative to non-autoimmune prone strain C57/BL6, 
suggesting that central tolerance mechanisms are intact. Furthermore, the frequency and 
function of single-positive Foxp3+ Treg cells in the thymus of NOD was comparable to 
diabetes-resistant C57/BL6 mice (Tritt, Sgouroudis et al. 2008). 
It is believed that regulatory T cells may represent a kind of master switch, and by 
understanding how they are made, how they function and how they survive, we may be 
able to stop disease from occurring. The use of beta-cell specific Tregs is also leading to a 
tissue specific immunotolerance without perturbing the general immunocompetence. If 
subsequent studies show that Tregs represent a safe and efficient source for therapy, they 
could become an important weapon in the fight against immune mediated pathology. 
4. Triggers of autoimmune cascade 
A critical question, independent of the mechanism by which the immune response kills 
beta-cells, is what actually triggers the autoimmune cascade. Immunologic, genetic, and 
environmental factors have been implicated. Normally an individual’s T lymphocytes are 
immunologically anergic or tolerant to self-antigens. T lymphocyte education and selection 
takes place in the thymus. T cells that do not receive a signal from an HLA-autoantigen 
complex die by neglect. T cells that receive a signal from an HLA-autoantigen complex that 
is too strong die by apoptosis. However, T cells that receive a weak, low affinity signal from 
an HLA-autoantigen complex are positively selected. These positively selected autoantigen-
specific T cells, generally present in very low numbers, escape from the thymus and migrate 
to peripheral organs throughout the body including the pancreas. Under ordinary 
circumstances they remain dormant and are kept under strict regulatory control by still 
poorly defined regulatory mechanisms (e.g. CD4+CD25+Foxp3+ Regulatory T cells or other 
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regulatory pathway). If, however, these antigen-specific T cells come in contact with cognate 
autoantigens presented by beta-cells or APCs, through MHC-I and MHC-II respectively, in 
the pancreas and if the regulatory controls fail, these dormant, antigen-specific T cells will 
be activated and the autoimmune cascade of beta-cell killing will be initiated. Thus, immune 
dysregulation may serve as one of the triggers for autoimmunity. Genetic and 
environmental factors have been implicated as possible initiating triggers. The fact that in 
identical twins the concordance rate for Type 1 (DM) is less than 50% argues for genetic 
predisposition upon which an environmental insult is superimposed. More than 20 putative 
diabetes predisposing genes have been identified, but most of them have only a weak 
association, and in many cases the association has been difficult to confirm. The one 
exception is the HLA genes, which are thought to contribute as much as 50% of the genetic 
risk for Type 1 (DM) (Noble, Valdes et al. 2010). Although HLA genes may be necessary, by 
themselves they seem not to be sufficient to produce the disease. From a genetic point of 
view, all the evidence points to Type 1 (DM) as a complex disease involving a combination 
of several different genes. However, it may be that there is no specific “diabetes” gene(s). 
Instead, there may be the “wrong combination” of perfectly normal genes (i.e. alleles, 
haplotypes) that regulate, at the level of the beta-cell, processes such as apoptosis or antigen 
processing and presentation which, in turn, may trigger an autoimmune response.Various 
environmental triggers, e.g. certain viruses and dietary factors, are also thought to initiate 
the autoimmune process, leading to the destruction of pancreatic beta-cells and consequent 
Type 1 (DM). The major focus of the following parts is on genetic and environmental factors 
that predispose and triggers the autoimmune cascade.  
4.1 Genetic etiology of Type 1 (DM)  
To date, twelve separate chromosome regions have been implicated in the development of 
human Type 1 (DM). The major disease locus, IDDM1 in the major histocompatibility 
complex (MHC) on chromosome 6p21, accounts for about 35% of the observed familial 
clustering and its contribution to disease susceptibility is likely to involve polymorphic 
residues of class II molecules in T-cell-mediated autoimmunity (Huber, Menconi et al. 2008). 
IDDM2 is encoded by a minisatellite locus embedded in the regulatory region of the insulin 
gene. Familial clustering of disease can be explained by the sharing of alleles of at least 10 
loci. IDDM1 and IDDM2 interact epistatically. For a multifactorial disease, such as Type 1 
(DM), important information concerning the pathways and mechanisms involved can be 
gained from examining such interactions between loci, using methods that simultaneously 
take account of the joint effects of the various underlying genetic components. 
The task of identifying susceptibility genes for complex human traits can be facilitated by 
first mapping susceptibility genes in an experimental species, such as the mouse or rat, and 
then performing mapping studies in humans by examining regions of disease in an animal 
model. However the animal models might not be same as the human susceptibility genes, in 
terms of the number of genes involved, interactions between loci and the physiological 
disease processes. For IDDM, the (NOD) mouse spontaneously develops Type1 (DM) with 
remarkable similarities to the human disorder. Moreover, IDDM1, the major genetic locus 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 34 
3.5. Immunoregulatory problems underlie loss to beta-cell tolerance 
Regulatory CD4+ T-cells (Treg), whose development and function is dictated by the Foxp3 
gene in mice and humans have the primary function of pouring a cold shower on 
inflammatory responses. They suppress and regulate the function of various immune 
responses to microbes, tumors, allergens and transplants (Sakaguchi, Setoguchi et al. 2006). 
It is suspected that defects in Treg number and activity are causally related to the 
development of Type 1 (DM). It is likely, that certain genetic predispositions, coupled with 
the possible contribution of external environmental factors or infections, could potentially 
alter regulatory T-cell function in susceptible individuals and trigger a full-scale diabetic 
autoimmune reaction in the pancreas.  
Many studies have implicated Treg cells in the control of diabetes onset and progression, 
and that reduced Foxp3+ Treg cell frequencies or functions in NOD mice, represent a 
primary predisposing factor to diabetes. Whether thymic development of Treg cells is 
normal in NOD mice has been a contentious issue. Recent studies show that thymic 
development of Treg cells seems to be normal, as thymectomy in NOD mice up to 3 weeks 
of age results in exacerbated Type 1 (DM) due to a marked reduction in Treg cells 
(Dardenne, Lepault et al. 1989). Surprisingly, the NOD background proved superior in 
generating Treg cells in the thymus relative to non-autoimmune prone strain C57/BL6, 
suggesting that central tolerance mechanisms are intact. Furthermore, the frequency and 
function of single-positive Foxp3+ Treg cells in the thymus of NOD was comparable to 
diabetes-resistant C57/BL6 mice (Tritt, Sgouroudis et al. 2008). 
It is believed that regulatory T cells may represent a kind of master switch, and by 
understanding how they are made, how they function and how they survive, we may be 
able to stop disease from occurring. The use of beta-cell specific Tregs is also leading to a 
tissue specific immunotolerance without perturbing the general immunocompetence. If 
subsequent studies show that Tregs represent a safe and efficient source for therapy, they 
could become an important weapon in the fight against immune mediated pathology. 
4. Triggers of autoimmune cascade 
A critical question, independent of the mechanism by which the immune response kills 
beta-cells, is what actually triggers the autoimmune cascade. Immunologic, genetic, and 
environmental factors have been implicated. Normally an individual’s T lymphocytes are 
immunologically anergic or tolerant to self-antigens. T lymphocyte education and selection 
takes place in the thymus. T cells that do not receive a signal from an HLA-autoantigen 
complex die by neglect. T cells that receive a signal from an HLA-autoantigen complex that 
is too strong die by apoptosis. However, T cells that receive a weak, low affinity signal from 
an HLA-autoantigen complex are positively selected. These positively selected autoantigen-
specific T cells, generally present in very low numbers, escape from the thymus and migrate 
to peripheral organs throughout the body including the pancreas. Under ordinary 
circumstances they remain dormant and are kept under strict regulatory control by still 
poorly defined regulatory mechanisms (e.g. CD4+CD25+Foxp3+ Regulatory T cells or other 
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regulatory pathway). If, however, these antigen-specific T cells come in contact with cognate 
autoantigens presented by beta-cells or APCs, through MHC-I and MHC-II respectively, in 
the pancreas and if the regulatory controls fail, these dormant, antigen-specific T cells will 
be activated and the autoimmune cascade of beta-cell killing will be initiated. Thus, immune 
dysregulation may serve as one of the triggers for autoimmunity. Genetic and 
environmental factors have been implicated as possible initiating triggers. The fact that in 
identical twins the concordance rate for Type 1 (DM) is less than 50% argues for genetic 
predisposition upon which an environmental insult is superimposed. More than 20 putative 
diabetes predisposing genes have been identified, but most of them have only a weak 
association, and in many cases the association has been difficult to confirm. The one 
exception is the HLA genes, which are thought to contribute as much as 50% of the genetic 
risk for Type 1 (DM) (Noble, Valdes et al. 2010). Although HLA genes may be necessary, by 
themselves they seem not to be sufficient to produce the disease. From a genetic point of 
view, all the evidence points to Type 1 (DM) as a complex disease involving a combination 
of several different genes. However, it may be that there is no specific “diabetes” gene(s). 
Instead, there may be the “wrong combination” of perfectly normal genes (i.e. alleles, 
haplotypes) that regulate, at the level of the beta-cell, processes such as apoptosis or antigen 
processing and presentation which, in turn, may trigger an autoimmune response.Various 
environmental triggers, e.g. certain viruses and dietary factors, are also thought to initiate 
the autoimmune process, leading to the destruction of pancreatic beta-cells and consequent 
Type 1 (DM). The major focus of the following parts is on genetic and environmental factors 
that predispose and triggers the autoimmune cascade.  
4.1 Genetic etiology of Type 1 (DM)  
To date, twelve separate chromosome regions have been implicated in the development of 
human Type 1 (DM). The major disease locus, IDDM1 in the major histocompatibility 
complex (MHC) on chromosome 6p21, accounts for about 35% of the observed familial 
clustering and its contribution to disease susceptibility is likely to involve polymorphic 
residues of class II molecules in T-cell-mediated autoimmunity (Huber, Menconi et al. 2008). 
IDDM2 is encoded by a minisatellite locus embedded in the regulatory region of the insulin 
gene. Familial clustering of disease can be explained by the sharing of alleles of at least 10 
loci. IDDM1 and IDDM2 interact epistatically. For a multifactorial disease, such as Type 1 
(DM), important information concerning the pathways and mechanisms involved can be 
gained from examining such interactions between loci, using methods that simultaneously 
take account of the joint effects of the various underlying genetic components. 
The task of identifying susceptibility genes for complex human traits can be facilitated by 
first mapping susceptibility genes in an experimental species, such as the mouse or rat, and 
then performing mapping studies in humans by examining regions of disease in an animal 
model. However the animal models might not be same as the human susceptibility genes, in 
terms of the number of genes involved, interactions between loci and the physiological 
disease processes. For IDDM, the (NOD) mouse spontaneously develops Type1 (DM) with 
remarkable similarities to the human disorder. Moreover, IDDM1, the major genetic locus 
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contributing to human IDDM in the MHC has been shown to be conserved between the two 
species of human and murine. A second locus, IDDM7 on chromosome 2q31, is homologous 
to a region containing the NOD locus, Idd5, on chromosome 1 (Copeman, Cucca et al. 1995). 
Thirdly, there is evidence that the gene region encoding the human interleukin 1 (IL-1) on 
chromosome 2q12-q21 is associated and linked to Type 1 (DM). This region would 
correspond to mouse chromosome 2, in which the region encoding IL-1 has also been linked 
to NOD diabetes (Serreze, Prochazka et al. 1994).  
A key issue in the identification of disease susceptibility genes is that of testing association 
versus testing linkage. Only through demonstrating association between specific alleles at a 
disease locus and the disease can the causal role of particular polymorphisms in the 
physiological disease processes be investigated. For mapping of disease loci, however, 
demonstration of linkage and estimation of the recombination fraction between a disease 
locus and known marker loci is required. Having mapped a disease locus to a particular 
chromosome region, the position of the disease locus can be further localized using tests of 
linkage disequilibrium between particular marker alleles and the disease, which assumes a 
founder effect for the ancestral mutation or selection of the mutation in the study 
population. 
The strongest genetic association for Type 1 (DM) is with the HLA class I and II genes, with 
a 30–50% of the genetic risk for progression of the disease. Therefor in the next section the 
contribution of HLA genes predisposing to Type 1 (DM) will be addressed more 
extensively.  
4.1.1. HLA genes predisposing to Type 1 (DM) 
From a genetic point of view, combinations of several different genes are involved in 
predisposition to Type1 (DM), and there is no specific diabetes gene(s). Human Leukocyte 
Antigen (HLA) genes are thought to contribute the massive part of the genetic risk for 
Type1 (DM). In humans, the MHC is known as the HLA complex and contains over 200 
genes. It is located on chromosome 6 and encodes HLA class I and class II molecules. The 
main function of these molecules is to present antigens that have been processed into peptides 
to antigen-specific receptors on CD4 and CD8+T lymphocytes. Class I molecules, expressed on 
most nucleated cells, are encoded by genes within the HLA-A, -B, and -C loci, whereas class II 
molecules, expressed primarily on antigen-presenting cells (e.g. macrophages and dendritic 
cells), are encoded by genes within the HLA-DP, -DQ, and -DR loci.  
HLA class I and II genes are highly polymorphic and consist of many different alleles. In 
type 1 diabetes, certain HLA class II alleles or combinations of alleles (haplotypes) show a 
strong association with the development of diabetes, whereas other haplotypes show a weak 
or even protective association. It is well established that the HLA-DR3 and HLA-DR4 genes 
at the HLA-DR locus on chromosome 6 are strongly associated with increased susceptibility 
to insulin-dependent diabetes (Field and McArthur 1987), and that the predisposition is 
greatest among individuals who possess both of these genes (HLA-DR3/4 heterozygotes). 
Furthermore, individuals with the HLA haplotype DRB1*0302- DQA1*0301, especially when 
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combined with DRB1*0201- DQA1*0501, are highly susceptible (10–20-fold increase) to 
Type1 (DM) (Pociot and McDermott 2002). In contrast, individuals with the haplotype 
DRB1*0602-DQA1*0102 rarely develop type 1 diabetes. Many other high and low risk 
haplotypes have been identified, and the frequency of specific haplotypes differs among 
ethnic groups (Pociot and McDermott 2002). Other genes within the HLA complex, 
particularly class I genes, also have been linked to type 1 diabetes, but the strongest linkage 
by far is with the DQ and DR class II genes. 
Experimental support for the importance of class II genes in the development of diabetes 
comes from a variety of sources including the deletion of specific MHC loci in mice and 
their replacement with human HLA homologs. Although the linkage of HLA class II 
molecules with Type1 (DM) is now well established and the binding of peptides to pockets 
within the groove of the HLA class II molecule understood, why the binding of peptides to 
certain HLA class II molecules, and not to others, is associated with autoimmune Type 1 
(DM) remains unresolved (concerning the fact that CD8+ T cell have the largest contribution 
in the pathogenesis of Type 1 (DM)). Regardless of mechanism, HLA typing has proved 
useful in population screening for identification and follow-up of individuals at high risk for 
disease. 
4.1.2. Non-HLA genes contributing to Type 1 (DM) 
Multiple studies have recently linked Type 1 (DM) to 50 non-HLA gene polymorphisms 
(Pociot and McDermott 2002). Major efforts have therefore been made to identify non-HLA 
genetic risk factors for Type 1 (DM). Interestingly enough, many of the genetic factors are 
important to the function of the immune system. For instance PTPN22 is a regulator of T-cell 
function and a genetic polymorphism results in a phosphatase variant that is increasing the 
risk not only for Type 1 (DM) but also for rheumatoid arthritis, juvenile rheumatoid 
arthritis, systemic lupus erythematosus, Graves’ disease, generalized vitiligo, and other 
human autoimmune diseases (Herr, Dudbridge et al. 2000). The PTPN22 polymorphism 
seems in particular to affect progression from pre-diabetes to clinical disease (Herr, 
Dudbridge et al. 2000) also in individuals with lower risk HLA genotypes. The variable 
nucleotide tandem repeat in the promoter region of the insulin gene INS VNTR seems to 
contribute to Type 1(DM) by the mechanisms of central tolerance (Takase, Yu et al. 2005). In 
newly diagnosed Type 1 (DM) patients the presence of insulin autoantibodies is associated 
with the INS VNTR polymorphism (Takase, Yu et al. 2005).  
The majority of the non-HLA genetic factors seem to be associated with the immune system. 
We have also demonstrated the association of the polymorphism of Th1 type cytokines (IL-
12, IL-18) as well as TGF-β in human patients with Type 1 (DM). It is therefore attractive to 
speculate that their contribution is related to the ability of the immune system to mount an 
autoimmune reaction specifically directed toward the islet beta-cells. 
The existence of genes predisposing to Type 1 (DM) in the region of the insulin (INS) gene 
now also established. Association analysis has demonstrated an increased frequency of class 
1 alleles of the 5' INS polymorphism in diabetics compared with controls. Interestingly, the 
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contributing to human IDDM in the MHC has been shown to be conserved between the two 
species of human and murine. A second locus, IDDM7 on chromosome 2q31, is homologous 
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A key issue in the identification of disease susceptibility genes is that of testing association 
versus testing linkage. Only through demonstrating association between specific alleles at a 
disease locus and the disease can the causal role of particular polymorphisms in the 
physiological disease processes be investigated. For mapping of disease loci, however, 
demonstration of linkage and estimation of the recombination fraction between a disease 
locus and known marker loci is required. Having mapped a disease locus to a particular 
chromosome region, the position of the disease locus can be further localized using tests of 
linkage disequilibrium between particular marker alleles and the disease, which assumes a 
founder effect for the ancestral mutation or selection of the mutation in the study 
population. 
The strongest genetic association for Type 1 (DM) is with the HLA class I and II genes, with 
a 30–50% of the genetic risk for progression of the disease. Therefor in the next section the 
contribution of HLA genes predisposing to Type 1 (DM) will be addressed more 
extensively.  
4.1.1. HLA genes predisposing to Type 1 (DM) 
From a genetic point of view, combinations of several different genes are involved in 
predisposition to Type1 (DM), and there is no specific diabetes gene(s). Human Leukocyte 
Antigen (HLA) genes are thought to contribute the massive part of the genetic risk for 
Type1 (DM). In humans, the MHC is known as the HLA complex and contains over 200 
genes. It is located on chromosome 6 and encodes HLA class I and class II molecules. The 
main function of these molecules is to present antigens that have been processed into peptides 
to antigen-specific receptors on CD4 and CD8+T lymphocytes. Class I molecules, expressed on 
most nucleated cells, are encoded by genes within the HLA-A, -B, and -C loci, whereas class II 
molecules, expressed primarily on antigen-presenting cells (e.g. macrophages and dendritic 
cells), are encoded by genes within the HLA-DP, -DQ, and -DR loci.  
HLA class I and II genes are highly polymorphic and consist of many different alleles. In 
type 1 diabetes, certain HLA class II alleles or combinations of alleles (haplotypes) show a 
strong association with the development of diabetes, whereas other haplotypes show a weak 
or even protective association. It is well established that the HLA-DR3 and HLA-DR4 genes 
at the HLA-DR locus on chromosome 6 are strongly associated with increased susceptibility 
to insulin-dependent diabetes (Field and McArthur 1987), and that the predisposition is 
greatest among individuals who possess both of these genes (HLA-DR3/4 heterozygotes). 
Furthermore, individuals with the HLA haplotype DRB1*0302- DQA1*0301, especially when 
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combined with DRB1*0201- DQA1*0501, are highly susceptible (10–20-fold increase) to 
Type1 (DM) (Pociot and McDermott 2002). In contrast, individuals with the haplotype 
DRB1*0602-DQA1*0102 rarely develop type 1 diabetes. Many other high and low risk 
haplotypes have been identified, and the frequency of specific haplotypes differs among 
ethnic groups (Pociot and McDermott 2002). Other genes within the HLA complex, 
particularly class I genes, also have been linked to type 1 diabetes, but the strongest linkage 
by far is with the DQ and DR class II genes. 
Experimental support for the importance of class II genes in the development of diabetes 
comes from a variety of sources including the deletion of specific MHC loci in mice and 
their replacement with human HLA homologs. Although the linkage of HLA class II 
molecules with Type1 (DM) is now well established and the binding of peptides to pockets 
within the groove of the HLA class II molecule understood, why the binding of peptides to 
certain HLA class II molecules, and not to others, is associated with autoimmune Type 1 
(DM) remains unresolved (concerning the fact that CD8+ T cell have the largest contribution 
in the pathogenesis of Type 1 (DM)). Regardless of mechanism, HLA typing has proved 
useful in population screening for identification and follow-up of individuals at high risk for 
disease. 
4.1.2. Non-HLA genes contributing to Type 1 (DM) 
Multiple studies have recently linked Type 1 (DM) to 50 non-HLA gene polymorphisms 
(Pociot and McDermott 2002). Major efforts have therefore been made to identify non-HLA 
genetic risk factors for Type 1 (DM). Interestingly enough, many of the genetic factors are 
important to the function of the immune system. For instance PTPN22 is a regulator of T-cell 
function and a genetic polymorphism results in a phosphatase variant that is increasing the 
risk not only for Type 1 (DM) but also for rheumatoid arthritis, juvenile rheumatoid 
arthritis, systemic lupus erythematosus, Graves’ disease, generalized vitiligo, and other 
human autoimmune diseases (Herr, Dudbridge et al. 2000). The PTPN22 polymorphism 
seems in particular to affect progression from pre-diabetes to clinical disease (Herr, 
Dudbridge et al. 2000) also in individuals with lower risk HLA genotypes. The variable 
nucleotide tandem repeat in the promoter region of the insulin gene INS VNTR seems to 
contribute to Type 1(DM) by the mechanisms of central tolerance (Takase, Yu et al. 2005). In 
newly diagnosed Type 1 (DM) patients the presence of insulin autoantibodies is associated 
with the INS VNTR polymorphism (Takase, Yu et al. 2005).  
The majority of the non-HLA genetic factors seem to be associated with the immune system. 
We have also demonstrated the association of the polymorphism of Th1 type cytokines (IL-
12, IL-18) as well as TGF-β in human patients with Type 1 (DM). It is therefore attractive to 
speculate that their contribution is related to the ability of the immune system to mount an 
autoimmune reaction specifically directed toward the islet beta-cells. 
The existence of genes predisposing to Type 1 (DM) in the region of the insulin (INS) gene 
now also established. Association analysis has demonstrated an increased frequency of class 
1 alleles of the 5' INS polymorphism in diabetics compared with controls. Interestingly, the 
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effect of INS region susceptibility on Type 1 (DM) cannot be detected by linkage analysis, 
suggesting that if a genetic marker locus is close to a disease susceptibility locus, association 
analysis may be a more sensitive method than linkage analysis for detecting the 
susceptibility locus.  
4.2. Potential environmental triggers of beta-cell autoimmunity in Type 1 (DM) 
The clinical presentation of type 1 diabetes is preceded by an asymptomatic period of highly 
variable duration. Aggressive beta-cell destruction may lead to disease manifestation within 
a few months in infants and young children, whereas in other individuals, the process may 
continue for years (in some cases, even for >10 years) before the eventual presentation of 
overt disease. 
Several lines of evidence support a critical role of exogenous factors in the pathogenesis of 
Type 1 (DM). Studies in monozygotic twins indicate that only 13–33% are pairwise 
concordant for Type 1 (DM) (Barnett, Eff et al. 1981), suggesting that there is either acquired 
postconceptional genetic discordance or differential exposure to the putative environmental 
factor(s). The geographic variation in the incidence of Type 1 (DM) in children is 
conspicuous. This difference in incidence can hardly be explained by genetic factors. A 
substantial increase in the incidence of Type 1 (DM) among children has been documented 
over the last decades, particularly in Europe—for example, in Finland, the incidence has 
increased 4.5-fold from the early 1950s (Gale 2002). Such an increase cannot be the 
consequence only of enhanced genetic disease susceptibility in the population but must 
mostly be due to changes in lifestyle and environment. As well, available data indicate that 
the incidence of Type 1 (DM) has increased in population groups who have moved from a 
low-incidence region to a high-incidence area, emphasizing the influence of environmental 
conditions (Akerblom and Knip 1998). Accumulating evidence suggests that the proportion 
of subjects with high-risk HLA genotypes has decreased over the last decades among 
patients with newly diagnosed type 1 diabetes, whereas the proportion of people with low-
risk or even protective HLA genotypes has increased (Resic-Lindehammer, Larsson et al. 
2008). These data are compatible with an increased environmental pressure resulting in 
progression to clinical diabetes with less genetic susceptibility.  
As mentioned earlier, the first signs of beta-cell autoimmunity and the autoantibodies may 
appear very early in life. Many studies have revealed that there is an unequivocal temporal 
variation in the appearance of the diabetes-associated autoantibodies reflecting the initiation 
of the disease process and paralleling the seasonal variation. Most initial autoantibodies 
appear during the cold period in the fall and winter but rarely in the spring or in the 
summer. There also seems to be some variation from one year to another in the timing and 
height of the autoantibody peaks. 
The pattern of the autoantibody appearance strongly points to the role of infectious agents 
with conspicuous seasonal variation as triggers of beta-cell autoimmunity. Such variations are 
typical for viral infections, and the pattern of laboratory-confirmed enterovirus infections. In 
addition to viral infections, one should also consider other environmental variables with 
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seasonal variation. There is definitely seasonal variation in the amount of daylight and 
sunshine hours, especially in Northern Europe, which has the highest incidence of Type 1 
(DM) in the world (Moltchanova, Penttinen et al. 2005). Without oral substitution, the sunlight-
dependent synthesis of vitamin D in the skin is the most important source of this 
immunologically active hormone. Some studies have indicated that the lack of oral vitamin D 
substitution in infancy increases the subsequent risk of type 1 diabetes. Also improved insulin 
sensitivity in the spring and summer because of more physical exercise can be taken into 
account as well. Improved insulin sensitivity diminishes beta-cell stress, as the workload on 
the beta-cells decreases. However, it is unlikely that there should be substantial seasonal 
variation in physical exercise in very young children, the target group in whom the seasonal 
variation in the appearance of the first diabetes-associated autoantibodies has been observed.  
Accordingly, we are left with viral infections as the most likely explanation for the seasonal 
variation in the emergence of the first signs of beta-cell autoimmunity. Taken into account 
the timing and profiles of the autoantibody peaks, such as enterovirus infections, appear to 
be the most probable trigger of beta-cell autoimmunity. The frequency of enterovirus 
infections has decreased over the last decades in the background population in developed 
countries, e.g., in Finland and Sweden (Viskari, Ludvigsson et al. 2005). Despite that, these 
countries have a high and increasing incidence of Type 1 (DM) among children. This 
appears to be paradoxical. The paradox can, however, be explained by the so-called “polio 
hypothesis” introduced by Viskari et al (Viskari, Koskela et al. 2000). The polioviruses 
comprise three serotypes among >60 enterovirus serotypes. When the frequency of acute 
poliovirus infections started to decrease at the beginning of the last century among the 
general population in countries with an increasing standard of hygiene, the incidence of 
paralytic polio being a complication of the acute infection began to increase. This was 
obviously the consequence of decreased levels of protective maternal poliovirus antibodies 
transferred transplacentally and through breast milk to the infant, leading to a situation 
where the risk increased that the infant would get his or her first poliovirus infection at the 
time of no maternal protection. Similarly, the decreasing frequency of enterovirus infections 
in the background population would increase the susceptibility of young children to the 
diabetogenic effect of enteroviruses. The same phenomenon may also contribute to the 
marked international variation in Type 1 (DM) incidence, because enterovirus infections 
seem to be rare in countries where the rate of type 1 diabetes is high. 
The tropism phenomenon (the characteristic of a virus to infect a particular tissue or cell 
type), in which the attachment of the virus to the viral receptors on the cell surface together 
with other interactions with cellular proteins is a central feature, is thought to explain why 
some variants of enteroviruses may be diabetogenic and others not. It has been proposed 
that pancreatic beta-cell tropic variants of the coxsackie B virus are present in the general 
population and that they are able to induce beta-cell damage in susceptible individuals. In 
vitro studies have shown that enteroviruses infect beta-cells easily and induce functional 
impairment and cell death (Roivainen, Rasilainen et al. 2000). 
Taken together, accumulated data support the hypothesis that a diabetogenic enterovirus 
infection is the likely trigger of beta-cell autoimmunity. This is supported by the observed 
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effect of INS region susceptibility on Type 1 (DM) cannot be detected by linkage analysis, 
suggesting that if a genetic marker locus is close to a disease susceptibility locus, association 
analysis may be a more sensitive method than linkage analysis for detecting the 
susceptibility locus.  
4.2. Potential environmental triggers of beta-cell autoimmunity in Type 1 (DM) 
The clinical presentation of type 1 diabetes is preceded by an asymptomatic period of highly 
variable duration. Aggressive beta-cell destruction may lead to disease manifestation within 
a few months in infants and young children, whereas in other individuals, the process may 
continue for years (in some cases, even for >10 years) before the eventual presentation of 
overt disease. 
Several lines of evidence support a critical role of exogenous factors in the pathogenesis of 
Type 1 (DM). Studies in monozygotic twins indicate that only 13–33% are pairwise 
concordant for Type 1 (DM) (Barnett, Eff et al. 1981), suggesting that there is either acquired 
postconceptional genetic discordance or differential exposure to the putative environmental 
factor(s). The geographic variation in the incidence of Type 1 (DM) in children is 
conspicuous. This difference in incidence can hardly be explained by genetic factors. A 
substantial increase in the incidence of Type 1 (DM) among children has been documented 
over the last decades, particularly in Europe—for example, in Finland, the incidence has 
increased 4.5-fold from the early 1950s (Gale 2002). Such an increase cannot be the 
consequence only of enhanced genetic disease susceptibility in the population but must 
mostly be due to changes in lifestyle and environment. As well, available data indicate that 
the incidence of Type 1 (DM) has increased in population groups who have moved from a 
low-incidence region to a high-incidence area, emphasizing the influence of environmental 
conditions (Akerblom and Knip 1998). Accumulating evidence suggests that the proportion 
of subjects with high-risk HLA genotypes has decreased over the last decades among 
patients with newly diagnosed type 1 diabetes, whereas the proportion of people with low-
risk or even protective HLA genotypes has increased (Resic-Lindehammer, Larsson et al. 
2008). These data are compatible with an increased environmental pressure resulting in 
progression to clinical diabetes with less genetic susceptibility.  
As mentioned earlier, the first signs of beta-cell autoimmunity and the autoantibodies may 
appear very early in life. Many studies have revealed that there is an unequivocal temporal 
variation in the appearance of the diabetes-associated autoantibodies reflecting the initiation 
of the disease process and paralleling the seasonal variation. Most initial autoantibodies 
appear during the cold period in the fall and winter but rarely in the spring or in the 
summer. There also seems to be some variation from one year to another in the timing and 
height of the autoantibody peaks. 
The pattern of the autoantibody appearance strongly points to the role of infectious agents 
with conspicuous seasonal variation as triggers of beta-cell autoimmunity. Such variations are 
typical for viral infections, and the pattern of laboratory-confirmed enterovirus infections. In 
addition to viral infections, one should also consider other environmental variables with 
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seasonal variation. There is definitely seasonal variation in the amount of daylight and 
sunshine hours, especially in Northern Europe, which has the highest incidence of Type 1 
(DM) in the world (Moltchanova, Penttinen et al. 2005). Without oral substitution, the sunlight-
dependent synthesis of vitamin D in the skin is the most important source of this 
immunologically active hormone. Some studies have indicated that the lack of oral vitamin D 
substitution in infancy increases the subsequent risk of type 1 diabetes. Also improved insulin 
sensitivity in the spring and summer because of more physical exercise can be taken into 
account as well. Improved insulin sensitivity diminishes beta-cell stress, as the workload on 
the beta-cells decreases. However, it is unlikely that there should be substantial seasonal 
variation in physical exercise in very young children, the target group in whom the seasonal 
variation in the appearance of the first diabetes-associated autoantibodies has been observed.  
Accordingly, we are left with viral infections as the most likely explanation for the seasonal 
variation in the emergence of the first signs of beta-cell autoimmunity. Taken into account 
the timing and profiles of the autoantibody peaks, such as enterovirus infections, appear to 
be the most probable trigger of beta-cell autoimmunity. The frequency of enterovirus 
infections has decreased over the last decades in the background population in developed 
countries, e.g., in Finland and Sweden (Viskari, Ludvigsson et al. 2005). Despite that, these 
countries have a high and increasing incidence of Type 1 (DM) among children. This 
appears to be paradoxical. The paradox can, however, be explained by the so-called “polio 
hypothesis” introduced by Viskari et al (Viskari, Koskela et al. 2000). The polioviruses 
comprise three serotypes among >60 enterovirus serotypes. When the frequency of acute 
poliovirus infections started to decrease at the beginning of the last century among the 
general population in countries with an increasing standard of hygiene, the incidence of 
paralytic polio being a complication of the acute infection began to increase. This was 
obviously the consequence of decreased levels of protective maternal poliovirus antibodies 
transferred transplacentally and through breast milk to the infant, leading to a situation 
where the risk increased that the infant would get his or her first poliovirus infection at the 
time of no maternal protection. Similarly, the decreasing frequency of enterovirus infections 
in the background population would increase the susceptibility of young children to the 
diabetogenic effect of enteroviruses. The same phenomenon may also contribute to the 
marked international variation in Type 1 (DM) incidence, because enterovirus infections 
seem to be rare in countries where the rate of type 1 diabetes is high. 
The tropism phenomenon (the characteristic of a virus to infect a particular tissue or cell 
type), in which the attachment of the virus to the viral receptors on the cell surface together 
with other interactions with cellular proteins is a central feature, is thought to explain why 
some variants of enteroviruses may be diabetogenic and others not. It has been proposed 
that pancreatic beta-cell tropic variants of the coxsackie B virus are present in the general 
population and that they are able to induce beta-cell damage in susceptible individuals. In 
vitro studies have shown that enteroviruses infect beta-cells easily and induce functional 
impairment and cell death (Roivainen, Rasilainen et al. 2000). 
Taken together, accumulated data support the hypothesis that a diabetogenic enterovirus 
infection is the likely trigger of beta-cell autoimmunity. This is supported by the observed 
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temporal variation in the appearance of the first diabetes-associated autoantibodies in 
young children, the profile of which resembles the temporal profile of enterovirus infections 
in the background population.  
Some other viruses, such as encephalomyocarditis virus, act directly by replicating in and 
destroying pancreatic beta-cells. A single amino acid substitution in the virus, presumably 
by altering its binding to beta-cells, determines whether or not diabetes develops. The 
Kilham rat virus, on the other hand, produces diabetes not by infecting beta-cells but by 
altering the immunoregulatory network of the host (Herr, Dudbridge et al. 2000). Still other 
viruses are thought to initiate or accelerate the autoimmune response through molecular 
mimicry (Copeman, Cucca et al. 1995) or by releasing sequestrated autoantigens from 
damaged beta-cells. In a transgenic autoimmune model (Serreze, Prochazka et al. 1994), the 
administration of infectious lymphocytic choriomeningitis virus (LCM) to transgenic 
animals expressing LCM viral proteins in their beta-cells results in diabetes, but the same 
LCM virus does not produce diabetes in non-transgenic animals.  
A recent study has also found evidence of Coxsackie virus infection in beta-cells in three out 
of six pancreases of patients with recent-onset Type 1 (DM). Coxsackie viruses are known to 
induce interferon alpha secretion by beta-cells and this could initiate the sequence of events 
that culminates in their autoimmune destruction. 
In summary of this part, Type 1 (DM) may be triggered by an environmental culprit at any 
age, although a majority of the processes appear to start early in childhood. Viruses have 
been the leading candidates. In animal experiments viruses have been shown to produce 
diabetes as well. In humans, case reports and sero-epidemiologic studies (Herr, Dudbridge 
et al. 2000) suggest that viruses, particularly enteroviruses, may play a role, but most likely 
as a cofactor, in individuals who already have suffered some autoimmune beta-cell loss. 
However, for the vast majority of the cases of Type 1 (DM) in humans, a viral cause has not 
been established. 
The identification of exogenous factors triggering and driving beta-cell destruction offers 
potential means for intervention aimed at the prevention of Type 1 (DM). Therefore, it is 
important to pursue studies on the role of environmental factors in the pathogenesis of this 
disease. Environmental modification is likely to offer the most powerful strategy for 
effective prevention of Type 1 (DM), since such an approach can target the whole 
population or at least that proportion of the population carrying increased genetic disease 
susceptibility and would therefore prevent both sporadic and familial type 1 diabetes if 
successful. 
5. Therapeutic interventions 
Before the isolation of insulin in the 1920s, most patients died within a short time after onset 
of Type 1 (DM). Untreated diabetes leads to ketoacidosis, the accumulation of ketones 
(products of fat breakdown) and acid in the blood. Continued buildup of these products of 
disordered carbohydrate and fat metabolism result in nausea and vomiting, and eventually 
the patient goes into a diabetic coma. 
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Treatment for diabetes mellitus is aimed at reducing blood glucose concentrations to normal 
levels. Achieving this is important in promoting well-being and in minimizing the 
development and progression of the long-term complications of diabetes. Despite the 
widespread use of exogenous insulin, morbidity and mortality caused by Type 1 (DM) 
continue to place a significant burden on society, both in terms of human suffering and cost. 
The care of diabetes on self-management is based on the patient’s clinical status and his/her 
ability to participate in self-care. Insulin replacement therapy is the mainstay for patients 
with Type 1 (DM) while diet and lifestyle modifications are also crucial for the treatment 
and management of this disease.  
Diabetics who are unable to produce insulin in their bodies receive regular injections of the 
insulin, which are often customized according to their individual and variable requirements. 
Beef or pork insulin, made from the pancreatic extracts of cattle or pigs, can be used to treat 
humans with diabetes. However, in the United States, beef and pork forms of insulin are no 
longer manufactured, having been discontinued in favor of human insulin production. 
Modern human insulin treatments are based on recombinant DNA technology. Human 
insulin may be given as a form that is identical to the natural form found in the body, which 
acts quickly but transiently, or as a form that has been biochemically modified so as to 
prolong its action for up to 24 hours. The optimal regimen of insulin administration is one 
that most closely mimics the normal pattern of insulin secretion, which is a constant low 
level of insulin secretion plus a pulse of secretion after each meal. This can be achieved by 
administration of a long-acting insulin preparation once daily plus administration of a 
rapid-acting insulin preparation with or just before each meal. Patients also have the option 
of using an insulin pump, which allows them to control variations in the rate of insulin 
administration. A satisfactory compromise for some patients is twice-daily administration of 
mixtures of intermediate-acting and short-acting insulin. Patients taking insulin also may 
need to vary food intake from meal to meal, according to their level of activity; as exercise 
frequency and intensity increase, less insulin and more food intake may be necessary. 
There are also several classes of oral drugs used to control blood glucose levels, including 
sulfonylureas, biguanides, and thiazolidinediones. Sulfonylureas, such as glipizide and 
glimepiride, are considered hypoglycemic agents because they stimulate the release of 
insulin from beta-cells in the pancreas, thus reducing blood glucose levels (Pernet, Trimble 
et al. 1985). The most common side effect associated with sulfonylureas is hypoglycemia 
(abnormally low blood glucose levels), which occurs most often in elderly patients who 
have impaired liver or kidney function. 
Biguanides, of which metformin is the primary member, are considered antihyperglycemic 
agents because they work by decreasing the production of glucose in the liver and by 
increasing the action of insulin on muscle and adipose tissues (Spaans, Kleefstra et al. 2011). 
A potentially fatal side effect of metformin is the accumulation of lactic acid in blood and 
tissues, often causing vague symptoms such as nausea and weakness. 
Thiazolidinediones, such as rosiglitazone and pioglitazone, act by reducing insulin 
resistance of muscle and adipose cells and by increasing glucose transport into these tissues 
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temporal variation in the appearance of the first diabetes-associated autoantibodies in 
young children, the profile of which resembles the temporal profile of enterovirus infections 
in the background population.  
Some other viruses, such as encephalomyocarditis virus, act directly by replicating in and 
destroying pancreatic beta-cells. A single amino acid substitution in the virus, presumably 
by altering its binding to beta-cells, determines whether or not diabetes develops. The 
Kilham rat virus, on the other hand, produces diabetes not by infecting beta-cells but by 
altering the immunoregulatory network of the host (Herr, Dudbridge et al. 2000). Still other 
viruses are thought to initiate or accelerate the autoimmune response through molecular 
mimicry (Copeman, Cucca et al. 1995) or by releasing sequestrated autoantigens from 
damaged beta-cells. In a transgenic autoimmune model (Serreze, Prochazka et al. 1994), the 
administration of infectious lymphocytic choriomeningitis virus (LCM) to transgenic 
animals expressing LCM viral proteins in their beta-cells results in diabetes, but the same 
LCM virus does not produce diabetes in non-transgenic animals.  
A recent study has also found evidence of Coxsackie virus infection in beta-cells in three out 
of six pancreases of patients with recent-onset Type 1 (DM). Coxsackie viruses are known to 
induce interferon alpha secretion by beta-cells and this could initiate the sequence of events 
that culminates in their autoimmune destruction. 
In summary of this part, Type 1 (DM) may be triggered by an environmental culprit at any 
age, although a majority of the processes appear to start early in childhood. Viruses have 
been the leading candidates. In animal experiments viruses have been shown to produce 
diabetes as well. In humans, case reports and sero-epidemiologic studies (Herr, Dudbridge 
et al. 2000) suggest that viruses, particularly enteroviruses, may play a role, but most likely 
as a cofactor, in individuals who already have suffered some autoimmune beta-cell loss. 
However, for the vast majority of the cases of Type 1 (DM) in humans, a viral cause has not 
been established. 
The identification of exogenous factors triggering and driving beta-cell destruction offers 
potential means for intervention aimed at the prevention of Type 1 (DM). Therefore, it is 
important to pursue studies on the role of environmental factors in the pathogenesis of this 
disease. Environmental modification is likely to offer the most powerful strategy for 
effective prevention of Type 1 (DM), since such an approach can target the whole 
population or at least that proportion of the population carrying increased genetic disease 
susceptibility and would therefore prevent both sporadic and familial type 1 diabetes if 
successful. 
5. Therapeutic interventions 
Before the isolation of insulin in the 1920s, most patients died within a short time after onset 
of Type 1 (DM). Untreated diabetes leads to ketoacidosis, the accumulation of ketones 
(products of fat breakdown) and acid in the blood. Continued buildup of these products of 
disordered carbohydrate and fat metabolism result in nausea and vomiting, and eventually 
the patient goes into a diabetic coma. 
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Treatment for diabetes mellitus is aimed at reducing blood glucose concentrations to normal 
levels. Achieving this is important in promoting well-being and in minimizing the 
development and progression of the long-term complications of diabetes. Despite the 
widespread use of exogenous insulin, morbidity and mortality caused by Type 1 (DM) 
continue to place a significant burden on society, both in terms of human suffering and cost. 
The care of diabetes on self-management is based on the patient’s clinical status and his/her 
ability to participate in self-care. Insulin replacement therapy is the mainstay for patients 
with Type 1 (DM) while diet and lifestyle modifications are also crucial for the treatment 
and management of this disease.  
Diabetics who are unable to produce insulin in their bodies receive regular injections of the 
insulin, which are often customized according to their individual and variable requirements. 
Beef or pork insulin, made from the pancreatic extracts of cattle or pigs, can be used to treat 
humans with diabetes. However, in the United States, beef and pork forms of insulin are no 
longer manufactured, having been discontinued in favor of human insulin production. 
Modern human insulin treatments are based on recombinant DNA technology. Human 
insulin may be given as a form that is identical to the natural form found in the body, which 
acts quickly but transiently, or as a form that has been biochemically modified so as to 
prolong its action for up to 24 hours. The optimal regimen of insulin administration is one 
that most closely mimics the normal pattern of insulin secretion, which is a constant low 
level of insulin secretion plus a pulse of secretion after each meal. This can be achieved by 
administration of a long-acting insulin preparation once daily plus administration of a 
rapid-acting insulin preparation with or just before each meal. Patients also have the option 
of using an insulin pump, which allows them to control variations in the rate of insulin 
administration. A satisfactory compromise for some patients is twice-daily administration of 
mixtures of intermediate-acting and short-acting insulin. Patients taking insulin also may 
need to vary food intake from meal to meal, according to their level of activity; as exercise 
frequency and intensity increase, less insulin and more food intake may be necessary. 
There are also several classes of oral drugs used to control blood glucose levels, including 
sulfonylureas, biguanides, and thiazolidinediones. Sulfonylureas, such as glipizide and 
glimepiride, are considered hypoglycemic agents because they stimulate the release of 
insulin from beta-cells in the pancreas, thus reducing blood glucose levels (Pernet, Trimble 
et al. 1985). The most common side effect associated with sulfonylureas is hypoglycemia 
(abnormally low blood glucose levels), which occurs most often in elderly patients who 
have impaired liver or kidney function. 
Biguanides, of which metformin is the primary member, are considered antihyperglycemic 
agents because they work by decreasing the production of glucose in the liver and by 
increasing the action of insulin on muscle and adipose tissues (Spaans, Kleefstra et al. 2011). 
A potentially fatal side effect of metformin is the accumulation of lactic acid in blood and 
tissues, often causing vague symptoms such as nausea and weakness. 
Thiazolidinediones, such as rosiglitazone and pioglitazone, act by reducing insulin 
resistance of muscle and adipose cells and by increasing glucose transport into these tissues 
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(Garg 2011). These agents can cause edema (fluid accumulation in tissues), liver toxicity, and 
adverse cardiovascular events in certain patients. Furthermore, oral hypoglycemic agents 
lower mean blood glucose concentrations by only about 50–80 mg per 100 ml (2.8–4.4 
mmol/l), and sensitivity to these drugs tends to decrease with time(Garg 2011). 
There are several other agents that can be highly effective in the treatment of diabetes. 
Pramlintide is an injectable synthetic hormone (based on the human hormone amylin) that 
regulates blood glucose levels by slowing the absorption of food in the stomach and by 
inhibiting glucagon, which normally stimulates liver glucose production(Riddle and 
Drucker 2006). Exenatide is an injectable antihyperglycemic drug that works similarly to 
incretins, or gastrointestinal hormones, such as gastric inhibitory polypeptide, that stimulate 
insulin release from the pancreas. Exenatide has a longer duration of action than incretins 
produced by the body because it is less susceptible to degradation by an enzyme called 
dipeptidyl peptidase-4 (DPP-4)(Sena, Nunes et al. 2008). A drug called sitagliptin 
specifically inhibits DPP-4, thereby increasing levels of naturally produced incretins. Side 
effects associated with these drugs are often mild, although pramlintide can cause profound 
hypoglycemia in patients with Type 1 (DM). 
All patients with diabetes mellitus, particularly those taking insulin, should measure blood 
glucose concentrations periodically at home, especially when they have symptoms of 
hypoglycemia. Diet and lifestyle strategies also are required to reduce weight, improve 
glycaemic control and reduce the risk of cardiovascular complications, which account for 
70% to 80% of deaths among those with diabetes.  
Research into other areas of insulin therapy includes pancreas transplantation, beta-cell 
transplantation, and generation of beta-cells from existing exocrine cells in the pancreas. 
Patients with Type I (DM) have been treated by transplantation of the pancreas or of the 
islets of Langerhans. However, limited quantities of pancreatic tissue are available for 
transplantation, prolonged immunosuppressive therapy is needed, and there is a high 
likelihood that the transplanted tissue be rejected even when the patient is receiving 
immunosuppressive therapy. Attempts to improve the outcome of transplantation and to 
develop mechanical islets are ongoing. 
Whole pancreas or islet transplantation is another treatment continues to develop and 
reduced the need for insulin, achieve better glucose stability, and reduce problems with 
hypoglycemia. The transplantation of vascularized pancreas, from a deceased donor, 
developed in the 1960s and usually performed concurrently with renal transplantation, can 
cure Type 1 (DM), as shown by results in more than 15,000 such transplants over about 30 
years. Transplantation of isolated pancreatic islets, instead of the whole organ, however, 
offers an attractive alternative that minimizes surgery and its complications. Although islet 
transplantation initially met with only modest success, recent changes in patient selection 
criteria, number and treatment of islets transplanted, and better immunosuppressive 
regimens dramatically improved the results. The development of clinical islet 
transplantation was driven by an unmet medical need within the diabetes mellitus patient 
population and was preceded by the introduction of transplantation of whole, vascularized 
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pancreas. Despite this promise, organ/islet availability remains an important limitation to 
this technology. A solution to the problem of limited materials for transplantation may be in 
the use of stem/progenitor cells. 
The presence of beta-cells in patients with long-standing Type 1 (DM), despite ongoing 
autoimmunity, implies that new formation of beta-cells may be occurring. Although an 
ambitious aim currently targeted regeneration of such beta-cells offers another strategy to 
prevent Type 1 (DM). Regeneration of beta-cells is therefore an area of major active 
investigation, with recent studies reporting differentiation of pancreatic and nonpancreatic 
progenitors as well as replication of existing islet beta-cells. In this regard some studies have 
shown that pre-existing beta-cells, rather than pluripotent stem cells, are the main source of 
new beta-cells during adult life and after pancreatectomy in mice. 
6. Cellular and molecular strategy for inhibition of the initiation and 
progression of beta-cell destruction 
Mononuclear cell infiltration into the islets of the pancreas (insulitis) is characteristic of 
autoimmune diabetes. T lymphocytes are the predominant subpopulation seen in insulitis, 
and are involved in the autoimmune process. Insulin-producing beta-cells are thought to be 
destroyed by cytotoxic T cells, cytokines or nitric oxide, and beta-cell death occurs, at least 
partly, via apoptosis. Beta-cell death induced by inflammatory cytokines can be inhibited by 
forced expression of Bcl-2 (B-cell lymphoma 2, thought to implicate in cell growth and 
survival) in those cells, suggesting its potential as a tool for gene therapy (Iwahashi, Itoh et 
al. 1998). The Fas/Fas-ligand system plays a critical role in inducing insulitis and overt 
diabetes in (NOD) mice as well. Beta-cells are destroyed by apoptosis through Fas-Fas 
ligand and TNF-TNF receptor interactions and by granzymes and perforin released from 
cytotoxic effector T cells. Therefore, the activated macrophages and T cells, and cytokines 
secreted from these immunocytes, act synergistically to destroy beta-cells, resulting in the 
development of Type 1 (DM). Preventive strategies might be developed by focusing on 
these molecules involved in beta-cell destruction.  
The feasibility of gene therapy in NOD mice by ex vivo genetic manipulation of normal 
hematopoietic stem cells (HSCs) with proinsulin II followed by transfer to recipient mice has 
been examined as an approach to treat T1D recently (10). The incidence and degree of 
insulitis was significantly reduced in recipient, and thus this molecular chimerism can 
potentially protect from destructive insulitis in an antigen-specific manner (10).  
In some studies the anti–T cell strategies were also examined to inhibit insulitis. Early 
studies of cyclosporin in the 1980s provided a proof of principal for the usefulness of 
immunomodulators in the treatment of Type 1 (DM); the adverse effects of cyclosporin, 
however, were incompatible with their widespread use. More sophisticated anti–T-cell 
strategies have been developed more recently. In the hOKT3γ1(Ala-Ala) trial, a humanized, 
modified anti-CD3 monoclonal antibody, analysis of peripheral blood samples 
demonstrated an increase in the CD8/CD4 ratio and in particular an increase in CD4+CD25+ 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 42 
(Garg 2011). These agents can cause edema (fluid accumulation in tissues), liver toxicity, and 
adverse cardiovascular events in certain patients. Furthermore, oral hypoglycemic agents 
lower mean blood glucose concentrations by only about 50–80 mg per 100 ml (2.8–4.4 
mmol/l), and sensitivity to these drugs tends to decrease with time(Garg 2011). 
There are several other agents that can be highly effective in the treatment of diabetes. 
Pramlintide is an injectable synthetic hormone (based on the human hormone amylin) that 
regulates blood glucose levels by slowing the absorption of food in the stomach and by 
inhibiting glucagon, which normally stimulates liver glucose production(Riddle and 
Drucker 2006). Exenatide is an injectable antihyperglycemic drug that works similarly to 
incretins, or gastrointestinal hormones, such as gastric inhibitory polypeptide, that stimulate 
insulin release from the pancreas. Exenatide has a longer duration of action than incretins 
produced by the body because it is less susceptible to degradation by an enzyme called 
dipeptidyl peptidase-4 (DPP-4)(Sena, Nunes et al. 2008). A drug called sitagliptin 
specifically inhibits DPP-4, thereby increasing levels of naturally produced incretins. Side 
effects associated with these drugs are often mild, although pramlintide can cause profound 
hypoglycemia in patients with Type 1 (DM). 
All patients with diabetes mellitus, particularly those taking insulin, should measure blood 
glucose concentrations periodically at home, especially when they have symptoms of 
hypoglycemia. Diet and lifestyle strategies also are required to reduce weight, improve 
glycaemic control and reduce the risk of cardiovascular complications, which account for 
70% to 80% of deaths among those with diabetes.  
Research into other areas of insulin therapy includes pancreas transplantation, beta-cell 
transplantation, and generation of beta-cells from existing exocrine cells in the pancreas. 
Patients with Type I (DM) have been treated by transplantation of the pancreas or of the 
islets of Langerhans. However, limited quantities of pancreatic tissue are available for 
transplantation, prolonged immunosuppressive therapy is needed, and there is a high 
likelihood that the transplanted tissue be rejected even when the patient is receiving 
immunosuppressive therapy. Attempts to improve the outcome of transplantation and to 
develop mechanical islets are ongoing. 
Whole pancreas or islet transplantation is another treatment continues to develop and 
reduced the need for insulin, achieve better glucose stability, and reduce problems with 
hypoglycemia. The transplantation of vascularized pancreas, from a deceased donor, 
developed in the 1960s and usually performed concurrently with renal transplantation, can 
cure Type 1 (DM), as shown by results in more than 15,000 such transplants over about 30 
years. Transplantation of isolated pancreatic islets, instead of the whole organ, however, 
offers an attractive alternative that minimizes surgery and its complications. Although islet 
transplantation initially met with only modest success, recent changes in patient selection 
criteria, number and treatment of islets transplanted, and better immunosuppressive 
regimens dramatically improved the results. The development of clinical islet 
transplantation was driven by an unmet medical need within the diabetes mellitus patient 
population and was preceded by the introduction of transplantation of whole, vascularized 
 
Immunologic and Genetic Factors in Type 1 Diabetes Mellitus 43 
pancreas. Despite this promise, organ/islet availability remains an important limitation to 
this technology. A solution to the problem of limited materials for transplantation may be in 
the use of stem/progenitor cells. 
The presence of beta-cells in patients with long-standing Type 1 (DM), despite ongoing 
autoimmunity, implies that new formation of beta-cells may be occurring. Although an 
ambitious aim currently targeted regeneration of such beta-cells offers another strategy to 
prevent Type 1 (DM). Regeneration of beta-cells is therefore an area of major active 
investigation, with recent studies reporting differentiation of pancreatic and nonpancreatic 
progenitors as well as replication of existing islet beta-cells. In this regard some studies have 
shown that pre-existing beta-cells, rather than pluripotent stem cells, are the main source of 
new beta-cells during adult life and after pancreatectomy in mice. 
6. Cellular and molecular strategy for inhibition of the initiation and 
progression of beta-cell destruction 
Mononuclear cell infiltration into the islets of the pancreas (insulitis) is characteristic of 
autoimmune diabetes. T lymphocytes are the predominant subpopulation seen in insulitis, 
and are involved in the autoimmune process. Insulin-producing beta-cells are thought to be 
destroyed by cytotoxic T cells, cytokines or nitric oxide, and beta-cell death occurs, at least 
partly, via apoptosis. Beta-cell death induced by inflammatory cytokines can be inhibited by 
forced expression of Bcl-2 (B-cell lymphoma 2, thought to implicate in cell growth and 
survival) in those cells, suggesting its potential as a tool for gene therapy (Iwahashi, Itoh et 
al. 1998). The Fas/Fas-ligand system plays a critical role in inducing insulitis and overt 
diabetes in (NOD) mice as well. Beta-cells are destroyed by apoptosis through Fas-Fas 
ligand and TNF-TNF receptor interactions and by granzymes and perforin released from 
cytotoxic effector T cells. Therefore, the activated macrophages and T cells, and cytokines 
secreted from these immunocytes, act synergistically to destroy beta-cells, resulting in the 
development of Type 1 (DM). Preventive strategies might be developed by focusing on 
these molecules involved in beta-cell destruction.  
The feasibility of gene therapy in NOD mice by ex vivo genetic manipulation of normal 
hematopoietic stem cells (HSCs) with proinsulin II followed by transfer to recipient mice has 
been examined as an approach to treat T1D recently (10). The incidence and degree of 
insulitis was significantly reduced in recipient, and thus this molecular chimerism can 
potentially protect from destructive insulitis in an antigen-specific manner (10).  
In some studies the anti–T cell strategies were also examined to inhibit insulitis. Early 
studies of cyclosporin in the 1980s provided a proof of principal for the usefulness of 
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regulatory T cells (36). Most studies of regulatory T cells have focused on a subset of 
naturally occurring CD4+ cells that have the capacity to control self-reactive T cells, and 
their depletion results in autoimmunity. Strategies that target the action of regulatory T cells 
in vivo offer one of the most attractive options for therapy in Type 1 (DM). The establishment 
of screening techniques for detecting prediabetic patients is also necessary to allow 
successful intervention.  
Immunosuppressive drugs and anti-T cell antibodies have shown varying degrees of 
success in suppression of beta-cell autoimmunity in NOD mice. However, these strategies 
require repeated drug administration and may cause nonspecific harmful effects such as 
interference with normal immune system functions. A new therapeutic approach for type 1 
diabetes is based on prevention of beta-cell loss through vaccine restoration of normal 
immune system function. Traditionally, vaccination refers to prevention of an infectious 
disease by exposing the immune system to a weakened or dead infectious agent. 
Alternatively, “inverse vaccination” (the inhibition of an immune response) arrests 
autoimmunity through manipulation of the innate and adaptive arms of the immune system 
(Steinman 2010). In type 1 diabetes, vaccination with β-cell autoantigens was shown to 
induce a partial state of immunological tolerance in NOD mice (Peakman and von Herrath 
2010). Beta-cell self-antigens can induce tolerance through three possible mechanisms: (1) 
induction of T cell deletion/anergy, (2) induction of anti-inflammatory T helper 2 (Th2) cells, 
and (3) stimulation of regulatory T cell proliferation (Maldonado and von Andrian 2010). 
Insulin, GAD and some heat shock proteins are considered to be the first pancreatic 
autoantigens detected early during diabetes onset in both humans and NOD mice. 
However, the primary beta-cell antigen responsible for triggering autoimmunity in Type 1 
(DM) remains under dispute. Thus, several pancreatic autoantigens have been selected for 
development into type 1 diabetes vaccines. These results suggest that multi-component 
vaccine strategies are promising for prevention and reversal of diabetes autoimmunity in 
humans, although some antigens determined to be most immunogenic, and not successful 
in trials. 
We are still some way from developing a pill to prevent Type 1 (DM), but all the divergent 
strands of ongoing research, from epidemiology to molecular biology, immunology to 
clinical trials, appear to be converging to provide clear perspectives on the therapeutic 
interventions that are most likely to be successful. Two strategies are open to physicians 
who have patients with Type 1 (DM): the first is to prevent initiation of autoimmunity; the 
second is to reverse the effects of ongoing autoimmunity coupled with beta-cell 
regeneration. Although highly ambitious, the prevention of Type 1 (DM) could be possible 
by identifying and eliminating environmental risk factors. The next line of defense would be 
to re-educate the immune system through exposure to beta-cell antigens with the use of oral 
or nasal tolerance strategies. The observation that insulin may be the primary autoantigen 
provides support for therapies using insulin to induce tolerance. The potential to re-educate 
the immune system, or to divert it using regulatory T cells, and the rapidly expanding field 
of islet beta-cell differentiation give hope that improved strategies to manage this chronic 
disease are on the horizon. 
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7. Concluding remarks 
Type 1 (DM), formerly known as juvenile diabetes is a complex disease caused by multiple 
environmental and genetic risk factors. It is a T cell-mediated disease characterized by the 
destruction of the endocrine insulin-producing beta-cells of the pancreatic islets, resulting in 
plasma glucose dysregulation, persistent hyperglycemia and long-term complications. 
Evidence for a constant global increase of incidents is worrisome. There is a major 
international challenge for optimal intervention and prevention strategies. Thus, a better 
understanding of the events going on in the autoimmune processes and understanding the 
relative contribution of genetics and environmental factors is necessary for the ultimate 
prevention/treatment. 
Research is ongoing to discover the exact cause of Type 1 (DM), which remains unknown. 
Eepidemiological studies support the notion that viral infections play a causative role in 
Type 1 (DM). Indeed, there is a strong association between certain HLA and non-HLA 
alleles or combinations of alleles that predispose to development of Type 1 (DM). HLA 
typing is one means in screening to identify individuals at high risk as well.  
Based on experimental results from studies using NOD mice and BB rats over the past 3 
decades, the possible interactions between beta-cell autoantigens and immunocytes such as 
macrophages, dendritic cells, T cells, and their secretory products in connection with MHC 
class I and II molecules has shown in this autoimmune disease. The animal models may not 
encompass all aspects of the pathogenic mechanisms involved in autoimmune diabetes in 
humans; nevertheless, it may provide helpful information with respect to the synergistic 
destruction of beta-cells by immunocytes and their cytokines and a basis for the formation of 
new hypotheses for further investigation. 
Although rarer than type 2, Type 1 (DM) is more severe, and constitutes the fourth or fifth 
leading cause of death worldwide. There is currently no cure or preventative measure for 
Type 1 (DM). Patients are dependent for the rest of their lives on regular injections of 
insulin to control their blood sugar levels. Combined with some conservative lifestyle 
choices, insulin lets people manage their diabetes, but the control of blood sugar is never 
perfect. In the long term, tolerogenic, antigen-specific and beta-cell-specific regenerative 
agents could provide a promising platform for the development of disease-modifying 
therapies. Thus, combination therapies could be most effective in delivering the long-
sought cure.  
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1. Introduction 
The intestinal mucosal surface represents a huge border where different pathogenic 
particles, such as bacteria, fungi, viruses or parasites can potentially invade and harm the 
body. One crucial task of the immune system in the intestine is to maintain this epithelial 
barrier, in order to prohibit or defeat a microbial invasion. Pro-inflammatory effector CD4+ T 
helper cells play a crucial role during this task. These effector T helper cells can be 
subdivided into different subsets (Figure 1), which are characterized by a master 
transcriptional regulator and a unique cytokine profile: Th17 cells express RORt that in turn 
promotes the transcription of Il17a, Il17f, Il21 and Il22. Th1 cells express T-bet and produce 
IFN-, IL-2 and TNF-. Th2 cells express GATA-3 and secrete IL-4, IL-5 and IL-13 [1-5]. The 
intestine also contains numerous non-pathogenic bacteria (commensal bacteria), which are 
beneficial to the host, as well as food antigens. This vast collection of non-self antigens can 
also promote the activation of T helper cells, and in turn cause immune-pathology. 
Therefore it is important for the immune system to control effector T helper cells. Indeed 
different types of regulatory T cells with anti-inflammatory properties team up in order to 
control effector T cells. The two most studied regulatory T cell subtypes are Foxp3+ 
regulatory T cells, which can be generated either in the thymus (nTreg) or induced in 
peripheral lymphoid organs (iTregs) and type 1 regulatory T cells (Tr1), which are induced 
in the periphery (Figure 1). 
2. Differentiation of naïve CD4+ T cells into effector T helper cells 
Naïve T cells, which are functionally immature, can be differentiated into different subsets 
of effector T cells upon activation. The fate of naïve T cell is directed by cytokines. These 
cytokines signal via different members of the STAT family, which induce master 
transcriptional regulators. Most of these transcriptional factors bind then to the effector 
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cytokine gene thereby inducing gene activation, repression or epigenetic modification [6] 
(Figure 1). It should be noted that there is a certain amount of T helper cell heterogeneity 
and plasticity regarding cytokine production and expression of the master transcriptional 
factor of each T helper cell subset. This fact is currently also one of the most intriguing 
aspect of the ongoing research in Immunobiology. However, the model of different T helper 
cell lineages as first proposed by Mosmann and Coffman [7] is still the most useful one in 
order to understand the function and differentiation of T helper cells.  
 
Figure 1. Differentiation of naïve T cells into different effector and regulatory T cells. A specific 
combination of cytokine signals leads to the differentiation of naïve T cells into different T helper cell 
subsets. Each T helper cell subset is characterized by the production of a combination of cytokines and 
exerts specific functions. 
2.1. Differentiation and function of Th1 cells 
Th1 cells produce IFN-γ as their signature cytokine. Th1 cells secrete also IL-2 and/ or TNF-
α. Naive T cells upon TCR stimulation in the presence of IL-12 differentiate in Th1 cells [8]. 
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IL-12 signals via STAT4 promoting the expression of T-bet, which transcribes the Ifng gene 
[9, 10]. T-bet is the master transcriptional regulator of Th1 cells, which is essential for the 
IFN-γ production [5]. Accordingly T-bet deficient mice have a defective Th1 differentiation 
[11]. One other important function of T-bet is the inhibition of GATA-3 expression, the 
master transcriptional regulator of Th2 cells [9]. 
Th1 cells are particularly important for the defense against intra-cellular bacteria. Some 
microorganisms such as mycobacteria, like Mycobacterium tuberculosis or Mycobacterium 
lepromatosis, are examples for these intracellular pathogens. These bacteria grow primarily in 
phagolysosomes of macrophages. Because of this feature these microorganisms are 
protected from the effects of antibodies and cytotoxic T cells. These bacteria can inhibit the 
fusion of lysosomes to the phagosomes, in which they grow and prevent the activation of 
the lysosomal proteases. The defense against these microorganisms is the important task of 
Th1 effector cells because they can activate macrophages, which are then able to kill ingested 
pathogens. Accordingly, deficiency in Th1 cells increases the susceptibility to infections with 
intracellular pathogens in humans [12]. These patients suffer from infections with 
mycobacteria, particularly Mycobacterium tuberculosis, but also with Salmonella. Of note both 
of these bacteria strains can typically infect the gastrointestinal system.  
2.2 Differentiation and function of Th2 cells 
The signature cytokines of Th2 cells are IL-4, IL-5, and IL-13. Some Th2 cells also produce 
TNF-α and/ or IL-9. Additionally, some Th2 cells can secrete small amounts of IL-2. The 
cytokines leading to Th2 differentiation are IL-2 and IL-4. Therefore the signature cytokine 
of Th2 cells, IL-4 also promotes the differentiation of Th2 cells [13-15]. STAT6 is the major 
signaling pathway of IL-4 mediated Th2 differentiation, and induces GATA-3 expression 
[16-20]. GATA-3 is the master transcriptional regulator of Th2 cells [3, 21] and the 
differentiation of these cells is indeed dependent on the induction of this master 
transcriptional regulator [22]. GATA-3 binds to the promoters of Il5 and Il13, and the 
enhancer of Il4 thereby promoting their transcription [6]. Additionally STAT5, which can be 
activated by IL-2, is important for Th2 differentiation and for the maintenance of GATA-3 
expression [23].  
Th2 cells and their effector cytokines IL-4, IL-5, and IL-13 are essential to control helminth 
infections in the intestine. In line with this, mice deficient in IL-4 receptor a-chain (IL-4Rα), 
STAT6 or GATA-3 show highly compromised anti-helminth immunity [24]. One of the most 
unique tasks of Th2 cells is the induction of B-cell immunoglobulin class switching. Through 
CD40-CD40L interaction, Th2 cells promote B cells to secret IgG1, IgE and (in humans) IgG4 
isotype antibodies. These antibodies are again important for mediating protection against 
helminth infections. The Th2-immune response involves also eosinophils, basophils and 
mast cells, which all together mount the immune response controlling helminth infection. 
The release of IL-4 and IL-13 is key for eliciting the alternative activation of macrophage, 
which is crucial in order to trap the intestinal parasite [25, 26]. Th2-cytokines, in particular 
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IL-4 and IL-13, promote the goblet cell differentiation, the enhancement of mucus secretion 
and the production of resistin-like molecule-β (RELMβ), an innate protein with direct anti-
helminth activity [27-29]. Moreover IL-4 stimulates intestinal muscle hyper-contractility and 
accelerates epithelial turnover to promote the ‘epithelial escalator’, which functions together 
with epithelial secretions to dislodge resident parasites [30, 31]. Another Th2 associated 
cytokine, namely IL-9, promotes the release of mast cell protease that can depredate tight 
junctions and in turn increase the fluid flow in the intestine. All together these mechanisms 
are part of the “weep and sweep” response, which is key for the control of a helminth 
invasion.   
2.3. Differentiation and function of Th17 cells 
The signature cytokines of Th17 cells are Il-17A and IL-17F. Th17 cells produce also, IL-22 
and TNF-α. TGF-, IL-1, IL-6, and IL-23 are the cytokines, which are important for Th17 
cell differentiation. IL-6 can activate STAT3, which induces IL-23R and RORt [32-34], the 
master transcriptional regulator of Th17 cells. This master transcriptional regulator leads to 
the production of IL-17A and IL-17F [1, 4, 35, 36]. IL-6 also promotes the release of IL-21 
[33], which synergizes with TGF-, IL-6, and IL-1, for the induction of IL-23 receptor 
expression [37]. In the presence of IL-23, CD4+ RORt+ IL-17A+ T cells can expand and fully 
mature in Th17 cells [38, 39].  
Human and mouse Th17 cells are rare in a non-pathological state [2, 40]. A specific member 
of commensal microbiota, known as segmented filamentous bacteria (SFB), attracts Th17 
cells in the terminal ileum of mice [41]. Therefore in steady state condition most of the few 
Th17 cells accumulate mainly in the intestine. The commensal microbiota promotes the 
release of serum amyloid A [41] and adenosine 5′-triphosphate (ATP), which activates 
lamima propria mononuclear phagocytes. These phagocytes in turn promote Th17 cell 
differentiation [42]. Among all cytokines known to induce the differentiation of Th17 cells, 
the presence of IL-1β rather than IL-6 is essential in the intestine [43]. TGF- β 1 is also not 
essential for the differentiation of Th17 cells in the intestine, but may influence the 
phenotype of Th17 cells together with IL-1 [44]. Th17 cells, which have been differentiated 
in the presence of TGF-β1 are less pathogenic and produce more IL-10 compared to Th17 
cell differentiated in the presence of IL-1 [45, 46]. 
Th17 cells also produce several other cytokines besides IL-17A and IL-17F. Cytokine 
production by Th17 cells is also modulated by environmental factors in the intestine. For 
example, the activation of the environmental chemical receptor and transcription factor aryl 
hydrocarbon receptor in Th17 cells is important for the production of IL-22 [47-49]. IL-22 is a 
critical cytokine for antimicrobial immunity exerted by Th17 cells [50]. On the other hand, 
the induction of c-maf upon stimulation with IL-27, promotes the release of IL-10 from Th17 
cells [51], and these IL-10 producing Th17 cells are also particularly induced in the intestine 
[40]. Therefore Th17 cells can have different cytokine profiles depending on environment 
factors. 
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In the absence of pathology, Th17 cells are very rare. However pathogenic infections, such 
as fungi infection with Candida albicans, or bacterial infection with gram positive or gram 
negative extracellular bacteria, such as Citrobacter rodentium or Klebsiella pneumoniae lead to a 
dramatic increase of the number of Th17 cells [52-56]. Viral infection also promotes a Th17-
cell mediated immune response [40]. In line with this, Th17 cells and their effector cytokines 
IL-17A, IL-17F, and IL-22 are critical for proper host defense against various infections, 
especially against extracellular bacteria and fungi. The receptors for IL-17A, IL-17F and IL-
22 are broadly expressed throughout the intestinal epithelial tissue. Therefore Th17 cells can 
provide crosstalk between immune system and tissues [2, 57]. 
IL-17A and IL-17F strongly induce the recruitment of neutrophils to the inflammatory site. 
The subsequent induction of the chemokine CCL20 attracts even more Th17 cells via CCR6, 
the chemokine receptor of CCL20, which is highly expressed by Th17 cells [58]. 
Additionally, both IL-17A and IL-17F promote β-defensin production [56, 59, 60]. β-
defensins play an important role in the immune responses against bacterial infections. 
Interestingly, IL-17A and IL-17F can compensate each other during the host defense against 
S. aureus [56]. However during other infections, such as Citrobacter rodentium, IL-17A and IL-
17F are both required in order to control the bacterial dissemination [56]. 
At the mucosal surface IL-22 has a crucial function for host defence and tissue homeostasis. 
IL-22 induces the expression of antimicrobial peptides from epithelial cells and limits 
bacterial replication and dissemination during Citrobacter rodentium infection [57, 61]. 
Furthermore IL-22 can promote epithelial cell proliferation, survival, and tissue repair in the 
intestine [62-64].  
However it should be noted that several other immune cells besides Th17 cells can produce 
IL-17A and IL-22, thereby also contributing to the defense against pathogens (for review see 
[50]).  
2.4. Differentiation and function of Foxp3+ Treg cells  
In 1995 Sakaguchi et al. first described a subpopulation of regulatory T cells characterized 
by the constitutive expression of the IL-2 receptor α-chain (CD25). These regulatory T 
cells were called CD4+CD25+ Treg [65]. Foxp3 was identified later on as the master 
transcriptional regulator of CD4+CD25+ Treg cells, which have been called Foxp3+ Treg 
cells thereafter [66, 67]. Foxp3+ Treg cells can be generated within the thymus (tTreg) [65]. 
However, Foxp3+ Treg cell numbers are also regulated in peripheral lymphoid organs 
both by expansion of pre-existing Foxp3+ Treg and by de novo generation of induced 
regulatory T cells (iTreg). The combination of the cytokines IL-2 and TGF-β1 are key for 
the differentiation of naïve T cells into Foxp3+ iTreg cells [68-73]. Foxp3+ Treg cells are 
essential to control auto-reactive T cells, which can react to self-antigens and cause 
damage to the host. The key role of Foxp3+ Treg cells in the peripheral immune response 
is evident in murine models [74] and in humans [75]: scurfy mice [74] and IPEX 
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(immunodysregulation polyendocrinopathy enteropathy X-linked syndrome) patients [75] 
lacking the master transcriptional factor of regulatory T cells - Foxp3 - consequently 
develop strong autoimmune disorders. Importantly, a severe form of autoimmune 
enteropathy is characteristic for scurfy mice and IPEX patients [75]. This underlines the 
importance of Foxp3+ Treg cells for controlling the immune response in the intestine. 
Foxp3+ Treg cells have different mechanism to suppress effector T cells. Some of these are 
mediated via soluble factors (i.e. IL-10, TGF-β1 [76, 77]) and others are cell contact 
dependent (i.e. CTLA-4, cAMP [78, 79]). Recent studies have demonstrated that Foxp3+ 
Treg cells can acquire some features of effector T helper cells in order to better control 
them (see paragraph 4.3). 
2.5. Differentiation and function of Tr1 cells 
In 1994, T regulatory type 1 (Tr1) cells were isolated from severe combined immuno 
deficiency (SCID) patients transplanted with allogeneic haematopoietic stem cells (HSCT). 
Subsequently it was possible to test the regulatory capacity of this new type of T cells 
directly in murine IBD models. To date Tr1 cells lack a defined cell surface signature, and 
their identification relays therefore on their unique cytokine profile. Tr1 cells secrete high 
levels of IL-10 as compared to IL-4 and IL-17A, the hallmark cytokines of Th2  
and Th17 cells respectively. Depending on the milieu Tr1 cells can produce variable levels 
of IFN-, the key cytokine produced by Th1 cells [80]. However, Tr1 cells posses the 
capacity to suppress inflammatory T cell responses and, therefore are distinct from bona 
fide Th1, Th2 and Th17 cells that largely promote rather than suppress the inflammatory 
responses.  
Tr1 cells are induced in the periphery, and they respond selectively to persistent foreign and 
self-antigens under steady-state conditions [81].  
After the discovery of Foxp3 as the master transcriptional regulator of Foxp3+ Treg cells, it 
became a key point, if also Tr1 cells express a master regulator. The double reporter mouse 
model for IL-10 and Foxp3 was instrumental in order to demonstrate that these two types of 
regulatory T cells are distinct. Indeed, Tr1 cells do not constitutively express Foxp3 [82, 83] 
and can be induced from IPEX patients who lack Foxp3 [84]. However the master 
transcriptional regulator for Tr1 cells has not been identified so far. 
IL-10 has been considered to be the driving force for Tr1-cell generation on the basis of 
experiments in which antigen-specific Tr1 cells are induced in vitro by repeated TCR 
stimulation in the presence of high doses of IL-10 [85, 86]. However, the frequency of Tr1 
cells in IL-10 deficient mice is not altered. Several recent publications have demonstrated a 
key role of IL-27, which can even synergize with TGF-, in the induction of Tr1 cells. During 
the induction of Tr1 cells by IL-27, the ligand-activated transcription factor hydrocarbon 
receptor (AhR) physically associates with c-avian musculoaponeurotic fibrosarcoma (c-Maf) 
and transactivates the Il10 and Il21 promoters. The secretion of IL-21 acts as an autocrine 
growth factor for Tr1 cells (Reviewed in [87]).    
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Tr1 cells can control Th1, Th2 and Th17 cell, and regulate immune responses mainly 
through the secretion of the immunosuppressive cytokines IL-10 and TGF-1 [88].  The 
antigen-specific activation of Tr1 cells is important to potentiate their regulatory function 
[86]. IL-10 acts by limiting the magnitude of immune responses, as proved by mice that lack 
IL-10 and that exhibit spontaneous enterocolitis. IL-10 down-regulates the expression of co-
stimulatory molecules, such as CD80, CD86, and MHC Class II, and pro-inflammatory 
cytokine production by APCs and inhibits the secretion of IL-2, TNF- and IL-17 by effector 
T cells [89]. In particular, Tr1-cell supernatant diminishes the capacity of monocytes to 
stimulate Th1-cell responses and blocks the differentiation and maturation of DCs via IL-10 
[90]. TGF- down-regulates the functions of APCs [91] and inhibits the proliferation and 
cytokine production by T cells [92]. Therefore, the suppressive effects of Tr1 cells are 
reversed by the addition of anti-IL10 and anti-TGF- neutralizing antibodies [85, 93, 94], but 
additional mechanisms may also contribute. Human Tr1 cells generated in vitro by 
crosslinking CD3 with CD46 can kill target cells through a granzyme B/ perforin dependent 
mechanism [95] [96]. Accordingly human Tr1 cells selectively kill myeloid cells (i.e., DC and 
monocytes) through granzyme B/ perforin [97]. This selective cell-killing is mediated by 
CD226, which is expressed on Tr1 cells. Only myeloid cells express the CD226-ligand 
(CD155). Thus, this type of regulatory mechanism by Tr1 cells requires a cell-cell contact 
with APCs.  
3. The immune homeostasis in the intestine 
The immune system has to respond selectively to harmful non-self pathogens and at the 
same time needs to minimize reactions against self and not-harmful antigens. This highly 
fine-tuned mechanism is possible due to a strict selection process, which happens in the 
thymus. Potentially auto-reactive CD4+ T cell progenitors, which recognize self-antigens 
with their T cell receptor (TCR), are either deleted or converted into thymic-derived CD4+ 
regulatory T cells (tTreg) with anti-inflammatory properties. This process, called central 
tolerance, is essential for the education of CD4+ T cells to respond selectively against foreign 
antigens. However this thymic control appears still to be insufficient. Therefore the immune 
system developed several other mechanisms to control potentially auto-reactive T cells, 
which take places in the periphery (peripheral tolerance). Among these mechanisms, the 
action of CD4+ regulatory T cells, which can be either selected in the thymus, (tTreg) or 
induced in the periphery (iTreg)[98], is one of the most studied. Treg cells are essential to 
control auto-reactive T cells, which can react to self-antigens and cause damage to the host. 
The intestine is not only a source of self-antigens, but also contains a vast collection of 
non-self antigens, such as commensal bacteria. These antigens can promote the activation 
of naïve T cells causing immune-pathology such as inflammatory bowel disease (IBD). 
Therefore the immune system has established a second checkpoint in the intestine where 
naïve T cells, which are potentially able to respond to non self-antigens, are educated to 
be tolerant. There are important differences between thymus and intestine in tolerance 
induction. The driving force for the selection in the thymus is the affinity of TCRs to 
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MHC, while the flora and cytokines are crucial to determine the fate of naïve T cells in the 
intestine. Accordingly different commensal bacteria can selectively drive a tolerogenic or 
pro-infammatory response. In line with this, the bacterial composition of the intestine has 
a substantial impact on the balance between pro-inflammatory and regulatory T cells in 
the intestine, and can also affect other organ specific diseases [41, 99-101]: For example 
mice lacking an innate sensor, which controls the intestinal micro-flora, are more susceptible 
to develop colitis [100]. Another interaction between the gut flora and an autoimmune 
disease was found in EAE (experimental autoimmune encephalomyelitis, a mouse model for 
multiple sclerosis). Multiple sclerosis is caused by an attack by auto-reactive T cells against 
brain white matter. Interestingly it was shown that the commensal gut flora can trigger 
these auto-reactive T cells, which then drive the disease. Finally it is known that the bacterial 
colonization between neonates born vaginally or by cesarean delivery differs, and 
interestingly these differences have been linked to an increased risk for atopic diseases such 
as allergic rhinitis and asthma in children born by cesarean delivery [102]. 
Considering the amount of self- and none self-antigens present in this organ and with it the 
potential to generate an unwanted immune response, different players are required to 
control the immune homeostasis in the intestine. The first one is a specialized subset of DC, 
which through the release of TGF- and retinoic acid, is able to induce iTreg cells [103]. 
These iTreg cells represent then the second players. It is also known that naïve T cells 
migrate to the intestine in order to acquire an iTreg cell phenotype [104, 105]. Interestingly, 
these iTreg cells have a TCR repertoire, which is specific to an individuals microflora. Based 
on these results, one could hypothesize that iTreg cells have an advantage over tTreg cells 
(3th player), which are also present in the intestine, but are obviously non-bacteria specific. 
However, it was shown that specific commensal bacteria can directly activate tTreg cells 
bypassing the antigen specificity [106]. Both tTreg and iTreg are able to suppress effector T 
cells in the intestine, thereby curing or preventing colitis development [68, 98, 107-110]. It 
seems that tTregs and iTreg can also supplement the function of each other partially by 
expanding the TCR diversity [111]. Tr1 cells (4th players) are expanded in the absence of 
iTregs, and can at least partially compensate the absence of iTregs [112, 113]. Consistent 
with this, Tr1 cells and Treg cells can compensate each other to suppress effector T cells in 
the intestine [114].  
In conclusion, commensal antigens in the intestine play an essential role in the regulation of 
the immune homeostasis. Naïve T cells, which could be potentially auto reactive,  
are converted into different types of regulatory T cells, which in turn control other effector T 
helper cells. The regulatory T cells originated in the thymus (nTregs) also participate  
in this regulatory environment by expanding the antigen specificity of the immune 
response. 
4. Breakdown of the immune homeostasis in the intestine 
Imbalance between pro- and anti-inflammatory T helper cells can cause intestinal pathology, 
such as IBD in humans. Crohn's disease (CD) and ulcerative colitis (UC) are the two main 
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forms of IBD. CD can attack any part of the digestive tract. It typically manifests in the 
ileum, although it can also selectively affect the large intestine. Histological Crohn's disease 
shows a transmural inflammation. This inflammation is characterized by focal infiltration of 
neutrophils into the epithelium. These neutrophils, along with mononuclear cells, can 
infiltrate the crypts, leading to inflammation or abscess. Granulomas, aggregates of 
macrophage derivatives, known as giant cells, are found in CD and are specific for the 
disease. Ulceration can also be seen in highly active CD. On the other hand, UC is a disease 
mainly of the colon that includes ulcerations. UC normally begins in the rectum, and can 
continuously affect the whole colon and also the terminal ileum. The pathology in ulcerative 
colitis involves distortion of crypt architecture, inflammation of crypts and hemorrhage. The 
inflammation is more superficial compared to CD and affects the mucosa and submucosa. 
The aetiology of IBD is still unknown, but it seems that genetic and environmental factors 
contribute to disease development. Initial studies suggested that CD and UC are mediated 
by Th1 and Th2 cells respectively. This was based on the cytokine profile seen in CD (IL-12 
and IFN-γ) and UC (IL-5, IL-13) [115]. However more recent work has shown that Th17 cells 
also infiltrate the intestine in CD and UC patients as well [116-118]. Accordingly the 
signature cytokines of Th17 cells (IL-17A, IL-17F, IL-22) are produced in the intestine of CD 
and UC patients [116, 118-120]. Additionally, genome wide association studies have linked 
polymorphism in Th17-related genes, such as IL-23R and STAT3 with IBD [121-124]. In line 
with these associations murine studies have also shown that Th17 cells are involved in 
numerous autoimmune and chronic inflammatory diseases [2], and IBD is one of these 
diseases [125]: RORγt deficient mice, which lack Th17 cells, exhibit attenuated 
experimentally induced autoimmune disease [4]. Adoptive transfer of in vitro or in vivo 
differentiated Th17 cells into lymphopenic hosts leads to the development of colitis [114, 
126-128]. IL-23, which is important for the maintenance, expansion and pathogenicity of 
Th17 cells [38, 39], is essential for the induction of colitis in mouse models. All together, 
these data argue for an important role of Th17 cells in IBD. However, Th17 cells produce 
several factors. And it is currently not completely understood, which of these is/are 
responsible for the pathogenicity of Th17 cells in the intestine [129-132].  
One key feature of Th17 cells is their plasticity, which might also contribute to the 
pathogenic potential of Th17 cells. Epigenetic studies have shown that Th17 cells are more 
plastic compared to Th1 and Th2 cells [56, 133-135]. Th17 cells have bivalent domains of 
histone modifications in the Tbx21 locus, which encodes for T-bet, the key transcriptional 
factor for Th1 cells. On the contrary, Th1 cells have only repressive markers in both Rorc and 
Il17a loci. These differences might account for the higher plasticity of Th17 cells relative to 
Th1 cells [133]. In line with these data, CD4+ T cells, which express both the key 
transcriptional factors and cytokines of Th17 and Th1 cells, have been found in the colon of 
mouse colitis models and moreover in colon of human IBD patients. They are also suggested 
to play an important role for the development of chronic disease [39, 114, 118]. 
Human IBD is characterized by a mixture of effector T cells. Therefore it is difficult to assess 
the relative contribution of a specific T helper cell subset in patients. However there are 
mouse IBD models, which are dominated by one specific T helper cells subset: Selective 
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MHC, while the flora and cytokines are crucial to determine the fate of naïve T cells in the 
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the intestine, and can also affect other organ specific diseases [41, 99-101]: For example 
mice lacking an innate sensor, which controls the intestinal micro-flora, are more susceptible 
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Considering the amount of self- and none self-antigens present in this organ and with it the 
potential to generate an unwanted immune response, different players are required to 
control the immune homeostasis in the intestine. The first one is a specialized subset of DC, 
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cells in the intestine, thereby curing or preventing colitis development [68, 98, 107-110]. It 
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helper cells. The regulatory T cells originated in the thymus (nTregs) also participate  
in this regulatory environment by expanding the antigen specificity of the immune 
response. 
4. Breakdown of the immune homeostasis in the intestine 
Imbalance between pro- and anti-inflammatory T helper cells can cause intestinal pathology, 
such as IBD in humans. Crohn's disease (CD) and ulcerative colitis (UC) are the two main 
 
Balancing Pro- and Anti-Inflammatory CD4+ T Helper Cells in the Intestine 59 
forms of IBD. CD can attack any part of the digestive tract. It typically manifests in the 
ileum, although it can also selectively affect the large intestine. Histological Crohn's disease 
shows a transmural inflammation. This inflammation is characterized by focal infiltration of 
neutrophils into the epithelium. These neutrophils, along with mononuclear cells, can 
infiltrate the crypts, leading to inflammation or abscess. Granulomas, aggregates of 
macrophage derivatives, known as giant cells, are found in CD and are specific for the 
disease. Ulceration can also be seen in highly active CD. On the other hand, UC is a disease 
mainly of the colon that includes ulcerations. UC normally begins in the rectum, and can 
continuously affect the whole colon and also the terminal ileum. The pathology in ulcerative 
colitis involves distortion of crypt architecture, inflammation of crypts and hemorrhage. The 
inflammation is more superficial compared to CD and affects the mucosa and submucosa. 
The aetiology of IBD is still unknown, but it seems that genetic and environmental factors 
contribute to disease development. Initial studies suggested that CD and UC are mediated 
by Th1 and Th2 cells respectively. This was based on the cytokine profile seen in CD (IL-12 
and IFN-γ) and UC (IL-5, IL-13) [115]. However more recent work has shown that Th17 cells 
also infiltrate the intestine in CD and UC patients as well [116-118]. Accordingly the 
signature cytokines of Th17 cells (IL-17A, IL-17F, IL-22) are produced in the intestine of CD 
and UC patients [116, 118-120]. Additionally, genome wide association studies have linked 
polymorphism in Th17-related genes, such as IL-23R and STAT3 with IBD [121-124]. In line 
with these associations murine studies have also shown that Th17 cells are involved in 
numerous autoimmune and chronic inflammatory diseases [2], and IBD is one of these 
diseases [125]: RORγt deficient mice, which lack Th17 cells, exhibit attenuated 
experimentally induced autoimmune disease [4]. Adoptive transfer of in vitro or in vivo 
differentiated Th17 cells into lymphopenic hosts leads to the development of colitis [114, 
126-128]. IL-23, which is important for the maintenance, expansion and pathogenicity of 
Th17 cells [38, 39], is essential for the induction of colitis in mouse models. All together, 
these data argue for an important role of Th17 cells in IBD. However, Th17 cells produce 
several factors. And it is currently not completely understood, which of these is/are 
responsible for the pathogenicity of Th17 cells in the intestine [129-132].  
One key feature of Th17 cells is their plasticity, which might also contribute to the 
pathogenic potential of Th17 cells. Epigenetic studies have shown that Th17 cells are more 
plastic compared to Th1 and Th2 cells [56, 133-135]. Th17 cells have bivalent domains of 
histone modifications in the Tbx21 locus, which encodes for T-bet, the key transcriptional 
factor for Th1 cells. On the contrary, Th1 cells have only repressive markers in both Rorc and 
Il17a loci. These differences might account for the higher plasticity of Th17 cells relative to 
Th1 cells [133]. In line with these data, CD4+ T cells, which express both the key 
transcriptional factors and cytokines of Th17 and Th1 cells, have been found in the colon of 
mouse colitis models and moreover in colon of human IBD patients. They are also suggested 
to play an important role for the development of chronic disease [39, 114, 118]. 
Human IBD is characterized by a mixture of effector T cells. Therefore it is difficult to assess 
the relative contribution of a specific T helper cell subset in patients. However there are 
mouse IBD models, which are dominated by one specific T helper cells subset: Selective 
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deficiency in iTreg cells causes Th2 dominated intestinal pathology, which is characterized 
by gastritis and plasmacytic enteritis with increased frequencies of plasma cells in the 
intestinal lamina propria [113]. Another mouse model of colitis, which is induced by the 
transfer of naïve T cells into a lymphopenic host, is dominated by Th1 cells. This colitis 
model is characterized by IFN-γ dependent mucosal ulceration in the colon [136, 137]. Th17 
cell-dominated intestinal pathology is characterized by mucosal hyperplasia but not 
ulceration [76, 136, 138]. IL-22, a signature cytokine of Th17 cells, can promote epithelial cell 
survival and proliferation. It is also important for the repair of the intestinal mucosa [63, 136, 
139]. Accordingly, IL-22 induces the hyperplasia in the Th17 dominated colitis models [136]. 
On the contrary IL-22 is beneficial in Th1 dominated colitis models, which are characterized 
by ulceration [62]. Of note, the histomorphology in these Th1, Th2, or Th17 cell dominated 
mouse IBD models features only some characteristics of human IBD. But still these models 
are useful to evaluate the function of specific T helper cell subsets. 
5. Control of pro-inflammatory T helper cells in the intestine 
There are three ways to control effector T cells. First, inhibition of the differentiation of naïve 
T cells into effector T cells. Second, endogenous mechanism limiting the pathogenic 
potential of effector T cells. Third, control of effector T cells through regulatory T cells. 
5.1. Inhibition of the de novo differentiation of effector T cells 
One possibility is to inhibit the de novo differentiation of naïve T cells into effector T cells and 
generate regulatory T cells in stead. Such a reciprocal development pathway has been 
described for Th17 cells: High concentrations of TGF- and/or retinoic acid up-regulate 
Foxp3 [140, 141], which in turn inhibits the induction of RORt [37], thereby preventing the 
differentiation of Th17 cells. Moreover, IL-2 together with TGF-1 promotes the induction of 
Foxp3+ regulatory T cells (iTregs) instead of Th17 cells [142]. Interestingly, IL-2 blocks Th17 
cell differentiation by directly inhibiting Il17a transcription. This second mechanism is 
largely independent of Foxp3 or RORγt expression, but dependent on the induction of 
STAT5, which competes with STAT3 for the common sites across the locus encoding IL-17A 
[143]. Finally, IL-27 through the activation and interaction of AhR and c-maf promotes the 
induction of type 1 regulatory T cells (Tr1) and efficiently counteracts the effects of TGF- 
and IL-6 on CD4+ T cells, resulting in the inhibition of Th17 development in a STAT1-
dependent manner (Reviewed in [144]). 
5.2. Endogenous control of effector T cells 
All effector T cell subsets (Th1, Th2, Th17) have the ability to acquire IL-10 production, 
thereby limiting their own pathogenicity [145]. This mechanism of self control has been very 
well described for Th17 cells (Figure 2): During particular bacterial and viral infection, naïve 
T cells maturate in effector Th17 cells and contribute to the eradication of infections. 
However, if the Th17 response is too strong and potentially life threatening, Th17 cells are 
redirected to the small intestine in order to be controlled [40]. The reason why mature Th17 
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cells migrate mainly to the small intestine is because of the high expression of the 
chemokine receptor CCR6 [146]. The highest concentration of CCL20, the ligand of CCR6, is 
indeed in the small intestine [40]. Interestingly, IL-17A and IL-17F promote the release of 
CCL20 from epithelial cells in the duodenum. The recruited Th17 cells also produce CCL20, 
furthermore amplifying CCL20 production. This suggests that Th17 cells implement 
through a positive feedback loop the recruitment of other Th17 cells to the small intestine. 
Once effector Th17 cells migrated to the intestine, two complementary mechanisms occur in 
order to control them. First, effector Th17 cells are washed out and eliminated via the 
intestinal lumen due to the strong tissue destruction and diarrhoea. Secondly, Th17 cells are 
reprogrammed in regulatory Th17 (rTh17) cells.  This last mechanism relays on the plasticity 
of these cells. In the intestine, effector Th17 cells acquire the capacity to produce IL-10 [40] 
and in parallel express IL-10R. If Th17 cells cannot respond to IL-10, they acquire a 
“promiscuous” phenotype co-expressing IFN- and promote the inflammation in the small 
intestine [114].  
 
Figure 2. Endogenous control of Th17 cells in the intestine. A strong Th17 response leads to the 
redirection of effector Th17 (eTh17) cells to the small intestine. Once eTh17 cells migrated to the 
intestine, two complementary mechanisms occur in order to control them. First, eTh17 cells are washed 
out and eliminated via the intestinal lumen due to the strong tissue destruction and diarrhoea. 
Secondly, Th17 cells are reprogrammed in regulatory Th17 (rTh17) cells. 
5.3. Exogenous control of effector T cells via regulatory T cells 
Importantly, other control mechanisms, which do not rely on the “sense of responsibility” of 
effector T helper cells, are also present (Figure 3). Regulatory T cells play an essential role for 
controlling T helper cells. The two most studied regulatory T cell subsets are Foxp3+ Treg 
and Tr1 cells. Foxp3+ Tregs can be induced in the periphery (Foxp3+ iTregs) or in the thymus 
(Foxp3+ tTregs). Interestingly, Foxp3+ iTregs are induced in the intestine by TCR recognition 
of commensal antigens [101, 104, 105, 147]. Foxp3+ tTregs cells are obviously non-bacteria 
specific, but nevertheless can be activated by some bacterial species in the intestine [106]. It 
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Foxp3+ regulatory T cells (iTregs) instead of Th17 cells [142]. Interestingly, IL-2 blocks Th17 
cell differentiation by directly inhibiting Il17a transcription. This second mechanism is 
largely independent of Foxp3 or RORγt expression, but dependent on the induction of 
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effector T helper cells, are also present (Figure 3). Regulatory T cells play an essential role for 
controlling T helper cells. The two most studied regulatory T cell subsets are Foxp3+ Treg 
and Tr1 cells. Foxp3+ Tregs can be induced in the periphery (Foxp3+ iTregs) or in the thymus 
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is also important that Foxp3+ iTregs and Foxp3+ tTregs perform complementary functions, in 
part by expanding the TCR diversity [111]. 
 
Figure 3. Control of effector T helper cells in the intestine. Different regulatory T cells can efficiently 
suppress specific T helper cell subsets in the intestine. 
Although different types of regulatory T cells can partially compensate each other, it seems 
that regulatory T cells can also have a more specialized function, and suppress specific types 
of effector T cells more potent then others: mice with a selective deficiency in iTreg cells 
develop spontaneous intestinal inflammation, which is characterized by an expansion of 
Th2 cells [113], indicating that iTregs play an important role in controlling Th2 cells in the 
intestine. Moreover expression of GATA-3 and IRF-4, master regulators of Th2 cells, by 
Foxp3+ Treg cells is important for the control of Th2 cells [148, 149]. Additionally, some 
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Foxp3+ Treg cells can express T-bet the master transcriptional regulator of Th1 cells. These T-
bet+Foxp3+ Tregs express CXCR3, which is also highly expressed by Th1 cells. Thanks to the 
expression of the same chemokine receptor T-bet+Foxp3+ Treg cells can better “follow” and 
in turn suppress Th1 cells [150]. Finally, it was shown that IL-10 can induce IL-10 
production by Foxp3+ Treg via STAT3 activation, and Foxp3+IL-10+ Tregs are particularly 
important to control Th17 cells [76, 138, 151]. In addition to Foxp3+ Treg the immune system 
uses an alternative type of regulatory T cell, which can compensate a possible paucity of 
Foxp3+ Treg in order to avoid immune pathology in the intestine [112]. These cells, Tr1 cells, 
which are characterized by an abundant production of IL-10 and by the absence of Foxp3 
expression, exert an efficient regulation of Th17 cells in the intestine [114]. Interestingly, IL-
10 seems to play a non-redundant role in controlling Th17 cells: acting on both Th17 cells 
and regulatory T cells. Th17 cells are suppressed directly via IL-10, which is produced by 
Tr1 and Foxp3+Treg cells [114, 136]. Additionally, IL-10 acts on Foxp3+Treg. It activates 
STAT3 in Foxp3+Tregs, which is crucial to enable them to suppress Th17 cells [138, 151]. 
Moreover IL-10 signalling in Foxp3+Treg cells is required to promote IL-10 production [138] 
(Figure 3).  
In conclusion Foxp3+ Treg cells can have different phenotypes. This feature allows Foxp3+ 
Tregs to suppress specific effector T cells more efficiently. Additionally Foxp3+ Tregs can 
team up with Tr1 cells to maintain the immune homeostasis in the intestine.  
However, regulatory T cells do not only suppress effector T cells but can also promote 
effector T cell function in some settings [152, 153], indicating that the immune system aims 
to maintain a proper balance between regulatory and effector T cells rather then 
uncontrolled suppression of effector T cells.  
6. Conclusions 
CD4+ T helper cells have important physiological functions at the large intestinal mucosal 
surface: they secrete cytokines thereby attracting other immune cells, inducing anti-
microbial peptides, and promoting tissue repair. Therefore effector CD4+ T helper cells play 
an important ‘border patrol’ function, and protect the body against infections. Thymic 
derived naïve CD4+ T cells express bacterial antigen specific TCRs. Encounter with these 
bacterial derived foreign antigens in the colon can drive the differentiation of regulatory T 
cells or pro-inflammatory effector T cells dependent on the bacteria and the environmental 
milieu. If effector CD4+ T helper cells are uncontrolled, they can elicit tissue damage and 
induce disease such as IBD. Therefore the immune system has established several 
mechanisms in order to control pro-inflammatory T helper cells. These mechanisms are 
primarily important to avoid immune pathology and in turn to maintain tolerance in the 
intestine. However a growing body of evidence suggests that these mechanisms can also be 
used to suppress other organ specific diseases. One example for this interaction between the 
intestine and another organ is that the commensal gut flora can trigger a T-cell mediated 
immune response, which leads to autoimmune disease in the brain [99]. Therefore one 
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is also important that Foxp3+ iTregs and Foxp3+ tTregs perform complementary functions, in 
part by expanding the TCR diversity [111]. 
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Foxp3+ Treg cells can express T-bet the master transcriptional regulator of Th1 cells. These T-
bet+Foxp3+ Tregs express CXCR3, which is also highly expressed by Th1 cells. Thanks to the 
expression of the same chemokine receptor T-bet+Foxp3+ Treg cells can better “follow” and 
in turn suppress Th1 cells [150]. Finally, it was shown that IL-10 can induce IL-10 
production by Foxp3+ Treg via STAT3 activation, and Foxp3+IL-10+ Tregs are particularly 
important to control Th17 cells [76, 138, 151]. In addition to Foxp3+ Treg the immune system 
uses an alternative type of regulatory T cell, which can compensate a possible paucity of 
Foxp3+ Treg in order to avoid immune pathology in the intestine [112]. These cells, Tr1 cells, 
which are characterized by an abundant production of IL-10 and by the absence of Foxp3 
expression, exert an efficient regulation of Th17 cells in the intestine [114]. Interestingly, IL-
10 seems to play a non-redundant role in controlling Th17 cells: acting on both Th17 cells 
and regulatory T cells. Th17 cells are suppressed directly via IL-10, which is produced by 
Tr1 and Foxp3+Treg cells [114, 136]. Additionally, IL-10 acts on Foxp3+Treg. It activates 
STAT3 in Foxp3+Tregs, which is crucial to enable them to suppress Th17 cells [138, 151]. 
Moreover IL-10 signalling in Foxp3+Treg cells is required to promote IL-10 production [138] 
(Figure 3).  
In conclusion Foxp3+ Treg cells can have different phenotypes. This feature allows Foxp3+ 
Tregs to suppress specific effector T cells more efficiently. Additionally Foxp3+ Tregs can 
team up with Tr1 cells to maintain the immune homeostasis in the intestine.  
However, regulatory T cells do not only suppress effector T cells but can also promote 
effector T cell function in some settings [152, 153], indicating that the immune system aims 
to maintain a proper balance between regulatory and effector T cells rather then 
uncontrolled suppression of effector T cells.  
6. Conclusions 
CD4+ T helper cells have important physiological functions at the large intestinal mucosal 
surface: they secrete cytokines thereby attracting other immune cells, inducing anti-
microbial peptides, and promoting tissue repair. Therefore effector CD4+ T helper cells play 
an important ‘border patrol’ function, and protect the body against infections. Thymic 
derived naïve CD4+ T cells express bacterial antigen specific TCRs. Encounter with these 
bacterial derived foreign antigens in the colon can drive the differentiation of regulatory T 
cells or pro-inflammatory effector T cells dependent on the bacteria and the environmental 
milieu. If effector CD4+ T helper cells are uncontrolled, they can elicit tissue damage and 
induce disease such as IBD. Therefore the immune system has established several 
mechanisms in order to control pro-inflammatory T helper cells. These mechanisms are 
primarily important to avoid immune pathology and in turn to maintain tolerance in the 
intestine. However a growing body of evidence suggests that these mechanisms can also be 
used to suppress other organ specific diseases. One example for this interaction between the 
intestine and another organ is that the commensal gut flora can trigger a T-cell mediated 
immune response, which leads to autoimmune disease in the brain [99]. Therefore one 
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possible strategy for the treatment of autoimmune diseases in future would be to specifically 
target the gut flora.  Although the mechanisms controlling effector T cells in the intestine 
work well in most humans, the frequency of autoimmune and chronic inflammatory disease 
is steadily increasing. Unfortunately, there are currently no curative treatments for these 
diseases available. Therefore the patients suffer from the side effects of the drugs and from 
the relapses of their disease. The the challenge will be to better understand the mechanisms 
controlling effector T cells in order to establish new and potentially curative treatments for 
autoimmune and chronic inflammatory diseases. The intestine has the potential to serve as 
the key target organ of these therapies. 
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1. Introduction 
Metabolism generates energy for organisms to sustain all kinds of biological functions, such 
as cell growth and cell apoptosis. The immune system requires an adequate energy supply 
for its optimal function [1]. During the activation and differentiation of T cells, the balance 
between glycolysis and lipid oxidation shifts in order to cater for the cell’s energy 
requirements [2]. There is increasing evidence that shows how metabolism has an important 
role in regulating immunity, and a series of molecules have been described to play a 
functional role in both metabolism and the regulation of immune responses [3; 4; 5]. 
Uncovering the transcriptional regulation of the proteins participating in these metabolic 
processes allows us to understand how metabolism regulates T cell fate [6]. A set of non-
coding RNAs called microRNA (miRNA), can also regulate these metabolic networks by 
binding to the 3’UTR of its target transcripts [7; 8; 9].  
Autoimmune diseases were thought to be primarily caused by the immune response 
towards self-antigens. Organ-specific autoimmune diseases, such as multiple sclerosis, 
thyroiditis and type I diabetes, tend to arise due to T cell-mediated damage [10]. Abnormal 
metabolic changes may thus alter T cell function leading to the development of human 
diseases, including autoimmune diseases [11]. 
In this chapter, we highlight the recent research advances in metabolism, in particular to: 
1. The role of metabolism in T cell differentiation and function. 
2. The role of miRNAs in metabolic processes. 
3. Dysregulation of metabolism during autoimmunity. 
2. The role of metabolism in T cell differentiation and function 
The role of cellular metabolism is to generate energy and supply biosynthetic demands in 
order to sustain normal biological functions. In the immune system, the control of cell 
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1. Introduction 
Metabolism generates energy for organisms to sustain all kinds of biological functions, such 
as cell growth and cell apoptosis. The immune system requires an adequate energy supply 
for its optimal function [1]. During the activation and differentiation of T cells, the balance 
between glycolysis and lipid oxidation shifts in order to cater for the cell’s energy 
requirements [2]. There is increasing evidence that shows how metabolism has an important 
role in regulating immunity, and a series of molecules have been described to play a 
functional role in both metabolism and the regulation of immune responses [3; 4; 5]. 
Uncovering the transcriptional regulation of the proteins participating in these metabolic 
processes allows us to understand how metabolism regulates T cell fate [6]. A set of non-
coding RNAs called microRNA (miRNA), can also regulate these metabolic networks by 
binding to the 3’UTR of its target transcripts [7; 8; 9].  
Autoimmune diseases were thought to be primarily caused by the immune response 
towards self-antigens. Organ-specific autoimmune diseases, such as multiple sclerosis, 
thyroiditis and type I diabetes, tend to arise due to T cell-mediated damage [10]. Abnormal 
metabolic changes may thus alter T cell function leading to the development of human 
diseases, including autoimmune diseases [11]. 
In this chapter, we highlight the recent research advances in metabolism, in particular to: 
1. The role of metabolism in T cell differentiation and function. 
2. The role of miRNAs in metabolic processes. 
3. Dysregulation of metabolism during autoimmunity. 
2. The role of metabolism in T cell differentiation and function 
The role of cellular metabolism is to generate energy and supply biosynthetic demands in 
order to sustain normal biological functions. In the immune system, the control of cell 
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numbers and activity of different T cell subsets is important for generating an appropriate 
immune response to combat foreign pathogens and prevent the risk of developing 
autoimmunity. The fate of T cells is strongly linked to metabolism by regulating cell growth, 
survival, function and differentiation. 
Naive T cells, having undergone positive and negative selection in the thymus [12; 13], enter 
the periphery and encounter their specific cognate antigens in the context of major 
histocompatibility complexes to become activated, and differentiate into effector T (Teff) or 
induced regulatory T (Treg) cells. Metabolically, naive T cells consume glucose and other 
essential nutrients at a low rate, enough to supply energy to maintain normal housekeeping 
functions [14]. Importantly, naive T cells require extrinsic signals to maintain sufficient 
levels of glucose metabolism to prevent atrophy and apoptosis [15]. 
T cells are activated through the T cell receptor (TCR) and CD28 by the engagement of 
MHC-peptide complexes and B7 family members on antigen presenting cells. During this 
process, the physiological and phenotypic repertoire of the T cells develop in a way to 
support rapid cell growth, proliferation, and the generation of effector T cells, in which 
metabolism plays a critical role [16]. To drive enhanced glucose metabolism in activated T 
cells, the upregulation of expression and trafficking of glucose transporter 1 (Glut1) is 
crucial [17] (Fig. 1). The downregulation of Glut1 in lymphoid cell lines can decrease 
proliferation and cause cell cycle arrest or apoptosis [18; 19]. In contrast, the transgenic 
overexpression of Glut1 in T cells increases cell size, cytokine production, and proliferation 
upon activation [20]. 
The expression of Glut1 in T cells is induced by activation with a strong TCR agonist or 
through the cross-linking of the TCR-associated CD3 protein [21]. Both the MAPK pathway 
(p38) and Myc activation are upstream of Glut1 activation [22; 23] and may mediate the TCR 
dependent control of Glut1. TCR signaling can also activate AMP-activated protein kinase 
(AMPK) [24], which upregulates glucose uptake to promote energy generation [25] and may 
be due in part to the upregulation of Glut1 expression. Following the loss of the TCR, naive 
T cells downregulate the expression of Glut1 [26]. Mitochondrial potential and cellular ATP 
levels are also reduced, which suggests the loss of glucose metabolism. Beside the TCR, 
interleukin (IL)-7 is also a key regulator of glucose uptake in T lymphocytes. IL-7 maintains 
glucose metabolism by promoting Glut1 trafficking [27]. The tyrosine residue at position 449 
of IL-7Rα is required for IL-7–mediated regulation of glucose uptake, which promotes rapid 
activation of signal transducer and activator of transcription 5 (STAT5) and a delayed yet 
sustained activation of Akt [28].  
The intracellular trafficking of Glut1 is important for its localization to the cell surface to 
support glucose uptake. Co-stimulation through CD28 ligation can provide a strong signal to 
direct the trafficking of Glut1 to the cell surface through the activation of the 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway [29]. Akt can be activated through 
the ligation of its N-terminal pleckstrin homology (PH) to phosphatidylinositol (3,4,5)-
triphosphate (PIP3) at the plasma membrane, generated by PI3K from PIP2, and its subsequent 
phosphorylation by 3'-phosphoinositide-dependent protein kinase-1 (PDK-1) [30]. Once 
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activated, Akt can interact with and modulate the activity of different binding partners. The 
increased glucose uptake and augmented glycolysis observed upon CD28 co-stimulation can 
be prevented by LY294002-mediated PI3K inhibition [29], which induces a significant down-
modulation of Glut1. Conversely, PI3K activation is inhibited by cytotoxic T lymphocyte 
antigen-4 (CTLA-4), results in Glut1 internalization where it is targeted to lysosomes for 
degradation and prevents the upregulation of glucose metabolism in activated T cells [31]. 
Although Glut1 plays a central role in T cell glucose metabolism, there are still other 
regulators downstream of the initial glucose uptake. For example, Akt increases hexokinase 
activity to increase glucose phosphorylation to prevent its transport out of the cell [32; 33]. 
In addition, Akt can also promote the activity of the key glycolytic enzyme, 
phosphofructokinase, by the phosphorylation of phosphofructokinase-2 and generation of 
the allosteric activator, 2,6-phospho-fructose [34]. Myc, better known as a regulator of 
proliferation and apoptosis [35], has also been shown to play a pivotal role in activation-
induced glycolysis, being necessary for the upregulation of glycolytic enzymes and 
transporters. However, it still remains unclear as to how these pathways are integrated into 
T cell metabolism. 
T cell activation induces a rapid elevation in oxygen consumption [36]; however, the 
most dramatic increase is in glycolysis. This results in the significant increase in the 
production of lactate, which can adequately guarantee an efficient but quick energy 
supply to the cell [1; 2; 37]. This glycolytic program supplies energy to T cells during 
their rapid differentiation, and the increase in intracellular glucose levels supports the 
pentose phosphate pathway required for the synthesis of nucleic acids, NADPH for 
producing ATP, and lipid synthesis [38]. This metabolism shift to high glycolysis can 
influence T cell function and survival. When glucose metabolism is limited in activated T 
cells, there is a decrease in the proliferation and production of interferon-γ (IFN-γ),  
and an increase in the expression and activation of pro-apoptotic Bcl-2 family proteins 
[39; 40].  
Naive T cells can differentiate into different T cell subsets after stimulation, and during 
differentiation the metabolic program must match the demands of each cell function. 
Treg cells and T helper cells have different metabolic phenotypes: Treg cells prefer lipid 
oxidation and helper T (Th) cells prefer the glycolytic program. Different metabolic 
culture conditions can thus influence T cell differentiation in vitro [2]. The inhibition of 
mTOR and activation of AMPK can increase and decrease the percentage of Treg and Th 
cells, respectively [2]. Hypoxia-inducible factor 1α (HIF1α) is required for the 
upregulation of glycolytic activity, the promotion of Th17 differentiation and inhibition 
of Treg cell differentiation. HIF1α is a key metabolic factor in the mTOR-dependent 
upregulation of glycolysis observed under Th17-skewing conditions [5] and negatively 
regulates Forkhead Box P3 (FOXP3) to inhibit Treg cell differentiation [41]. 
Leptin, a 16-kDa non-glycosylated protein encoded by the ob gene, is classically 
considered a hormone, as it regulates the balance between food intake and energy 
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numbers and activity of different T cell subsets is important for generating an appropriate 
immune response to combat foreign pathogens and prevent the risk of developing 
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functions [14]. Importantly, naive T cells require extrinsic signals to maintain sufficient 
levels of glucose metabolism to prevent atrophy and apoptosis [15]. 
T cells are activated through the T cell receptor (TCR) and CD28 by the engagement of 
MHC-peptide complexes and B7 family members on antigen presenting cells. During this 
process, the physiological and phenotypic repertoire of the T cells develop in a way to 
support rapid cell growth, proliferation, and the generation of effector T cells, in which 
metabolism plays a critical role [16]. To drive enhanced glucose metabolism in activated T 
cells, the upregulation of expression and trafficking of glucose transporter 1 (Glut1) is 
crucial [17] (Fig. 1). The downregulation of Glut1 in lymphoid cell lines can decrease 
proliferation and cause cell cycle arrest or apoptosis [18; 19]. In contrast, the transgenic 
overexpression of Glut1 in T cells increases cell size, cytokine production, and proliferation 
upon activation [20]. 
The expression of Glut1 in T cells is induced by activation with a strong TCR agonist or 
through the cross-linking of the TCR-associated CD3 protein [21]. Both the MAPK pathway 
(p38) and Myc activation are upstream of Glut1 activation [22; 23] and may mediate the TCR 
dependent control of Glut1. TCR signaling can also activate AMP-activated protein kinase 
(AMPK) [24], which upregulates glucose uptake to promote energy generation [25] and may 
be due in part to the upregulation of Glut1 expression. Following the loss of the TCR, naive 
T cells downregulate the expression of Glut1 [26]. Mitochondrial potential and cellular ATP 
levels are also reduced, which suggests the loss of glucose metabolism. Beside the TCR, 
interleukin (IL)-7 is also a key regulator of glucose uptake in T lymphocytes. IL-7 maintains 
glucose metabolism by promoting Glut1 trafficking [27]. The tyrosine residue at position 449 
of IL-7Rα is required for IL-7–mediated regulation of glucose uptake, which promotes rapid 
activation of signal transducer and activator of transcription 5 (STAT5) and a delayed yet 
sustained activation of Akt [28].  
The intracellular trafficking of Glut1 is important for its localization to the cell surface to 
support glucose uptake. Co-stimulation through CD28 ligation can provide a strong signal to 
direct the trafficking of Glut1 to the cell surface through the activation of the 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway [29]. Akt can be activated through 
the ligation of its N-terminal pleckstrin homology (PH) to phosphatidylinositol (3,4,5)-
triphosphate (PIP3) at the plasma membrane, generated by PI3K from PIP2, and its subsequent 
phosphorylation by 3'-phosphoinositide-dependent protein kinase-1 (PDK-1) [30]. Once 
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activated, Akt can interact with and modulate the activity of different binding partners. The 
increased glucose uptake and augmented glycolysis observed upon CD28 co-stimulation can 
be prevented by LY294002-mediated PI3K inhibition [29], which induces a significant down-
modulation of Glut1. Conversely, PI3K activation is inhibited by cytotoxic T lymphocyte 
antigen-4 (CTLA-4), results in Glut1 internalization where it is targeted to lysosomes for 
degradation and prevents the upregulation of glucose metabolism in activated T cells [31]. 
Although Glut1 plays a central role in T cell glucose metabolism, there are still other 
regulators downstream of the initial glucose uptake. For example, Akt increases hexokinase 
activity to increase glucose phosphorylation to prevent its transport out of the cell [32; 33]. 
In addition, Akt can also promote the activity of the key glycolytic enzyme, 
phosphofructokinase, by the phosphorylation of phosphofructokinase-2 and generation of 
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Leptin, a 16-kDa non-glycosylated protein encoded by the ob gene, is classically 
considered a hormone, as it regulates the balance between food intake and energy 
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expenditure. The level of serum leptin is levels is correlated directly with body-fat stores, 
increasing with fat accumulation and decreasing during fasting [4]. In recent years, 
leptin has been proved to be an immune response regulator. Mice with a genetic 
deficiency of leptin (ob/ob) or leptin receptor (ObR) have a reduced susceptibility to 
autoimmunity [42; 43]. Leptin has a specific effect on T cell responses partly by 
increasing Th1 and suppressing Th2 cytokine production. Also, leptin antibody can 
enhance the proliferation and suppress the function of Treg cells by down modulating 
the cyclin dependent kinase inhibitor p27 (p27kip1), and the phosphorylation of the 
extracellular-related kinases 1 (ERK1) and ERK2 [44]. 
There is still much unknown regarding the complete mechanisms of metabolism in T cell 
function in a physiological setting. These mechanisms could also be tissue specific, and the 





Figure 1. Glucose metabolism is activated by TCR, CD28 and cytokines in T cells.  The increase in 
glycolysis is dramatic during T cell activation. In this process, the expression and intracellular 
trafficking of glucose transporter 1 (Glut1) is important as Glut1 controls the first step of glycolysis by 
facilitating the transport of glucose across the plasma membrane. The expression of Glut1 is 
upregulated by TCR and CD28 activation, while the trafficking to the cell surface is potentiated by 
signals from TCR, CD28 and IL-7 via Akt.  
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3. The role of miRNAs in metabolic processes 
Metabolism interferes with the fate of T cells and plays a crucial role in the regulation of 
immunity. Cytokine/TCR signals and many growth factors have been reported to regulate 
metabolic processes [28; 29]. Moreover, microRNAs, a group of short non-coding RNA 
molecules that control gene expression by binding to the 3’ untranslated region (UTR) of 
complementary target mRNAs, are also involved in the regulation of metabolic networks 
[45; 46]. Here, we summarize the recent findings of metabolism regulating miRNAs and 
whether they currently play a role in T cell perturbation either directly or indirectly. 
Insulin-related cell signal pathways regulate glucose metabolism and are related to the 
development of diabetes. The first miRNA identified in this program is the evolutionarily 
conserved and islet-specific miRNA, miR-375, which regulates glucose-induced insulin 
secretion by inhibiting the expression of Myotrophin (Mtpn) [47]. Further studies have 
indicated that miR-375 is regulated by glucose and that miR-375 inhibits glucose-induced 
INS-1E cell proliferation via the targeting of PDK-1 [48]. miR-375 has also been found to 
affect palmitate-induced lipoapoptosis in NIT-1 cells, a NOD-derived β-cell line [49]; here, 
mir-375 increases the susceptibility to palmitate-induced lipoapoptosis by targeting Mtpn. 
Thus, miR-375 emerges as a novel pharmacological target for the treatment of diabetes. 
Additionally, it has been shown that miR-375 can regulate the expression of thymic 
stromal lymphopoietin, a Th2-skewing cytokine in epithelia to help control parasitic 
infection [50]. 
miR-9 is another miRNA that has a possible role in insulin secretion by targeting Onecut-2 
(OC-2) [51]. As OC-2 is a negative regulator of granuphilin, which is known as a key 
regulator of insulin secretion by repressing insulin exocytosis [52], miR-9 is proposed to 
negatively regulate insulin exocytosis. Furthermore, miR-9 expression is regulated during 
glucose-stimulated insulin secretion and modulates Sirtuin 1 (Sirt1) expression in vivo [53], a 
deacetylase that has been implicated in stabilizing Treg cells by stabilizing the expression of 
its master transcription factor FOXP3 [54]. 
The Lin-28/let-7 axis is also involved in glucose metabolism. Overexpression of Lin28a/B in 
mice results in insulin sensitivity, enhanced glucose tolerance, and resistance to diabetes, 
while overexpression of let-7 has the opposite effect [7]. The insulin-PI3K-mTOR signalling 
pathway, which regulates growth and glucose metabolism can be activated by Lin28a/B and 
suppressed by let-7. let-7 target genes in human are associated with type 2 diabetes, and it is 
suggested that enhancing Lin28 or abrogating let-7 may be therapeutically promising for 
treating diseases such as obesity and diabetes. Although the role of this axis has not been 
extensively investigated in T cells, it has been shown that let-7 is involved in regulating the 
sensitivity of T cells to Fas-mediated apoptosis [55]. The mTOR signalling pathway has also 
been shown to be regulated by miR-199a-3p, which alters the susceptibility of tumour cells 
to hypoxia [56]. 
In cardiomyocytes, miR-133 reduces insulin-mediated glucose uptake by decreasing GLUT4 
expression. miR-133 is believed to be expressed specifically in adult cardiac and skeletal 
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muscle tissues where it regulates the differentiation and proliferation of these cells [57]. It 
has been confirmed that the overexpression of miR-133 reduces the protein level of Kruppel-
like factor 15 (KLF15) followed by its downstream target GLUT4. Silencing endogenous 
miR-133 in vitro increases the levels of KLF15 and GLUT4, which indicates a role of miR-133 
in the metabolism of cardiac myocytes [8]. Insulin signalling can be regulated by miR-33a/b, 
which targets the insulin receptor substrate 2, an essential component of the insulin-
signalling pathway in the liver [58]. miR-33a/b also regulates fatty acid metabolism by 
targeting several key enzymes involved in the regulation of fatty acid oxidation, including 
carnitine O-octaniltransferase, carnitine palmitoyltransferase 1A, hydroxyacyl-
CoAdehydrogenase, Sirt6, and AMP kinase subunit-α [58]. Thus, mir-33a/b acts as a 
negative regulator of both insulin signalling and fatty acid oxidation in hepatic cell lines. 
There has yet to be any findings regarding the role of miR-133 and miR-33a/b in the 
modulation of T cells. 
The liver specific miRNA, miR-122, is a key regulator of cholesterol and fatty-acid 
metabolism. Inhibition of miR-122 in the mouse liver results in reduced plasma cholesterol 
levels, increased hepatic fatty-acid oxidation, a decrease in hepatic fatty-acid and cholesterol 
synthesis rates, and the activation of AMPK [59]; interestingly, miR-122 can be induced by 
miR-370, which in turn induces lipogenic genes leading to the regulation of Cpt1α [60]. 
Although primarily thought to be expressed in the liver, miR-122 has been shown to be 
expressed in lymphoma cells. Its upregulation protects these cells towards chemotherapy-
induced cytotoxicity [61]. AMPK is also regulated by miR-451. In glioma cells it has been 
found that increased glucose levels upregulates miR-451 which in turn regulates the AMPK 
pathway to promote cell growth [62].  
HIF1, shown to promote Th17 but inhibit Treg cell differentiation [41], has been found to 
upregulate miR-210 in hypoxic cells. This increase is proposed to provide tumour cells the 
ability to survive under stressful conditions [63; 64]. The negative regulation of HIF1 itself 
has been found through the miR-17-92 cluster [65], miR-22 [66], miR-20b [67; 68], and 
miR-519c [69], and positively regulated indirectly through miR-31 [70] by the 
downregulation of factor-inhibiting hypoxia inducible factor and miR-130 through the P-
body protein DDX6 [71]. In turn, miR-31 and miR-210 negatively regulates FOXP3 
expression in Treg cells [72; 73], which would correlate with their roles in positively 
regulating HIF1 responses and Th17, but not Treg differentiation. Interestingly, HIF1α can 
also be negatively regulated by miR-155 [74], a miRNA that is highly upregulated in Treg 
cells induced by FOXP3 [75]. Also, miR-199a targets both HIF-1α and Sirt1, and thus may 
play a role in Treg cell differentiation [76; 77]. The miR-17-92 cluster also promotes Th1 
responses and prevents induced Treg cell differentiation [78]. Finally miR-130, has also 
been found to be upregulated upon TCR stimulation of CD8+ T cells, and downregulates 
CD69 during differentiation [79]. Even with the wealth of information above, there is a 
lack of evidence that these miRNAs regulate HIF1 in T cells to contribute to the control of 
the differentiation of various T cell subsets. 
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Recent studies have demonstrated that miRNAs are pivotal in T cell development and 
function [80; 81; 82], which indicates that miRNAs are one of the important regulators of the 
immune system. miRNAs have also been implicated in regulating metabolic pathways, 
mostly identified thus far in non-immune cells in controlling blood glucose levels (Fig. 2). 
More research is required to identify whether miRNAs are also involved in the metabolic 
regulation of T cells. The identification of miRNA signatures in various T cell subtypes may 
provide clues towards the cross-regulation between metabolism and miRNA networks in 
lymphocytes [83].  
 
Figure 2. The regulatory network of microRNAs in pancreatic β-Cells. In pancreatic β-Cells some 
miRNAs participate in the insulin signal pathway. miR-375, which is downregulated by glucose, 
suppresses glucose-induced insulin secretion by inhibiting the expression of Myotrophin (Mtpn) and 
inhibits glucose-induced cell proliferation by targeting PDK-1. Glucose can enhance the expression of 
miR-9-2 and miR-9-3, which target Sirt1.  
4. Dysregulation of metabolism during autoimmunity 
The metabolic status of immune cells determines their fate and role in the immune system. 
The basic bioenergetic demands of resting lymphocytes can be essentially supplied by 
oxidative phosphorylation [84], while the increased amount of energy required during their 
activation implies a shift towards aerobic glycolysis. Much evidence exists regarding the 
role of Akt in the activation of mTOR, involved in a myriad of cellular processes, including 
translation, transcription, autophagy, growth and proliferation. mTOR is also known as a 
nutrient and energy “sensor”, since it regulates the expression of multiple nutrient 
transporters [85]. Several studies have indicated that the Akt and mTOR pathways are 
intimately connected, given that the latter can be modulated by Akt, which in turn seems to 
be sensitive to mTOR inhibition by rapamycin [86; 87]. 
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Autoimmune diseases comprises a large number of pathologies characterized by 
exacerbated immune responses against self-antigens. The mechanisms leading to 
autoimmunity are not yet fully understood, but their multifactorial basis is almost clear. 
Given the involvement of these pathways in the activation and differentiation of multiple T 
cell subsets, it is conceivable that alterations in the expression and/or function of one or 
more of the factors involved can lead to a breakdown in immune homeostasis. 
Indeed, both systemic and organ-specific autoimmune diseases seem to rely on genetic, 
infectious and environmental predisposing factors [88]. Systemic lupus erythematosus (SLE) 
is the prototype of systemic autoimmune diseases. Subjects affected are characterized by a 
strong hyperactivation of autoreactive CD4+ T cells and a consequent aberrant expansion of 
B lymphocytes. Large amounts of autoantibodies are secreted, mostly targeting nuclear 
antigens and affecting skin, joints, blood vessels and the central nervous system (CNS) [89]. 
Glomerulonephritis can also occur, due to deposition of immunocomplexes in the kidney. 
Several studies have found in SLE patients marked deficiencies in the number and/or 
suppressive capacity of CD4+CD25high Treg cells [90; 91], although early works also 
identified the abnormal resistance to suppression of Teff cells as a major issue in the loss of 
tolerance characterizing SLE [92]. 
From a molecular point of view, current hypotheses support a sustained activation of the 
Akt-mTOR axis in SLE. In a well known model of murine lupus, the New Zealand Black 
White (NZBW)/F1 hybrid has an elevated expression and activation of Akt and mTOR at the 
glomerular level. Treatment of mice with rapamycin inhibits Akt and mTOR activation, thus 
prolonging mice survival and ameliorating the clinical course of the disease [93]. The hyper-
activation of the Akt pathway in CD4+ T cells from MRL/lpr mice, a model of spontaneous 
lupus, could also be inhibited by the use of specific PI3Kγ inhibitors [94]. An increase in Akt 
activation has been demonstrated in the peripheral blood from SLE patients, concurrently 
with an up-regulation of the phosphorylation of one of its downstream targets, GSK3β [95], 
known as a negative regulator of cell cycle progression [96]. An abnormal activation of 
mTOR has been demonstrated in human SLE [97], and promising results in the treatment of 
the disease have been obtained with rapamycin, which could act by facilitating the 
differentiation of Treg cells and promoting the expansion of other subsets able to limit the T 
cell stimulation of auto-reactive B cells [98]. Beyond Akt and mTOR, a dysregulation in 
leptin expression has also been found in SLE patients [99; 100], but further studies are 
required to unlock the mechanisms that control its secretion. 
A role for the Akt-mTOR axis has also been demonstrated in the pathogenesis of multiple 
sclerosis (MS). MS is an inflammatory disease of the central nervous system, characterized 
by the presence of CD4+ autoreactive T cells able to target myelin-based antigens, thus 
causing the progressive formation of demyelinating lesions and neuronal degeneration 
[101]. Given the target of inflammation, MS is considered an organ-specific autoimmune 
disease. Several studies have tried to clarify the role of different T cell subsets in MS, but 
the complex network of immune cells in this pathology does not make this an easy task. 
In particular, the role of the Treg subsets has not yet been clearly addressed. No 
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differences in numbers of Treg cells seem to exist between healthy subjects and MS 
patients, at least in the peripheral blood, and an increased number has been observed in 
the cerebrospinal fluid [102]. However, alterations in the Treg pool and function have 
been found [102; 103; 104]. Interestingly, gene-expression profile analysis of brains from 
post-mortem MS patients revealed a strong up-regulation of genes involved in cellular 
metabolism, such as Akt and HIF1α [105]. This is consistent with the findings that T cells 
from HIFα-/- mice restimulated ex vivo with myelin oligodendrocyte glycoprotein (MOG) 
peptide display a reduced secretion of IL-17 and are poorly efficient to induce 
experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice [52]. Moreover, 
rapamycin administration is efficacious in treating EAE due to its dual action both on 
Treg and Teff cells [106]. The Akt-mTOR pathway seems to be subjected to leptin 
regulation during the development of EAE. Indeed, MOG-specific CD4+ T cells from 
leptin deficient (ob/ob) mice display a reduction in the activation of Akt and S6, 
downstream of mTOR. Ob/ob mice are resistant to adoptively transferred EAE [42; 107], a 
condition that can be restored by recombinant leptin administration [42]. In humans, 
increased levels of leptin has been detected in the CNS of MS patients [108].  
Inhibitors of the mTOR pathway, such as sirolimus (rapamycin), are already used for the 
treatment of some autoimmune diseases, and many of its analogs constitute as promising 
candidates for a wide range of autoimmune diseases. Further study is required to reveal the 
metabolic signature of each disease in more depth, hence allowing the development of more 
specific and efficacious treatments. 
A clear link has been established between Treg cells and type 1 diabetes (T1D), an 
inflammatory-autoimmune disease characterized by the inflammation and destruction of 
insulin-producing beta cells of the pancreas. This is particularly evident in individuals with 
IPEX (Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked syndrome), in 
which the lack of Treg cells is associated with an increased susceptibility to diabetes [109]. 
The onset and progression of the pathology does not seem to be related to an altered 
number of Treg cells, since most works have demonstrated that there are no differences 
between T1D subjects and healthy controls in the peripheral blood [110; 111]. Most likely, a 
decreased suppressive capacity of Treg cells and an enhanced resistance to suppression of 
Teff cells seem to be the basis of the loss of self-tolerance observed in T1D [112; 113]. What 
really is hidden behind the alterations in T cell functions is still a matter of debate, but 
results from an early study have pointed out a strong activation of Akt in splenocytes from 
NOD mice, which could be prevented by the use of the PI3Kγ inhibitor AS605240 [114]. The 
amelioration observed in the clinical signs of diabetes after PI3K inhibition could be a 
consequence of the increase in Treg expansion as well as Teff suppression, probably due to 
the activation of cAMP response element-binding protein (CREB), a transcription factor 
shown to be involved in Foxp3 expression [115]. Anomalies in the number and function of T 
cell subsets have been also proved in other autoimmune diseases, such as rheumatoid 
arthritis (RA) [116] and psoriasis [117], but we are still far from clarifying the underlying 
molecular mechanisms behind their progression (Fig. 3).  
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the complex network of immune cells in this pathology does not make this an easy task. 
In particular, the role of the Treg subsets has not yet been clearly addressed. No 
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differences in numbers of Treg cells seem to exist between healthy subjects and MS 
patients, at least in the peripheral blood, and an increased number has been observed in 
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been found [102; 103; 104]. Interestingly, gene-expression profile analysis of brains from 
post-mortem MS patients revealed a strong up-regulation of genes involved in cellular 
metabolism, such as Akt and HIF1α [105]. This is consistent with the findings that T cells 
from HIFα-/- mice restimulated ex vivo with myelin oligodendrocyte glycoprotein (MOG) 
peptide display a reduced secretion of IL-17 and are poorly efficient to induce 
experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice [52]. Moreover, 
rapamycin administration is efficacious in treating EAE due to its dual action both on 
Treg and Teff cells [106]. The Akt-mTOR pathway seems to be subjected to leptin 
regulation during the development of EAE. Indeed, MOG-specific CD4+ T cells from 
leptin deficient (ob/ob) mice display a reduction in the activation of Akt and S6, 
downstream of mTOR. Ob/ob mice are resistant to adoptively transferred EAE [42; 107], a 
condition that can be restored by recombinant leptin administration [42]. In humans, 
increased levels of leptin has been detected in the CNS of MS patients [108].  
Inhibitors of the mTOR pathway, such as sirolimus (rapamycin), are already used for the 
treatment of some autoimmune diseases, and many of its analogs constitute as promising 
candidates for a wide range of autoimmune diseases. Further study is required to reveal the 
metabolic signature of each disease in more depth, hence allowing the development of more 
specific and efficacious treatments. 
A clear link has been established between Treg cells and type 1 diabetes (T1D), an 
inflammatory-autoimmune disease characterized by the inflammation and destruction of 
insulin-producing beta cells of the pancreas. This is particularly evident in individuals with 
IPEX (Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked syndrome), in 
which the lack of Treg cells is associated with an increased susceptibility to diabetes [109]. 
The onset and progression of the pathology does not seem to be related to an altered 
number of Treg cells, since most works have demonstrated that there are no differences 
between T1D subjects and healthy controls in the peripheral blood [110; 111]. Most likely, a 
decreased suppressive capacity of Treg cells and an enhanced resistance to suppression of 
Teff cells seem to be the basis of the loss of self-tolerance observed in T1D [112; 113]. What 
really is hidden behind the alterations in T cell functions is still a matter of debate, but 
results from an early study have pointed out a strong activation of Akt in splenocytes from 
NOD mice, which could be prevented by the use of the PI3Kγ inhibitor AS605240 [114]. The 
amelioration observed in the clinical signs of diabetes after PI3K inhibition could be a 
consequence of the increase in Treg expansion as well as Teff suppression, probably due to 
the activation of cAMP response element-binding protein (CREB), a transcription factor 
shown to be involved in Foxp3 expression [115]. Anomalies in the number and function of T 
cell subsets have been also proved in other autoimmune diseases, such as rheumatoid 
arthritis (RA) [116] and psoriasis [117], but we are still far from clarifying the underlying 
molecular mechanisms behind their progression (Fig. 3).  
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between Treg and Teff function is crucial toward the maintenance of self tolerance. Akt, mTOR, HIF1α, 
Myc and Leptin are involved in tipping this balance, and the result of the dampening of Treg function 
or augmentation of Teff function could lead to the development of SLE, MS, T1D or RA. 
Several studies have tried to highlight the genetic and metabolic background that predisposes 
individuals to autoimmune diseases preceding their onset, but this has been difficult due to 
the complex network of the different factors involved. A clear risk factor for the development 
of autoimmunity is represented by the presence of polymorphisms in the Human Leukocyte 
Antigen (HLA) class II locus, but non-HLA loci have also recently been identified. Some 
“autoimmune loci”, such as IL2RA, CTLA4, IL23R, IL10 and PTPN22 are shared by a wide 
range of diseases, while others seem to be specific, such as the VTCN1 (V-set domain 
containing T cell activation inhibitor 1) locus for SLE [118]. Allelic variants in the PTPN22 
locus, encoding for Lymphoid protein tyrosine phosphatase (Lyp), have been associated with a 
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high predisposition to autoimmune diseases, including T1D, MS, SLE and RA. Protein tyrosine 
phosphatases (PTPs) catalyse the release of phosphate groups from tyrosine residues on 
signalling intermediates, thus playing a fundamental role in activating/deactivating specific 
transduction pathways. PTPs have been demonstrated to modulate the signalling events 
following T cell receptor (TCR) engagement with MHC-peptide complexes that lead to the 
activation and differentiation of T cells [119]. From a metabolic point of view, follow-up 
studies indicate that specific “lipidomic” profiles, such as low triglycerides, low levels of 
lysophosphatidylcholine and multiple phospholipids characterize the sera of children that 
later progress to T1D, as well as anomalies in the levels of glutamine, α-ketoglutarate and 
other amino acids [120; 121; 122; 123]. The adoption of metabolomics at a high-throughput 
level has also been useful to uncover these patterns [124]. Vitamin D deficiency has been 
associated with the increased likelihood of the development of autoimmune disease [125], 
including type 1 diabetes, and has been linked to key genes involved in the metabolism of 
25(OH)D [126]. Despite the lack of direct evidence regarding the behaviour of different T cells 
subsets prior to the onset onset of autoimmune diseases, specific alterations in the levels of 
these modulators can be used to assess an individual's predisposing susceptibility to 
autoimmunity. Analysing specific T cell markers on a large scale and integrating them with 
certain genetic and metabolic biomarkers could become a powerful tool for predicting the risk 
and prognosis of specific autoimmune diseases. 
5. Conclusion 
Metabolism has an undoubtedly important role in the definition of the T cell repertoire. The 
constituents of the microenvironment or modulation of T cell responsiveness towards the 
environment controls the direction in which T cells differentiate. This, in turn, could lead to the 
development of autoimmune disease if the proinflammatory players prevail against opposing 
antiinflammatory cues. Although it is becoming clearer as to the role of metabolic networks in 
defining T cell fate and the development of autoimmunity—the molecular basis, especially the 
role of miRNAs in controlling T cell metabolism and sensitivity towards extracellular metabolic 
factors, remain unclear. Various drugs have been produced to tackle tumour growth from a 
metabolic point of view, and new strategies are emerging to target miRNAs as a therapy. Thus, 
the lessons learned from these fields may also contribute towards future therapeutic solutions 
against autoimmunity by specifically targeting T cells at the heart of metabolism. 
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1. Introduction 
Apoptosis, or programmed cell death, comes from a Greek term meaning “the falling off of 
the leaves.”  Apoptosis is also known as cell suicide and is a mechanism that is present in 
most eukaryotic cells to regulate cell numbers. It can be considered as the opposite of 
mitosis. Apoptosis is a normal part of development and is required during development, 
creation of the central nervous system, degeneration of the tadpole tail during 
metamorphosis, and the loss of certain appendages during the larval to pupal 
metamorphosis in holometabolous insects.  
Apoptosis is a major aspect of development and homeostasis. Apoptosis contributes to the 
sculpting of developing structures in vertebrate and invertebrate embryos. Deletion of 
interdigital webs in developing limbs (Hammar & Mottet, 1971), development of the fetal 
intestinal mucosa (Harmon et al., 1984), and retinal development (Penfold & Provis, 1986) all 
involve apoptosis. Apoptosis serves as a major mechanism for the regulation of cell 
numbers. For example, in the visual system of developing vertebrates, apoptosis 
preferentially eliminates neurons that form improper connections (Cowan et al., 1984). In 
the mammalian embryonic central nervous system, over 1/3 of newly formed cells die 
(Oppenheim et al., 1982) and during development of Caenorhabditis elegans 131 of the 1090 
somatic cells die (Ellis & Horvitz, 1986). Some cells seem to die because they have no 
apparent function, such as the Mullerian duct in male embryos (Price et al., 1977). Apoptosis 
can serve as a defense mechanism to remove unwanted and potentially dangerous cells, 
such as self-reactive lymphocytes (Smith et al., 1989).  
During development, the survival of lymphocytes is mediated by both active signaling and 
passive processes that regulate survival. These processes are extremely selective resulting in 
the elimination of the majority of developing lymphocytes (Owen & Jenkinson, 1992). Both 
T- and B-lymphocytes undergo developmental stages and appear to share many regulatory 
mechanisms. For example, the early survival of lymphocyte precursors is mediated 
primarily by cytokines, which both regulate the numbers of progenitors and play critical 
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the mammalian embryonic central nervous system, over 1/3 of newly formed cells die 
(Oppenheim et al., 1982) and during development of Caenorhabditis elegans 131 of the 1090 
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roles in initiating the rearrangement of the antigen receptor genes (Baird et al., 1999). 
Developing lymphocytes must create unique antigen receptors by rearrangement to 
generate the incredible diversity characteristic of an adaptive immune response (Jung et al., 
2006). A consequence of the stochastic nature of this process is that only 1/3 of 
rearrangements are joined appropriately and give rise to a functional antigen receptor (Jung 
et al., 2006). Although several mechanisms ( use of alternative antigen receptor gene loci and 
receptor editing) exist to allow further opportunities for successful rearrangement, the 
majority of lymphocytes fail to generate functional antigen receptors and are thus 
eliminated by programmed cell death (Berg & Kang, 2001; Nemazee, 2006).  
2. Apoptosis and disease 
The suppression of apoptosis increases the susceptibility of an individual to malignancy 
whereas uncontrolled apoptosis is associated with degenerative diseases. These include 
acquired immunodeficiency syndrome (AIDS; Ameison & Capron, 1991), cancer (Ling et al., 
1993), Parkinson's disease (Walkinshaw & Waters, 1995), and Alzheimer's disease (Landfield 
et al., 1992). Abnormally elevated levels of apoptosis have been found in the lymph nodes of 
HIV-infected persons (Muro-Cacho et al., 1995). Indeed a clearer understanding of the 
regulation of apoptosis may result in better therapies.  
In this chapter, we will examine how inappropriate or excessive apoptosis can lead to 
autoimmune disorders, such as type I diabetes, autoimmune thyroid disease, rheumatoid 
arthritis, lupus and others. Furthermore, we present data demonstrating that apoptosis-
related treatments can be effective against various autoimmune disorders.  
3. Type I Diabetes 
Type I diabetes (T1D; also known as insulin-dependent or juvenile-onset diabetes) results 
from a presumed T-cell attack on the insulin-secreting β-cells of the pancreas. Controlled 
apoptotic cell death contributes to normal T-cell selection and education. Among the 
regulatory T-cells that actively suppress effector T-cells, the FOXP3+CD4+CD25high T-cells 
(Tregs) represent one of the best characterized sub-populations. There is accumulating 
evidence of a deficiency in either the frequency or function of Tregs in various human 
autoimmune diseases (Bacchetta et al., 2007), as well as in the pathogenesis of T1D (Brusko 
et al., 2005; Putnam et al., 2005). An increase in Treg apoptosis was found to correlate with a 
decline in suppressive potential of these cells. The fact that both hyperglycemic T1D subjects 
and normoglycemic at-risk subjects showed this phenomenon suggests that Treg apoptosis is 
more a precursor to, rather than a consequence of diabetes (Jailwala et al., 2009). Although 
Treg apoptosis is likely to be one of the peripheral imbalances in T1D, there is very little 
known about the pathways and genes that make Tregs sensitive to apoptosis during the 
period right after the onset of disease. Understanding the mechanism by which cytokine 
deprivation in T1D induces expression of apoptotic genes should identify potential targets 
for novel treatments. 
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Therefore, interruption of normal T-cell selection can result in the generation of autoreactive 
cells (Takuma & Faustman, 2003). However, the mechanisms by which most candidate 
genes predispose to type 1 diabetes remain unclear. A recent study reports that PTPN2, a 
candidate gene for type 1 diabetes, modulates β-cell apoptosis after exposure to type I and II 
interferons (IFNs), cytokines that contribute to β-cell loss in early type 1 diabetes (Santin et 
al., 2011). The PTPN2 gene encodes a phosphatase that is ubiquitously expressed (Doody et 
al., 2009). This phosphatase is induced by IFNγ and a synthetic dsRNA, polyinosinic-
polycitidilic acid (PIC), in β-cells and exacerbates IFNγ- and PIC-induced β-cell apoptosis by 
modulating STAT1 activation (Coli et al., 2010; Moore et al., 2009). However, the 
mechanisms connecting this candidate gene to actual β-cell death remain unclear. Inhibition 
of PTPN2 sensitizes pancreatic β-cells to apoptosis induced by both type I and II IFNs 
(Santin et al, 2011).  
4. Autoimmune Thyroid Diseases 
The Fas and TRAIL pathways are present and functional in the thyroid, and there is 
evidence suggesting their involvement in autoimmune diseases of the thyroid (Bretz et al., 
1999; Kawakami et al 2000). Giordano et al. (1997) reported the constitutive expression of 
FasL (Fas ligand) on normal and Hashimoto's thyroiditis (HT) thyrocytes using 
immunohistochemistry, flow cytometry, and RT-PCR. The percentage of FasL-positive 
thyrocytes in Graves’ thyroid was less than in normal thyroids (Sera et al., 2000). In contrast, 
another study was unable to detect FasL in thyrocytes (Xerri et al., 1997).  
Although it is widely accepted that thyrocytes express the death receptor Fas, little is known 
about how this expression is modulated. It has been demonstrated that there is increased 
expression of Fas in the thyrocytes of patients with Hashimoto’s thyroiditis (Hammond et 
al., 1997). Fas was also upregulated in the thyrocytes of patients with Graves’ disease (Sera 
et al., 2000). The thyroid gland of Graves’ disease patients contains TUNEL-positive 
thyrocytes and PCNA-positive thyrocytes, together with monocuclear cell infiltration (Sera 
et al., 2000). These data suggest that apoptosis and proliferation of thyrocytes may be 
abnormally accelerated, however, the proliferation of thyrocytes may outweigh their 
apoptosis, resulting in hyperplasia. IL-1β-treated thyrocytes become sensitive to apoptosis 
by anti-Fas IgM and activated T cells (Eguchi, 2001). Moreover, IL-1β-stimulated thyrocytes 
show reduced cytotoxic activity toward activated T cells. These results indicate that the IL-
1β produced in the thyroid gland of Graves’ disease patients might act on the thyroctyes to 
reduce their resistance to Fas-mediated apoptosis and lose their cytotoxic activity against 
activated T-cells, thus abolishing the immune-privilege status of the thyroid (Eguchi, 2001). 
This may provide an explanation for the accumulation of activated T cells in the of Graves’ 
disease patients. 
TSH receptor (TSHR) antibodies may be stimulating, blocking, or neutral in their functional 
influences and are found in patients with autoimmune thyroid disease, especially Graves’ 
disease (Morshed et al., 2010). Although neutral TSHR antibodies failed to generate cAMP 
via Gαs effectors, they initiated unique molecular signaling, possibly via recruitment of 
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multiple G proteins (Laugwitz et al., 1996; Büch et al., 2008), and thus influenced multiple 
downstream signal transduction cascades including PKC/MAPK, mTOR/S6K, NF-κB, 
certain cytokines, and oxidative stress signaling and ultimately caused rat thyroid cell 
apoptosis on chronic exposure. These findings suggest that oxidative stress may play a 
significant role in such antibody-induced thyrocyte death and thus exacerbate the chronic 
inflammatory process via antigen-driven mechanisms seen in autoimmune thyroid disease. 
Bcl-2 is mitochondiral protein that inhibits apoptosis (Park & Hockenbery, 1996). Increased 
serum Bcl-2 may be linked to accelerated apoptosis and was observed in patients with 
malignancies (Tas et al., 2006). In euthyroid Hashimoto’s thyroiditis patients compared with 
controls and euthyroid Graves’ disease, increased serum Bcl-2 has been reported (Myśliwiec 
et al., 2006). In a recent study, a tendency towards higher Bcl-2 in Hashimoto’s thyroiditis 
patients was found (Jiskra et al., 2009). Jiskra et al. (2009) further showed that there was no 
difference in serum Bcl-2 between hyperthyroid Graves’ disease and when the euthyroid 
state was achieved.  
5. Systemic Lupus Erythematosus 
A common feature of autoimmune diseases such as systemic lupus erythematosus (SLE), 
systemic sclerosis, and mixed connective tissue disease is the breakdown of tolerance of self 
antigens, a consequence of which is the production of antibodies reactive with multiple self 
proteins (von Mühlen & Tan, 1995). In patients with SLE, increased numbers of apoptotic 
lymphocytes and macrophages have been observed (Emlen et al., 1994). Other proteins have 
been implicated to play a contributing role in the pathogenesis of SLE. Protein phosphatase 
2A (PP2A) is an abundant and ubiquitously expressed, highly conserved enzyme (Janssens 
et al., 2008). It regulates a variety of cellular processes, including cell cycle progression and 
cell division, cell death, cytoskeleton dynamics, and signaling pathways (Janssens & Goris, 
2001; Sontag, 2001). PP2A is composed of a scaffold subunit (A), a catalytic subunit (C), and 
a regulatory (B) subunit. A recent study showed that the subunit Bβ is involved in the 
regulation of programmed cell death triggered by IL-2 deficiency and identified a subset of 
patients with SLE in which altered regulation of PP2A Bβ is associated with resistance to IL-
2 deprivation-induced apoptosis (Crispín et al., 2011). Apoptosis is an essential phenomenon 
that modulates the duration of immune responses and maintains the diversity of the 
lymphoid armamentarium. The importance of this process is well known, and the deficiency 
of central molecules involved in lymphocyte apoptosis causes lymphoproliferative and 
autoimmune diseases in mice and humans (Turbyville & Rao, 2010; Cohen, 2006). Apoptosis 
induced by IL-2 deprivation is triggered by intrinsic cellular signals (Lenardo et al., 1999). 
The balance between anti- and pro-apoptotic Bcl-2 family proteins determines the 
maintenance of the mitochondrial membrane potential. In the presence of IL-2, Bad is 
phosphorylated and sequestered in the cytoplasm by 14-3-3 proteins (Zha et al., 1996; 
Pastorino et al., 1999). Bim, another pro-apoptotic molecule, is absent, and levels of anti-
apoptotic Bcl-2 and Bcl-x are high. During IL-2 deprivation, Bad becomes 
dephosphorylated, dissociates from 14-3-3, and translocates to the mitochondrial membrane 
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where it binds to Bcl-2 and Bcl-x and neutralizes their anti-apoptotic capacity (Zha et al., 
1996; Yang et al., 1995). This process results in the loss of the mitochondrial membrane 
potential and leads to apoptosis. The regulation of T-cell death following activation is 
known to be altered in patients with SLE (Gergely et al., 2002; Xu et al., 2004). Recent results 
indicate that the kinetics of apoptosis following IL-2 deprivation is affected in a fraction of 
patients with SLE (Crispín et al., 2011). Importantly, induction of PP2A Bβ upon IL-2 
withdrawal was suboptimal or completely absent in these patients, which confirms the 
importance of PP2A Bβ as a molecule induced in cytokine withdrawal apoptosis and 
suggests that its faulty expression may underlie the observed phenotype. Mitochondrial 
hyperpolarization (MHP) could also contribute to the apoptosis resistance observed in SLE 
patients upon IL-2 deprivation (Gergely et al., 2002; Fernandez et al., 2006). 
6. Apoptosis in rheumatoid arthritis 
Fas and FasL both exist in membrane (mFas, mFasL) and soluble (sFas, sFasL) forms, but 
only engagement of mFas leads to the activation of caspase-8 via the Fas-associated death 
domain protein (FADD; Okamoto et al., 2000). Activated caspase-8 may lead to apoptosis 
via at least two well-described pathways: direct activation of caspase-3; and alteration of 
mitochondrial transmembrane potentials via Bcl-2 homology 3 (BH3)-interacting death-
domain agonist (BID), leading to the cytoplasmic translocation of cytochrome c, which leads 
to activation of caspase-9, which in turn activates caspase-3 (Peng, 2006). Both pathways are 
regulated at the level of caspase-8 activation by the endogenous inhibitor FADD-like IL-1β-
converting enzyme (FLICE)-inhibitory protein (FLIP), which may also be recruited by 
FADD. Interestingly, FLIP may also participate in an alternate signalling pathway, 
recruiting tumour necrosis factor-associated factor (TRAF) 1, TRAF2, the MAP kinase kinase 
kinase Raf1 and receptor-interacting protein (RIP) to activate extracellular signal-regulated 
kinase (ERK) and nuclear factor κB (NF-κB) pathways, leading to proliferation and/or 
inflammation (Peng, 2006).  
Apoptotic cells are uncommonly observed in rheumatoid arthritis (RA) tissues in vivo, but 
synoviocytes, synovial T cells and macrophages have often been observed to express high 
levels of Fas and/or FasL, and are highly susceptible to Fas/FasL-induced apoptosis in vitro. 
This contrasts with osteoarthritis, in which such abnormalities in Fas/FasL expression and 
susceptibility to Fas-induced apoptosis are generally not observed (Firestein et al., 1995; 
Nakajima et al., 1995). The discrepancy between an absence of apoptotic cells in situ and 
enhanced susceptibility to Fas-induced apoptosis in vitro probably reflects multiple anti-
apoptotic processes and/or phenomena in the rheumatoid synovium (Peng, 2006). For 
instance, increased intrasynovial and/or serum sFas appears to compete with mFas and 
prevent apoptosis of synoviocytes (Hasunuma et al., 1997). Also, in some studies, invading 
T cells have been found to be defective in FasL expression, which may account for 
ineffective clearance of activated (Fas-expressing) cells (Cantwell et al., 1997). In addition, 
synoviocyte- and/or stromal cell-derived cytokines [including transforming growth factor 
(TGF) β1 (Kawakami et al., 1996), basic fibroblast growth factor, TNF-α ,and interleukin-1 
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multiple G proteins (Laugwitz et al., 1996; Büch et al., 2008), and thus influenced multiple 
downstream signal transduction cascades including PKC/MAPK, mTOR/S6K, NF-κB, 
certain cytokines, and oxidative stress signaling and ultimately caused rat thyroid cell 
apoptosis on chronic exposure. These findings suggest that oxidative stress may play a 
significant role in such antibody-induced thyrocyte death and thus exacerbate the chronic 
inflammatory process via antigen-driven mechanisms seen in autoimmune thyroid disease. 
Bcl-2 is mitochondiral protein that inhibits apoptosis (Park & Hockenbery, 1996). Increased 
serum Bcl-2 may be linked to accelerated apoptosis and was observed in patients with 
malignancies (Tas et al., 2006). In euthyroid Hashimoto’s thyroiditis patients compared with 
controls and euthyroid Graves’ disease, increased serum Bcl-2 has been reported (Myśliwiec 
et al., 2006). In a recent study, a tendency towards higher Bcl-2 in Hashimoto’s thyroiditis 
patients was found (Jiskra et al., 2009). Jiskra et al. (2009) further showed that there was no 
difference in serum Bcl-2 between hyperthyroid Graves’ disease and when the euthyroid 
state was achieved.  
5. Systemic Lupus Erythematosus 
A common feature of autoimmune diseases such as systemic lupus erythematosus (SLE), 
systemic sclerosis, and mixed connective tissue disease is the breakdown of tolerance of self 
antigens, a consequence of which is the production of antibodies reactive with multiple self 
proteins (von Mühlen & Tan, 1995). In patients with SLE, increased numbers of apoptotic 
lymphocytes and macrophages have been observed (Emlen et al., 1994). Other proteins have 
been implicated to play a contributing role in the pathogenesis of SLE. Protein phosphatase 
2A (PP2A) is an abundant and ubiquitously expressed, highly conserved enzyme (Janssens 
et al., 2008). It regulates a variety of cellular processes, including cell cycle progression and 
cell division, cell death, cytoskeleton dynamics, and signaling pathways (Janssens & Goris, 
2001; Sontag, 2001). PP2A is composed of a scaffold subunit (A), a catalytic subunit (C), and 
a regulatory (B) subunit. A recent study showed that the subunit Bβ is involved in the 
regulation of programmed cell death triggered by IL-2 deficiency and identified a subset of 
patients with SLE in which altered regulation of PP2A Bβ is associated with resistance to IL-
2 deprivation-induced apoptosis (Crispín et al., 2011). Apoptosis is an essential phenomenon 
that modulates the duration of immune responses and maintains the diversity of the 
lymphoid armamentarium. The importance of this process is well known, and the deficiency 
of central molecules involved in lymphocyte apoptosis causes lymphoproliferative and 
autoimmune diseases in mice and humans (Turbyville & Rao, 2010; Cohen, 2006). Apoptosis 
induced by IL-2 deprivation is triggered by intrinsic cellular signals (Lenardo et al., 1999). 
The balance between anti- and pro-apoptotic Bcl-2 family proteins determines the 
maintenance of the mitochondrial membrane potential. In the presence of IL-2, Bad is 
phosphorylated and sequestered in the cytoplasm by 14-3-3 proteins (Zha et al., 1996; 
Pastorino et al., 1999). Bim, another pro-apoptotic molecule, is absent, and levels of anti-
apoptotic Bcl-2 and Bcl-x are high. During IL-2 deprivation, Bad becomes 
dephosphorylated, dissociates from 14-3-3, and translocates to the mitochondrial membrane 
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where it binds to Bcl-2 and Bcl-x and neutralizes their anti-apoptotic capacity (Zha et al., 
1996; Yang et al., 1995). This process results in the loss of the mitochondrial membrane 
potential and leads to apoptosis. The regulation of T-cell death following activation is 
known to be altered in patients with SLE (Gergely et al., 2002; Xu et al., 2004). Recent results 
indicate that the kinetics of apoptosis following IL-2 deprivation is affected in a fraction of 
patients with SLE (Crispín et al., 2011). Importantly, induction of PP2A Bβ upon IL-2 
withdrawal was suboptimal or completely absent in these patients, which confirms the 
importance of PP2A Bβ as a molecule induced in cytokine withdrawal apoptosis and 
suggests that its faulty expression may underlie the observed phenotype. Mitochondrial 
hyperpolarization (MHP) could also contribute to the apoptosis resistance observed in SLE 
patients upon IL-2 deprivation (Gergely et al., 2002; Fernandez et al., 2006). 
6. Apoptosis in rheumatoid arthritis 
Fas and FasL both exist in membrane (mFas, mFasL) and soluble (sFas, sFasL) forms, but 
only engagement of mFas leads to the activation of caspase-8 via the Fas-associated death 
domain protein (FADD; Okamoto et al., 2000). Activated caspase-8 may lead to apoptosis 
via at least two well-described pathways: direct activation of caspase-3; and alteration of 
mitochondrial transmembrane potentials via Bcl-2 homology 3 (BH3)-interacting death-
domain agonist (BID), leading to the cytoplasmic translocation of cytochrome c, which leads 
to activation of caspase-9, which in turn activates caspase-3 (Peng, 2006). Both pathways are 
regulated at the level of caspase-8 activation by the endogenous inhibitor FADD-like IL-1β-
converting enzyme (FLICE)-inhibitory protein (FLIP), which may also be recruited by 
FADD. Interestingly, FLIP may also participate in an alternate signalling pathway, 
recruiting tumour necrosis factor-associated factor (TRAF) 1, TRAF2, the MAP kinase kinase 
kinase Raf1 and receptor-interacting protein (RIP) to activate extracellular signal-regulated 
kinase (ERK) and nuclear factor κB (NF-κB) pathways, leading to proliferation and/or 
inflammation (Peng, 2006).  
Apoptotic cells are uncommonly observed in rheumatoid arthritis (RA) tissues in vivo, but 
synoviocytes, synovial T cells and macrophages have often been observed to express high 
levels of Fas and/or FasL, and are highly susceptible to Fas/FasL-induced apoptosis in vitro. 
This contrasts with osteoarthritis, in which such abnormalities in Fas/FasL expression and 
susceptibility to Fas-induced apoptosis are generally not observed (Firestein et al., 1995; 
Nakajima et al., 1995). The discrepancy between an absence of apoptotic cells in situ and 
enhanced susceptibility to Fas-induced apoptosis in vitro probably reflects multiple anti-
apoptotic processes and/or phenomena in the rheumatoid synovium (Peng, 2006). For 
instance, increased intrasynovial and/or serum sFas appears to compete with mFas and 
prevent apoptosis of synoviocytes (Hasunuma et al., 1997). Also, in some studies, invading 
T cells have been found to be defective in FasL expression, which may account for 
ineffective clearance of activated (Fas-expressing) cells (Cantwell et al., 1997). In addition, 
synoviocyte- and/or stromal cell-derived cytokines [including transforming growth factor 
(TGF) β1 (Kawakami et al., 1996), basic fibroblast growth factor, TNF-α ,and interleukin-1 
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(Kobayashi et al., 2000a; Tsuboi et al., 1996)] protect RA synoviocytes from Fas-induced 
apoptosis, and such factors may account for the ability of RA T cells to be protected from 
apoptosis via their close interactions with fibroblast-like synoviocytes (Salmon et al., 1997). 
Furthermore, rheumatoid synovial fluid contains high levels of nitric oxide, which inhibits 
caspase-3 (Migita et al., 2001), as well as stromelysin-1 (matrix metalloproteinase-3), which 
can cleave mFasL to produce sFasL, which can compete with death-inducing mFasL 
(Matsuno et al., 2001). Thus, multiple pathways, both intra- and extracellular, impair Fas-
induced apoptosis in RA joints. Still, whether these phenomena actually underlie the disease 
etiology or simply result from the initial inflammatory pathways of RA itself remains 
undetermined. 
7. Sjogren’s Syndrome 
Sjogren’s syndrome (SS) is an autoimmune disorder that affects multiple exocrine glands, 
particular those that produce moisture to coat exposed epithelia such as the oral and ocular 
surfaces. The role of apoptosis in loss of glandular tissue in SS is less clear (Wang et al., 
2006). Environmental and genetic factors appear to contribute to the etiology of SS, although 
the evidence is relatively premature (Bolstad & Jonsson, 2002; Yamamoto, 2003). T-cell-
mediated cytotoxicity (Manganelli & Fietta, 2003; Hayashi et al., 2004) and autoantibodies 
are important in loss of gland function. There is also a failure to remove autoimmune T-cells 
at the level of thymic selection, resistance of T-cells within the gland to undergo apoptosis, 
aberrant expression of increased levels of cell adhesion molecules on glandular epithelial 
cells (facilitating infiltration of autoimmune lymphocytes to glands), up regulation of 
human leukocyte antigen (HLA)-DR, and polyclonal activation of B-lymphocytes (Rehman, 
2003). Glandular epithelial cells contribute to the autoimmune process by secreting pro-
inflammatory cytokines. Specifically, pro-inflammatory cytokines, such as tumor necrosis 
factor (TNF)-α, interleukin (IL)-1β and 6 (Roescher et al., 2010) and (Muraki et al., 2004) in 
the exocrine glands in response to immune-mediated inflammation, are found over-
expressed in the SS patients. IL-6, a potent inflammatory cytokine, is involved in acute 
phase reactions and both B and T-cell responses and the formation of germinal center-like 
structure (Roescher et al., 2010). It was found to be consistently high in saliva and serum and 
in the salivary glands of SS patients, not in subjects with xerostomia (dry mouth) only 
(Roescher et al., 2009). Furthermore, IL-1β is an effective inducer of other inflammatory 
cytokines such as IL-6, IL-8, TNF-α, and granulocyte-macrophage colony-stimulating factor 
(Fibbe et al., 1989; Chrousos, 1995). Dry-eye disease is accompanied by an increase in the 
proinflammatory forms of IL-1 (IL-1 α and mature IL-1 β) and a decrease in the biologically 
inactive precursor IL-1 β in tear fluid of SS patients (Solomon et al., 2001).  
Several studies have analyzed the role of the Fas/FasL system in salivary gland lesions of 
patients with SS. Bolstad et al. (2003) demonstrated a substantial increase in the salivary 
gland tissue expression of the negative regulator molecules PD-1 and CTLA-4 and the 
apoptotic signal molecules Fas and FasL in SS patients compared with controls, suggesting 
the involvement of the Fas/FasL system in the apoptosis of ductal and acinar epithelial cells. 
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Abu-Helu et al. (2001) showed that salivary gland epithelial cell lines (SGEC) constitutively 
expressed more membranous Fas and intracellular FasL than controls, while Shibata et al. 
(2002) detected Fas/FasL expression in ductal and acinar cells of SS patients but not in 
controls. Other studies have suggested that Fas may accelerate the apoptotic death of 
peripheral CD4 T cells in SS patients (Zeher et al., 1999; Ohashi et al., 1996). However, 
Ohlsson et al. (2001) found Fas-induced epithelial cell apoptosis to be a rare event, with a 
frequency of less than 1% in salivary glands from 18 SS patients.  
Loss of p53 activity allows the survival and proliferation of cells that should otherwise be 
eliminated. In primary SS, the expression of p53 and p21 was analyzed in salivary glands 
from 10 patients and 10 controls (Mariette et al., 2002). The p53 antigen was detected in the 
ductal cells of nine SS patients and only one control, and the p21 antigen in eight patients 
and two controls. Both antigens were located in the ductal cells of SS patients, but not in 
acinar cells. The expression of p53 and p21 in the ductal cells located around lymphoid 
infiltrates may represent a defense mechanism allowing DNA repair and thus preventing 
apoptosis, while the lack of over-expression of p53 and p21 in acinar cells could be one of 
the mechanisms responsible for acinar destruction by apoptosis in SS salivary glands.  
Kong et al. (1997) demonstrated in SS that the expression of Bcl-2 makes them resistant to 
apoptotic cell death. Nakamura et al. (2000a) showed that Bcl-2 and Bcl-x were preferentially 
expressed in infiltrating mononuclear cells rather than in the acinar and ductal epithelial 
cells from salivary glands of 17 SS patients, while Ohlsson et al. (2002) detected Bcl-2 (but 
rarely Bax) in the infiltrating lymphocytes of salivary glands from SS patients. However, 
Abu-Helu et al. (2001) found that SGEC cell lines constitutively expressed antiapoptotic 
proteins, such as Bcl-2 and cFLIP, that might protect them from both spontaneous and anti-
Fas mAb-mediated apoptosis. Kamachi et al. (2002) found an inhibitory effect of IFN-γ  in 
Bcl-2 expression, which was enhanced by coadministration of TNFα, leading to an increase 
in the apoptosis of salivary gland cells. It seems that apoptosis of the epithelial acinar and 
ductal cells may depend on the imbalance between up-regulated death-promoters (Fas and 
Bax) and down-regulated apoptosis-suppressor signals (Bcl-2). 
A stronger expression of activated caspase-3 and cleaved PARP in the acinar and ductal cells 
of salivary glands was found in 13/15 (87%) SS patients, while staining for activated caspase-
9 was negative. Nakamura et al. (2000b) analyzed the role of the X chromosome-linked 
inhibitor of apoptosis (XIAP), a member of the IAP family that inhibits the activation of 
caspases, and found a strong expression in the acinar and ductal epithelial cells of SS 
patients but not in those of controls. Because caspase-3 and caspase-7 are effector enzymes, 
XIAP might protect salivary epithelial cells from apoptotic death in SS (Nakamura et al., 
2000b). Hayashi et al. (2003) suggested that treatment with caspase inhibitors might prevent 
the development of the inflammatory process in salivary glands, and Inoue et al. (2001) 
found that caspase-inhibiting agents could inhibit the cleavage of α-fodrin. Increased 
caspase cascade activity may be involved in the progression of autoantigen proteolysis and 
tissue destruction in primary SS. The presence of activated caspase-3 in salivary glands 
indicates that excessive apoptosis may contribute to epithelial destruction in primary SS. 
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(Kobayashi et al., 2000a; Tsuboi et al., 1996)] protect RA synoviocytes from Fas-induced 
apoptosis, and such factors may account for the ability of RA T cells to be protected from 
apoptosis via their close interactions with fibroblast-like synoviocytes (Salmon et al., 1997). 
Furthermore, rheumatoid synovial fluid contains high levels of nitric oxide, which inhibits 
caspase-3 (Migita et al., 2001), as well as stromelysin-1 (matrix metalloproteinase-3), which 
can cleave mFasL to produce sFasL, which can compete with death-inducing mFasL 
(Matsuno et al., 2001). Thus, multiple pathways, both intra- and extracellular, impair Fas-
induced apoptosis in RA joints. Still, whether these phenomena actually underlie the disease 
etiology or simply result from the initial inflammatory pathways of RA itself remains 
undetermined. 
7. Sjogren’s Syndrome 
Sjogren’s syndrome (SS) is an autoimmune disorder that affects multiple exocrine glands, 
particular those that produce moisture to coat exposed epithelia such as the oral and ocular 
surfaces. The role of apoptosis in loss of glandular tissue in SS is less clear (Wang et al., 
2006). Environmental and genetic factors appear to contribute to the etiology of SS, although 
the evidence is relatively premature (Bolstad & Jonsson, 2002; Yamamoto, 2003). T-cell-
mediated cytotoxicity (Manganelli & Fietta, 2003; Hayashi et al., 2004) and autoantibodies 
are important in loss of gland function. There is also a failure to remove autoimmune T-cells 
at the level of thymic selection, resistance of T-cells within the gland to undergo apoptosis, 
aberrant expression of increased levels of cell adhesion molecules on glandular epithelial 
cells (facilitating infiltration of autoimmune lymphocytes to glands), up regulation of 
human leukocyte antigen (HLA)-DR, and polyclonal activation of B-lymphocytes (Rehman, 
2003). Glandular epithelial cells contribute to the autoimmune process by secreting pro-
inflammatory cytokines. Specifically, pro-inflammatory cytokines, such as tumor necrosis 
factor (TNF)-α, interleukin (IL)-1β and 6 (Roescher et al., 2010) and (Muraki et al., 2004) in 
the exocrine glands in response to immune-mediated inflammation, are found over-
expressed in the SS patients. IL-6, a potent inflammatory cytokine, is involved in acute 
phase reactions and both B and T-cell responses and the formation of germinal center-like 
structure (Roescher et al., 2010). It was found to be consistently high in saliva and serum and 
in the salivary glands of SS patients, not in subjects with xerostomia (dry mouth) only 
(Roescher et al., 2009). Furthermore, IL-1β is an effective inducer of other inflammatory 
cytokines such as IL-6, IL-8, TNF-α, and granulocyte-macrophage colony-stimulating factor 
(Fibbe et al., 1989; Chrousos, 1995). Dry-eye disease is accompanied by an increase in the 
proinflammatory forms of IL-1 (IL-1 α and mature IL-1 β) and a decrease in the biologically 
inactive precursor IL-1 β in tear fluid of SS patients (Solomon et al., 2001).  
Several studies have analyzed the role of the Fas/FasL system in salivary gland lesions of 
patients with SS. Bolstad et al. (2003) demonstrated a substantial increase in the salivary 
gland tissue expression of the negative regulator molecules PD-1 and CTLA-4 and the 
apoptotic signal molecules Fas and FasL in SS patients compared with controls, suggesting 
the involvement of the Fas/FasL system in the apoptosis of ductal and acinar epithelial cells. 
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Abu-Helu et al. (2001) showed that salivary gland epithelial cell lines (SGEC) constitutively 
expressed more membranous Fas and intracellular FasL than controls, while Shibata et al. 
(2002) detected Fas/FasL expression in ductal and acinar cells of SS patients but not in 
controls. Other studies have suggested that Fas may accelerate the apoptotic death of 
peripheral CD4 T cells in SS patients (Zeher et al., 1999; Ohashi et al., 1996). However, 
Ohlsson et al. (2001) found Fas-induced epithelial cell apoptosis to be a rare event, with a 
frequency of less than 1% in salivary glands from 18 SS patients.  
Loss of p53 activity allows the survival and proliferation of cells that should otherwise be 
eliminated. In primary SS, the expression of p53 and p21 was analyzed in salivary glands 
from 10 patients and 10 controls (Mariette et al., 2002). The p53 antigen was detected in the 
ductal cells of nine SS patients and only one control, and the p21 antigen in eight patients 
and two controls. Both antigens were located in the ductal cells of SS patients, but not in 
acinar cells. The expression of p53 and p21 in the ductal cells located around lymphoid 
infiltrates may represent a defense mechanism allowing DNA repair and thus preventing 
apoptosis, while the lack of over-expression of p53 and p21 in acinar cells could be one of 
the mechanisms responsible for acinar destruction by apoptosis in SS salivary glands.  
Kong et al. (1997) demonstrated in SS that the expression of Bcl-2 makes them resistant to 
apoptotic cell death. Nakamura et al. (2000a) showed that Bcl-2 and Bcl-x were preferentially 
expressed in infiltrating mononuclear cells rather than in the acinar and ductal epithelial 
cells from salivary glands of 17 SS patients, while Ohlsson et al. (2002) detected Bcl-2 (but 
rarely Bax) in the infiltrating lymphocytes of salivary glands from SS patients. However, 
Abu-Helu et al. (2001) found that SGEC cell lines constitutively expressed antiapoptotic 
proteins, such as Bcl-2 and cFLIP, that might protect them from both spontaneous and anti-
Fas mAb-mediated apoptosis. Kamachi et al. (2002) found an inhibitory effect of IFN-γ  in 
Bcl-2 expression, which was enhanced by coadministration of TNFα, leading to an increase 
in the apoptosis of salivary gland cells. It seems that apoptosis of the epithelial acinar and 
ductal cells may depend on the imbalance between up-regulated death-promoters (Fas and 
Bax) and down-regulated apoptosis-suppressor signals (Bcl-2). 
A stronger expression of activated caspase-3 and cleaved PARP in the acinar and ductal cells 
of salivary glands was found in 13/15 (87%) SS patients, while staining for activated caspase-
9 was negative. Nakamura et al. (2000b) analyzed the role of the X chromosome-linked 
inhibitor of apoptosis (XIAP), a member of the IAP family that inhibits the activation of 
caspases, and found a strong expression in the acinar and ductal epithelial cells of SS 
patients but not in those of controls. Because caspase-3 and caspase-7 are effector enzymes, 
XIAP might protect salivary epithelial cells from apoptotic death in SS (Nakamura et al., 
2000b). Hayashi et al. (2003) suggested that treatment with caspase inhibitors might prevent 
the development of the inflammatory process in salivary glands, and Inoue et al. (2001) 
found that caspase-inhibiting agents could inhibit the cleavage of α-fodrin. Increased 
caspase cascade activity may be involved in the progression of autoantigen proteolysis and 
tissue destruction in primary SS. The presence of activated caspase-3 in salivary glands 
indicates that excessive apoptosis may contribute to epithelial destruction in primary SS. 
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From the studies above, it can be concluded that the extrinsic apoptotic pathway as well as 
the intrinsic apoptotic pathway are involved in the pathogenesis of SS. FasL and its receptor, 
Fas, are essential in the homeostasis of the peripheral immune system. It can be considered 
that a defect in activation-induced cell death of effector T cells may result in the 
development of autoimmune exocrinopathy in Sjogren syndrome (Hayashi et al., 2004). 
Conversely, the increased rate of apoptosis of in epithelial cells in SS may result from either 
the imbalance between the down-regulated apoptosis-inhibitor Bcl-2 and the up-regulated 
apoptosis-inducer Bax, via the intrinsic pathway (Manganelli P & Fietta, 2003). 
8. Apoptosis-related therapies for autoimmune disorders 
Injection of high doses of soluble peptides leads to a state of T‑cell unresponsiveness 
(referred to as anergy) owing to a block in T‑cell proliferation and/or IL-2 production, or 
results in activation-induced cell death (AICD) after T-cell re‑stimulation with the cognate 
peptide (Burstein et al., 1992; Critchfield et al., 1994). It is thought that tolerance induced by 
soluble peptides may be useful for antigen-specific immunotherapy for the treatment of 
human autoimmune diseases. Non-obese diabetic (NOD) mice spontaneously develop type 
1 diabetes, which is characterized by T‑cell-mediated inflammation of the pancreatic islets 
(insulitis) and the eventual destruction of the insulin-producing β‑cells7. Prevention of type 
1 diabetes in NOD mice can be achieved by inducing specific T‑cell tolerance to pancreatic 
β‑cell autoantigens prior to the total destruction of all the islet β-cells (Miller et al., 2007).  
One of the more promising methods to induce tolerance for the prevention and treatment of 
autoimmune diseases, and the prevention of transplant rejection, is intravenous treatment 
with antigen-coupled, ethylene carbodiimide (ECDI)-fixed splenocytes (referred to here as 
antigen coupled cells). Treatment with antigen-coupled cells can induce anergy in vitro and 
peripheral tolerance in vivo (Miller et al., 1979; Sriram et al., 1983). The induction of tolerance 
by antigen‑coupled cell treatment has also been shown to be an effective therapy in other 
disease models, including experimental autoimmune thyroiditis (Braley-Mullen et al., 1980) 
and in the NOD mouse model of diabetes (Fife et al., 2006). Unlike soluble-peptide therapy, 
in which (depending on the disease-inducing autoantigen) the tolerizing antigen can induce 
an anaphylactic response that results in the death of treated mice, antigen-coupled-cell 
therapy does not induce an allergic response, regardless of the antigen used, and appears to 
be well tolerated at all stages of disease (Smith et al., 2005; Pedotti et al., 2001). 
Zauli et al. (2010) showed that recombinant human tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) ameliorated the severity of streptozotocin (STZ)-induced 
type 1 diabetes in a mouse model. Specifically, exogenous recombinant TRAIL, co-injected 
with STZ, significantly reduced the levels of islet damage with respect to animals injected 
with STZ alone (Zauli et al., 2010). Of note, treatment with recombinant TRAIL does not 
impair the viability of pancreatic islets, even when overexpressed (Dirice et al., 2009).  
Thyroid arterial embolization was shown to effectively enhance the positive expression of 
pro-apoptotic genes of Fas, FasL, Bax, Bcl-2 and P53 in Grave’s disease (GD) thyroid, thus 
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promoting apoptosis of GD thyroid and restoring the thyroid size and function to normal 
conditions (Zhao et al., 2009). Furthermore, T lymphocytes from GD patients treated with 
thyroid hormones accompany reduction of Bcl-2 protein expression, production of reactive 
oxygen species, and reduction of mitochondrial delta psi, resulting in apoptotic lymphocyte 
death (Mihara et al., 1999). In a study of patients with Hashimoto’s thyroiditis treated with 
Simvastatin, it was shown that CD4+ cells and B lymphocytes increased while CD8+ cells, 
natural killer cells, and activated T lymphocytes decreased significantly (Gullu et al., 2005). 
This effect is probably mediated via lymphocyte apoptosis as demonstrated with in vitro 
experiments and is not confined to Simvastatin since Mevastatin, Pravastatin and 
Cerivastatin also induced apoptosis in lymphocytes (Gullu et al., 2005). Thyroid cells can be 
sensitized to die via apoptosis by a unique combination of interferon-gamma and IL-1beta 
cytokines. Interferon-gamma/IL-1beta pretreatment sensitizes human thyroid cells to Fas-
mediated apoptosis in a complex manner that overcomes the blockade of initiator caspases 
through increased expression of cell surface Fas receptor, increases in proapoptotic 
molecules that result in mitochondrial activation, and late caspase cleavage (Mezosi et al., 
2005). 
Lupus-prone (NZB x NZW)F1 mice spontaneously develop elevated titers of anti-DNA Abs 
that contain T cell determinants in their V(H) regions. It has been shown that tolerization 
with an artificial peptide based on these T cell determinants (pConsensus (pCons)) can block 
production of anti-DNA Abs and prolong survival of the mice (Singh et al., 1995). These 
data indicate that clinical suppression of autoimmunity after administration of pCons 
depends in part on the generation of CD8+ Ti cells that suppress secretion of anti-DNA Ig 
using mechanisms that include Foxp3, TGFβ, and resistance to apoptosis (Hahn et al., 2005). 
It is postulated that in the CD8+ Ti cells, secretion of TGFβ, expression of Foxp3, and reduced 
apoptosis may likely be linked (Hahn et al., 2005). 
The above studies strongly suggest that modulation of the Fas pathway may serve as 
attractive therapeutic targets. Many current RA therapies are in fact known to induce 
apoptosis in synovial cells, such as methotrexate and TNF-directed therapies, and appear to 
do so at least in part via Fas, at least in some pathogenic cell populations, such as T cells 
and/or synovial macrophages (Oshima et al., 2000; Genestier et al., 1998; Catrina et al., 2005). 
Thus, approaches targeted more specifically against Fas/FasL may be of benefit. 
More direct evidence includes one study demonstrating the ability of anti-sense 
oligonucleotides against FLIP to sensitize RA synoviocytes strongly to Fas-induced 
apoptosis (Palao et al., 2005). Furthermore, in a model in which severe combined 
immunodeficient (scid) mice are engrafted with RA synovium, treatment with an apoptosis-
inducing anti-Fas antibody, as well as gene therapy with FasL or FADD, induces apoptosis 
in both synoviocytes and mononuclear cell populations, diminishing cellular infiltrates 
(Okamoto et al., 1998; Kobayashi et al., 2000b; Matsuno et al., 2002). Thus, if apoptotic 
strategies are to be used therapeutically in inflammatory arthritis, current evidence 
altogether strongly supports activation of the apoptotic Fas pathway as a primary objective, 
at least in RA.  
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Cerivastatin also induced apoptosis in lymphocytes (Gullu et al., 2005). Thyroid cells can be 
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Lupus-prone (NZB x NZW)F1 mice spontaneously develop elevated titers of anti-DNA Abs 
that contain T cell determinants in their V(H) regions. It has been shown that tolerization 
with an artificial peptide based on these T cell determinants (pConsensus (pCons)) can block 
production of anti-DNA Abs and prolong survival of the mice (Singh et al., 1995). These 
data indicate that clinical suppression of autoimmunity after administration of pCons 
depends in part on the generation of CD8+ Ti cells that suppress secretion of anti-DNA Ig 
using mechanisms that include Foxp3, TGFβ, and resistance to apoptosis (Hahn et al., 2005). 
It is postulated that in the CD8+ Ti cells, secretion of TGFβ, expression of Foxp3, and reduced 
apoptosis may likely be linked (Hahn et al., 2005). 
The above studies strongly suggest that modulation of the Fas pathway may serve as 
attractive therapeutic targets. Many current RA therapies are in fact known to induce 
apoptosis in synovial cells, such as methotrexate and TNF-directed therapies, and appear to 
do so at least in part via Fas, at least in some pathogenic cell populations, such as T cells 
and/or synovial macrophages (Oshima et al., 2000; Genestier et al., 1998; Catrina et al., 2005). 
Thus, approaches targeted more specifically against Fas/FasL may be of benefit. 
More direct evidence includes one study demonstrating the ability of anti-sense 
oligonucleotides against FLIP to sensitize RA synoviocytes strongly to Fas-induced 
apoptosis (Palao et al., 2005). Furthermore, in a model in which severe combined 
immunodeficient (scid) mice are engrafted with RA synovium, treatment with an apoptosis-
inducing anti-Fas antibody, as well as gene therapy with FasL or FADD, induces apoptosis 
in both synoviocytes and mononuclear cell populations, diminishing cellular infiltrates 
(Okamoto et al., 1998; Kobayashi et al., 2000b; Matsuno et al., 2002). Thus, if apoptotic 
strategies are to be used therapeutically in inflammatory arthritis, current evidence 
altogether strongly supports activation of the apoptotic Fas pathway as a primary objective, 
at least in RA.  
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A recent study evaluated whether cholinergic autoantibodies contained in IgG purified from 
Sjogren sera could trigger apoptosis of A253 cell line (Reina et al., 2012). The use of A253 cell 
lines has revealed that salivary gland epithelial cells are particularly susceptible to Fas-
mediated as well as Fas-independent apoptotic death after stimulation with IFN-γ, probably 
via the downregulation of the apoptosis inhibitor protein c-FLIP (Abu-Helu et al., 2001). 
Reina et al. (2012) demonstrated that anti-cholinergic autoantibodies in IgG purified from  
primary SS patient’s sera mediates apoptosis of the A253 cell line in an inositol phosphate, 
caspase-3 and metalloproteinase-3 dependent manner. 
9. Summary 
The research reviewed in this chapter clearly demonstrates that there is a delicate balance 
between death and survival signals in the pathogenesis of autoimmune disorders. The 
apoptotic pathways involved may be disease-specific or shared in common. Although the 
precise mechanisms by which apoptosis modulates autoimmune disorders in not fully 
understood, deciphering the role played by apoptosis in these disorders will lead to 
improved treatment modalities for patients. 
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1. Introduction 
Systemic autoimmune diseases, such as systemic lupus erythematosus (lupus, SLE), 
rheumatoid arthritis and systemic sclerosis (scleroderma), occur in up to 5-8% of the human 
population. Based on frequency of occurrence, they are the third most common diseases 
after cardiovascular pathologies and cancers. The overwhelming majority of cases of 
autoimmune diseases are in women (Fairweather & Rose, 2004). 
Nowadays, great attention is paid to studying the impact of environment on the 
development of autoimmunity and autoimmune diseases. This is due to the increased 
influence of anthropogenic factors on the quality of human life. There is a good reason to 
suppose that repeated exposure of people to low doses of heavy metal compounds may 
promote the development of such diseases (Havarinasab et al., 2009). Humans can be 
exposed to these noxious substances from atmospheric pollution, food, cosmetics 
(Bagenstose et al., 1999; Bigazzi, 1998; Pelletier et al., 1994; Rowley & Monestier, 2005), 
dental amalgams (Eneström & Hultman, 1995; Guzzi et al., 2008; Pigatto & Guzzi, 2010), 
thimerosal-containing vaccines (Mutter & Yeter, 2008) and through the regular contacts with 
materials in manufacturing processes (da Costa et al., 2008). 
Mercury is one of the most global environmental pollutants, with human exposure to 
organic, inorganic, and elemental species of mercury occurring in many diverse settings. 
Relatively few studies exist in the literature on the relationship of mercury exposure and 
biomarkers of autoimmunity or autoimmune diseases in humans. Cases of mercury-induced 
autoimmune kidney disease mediated by immune complex (IC) deposition have been noted 
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historically in highly exposed populations (Gardner et al., 2010). A case-control study of 
scleroderma patients found an association between urinary mercury level and severity of 
the disease (Arnett et al., 1996). It is notable that the great artists who used paints containing 
mercury, suffered from autoimmune pathologies. Thus, P. Rubens, P.-A. Renoir, Robert O. 
Duffy suffered from rheumatoid arthritis, while P. Klee had systemic scleroderma (Pedersen 
& Permin, 1988). 
Anti-nuclear (ANA) and anti-nucleolar (ANoA) autoantibodies presence in serum are used 
in the clinical diagnosis of lupus and scleroderma (Ho & Reveille, 2003; Kurien & Scofield, 
2006), and some similarities have been noted between ANA/ANoA profiles in mercury-
induced autoimmunity (HgIA) models and in some patients with scleroderma (Takeuchi et 
al., 1995). The possible influence of mercury on the human population was confirmed by the 
results obtained from the experiments with people exposed by mercury on the gold mine 
sites in Amazonian Brazil (Silbergeld et al., 2005; Silva et al., 2004). Exposure to mercury in 
these populations is related to the use of mercury in riverine small-scale artisanal gold 
mining operations, in which miners are directly exposed to inorganic and elemental 
mercury, and downstream communities can be exposed by consumption of fish 
contaminated by methylmercury in impacted watersheds (Gardner et al., 2010). Exposure to 
either methyl or inorganic mercury in such populations is associated with elevated titers of 
detectable ANA and ANoA (Alves et al., 2006). 
Furthermore, through the use of rodent models, awareness of the direct effects of mercury 
on the immune system has increased. It is well known that the chronic administration of 
subtoxic doses of HgCl2 (mercuric chloride) induces a SLE-like autoimmune disease in 
genetically susceptible inbred mice with H-2s, H-2q, and H-2f haplotypes or their hybrids 
(Hansson & Abedi-Valugerdi, 2003; Hultman et al., 1999; Reuter et al., 1989; Roether et al., 
2002; Rowley & Monestier, 2005; Takeuchi et al., 1995). This HgIA is characterized by T-cell-
dependent polyclonal activation of B-lymphocytes (Abedi-Valugerdi, 2008; Johansson et al., 
1998), increased level of serum immunoglobulins (IgG1 and IgE) (Abedi-Valugerdi et al., 
2000, 2008), production of ANoA and by the formation of IC in different organs impaired 
their functions (Arefieva et al., 2010; Bagenstose et al., 1999; Eneström et al., 1984; 
Havarinasab et al., 2008; Hultman et al., 1989; Robinson et al., 1997). Female mice tend to be 
more susceptible to HgIA, consistent with sex differences observed in autoimmune diseases 
in humans (Fairweather et al., 2008). It is important to notice, that thimerosal (constituent 
part of some vaccines for human) is equipotent to inorganic mercury in eliciting a lupus-like 
immune response in susceptible animals, but mice treated with methylmercury do not 
develop renal or systemic IC deposition (Haggqvist et al., 2005; Havarinasab et al., 2005, 
2007; Havarinasab & Hultman, 2005). 
The interesting thing is that the nucleolar 34-kDa protein fibrillarin is the major 
autoantigen in such autoimmune disorders either in mice or in human. Fibrillarin is one 
of the most evolutionarily conserved proteins and is involved in the early stages of 
maturation of ribosomal RNA (rRNA). This protein can often be a target of autoantibodies 
in various autoimmune disorders (Ho & Reveille, 2003; Rhodes & Vyse, 2007; van 
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Eenennaam et al., 2002; Yang et al., 2003): systemic scleroderma (58% of cases), SLE (39% 
of cases), rheumatoid arthritis (60% of cases). The presence of autoantibodies to fibrillarin 
in patients' blood is a suitable diagnostic marker for the early stages of autoimmune 
diseases development (Tormey et al., 2001). In addition, a recent case-control study 
reported that severely affected scleroderma patients with anti-fibrillarin antibodies (AFA) 
were more likely to have higher levels of mercury in urine as compared either to less 
severely affected cases without AFA or controls suggesting an etiologic role for mercury 
in this autoimmune disease (Arnett et al., 2000). 
It is worth noting that, along with mercury which can induce the production of AFA among 
the genetically predisposed animals, some heavy metals such as silver (Abedi-Valugerdi, 
2008; Hansson & Abedi-Valugerdi, 2003; Suzuki et al., 2011) and gold (Havarinasab et al., 
2007, 2009) have the same ability. In addition, cadmium (Leffel et al., 2003), platinum (Chen 
et al., 2002) and lead (Tabata et al., 2003) are also known to have a negative impact on 
humans and animals. They induce/exacerbate the autoimmune processes in human and 
murine models of autoimmune diseases. However, unlike mercury, they do not cause such 
strong lymphoproliferation, polyclonal activation of lymphocytes and deposition of IC in 
kidneys - the most important features of autoimmune diseases. 
Taken all the foregoing into account, it becomes clear why HgIA in mice is used as a model 
of human systemic autoimmune disorders for testing of immunosuppressive agents and for 
investigating of the molecular mechanisms of heavy metal-induced autoimmunity. 
Following the modern hypothesis of a strong genetical predisposition to autoimmune 
diseases, the majority of animal experiments are conducted on inbred and genetically 
modified mice prone to mercury-induced or spontaneous autoimmunity. However, results 
obtained on such susceptible homozygous mice cannot be fully extrapolated on genetically 
heterogenous human population. That is why it is more correct to use different genetically 
heterogenous (outbred) mouse stocks as laboratory model in analysis of mercury exposure 
and consequences of it on humans. But, there are only a few studies supporting the idea that 
outbred mice are also susceptible to mercury and produce ANoA. It is earlier affirmed that 
development of ANoA production is controlled strictly by the class II of H-2 genes, i.e. only 
certain mouse strains with specific H-2 genotypes (e.g. H-2s and H-2q) produce ANoA upon 
exposure to mercury. Therefore, it was expected that mice carrying the heterozygous H-2 
genotype will be highly resistant to mercury-induced ANoA production. In controversial, it 
has been recently found that chronic treatment with mercury induces production of ANoA 
in a large number of outbred ICR, NMRI and Black Swiss mice (Abedi-Valugerdi, 2008). 
Regarding this matter Dr. Abedi-Valugerdi has spoken his hypothesis about the absence of 
the particular genetical susceptibility to HgIA. It means that unlike in inbred mouse strains, 
H-2 heterozygosity does not confer resistance to mercury-induced ANoA production. In 
other words, environmental factors can induce autoimmunity in the absence of specific 
susceptible genes in members of a genetically heterogenous population. Thus, it allows to 
use outbred mice as suitable model for research of HgIA. 
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As mentioned above, one of the most significant features of HgCl2-induced autoimmune 
process along with appearance of AFA is deposition of immune complexes in kidneys. It is 
necessary to notice that formation of IC in human kidneys is one of the consequences of 
heavy metals exposure or autoimmune diseases (Ohsawa, 1997; Markowitz & D'Agati, 
2009). However, the exact localization and composition of the IC in kidneys, mechanisms of 
its formation and possible cytotoxic effects still remain poorly understood. We have 
performed this work to elucidate these questions and in order to examine whether IC are 
present in other organs of inbred mice. Another goal of our study was to discover whether 
AFA production and IC deposition, which are typical for mercury-induced autoimmunity in 
H-2s and H-2q inbred mouse strains, could be reproduced in outbred mice. 
2. Material and methods 
2.1. Mice 
All studies presented were carried out in female inbred SJL/J and outbred CFW mice, which 
were 8 weeks old at the beginning of each experiment. Animals were obtained from Animal 
Breeding Facility-Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry 
(AAALAC accredited). All animals obtained were axenic at the time of arrival. The health 
status for these mice was confirmed by monitoring in the AnLab laboratory (Czech 
Republic). The mice were housed at the Animal Facilities of the Shemyakin-Ovchinnikov 
Institute of Bioorganic Chemistry of the Russian Academy of Sciences (Moscow, Russian 
Federation) under specific pathogen-free (SPF) conditions with access to tap water and 
standard chow ad libitum. All animal experiments described here were conducted in 
accordance with the "Good Laboratory Practice in Russian Federation" (Decree of the 
Minister of Health of RF #267, dated June 19, 2003), Section 11 of the Declaration of Helsinki 
of the World Medical Association (1964) and the International Guiding Principles for 
Biomedical Research Involving Animals (1985). 
2.2. HgCl2 treatment 
A solution of 0.4 mg/mL HgCl2 (Sigma-Aldrich, St. Louis, MO, USA) was prepared in sterile 
0.9% NaCl solution (OJSC Biochemist, Saransk, Russia). Groups of mice were injected 
subcutaneously (s.c.) with either 0.1 mL of HgCl2 (1.6 mg/kg body weight) or 0.1 mL of 
sterile 0.9% NaCl every third day for 6 weeks. 
2.3. Blood and tissue sampling 
Before the experiment and after 6 weeks of HgCl2 treatment, blood was obtained by retro-
orbital puncture under ether anesthesia. The collected blood was allowed to clot for 30 min 
at 37ºC, centrifuged (800g, 10 min) and the serum obtained was used or stored at -70ºC. 
Then, the mice were euthanized in a CO2 chamber. Their kidneys, liver and spleen were 
dissected out aseptically during the autopsy. The organ pieces were used for cryotomy or 
stored in liquid nitrogen until used. 
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2.4. Detection of anti-nucleolar antibodies 
The presence of serum ANoA was determined by indirect immunofluorescence (IIF) using 
murine NIH/3Т3 cells as a substrate. The cells were grown on glass coverslips in DMEM 
supplemented with 10% FCS, glutamine, penicillin, and streptomycin (Paneco, Moscow, 
Russia) at 37ºC in a 5% CO2 / 95% air atmosphere. Coverslips with attached cells were 
washed in PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 15 min at room 
temperature, rinsed in PBS three times for 10 min, and permeabilized with 0.1% Triton X-
100 in PBS for 10 min on ice, then washed in PBS four times for 5 min. The cells were 
incubated with the primary antibodies (murine sera from autoimmune and control mice) 
diluted 1:100 to 1:10000 in PBS and kept in the dark in a moist chamber for 45 min. Then, the 
cells were washed in PBS three times for 10 min, and incubated with Cy2-conjugated goat 
anti-mouse immunoglobulin G (IgG) antibodies (Jackson ImmunoResearch Lab., West 
Grove, PA, USA), diluted 1:200, for 45 min under the same conditions. Control cells were 
processed at the same time and in the same way, except that PBS was used instead of the 
murine sera. No stained structures were seen in the controls. Then, the cells were washed 
again three times for 10 min, incubated in 1 μg/mL DAPI (4’,6’-diamidino-2’-phenyindole) 
(Sigma-Aldrich, St. Louis, MO, USA) solution at room temperature for 10 min and then 
mounted on slides with Mowiol containing DABCO (1,4-diazabicyclo[2.2.2]octane) (Sigma-
Aldrich, St. Louis, MO, USA). During the experimental period, slides were stored at 4ºC in 
the dark. The titer of ANoA was defined as the highest serum dilution that gave specific 
nucleolar staining (Havarinasab et al., 2008). 
The cells were examined using an Axiovert 200 epifluorescence microscope (Carl Zeiss, 
Oberkochen, Germany) with PlanNeoFluar 40×/NA 0.75, Fluar 100×/NA 1.25, and 
AchroPlan 100×/NA 1.3 objectives. Images were obtained using a 13-bit monochrome 
camera (CoolSnapcf; Roper Scientific, Tucson, AZ, USA). 
2.5. Analysis of immune complexes in kidneys 
The presence of renal IC in kidneys of inbred and outbred mice was detected by direct 
immunofluorescence (DIF). The slides with attached 5-μm thick cryosections (Microm HM 
525, ThermoFisher Scientific, Waltham, MA, USA) were washed in cold PBS and then air-
dried or fixed under various conditions: in absolute acetone/methanol for 5 min or in 4% 
PFA in PBS for 15 min. Some sections were then air-dried after fixation in absolute acetone 
or methanol. After incubation in 4% PFA, slides were washed three times for 10 min and 
permeabilized with 0.1% Triton X-100 in PBS for 10 min on ice, then washed in PBS four 
times for 5 min. After that, the sections were incubated with serial dilutions of either a 
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse total Ig (IgG + IgA + IgM) 
antibodies (Imtek, Moscow, Russia) and/or rabbit anti-mouse complement factor C3 primary 
antibodies (Abcam, Cambridge, UK), diluted 1:10, and Texas Red-conjugated donkey anti-
rabbit IgG secondary antibodies (Jackson ImmunoResearch Lab, West Grove, PA, USA), 
diluted 1:400, in the dark in the moist chamber for 45 min. The initial dilution for FITC-
conjugated antibodies was 1:50. The end-point titer for total immunoglobulins (Ig) was 
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As mentioned above, one of the most significant features of HgCl2-induced autoimmune 
process along with appearance of AFA is deposition of immune complexes in kidneys. It is 
necessary to notice that formation of IC in human kidneys is one of the consequences of 
heavy metals exposure or autoimmune diseases (Ohsawa, 1997; Markowitz & D'Agati, 
2009). However, the exact localization and composition of the IC in kidneys, mechanisms of 
its formation and possible cytotoxic effects still remain poorly understood. We have 
performed this work to elucidate these questions and in order to examine whether IC are 
present in other organs of inbred mice. Another goal of our study was to discover whether 
AFA production and IC deposition, which are typical for mercury-induced autoimmunity in 
H-2s and H-2q inbred mouse strains, could be reproduced in outbred mice. 
2. Material and methods 
2.1. Mice 
All studies presented were carried out in female inbred SJL/J and outbred CFW mice, which 
were 8 weeks old at the beginning of each experiment. Animals were obtained from Animal 
Breeding Facility-Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry 
(AAALAC accredited). All animals obtained were axenic at the time of arrival. The health 
status for these mice was confirmed by monitoring in the AnLab laboratory (Czech 
Republic). The mice were housed at the Animal Facilities of the Shemyakin-Ovchinnikov 
Institute of Bioorganic Chemistry of the Russian Academy of Sciences (Moscow, Russian 
Federation) under specific pathogen-free (SPF) conditions with access to tap water and 
standard chow ad libitum. All animal experiments described here were conducted in 
accordance with the "Good Laboratory Practice in Russian Federation" (Decree of the 
Minister of Health of RF #267, dated June 19, 2003), Section 11 of the Declaration of Helsinki 
of the World Medical Association (1964) and the International Guiding Principles for 
Biomedical Research Involving Animals (1985). 
2.2. HgCl2 treatment 
A solution of 0.4 mg/mL HgCl2 (Sigma-Aldrich, St. Louis, MO, USA) was prepared in sterile 
0.9% NaCl solution (OJSC Biochemist, Saransk, Russia). Groups of mice were injected 
subcutaneously (s.c.) with either 0.1 mL of HgCl2 (1.6 mg/kg body weight) or 0.1 mL of 
sterile 0.9% NaCl every third day for 6 weeks. 
2.3. Blood and tissue sampling 
Before the experiment and after 6 weeks of HgCl2 treatment, blood was obtained by retro-
orbital puncture under ether anesthesia. The collected blood was allowed to clot for 30 min 
at 37ºC, centrifuged (800g, 10 min) and the serum obtained was used or stored at -70ºC. 
Then, the mice were euthanized in a CO2 chamber. Their kidneys, liver and spleen were 
dissected out aseptically during the autopsy. The organ pieces were used for cryotomy or 
stored in liquid nitrogen until used. 
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2.4. Detection of anti-nucleolar antibodies 
The presence of serum ANoA was determined by indirect immunofluorescence (IIF) using 
murine NIH/3Т3 cells as a substrate. The cells were grown on glass coverslips in DMEM 
supplemented with 10% FCS, glutamine, penicillin, and streptomycin (Paneco, Moscow, 
Russia) at 37ºC in a 5% CO2 / 95% air atmosphere. Coverslips with attached cells were 
washed in PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 15 min at room 
temperature, rinsed in PBS three times for 10 min, and permeabilized with 0.1% Triton X-
100 in PBS for 10 min on ice, then washed in PBS four times for 5 min. The cells were 
incubated with the primary antibodies (murine sera from autoimmune and control mice) 
diluted 1:100 to 1:10000 in PBS and kept in the dark in a moist chamber for 45 min. Then, the 
cells were washed in PBS three times for 10 min, and incubated with Cy2-conjugated goat 
anti-mouse immunoglobulin G (IgG) antibodies (Jackson ImmunoResearch Lab., West 
Grove, PA, USA), diluted 1:200, for 45 min under the same conditions. Control cells were 
processed at the same time and in the same way, except that PBS was used instead of the 
murine sera. No stained structures were seen in the controls. Then, the cells were washed 
again three times for 10 min, incubated in 1 μg/mL DAPI (4’,6’-diamidino-2’-phenyindole) 
(Sigma-Aldrich, St. Louis, MO, USA) solution at room temperature for 10 min and then 
mounted on slides with Mowiol containing DABCO (1,4-diazabicyclo[2.2.2]octane) (Sigma-
Aldrich, St. Louis, MO, USA). During the experimental period, slides were stored at 4ºC in 
the dark. The titer of ANoA was defined as the highest serum dilution that gave specific 
nucleolar staining (Havarinasab et al., 2008). 
The cells were examined using an Axiovert 200 epifluorescence microscope (Carl Zeiss, 
Oberkochen, Germany) with PlanNeoFluar 40×/NA 0.75, Fluar 100×/NA 1.25, and 
AchroPlan 100×/NA 1.3 objectives. Images were obtained using a 13-bit monochrome 
camera (CoolSnapcf; Roper Scientific, Tucson, AZ, USA). 
2.5. Analysis of immune complexes in kidneys 
The presence of renal IC in kidneys of inbred and outbred mice was detected by direct 
immunofluorescence (DIF). The slides with attached 5-μm thick cryosections (Microm HM 
525, ThermoFisher Scientific, Waltham, MA, USA) were washed in cold PBS and then air-
dried or fixed under various conditions: in absolute acetone/methanol for 5 min or in 4% 
PFA in PBS for 15 min. Some sections were then air-dried after fixation in absolute acetone 
or methanol. After incubation in 4% PFA, slides were washed three times for 10 min and 
permeabilized with 0.1% Triton X-100 in PBS for 10 min on ice, then washed in PBS four 
times for 5 min. After that, the sections were incubated with serial dilutions of either a 
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse total Ig (IgG + IgA + IgM) 
antibodies (Imtek, Moscow, Russia) and/or rabbit anti-mouse complement factor C3 primary 
antibodies (Abcam, Cambridge, UK), diluted 1:10, and Texas Red-conjugated donkey anti-
rabbit IgG secondary antibodies (Jackson ImmunoResearch Lab, West Grove, PA, USA), 
diluted 1:400, in the dark in the moist chamber for 45 min. The initial dilution for FITC-
conjugated antibodies was 1:50. The end-point titer for total immunoglobulins (Ig) was 
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defined as the highest dilution that gave specific staining. Then, the slides were washed 
three times for 10 min, incubated in DAPI solution, as described above, and then mounted 
with Mowiol containing DABCO. During the experimental period, the slides were stored at 
4ºC in the dark. 
To visualize renal blood vessels varying in size and colocalize them with IC we used 
additional staining of organs with special dye Col-F (kindly furnished by Dr. Jerzy 
Dobrucki), which reveals collagen and elastin fibers that are part of the coats and elastic 
membranes of blood vessels. Halves of organs were washed in DMEM and put in Col-F dye 
solution in DMEM at 37ºC for 1 h. Then, the pieces of kidney were rapidly washed again, 
and cut for cryosections as described previously. To remove damaged/non-specifically 
stained tissue, the first 50-μm thick section was discarded. Fixed in 4% PFA cryosections 
were then washed and incubated according to the DIF method described above. 
With the aim of distinguishing between proximal and distal renal tubules and colocalizing 
them with IC, we performed a staining assay using phalloidin-tetramethylrhodamine B 
isothiocyanate (TRITC; Sigma-Aldrich, St. Louis, MO, USA). This is a fluorescent 
phallotoxin that can be used to detect actin-rich structures, such as the brush border of the 
proximal renal tubules. After fixation cryosections were incubated with a mix of 5 μg/mL 
TRITC-conjugated phalloidin solution and FITC-conjugated goat anti-mouse total Ig 
antibody in the dark in a moist chamber for 45 min, washed, incubated in DAPI and 
mounted with Mowiol. 
The slides were examined using Axiovert 200 epifluorescence and confocal LSM510 
microscopes (Carl Zeiss, Oberkochen, Germany). Images were obtained using a 13-bit 
monochrome camera (CoolSnapcf, Roper Scientific, Tucson, AZ, USA). 
2.5.1. Detection of immunoglobulin isotypes as components of renal IC 
Presence of IgG1, IgG2a and IgM immunoglobulins in kidneys of mercury-treated and 
control mice were determined using DIF, as described previously. To distinguish between 
IgG and IgM classes, we used fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
total Ig (IgG + IgA + IgM) antibodies (Imtek, Moscow, Russia) in combination with TRITC-
conjugated goat anti-mouse IgM secondary antibodies (Jackson ImmunoResearch Lab, West 
Grove, PA, USA). 
To evaluate the presence of IgG1 and IgG2a immunoglobulin isotypes, we used TRITC-
conjugated goat anti-mouse IgG antibodies (Jackson ImmunoResearch Lab, West Grove, PA, 
USA) in combination with FITC-conjugated goat anti-mouse IgG1 or IgG2a secondary 
antibodies (SouthernBiotech, Birmingham, AL, USA). The dilution for all the antibodies 
mentioned was 1:50. 
2.5.2. Glomerular cell death assessment 
The terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) method 
was performed on the kidney cryosections to visualize apoptotic glomerular cells to assess 
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the cytotoxicity of immune deposits. It is widely known that the most common biochemical 
property of apoptosis is the endonucleolytic cleavage of chromatin. This method identifies 
apoptotic cells in situ using terminal deoxynucleotidyl transferase (TdT) to transfer biotin-
dUTP to the free 3’-OH of cleaved DNA. The biotin-labeled cleavage sites were then 
visualized by reaction with fluorescein-conjugated avidin (avidin-FITC). TUNEL staining 
was conducted with a kit (TUNEL Apoptosis Detection Kit, Upstate Biotechnology, Lake 
Placid, NY, USA) according to the manufacturer’s protocol. Next, the slides were incubated 
in DAPI solution, then mounted with Mowiol containing DABCO. The cells were then 
observed using a fluorescence microscope. Sections treated with 1 μg/mL bovine DNase I 
were used as a positive control for the TUNEL assay and DNA fragmentation. 
2.6. Analysis of immune complexes in liver and spleen 
The presence of IC in liver and spleen of inbred and outbred mice was also detected by DIF. 
The slides with attached cryosections were washed in cold PBS and then fixed in 4% PFA in 
PBS for 15 min. After that, the slides were prepared as described above.  
For the blood vessels detection we used the same technique as it was described for kidneys.  
2.7. Assay for in vivo binding of mercury-induced ANoA to the nucleoli of living 
cells 
The colocalization of the mercury-induced ANoA with nucleolar protein fibrillarin within 
the cell nucleoli in mercury-treated outbred mice was detected by the IIF method. Briefly, 
the sections were fixed in 4% PFA, washed, permeabilized and incubated with 1:50 dilution 
of the primary rabbit polyclonal anti-fibrillarin antibodies (Abcam, Cambridge, UK) in the 
dark in the moist chamber for 45 min and washed again. FITC-conjugated goat anti-mouse 
total Ig (IgG + IgA + IgM) antibodies (Imtek, Moscow, Russia) in combination with Texas 
Red-conjugated donkey anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch 
Lab, West Grove, PA, USA), diluted 1:100 and 1:200 respectively, were used as secondary 
antibodies. Then the slides were washed again, stained with DAPI and mounted with 
Mowiol according the IIF technique. 
2.8. Statistical analysis 
Serum levels of ANoA and IC titers are all expressed as means±standard deviation. 
Differences between these parameters for the control and Hg-treated groups were analyzed 
for statistical significance using the Mann-Whitney U-test. P values < 0.05 were considered 
to indicate statistical significance. 
3. Results 
3.1. HgCl2 induces ANoA production in inbred and outbred mice 
To test the ability of mercury to induce ANoA production in inbred and outbred mice, sera 
obtained from experimental and control mice were tested using an IIF technique. Analysis of 
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defined as the highest dilution that gave specific staining. Then, the slides were washed 
three times for 10 min, incubated in DAPI solution, as described above, and then mounted 
with Mowiol containing DABCO. During the experimental period, the slides were stored at 
4ºC in the dark. 
To visualize renal blood vessels varying in size and colocalize them with IC we used 
additional staining of organs with special dye Col-F (kindly furnished by Dr. Jerzy 
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were then washed and incubated according to the DIF method described above. 
With the aim of distinguishing between proximal and distal renal tubules and colocalizing 
them with IC, we performed a staining assay using phalloidin-tetramethylrhodamine B 
isothiocyanate (TRITC; Sigma-Aldrich, St. Louis, MO, USA). This is a fluorescent 
phallotoxin that can be used to detect actin-rich structures, such as the brush border of the 
proximal renal tubules. After fixation cryosections were incubated with a mix of 5 μg/mL 
TRITC-conjugated phalloidin solution and FITC-conjugated goat anti-mouse total Ig 
antibody in the dark in a moist chamber for 45 min, washed, incubated in DAPI and 
mounted with Mowiol. 
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monochrome camera (CoolSnapcf, Roper Scientific, Tucson, AZ, USA). 
2.5.1. Detection of immunoglobulin isotypes as components of renal IC 
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control mice were determined using DIF, as described previously. To distinguish between 
IgG and IgM classes, we used fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
total Ig (IgG + IgA + IgM) antibodies (Imtek, Moscow, Russia) in combination with TRITC-
conjugated goat anti-mouse IgM secondary antibodies (Jackson ImmunoResearch Lab, West 
Grove, PA, USA). 
To evaluate the presence of IgG1 and IgG2a immunoglobulin isotypes, we used TRITC-
conjugated goat anti-mouse IgG antibodies (Jackson ImmunoResearch Lab, West Grove, PA, 
USA) in combination with FITC-conjugated goat anti-mouse IgG1 or IgG2a secondary 
antibodies (SouthernBiotech, Birmingham, AL, USA). The dilution for all the antibodies 
mentioned was 1:50. 
2.5.2. Glomerular cell death assessment 
The terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) method 
was performed on the kidney cryosections to visualize apoptotic glomerular cells to assess 
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was conducted with a kit (TUNEL Apoptosis Detection Kit, Upstate Biotechnology, Lake 
Placid, NY, USA) according to the manufacturer’s protocol. Next, the slides were incubated 
in DAPI solution, then mounted with Mowiol containing DABCO. The cells were then 
observed using a fluorescence microscope. Sections treated with 1 μg/mL bovine DNase I 
were used as a positive control for the TUNEL assay and DNA fragmentation. 
2.6. Analysis of immune complexes in liver and spleen 
The presence of IC in liver and spleen of inbred and outbred mice was also detected by DIF. 
The slides with attached cryosections were washed in cold PBS and then fixed in 4% PFA in 
PBS for 15 min. After that, the slides were prepared as described above.  
For the blood vessels detection we used the same technique as it was described for kidneys.  
2.7. Assay for in vivo binding of mercury-induced ANoA to the nucleoli of living 
cells 
The colocalization of the mercury-induced ANoA with nucleolar protein fibrillarin within 
the cell nucleoli in mercury-treated outbred mice was detected by the IIF method. Briefly, 
the sections were fixed in 4% PFA, washed, permeabilized and incubated with 1:50 dilution 
of the primary rabbit polyclonal anti-fibrillarin antibodies (Abcam, Cambridge, UK) in the 
dark in the moist chamber for 45 min and washed again. FITC-conjugated goat anti-mouse 
total Ig (IgG + IgA + IgM) antibodies (Imtek, Moscow, Russia) in combination with Texas 
Red-conjugated donkey anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch 
Lab, West Grove, PA, USA), diluted 1:100 and 1:200 respectively, were used as secondary 
antibodies. Then the slides were washed again, stained with DAPI and mounted with 
Mowiol according the IIF technique. 
2.8. Statistical analysis 
Serum levels of ANoA and IC titers are all expressed as means±standard deviation. 
Differences between these parameters for the control and Hg-treated groups were analyzed 
for statistical significance using the Mann-Whitney U-test. P values < 0.05 were considered 
to indicate statistical significance. 
3. Results 
3.1. HgCl2 induces ANoA production in inbred and outbred mice 
To test the ability of mercury to induce ANoA production in inbred and outbred mice, sera 
obtained from experimental and control mice were tested using an IIF technique. Analysis of 
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sera obtained from mice at the end of the experiment (after 6 weeks of HgCl2 treatment) showed 
that mercury was able to induce ANoA, in contrast to the saline-injected controls. The mean 
titer of ANoA in group of mercury-treated inbred mice was about 1520, in group of outbred 

















6 weeks of 
HgCl2 5 1520±1772
1,2 17600±78382 14400±32002 40002 
6 weeks of 
NaCl 4 0 1400±400 0 1400±400 
Outbred 
CFW 
6 weeks of 
HgCl2 12 10545±3236
2 6083±20182 4750±18682 13167±84622 
6 weeks of 
NaCl 12 0 1700±249 0 2000±1083 
1 The numbers refer to mean reciprocal titer ± standard deviation; 2 P < 0.05, vs. saline-treated controls (Mann-Whitney 
U-test). 
Table 1. Titers of serum ANoA and IC in kidneys of autoimmune and control mice. 
Sera were incubated on NIH/3T3 cells followed by incubation with FITC-conjugated anti-
mouse immunoglobulin antibodies; they characteristically stained nucleoli of interphase 
cells and peripheral chromosomal material (PCM) in mitotic cells (Fig. 1). Such stained 
regions matched the areas in which the major autoantigen in HgIA, fibrillarin, was revealed. 
 
Figure 1. The nucleolar protein fibrillarin in murine NIH/3T3 cells is identified by serum from SJL/J 
autoimmune mouse treated with HgCl2. A - indirect immunocytochemistry reveals fibrillarin in the 
nucleoli of interphase cells (arrows) and in the peripheral chromosomal material of metaphase cells 
(insert); sera from CFW autoimmune mice reveal the same staining patterns. B - DAPI staining of 
interphase nuclei and metaphase chromosomes. Scale bar - 10 μm. 
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So, we have concluded that six weeks of HgCl2 treatment to female SJL/J and CFW mice 
resulted in strong ANoA production. 
3.2. HgCl2 induces heavy immune complex deposition in kidneys of inbred and 
outbred mice 
3.2.1. Identification of glomerular IC in murine kidneys 
Glomerular IC were revealed with all variants of tissue treatment (Table 2). However, on 
fixed cryosections, the general tissue morphology was better than on unfixed sections. In all 
cases, immune deposits were seen in the form of granules, which in places with the highest 
congestion merged and looked like brightly fluorescing spots (Fig. 2). Under epifluorescence 
and confocal microscopes, immune deposits often repeated the form of the mesangial cells 
and were clearly visible in the plane of the nuclei, as revealed using the dye DAPI or phase 
contrast (Fig. 2, 3). Additionally, only fixing with 4% paraformaldehyde strongly reduced 
the background fluorescence and increased clarity when looking at a tissue; the borders of 
the immune deposits appeared to be much sharper than with the other fixing techniques. 
Additionally, fixed sections could be stored for about 3 months at -70ºC without any 




Air-drying Acetone Acetone/ air-drying Methanol 
Methanol/ 
air-drying 4% PFA 
Glomerular 
mesangium +
1 + + + + + 
Blood vessel walls + + + + + + 
Proximal tubules -2 - - - - + 
1 Presence of IC; 2 absence of IC. 
Table 2. IC in kidneys of HgCl2-treated mice, revealed with various fixing conditions. 
Our results showed a significantly increased titer of immunoglobulins in the glomerular 
mesangium in kidneys of HgCl2-treated animals compared with control mice (Table 1). The 
HgCl2-treated groups of mice showed a mean titer of mesangial Ig of about 17600 (inbred 
mice) and 6083 (outbred mice). The saline-injected control groups showed only 1400 
(inbred) and 1700 (outbred) mean titers of secondary antibodies. 
Moreover, we also have found the deposition of C3 component of complement system as 
part of glomerular IC (Fig. 4). It is necessary to notice that such С3 deposits do not always 
colocalize with regions containing immunoglobulins. This means that there are such areas in 
glomeruli where only C3 is revealed, but at the same time immunoglobulins are not seen. 
The saline-injected control mice were completely devoid of С3 deposits. 
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Figure 1. The nucleolar protein fibrillarin in murine NIH/3T3 cells is identified by serum from SJL/J 
autoimmune mouse treated with HgCl2. A - indirect immunocytochemistry reveals fibrillarin in the 
nucleoli of interphase cells (arrows) and in the peripheral chromosomal material of metaphase cells 
(insert); sera from CFW autoimmune mice reveal the same staining patterns. B - DAPI staining of 
interphase nuclei and metaphase chromosomes. Scale bar - 10 μm. 
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So, we have concluded that six weeks of HgCl2 treatment to female SJL/J and CFW mice 
resulted in strong ANoA production. 
3.2. HgCl2 induces heavy immune complex deposition in kidneys of inbred and 
outbred mice 
3.2.1. Identification of glomerular IC in murine kidneys 
Glomerular IC were revealed with all variants of tissue treatment (Table 2). However, on 
fixed cryosections, the general tissue morphology was better than on unfixed sections. In all 
cases, immune deposits were seen in the form of granules, which in places with the highest 
congestion merged and looked like brightly fluorescing spots (Fig. 2). Under epifluorescence 
and confocal microscopes, immune deposits often repeated the form of the mesangial cells 
and were clearly visible in the plane of the nuclei, as revealed using the dye DAPI or phase 
contrast (Fig. 2, 3). Additionally, only fixing with 4% paraformaldehyde strongly reduced 
the background fluorescence and increased clarity when looking at a tissue; the borders of 
the immune deposits appeared to be much sharper than with the other fixing techniques. 
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mice) and 6083 (outbred mice). The saline-injected control groups showed only 1400 
(inbred) and 1700 (outbred) mean titers of secondary antibodies. 
Moreover, we also have found the deposition of C3 component of complement system as 
part of glomerular IC (Fig. 4). It is necessary to notice that such С3 deposits do not always 
colocalize with regions containing immunoglobulins. This means that there are such areas in 
glomeruli where only C3 is revealed, but at the same time immunoglobulins are not seen. 
The saline-injected control mice were completely devoid of С3 deposits. 
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Figure 2. Immunohistochemical detection of immunoglobulins in glomeruli of autoimmune inbred (A-C) 
and outbred (D-F) mice. Left column - phase contrast, middle column - total immunoglobulin staining, right 
column - merge of immunoglobulin staining and nuclear chromatin DAPI–staining. Arrows point to 
glomerular cells in which it can be clearly seen that immunoglobulins are located in the cytoplasm around 
the cell nucleus. Immunoglobulins in the nuclei of outbred mice are also clearly seen. Scale bar - 30 μm. 
 
Figure 3. Visualization of immunoglobulins in glomerulus of autoimmune mouse under confocal laser 
scanning microscope. A–E: glomerular area reconstructed on the base of serial optical sections (counter-
clockwise rotation model); F: side-view of the reconstructed area (thickness of this area is about 7 μm). 
Scale bar - 30 μm. 
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Figure 4. Localization of immunoglobulins and the C3 component of the complement system as 
components of immune deposits in glomerulus of autoimmune mouse after HgCl2 treatment. A - phase 
contrast, B - total immunoglobulin staining, C - staining of C3 component of the complement system. 
Arrows show the C3-containing areas without immunoglobulins. Scale bar - 30 μm. 
3.2.2. Identification of vascular IC in murine kidneys 
Additionally, only the mercury-treated mice, not the control groups (Table 1), showed IC (Ig 
+ C3) in the walls of renal blood vessels with all variants of tissue treatment (Table 2). This 
finding was confirmed by colocalization of IC with collagen and elastin fibers that are part 
of the coats and elastic membranes of blood vessels, which we revealed using the Col-F dye 
(Fig. 5). Comparison of places with immune deposit localization with collagen and elastin 
staining allowed us to conclude that IC were present in both the endothelial zone of vessels 
and in different layers of the basement of the vessel walls. Using the Col-F dye allowed us to 
conclude that deposits were present in all renal vessel walls, regardless of their size. 
Moreover, Col-F revealed even vessels that were not seen clearly with phase contrast. 
Similarly, glomerular IC could be seen in the form of granules, which in places with the 
highest concentration merged and looked like brightly fluorescing spots.  
The mean titer of vascular Ig in the kidneys of the HgCl2-treated groups of mice reached 
14400 (inbred mice) and 4750 (outbred mice). The saline-injected control groups were 
completely devoid of deposits (Table 1). 
3.2.3. Identification of tubular IC in murine kidneys 
Immune deposits in renal tubules were seen out only when using 4% PFA as a fixative 
(Table 2). IC were seen in discrete granules of approximately equal size (about 1 μm) located 
in tubular epithelial cells (Fig. 6B, C).  
We note that part of the renal tubules contained immune deposits whereas another part had 
none. To determine in which type(s) of renal tubules IC were present, we performed a 
combination of IHC analysis and staining with phalloidin-TRITC. As is well-known, 
phalloidin binds to actin, the basic structural component of the brush border, which is 
present in proximal renal tubules and is not expressed in distal parts. These results suggest 
that immune deposits were seen only in the proximal renal tubules, with a brush border, 
and not in the distal tubules, without a brush border (Fig. 6A, B). 
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Figure 3. Visualization of immunoglobulins in glomerulus of autoimmune mouse under confocal laser 
scanning microscope. A–E: glomerular area reconstructed on the base of serial optical sections (counter-
clockwise rotation model); F: side-view of the reconstructed area (thickness of this area is about 7 μm). 
Scale bar - 30 μm. 
Immune Complex Deposits as a Characteristic Feature  
of Mercury-Induced SLE-Like Autoimmune Process in Inbred and Outbred Mice 129 
 
Figure 4. Localization of immunoglobulins and the C3 component of the complement system as 
components of immune deposits in glomerulus of autoimmune mouse after HgCl2 treatment. A - phase 
contrast, B - total immunoglobulin staining, C - staining of C3 component of the complement system. 
Arrows show the C3-containing areas without immunoglobulins. Scale bar - 30 μm. 
3.2.2. Identification of vascular IC in murine kidneys 
Additionally, only the mercury-treated mice, not the control groups (Table 1), showed IC (Ig 
+ C3) in the walls of renal blood vessels with all variants of tissue treatment (Table 2). This 
finding was confirmed by colocalization of IC with collagen and elastin fibers that are part 
of the coats and elastic membranes of blood vessels, which we revealed using the Col-F dye 
(Fig. 5). Comparison of places with immune deposit localization with collagen and elastin 
staining allowed us to conclude that IC were present in both the endothelial zone of vessels 
and in different layers of the basement of the vessel walls. Using the Col-F dye allowed us to 
conclude that deposits were present in all renal vessel walls, regardless of their size. 
Moreover, Col-F revealed even vessels that were not seen clearly with phase contrast. 
Similarly, glomerular IC could be seen in the form of granules, which in places with the 
highest concentration merged and looked like brightly fluorescing spots.  
The mean titer of vascular Ig in the kidneys of the HgCl2-treated groups of mice reached 
14400 (inbred mice) and 4750 (outbred mice). The saline-injected control groups were 
completely devoid of deposits (Table 1). 
3.2.3. Identification of tubular IC in murine kidneys 
Immune deposits in renal tubules were seen out only when using 4% PFA as a fixative 
(Table 2). IC were seen in discrete granules of approximately equal size (about 1 μm) located 
in tubular epithelial cells (Fig. 6B, C).  
We note that part of the renal tubules contained immune deposits whereas another part had 
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Interestingly, the tubular IC consisted of immunoglobulins, but not the C3 component of 
complement. The mean titer of such deposits in proximal tubules was nearby 4000 (inbred) 
and 13167 (outbred). Besides, elevated titer of IC in the proximal tubules in outbred mice 
(compared with inbred mice) correlated with elevated titer of ANoA in their blood. 
Furthermore, the control group exhibited a lower mean titer of IC - 1400 for inbred mice and 
2000 for outbred mice (Table 1). To our knowledge, this is the first report of immune 
deposits in the proximal renal tubules. 
 
Figure 5. Immunoglobulins in renal blood vessels of varying sizes in autoimmune mice revealed with 
Col-F - a dye specific for collagen and elastic fibers. A, B - immunoglobulins in the blood vessel, which 
is clearly seen under phase contrast: A - phase contrast, B - staining with antiimmunoglobulin 
antibodies (red), Col-F dye (green) and nuclear chromatin staining with DAPI (blue); inserts, arrows - 
immunoglobulins in the endothelial part of this vessel. C, D - immunoglobulins in the blood vessel, 
revealed only by the Col-F dye: C - Col-F dye, D - staining with anti-immunoglobulin antibodies (red) 
and Col-F dye (green). Scale bar - 50 μm. 
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Figure 6. Localization of immunoglobulins in proximal renal tubules in inbred (A, B) and outbred (C) 
mice. A - revealing of brush border (arrows) in proximal tubules of inbred mice with the help of 
Phalloidin-TRITC staining, B - revealing of immunoglobulins in cytoplasm of epithelial cells in 
proximal tubules (arrows) of inbred mice; scale bar - 30 μм. C - revealing of immunoglobulins in 
cytoplasm and nuclei (arrows) of epithelial cells in outbred mice; scale bar - 20 μm. 
3.2.4. Identification of immunoglobulin isotypes as components of IC in kidneys of inbred 
and outbred mice after HgCl2 treatment 
To understand which classes and isotypes of immunoglobulins are found in IC in different 
parts of murine kidneys, we performed combined multicolor DIF. Our results showed that 
immunoglobulin class G (IgG) occurred in all locations of IC: in glomeruli, blood vessel 
walls, and proximal tubules of autoimmune mice, and in glomeruli and proximal tubules of 
control mice. Immunoglobulin class M (IgM) was seen in glomeruli, proximal tubules, 
vessel walls of outbred autoimmune mice, and only in the glomeruli of both inbred 
autoimmune and control mice (Table 3). We did not assess whether immunoglobulin class A 
(IgA) was part of the immune complexes. 
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Mouse 
stock Localization 
IgG + IgM + 
IgA IgG1 IgG2a IgM 










1 + + + -2 ±3 + + 
Blood vessel 
walls - + - + - - - - 
Proximal 
tubules + + + + - + - - 









mesangium ± + ± + - - ± + 
Blood vessel 
walls - + - + - - - ± 
Proximal 
tubules + + ± + - ± - + 
Nucleoli - + - + - + - - 
1 Presence of IC; 2 absence of IC; 3 slight deposits. 
Table 3. Occurrence of different immunoglobulin isotypes as components of IC in kidneys of 
autoimmune and control mice. 
Next, we tried to determine the IgG isotypes in IC. The results showed that the mesangial 
IgG deposits were dominated by the IgG1 isotype, but also contained IgG2a, consistent with 
Havarinasab et al. (2008). At the same time, we found only the IgG1 isotype in renal vessel 
wall deposits and both IgG1 and IgG2a isotypes in proximal tubule deposits (Table 3). The 
saline-injected control mice showed an absence of IgG2a deposits. 
3.2.5. Assessment of possible IC toxicity in murine kidneys 
To analyze the possible cytotoxicity of renal IC, we used the TUNEL method, which reveals 
fragmentation of DNA, a sign of cell destruction, in situ. The results showed that in 
glomeruli of both experimental and control animal groups, there was no significant increase 
in TUNEL-positive (i.e., apoptotic) cells. 
3.3. Identification of IC in liver and spleen of inbred and outbred mice after 
HgCl2 treatment 
In the liver, a granular fixation of the anti-Ig antibodies was observed in the blood vessel walls 
of mercury-treated mice and, in contrast with earlier studies, in the liver hepatocytes in all 
groups of mice (Fig. 7). As in the kidneys, our results showed a significantly increased titer of 
Ig in the hepatocytes of HgCl2-treated animals compared with control mice (not shown). 
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In the spleen, an intense granular pattern of the anti-Ig antibodies fixation was observed in 
the blood vessel walls and in the cells of lymphoid follicles, germinal centers, marginal 
zones and periarterial lymphatic sheaths (PALS) in mercury-treated mice (Fig. 8A, B).  
White pulp of control animals had very rare and small germinal centers (these centers are 
known to appear during the Th2-dependent immune reactions). In contrast, germinal 
centers after the mercury chloride treatment were enlarged, prominent and quite frequent in 
all mice. Therefore, clear morphological attributes of Th2-antibody-producing immune 






Figure 7. Immunohistochemical detection of immunoglobulins in liver of autoimmune inbred (A-B) 
and outbred (C-D) mice. A, C - immunoglobulins in liver blood vessels (total immunoglobulin staining); 
B, D - immunoglobulins in hepatocytes (merge of immunoglobulin staining and nuclear chromatin 
DAPI–staining), arrows point to nuclei in which immunoglobulins can be clearly seen. Scale bar - 20 μm. 
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Figure 8. Immunohistochemical detection of immunoglobulins in spleen of autoimmune inbred (A) and 
outbred (B-E) mice. A, B - immunoglobulins in spleen blood vessels (A-central artery, arrows) and white 
pulp (F-follicle, G-germinal center, P-PALS), scale bar - 50 μm. C-E - results of colocalizing procedure: C - 
total immunoglobulin staining, D - staining with antifibrillarin antibodies, E - merge of 
immunoglobulin and fibrillarin staining patterns (yellow - arrows), scale bar - 20 μm. 
3.4. Mercury-induced ANoA bind to the nucleoli of the kidney, liver and spleen 
cells in outbred mice in vivo 
After analyzing the organs such as kidney, liver and spleen in all animals after 6 weeks of 
HgCl2 treatment, we noticed some differences in the staining patterns in tissues from inbred 
and outbred mice following the method of DIF. As shown in Fig. 2, 6, 7, 8 most of the cells in 
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the kidney, liver and spleen sections of mercury-treated outbred mice exhibited a strong 
nucleolar staining pattern with high titers of IgG1 and IgG2a immunoglobulins (Table 3). A 
nucleolar green fluorescence was found in the cells of the tissue sections prepared from the 
mercury- but not saline-injected mice. It should be noted that such intranucleolar staining 
was absent in nucleoli of inbred mercury-treated mice. 
In a purpose of better understanding of autoantigen specificity, we colocalized such 
nucleolar patterns recognized by FITC- conjugated anti-Ig antibodies with loci recognized 
by commercial antibodies to nucleolar protein fibrillarin. The colocalizing procedure 
showed the whole coincidence of regions containing immunoglobulins with sites of 
nucleolar protein fibrillarin localization (Fig. 8C, D, E), allowing us to offer the hypothesis 
about different capability of autoantibodies to penetrate the cells in inbred and outbred mice 
after HgCl2 treatment. 
These results demonstrate for the first time that injection of mercury into the genetically 
geterogenous outbred mice induced autoantibodies which are able to penetrate into the cells 
of certain organs and react with their corresponding nucleolar antigens in vivo.  
4. Discussion 
The main hallmark of mercury-induced autoimmunity in genetically susceptible mice is the 
production of ANoA against the 34 kDa nucleolar protein fibrillarin (Abedi-Valugerdi, 
2008). Because lots of studies have demonstrated that only homozygous mouse strains with 
susceptible H-2 genotypes are able to produce ANoA after mercury treatment, we next 
performed this work to test the ability of such heavy metal to induce ANoA production and 
IC deposition in heterozygous mouse population.  
As demonstrated in Table 1 , 6 weeks of HgCl2 treatment induced the ANoA production in 
both inbred and outbred mice in variable titers, whereas control saline-treated mice did not 
show any ANoA production. Moreover, it should be noted that magnitude of mercury-
induced ANoA in outbred mice was even higher than that induced in inbred mice.  
Another characteristic feature of HgIA we tested was the deposition of immune complexes 
in the kidney. According to literature reports, revealing IC in different parts of the kidney in 
autoimmune animals is usually done in two basic ways: on air-dried and acetone-fixed 
cryosections or on formaldehyde-fixed and paraffin-embedded sections (Chowdhury et al., 
2005; Gobe & Nikolic-Paterson, 2005). Each of these procedures has its own advantages and 
disadvantages. Immunofluorescence (IF) staining of renal biopsies for the deposition of 
immunoglobulins and complement components is often the primary approach for a 
differential diagnosis of glomerular disease. However, a limitation of such IF applications is 
that they require frozen sections, which can suffer a loss of structural integrity during the 
process of tissue freezing (Gobe & Nikolic-Paterson, 2005). On the other hand, the problem 
with formaldehyde-fixed and paraffin-embedded sections is that tissue antigens are often 
denatured or masked (Chowdhury et al., 2005). 
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Thus, in the present work we tried to combine these approaches by fixing renal cryosections 
with formaldehyde under standard conditions along with routine clinical air-drying or 
acetone-fixing. This allowed us to use the highly informative IF method.  
We showed that treatment of the cryosections with organic fixatives (acetone and methanol) 
led to appreciable damage of the renal tissue, but did not interfere with revealing IC in 
kidneys. These observations correlate well with scanning electron microscopy data, which 
showed damage to the plasma membrane of cells by fixing with acetone and methanol 
(Hoetelmans et al., 2001). We do not favor the air-drying of sections; despite its simplicity, 
preservation of cells on such cryosections was poor. Thus, the best choice of fixative for cell 
preservation was paraformaldehyde; it also appeared to be best in the context of 
information in that using it, we found out IC in renal proximal tubules in kidneys in all 
groups of mice. To our knowledge, there is no previous report on the presence of IC in 
proximal renal tubes. 
In view of the fact that treatment with the organic fixatives leads to dehydration of the 
tissue, removing many water-soluble intracellular proteins, we suggest that the IC in 
proximal renal tubules consist largely of water-soluble complexes. Further, it does not seem 
strange that only the proximal tubules contained IC, while the distal tubules lacked them. It 
is known that molecules as big as immunoglobulins can be reabsorbed only in the proximal 
tubules, while the main function of the distal parts of the nephron is reabsorbtion of 
electrolytes. 
In contrast to deposits in proximal renal tubules, glomerular IC in kidneys of autoimmune 
animals have been mentioned in the literature many times (Abedi-Valugerdi et al., 1997; 
Bigazzi, 1999; Havarinasab et al., 2008; Hultman et al., 1987, 1992, 1993; Kono et al., 2001). 
However, there is a question as to where (in mesangial cells and/or on their surface) they are 
located. Our results, merging areas with IC and DAPI staining by epifluorescence and 
confocal microscopy, suggest that, at least, the major part of deposits is localized inside the 
cells. Nevertheless, we cannot exclude the possibility that some part of the deposits is 
situated on the cell surface. For a definitive conclusion about the localization of glomerular 
IC, a study using electron IHC is necessary. 
In addition to renal IC, we have found immune deposits in increased titers in liver 
hepatocytes and the white pulp spleen cells, suggesting in favor that HgIA is a 
comprehensive process involving many organs. 
Furthermore, the development of HgIA is accompanied by the occurrence of IC in blood 
vessel walls (Hultman et al., 1993). It was recently shown that the dye Col-F binds 
selectively with the collagen and elastin fibrils in coats and elastic membranes of blood 
vessels in native tissues. However, the possibility of using Col-F in combination with the 
IHC analysis has not been reported previously. Thus, an original protocol for the 
simultaneous staining of collagen and elastin fibrils and immunolabeling of immune 
deposits was developed. Our observations, based on specific staining of collagen and elastic 
fibers as a part of vessel walls with the dye Col-F, allowed us to localize the IC in both the 
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endothelial zone and across the whole width of the vessel walls in kidney, liver and spleen 
of mercury-treated mice. Additionally, revealing fibers using Col-F allowed us to visualize 
even the small vessels that were poorly identified with phase contrast because of elastic 
membrane thinning and luminal occlusion after tissue freezing. 
According to our results, IC were present not only in organs of autoimmune mice, but also 
in the glomeruli, renal proximal tubules, hepatocytes and in the cells of spleen lymphoid 
follicles of control animals, although at a much lower level. This does not seem strange, 
because it is well-known in medicine that autoantibodies are found not only in the blood of 
autoimmune patients, but also in healthy individuals. In particular, sera from healthy 
people are capable of staining different cells (e.g., Hep-2) in an IIF reaction (Koelsch et al., 
2007). However, the concentration (titer) of such antibodies is at least an order of magnitude 
less than in autoimmune patients. So, it seems possible that such antibodies in renal 
glomeruli, hepatocytes and proximal tubules could be derived from blood by filtration and 
primary urine by reabsorbtion, respectively, and become deposited in the cells. And the 
presence of immunoglobulins in cells of lymphoid follicles in the spleen is a sign of the 
normal functioning of the immune system. 
Our investigation shows that immune complex deposits can differ not only in quantity, but 
also in composition. The C3 component of the complement system was seen as part of the 
renal IC only in the glomeruli and blood vessel walls, but not in the proximal tubules. In 
contrast with earlier studies (Hultman et al., 1987), the present investigation showed that 
some areas of the glomeruli containing С3 lacked Ig. Reasons for these features of IC 
composition can be a subject of future research. For these purposes, use of a laser 
microdissector with subsequent mass-spectrometric analysis of the cut areas may be useful. 
Moreover, as described in the Results, renal IC consist of not only different classes but also 
different immunoglobulin isotypes. We demonstrated that glomerular IC include IgG, IgM, 
and, possibly, IgA immunoglobulins, while the vessel wall and proximal tubules contain 
almost no IgM. 
More interesting is the occurrence of IgG immunoglobulin isotypes in the immune 
complexes. Results from initial studies suggested that HgIA in mice is mediated by a T 
helper type 2 (Th2) response (i.e., polyclonal B cell activation with hyper-IgE and -IgG1 
production) (Abedi-Valugerdi, 2008; Gillespie et al,. 1995, 1996; Goldman et al., 1991; Ochel 
et al., 1991). However, further studies have revealed that the development of mercury-
induced autoimmune manifestations cannot be explained simply by Th2-based immune 
response (Abedi-Valugerdi, 2008). In particular, IFN-ɣ, a key cytokine produced by 
activated T helper type 1 (Th1) cells, induces IgG2a response in the mouse and is absolutely 
required for the induction of ANoA production in this autoimmune condition (Abedi-
Valugerdi 2008; Kono et al., 1998). Our results are consistent with this. Despite the Th2-
dependent appearing of germinal centers in spleen after HgCl2-treatment and the 
prevalence of the Th2-mediated IgG1 isotype as a component of IC, we also saw some IgG2a 
in the deposits, arguing in favor of Th1 activation too. 
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Thus, in the present work we tried to combine these approaches by fixing renal cryosections 
with formaldehyde under standard conditions along with routine clinical air-drying or 
acetone-fixing. This allowed us to use the highly informative IF method.  
We showed that treatment of the cryosections with organic fixatives (acetone and methanol) 
led to appreciable damage of the renal tissue, but did not interfere with revealing IC in 
kidneys. These observations correlate well with scanning electron microscopy data, which 
showed damage to the plasma membrane of cells by fixing with acetone and methanol 
(Hoetelmans et al., 2001). We do not favor the air-drying of sections; despite its simplicity, 
preservation of cells on such cryosections was poor. Thus, the best choice of fixative for cell 
preservation was paraformaldehyde; it also appeared to be best in the context of 
information in that using it, we found out IC in renal proximal tubules in kidneys in all 
groups of mice. To our knowledge, there is no previous report on the presence of IC in 
proximal renal tubes. 
In view of the fact that treatment with the organic fixatives leads to dehydration of the 
tissue, removing many water-soluble intracellular proteins, we suggest that the IC in 
proximal renal tubules consist largely of water-soluble complexes. Further, it does not seem 
strange that only the proximal tubules contained IC, while the distal tubules lacked them. It 
is known that molecules as big as immunoglobulins can be reabsorbed only in the proximal 
tubules, while the main function of the distal parts of the nephron is reabsorbtion of 
electrolytes. 
In contrast to deposits in proximal renal tubules, glomerular IC in kidneys of autoimmune 
animals have been mentioned in the literature many times (Abedi-Valugerdi et al., 1997; 
Bigazzi, 1999; Havarinasab et al., 2008; Hultman et al., 1987, 1992, 1993; Kono et al., 2001). 
However, there is a question as to where (in mesangial cells and/or on their surface) they are 
located. Our results, merging areas with IC and DAPI staining by epifluorescence and 
confocal microscopy, suggest that, at least, the major part of deposits is localized inside the 
cells. Nevertheless, we cannot exclude the possibility that some part of the deposits is 
situated on the cell surface. For a definitive conclusion about the localization of glomerular 
IC, a study using electron IHC is necessary. 
In addition to renal IC, we have found immune deposits in increased titers in liver 
hepatocytes and the white pulp spleen cells, suggesting in favor that HgIA is a 
comprehensive process involving many organs. 
Furthermore, the development of HgIA is accompanied by the occurrence of IC in blood 
vessel walls (Hultman et al., 1993). It was recently shown that the dye Col-F binds 
selectively with the collagen and elastin fibrils in coats and elastic membranes of blood 
vessels in native tissues. However, the possibility of using Col-F in combination with the 
IHC analysis has not been reported previously. Thus, an original protocol for the 
simultaneous staining of collagen and elastin fibrils and immunolabeling of immune 
deposits was developed. Our observations, based on specific staining of collagen and elastic 
fibers as a part of vessel walls with the dye Col-F, allowed us to localize the IC in both the 
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endothelial zone and across the whole width of the vessel walls in kidney, liver and spleen 
of mercury-treated mice. Additionally, revealing fibers using Col-F allowed us to visualize 
even the small vessels that were poorly identified with phase contrast because of elastic 
membrane thinning and luminal occlusion after tissue freezing. 
According to our results, IC were present not only in organs of autoimmune mice, but also 
in the glomeruli, renal proximal tubules, hepatocytes and in the cells of spleen lymphoid 
follicles of control animals, although at a much lower level. This does not seem strange, 
because it is well-known in medicine that autoantibodies are found not only in the blood of 
autoimmune patients, but also in healthy individuals. In particular, sera from healthy 
people are capable of staining different cells (e.g., Hep-2) in an IIF reaction (Koelsch et al., 
2007). However, the concentration (titer) of such antibodies is at least an order of magnitude 
less than in autoimmune patients. So, it seems possible that such antibodies in renal 
glomeruli, hepatocytes and proximal tubules could be derived from blood by filtration and 
primary urine by reabsorbtion, respectively, and become deposited in the cells. And the 
presence of immunoglobulins in cells of lymphoid follicles in the spleen is a sign of the 
normal functioning of the immune system. 
Our investigation shows that immune complex deposits can differ not only in quantity, but 
also in composition. The C3 component of the complement system was seen as part of the 
renal IC only in the glomeruli and blood vessel walls, but not in the proximal tubules. In 
contrast with earlier studies (Hultman et al., 1987), the present investigation showed that 
some areas of the glomeruli containing С3 lacked Ig. Reasons for these features of IC 
composition can be a subject of future research. For these purposes, use of a laser 
microdissector with subsequent mass-spectrometric analysis of the cut areas may be useful. 
Moreover, as described in the Results, renal IC consist of not only different classes but also 
different immunoglobulin isotypes. We demonstrated that glomerular IC include IgG, IgM, 
and, possibly, IgA immunoglobulins, while the vessel wall and proximal tubules contain 
almost no IgM. 
More interesting is the occurrence of IgG immunoglobulin isotypes in the immune 
complexes. Results from initial studies suggested that HgIA in mice is mediated by a T 
helper type 2 (Th2) response (i.e., polyclonal B cell activation with hyper-IgE and -IgG1 
production) (Abedi-Valugerdi, 2008; Gillespie et al,. 1995, 1996; Goldman et al., 1991; Ochel 
et al., 1991). However, further studies have revealed that the development of mercury-
induced autoimmune manifestations cannot be explained simply by Th2-based immune 
response (Abedi-Valugerdi, 2008). In particular, IFN-ɣ, a key cytokine produced by 
activated T helper type 1 (Th1) cells, induces IgG2a response in the mouse and is absolutely 
required for the induction of ANoA production in this autoimmune condition (Abedi-
Valugerdi 2008; Kono et al., 1998). Our results are consistent with this. Despite the Th2-
dependent appearing of germinal centers in spleen after HgCl2-treatment and the 
prevalence of the Th2-mediated IgG1 isotype as a component of IC, we also saw some IgG2a 
in the deposits, arguing in favor of Th1 activation too. 
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With all that the most important result of our research is the discovery of the ability of 
HgCl2-induced ANoA to transverse the plasma and nuclear membrane of living cells and 
translocate to the nucleoli of different cells in outbred mice in vivo. We found that mercury-
induced ANoA penetrated into the cells of certain organs (kidney, liver and spleen) and 
colocalized with special nucleolar protein fibrillarin - the major autoantigen in HgIA. This 
fact once again place outbred mice in close quarters with humans. As is well known from 
the literature, the autoantibodies from SLE patients are able to penetrate into the nuclei of 
cells in certain organs (Foster et al., 1994; Vlahakos et al., 1992; Yanase et al., 1997; Zack et 
al., 1996). It is likely that mercury-induced ANoA contain basic amino acid-rich sequences 
similar to those seen in anti-DNA autoantibodies derived from lupus-prone mice, allowing 
them to penetrate into the cell nuclei (Abedi-Valugerdi et al., 1999). Several studies have 
shown that penetrating autoantibodies cause cellular dysfunction after entering the cell and 
reacting with their intracellular antigens (Abedi-Valugerdi et al., 1999; Koscec et al., 1997; 
Reichlin, 1995). Therefore, it has been suggested that these antibodies might have 
pathogenic roles. However, our results do not confirm this, at least, at the beginning of the 
development of such mercury-induced autoimmune response. Formation of IC in different 
parts of the kidney was not accompanied by visible destruction or cell death, at least as 
evidenced by the TUNEL assay. The article of Abedi-Valugerdi et al. (1999) offers two 
possible explanations of this fact. First of all, the main target for mercury-induced ANoA is 
fibrillarin, which is known to be associated with snRNAs. In mammals the exact function of 
fibrillarin is not known, but it has been suggested that this nucleolar protein possibly 
participates in ribosomal biosynthesis. Based on this suggestion, it is likely that fibrillarin 
does not have a crucial role in the DNA synthesis and interfering with its function/structure 
by ANoA would not impair the cell proliferation. Second, since besides fibrillarin, several 
other nucleolar proteins (nucleolin, Surf-6, etc.) are also present in the mammalian nucleoli, 
it is likely that if fibrillarin is required for DNA synthesis and if binding of ANoA to 
fibrillarin impairs it’s function, other nucleoproteins will take over fibrillarin’s function. 
Since it has been suggested that fibrillarin is involved in the synthesis of ribosomal RNA, 
further studies are needed to test if nucleolar localization of ANoA would affect other cell 
functions such as protein synthesis. But, nevertheless, we cannot exclude the third 
possibility that destructive alterations could appear in later stages of disease development, 
because it is known that renal failure is one of the negative features associated with human 
autoimmune diseases (Tormey et al., 2001). 
5. Conclusion 
Thus, in our work we have shown that HgCl2 induce very strong autoimmune process both 
in inbred and outbred mice, accompanied by ANoA production and heavy IC deposition. 
We have described novel localization and composition of such immune deposits in different 
organs. Also, we have come to conclusion about the higher penetrating capability of 
autoantibodies in outbred mice as compared with inbred mice. So, we have discovered that 
genetically heterogenous outbred CFW mice produce the same reaction on standard HgCl2 
treatment (1.6 mg/kg twice a week) as inbred SJL/J mice previously described to be most 
susceptible.  
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Our data thoroughly confirm and continue the findings of Dr. Abedi-Valugerdi suggesting 
that certain environmental factors, without requiring the presence of specific susceptibility 
genes, can induce some autoimmune manifestations in members of a genetically 
heterogenous population. 
We think that outbred mice with HgCl2-induced autoimmunity may also be used for testing 
of immunosuppressive drugs because they better reflect the human population then 
homozygous inbred mice. Thus, the present study could be very useful for further 
understanding, prediction and therapy of human systemic autoimmune diseases, in 
particular developing after the regular exposure of mercury compounds. 
Author details 
Alla Arefieva*, Marina Krasilshchikova and Olga Zatsepina 
Shemyakin-Ovchinnikov Institute of Bioorganic  
Chemistry of the Russian Academy of Sciences, Moscow, Russian Federation 
Acknowledgement 
Authors are grateful to Dr. K.A. Lukyanov (Shemyakin-Ovchinnikov Institute of Bioorganic 
Chemistry of the Russian Academy of Sciences, Moscow, Russian Federation) for the help in 
image recording and Dr. J.W. Dobrucki (Jagiellonian University, Krakow, Poland) for the 
provision of the dye ColF.  
This work was supported by the Russian Foundation for Basic Research [grant number 08-
04-00854]; the Ministry of Education and Science of the Russian Federation [Government 
Contracts numbers 14.740.11.0121, 14.740.11.0925]. 
6. References 
Abedi-Valugerdi, M.; Hu, H. & Möller, G. (1997). Mercury-induced renal immune complex 
deposits in young (NZB x NZW) F1 mice: characterization of antibodies/autoantibodies. 
Clinical and experimental immunology,Vol.110, No.1, (October 1997), pp. 86-91 
Abedi-Valugerdi, M.; Hu, H. & Möller, G. (1999). Mercury-induced anti-nucleolar 
autoantibodies can transgress the membrane of living cells in vivo and in vitro. 
International immunology, Vol.11, No.4, (April 1999), pp. 605-615 
Abedi-Valugerdi, M. & Möller, G. (2000). Contribution of H-2 and non-H-2 genes in the 
control of mercury-induced autoimmunity. International immunology,Vol.12, No.10, 
(October 2000), pp. 1425-1430 
Abedi–Valugerdi, M. (2008). Mercury and silver induce B cell activation and anti–nucleolar 
autoantibody production in outbred mouse stocks: are environmental factors more 
important than the susceptibility genes in connection with autoimmunity? Clinical and 
experimental immunology, Vol.155, No.1, (January 2008), pp. 117–124 
                                                                                    
* Corresponding Author 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 138 
With all that the most important result of our research is the discovery of the ability of 
HgCl2-induced ANoA to transverse the plasma and nuclear membrane of living cells and 
translocate to the nucleoli of different cells in outbred mice in vivo. We found that mercury-
induced ANoA penetrated into the cells of certain organs (kidney, liver and spleen) and 
colocalized with special nucleolar protein fibrillarin - the major autoantigen in HgIA. This 
fact once again place outbred mice in close quarters with humans. As is well known from 
the literature, the autoantibodies from SLE patients are able to penetrate into the nuclei of 
cells in certain organs (Foster et al., 1994; Vlahakos et al., 1992; Yanase et al., 1997; Zack et 
al., 1996). It is likely that mercury-induced ANoA contain basic amino acid-rich sequences 
similar to those seen in anti-DNA autoantibodies derived from lupus-prone mice, allowing 
them to penetrate into the cell nuclei (Abedi-Valugerdi et al., 1999). Several studies have 
shown that penetrating autoantibodies cause cellular dysfunction after entering the cell and 
reacting with their intracellular antigens (Abedi-Valugerdi et al., 1999; Koscec et al., 1997; 
Reichlin, 1995). Therefore, it has been suggested that these antibodies might have 
pathogenic roles. However, our results do not confirm this, at least, at the beginning of the 
development of such mercury-induced autoimmune response. Formation of IC in different 
parts of the kidney was not accompanied by visible destruction or cell death, at least as 
evidenced by the TUNEL assay. The article of Abedi-Valugerdi et al. (1999) offers two 
possible explanations of this fact. First of all, the main target for mercury-induced ANoA is 
fibrillarin, which is known to be associated with snRNAs. In mammals the exact function of 
fibrillarin is not known, but it has been suggested that this nucleolar protein possibly 
participates in ribosomal biosynthesis. Based on this suggestion, it is likely that fibrillarin 
does not have a crucial role in the DNA synthesis and interfering with its function/structure 
by ANoA would not impair the cell proliferation. Second, since besides fibrillarin, several 
other nucleolar proteins (nucleolin, Surf-6, etc.) are also present in the mammalian nucleoli, 
it is likely that if fibrillarin is required for DNA synthesis and if binding of ANoA to 
fibrillarin impairs it’s function, other nucleoproteins will take over fibrillarin’s function. 
Since it has been suggested that fibrillarin is involved in the synthesis of ribosomal RNA, 
further studies are needed to test if nucleolar localization of ANoA would affect other cell 
functions such as protein synthesis. But, nevertheless, we cannot exclude the third 
possibility that destructive alterations could appear in later stages of disease development, 
because it is known that renal failure is one of the negative features associated with human 
autoimmune diseases (Tormey et al., 2001). 
5. Conclusion 
Thus, in our work we have shown that HgCl2 induce very strong autoimmune process both 
in inbred and outbred mice, accompanied by ANoA production and heavy IC deposition. 
We have described novel localization and composition of such immune deposits in different 
organs. Also, we have come to conclusion about the higher penetrating capability of 
autoantibodies in outbred mice as compared with inbred mice. So, we have discovered that 
genetically heterogenous outbred CFW mice produce the same reaction on standard HgCl2 
treatment (1.6 mg/kg twice a week) as inbred SJL/J mice previously described to be most 
susceptible.  
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Our data thoroughly confirm and continue the findings of Dr. Abedi-Valugerdi suggesting 
that certain environmental factors, without requiring the presence of specific susceptibility 
genes, can induce some autoimmune manifestations in members of a genetically 
heterogenous population. 
We think that outbred mice with HgCl2-induced autoimmunity may also be used for testing 
of immunosuppressive drugs because they better reflect the human population then 
homozygous inbred mice. Thus, the present study could be very useful for further 
understanding, prediction and therapy of human systemic autoimmune diseases, in 
particular developing after the regular exposure of mercury compounds. 
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1. Introduction 
The co-existence of immunodeficiency and autoimmunity called as “old couple” is known 
from the clinics, but the background and mechanism responsible for this phenomenon is far 
from explanation. The both; immunodeficiency and autoimmune diseases belong to group 
of rare diseases. The population of children with immunodeficiency of humoral immunity 
demonstrating clinical symptoms of deficiency is small and only a part of them develops 
autoimmune disease which means these patients are really very small group. Because of low 
number of such patients there is a lack of standards of diagnostic procedures and 
therapeutic approach.  
The clinical observations and analysis of co-existence of these  two different 
pathomechanisms lead to questions –  
1. why, in diseases with impaired function of immune system, the antibodies and 
autoantibodies are produced,   
2. why the prolonged inflammation develops leading to tissue and organ damage,  
3. why these autoimmune diseases are different in clinical features, course and response 
to therapy,  
4. why we are not able to find the factors helping in selection of patients with high risk of 
autoimmune disease within immunodeficiency group.  
The develop of autoimmune diseases is a result of many factors occurring in sequence or at 
the same time what seems to be the puzzle with hundreds of pieces. In the immune 
deficiency some of these pieces are missed at the beginning but despite this the puzzle is 
fulfilled and the autoimmunity develops. It is why, this phenomenon is still fascinating….  
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2. The role of antibodies in pathomechanism of celiac and inflammatory 
bowel diseases 
2.1. The production of autoantibodies 
The autoantibodies are produced by B-1 subpopulation of B lymphocytes, plasma cells 
localized in lymph nodes and bone marrow, similarly to production of specific antibodies to 
pathogens; bacterial, viral or parasitic. They react with autoantigens e.g. determinants, 
receptors present on cell surface, products of cells (e.g. hormones, cytokines, insulin, 
enzymes), nuclei, DNA and organelles released after cells death. In healthy people the 
autoantibodies (e.g. antinuclear, rheumatoid factor) are noted in the serum in low titer what 
is probably an effect of persist low affinity self-reacting T and B lymphocytes in the thymus 
and bone marrow. The increase of occurrence and amount of  autoantibodies with age in the 
healthy people is supporting the view that this small population of self-reactive 
lymphocytes is present during whole life [1].  
The induction of autoantibodies production is not fully elucidated and the hypothesis about 
trigger by chronic inflammation, molecular mimicry with microbial antigens, aberrant 
expression of HLA-DR on cell surface as facilitating factor, are postulated. In systemic 
autoimmune diseases like lupus the antigens are intracellular so the above  suggestions are 
not very suitable. The possible explanations of anti-DNA antibodies production includes the 
process of apoptosis and formation of nucleosomes containing pure DNA. It is highly 
probable, that dying cells e.g. within inflammatory infiltrations of tissues release many 
different organelles, proteins and enzymes induce production of antibodies to them. The 
antibodies against structure of nucleus (e.g. histones, centromers, centriols, nucleoli), Golgi 
apparatus, mitochondria, peroxidase, specific proteins (e.g. Scl-70, RNP), enzymes are 
associated with different types of autoimmune diseases. Delayed clearing of dying cells and 
abundance, stability, resistance to degradation of some nucleoproteins are stimulating the 
immune response through activation of Toll-like receptors. This hypothesis might apply to 
some of systemic autoimmune diseases [1]. 
The presence of autoantibodies in high titer is generally associated with damage of target 
cells or organs and occurrence of clinical symptoms of disease. The deposits of immune 
complexes (autoantibodies – antigens – complement) in the vessels or located directly in the 
tissue expressing the autoantigen are injurious for the surrounding tissue. These complexes 
bind the complement, activate the cascade, stimulate the production of pro-inflammatory 
cytokines, chemotactic factors for infiltrating cells leading to support of autoantibodies 
production and amplification of the inflammation (self-perpetuating inflammatory process). 
In animal models this damaging effect of autoantibodies and immune complexes was 
showed for systemic autoimmune diseases. In celiac disease,  the anti transglutaminase 
antibodies are associated with reduction of intestinal epithelial cells endocytosis, 
differentiation and proliferation. In general, they lead to decrease of intestinal/epithelial 
barrier function. The studies demonstrated the reduction of the epithelial cells adhesion in 
experimental model with CaCo cell line and anti-transglutaminase antibodies implicated the 
role of these antibodies in pathogenesis of celiac disease. In histology of mucous membrane 
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from  patients with untreated celiac disease, the epithelium tends to blister or totally detach 
from the basement membrane. The antibodies  mediated inhibition of epithelial cells 
adhesion might be an explanation for the detachment [2]. The mechanism of tissue damage 
and role of autoantibodies in IBD (Leśniowski-Crohn’s disease and ulcerative colitis) are not 
fully described [3-5]. 
3. Primary deficiency of humoral immunity 
3.1. Isolated IgA deficiency (IgAD)  
IgAD is the most common immunodeficiency of humoral immunity. The frequency of this 
deficiency is variable in different regions e.g. 1:400 in Finland, 1:600 in USA and 1:15000 
children in Japan. The environmental factors, diet and food type, climate are suggested as 
explanation for this wide range of IgAD frequency [6-8]. The diagnosis of IgAD is based on 
low level (often below detection) of IgA, normal or compensatory high level of IgG, normal 
level of  IgM in child older than 4 years of life.  In this defect the majority of affected 
children (70-80%) is asymptomatic [6,7]. The remaining (20-30%) IgAD patients suffer from 
recurrent infections, allergies and autoimmune diseases. The respiratory and 
gastrointestinal tract are mainly involved. Recurrent infections of upper respiratory tract 
caused by different bacterias, often encapsulated  are noted in younger children, the 
prolonged sinusitis is typical for older children and teenagers. Within IgAD patients the 
incidence of allergies is 20 times higher then in healthy population. The asthma, allergic 
rhinitis, conjunctivitis, food allergy, atopic dermatitis and urticaria are common. The 
autoimmunity is represented by hematological symptoms e.g. thrombocytopenia, 
neutropenia, hemolytic anemia and gastrointestinal disease like celiac disease, IBD. In adults 
with IgAD the lupus erythematodes, rheumatoid arthritis, thyroid diseases and chronic 
active hepatitis are noted [6,9-12]. In gastrointestinal tract, besides the autoimmune chronic 
inflammatory disease, the infestation with Giardia lamblia, bacterial infections, nodular 
hyperplasia are very often observed within IgAD patients [6,12]. The occurrence of clinical 
symptoms like abdominal pain, discomfort, diarrhea, constipation is 10-20 times higher 
within IgAD than within healthy children. The most probable explanation is deficient 
production of secretory IgA [9,13].  
The pathogenesis of IgAD is based on defective terminal maturation of B cells into IgA 
secreting plasma cells leading to reduced level of serum and secretory (mucosal) IgA [13]. 
The IgA exists in both monomeric and polymeric (mainly dimeric) forms. In humans two 
subclasses are distinguished – IgA1 and IgA2. The dimeric IgA is formed with joining (J)-
chain. The secretory IgA (sIgA) is produced locally within lymphoid tissue under the 
mucous membrane and released at the luminal surface of jejunum [14]. sIgA composed of 
IgA2 molecules characterizes high resistance to enzymatic digestion by bacterial proteases. 
This immunoglobulin plays an important role in protection of mucous membranes lining 
the gastrointestinal, respiratory and urinary tracts from pathogens present within the 
lumen. It is the first line of defense against microorganisms based on agglutinating activity 
and facilitating the clearance of pathogens [12]. The role of sIgA in selection of antigens 
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fully described [3-5]. 
3. Primary deficiency of humoral immunity 
3.1. Isolated IgA deficiency (IgAD)  
IgAD is the most common immunodeficiency of humoral immunity. The frequency of this 
deficiency is variable in different regions e.g. 1:400 in Finland, 1:600 in USA and 1:15000 
children in Japan. The environmental factors, diet and food type, climate are suggested as 
explanation for this wide range of IgAD frequency [6-8]. The diagnosis of IgAD is based on 
low level (often below detection) of IgA, normal or compensatory high level of IgG, normal 
level of  IgM in child older than 4 years of life.  In this defect the majority of affected 
children (70-80%) is asymptomatic [6,7]. The remaining (20-30%) IgAD patients suffer from 
recurrent infections, allergies and autoimmune diseases. The respiratory and 
gastrointestinal tract are mainly involved. Recurrent infections of upper respiratory tract 
caused by different bacterias, often encapsulated  are noted in younger children, the 
prolonged sinusitis is typical for older children and teenagers. Within IgAD patients the 
incidence of allergies is 20 times higher then in healthy population. The asthma, allergic 
rhinitis, conjunctivitis, food allergy, atopic dermatitis and urticaria are common. The 
autoimmunity is represented by hematological symptoms e.g. thrombocytopenia, 
neutropenia, hemolytic anemia and gastrointestinal disease like celiac disease, IBD. In adults 
with IgAD the lupus erythematodes, rheumatoid arthritis, thyroid diseases and chronic 
active hepatitis are noted [6,9-12]. In gastrointestinal tract, besides the autoimmune chronic 
inflammatory disease, the infestation with Giardia lamblia, bacterial infections, nodular 
hyperplasia are very often observed within IgAD patients [6,12]. The occurrence of clinical 
symptoms like abdominal pain, discomfort, diarrhea, constipation is 10-20 times higher 
within IgAD than within healthy children. The most probable explanation is deficient 
production of secretory IgA [9,13].  
The pathogenesis of IgAD is based on defective terminal maturation of B cells into IgA 
secreting plasma cells leading to reduced level of serum and secretory (mucosal) IgA [13]. 
The IgA exists in both monomeric and polymeric (mainly dimeric) forms. In humans two 
subclasses are distinguished – IgA1 and IgA2. The dimeric IgA is formed with joining (J)-
chain. The secretory IgA (sIgA) is produced locally within lymphoid tissue under the 
mucous membrane and released at the luminal surface of jejunum [14]. sIgA composed of 
IgA2 molecules characterizes high resistance to enzymatic digestion by bacterial proteases. 
This immunoglobulin plays an important role in protection of mucous membranes lining 
the gastrointestinal, respiratory and urinary tracts from pathogens present within the 
lumen. It is the first line of defense against microorganisms based on agglutinating activity 
and facilitating the clearance of pathogens [12]. The role of sIgA in selection of antigens 
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entering through the mucous membrane is also postulated. Functions of sIgA include direct 
neutralization of pathogens, intracellular neutralization of viruses during transepithelial 
transport and inhibition of receptors mediated activation of immune system [12]. The lack of 
sIgA is compensated by IgG and IgM [12]. The chronic inflammatory diseases as celiac 
disease, Leśniowski-Crohn’s disease, ulcerative colitis are only a part of gastrointestinal 
symptoms seen in IgAD patients. The other causes of clinical symptoms (abdominal pain, 
discomfort, constipation or diarrhea) include bacterial infections e.g. Helicobacter pylori, 
Campylobacter jejuni (preferentially in adults) and parasitic Giardia lamblia infestation. In 
jejunum biopsy the type of mucosal damage, villous flattening are suggesting celiac disease. 
After therapy eliminating Giardia lamblia the damage of mucous is repaired, however, in 
some cases this damage may be irreversible. The deep mucous damage difficult to repair is 
also an effect of the prolonged infection and diarrhea. sIgA is necessary for clearance of 
jejunum surface from e.g. parasites, bacterias and yeasts so the lack of this immunoglobulin 
facilitates attachment and proliferation of the organism on the surface of intestinal 
epithelium [6,9,11,12,15].   
The frequency of Leśniowski-Crohn’s disease, ulcerative colitis (mainly in adults) is not well 
recognized in IgAD [13,16]. Moreover, in adult patients with IgAD and gastrointestinal 
symptoms the nodular lymphoid hyperplasia (NLH) is observed and diagnosed as a 
separate clinical entity. In histology, the nodules contain the large amount of IgM-bearing 
cells. There are found in lamina propria, superficially in submucosa of small intestine, 
occasionally in large bowel, rectum  or stomach. Massive occurrence of these nodules and/or 
large size are associated with malabsorption, flattening of villi and with obstruction in some 
cases [16]. The differential diagnosis of Leśniowski-Crohn’s disease, nodular lymphoid 
hypertrophy (NLH) or celiac disease is difficult because the clinical symptoms and 
histological changes are overlapping.  
3.2. Common variable immunodeficiency (CVID) 
The common variable immunodeficiency is a heterogeneous disease with the frequency of 
1:25000 to 1:66000 diagnosed first in adults. Following this, the description of clinical 
features and course of disease was based on observations of adult patients. CVID is 
diagnosed after exclusion all other known causes of hypogammaglobulinemia in adults and 
in children older than 4 years of life. The criteria of CVID include hypogammaglobulinemia 
(IgG only or IgG and IgA, IgM), low production of specific antibodies in response to 
vaccination and, in reasonable amount of patients, disorders of cellular response e.g. low 
number of T cells, reverse CD4:CD8 ratio, low response of T lymphocytes to stimulation in 
vitro [7,12,17-20]. The hypogammaglobulinemia is a result of deregulation of B-cell 
differentiation process and disturbances of T-cell regulatory function [18]. Impaired T-cell 
function (e.g. proliferation) and signaling have also been reported, including abnormalities 
in expression and function of T cell receptor. Number of B lymphocytes in peripheral blood 
and in lymph nodes are within normal range usually but the amount of plasma cells is 
diminished. However, in 12% of CVID patients the number of B lymphocytes in peripheral 
blood is below detection level [21]. Analysis of B cell subpopulation showed the reduction of 
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memory B cells (CD19+CD27+IgD-) number in majority of CVID patients. The reduction of 
memory B cells is associated with more severe clinical course of CVID (e.g. splenomegaly, 
bronchiectases, autoimmunity). Up to now, it is the one and only parameter with predictive 
value for the clinical course of CVID [22,23]. However, the reduction of memory B cells did 
not correlate with genetic mutation described in CVID patients [17]. In subset of CVID 
patients (5-10%) mutation in TACI (transmembrane activator and calcium-modulator) gene 
was discovered. TACI is a member of TNF-like receptor family involved in transduction of 
signals associated with cell survival, apoptosis and isotype switching. The ligands for TACI 
expressed on peripheral B cells include BAFF (B-cell activating factor) and APRIL (a 
proliferation-inducing ligand) both in TNF ligand family expressed on monocytes and 
dendritic cells. BAFF and APRIL can induce isotype switching but in the absence of TACI 
(their receptor) plasma cell maturation and immunoglobulins production is inhibited [18]. 
The heterogeneity of clinical features noted within CVID patients might resembled defects 
like TACI deficiency, BAFF deficiency, APRIL deficiency, loss of inducible co-stimulator and 
others diagnosed as one disease although named “variable” [18].  
The observations of CVID in children showed the difference between these patients and 
adults in clinical symptoms and course of disease [24]. Within patients diagnosed as adults, 
the chronic sinusitis, bronchiectases, chronic lung disease are more common than in CVID 
diagnosed in childhood (Table 1). The level of IgG (before substitution) is not predictive for 
type, severity and clinical course of infections [21,28].  The bacterial cultures showed 
Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus and Streptococcus 
pneumoniae in european population of CVID patients [16,25-26]. Moreover, the susceptibility 
of CVID patients to specific type of microorganism is noted so Ureaplasma uraelyticum, 
Mycoplasma (different species), enteroviruses are leading to infections and destructive 
chances of organs (e.g. fibrotic process in bladder). Despite the cumulating data about 
deficiencies of humoral immunity, the diagnosis of CVID is delayed 6 to 8 years an average, 
what lead to sequelae of recurrent infections e.g. lung fibrosis, bronchiectases, chronic 
sinusitis, underweight, inhibition of growth, anemia [20-21,25-27]. In a large study of 248 
CVID patients (children and adults) the severe and recurrent infections, mostly in 
respiratory system, were noted in 90% of patients [19]. The chronic lung disease was noted 
in 27% of adult patients. The recurrent infections of lower respiratory tract may be 
associated with the bronchiectases. However, the bronchiectases often are a consequence of 
few but severe lung infections. In children, the chronic lung disease and bronchiectases are 
rare and seen in group of teenagers (the time of disease seemed to be an important factor). 
Moreover, in children with CVID the lymphoid interstitial pneumonia (LIP); unusual and 
rare type of lung disease is seen. In our group of 52 children with CVID  the histology of 
lung biopsy showed LIP in 2 patients (boy and girl). In both cases the prolonged therapy 
with steroids was effective but adverse reactions to steroids limited this therapy. The lung 
fibrosis was slowed down although still progressing what lead to respiratory insufficiency 
despite of regular IgG substitution [personal observations]. The chronic sinusitis, LIP or 
bronchiectases are developing independently to regular substitution of IgG, even in higher 
dose [28].  
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memory B cells (CD19+CD27+IgD-) number in majority of CVID patients. The reduction of 
memory B cells is associated with more severe clinical course of CVID (e.g. splenomegaly, 
bronchiectases, autoimmunity). Up to now, it is the one and only parameter with predictive 
value for the clinical course of CVID [22,23]. However, the reduction of memory B cells did 
not correlate with genetic mutation described in CVID patients [17]. In subset of CVID 
patients (5-10%) mutation in TACI (transmembrane activator and calcium-modulator) gene 
was discovered. TACI is a member of TNF-like receptor family involved in transduction of 
signals associated with cell survival, apoptosis and isotype switching. The ligands for TACI 
expressed on peripheral B cells include BAFF (B-cell activating factor) and APRIL (a 
proliferation-inducing ligand) both in TNF ligand family expressed on monocytes and 
dendritic cells. BAFF and APRIL can induce isotype switching but in the absence of TACI 
(their receptor) plasma cell maturation and immunoglobulins production is inhibited [18]. 
The heterogeneity of clinical features noted within CVID patients might resembled defects 
like TACI deficiency, BAFF deficiency, APRIL deficiency, loss of inducible co-stimulator and 
others diagnosed as one disease although named “variable” [18].  
The observations of CVID in children showed the difference between these patients and 
adults in clinical symptoms and course of disease [24]. Within patients diagnosed as adults, 
the chronic sinusitis, bronchiectases, chronic lung disease are more common than in CVID 
diagnosed in childhood (Table 1). The level of IgG (before substitution) is not predictive for 
type, severity and clinical course of infections [21,28].  The bacterial cultures showed 
Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus and Streptococcus 
pneumoniae in european population of CVID patients [16,25-26]. Moreover, the susceptibility 
of CVID patients to specific type of microorganism is noted so Ureaplasma uraelyticum, 
Mycoplasma (different species), enteroviruses are leading to infections and destructive 
chances of organs (e.g. fibrotic process in bladder). Despite the cumulating data about 
deficiencies of humoral immunity, the diagnosis of CVID is delayed 6 to 8 years an average, 
what lead to sequelae of recurrent infections e.g. lung fibrosis, bronchiectases, chronic 
sinusitis, underweight, inhibition of growth, anemia [20-21,25-27]. In a large study of 248 
CVID patients (children and adults) the severe and recurrent infections, mostly in 
respiratory system, were noted in 90% of patients [19]. The chronic lung disease was noted 
in 27% of adult patients. The recurrent infections of lower respiratory tract may be 
associated with the bronchiectases. However, the bronchiectases often are a consequence of 
few but severe lung infections. In children, the chronic lung disease and bronchiectases are 
rare and seen in group of teenagers (the time of disease seemed to be an important factor). 
Moreover, in children with CVID the lymphoid interstitial pneumonia (LIP); unusual and 
rare type of lung disease is seen. In our group of 52 children with CVID  the histology of 
lung biopsy showed LIP in 2 patients (boy and girl). In both cases the prolonged therapy 
with steroids was effective but adverse reactions to steroids limited this therapy. The lung 
fibrosis was slowed down although still progressing what lead to respiratory insufficiency 
despite of regular IgG substitution [personal observations]. The chronic sinusitis, LIP or 
bronchiectases are developing independently to regular substitution of IgG, even in higher 
dose [28].  
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Table 1. The differences between CVID in adults and children 
The autoimmunity is associated with CVID in about 20-30% of patients and the 
hematological symptoms are most common [10,16,17,19,21,29-34]. The dysregulation of 
immune system in CVID seemed to be paradoxical; while antibody production in response 
to pathogens and vaccines is impaired, at the same time the production autoantibodies 
might be excessive [32]. In large study of 311 adult patients with CVID the autoimmunity 
was diagnosed in 37% (116 patients). The cytopenias were noted in 55 patients including 
thrombocytopenia (41 patients), hemolytic anemia (17 patients) and neutropenia (10 
patients) [30]. The slightly lower percentage of autoimmunity (22%) was noted within other 
studied group of  248 CVID adult patients but the thrombocytopenia was most frequent 
[19,32]. In reasonable number of patients the autoimmune symptoms preceded the diagnosis 
of CVID [17,19,21,34].  
The autoimmune/inflammatory diseases of gastrointestinal tract (IBD) including Leśniowski-
Crohn’s disease, celiac disease, pernicious anemia, autoimmune liver disease, ulcerative 
colitis and nodular lymphoid hyperplasia (NLH) are the second group of complications 
(coexisting symptoms/diseases) noted in 20-50% of CVID patients [9,13,16,18-19,21,28-29,34-
36]. The clinical symptoms of IBD in CVID are similar to patients without CVID but often 
more discrete, milder and unspecific. In children  unspecific abdominal pain, weight loss and 
inhibition of growth are prominent. The typical symptoms like diarrhea, constipation and 
dyspepsia, disturbances of jejunum motility, weakness are present too but they could be often 
neglected and explained by school stress, problems of diet, life style and maturation. In both 
groups of CVID patients the results of malabsorption are observed [13,16,19]. 
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The diagnosis of autoimmune diseases is based on presence of antibodies and 
autoantibodies in serum. In CVID there are two problems: low production of specific 
antibodies as a marker of immune system dysfunction and lack of antibodies of given 
immunoglobulin class e.g. IgA in cases of CVID with IgA deficiency. The second problem is 
associated with histology of tissues involved in autoimmune process. The disturbances of B 
cell ontogeny seen as abnormal maturation, impaired somatic hypermutation and lack of 
memory B cell are associated with different histology of jejunum in IBD in CVID [13,36]. In 
biopsy of jejunum mucous of patients with celiac or Leśniowski-Crohn’s disease the low 
number, even lack of B cells and plasma cells in infiltrations are observed. This atypical 
pattern of infiltrating cells in CVID became a reason for named the celiac disease as celiac-
like, similar – Crohn’s-like instead Crohn’s disease [13,37]. 
3.3. Substitution of immunoglobulins in CVID 
The main goal of regular substitution of immunoglobulin IgG (intravenous or 
subcutaneous) in CVID is replacing the specific antibodies. These antibodies produced by 
healthy blood donors after vaccinations and contact with common pathogens prevent the 
infections with spectrum of common pathogens. The dose for substitution is wide (0.4 - 0.8 
g/kg body weight) with the suggestion for higher dose in first period of IgG substitution to 
obtained patient’s stabilization (“steady-state”). After 6-8 months of regular substitution, the 
maintaining dose is usually about 0.4 g/kg body weight. The half-life of IgG is 21-24 days 
indicating intravenous infusion of IgG (IVIG) in every 3-4 weeks [16-17,20,28,38-40]. The 
modifications of dose are possible in two ways – higher (or lower) dose for singular infusion 
and shorter (or longer) distance between infusions. The bacterial infections, wounds healing 
after injuries or surgery are consuming immunoglobulins so higher dose of IgG is 
recommended. Moreover, the individual variations in half-life of administered IgG, shorter 
half-time in patients with chronic lung disease or gastrointestinal disease need the 
modifications of IVIG substitution (patient-tailored), precise monitoring of IgG level and 
clinical status of patient [20]. The purpose of substitution is to prevent infections, at least, to 
decrease their frequency and moderate their clinical course. Moreover, the regular 
substitution of IgG in replacing dose is effective in some autoimmune disease like chronic 
thrombocytopenia, chronic neutropenia [16]. This effect is probably associated with anti 
inflammatory activity of IgG, although the precise mechanisms are not described. The 
different mechanisms responsible for anti-inflammatory activity on IgG preparation are 
defined for the high dose of immunoglobulins used in autoimmune diseases. It might be 
that; the regularity, long time of substitution and accumulation of small repeated effects are 
responsible for anti-inflammatory activity of IVIG in low dose, similar to anti-inflammatory 
effects of IVIG high dose (1.0-2.0 g/kg b.w.) [20,38]. The adverse reactions of IVIG occurred 
immediately during the infusion or after up to 4 days. They are mild or sever including 
anaphylactic shock [16,41]. Most often the fever, chills, pain (headache, abdominal pain) are 
noted in children during the infusion. The most severe, late reactions are the consequence of 
tissue distribution of immunoglobulin particularly into central nervous system. Heavy and 
progressive headache, vomiting, disturbances of vision, speech and balance keeping are 
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groups of CVID patients the results of malabsorption are observed [13,16,19]. 
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and shorter (or longer) distance between infusions. The bacterial infections, wounds healing 
after injuries or surgery are consuming immunoglobulins so higher dose of IgG is 
recommended. Moreover, the individual variations in half-life of administered IgG, shorter 
half-time in patients with chronic lung disease or gastrointestinal disease need the 
modifications of IVIG substitution (patient-tailored), precise monitoring of IgG level and 
clinical status of patient [20]. The purpose of substitution is to prevent infections, at least, to 
decrease their frequency and moderate their clinical course. Moreover, the regular 
substitution of IgG in replacing dose is effective in some autoimmune disease like chronic 
thrombocytopenia, chronic neutropenia [16]. This effect is probably associated with anti 
inflammatory activity of IgG, although the precise mechanisms are not described. The 
different mechanisms responsible for anti-inflammatory activity on IgG preparation are 
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that; the regularity, long time of substitution and accumulation of small repeated effects are 
responsible for anti-inflammatory activity of IVIG in low dose, similar to anti-inflammatory 
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noted in children during the infusion. The most severe, late reactions are the consequence of 
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progressive headache, vomiting, disturbances of vision, speech and balance keeping are 
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typical. The therapy with intensive hydration and steroids given intravenously are usually 
effective. In a case of  occurrence of severe adverse reactions the subcutaneous (SCIG) form 
of substitution is recommended. The amount of immunoglobulins given monthly is divided 
in four portions (0.1 g/kg of body weight per week) administered with special pomp. The 
effectiveness is similar to intravenous substitution, the adverse reaction are very rare and 
limited to the place of injection. SCIG is form of home therapy very comfortable for patients, 
offering the independence from the hospital.  
3.4. Antibiotics in prophylaxis of infections   
In part of children with CVID the effect of IVIG or  SCIG is weak and the infections occurred 
despite regular substitution. In this group of patients, especially with chronic inflammation 
(sinusitis, lymphocyte infiltrating pneumonia – LIP), bronchiectases, lung fibrosis and (in 
some cases) permanent leukopenia; the prophylaxis with antibiotics is suggested. The 3-4 
months’ periods of antibiotics or trimetoprim introduced in prophylactic dose help in 
control of infections and improve the patient’s comfort. The therapy with antibiotics is still a 
matter of discussion and approaches to this therapy varies depending of clinical centre, 
severity of cases. The recommendation for antibiotics prophylaxis is prevention of the 
endocarditis during invasive procedures [28]. 
4. Diagnostic procedures in celiac disease and inflammatory bowel 
diseases 
4.1. The standards of IBD and celiac disease diagnosis 
Standard of IBD diagnosis includes the clinical symptoms, laboratory tests (e.g. antibodies 
detection), imaging procedures (gastroscopy, colonoscopy, other radiological methods) and 
histological examination of jejunum biopsy [4,42-49]. The laboratory markers are helpful in 
early diagnosis preceding the onset of severe clinical symptoms in many patients. In last 
years the detection of antibodies associated with autoimmune process in gastrointestinal 
tract are commonly used as screening in risk group of children including 
immunodeficiencies (IgAD, CVID).  
4.1.1. The immunological markers 
The typical clinical symptoms of celiac disease (periods of diarrhea or constipation, 
abdominal pain, cramps, feeling of discomfort, low weight with difficulty to gain) in small 
children are noted in about 20% of all patients diagnosed as celiac [51]. The remaining 
patients demonstrate the results of jejunum functional disorders leading to sideropenic 
anemia, osteopenia, afts, enamel damage, delay of puberty, concentrations problems and 
hypoproteinemia or many others without direct association with gastrointestinal tract. The 
latent, silent or asymptomatic forms of celiac disease are diagnosed in older children, 
teenagers and adults. The familiar predisposition is associated with expression of HLA-DQ2 
and HLA-DQ8 determinants [43,48-50].  
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For celiac disease the serological assays include antibodies to: endomysium, 
transglutaminase and gliadin. The antibodies against gliadin (deamidated form – GAF) are 
tested in IgA and IgG class with indirect immunofluorescence in serum diluted 1:10 [52]. 
The sensitivity and specificity is declared as 100% in IgG class and 95-99% in IgA class [53]. 
The endomysial antibodies (EMA) are associated with reticulin-gliadin complex and 
transglutaminase as enzyme active in formation of this complex. Antibodies are tested with 
indirect immunofluorescence in serum (dilution 1:10) with tissue slides of monkey’s 
jejunum or smooth muscles (endomysium contains reticulin type 1 (R1) - basic antigen for 
endomysial antibodies). The serial dilution of serum is helpful in monitoring the results of 
Gluten Free Diet (GFD). The sensitivity and specificity of these antibodies in IgA class is up 
to 100% [48,50]. The test performed in IgG class is valid and clinically significant for IgAD 
patients. 
The discovery of role of tissue transglutaminase (tTg) in pathomechanism of celiac disease 
helped in understanding the induction of immune response to gliadin. This enzyme 
deamidated and/or transamidated gliadin proteins increasing their immunogenicity. 
Moreover, tTg is facilitating the formation of gliadin-reticulin complex and location of these 
complexes deposits on subepithelial basic membrane. The role of tTg in reduction of 
intestinal epithelial cell adhesion and in detachment of epithelium was described recently 
[2]. Antibodies against tTg are tested with ELISA commercially available kits for IgA and 
IgG class of immunoglobulins. The sensitivity of this test is 96%, the specificity – 98% 
[48,50].  The results of detection tTg antibodies are showed as optical density recalculated to 
standard curve. Results above 20 units are recognized as positive. High specificity of tTg 
antibodies and occurrence in level above 200 units seemed to be satisfactory for celiac 
disease diagnose without further biopsy of jejunum [50]. These antibodies are clinically 
significant in IgA class preferentially; with exception for IgAD when antibodies in IgG class 
are considered [52]. The introduction of GFD leads to decrease of antibodies production 
below detection level in 3-6 months in majority of patients [48,50]. Persistent high level of 
antibodies to tTg is observed in celiac disease refractory to GFD (RCD type I and RCD type 
II)[54]. Moreover, antibodies against tTg are observed in about 20% of patients with 
Leśniowski-Crohn’s disease. The clinical significance of these antibodies in Leśniowski-
Crohn’s disease is unknown. It might be thought; that the inflammation and lymphocytic 
infiltrates are spreading from region typical for celiac disease to another part of jejunum. 
However, the localization of Leśniowski-Crohn’s disease in other parts of gastrointestinal 
tract like esophagus or large bowel and presence of anti tTg antibodies is not supporting this 
idea [50].  
The antibodies against Saccharomyces cerevisiae (ASCA) antigens are observed in 60-80% of  
Leśniowski-Crohn’s disease patients [5,55]. Occurrence of these antibodies is explained by 
increased permeability of barrier between jejunum lumen:submucosal tissue and loss of 
precise selective role of this barrier. The direct contact between yeast and immunocompetent 
cells is possible and uncontrolled what stimulates production of antibodies. In healthy 
people this yeast is normally seen in distal region of jejunum (Bauchin’ valve) without the 
induction of antibodies production. ASCA in IgA class are clinically significant in patients 
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typical. The therapy with intensive hydration and steroids given intravenously are usually 
effective. In a case of  occurrence of severe adverse reactions the subcutaneous (SCIG) form 
of substitution is recommended. The amount of immunoglobulins given monthly is divided 
in four portions (0.1 g/kg of body weight per week) administered with special pomp. The 
effectiveness is similar to intravenous substitution, the adverse reaction are very rare and 
limited to the place of injection. SCIG is form of home therapy very comfortable for patients, 
offering the independence from the hospital.  
3.4. Antibiotics in prophylaxis of infections   
In part of children with CVID the effect of IVIG or  SCIG is weak and the infections occurred 
despite regular substitution. In this group of patients, especially with chronic inflammation 
(sinusitis, lymphocyte infiltrating pneumonia – LIP), bronchiectases, lung fibrosis and (in 
some cases) permanent leukopenia; the prophylaxis with antibiotics is suggested. The 3-4 
months’ periods of antibiotics or trimetoprim introduced in prophylactic dose help in 
control of infections and improve the patient’s comfort. The therapy with antibiotics is still a 
matter of discussion and approaches to this therapy varies depending of clinical centre, 
severity of cases. The recommendation for antibiotics prophylaxis is prevention of the 
endocarditis during invasive procedures [28]. 
4. Diagnostic procedures in celiac disease and inflammatory bowel 
diseases 
4.1. The standards of IBD and celiac disease diagnosis 
Standard of IBD diagnosis includes the clinical symptoms, laboratory tests (e.g. antibodies 
detection), imaging procedures (gastroscopy, colonoscopy, other radiological methods) and 
histological examination of jejunum biopsy [4,42-49]. The laboratory markers are helpful in 
early diagnosis preceding the onset of severe clinical symptoms in many patients. In last 
years the detection of antibodies associated with autoimmune process in gastrointestinal 
tract are commonly used as screening in risk group of children including 
immunodeficiencies (IgAD, CVID).  
4.1.1. The immunological markers 
The typical clinical symptoms of celiac disease (periods of diarrhea or constipation, 
abdominal pain, cramps, feeling of discomfort, low weight with difficulty to gain) in small 
children are noted in about 20% of all patients diagnosed as celiac [51]. The remaining 
patients demonstrate the results of jejunum functional disorders leading to sideropenic 
anemia, osteopenia, afts, enamel damage, delay of puberty, concentrations problems and 
hypoproteinemia or many others without direct association with gastrointestinal tract. The 
latent, silent or asymptomatic forms of celiac disease are diagnosed in older children, 
teenagers and adults. The familiar predisposition is associated with expression of HLA-DQ2 
and HLA-DQ8 determinants [43,48-50].  
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For celiac disease the serological assays include antibodies to: endomysium, 
transglutaminase and gliadin. The antibodies against gliadin (deamidated form – GAF) are 
tested in IgA and IgG class with indirect immunofluorescence in serum diluted 1:10 [52]. 
The sensitivity and specificity is declared as 100% in IgG class and 95-99% in IgA class [53]. 
The endomysial antibodies (EMA) are associated with reticulin-gliadin complex and 
transglutaminase as enzyme active in formation of this complex. Antibodies are tested with 
indirect immunofluorescence in serum (dilution 1:10) with tissue slides of monkey’s 
jejunum or smooth muscles (endomysium contains reticulin type 1 (R1) - basic antigen for 
endomysial antibodies). The serial dilution of serum is helpful in monitoring the results of 
Gluten Free Diet (GFD). The sensitivity and specificity of these antibodies in IgA class is up 
to 100% [48,50]. The test performed in IgG class is valid and clinically significant for IgAD 
patients. 
The discovery of role of tissue transglutaminase (tTg) in pathomechanism of celiac disease 
helped in understanding the induction of immune response to gliadin. This enzyme 
deamidated and/or transamidated gliadin proteins increasing their immunogenicity. 
Moreover, tTg is facilitating the formation of gliadin-reticulin complex and location of these 
complexes deposits on subepithelial basic membrane. The role of tTg in reduction of 
intestinal epithelial cell adhesion and in detachment of epithelium was described recently 
[2]. Antibodies against tTg are tested with ELISA commercially available kits for IgA and 
IgG class of immunoglobulins. The sensitivity of this test is 96%, the specificity – 98% 
[48,50].  The results of detection tTg antibodies are showed as optical density recalculated to 
standard curve. Results above 20 units are recognized as positive. High specificity of tTg 
antibodies and occurrence in level above 200 units seemed to be satisfactory for celiac 
disease diagnose without further biopsy of jejunum [50]. These antibodies are clinically 
significant in IgA class preferentially; with exception for IgAD when antibodies in IgG class 
are considered [52]. The introduction of GFD leads to decrease of antibodies production 
below detection level in 3-6 months in majority of patients [48,50]. Persistent high level of 
antibodies to tTg is observed in celiac disease refractory to GFD (RCD type I and RCD type 
II)[54]. Moreover, antibodies against tTg are observed in about 20% of patients with 
Leśniowski-Crohn’s disease. The clinical significance of these antibodies in Leśniowski-
Crohn’s disease is unknown. It might be thought; that the inflammation and lymphocytic 
infiltrates are spreading from region typical for celiac disease to another part of jejunum. 
However, the localization of Leśniowski-Crohn’s disease in other parts of gastrointestinal 
tract like esophagus or large bowel and presence of anti tTg antibodies is not supporting this 
idea [50].  
The antibodies against Saccharomyces cerevisiae (ASCA) antigens are observed in 60-80% of  
Leśniowski-Crohn’s disease patients [5,55]. Occurrence of these antibodies is explained by 
increased permeability of barrier between jejunum lumen:submucosal tissue and loss of 
precise selective role of this barrier. The direct contact between yeast and immunocompetent 
cells is possible and uncontrolled what stimulates production of antibodies. In healthy 
people this yeast is normally seen in distal region of jejunum (Bauchin’ valve) without the 
induction of antibodies production. ASCA in IgA class are clinically significant in patients 
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with normal IgA level as for IgAD patients the IgG class antibodies are assayed. For both 
class IgG and IgA the level above 20 RU/ml is considered as positive. However, comparison 
of ASCA in IgA and IgG in Leśniowski-Crohn’s patients showed ASCA in both 
immunoglobulin’s classes in majority of patients what suggested (according the author) that 
both IgA and IgG ASCA should be measured [5]. The diagnostic specificity of ASCA is 99% 
and sensitivity in Leśniowski-Crohn’s patients is 80%, positive predictive value - 88% [5]. 
The new tests (for ELISA) are based on eluated singular proteins of Saccharomyces cerevisiae 
membrane with the similar specificity for Leśniowski-Crohn’s disease.  
The immunofluorescence indirect test offers detection of antibodies to exocrine pancreas cells 
cytoplasm (PAB) and their products as useful for diagnosis of Leśniowski-Crohn’s disease 
[55]. Two distinct patterns were noted with the patients’ sera tested on human pancreas 
tissue. The following pancreatic autoantigens were identified;  glycoproteins expressed as 
glycosyl phosphoinositol (GP1) and membrane-anchored protein (GP2) [4]. GP2 is a 
glycosylated protein accounting for more than half of the zymogen granule membrane 
proteins in acinar cells. Recent studies showed the expression of GP2 is not limited to 
pancreatic acinar cells but is noted on epithelial cells follicle-associated or in Peyer’s patches 
too [4]. In the follicle-associated epithelial cells GP2 is restricted to M cells. These cells are 
located mainly in distal part of ileum being a site of original inflammation in reasonable 
percentage of patients with Leśniowski-Crohn’s disease [4]. The frequency of PAB antibodies 
in patients with Leśniowski-Crohn’s disease is rather low (14%-30%)[4,55-56] however, the 
specificity of this assay is 93%, positive predictive value is 77% and negative predictive value 
– 45% [55-56]. The clinical observations indicated the association of PAB with stricturing or 
penetrating form of the Leśniowski-Crohn’s disease [4] but this data were not supported by 
others. It means, that PAB are independent to disease activity, localization, clinical course and 
response to therapy with corticosteroids and/or immunosuppression [4,55]. 
The antinuclear (ANA), antimyeloperoxidase antibodies (pANCA) and against goblet cells 
(mucins are autoantigen, GAB) antibodies are commonly used for immunological diagnosis 
of ulcerative colitis (UC). Presence of these antibodies is detected with immunofluorescence 
and ELISA. The antibodies against neutrophils cytoplasmic antigens (ANCA) are recognized 
as cytoplasmic (proteins 3 - cANCA) and perinuclear (myeloperoxidase - pANCA) based on 
microscopic pattern [5,56]. pANCA prevalence in UC is estimated as 71.4%, in comparison to 
Leśniowski-Crohn’s patients – 2.3% and healthy control – 4.8% of positive seras. Comparison 
of IgA and IgG class of pANCA in group of 28 UC patients showed higher titer for IgA but in 
majority of patients pANCA were present in both classes of immunoglobulins.  The results of 
ELISA assay for ANCA with different eluated antigens showed lower percentage of patients 
with positive results than immunofluorescence. Probably the antigens used for ELISA are not 
covering all possible neutrophil cytoplasmic antigens reacting with patients serum [56]. The 
antigens identified as responsible for pANCA immune response in UC patients are localized 
not only in cytoplasm of neutrophils but also inside nucleus (histone 1, nonhistone 
chromosomal protein, high mobility group of proteins) [56].   
The presence of antibodies against goblet cells (GAB) is tested with immunofluorescence 
(normal jejunum slides) or ELISA. In study of 28 UC patients GAB was detected in 46.4% 
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[56] in both classes of immunoglobulins with much higher titer for antibodies in IgA class. 
The sensitivity of GAB is estimated as 46%, specificity – 100% predictive positive value – 
100% and predictive negative value – 73% [56]. Studies of reactivity of GAB with different 
tissue slides from gastrointestinal tract showed the best reactivity in appendix tissue [3]. The 
reaction with ileum, sigmoid and rectum tissue was from weak to strong with the tendency 
to resemble clinically affected intestinal segments [3].  
The antibodies to enterocytes were described as clinically significant marker for 
autoimmune enteropathy [43,57]. The detection of these antibodies with indirect 
immunofluorescence showed a linear pattern most frequently along the apex or brush 
border of enterocyte on frozen section of human small bowel. These antibodies are 
predominantly IgG class and have been reported to occur after the mucosal damage onset 
[57].  
4.1.2.The histology of jejunum in celiac disease and Leśniowski-Crohn’s disease 
The typical changes in celiac disease are classified according Marsh, Oberhuber and 
Corazza [48]. The classification according Marsh (4 types) is commonly used and number 
of intraepithelial lymphocytes (IEL), ratio crypts:villi heights, villi structure and height 
are basic parameters. In advanced stage (Marsh type 3) severe inflammation, flat villi and 
hyperplastic crypts are noted. In other classification e.g. Oberhuber the mucous of 
jejunum damage is divide into 8 stages including stage 0 of normal mucous structure, 
without changes. Classification proposed by Corazza is simplest and described only 3 
stages – grade A – normal architecture of mucous, grade B1 and grade B2 – with atrophic 
villi up to flat mucous. The problem of celiac disease diagnosis arises when patients with 
clinical symptoms and serology tests results suggesting celiac disease have no visible 
changes in histology of mucous membrane (Marsh type 0, Oberhuber type 0, Corazza 
grade A) [48,58]. For these patients, electron microscopy assay is useful for detection of 
submicroscopical changes of enterocytes which support celiac disease diagnosis or 
suggest the diagnosis of microscopic enteritis [48,51,57-59]. However, observations of 
patients with typical clinical symptoms of celiac disease without changes of mucous 
showed improvement on GFD supporting the clinical diagnosis of latent type of celiac 
disease [50]. 
The infiltrations and formation of new lymphoid nodules, increase of IEL number are 
typical for chronic inflammation of jejunum. Infiltration in celiac disease consists 
lymphocytes (T and B), plasma cells and some monocytes. Within the lymphocytes present 
in mucous membrane the cells with TCRγ/δ characteristic are observed. In Leśniowski-
Crohn’s disease the infiltration contains lymphocytes, monocytes, neutrophils and plasma 
cells. The similar pattern with increased number of neutrophils is noted in UC. The 
proportion between the cells within infiltrate is associated with profile of proinflammatory 
cytokines released locally and induction of antibodies production as effect of contact of 
antigen presenting cells (APC) with e.g. MPO from neutrophils or the nuclei debris after cell 
death in situ [45-46]. 
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with normal IgA level as for IgAD patients the IgG class antibodies are assayed. For both 
class IgG and IgA the level above 20 RU/ml is considered as positive. However, comparison 
of ASCA in IgA and IgG in Leśniowski-Crohn’s patients showed ASCA in both 
immunoglobulin’s classes in majority of patients what suggested (according the author) that 
both IgA and IgG ASCA should be measured [5]. The diagnostic specificity of ASCA is 99% 
and sensitivity in Leśniowski-Crohn’s patients is 80%, positive predictive value - 88% [5]. 
The new tests (for ELISA) are based on eluated singular proteins of Saccharomyces cerevisiae 
membrane with the similar specificity for Leśniowski-Crohn’s disease.  
The immunofluorescence indirect test offers detection of antibodies to exocrine pancreas cells 
cytoplasm (PAB) and their products as useful for diagnosis of Leśniowski-Crohn’s disease 
[55]. Two distinct patterns were noted with the patients’ sera tested on human pancreas 
tissue. The following pancreatic autoantigens were identified;  glycoproteins expressed as 
glycosyl phosphoinositol (GP1) and membrane-anchored protein (GP2) [4]. GP2 is a 
glycosylated protein accounting for more than half of the zymogen granule membrane 
proteins in acinar cells. Recent studies showed the expression of GP2 is not limited to 
pancreatic acinar cells but is noted on epithelial cells follicle-associated or in Peyer’s patches 
too [4]. In the follicle-associated epithelial cells GP2 is restricted to M cells. These cells are 
located mainly in distal part of ileum being a site of original inflammation in reasonable 
percentage of patients with Leśniowski-Crohn’s disease [4]. The frequency of PAB antibodies 
in patients with Leśniowski-Crohn’s disease is rather low (14%-30%)[4,55-56] however, the 
specificity of this assay is 93%, positive predictive value is 77% and negative predictive value 
– 45% [55-56]. The clinical observations indicated the association of PAB with stricturing or 
penetrating form of the Leśniowski-Crohn’s disease [4] but this data were not supported by 
others. It means, that PAB are independent to disease activity, localization, clinical course and 
response to therapy with corticosteroids and/or immunosuppression [4,55]. 
The antinuclear (ANA), antimyeloperoxidase antibodies (pANCA) and against goblet cells 
(mucins are autoantigen, GAB) antibodies are commonly used for immunological diagnosis 
of ulcerative colitis (UC). Presence of these antibodies is detected with immunofluorescence 
and ELISA. The antibodies against neutrophils cytoplasmic antigens (ANCA) are recognized 
as cytoplasmic (proteins 3 - cANCA) and perinuclear (myeloperoxidase - pANCA) based on 
microscopic pattern [5,56]. pANCA prevalence in UC is estimated as 71.4%, in comparison to 
Leśniowski-Crohn’s patients – 2.3% and healthy control – 4.8% of positive seras. Comparison 
of IgA and IgG class of pANCA in group of 28 UC patients showed higher titer for IgA but in 
majority of patients pANCA were present in both classes of immunoglobulins.  The results of 
ELISA assay for ANCA with different eluated antigens showed lower percentage of patients 
with positive results than immunofluorescence. Probably the antigens used for ELISA are not 
covering all possible neutrophil cytoplasmic antigens reacting with patients serum [56]. The 
antigens identified as responsible for pANCA immune response in UC patients are localized 
not only in cytoplasm of neutrophils but also inside nucleus (histone 1, nonhistone 
chromosomal protein, high mobility group of proteins) [56].   
The presence of antibodies against goblet cells (GAB) is tested with immunofluorescence 
(normal jejunum slides) or ELISA. In study of 28 UC patients GAB was detected in 46.4% 
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[56] in both classes of immunoglobulins with much higher titer for antibodies in IgA class. 
The sensitivity of GAB is estimated as 46%, specificity – 100% predictive positive value – 
100% and predictive negative value – 73% [56]. Studies of reactivity of GAB with different 
tissue slides from gastrointestinal tract showed the best reactivity in appendix tissue [3]. The 
reaction with ileum, sigmoid and rectum tissue was from weak to strong with the tendency 
to resemble clinically affected intestinal segments [3].  
The antibodies to enterocytes were described as clinically significant marker for 
autoimmune enteropathy [43,57]. The detection of these antibodies with indirect 
immunofluorescence showed a linear pattern most frequently along the apex or brush 
border of enterocyte on frozen section of human small bowel. These antibodies are 
predominantly IgG class and have been reported to occur after the mucosal damage onset 
[57].  
4.1.2.The histology of jejunum in celiac disease and Leśniowski-Crohn’s disease 
The typical changes in celiac disease are classified according Marsh, Oberhuber and 
Corazza [48]. The classification according Marsh (4 types) is commonly used and number 
of intraepithelial lymphocytes (IEL), ratio crypts:villi heights, villi structure and height 
are basic parameters. In advanced stage (Marsh type 3) severe inflammation, flat villi and 
hyperplastic crypts are noted. In other classification e.g. Oberhuber the mucous of 
jejunum damage is divide into 8 stages including stage 0 of normal mucous structure, 
without changes. Classification proposed by Corazza is simplest and described only 3 
stages – grade A – normal architecture of mucous, grade B1 and grade B2 – with atrophic 
villi up to flat mucous. The problem of celiac disease diagnosis arises when patients with 
clinical symptoms and serology tests results suggesting celiac disease have no visible 
changes in histology of mucous membrane (Marsh type 0, Oberhuber type 0, Corazza 
grade A) [48,58]. For these patients, electron microscopy assay is useful for detection of 
submicroscopical changes of enterocytes which support celiac disease diagnosis or 
suggest the diagnosis of microscopic enteritis [48,51,57-59]. However, observations of 
patients with typical clinical symptoms of celiac disease without changes of mucous 
showed improvement on GFD supporting the clinical diagnosis of latent type of celiac 
disease [50]. 
The infiltrations and formation of new lymphoid nodules, increase of IEL number are 
typical for chronic inflammation of jejunum. Infiltration in celiac disease consists 
lymphocytes (T and B), plasma cells and some monocytes. Within the lymphocytes present 
in mucous membrane the cells with TCRγ/δ characteristic are observed. In Leśniowski-
Crohn’s disease the infiltration contains lymphocytes, monocytes, neutrophils and plasma 
cells. The similar pattern with increased number of neutrophils is noted in UC. The 
proportion between the cells within infiltrate is associated with profile of proinflammatory 
cytokines released locally and induction of antibodies production as effect of contact of 
antigen presenting cells (APC) with e.g. MPO from neutrophils or the nuclei debris after cell 
death in situ [45-46]. 
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The nature and function of T regulatory (Treg) subpopulation of T lymphocytes was 
extensively studied in relation to IBD. Natural Treg (CD4+/CD25+/FoxP3+) from  thymus 
and iTreg (inducible Treg) are involved in monitoring the immune response, maintaining 
the immune balance, prevention of excessive and potentially harmful immune activation 
within mucous of gastrointestinal tract [47,61-62]. The study of Treg lymphocytes 
(CD4/CD25/FoxP3) within the lamina propria patients with Leśniowski-Crohn’s disease and 
UC showed increased number of these cells; whereas the number in peripheral blood was 
decreased as compare to healthy people. It suggested central role of this population in local 
regulation of prolonged inflammatory process within jejunum wall [44]. 
Immunohistochemistry is the basic method for detection of Treg lymphocytes in biopsy 
specimens, the flow cytometry is used for assay of Treg number in peripheral blood. The 
immunohistochemistry is commonly used for analysis of proportion and characteristics of 
different cells within inflammation e.g. macrophages, T and B lymphocytes, plasma cells 
and others. This approach based on histopathology of jejunum helps to classify the 
subgroups of IBD patients. It will create specific “biological signature” unique to each 
patient so this patient can be treated with rational, individual therapy targeting the specific 
defect or aberrations underlying intestinal inflammatory pathway [47].   
5. Problems of gastrointestinal autoimmune diseases in children  
with PID 
5.1. Celiac disease in IgAD and CVID patients 
Celiac disease diagnosed as latent, silent or untypical form in children older than infants 
comprises about 80% of celiac patients. The clinical symptoms are discrete or absent so 
the diagnosis is often delayed. There have been more than 200 symptoms reported in 
association with gluten sensitivity [51]. The effects of jejunum dysfunction 
(malabsorption) presented as low level of iron resistant to oral therapy, vitamins, 
calcium, zinc and other minerals deficiency are suggesting celiac disease in children and 
teenagers [63]. The problem of celiac disease diagnosis in CVID and IgAD children lays 
in paucity and unspecificity of symptoms and overlapping with symptoms typical for 
IgAD or CVID with lack of IgA (e.g. abdomen pain, episodes of diarrhea, chronic 
diarrhea, food allergy).  
High prevalence of celiac disease in IgAD patients (10-20 times higher risk than in 
population) suggested the common genetic background for these two diseases. It was 
demonstrated that ancestral haplotype HLA-A1,Cw7,B8,DR3,DQ2 is important for 
association between IgA and celiac disease [6,12-13]. However, the observations of 
frequency of celiac disease within  IgAD population did not support this correlation because 
the observed frequency of celiac disease is still lower than expected based on genetic 
background [13]. Other hypothesis indicated that abnormal handling of gluten and gliadin 
in absence of IgA might induce the mucous damage and onset of clinical symptoms of celiac 
disease. The study of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand 
(APRIL) in patients with IgAD and celiac disease showed increased of both factors in IgAD 
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as compared to healthy persons but differences between IgAD with celiac disease and 
without celiac disease were below significance. Increase of APRIL level might be interpreted 
as part of the mechanism of compensation leading to overproduction of IgG and IgM [64]. 
The analysis of IEL TCRγ/δ showed highest level in IgAD with celiac disease,  increased 
number in IgAD - higher than control [60].  
The production of antibodies to gliadin, endomysium and to transglutaminase are 
preserved in IgAD patients but in IgG class. However, in some cases of IgAD the presence 
and high level of anti transglutaminase antibodies in IgA class is seen. In these cases the 
trace level of IgA (below detection in nephelometry) is enough to show antibodies to tTg 
with high sensitive technique of ELISA (personal observations). Within our 47 children with 
IgAD antibodies for celiac disease were noted in 11 patients (23%) – antibodies for gliadin – 
in 9 patients, for endomysium and for tTg in one patient each. Celiac disease was diagnosed 
based on anti tTg antibodies (in IgA and IgG class) in one patient without clinical 
symptoms. The histology of jejunum is typical for the celiac disease including cases 
diagnosed early with no changes (Marsh type 0) and similar to changes observed in children 
without IgAD. It is obvious, that in IgAD  plasma cells producing IgA are missing, although 
total number of plasma cells is preserved. In majority of IgAD patients the gluten-free diet 
(GFD) is effective [16].  
In CVID the problem of serological diagnosis of celiac diseases is more complex because of 
low production of antibodies and IgA deficiency in part of CVID patients. In consequence of 
these the possibility of serological diagnosis of autoimmune disease in CVID is excluded by 
many authors [9,13,37]. However, the permanent stimulation with autoantigens is leading to 
production of antibodies despite of decreased function of immune system. Level of 
autoantibodies is detectable but lower than in patients without immune deficiency [personal 
observation, 36]. In our study of 40 children with CVID antibodies for gliadin were noted in 
3 patients (7.5%), for endomysium and tTg in 2 patients followed with diagnosis of celiac 
disease. Algorithm for celiac disease diagnosis is shown in Table 2. In jejunum biopsy the 
mucous contains excess of IEL (mainly T), lymphoid aggregates, granulomas, crypts 
distortion. Within this group of patients the celiac disease is often refractory to GFD (RCD) 
leading to malabsorption syndrome and severe clinical conditions [20]. Poor response to 
GFD suggests the distinct pathogenesis of celiac disease with 2 forms recently recognized 
[13]. In type I of RCD the IEL expressed normally CD3 and CD8 determinants as well as 
polyclonal T-cell receptor (TCR) arrangement. In RCD type II the aberrant lymphocyte 
population is expanded with loss of surface expression of CD3 and CD8, intracellular 
presence of CD3 determination and monoclonal TCR arrangement. Type II of RCD is 
associated with poor prognosis, increased mortality due to progressing malabsorption 
syndrome and due to T-cell lymphoma in reasonable number of patients [54]. Therapy 
includes supplementation with proteins, vitamins and microelements, parenteral nutrition, 
probiotics, steroids (given intravenously in high dose) and antibiotics for bacterial 
overgrowth in jejunum [16]. The second line of therapy offers immunosuppression 
(azathioprine) and/or monoclonal antibodies against TNF (infliximab, etanercept, humira) in 
patients with  active, progressive disease [65]. 
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extensively studied in relation to IBD. Natural Treg (CD4+/CD25+/FoxP3+) from  thymus 
and iTreg (inducible Treg) are involved in monitoring the immune response, maintaining 
the immune balance, prevention of excessive and potentially harmful immune activation 
within mucous of gastrointestinal tract [47,61-62]. The study of Treg lymphocytes 
(CD4/CD25/FoxP3) within the lamina propria patients with Leśniowski-Crohn’s disease and 
UC showed increased number of these cells; whereas the number in peripheral blood was 
decreased as compare to healthy people. It suggested central role of this population in local 
regulation of prolonged inflammatory process within jejunum wall [44]. 
Immunohistochemistry is the basic method for detection of Treg lymphocytes in biopsy 
specimens, the flow cytometry is used for assay of Treg number in peripheral blood. The 
immunohistochemistry is commonly used for analysis of proportion and characteristics of 
different cells within inflammation e.g. macrophages, T and B lymphocytes, plasma cells 
and others. This approach based on histopathology of jejunum helps to classify the 
subgroups of IBD patients. It will create specific “biological signature” unique to each 
patient so this patient can be treated with rational, individual therapy targeting the specific 
defect or aberrations underlying intestinal inflammatory pathway [47].   
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(malabsorption) presented as low level of iron resistant to oral therapy, vitamins, 
calcium, zinc and other minerals deficiency are suggesting celiac disease in children and 
teenagers [63]. The problem of celiac disease diagnosis in CVID and IgAD children lays 
in paucity and unspecificity of symptoms and overlapping with symptoms typical for 
IgAD or CVID with lack of IgA (e.g. abdomen pain, episodes of diarrhea, chronic 
diarrhea, food allergy).  
High prevalence of celiac disease in IgAD patients (10-20 times higher risk than in 
population) suggested the common genetic background for these two diseases. It was 
demonstrated that ancestral haplotype HLA-A1,Cw7,B8,DR3,DQ2 is important for 
association between IgA and celiac disease [6,12-13]. However, the observations of 
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disease. The study of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand 
(APRIL) in patients with IgAD and celiac disease showed increased of both factors in IgAD 
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as compared to healthy persons but differences between IgAD with celiac disease and 
without celiac disease were below significance. Increase of APRIL level might be interpreted 
as part of the mechanism of compensation leading to overproduction of IgG and IgM [64]. 
The analysis of IEL TCRγ/δ showed highest level in IgAD with celiac disease,  increased 
number in IgAD - higher than control [60].  
The production of antibodies to gliadin, endomysium and to transglutaminase are 
preserved in IgAD patients but in IgG class. However, in some cases of IgAD the presence 
and high level of anti transglutaminase antibodies in IgA class is seen. In these cases the 
trace level of IgA (below detection in nephelometry) is enough to show antibodies to tTg 
with high sensitive technique of ELISA (personal observations). Within our 47 children with 
IgAD antibodies for celiac disease were noted in 11 patients (23%) – antibodies for gliadin – 
in 9 patients, for endomysium and for tTg in one patient each. Celiac disease was diagnosed 
based on anti tTg antibodies (in IgA and IgG class) in one patient without clinical 
symptoms. The histology of jejunum is typical for the celiac disease including cases 
diagnosed early with no changes (Marsh type 0) and similar to changes observed in children 
without IgAD. It is obvious, that in IgAD  plasma cells producing IgA are missing, although 
total number of plasma cells is preserved. In majority of IgAD patients the gluten-free diet 
(GFD) is effective [16].  
In CVID the problem of serological diagnosis of celiac diseases is more complex because of 
low production of antibodies and IgA deficiency in part of CVID patients. In consequence of 
these the possibility of serological diagnosis of autoimmune disease in CVID is excluded by 
many authors [9,13,37]. However, the permanent stimulation with autoantigens is leading to 
production of antibodies despite of decreased function of immune system. Level of 
autoantibodies is detectable but lower than in patients without immune deficiency [personal 
observation, 36]. In our study of 40 children with CVID antibodies for gliadin were noted in 
3 patients (7.5%), for endomysium and tTg in 2 patients followed with diagnosis of celiac 
disease. Algorithm for celiac disease diagnosis is shown in Table 2. In jejunum biopsy the 
mucous contains excess of IEL (mainly T), lymphoid aggregates, granulomas, crypts 
distortion. Within this group of patients the celiac disease is often refractory to GFD (RCD) 
leading to malabsorption syndrome and severe clinical conditions [20]. Poor response to 
GFD suggests the distinct pathogenesis of celiac disease with 2 forms recently recognized 
[13]. In type I of RCD the IEL expressed normally CD3 and CD8 determinants as well as 
polyclonal T-cell receptor (TCR) arrangement. In RCD type II the aberrant lymphocyte 
population is expanded with loss of surface expression of CD3 and CD8, intracellular 
presence of CD3 determination and monoclonal TCR arrangement. Type II of RCD is 
associated with poor prognosis, increased mortality due to progressing malabsorption 
syndrome and due to T-cell lymphoma in reasonable number of patients [54]. Therapy 
includes supplementation with proteins, vitamins and microelements, parenteral nutrition, 
probiotics, steroids (given intravenously in high dose) and antibiotics for bacterial 
overgrowth in jejunum [16]. The second line of therapy offers immunosuppression 
(azathioprine) and/or monoclonal antibodies against TNF (infliximab, etanercept, humira) in 
patients with  active, progressive disease [65]. 
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Table 2. Algorithm of the diagnostic procedures for celiac disease and IBD in CVID and IgAD patients 
5.2. Leśniowski-Crohn’s disease and UC in IgAD and CVID patients 
Chronic diarrhea is noted as a typical clinical symptom of gastrointestinal involvement seen 
in wide range of adult patients (10% - 50%) with CVID [13,16,18,20]. In children with CVID 
and IgAD the chronic diarrhea is much less frequent but data are based on relatively small 
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number of patients. IBD are sporadic in IgAD children with clinical course similar to 
children without IgAD. Within CVID patients IBD remain a significant problem in 19-32% of 
patients [20]. Moreover, IBD in patients with CVID is recognized as distinct form sharing 
histological features consistent more with lymphocytic colitis, collagenous colitis than 
classic IBD [13,37]. In patients, mainly adults, with Leśniowski-Crohn’s disease and CVID 
the formation of granuloma within jejunum wall is observed. Furthermore, the substitution 
of immunoglobulins does not inhibit and/or reverse symptoms of chronic colitis [13,15]. The 
different explanations are proposed but hypothesis that IgG from immunoglobulin 
preparations are not able to reach the lumen of intact jejunum particularly in CVID patients 
without IgA seemed to be interesting. Other possible explanations include Treg defects, T 
cell driven inflammation, different patterns of locally produced cytokines as compared to 
Leśniowski-Crohn’s disease in patients without CVID [13]. The special role of T 
lymphocytes in CVID patients with gastrointestinal symptoms was indicated by different 
histology of jejunum. Despite the lack of plasma cells in biopsy specimens as typical and 
characteristic; the villi flattening, increased number of IEL and lymphocytes in lamina 
propria, increased epithelial apoptosis were observed in CVID patients [13,15,20]. The study 
of cytokines produced locally in lamina propria showed decreased production of IL-23, IL-
17 and TNF in CVID patients with Leśniowski-Crohn’s disease as compare to patients 
without CVID, what suggest alternative pathway of inflammation [13]. 
Therapy of Leśniowski-Crohn’s disease in CVID is generally similar as for patients without 
immunodeficiency although inflammation in CVID might be more difficult to control. 
Immunosuppression (e.g.azathioprine, cyclosporine) is used when anti inflammatory drugs 
and steroids (rapidly metabolized budesonide) are without results and process of 
inflammation is still active. Induction of remission with anti cytokine monoclonal antibodies 
(infliximab, etanercept) is effective in CVID patients but the very careful monitoring of 
infections, particularly fungal, is necessary due to T cell defects [13]. 
The frequency of UC within CVID and IgAD patients is not known. The large study of 248 
patients with CVID including children and adults showed the UC only in 7 patients [19]. In 
this study ten patients was described as having a significant malabsorption but without 
specific gastrointestinal diagnosis what showed the problems of establishing the diagnosis 
in immune deficiency patients [19].  
5.3. Differential diagnosis – Collagenous sprue and autoimmune enteropathy 
The difficulties in diagnosis of celiac disease, poor response to GFD, IBD with different 
histology of jejunum seen in patients with CVID, IgAD and gastrointestinal symptoms 
suggested searching for other diseases overlapping clinical features. The collagenous sprue 
is severe malabsorptive disorder with histology similar to celiac disease. It is rare disorder 
characterized by small intestinal villi and crypts atrophy, increased IEL number, 
subepithelial collagen deposit entrapping cellular components of lamina propria [49]. The 
clinical and histological similarities (villi atrophy, poor response to GFD during one year) 
might suggest the refractory or poorly controlled celiac disease. However, in collagenous 
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sprue the  serological test and HLA-DQ2 or HLA-DQ8 are negative what indicate separate 
entity. The relation between celiac disease, refractory sprue and collagenous sprue is still a 
matter of discussion but collagenous sprue seemed to be a part of refractory sprue based 
on poor response to GFD [49]. In histology in collagenous sprue; the subepithelial collagen 
layer thicker than 12 μm, embedding small capillaries and lamina propria entrapping cells 
e.g. lymphocytes, fibroblasts are typical. These entrapped cellular elements are a 
mandatory criterion for this disease. Celiac disease is characterized by increased number of 
IEL whereas in collagenous sprue these lymphocytes are absent. The precise diagnosis is 
important because the collagenous sprue is progressing with high ratio of death due to 
malabsorption and malnutrition. The aggressive therapy includes steroids, 
immunosuppression and total parenteral nutrition. Up to now, the collagenous sprue was 
not observed in CVID and IgAD patients but the occurrence of RCD, progressing 
malabsorption syndrome might suggest existence of this disease within immune deficiency 
patients.  
The term of microscopic enteritis was used for patients with symptoms of malabsorption 
without prominent inflammation, villous effacement or ulceration seen in conventional 
light microscopy [59]. This observation may explain the co-existence of symptomatic gluten 
sensitivity, malabsorption and normally looking mucosa (Marsh 0) [48,58-59]. In patients 
with RCD the electron microscopy assay seemed to be useful for diagnosis of microscopic 
enteritis what helps to recognize celiac disease with mild or minimal mucosal 
abnormalities.  
The autoimmune enteropathy is not associated with celiac disease but represents 
heterogeneous entity consisting protracted diarrhea in young children with circulating 
antibodies. Affected patients appear to fall into 2 groups: with or without immune 
deficiency. The syndrome of intractable or protracted diarrhea of infancy was associated 
with high mortality. Now, the parenteral nutrition, symptomatic therapy of complications, 
improvement of diagnostic modalities has permitted prolonged survival of these children 
[57]. Immune deficiency seen in these patients were X-linked syndrome of neonatal diabetes 
with polyendocrinopathy, IPEX (Immunodysregulation, Polyendocrinopathy, Enteropathy, 
X-linked), T-cell defects, CVID and IgAD. The immunological tests showed a variety of 
antibodies but most important for diagnosis are antibodies against enterocyte circulating in 
patients serum. Other antibodies were typical for autoimmune disease of endocrine glands 
(anti thyroid peroxidase - TPO, Langerhan’s islet) and kidney, liver diseases (anti tubular 
basement membrane, antinuclear, anti-smooth muscles, liver-kidney antigen). Antigens for 
enterocyte antibodies were characterized as 50 kD and 75 kD proteins present in enterocyte 
cytoplasm. Diagnosis in neonate and infants with chronic severe diarrhea is based on small 
jejunum biopsy and immunological tests. The antibodies anti enterocyte are suggesting the 
autoimmune enteropathy. Symptomatic therapy include diet, parenteral nutrition, 
“immunological” therapy include steroids (but with no great success), immunosuppression 
with different drugs e.g. azathioprine, cyclophosphamide and cyclosporine. The second line 
of therapy offers tacrolimus with a good response. IPEX syndrome patient has been treated 
with hematopoietic stem cell transplantation [57]. 
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6. General remarks 
The diagnosis of IBD and celiac disease is based on clinical symptoms, laboratory tests and 
endoscopic procedures. Antibodies are the markers of these diseases despite that their role 
in pathomechanism of chronic inflammation is not fully recognized. The weak production of 
antibodies in response to vaccine antigens in humoral immunity deficiency seemed to be 
overestimated since the prolonged stimulation with antigens persistent in contact with 
immunocompetent cells induce production of antibodies. The antibodies detection used as 
screening is helpful in early diagnosis due to predictive value of these antibodies. From the 
other side, in patients with immunodeficiency clinical symptoms might be mild, unspecific 
and suggesting the association with basic disease (CVID or IgAD) not the concomitant 
autoimmunity. The high risk of autoimmune diseases in CVID and IgAD is an indication for 
antibodies screening in these patients but the results should be analyzed with caution. 
Patients with immunodeficiency are different in all aspects of their immune system function 
including response to infections, chronic inflammations, autoimmunity prevalence and high 
risk of tumours. The replacement of specific antibodies with substitution of 
immunoglobulin for CVID patients is covering only a small part from the complex defect in 
function of immune system. 
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1. Introduction 
Neuroinflammatory and central nervous system (CNS) demyelinating diseases have most of 
its pathological features based on immune cells infiltrating brain parenchyma and leading to 
neuronal death and focal or diffuse destruction of the CNS architecture, as extensively 
reviewed (Rodriguez 2007; Weiner 2008; Shie FS 2011). In this context, the role for resident 
and infiltrating inflammatory cells is very relevant, as they may be both the trigger and the 
maintainers of the neuroinflammatory process (Almolda B 2011). The combination of 
interesting concepts of neurology to the immunology laboratory, has rendered glial cells 
with a more dynamic and immunological shape. 
Stroke and Multiple Sclerosis (MS) are on the opposite sides of the coin of the neuroimmune 
diseases, depending on innate and adaptive immunity, respectively. That is the main reason 
why stroke is denominated as a neuroinflammatory rather than an autoimmune disease, 
and the opposite for MS. Despite this difference, which relies on the fact that cognate 
antigens for T cells were described for MS but not for stroke, central nervous system 
resident cells play a pivotal role on both cases. This greatly evidences the importance of 
brain parenchymal cells in the pathogenesis of neuroinflammatory and neurodegenerative 
diseases.  
Innate immune system greatly differs from adaptive immune system in many ways. Innate 
immunity is much older concerning its phylogeny, whereas adaptive immunity is relatively 
recent. It is interesting to mention that the first lymphocytes appeared with the gnatus 
cartilaginous fish, such as sharks and rays (Matsunaga T 1998), whereas in 1882 Metchikoff 
E demonstrated that starfish had singular phagocytic cells which are now believed to be the 
macrophage ancestral, as reviewed (Janeway CA Jr 2001). Besides its phylogenetic 
discrepancies, innate and adaptive immune systems also greatly differ in function and 
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recognition. One important difference is that lymphocytes express Recombinase Activating 
Genes (RAG), conferring unique T and B cell receptors. Further differences between innate 
and adaptive immunity are described in Table 1 ( adapted from (Abbul K Abbas 2006).  
 
Specific Feature Innate Immunity Adaptive Immunity 
Specificity 
Macrophages, dendritic cells, 
neutrophils recognize 
Pathogen Associated 
Molecular Patterns (PAMPs) 
as Lipopolissacharide, 
peptidoglycan, ssRNA, 
dsRNA, unmethylated CpG 
nucleotides, mannose rich 
glycans among many others. 
T lymphocytes recognize by 
its T cell receptor (TCRs), 
peptides presented by 
antigen presenting cells in the 
context of the MHC 
molecules. B cells recognize 
through the B cell receptor 
(BCRs) several different 
molecules, such as DNA, 
RNA, Lipids, Carbohydrates 
that may or may not be 
associated to carrier proteins. 
Receptors 
Pattern Recognition Receptors 
( PRRs) such as Toll-like 
receptors 1-12, NOD, Dectin-1, 
NLRPs. 
T cell receptor (TCRs) and B 
cell receptor (BCRs) 
Clonality No Yes. Each cell expresses only one type of TCR or BCR. 
Self-tolerance No mechanism to maintain tolerance to self. 
T and B lymphocytes 
undergo selection 
mechanisms in the thymus 
and bone marrow, 
respectively. 
Table 1. Table one pinpoints some important differences between innate and adaptive immune system. 
In this sense, the discrepancy between stroke and MS pathology is mainly due to the fact 
that Multiple Sclerosis (MS) and its murine model Experimental Autoimmune 
Encephalomyelitis (EAE) are secondary to a peripheral still-to-be-defined activation of T 
CD4 cells specific for myelin derived epitopes. On the other hand, during stroke, no cognate 
antigens have been clearly established so far, and innate immune cells such as macrophages 
and neutrophils play the master role. 
Acute stroke, defined as the occlusion or hemorrhage of brain blood vessels, culminates in 
neuronal and glial cell death and the local release of pro-inflammatory molecules (S Stoll G 
2010). These molecules, named Danger Associated Molecular Patterns (DAMPs), such as 
Heat Shock Proteins (HSPs), degraded extracellular matrix, F-actin filaments (Ahrens S 
2012),  ATP and many others (Seong Seong 2004), may induce blood brain barrier (BBB) 
disruption and activation of resident  cells (Ceulemans AG 2010; Stoll G 2010). This is 
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followed by polymorphonuclear and mononuclear cells infiltration establishing the 
inflammatory foci (Stoll G 2010; Thiel A 2011). It is noteworthy that ischemic stroke 
comprises more than 80% of the cases, caused by embolus or thrombus (Stoll G 2010). Stroke 
is also considered a heavy burden for Public Health Policies as almost 80% of patients suffer 
from further disability [18]. Stroke lesions are time-dependent, and longer periods of 
ischemia induce greater lesions than shorter periods. This is intimately linked to the 
reminiscent blood supply offered to the tissue. After stroke, two well defined regions are 
described: i) the region with completely abolished blood supply is the core, with intense 
necrosis, and ii) peripherally to the core is the penumbra, with the presence of inflammatory 
infiltrate. 
Acute lesions are immune independent, and most cell death is due to altered ionic balance, 
enhanced water input to the cell body resulting in edema, high calcium influx and 
secondary high glutamate release (Dirnagl U 1999; Ceulemans A 2010). For instance, 
glutamate release spreads early throughout brain parenchyma inducing neuronal death by a 
phenomenon called excitotoxicity, mediated by ionotropic glutamate receptors, such as 
NMDAR (N-methyl-D-aspartate) (Ceulemans A 2010). Besides biochemical alterations, the 
release of inflammatory molecules, as Heat-shock proteins (HSPs), histamine, 
prostaglandins, TNF-, is also observed in the injured area. Altogether, these inflammatory 
factors released after necrotic cell death induce the activation of resident cells, such as 
astrocytes, microglia, endothelial cells and even neurons, to secrete more pro-inflammatory 
cytokines and chemokines, and not only recruiting but also favoring the migration of 
inflammatory cells to the ischemic site. These mechanisms will be discussed in this chapter. 
Secondary to the acute phase, a leukocyte-dependent period emerges. Due to the 
disruption of the BBB, and the local secretion of chemokines and other leukocyte-
recruiting factors, inflammatory cells such as neutrophils, macrophages and even 
lymphocytes arrive from the periphery and then interact with brain parenchymal cells 
establishing the inflammatory process itself. Neutrophils and macrophages secrete high 
amounts of innate immunity derived cytokines such as IL-1 , IL-6, IL-8, IL-12, IL-15, IL-17, 
IL-18, IL-23, TNF-α, LIF, and chemokines as CCL2, CCL6, CCL21 and many others 
(Charles A Janeway 2002; Ghiringuelli F 2007; Suzuki T. 2007; Song C 2008; Weiner 2008). 
Just to mention, several other inflammatory factors were also found in ischemic area, such 
as matrix metalloproteinases (MMPs) (Del Zoppo GJ 2012), Adenosine Triphosphate 
(ATPs) (Arbeloa J 2011), High Mobility Group-box 1 (HMGB1)(Wang H 1999),  HSPs 
(Romi F 2011), leucotrienes, prostaglandins, glutamate (Dhawan J 2011), leptin (Avraham 
Y 2011), complement factors and many others (Dirnagl U 1999; Ceulemans AG 2010). 
However, it is interesting to mention that these factors may also be secreted by many 
resident cells, such as microglia, astrocytes and also endothelial cells, overlapping the role 
of resident Vs. infiltrating cells. To make an example, IL-1β, whose source may be both 
macrophages and astrocytes, greatly contributes to the activation of the vascular beds 
facilitating adherence and transmigration of circulating leukocytes, as well as to the 
increased intracellular calcium in neurons and astrogliosis (Stoll G 2010). To corroborate 
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recognition. One important difference is that lymphocytes express Recombinase Activating 
Genes (RAG), conferring unique T and B cell receptors. Further differences between innate 
and adaptive immunity are described in Table 1 ( adapted from (Abbul K Abbas 2006).  
 
Specific Feature Innate Immunity Adaptive Immunity 
Specificity 
Macrophages, dendritic cells, 
neutrophils recognize 
Pathogen Associated 
Molecular Patterns (PAMPs) 
as Lipopolissacharide, 
peptidoglycan, ssRNA, 
dsRNA, unmethylated CpG 
nucleotides, mannose rich 
glycans among many others. 
T lymphocytes recognize by 
its T cell receptor (TCRs), 
peptides presented by 
antigen presenting cells in the 
context of the MHC 
molecules. B cells recognize 
through the B cell receptor 
(BCRs) several different 
molecules, such as DNA, 
RNA, Lipids, Carbohydrates 
that may or may not be 
associated to carrier proteins. 
Receptors 
Pattern Recognition Receptors 
( PRRs) such as Toll-like 
receptors 1-12, NOD, Dectin-1, 
NLRPs. 
T cell receptor (TCRs) and B 
cell receptor (BCRs) 
Clonality No Yes. Each cell expresses only one type of TCR or BCR. 
Self-tolerance No mechanism to maintain tolerance to self. 
T and B lymphocytes 
undergo selection 
mechanisms in the thymus 
and bone marrow, 
respectively. 
Table 1. Table one pinpoints some important differences between innate and adaptive immune system. 
In this sense, the discrepancy between stroke and MS pathology is mainly due to the fact 
that Multiple Sclerosis (MS) and its murine model Experimental Autoimmune 
Encephalomyelitis (EAE) are secondary to a peripheral still-to-be-defined activation of T 
CD4 cells specific for myelin derived epitopes. On the other hand, during stroke, no cognate 
antigens have been clearly established so far, and innate immune cells such as macrophages 
and neutrophils play the master role. 
Acute stroke, defined as the occlusion or hemorrhage of brain blood vessels, culminates in 
neuronal and glial cell death and the local release of pro-inflammatory molecules (S Stoll G 
2010). These molecules, named Danger Associated Molecular Patterns (DAMPs), such as 
Heat Shock Proteins (HSPs), degraded extracellular matrix, F-actin filaments (Ahrens S 
2012),  ATP and many others (Seong Seong 2004), may induce blood brain barrier (BBB) 
disruption and activation of resident  cells (Ceulemans AG 2010; Stoll G 2010). This is 
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followed by polymorphonuclear and mononuclear cells infiltration establishing the 
inflammatory foci (Stoll G 2010; Thiel A 2011). It is noteworthy that ischemic stroke 
comprises more than 80% of the cases, caused by embolus or thrombus (Stoll G 2010). Stroke 
is also considered a heavy burden for Public Health Policies as almost 80% of patients suffer 
from further disability [18]. Stroke lesions are time-dependent, and longer periods of 
ischemia induce greater lesions than shorter periods. This is intimately linked to the 
reminiscent blood supply offered to the tissue. After stroke, two well defined regions are 
described: i) the region with completely abolished blood supply is the core, with intense 
necrosis, and ii) peripherally to the core is the penumbra, with the presence of inflammatory 
infiltrate. 
Acute lesions are immune independent, and most cell death is due to altered ionic balance, 
enhanced water input to the cell body resulting in edema, high calcium influx and 
secondary high glutamate release (Dirnagl U 1999; Ceulemans A 2010). For instance, 
glutamate release spreads early throughout brain parenchyma inducing neuronal death by a 
phenomenon called excitotoxicity, mediated by ionotropic glutamate receptors, such as 
NMDAR (N-methyl-D-aspartate) (Ceulemans A 2010). Besides biochemical alterations, the 
release of inflammatory molecules, as Heat-shock proteins (HSPs), histamine, 
prostaglandins, TNF-, is also observed in the injured area. Altogether, these inflammatory 
factors released after necrotic cell death induce the activation of resident cells, such as 
astrocytes, microglia, endothelial cells and even neurons, to secrete more pro-inflammatory 
cytokines and chemokines, and not only recruiting but also favoring the migration of 
inflammatory cells to the ischemic site. These mechanisms will be discussed in this chapter. 
Secondary to the acute phase, a leukocyte-dependent period emerges. Due to the 
disruption of the BBB, and the local secretion of chemokines and other leukocyte-
recruiting factors, inflammatory cells such as neutrophils, macrophages and even 
lymphocytes arrive from the periphery and then interact with brain parenchymal cells 
establishing the inflammatory process itself. Neutrophils and macrophages secrete high 
amounts of innate immunity derived cytokines such as IL-1 , IL-6, IL-8, IL-12, IL-15, IL-17, 
IL-18, IL-23, TNF-α, LIF, and chemokines as CCL2, CCL6, CCL21 and many others 
(Charles A Janeway 2002; Ghiringuelli F 2007; Suzuki T. 2007; Song C 2008; Weiner 2008). 
Just to mention, several other inflammatory factors were also found in ischemic area, such 
as matrix metalloproteinases (MMPs) (Del Zoppo GJ 2012), Adenosine Triphosphate 
(ATPs) (Arbeloa J 2011), High Mobility Group-box 1 (HMGB1)(Wang H 1999),  HSPs 
(Romi F 2011), leucotrienes, prostaglandins, glutamate (Dhawan J 2011), leptin (Avraham 
Y 2011), complement factors and many others (Dirnagl U 1999; Ceulemans AG 2010). 
However, it is interesting to mention that these factors may also be secreted by many 
resident cells, such as microglia, astrocytes and also endothelial cells, overlapping the role 
of resident Vs. infiltrating cells. To make an example, IL-1β, whose source may be both 
macrophages and astrocytes, greatly contributes to the activation of the vascular beds 
facilitating adherence and transmigration of circulating leukocytes, as well as to the 
increased intracellular calcium in neurons and astrogliosis (Stoll G 2010). To corroborate 
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the importance of IL-1, recently the use of Anankira®, the recombinant IL-1Ra (IL-1 
receptor antagonist) has been proposed to be used in therapy, as an attempt to abrogate 
the deleterious IL-1-derived features (Emsley HC 2005). 
Thus, it is clear that during stroke, the importance of different cellular populations has been 
established; no matter these cells are infiltrating macrophages and neutrophils or resident 
astrocytes and microglia. Thus, therapeutic approaches whose mechanisms focus on the 
reduction of local inflammation and cellular recruitment may be consider as promising 
alternatives for reducing the overall disability so usually observed in these patients. 
Very different from stroke, where the inflammatory process starts inside the CNS, during 
MS, self-reacting T CD4 cells are somehow activated in the periphery and further migrate to 
the target organ. In this context, there are two main differences between MS and stroke: i) 
the need for activated T cells to gain access to the CNS, and ii) the disease is autoimmune in 
nature, thus cognate antigens, such as myelin and proteolipoprotein epitopes are well 
described. Although it is a consensus that these self-reacting cells are specific for myelin-
derived antigens (Weiner HL 1993; Korn T 2007; Rodriguez 2007), the trigger for these cells 
to be activated in the periphery is still matter of intense debate. Other possibilities related to 
MS incidence and prevalence range from association to certain HLA haplotypes, as for 
HLA-DRB1*1501 e HLA-DRB5*0101, HLA-DQB1 (Oksenberg Jr 2005), to genetic 
polymorphisms, and although not very accepted, even viral infections, as recently reviewed 
(Owens GP 2011).  
MS is a neuroinflammatory and demyelinating disease of the CNS that leads to great 
disability in younger adults, and most of its incidence is observed in northern countries of 
Europe and also the United States (WHO 2006). Multiple Sclerosis stands for multiple scars, 
referring to the inflammatory plaques where myelin is lost mostly in perivascular regions of 
the white matter and whose observation by Magnetic Resonance Imaging (MRI) is 
considered the most reliable diagnostic approach. Myelin sheets are produced by neuron-
surrounding oligodendrocytes, the main target cells during MS. Death of these cells results 
in axonal dissection, followed by neuronal lost and thus reduction in neuronal impulse 
transmission, resulting in weakness, fatigue, numbness and overall disability. Concerning 
its onset and evolution, MS may be separated in i) primary progressive ii) secondary 
progressive and also iii) the relapsing-remitting type. Usually the disease starts with a 
relapse-remitting pattern of the symptoms followed by a progressive stage of increasing 
disability, considered the more severe cases (Weiner 2008). Many patients evolve to a more 
chronic stage of the disease, with no relapses, but a more prominent progressive lost of 
motor coordination, sensory and autonomic function is observed. It is noteworthy that 
many of these symptoms are tightly regulated by the local inflammatory milieu in the CNS, 
as well as by the activation status of the resident cells.   
Much of our understanding concerning the molecular and cellular mechanisms of MS was 
obtained after observations made on its murine model, Experimental Autoimmune 
Encephalomyelitis (EAE). With historical relevance, it is worthy to mention that the EAE 
model started after Prof. Thomas Rivers decided to understand why many years before, 
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Prof. Louis Pasteur experimental animals used to develop paralysis after vaccination against 
rabies. Rivers proceeded with the same protocol as Pasteur, immunizing rabbits with spinal 
cords extracts from rabbits that were inoculated with the rabies virus. At the same time he 
included a control group which consisted of extracts from non-contaminated animals. 
Interestingly, animals that received these extracts also developed paralysis, highlighting the 
fact that the secondary paralysis was not a rabies virus-dependent observation. 
Interestingly, the features develop by the animals was very similar to those observed by 
Pasteur many years earlier. It was also very exciting to recall that at that time Freund was 
describing its complete adjuvant (Complete Freund Adjuvant), what made Rivers research 
much easier, as the immunization for EAE induction changed from around 20 inoculations 
of brain extracts to only one injection. Then, one of the most used model to study not only 
neuroinflammation and neurodegeneration but also autoimmunity mechanisms had been 
brought to scientific community, as reviewed (Baxter 2007). 
MS was previously considered to be the prototype of a Th1 type of autoimmune disease, 
where IFN-γ-secreting T CD4 (Kroenke MA 2007; Dardalhon V 2008)  and CD8 (Michael P. 
Crawford 2004; Goverman J 2005) cells are greatly relevant and widely found in the 
periphery, liquor and brain parenchyma (Matusevicius D 1999). On the other hand, many 
contrasting data were obtained using the EAE model. In fact, it was known by a long date 
that mice deficient for IFN-γ were more susceptible to EAE induction when compared to 
control animals (Chu CQ 2000). This is in fact corroborated by other autoimmune disease 
model, the Experimental Autoimmune Uveitis (EAU) (Jones LS 1997). This was much 
unexpected, and for a great period of time a matter of intense speculation. Moreover, 
corroborating these findings, studies using animals deficient for p19, p35 and p40, the 
subunits for the heterodimers IL-12 (p35 + p40) and IL-23 (p19 + p40), had demonstrated 
that, unexpectedly, IL-23 was more relevant then IL-12 in these same models, raising still 
more questions in the field of EAE pathology (Cua DJ 2003). Thus, for many years there was 
a gap in the understanding on the actual role for IFN--secreting Th1 cells in the EAE model. 
It is worthy to mention that much less was known for the human disease. 
The final answer for that was obtained many years later when, using the EAE model, a new 
population of T cells was described as the main players in the pathogenesis of EAE  The so-
called Th17 cells secrete high amounts of the cytokines IL-17A, IL-17F (Ivanov I 2006), IL-21 
(Zhou L 2007) and GM-CSF (Codarri L 2011), and its master regulator is the rorc gene which 
encodes the gene for the retinoic acid orphan receptor, RORγt (Ivanov I 2006). To further 
corroborate this hypothesis, it was demonstrated that IL-17 knockout mice are resistant to 
EAE induction, which was very contrasting with data obtained from IFN-γ knockout mice, 
as reviewed (Komiyama Y 2006). Besides, it became clear that these cells arise in the 
periphery in the dependence of two cytokines, IL-6 + TGF-β, whose activity was 
demonstrated to be inducers of rorc expression and thus Th17 commitment. Corroborating 
previous data, it was clarified that IL-23 is the maintenance factor for these cells to remain 
viable and active. In fact, IL-23r deficient cells are unable to be maintained viable and thus 
induce disease (Cua DJ 2003; Zhou L 2007).  Thus, the findings in p19 KO mice highlighted 
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the importance of IL-1, recently the use of Anankira®, the recombinant IL-1Ra (IL-1 
receptor antagonist) has been proposed to be used in therapy, as an attempt to abrogate 
the deleterious IL-1-derived features (Emsley HC 2005). 
Thus, it is clear that during stroke, the importance of different cellular populations has been 
established; no matter these cells are infiltrating macrophages and neutrophils or resident 
astrocytes and microglia. Thus, therapeutic approaches whose mechanisms focus on the 
reduction of local inflammation and cellular recruitment may be consider as promising 
alternatives for reducing the overall disability so usually observed in these patients. 
Very different from stroke, where the inflammatory process starts inside the CNS, during 
MS, self-reacting T CD4 cells are somehow activated in the periphery and further migrate to 
the target organ. In this context, there are two main differences between MS and stroke: i) 
the need for activated T cells to gain access to the CNS, and ii) the disease is autoimmune in 
nature, thus cognate antigens, such as myelin and proteolipoprotein epitopes are well 
described. Although it is a consensus that these self-reacting cells are specific for myelin-
derived antigens (Weiner HL 1993; Korn T 2007; Rodriguez 2007), the trigger for these cells 
to be activated in the periphery is still matter of intense debate. Other possibilities related to 
MS incidence and prevalence range from association to certain HLA haplotypes, as for 
HLA-DRB1*1501 e HLA-DRB5*0101, HLA-DQB1 (Oksenberg Jr 2005), to genetic 
polymorphisms, and although not very accepted, even viral infections, as recently reviewed 
(Owens GP 2011).  
MS is a neuroinflammatory and demyelinating disease of the CNS that leads to great 
disability in younger adults, and most of its incidence is observed in northern countries of 
Europe and also the United States (WHO 2006). Multiple Sclerosis stands for multiple scars, 
referring to the inflammatory plaques where myelin is lost mostly in perivascular regions of 
the white matter and whose observation by Magnetic Resonance Imaging (MRI) is 
considered the most reliable diagnostic approach. Myelin sheets are produced by neuron-
surrounding oligodendrocytes, the main target cells during MS. Death of these cells results 
in axonal dissection, followed by neuronal lost and thus reduction in neuronal impulse 
transmission, resulting in weakness, fatigue, numbness and overall disability. Concerning 
its onset and evolution, MS may be separated in i) primary progressive ii) secondary 
progressive and also iii) the relapsing-remitting type. Usually the disease starts with a 
relapse-remitting pattern of the symptoms followed by a progressive stage of increasing 
disability, considered the more severe cases (Weiner 2008). Many patients evolve to a more 
chronic stage of the disease, with no relapses, but a more prominent progressive lost of 
motor coordination, sensory and autonomic function is observed. It is noteworthy that 
many of these symptoms are tightly regulated by the local inflammatory milieu in the CNS, 
as well as by the activation status of the resident cells.   
Much of our understanding concerning the molecular and cellular mechanisms of MS was 
obtained after observations made on its murine model, Experimental Autoimmune 
Encephalomyelitis (EAE). With historical relevance, it is worthy to mention that the EAE 
model started after Prof. Thomas Rivers decided to understand why many years before, 
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Prof. Louis Pasteur experimental animals used to develop paralysis after vaccination against 
rabies. Rivers proceeded with the same protocol as Pasteur, immunizing rabbits with spinal 
cords extracts from rabbits that were inoculated with the rabies virus. At the same time he 
included a control group which consisted of extracts from non-contaminated animals. 
Interestingly, animals that received these extracts also developed paralysis, highlighting the 
fact that the secondary paralysis was not a rabies virus-dependent observation. 
Interestingly, the features develop by the animals was very similar to those observed by 
Pasteur many years earlier. It was also very exciting to recall that at that time Freund was 
describing its complete adjuvant (Complete Freund Adjuvant), what made Rivers research 
much easier, as the immunization for EAE induction changed from around 20 inoculations 
of brain extracts to only one injection. Then, one of the most used model to study not only 
neuroinflammation and neurodegeneration but also autoimmunity mechanisms had been 
brought to scientific community, as reviewed (Baxter 2007). 
MS was previously considered to be the prototype of a Th1 type of autoimmune disease, 
where IFN-γ-secreting T CD4 (Kroenke MA 2007; Dardalhon V 2008)  and CD8 (Michael P. 
Crawford 2004; Goverman J 2005) cells are greatly relevant and widely found in the 
periphery, liquor and brain parenchyma (Matusevicius D 1999). On the other hand, many 
contrasting data were obtained using the EAE model. In fact, it was known by a long date 
that mice deficient for IFN-γ were more susceptible to EAE induction when compared to 
control animals (Chu CQ 2000). This is in fact corroborated by other autoimmune disease 
model, the Experimental Autoimmune Uveitis (EAU) (Jones LS 1997). This was much 
unexpected, and for a great period of time a matter of intense speculation. Moreover, 
corroborating these findings, studies using animals deficient for p19, p35 and p40, the 
subunits for the heterodimers IL-12 (p35 + p40) and IL-23 (p19 + p40), had demonstrated 
that, unexpectedly, IL-23 was more relevant then IL-12 in these same models, raising still 
more questions in the field of EAE pathology (Cua DJ 2003). Thus, for many years there was 
a gap in the understanding on the actual role for IFN--secreting Th1 cells in the EAE model. 
It is worthy to mention that much less was known for the human disease. 
The final answer for that was obtained many years later when, using the EAE model, a new 
population of T cells was described as the main players in the pathogenesis of EAE  The so-
called Th17 cells secrete high amounts of the cytokines IL-17A, IL-17F (Ivanov I 2006), IL-21 
(Zhou L 2007) and GM-CSF (Codarri L 2011), and its master regulator is the rorc gene which 
encodes the gene for the retinoic acid orphan receptor, RORγt (Ivanov I 2006). To further 
corroborate this hypothesis, it was demonstrated that IL-17 knockout mice are resistant to 
EAE induction, which was very contrasting with data obtained from IFN-γ knockout mice, 
as reviewed (Komiyama Y 2006). Besides, it became clear that these cells arise in the 
periphery in the dependence of two cytokines, IL-6 + TGF-β, whose activity was 
demonstrated to be inducers of rorc expression and thus Th17 commitment. Corroborating 
previous data, it was clarified that IL-23 is the maintenance factor for these cells to remain 
viable and active. In fact, IL-23r deficient cells are unable to be maintained viable and thus 
induce disease (Cua DJ 2003; Zhou L 2007).  Thus, the findings in p19 KO mice highlighted 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 178 
the fact that these mice were resistant to EAE induction due to the reduced survival of 
encephalitogenic Th17 cells in the periphery. However, it is well accepted that both Th1 and 
Th17 cells are found in focal lesions in MS and EAE, comprising around 20-25% and 10-15% 
of the CNS infiltrating T CD4 cells respectively (Murphy AC 2010; Peron JP 2010). Moreover, 
it is well accepted the fact both populations intimately interact with CNS resident cells, as 
astrocytes, microglia and neurons. 
Aside from the discussion whether this or that population of CD4 cells is more important, it 
is a fact that a mixed population is found in the inflamed brain parenchyma, and in most 
cases Th1 cells outnumber Th17 cells. Interestingly, it has now been established that each 
population possibly infiltrate the CNS through different mechanisms. Actually, infiltrating 
cells may reach the CNS by three separate routes: 1) by direct transmigration through the 
capillary and post-capillary venules of the BBB and 2) from the blood to the cerebrospinal 
fluid at the choroid plexus and 3) migration through meningeal vessels to the subarachnoid 
space (B. 2006). In this sense, it has been recently demonstrated that Th1 cells use the 4β1 
integrins (Very Late Antigen- 4 – VLA-4) to infiltrate the spinal cord during EAE. The 
blockade of VLA-4 did not block Th17 cells to infiltrate the brain, expressing both IL-23R 
and CCR6. Accordingly, T cell-conditional α4-deficient mice were not resistant to actively 
induced EAE but showed an ataxic syndrome with predominantly supraspinal infiltrates of 
T cells (Rothhammer V 2011). Corroborating this idea, it was previously showed that Th17 
cells constitutively express the chemokine receptor CCR6, whose ligand, CCL20 is also 
constitutively expressed by choroid plexus cells. Thus, it is clear that Th1 and Th17 cells 
differ not only in phenotype and function, but also in its ways to gain access to the CNS 
(Jäger A 2009; Murphy AC 2010). 
It is well established that after the entry of Th1 and Th17 cells to the brain parenchyma, 
these cells need to be reactivated upon encounter with MHC-Ag bearing cells on a second 
hit phenomenon. After re-activation in situ, Th1 and Th17 lymphocytes release its contents, 
most of which are pro-inflammatory cytokines, such as IFN-, TNF- and IL-6 for Th1, and 
IL-17A, IL-17F, IL-21 and IL-22 for Th17 cells. In this context, CNS resident cells play an 
important role, not only because of its capacity to second hit T cells, but also because they 
express cytokine receptors and Toll-like receptors (TLRs), very important for the 
amplification of the inflammation. Thus, studies on the biology of astrocytes, microglia, 
endothelial cells and also neurons during inflammatory processes will greatly contribute to 
the understanding of the pathogenesis of neuroinflammatory and neurodegenerative 
disease. 
1.1. Central nervous system resident cells and stroke 
Due to the high necessity for blood supply and oxygen, brain resident cells are very 
sensitive to hypoxic injury. Neurons are the most affected, followed by astrocytes, microglia 
and finally endothelial cells (Dirnagl U 1999). During stroke, necrotic cell death is followed 
by the release of intracellular content, such as pro-inflammatory cytokines, that greatly 
accounts for the initiation of the process. In fact, activation of astrocytes and microglial cells 
 
Central Nervous System Resident Cells in Neuroinflammation: A Brave New World 179 
during stroke, either by the early necrotic cell death or by the later inflammatory cells-
derived cytokines, is an important process directly involved with the disease pathology 
(Dirnagl U 1999; Ceulemans A 2010). However, we must not exclude the role for infiltrating 
macrophages, a rich source of cytokines and chemokines, found in the ischemic foci as soon 
as 10 hours. 
Microglial cells are CNS resident phagocytic cells, with great resemblance to macrophages, 
however, it has been recently demonstrated that these macrophage-like cells in fact differ in 
ontogeny. Microglial cells were believed to derive from a myeloid precursor whose marker 
is the transcription factor PU.1. However, PU.1 knockout mice were absent not only of 
microglia but also macrophages, showing that microglial cells were in fact derived from a 
myeloid lineage, but PU.1  was a not a specific marker [1, 2]. Interesting results have 
demonstrated that bone marrow (BM) transplantation restored microglia presence in the 
central nervous system, what led to the interpretation that microglial cells do in fact derive 
from a common precursor in the BM [1] (Kettenmann H 2011). However, many of these 
experiments were performed after whole-body or central nervous system (CNS) irradiation. 
Using a parabiotic system, where the circulatory systems of two mice are connected, 
experiments demonstrated that no donor-derived cells are found in the CNS of parabiotic 
mice [3]. Recent reports using Green Fluorescent Protein  (GFP) couple  to the fractalkine 
receptor (CX3CR1- GFP) and Runt- related transcription factor 1 (Runx1) - Cre reporter mice 
described the presence of fetal yolk sac- derived microglial precursor cells at day E9.5. On 
day E10.5, microglial cells are already found in CNS, as circulatory system has been 
established. Thus, microglial are generated upon primitive haematopoiesis in the yolk sac, 
independent from bone marrow haematopoiesis [4]. Actually there is still a search for a 
reliable marker to indentify microglial cells by flow cytometry. One option is to use the 
markers CD45 and CD11b, where CD11b+CD45low cells are considered microglia and 
CD11b+CD45high are considered macrophages. 
At resting state, microglial cells have a body shape very similar to dendritic cells, as they 
posses many dendrites or branches. Those are believed to be actively involved in the 
clearance of cellular debris as well as in the immunesurveillance, as some viruses and 
bacteria may reach the brain [13-14]. Moreover, it was already demonstrated that after 
ischemic brain injury, microglia migrate to the penumbra covering the remaining living 
neurons. As these neurons die by apoptosis, proper caping by microglia results in fast 
phagocytosis and thus avoiding more inflammation. This was demonstrated to be 
dependent on the expression of the LFA-1 integrin.  
Non-activated microglia are described to be very quiescent with an anergic-like state. 
Resting microglia have very little capacity to prime naïve T cells as they express very low 
levels of MHC II molecules, and are negative for CD80, CD86 and CD40 (Kettenmann H 
2011).This status seem to be maintained by several different mechanisms. For instance, it 
was recently demonstrated that, microglial cells express a high amount of the miRNA-124. 
This oligonucleotide directly inhibits the CCAAT/enhancer-binding protein-α (C/EBP-α) 
and also its target, the above mentioned PU.1. Further, this inhibition down-regulates CD45 
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the fact that these mice were resistant to EAE induction due to the reduced survival of 
encephalitogenic Th17 cells in the periphery. However, it is well accepted that both Th1 and 
Th17 cells are found in focal lesions in MS and EAE, comprising around 20-25% and 10-15% 
of the CNS infiltrating T CD4 cells respectively (Murphy AC 2010; Peron JP 2010). Moreover, 
it is well accepted the fact both populations intimately interact with CNS resident cells, as 
astrocytes, microglia and neurons. 
Aside from the discussion whether this or that population of CD4 cells is more important, it 
is a fact that a mixed population is found in the inflamed brain parenchyma, and in most 
cases Th1 cells outnumber Th17 cells. Interestingly, it has now been established that each 
population possibly infiltrate the CNS through different mechanisms. Actually, infiltrating 
cells may reach the CNS by three separate routes: 1) by direct transmigration through the 
capillary and post-capillary venules of the BBB and 2) from the blood to the cerebrospinal 
fluid at the choroid plexus and 3) migration through meningeal vessels to the subarachnoid 
space (B. 2006). In this sense, it has been recently demonstrated that Th1 cells use the 4β1 
integrins (Very Late Antigen- 4 – VLA-4) to infiltrate the spinal cord during EAE. The 
blockade of VLA-4 did not block Th17 cells to infiltrate the brain, expressing both IL-23R 
and CCR6. Accordingly, T cell-conditional α4-deficient mice were not resistant to actively 
induced EAE but showed an ataxic syndrome with predominantly supraspinal infiltrates of 
T cells (Rothhammer V 2011). Corroborating this idea, it was previously showed that Th17 
cells constitutively express the chemokine receptor CCR6, whose ligand, CCL20 is also 
constitutively expressed by choroid plexus cells. Thus, it is clear that Th1 and Th17 cells 
differ not only in phenotype and function, but also in its ways to gain access to the CNS 
(Jäger A 2009; Murphy AC 2010). 
It is well established that after the entry of Th1 and Th17 cells to the brain parenchyma, 
these cells need to be reactivated upon encounter with MHC-Ag bearing cells on a second 
hit phenomenon. After re-activation in situ, Th1 and Th17 lymphocytes release its contents, 
most of which are pro-inflammatory cytokines, such as IFN-, TNF- and IL-6 for Th1, and 
IL-17A, IL-17F, IL-21 and IL-22 for Th17 cells. In this context, CNS resident cells play an 
important role, not only because of its capacity to second hit T cells, but also because they 
express cytokine receptors and Toll-like receptors (TLRs), very important for the 
amplification of the inflammation. Thus, studies on the biology of astrocytes, microglia, 
endothelial cells and also neurons during inflammatory processes will greatly contribute to 
the understanding of the pathogenesis of neuroinflammatory and neurodegenerative 
disease. 
1.1. Central nervous system resident cells and stroke 
Due to the high necessity for blood supply and oxygen, brain resident cells are very 
sensitive to hypoxic injury. Neurons are the most affected, followed by astrocytes, microglia 
and finally endothelial cells (Dirnagl U 1999). During stroke, necrotic cell death is followed 
by the release of intracellular content, such as pro-inflammatory cytokines, that greatly 
accounts for the initiation of the process. In fact, activation of astrocytes and microglial cells 
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during stroke, either by the early necrotic cell death or by the later inflammatory cells-
derived cytokines, is an important process directly involved with the disease pathology 
(Dirnagl U 1999; Ceulemans A 2010). However, we must not exclude the role for infiltrating 
macrophages, a rich source of cytokines and chemokines, found in the ischemic foci as soon 
as 10 hours. 
Microglial cells are CNS resident phagocytic cells, with great resemblance to macrophages, 
however, it has been recently demonstrated that these macrophage-like cells in fact differ in 
ontogeny. Microglial cells were believed to derive from a myeloid precursor whose marker 
is the transcription factor PU.1. However, PU.1 knockout mice were absent not only of 
microglia but also macrophages, showing that microglial cells were in fact derived from a 
myeloid lineage, but PU.1  was a not a specific marker [1, 2]. Interesting results have 
demonstrated that bone marrow (BM) transplantation restored microglia presence in the 
central nervous system, what led to the interpretation that microglial cells do in fact derive 
from a common precursor in the BM [1] (Kettenmann H 2011). However, many of these 
experiments were performed after whole-body or central nervous system (CNS) irradiation. 
Using a parabiotic system, where the circulatory systems of two mice are connected, 
experiments demonstrated that no donor-derived cells are found in the CNS of parabiotic 
mice [3]. Recent reports using Green Fluorescent Protein  (GFP) couple  to the fractalkine 
receptor (CX3CR1- GFP) and Runt- related transcription factor 1 (Runx1) - Cre reporter mice 
described the presence of fetal yolk sac- derived microglial precursor cells at day E9.5. On 
day E10.5, microglial cells are already found in CNS, as circulatory system has been 
established. Thus, microglial are generated upon primitive haematopoiesis in the yolk sac, 
independent from bone marrow haematopoiesis [4]. Actually there is still a search for a 
reliable marker to indentify microglial cells by flow cytometry. One option is to use the 
markers CD45 and CD11b, where CD11b+CD45low cells are considered microglia and 
CD11b+CD45high are considered macrophages. 
At resting state, microglial cells have a body shape very similar to dendritic cells, as they 
posses many dendrites or branches. Those are believed to be actively involved in the 
clearance of cellular debris as well as in the immunesurveillance, as some viruses and 
bacteria may reach the brain [13-14]. Moreover, it was already demonstrated that after 
ischemic brain injury, microglia migrate to the penumbra covering the remaining living 
neurons. As these neurons die by apoptosis, proper caping by microglia results in fast 
phagocytosis and thus avoiding more inflammation. This was demonstrated to be 
dependent on the expression of the LFA-1 integrin.  
Non-activated microglia are described to be very quiescent with an anergic-like state. 
Resting microglia have very little capacity to prime naïve T cells as they express very low 
levels of MHC II molecules, and are negative for CD80, CD86 and CD40 (Kettenmann H 
2011).This status seem to be maintained by several different mechanisms. For instance, it 
was recently demonstrated that, microglial cells express a high amount of the miRNA-124. 
This oligonucleotide directly inhibits the CCAAT/enhancer-binding protein-α (C/EBP-α) 
and also its target, the above mentioned PU.1. Further, this inhibition down-regulates CD45 
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and MHC II expression and also TNF- secretion [15]. Interestingly, peritoneal macrophages 
do not express miRNA-124 and bone marrow derived macrophages are rendered less 
activated when transfected with miRNA-124 [15]. Thus, the specific expression of such 
miRNA greatly accounts for the anergic state of microglial cells.  
The intimate contact with norepinephrine-releasing adrenergic neurons, as in the locus 
coeruleus may be also responsible for maintaining microglia hyporesponsive. Microglial 
cells express β2-adrenergic receptors associated to G stimulatory proteins. These proteins 
trigger the activity of adenilate cyclase increasing cAMP synthesis. Elevated intracellular 
cAMP concentrations activate Protein Kinase A (PKA) which may have many suppressive 
activities. PKA phosphorylates Csk and Ezhrin, whose kinase activity phosphorylates 
inhibitory proteins of Lck (Ruppelt A 2007).  High cAMP levels also phosphorylates CREB 
(Cyclic AMP Responsive Elements Binding Protein) that translocates to the nucleus [16, 17]. 
CREB interacts with CREB Binding Protein (CBP) activating several promoters, such as IL-
10. PKA is also able to phosphorylate the Nuclear Factor of Activated T Cells (NF-AT). It is 
worthy to remember that NF-AT is inactive at its phosphorylated state. Altogether these are 
some of the mechanisms that greatly contribute to the hyporesponsiveness of microglial 
cells. 
Although at resting state microglial cells are very “polite”, after activation they start to 
express a whole different set of genes, acquiring the capacity not only to secrete significant 
amounts of cytokines, chemokines and other inflammatory molecules, but also to present 
antigens and activate CNS infiltrating T cells. In fact, there are at least three acceptable ways 
to activate microglial cells: i) with pro-inflammatory cytokines, such as IFN-, TNF- and IL-
17; ii) engagement of TLRs ligands, such as LPS, PGN, HSPs, and iii) the phagocytosis of 
myelin debris from demyelinating regions. Altogether, these are the main mechanisms by 
which microglial cells subverts the anergic-induced state, and thus acquiring an active role 
in neuroinflammation, as observed during acute brain ischemia. 
It was recently proposed that microglia posses all inflammasome derived machinery, thus 
conferring these cells positive for IL-1 / IL-18. IL-1β interacts with its receptor activating a 
signaling pathway that is shared with Toll-like receptors (TLRs) through MyD88 and 
culminating in NF-κB phosphorylation and translocation to the nucleus. IL-1R was shown to 
be widely found in rat hippocampus, but preferentially at synaptic sites. More interesting, it 
was also demonstrated that IL-1R co-localizes with the ionotropic glutamate receptor 
NMDA through its GluN2B subunit (Gardoni F 2011). Just to mention, a few overall effects 
of IL-1β are: induces rapid local inflammation and up-regulates the synthesis of other 
cytokines and costimulatory molecules, as CD80, CD86 and CD40. IL-1β also disturbs ionic 
balance, increases Ca2+ influx in neurons leading to degeneration, facilitates BBB disruption 
and most important, it is a potent stimuli for endothelial cells to express adhesion molecules 
which amplifies local inflammatory cells recruitment (Ceulemans AG 2010).  
IL-6 is not found in the CNS at resting state. On the other hand, it is widely found after 
stroke, and may be secreted by many resident cells, as microglia, astrocytes, endothelial cells 
and also infiltrating monocytes and T cells. Interestingly, microglia are not only able to 
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secrete IL-6 but also they express IL-6R, evidencing a positive feedback loop. IL-6 signaling 
in microglia phosphorylates STAT-1, STAT-3 and ERK, culminating in MHC II, CD40 and 
IL-12p70 up-regulation and increasing inflammation (Lin HW 2009). However it is also 
accepted a dichotomy for IL-6 function, as many reports have also demonstrated its 
protective role after stroke. In this concern, it is interesting to mention that IL-6 up-regulates 
the transcription of the suppressive molecule IL-1ra (IL-1 Receptor Antagonist), thus 
blocking some of the deleterious functions of IL-1. In fact, higher IL-6 levels may positively 
correlate with a better neuropathological outcome (Emsley HC 2005).  
It is noteworthy that microglial cells secrete so many inflammatory factors, such as IL-1, IL-
4, IL-6, IL-17, TNF-α, synthesize reactive oxygen and nitrogen species, secrete matrix 
metaloproteinase as MMP-2, MMP-9, and other factors. Microglia also express several 
membrane receptors, as TLR-2, TLR-4, NLRP3 (Nalp3), gp91 phox (Dohi K 2010), 
ciclooxinagenase-2 (Cox-2), oncostatin M, heme-oxigenase -1 (HO-1) [10, 15-17]. Onconstatin 
M shares the IL-6R beta chain and thus phosphorylates STAT-3 and also NF-κB 
transcription factors, up-regulating TNF- secretion and iNOS expression (Baker BJ 2010). It 
is also known that activated microglia secrete high amounts of glutamate and TNF-. These 
molecules are able to induce apoptosis of neurons but especially of oligodendrocytes, 
leading to demyelination, a hallmark of MS and EAE. For this reason, it has been more and 
more evidenced that microglial cells have a very important role in the pathogenesis of 
several different inflammatory diseases of the CNS, as stroke [13, 18], multiple sclerosis [17], 
Alzheimer disease, amyotrophic lateral sclerosis and also different types of brain and liquor 
infections, as reviewed [19].  
The products of NADPH oxidase activation, the reactive oxygen species (ROIs), are also a 
very relevant source for cellular injuries. In this concern, ischemia can also induce this 
pathway whose importance in the pathogenesis of stroke is well established. The voltage-
gated proton channel Hv1 counterbalances NADPH oxidase and subsequent cellular loss of 
electrons with protons. It has recently been shown that mouse and human brain microglia, 
but not neurons or astrocytes, expressed large Hv1-mediated currents and that Hv1 was 
required for NAPDH oxidase activity and ROI generation in brain microglia in situ and in 
vivo. Thus, Hv1 knockout mice are less prone to develop neuronal death and brain damage 
after stroke. These indicate that, aside the cytokine and glutamate burst, ROIs are 
responsible for a substantial fraction of brain damage at early time points after ischemia, 
and rendering Hv1 with a promising therapeutic approach (Wu LJ 2012). 
In summary, there is a never ending list of features, such as released factors, receptors 
expressed, ROIs, membrane molecules, MMPs, that points out microglia as a very important 
resident cell population, with an unquestionable relevance in the mechanisms of triggering 
and perpetuating CNS inflammation. On the other hand, although mostly shown as an 
important pro-neuroinflammatory agent, it is conceivable that microglial cells may have a 
modulatory function, in an attempt to reduce neuroinflammation. In fact, it has been 
demonstrated that microglia may also secrete anti-inflammatory molecules such as IL-10 
[20], TGF-β, IL-1Ra and express suppressive molecules as Suppressor of Cytokine Signaling 
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and MHC II expression and also TNF- secretion [15]. Interestingly, peritoneal macrophages 
do not express miRNA-124 and bone marrow derived macrophages are rendered less 
activated when transfected with miRNA-124 [15]. Thus, the specific expression of such 
miRNA greatly accounts for the anergic state of microglial cells.  
The intimate contact with norepinephrine-releasing adrenergic neurons, as in the locus 
coeruleus may be also responsible for maintaining microglia hyporesponsive. Microglial 
cells express β2-adrenergic receptors associated to G stimulatory proteins. These proteins 
trigger the activity of adenilate cyclase increasing cAMP synthesis. Elevated intracellular 
cAMP concentrations activate Protein Kinase A (PKA) which may have many suppressive 
activities. PKA phosphorylates Csk and Ezhrin, whose kinase activity phosphorylates 
inhibitory proteins of Lck (Ruppelt A 2007).  High cAMP levels also phosphorylates CREB 
(Cyclic AMP Responsive Elements Binding Protein) that translocates to the nucleus [16, 17]. 
CREB interacts with CREB Binding Protein (CBP) activating several promoters, such as IL-
10. PKA is also able to phosphorylate the Nuclear Factor of Activated T Cells (NF-AT). It is 
worthy to remember that NF-AT is inactive at its phosphorylated state. Altogether these are 
some of the mechanisms that greatly contribute to the hyporesponsiveness of microglial 
cells. 
Although at resting state microglial cells are very “polite”, after activation they start to 
express a whole different set of genes, acquiring the capacity not only to secrete significant 
amounts of cytokines, chemokines and other inflammatory molecules, but also to present 
antigens and activate CNS infiltrating T cells. In fact, there are at least three acceptable ways 
to activate microglial cells: i) with pro-inflammatory cytokines, such as IFN-, TNF- and IL-
17; ii) engagement of TLRs ligands, such as LPS, PGN, HSPs, and iii) the phagocytosis of 
myelin debris from demyelinating regions. Altogether, these are the main mechanisms by 
which microglial cells subverts the anergic-induced state, and thus acquiring an active role 
in neuroinflammation, as observed during acute brain ischemia. 
It was recently proposed that microglia posses all inflammasome derived machinery, thus 
conferring these cells positive for IL-1 / IL-18. IL-1β interacts with its receptor activating a 
signaling pathway that is shared with Toll-like receptors (TLRs) through MyD88 and 
culminating in NF-κB phosphorylation and translocation to the nucleus. IL-1R was shown to 
be widely found in rat hippocampus, but preferentially at synaptic sites. More interesting, it 
was also demonstrated that IL-1R co-localizes with the ionotropic glutamate receptor 
NMDA through its GluN2B subunit (Gardoni F 2011). Just to mention, a few overall effects 
of IL-1β are: induces rapid local inflammation and up-regulates the synthesis of other 
cytokines and costimulatory molecules, as CD80, CD86 and CD40. IL-1β also disturbs ionic 
balance, increases Ca2+ influx in neurons leading to degeneration, facilitates BBB disruption 
and most important, it is a potent stimuli for endothelial cells to express adhesion molecules 
which amplifies local inflammatory cells recruitment (Ceulemans AG 2010).  
IL-6 is not found in the CNS at resting state. On the other hand, it is widely found after 
stroke, and may be secreted by many resident cells, as microglia, astrocytes, endothelial cells 
and also infiltrating monocytes and T cells. Interestingly, microglia are not only able to 
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secrete IL-6 but also they express IL-6R, evidencing a positive feedback loop. IL-6 signaling 
in microglia phosphorylates STAT-1, STAT-3 and ERK, culminating in MHC II, CD40 and 
IL-12p70 up-regulation and increasing inflammation (Lin HW 2009). However it is also 
accepted a dichotomy for IL-6 function, as many reports have also demonstrated its 
protective role after stroke. In this concern, it is interesting to mention that IL-6 up-regulates 
the transcription of the suppressive molecule IL-1ra (IL-1 Receptor Antagonist), thus 
blocking some of the deleterious functions of IL-1. In fact, higher IL-6 levels may positively 
correlate with a better neuropathological outcome (Emsley HC 2005).  
It is noteworthy that microglial cells secrete so many inflammatory factors, such as IL-1, IL-
4, IL-6, IL-17, TNF-α, synthesize reactive oxygen and nitrogen species, secrete matrix 
metaloproteinase as MMP-2, MMP-9, and other factors. Microglia also express several 
membrane receptors, as TLR-2, TLR-4, NLRP3 (Nalp3), gp91 phox (Dohi K 2010), 
ciclooxinagenase-2 (Cox-2), oncostatin M, heme-oxigenase -1 (HO-1) [10, 15-17]. Onconstatin 
M shares the IL-6R beta chain and thus phosphorylates STAT-3 and also NF-κB 
transcription factors, up-regulating TNF- secretion and iNOS expression (Baker BJ 2010). It 
is also known that activated microglia secrete high amounts of glutamate and TNF-. These 
molecules are able to induce apoptosis of neurons but especially of oligodendrocytes, 
leading to demyelination, a hallmark of MS and EAE. For this reason, it has been more and 
more evidenced that microglial cells have a very important role in the pathogenesis of 
several different inflammatory diseases of the CNS, as stroke [13, 18], multiple sclerosis [17], 
Alzheimer disease, amyotrophic lateral sclerosis and also different types of brain and liquor 
infections, as reviewed [19].  
The products of NADPH oxidase activation, the reactive oxygen species (ROIs), are also a 
very relevant source for cellular injuries. In this concern, ischemia can also induce this 
pathway whose importance in the pathogenesis of stroke is well established. The voltage-
gated proton channel Hv1 counterbalances NADPH oxidase and subsequent cellular loss of 
electrons with protons. It has recently been shown that mouse and human brain microglia, 
but not neurons or astrocytes, expressed large Hv1-mediated currents and that Hv1 was 
required for NAPDH oxidase activity and ROI generation in brain microglia in situ and in 
vivo. Thus, Hv1 knockout mice are less prone to develop neuronal death and brain damage 
after stroke. These indicate that, aside the cytokine and glutamate burst, ROIs are 
responsible for a substantial fraction of brain damage at early time points after ischemia, 
and rendering Hv1 with a promising therapeutic approach (Wu LJ 2012). 
In summary, there is a never ending list of features, such as released factors, receptors 
expressed, ROIs, membrane molecules, MMPs, that points out microglia as a very important 
resident cell population, with an unquestionable relevance in the mechanisms of triggering 
and perpetuating CNS inflammation. On the other hand, although mostly shown as an 
important pro-neuroinflammatory agent, it is conceivable that microglial cells may have a 
modulatory function, in an attempt to reduce neuroinflammation. In fact, it has been 
demonstrated that microglia may also secrete anti-inflammatory molecules such as IL-10 
[20], TGF-β, IL-1Ra and express suppressive molecules as Suppressor of Cytokine Signaling 
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(SOCS-3) [21], the tryptophan depleting enzyme indoleamine-2,3-dioxigenase (IDO) [22] 
and also IL-4 (Ponomarev ED 2007). It has recently been accepted that, as observed in 
macrophages, microglial cells may also be divided in those with pro-inflammatory activity, 
called Microglia 1 (M1) and those with regulatory activity, called Microglia 2 (M2), as 
extensively reviewed (Martinez FO 2009). Such findings, much contributes towards the 
great relevance of microglial cells during neuroinflammatory diseases. However, further 
studies must be performed to a better understanding of the suppressive activities of 
microglial cells. 
Activated astrocytes also play a significant role in the pathogenesis of stroke. Astrocytes 
may not only secret many cytokines, chemokines and MMPs but also undergo astrogliosis, 
which is an exacerbated proliferation of astrocytes as a wound-healing like process. 
Astrocytes may secrete significant amounts of TNF-, interestingly with both 
neuroprotective and neurotoxic properties. TNF- belongs to a great family of cytokines and 
also membrane bound molecules, such as Fas, FasL, Glucocorticoid Induced TNF Receptor 
(GITR) and several others (Abbul K Abbas 2006). It has been proposed that TNF- follows a 
biphasic pattern of secretion after brain ischemia, and the first wave is detected as soon as 1-
3 hours probably, and the second after 24-36 hours. This fluctuation may be a consequence 
of two separate sources for this cytokine, as it may be first derived by the tissular injury 
itself, and the second one derived from resident cells activation and also from infiltrating 
inflammatory cells (Ceulemans AG 2010). Moreover, TNF- using its death domains, 
induces apoptosis of endothelial cells, and thus promoting CNS infiltration, as it disrupts 
BBB (Ceulemans AG 2010). However, contrasting data showing that previous treatment 
with TNF- protect from neuronal death, although the mechanisms are still to be elucidated. 
AVC 
Transglutaminase 2 (TG2) is a Ca(2+)-dependent transamidating enzyme ubiquitously 
expressed in the body. TG2 is the predominant form of transglutaminase expressed in the 
mammalian nervous system. Previously, it was shown that TG2 can affect both cell death 
and cell survival mechanisms depending on the cell type and the stressor. Intriguingly, 
infarct volumes in TG2 knockout mice were significantly reduced when compared to 
controls. Neurons from TG2 knockout mice showed decreased viability in response to 
oxygen-glucose deprivation, which was not observed in astrocytes, as they were resistant to 
oxygen-glucose deprivation in situ. Interestingly, wild type and knock out neurons were 
protected against oxygen glucose deprivation when they were co-cultured with astrocytes 
from TG2 knockout mice (Colak G 2012). Therefore, the decreased stroke volumes observed 
in TG2 knock out evidences that its expression is more important in astrocytes. Altogether, 
this serves to corroborate the idea that neuron-astrocyte crosstalk plays a significant role in 
mediating stroke pathogenesis.  
Matrix metalloproteinases (MMPs) are extracellular matrix remodeling enzyme, very 
important for tecidual infiltration. Recent data on non-nervous system tissue showed 
intracellular and even intranuclear localizations for different MMPs. In this concern it was 
recently demonstrated that MMPs localization to the nucleus of neurons may correlate to 
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apoptotic cell death. More interesting, cells expressing MMP-9 in the nuclear compartment 
also co-expressed activated-caspase 3, linking MMP-9 expression to neuronal and glial death 
(Del Zoppo GJ 2012). The research has shown for the first time the localization of MMP-9 to 
the nucleus of human neurons. Altogether this gives more relevance to MMPs secretion in 
the CNS as it correlates not only with facilitation of the cellular infiltration. 
Moreover, the mechanisms through which astrogliosis is orchestrated is still considered to 
be unknown. However, it has been recently demonstrated that CD36 plays a pivotal role in 
astrocytic survival, and proliferation In fact, CD36 deficient and CD36 -siRNA treated 
animals had reduced astrogliosis and wound healing. Thus, it is now accepted that CD36 
signaling intimately correlates with astroglial proliferation (Bao Y 2012).  
The presence and the role of certain types of dendritic cells (DCs) in the CNS is constant 
matter of intense debate. Things get even darker when it concerns stroke pathogenesis. 
Some reports have shown that both resident and peripheral DCs may route to CNS after 
ischemic injury. Using CD11c-GFP animals, it was clearly shown that as soon as 24 hours 
after medial cerebral artery occlusion (MCAO), brain dendritic cells (bDCs) are found 
peripherally to the penumbra area. Using bone marrow chimeras, where both wild type and 
CD11c - GFP animals were irradiated followed by bone marrow reconstitution interestingly 
demonstrated that bDCs migrate to the penumbra, whereas peripherally recruited DCs are 
mostly found in the core. These cells were highly positive for the expression of the dendritic 
cells marker CD11c and several T cell activation-related molecules, as MHC II, CD80 and 
CD86. However, this was not observed early after MCAO occlusion, and thus, the initial 
activation observed in the CNS is most probably dependent on microglial activation rather 
than on bDCs (Felger JC 2010). 
As professional antigen presenting cells as DCs are important in the pathogenesis of stroke, 
it is conceivable that T cells may also have a relevant role due to antigen recognition. 
However, one may not forget that, differently from MS, stroke is not an autoimmune 
disease, and the cognate epitopes recognized by T and B cells after ischemia are still matter 
of debate. However, elegant researches have demonstrated a pivotal role for T cells in stroke 
lesions, mostly on a later period after ischemia. In fact, IFN- deficient mice develop much 
smaller lesions than control animals. Although this IFN- may derive from different sources, 
it is accepted that Th1 cells play a relevant role in this phenomenon. Moreover, T CD4 
deficient animals are much more resistant to ischemic injury and this may corroborate the 
role for these lymphocytes, as recently reviewed (Brait VH 2012). This only contributes to 
the hypothesis that T cells may have an important role in the ischemic brain lesions.  
IL-17 is the hallmark of the T CD4 lymphocytes with Th17 phenotype (Ivanov I 2006; 
Iwakura Y 2006). It is now accepted that many other cell types may also secrete this 
cytokine, as microglia and astrocytes (Kawanokuchi J 2008), alveolar macrophages (Song C 
2008), and many others. Several important roles for the biological function of IL-17 have 
been evidenced during neuroinflammation. For instance, it was demonstrated that human 
BBB endothelial cells express IL-17R constitutively. Thus, bioactive IL-17 facilitates the 
disruption of the BBB reducing the tight cellular interaction of endothelial cells through 
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called Microglia 1 (M1) and those with regulatory activity, called Microglia 2 (M2), as 
extensively reviewed (Martinez FO 2009). Such findings, much contributes towards the 
great relevance of microglial cells during neuroinflammatory diseases. However, further 
studies must be performed to a better understanding of the suppressive activities of 
microglial cells. 
Activated astrocytes also play a significant role in the pathogenesis of stroke. Astrocytes 
may not only secret many cytokines, chemokines and MMPs but also undergo astrogliosis, 
which is an exacerbated proliferation of astrocytes as a wound-healing like process. 
Astrocytes may secrete significant amounts of TNF-, interestingly with both 
neuroprotective and neurotoxic properties. TNF- belongs to a great family of cytokines and 
also membrane bound molecules, such as Fas, FasL, Glucocorticoid Induced TNF Receptor 
(GITR) and several others (Abbul K Abbas 2006). It has been proposed that TNF- follows a 
biphasic pattern of secretion after brain ischemia, and the first wave is detected as soon as 1-
3 hours probably, and the second after 24-36 hours. This fluctuation may be a consequence 
of two separate sources for this cytokine, as it may be first derived by the tissular injury 
itself, and the second one derived from resident cells activation and also from infiltrating 
inflammatory cells (Ceulemans AG 2010). Moreover, TNF- using its death domains, 
induces apoptosis of endothelial cells, and thus promoting CNS infiltration, as it disrupts 
BBB (Ceulemans AG 2010). However, contrasting data showing that previous treatment 
with TNF- protect from neuronal death, although the mechanisms are still to be elucidated. 
AVC 
Transglutaminase 2 (TG2) is a Ca(2+)-dependent transamidating enzyme ubiquitously 
expressed in the body. TG2 is the predominant form of transglutaminase expressed in the 
mammalian nervous system. Previously, it was shown that TG2 can affect both cell death 
and cell survival mechanisms depending on the cell type and the stressor. Intriguingly, 
infarct volumes in TG2 knockout mice were significantly reduced when compared to 
controls. Neurons from TG2 knockout mice showed decreased viability in response to 
oxygen-glucose deprivation, which was not observed in astrocytes, as they were resistant to 
oxygen-glucose deprivation in situ. Interestingly, wild type and knock out neurons were 
protected against oxygen glucose deprivation when they were co-cultured with astrocytes 
from TG2 knockout mice (Colak G 2012). Therefore, the decreased stroke volumes observed 
in TG2 knock out evidences that its expression is more important in astrocytes. Altogether, 
this serves to corroborate the idea that neuron-astrocyte crosstalk plays a significant role in 
mediating stroke pathogenesis.  
Matrix metalloproteinases (MMPs) are extracellular matrix remodeling enzyme, very 
important for tecidual infiltration. Recent data on non-nervous system tissue showed 
intracellular and even intranuclear localizations for different MMPs. In this concern it was 
recently demonstrated that MMPs localization to the nucleus of neurons may correlate to 
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apoptotic cell death. More interesting, cells expressing MMP-9 in the nuclear compartment 
also co-expressed activated-caspase 3, linking MMP-9 expression to neuronal and glial death 
(Del Zoppo GJ 2012). The research has shown for the first time the localization of MMP-9 to 
the nucleus of human neurons. Altogether this gives more relevance to MMPs secretion in 
the CNS as it correlates not only with facilitation of the cellular infiltration. 
Moreover, the mechanisms through which astrogliosis is orchestrated is still considered to 
be unknown. However, it has been recently demonstrated that CD36 plays a pivotal role in 
astrocytic survival, and proliferation In fact, CD36 deficient and CD36 -siRNA treated 
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disease, and the cognate epitopes recognized by T and B cells after ischemia are still matter 
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lesions, mostly on a later period after ischemia. In fact, IFN- deficient mice develop much 
smaller lesions than control animals. Although this IFN- may derive from different sources, 
it is accepted that Th1 cells play a relevant role in this phenomenon. Moreover, T CD4 
deficient animals are much more resistant to ischemic injury and this may corroborate the 
role for these lymphocytes, as recently reviewed (Brait VH 2012). This only contributes to 
the hypothesis that T cells may have an important role in the ischemic brain lesions.  
IL-17 is the hallmark of the T CD4 lymphocytes with Th17 phenotype (Ivanov I 2006; 
Iwakura Y 2006). It is now accepted that many other cell types may also secrete this 
cytokine, as microglia and astrocytes (Kawanokuchi J 2008), alveolar macrophages (Song C 
2008), and many others. Several important roles for the biological function of IL-17 have 
been evidenced during neuroinflammation. For instance, it was demonstrated that human 
BBB endothelial cells express IL-17R constitutively. Thus, bioactive IL-17 facilitates the 
disruption of the BBB reducing the tight cellular interaction of endothelial cells through 
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GAP junctions (Kebir H 2007). Moreover, IL-17 is also considered a potent neutrophil 
recruiting factor, increasing cellular infiltrate. To further corroborate the importance of IL-17 
on the pathogenesis of stroke, it was interestingly demonstrated that IL-17 deficient animals 
have smaller brain focal lesions when compared to wild-type controls. More interesting, 
using conditional deletion approaches, it was well established that this IL-17 was secreted 
by T  lymphocytes. The abrogation of IL-17 secretion only in this population resulted in an 
increased resistance in developing lesions. It is interesting to mention that these 
observations were performed on day seven after MCAO (Shichita T 2010). Thus, these 
observations pointed not only to the importance of the IL-17 cytokine but also to the pivotal 
role played by T  lymphocytes. It is worthy to mention that myelin sheets are lipid-rich 
structures and T  cells recognize lipidic antigens. 
In summary, the importance of CNS resident cells during neuroinflammatory processess is out 
of question. The primary secretion of inflammatory factors that follows necrotic cell death is 
the first trigger for local inflammation. This greatly increases endothelial permeability 
resulting in the recruitment of inflammatory cells from the periphery. These cells will 
physically interact with CNS resident cells, and thus, perpetuating the process. It is interesting 
to mention that some anti-inflammatory factors may also be detected. However, the 
knowledge about its regulatory functions is just starting, at least after ischemic brain injury.  
1.2. Central nervous system resident cells and MS/EAE 
Most autoimmune diseases result from the peripheral activation of T CD4 cells against 
endogenous peptides, as is the case for arthritis, Systemic Lupus Erithematosus (SLE), 
myastenia gravis (MG), ankilosing spondilytis (AS), Vogt-Kainag-Harada Syndrome (VKH) 
and multiple sclerosis (MS). It is well accepted that in MS such antigens are myelin-derived 
epitopes. After activation in the periphery, these T cells migrate to the target organ where 
they need to be reactivated on a second hit phenomenon. Through this phenomenon a new 
set of genes are transcribed and translated. For instance, pro-inflammatory cytokines, 
chemokines, and T cell-activating membrane receptors are promptly up-regulated. MHC I 
and II, CD80, CD86, CD40, TLR-2, and many cytokines receptors, as IFN-R and IL-17R are 
up-regulated in microglia after CNS infiltration of encephalitogenic T CD4 cells. In this 
concern, which population of CNS resident cells is indispensable for this in situ interaction 
with infiltrating T cells is still a matter of intense debate, and microglia and resident 
dendritic cells (DCs) are the main candidates. 
Multiple sclerosis (MS) and its murine model, EAE, are characterized by an autoimmune 
response against myelin-derived epitopes, which culminates in inflammatory infiltrate, 
gliosis, damage of the myelin sheath and also neuronal death (Neumann 2003; Rebenko-
Moll NM 2006; Rodriguez 2007). Many studies have focused on the correlation between 
different cell types infiltrating the CNS during EAE and the clinical features of the disease. 
For instance, it has been shown that T CD4+ (Kroenke MA 2007) and CD8+ (Goverman J 
2005) cells, as well as macrophages and microglial cells are involved in EAE pathogenesis  
(Weiner 2008). It is worthy to remember that, as discussed in the introduction, MS 
pathogenesis is orchestrated by both Th1 and Th17 encephalitogenic cells.  
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The discovery of DCs by Ralph Steinman was considered a huge breakthrough in the 
immunology field, rendering Steinman with a Nobel Prize in 2011. Since then, DCs are 
widely studied and used in many different fields, and it is now accepted as CNS resident 
cells, as bDCs. In the search for resident DCs in the brain, the use of CD11c –GFP animals 
was very useful. It was clearly demonstrated that GFP+ cells were find in brain parenchyma 
of naïve animals, and thus called brain dendric cells or bDCs. More interesting, it was 
shown that bDCs were found in the circunventricular organs, whose characteristics are not 
to be isolated by the BBB. Thus, it seems clear that bDCs may have an important role in 
brain surveillance. Moreover, and corroborating this idea, bDCs have migrating abilities, as 
they route to lesions of kainic acid-induced neuronal death.  Concerning bDCs, is 
established that they are important players in the second-hit of brain and spinal cord 
infiltrating T CD4 cells. Using the murine model for EAE, it was demonstrated that bDCs 
not only present CNS-derived antigens to T cells, but they also input both Th1 and Th17 
phenotype to naïve T CD4 cells (Felger JC 2010). It is interesting to remember that, as 
discussed in the introduction, both populations play a very relevant role in MS 
pathogenesis. Corroborating this idea, another research has shown that CD14 infiltrating 
monocytes acquire the CD83+CD209+ dendritic cell phenotype with a significant capacity to 
prime T cells after passing the BBB. These cells were able to secrete IL-12p70, IL-6 and TGF-β 
and thus generating Th1 and Th17 cells .  
Although questioned by some researchers, it is believed that under resting conditions 
microglial cells do not express significant levels MHC I and II molecules, impairing its 
ability to activate T cells. This, greatly differ from resident dendritic cells, what points out 
for a most likely role for bDCs in the activation of infiltrating T cells than microglial cells. 
However, further presentation of myelin-derived epitopes by microglia to T cells triggers T 
cells to release a great deal of pro-inflammatory cytokines, as IFN- and TNF- for Th1, and 
IL-17, IL-22 and GM-CSF for Th17 cells, establishing focal inflammation (Murphy AC 2010; 
Almolda B 2011). Microglia also secrete significant amounts of IL-23, as observed from 
human samples. Moreover, besides Th17 cells, both microglia and astrocytes are able to 
secrete IL-17 (Kawanokuchi J 2008). It has also been established that these populations also 
constitutively express IL-17R. It is interesting to mention that in vitro activation of astrocytes 
and microglial with rIL-17 resulted in interesting outcomes, such as the up-regulation of 
MCP-1, MCP-5, MIP-2 and KC. Thus, it is unquestionable that IL-17 greatly contributes fort 
the amplification of the inflammatory infiltrate, and its source may be resident cells as well 
as Th17 infiltrating lymphocytes. 
Interestingly, using a microglial paralysis approach, it was clearly shown that functional 
microglia are fully needed for the establishment of the CNS inflammation. CD11b-HSVTK 
transgenic mice, which express herpes simplex thymidine kinase in macrophages and 
microglia after ganciclovir treatment impairs microglial activation, as observed by the 
interruption on the release of nitrite, proinflammatory cytokines and chemokines. As a 
consequence, mice are more resistant to EAE induction, with reduced CNS lesions, myelin 
degradation, cellular infiltration and cytokine release (Heppner HL 2005). 
Due to its resemblance with macrophages, it is conceivable that microglia expression all 
inflammasome associated molecules, which in fact happens to be true. Microglia secrete not 
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only IL-1β, but also IL-18 and IL-33, all of them caspase-1 derived cytokines. As discussed in 
the stroke session, IL-1 β has a very important role in the initiation of the inflammatory 
infiltrate. NOD (Nucleotide-binding domain, Leucine-rich Repeat containing family) like 
receptors (NLRs) have also been reported as important DAMP receptors in the CNS, being 
easily found in microglia (Chakraborty S 2010). Altogether, inflammasome-derived 
cytokines as well as NLRs and TLRs activation greatly contributes for local inflammation 
and thus influencing overall outcome. 
Although it was known that IL-17 had a very important role in the pathogenesis of MS and 
EAE, either from resident cells or from Th17 cells, it was not well established the target of 
IL-17. Thus, it was elegantly demonstrated that IL-17-derived action is mostly played by 
astrocytes. Using conditional deletion of the Act-1 gene, that encodes an adaptor molecule of 
the IL-17R, it was clearly demonstrated that astrocytes change into a much activated state 
after engagement with IL-17. It is interesting to mention that IL-17 induced the expression of 
CXCL1, CXCL2, CXCL9, CXCL-12, IL-6, MMP-3 and MMP-9 in vitro and in vivo. Thus, 
NesCre / Act-1flox/flox mice are very resistant to EAE induction, with reduced CD4, CD19 
and monocytes infiltration of the CNS. More interesting, Act-1 abrogation from 
microglia/macrophage or endothelial cells did not show any difference (Kang Z 2010) .This 
points out not only the main target of IL-17 activity, but also the importance of the CNS 
resident cells as astrocytes in the pathogenesis of EAE. Moreover, using astrocytes cultures, 
researchers demonstrated that these cells are able to induce Th1 and Th17 cells (Li Y 2007). 
In fact, neuroglia cells, as astrocytes, microglia constitutively express many cytokines and 
chemokines  receptors, such as IL-1R, IL-4R, IL-10R, IL-12R, TNFR1, TNFR2, GM-CSFR, 
IFN-R, IL-17RA, CCR2, CCR5, TLR-2, TLR-4 among many others (Sedjwick 1991; Lin HW 
2009). The engagement of these cytokines with its receptors triggers a cascade of events 
resulting in the expression of molecules such as, MHC I and II, iNOS, CD45, CD80, CD86, 
IL-1, IL-6, MMP-2, MMP-9, CCL2, among many others. Thus, the direct interaction of 
infiltrating encephalitogenic Th1 and Th17 cells with CNS resident cells, as microglia and 
astrocytes, is of great importance for the understanding of the pathogenesis of MS and also 
other neuroinflammatory diseases.  
At last but not least, it is interesting to mention the role of oligodendrocytes during MS. In 
fact, oligodendrocytes are the main targets of peripherally activated T CD8 cells, whose 
antigen recognition induces oligodendendrocyte death by apoptosis, and thus 
demyelination, the hallmark of MS and EAE (Neumann 2003). Oligodendrocytes may be 
killed by several distinct mechanisms, such as FasL – Fas interaction, granzymes from 
cytotoxic T CD8 cells and also high amounts of TNF- (Neumann 2003). More recently it has 
also been demonstrated that during EAE, the neuroinflammatory process significantly 
reduces the amount of Connexins (Cx), such as Cx32, Cx43 and Cx47. This reduction is 
associated with a disturbance in the gap junctions of oligodendrocytes and altered ionic 
balance, inducing cell death (Markoullis K 2012). In this context, besides the aforementioned 
ways to induce demyelination, intercellular interaction among glial cells also seem to have a 
pivotal relevance. The integrity of the myelin sheet is mandatory for a well functioning CNS. 
However, this integrity is breached during MS, damaging and destroying neuronal ability to 
transmit information, leading to a severe overall impairment.  
 
Central Nervous System Resident Cells in Neuroinflammation: A Brave New World 187 
2. Conclusions 
The term glia, stands for glue, referring to the architectural role of these populations, such as 
astrocytes and microglial cells. Nowadays however, much new information was obtained 
concerning their biology, not only at resting state but also during neuroinflammatory 
processes. In this concern, microglia and astrocytes had gained more and more attention in 
the neuroimmunology field, specially due to its great capacity to generate important 
inflammatory factors, and also to directly interact with infiltrating T cells or monocytes. This 
results in the amplification of neuroinflammatory process and establishing the lesions 
themselves. In fact, it has been recently proposed a shift from T cell to innate immune 
dependence during the chronic phase of multiple sclerosis. Overall, data pointed out to 
microglial cells and astrocytes as master players during neuroinflammation, and therapeutic 
approaches focusing on reducing it activation status may greatly contribute to the treatment 
of neurological diseases, such as MS and stroke. 
 
 Relevance in Stroke Relevance in EAE / MS 
Microglia 
Express several receptors as IL-1R, IL-
4R, IL-10R, IL-12R, TNFR1, TNFR2, 
GM-CSFR, IFN-R, IL-17RA, CCR2 and 
CCR5. 
Express several receptors as IL-1R, IL-
4R, IL-10R, IL-12R, TNFR1, TNFR2, 
GM-CSFR, IFN-R, IL-17RA, CCR2 
and CCR5.  
 Migrate to the penumbra caping dying 
neurons to reduce inflammation. 
After activation up-regulates MHC I 
and II, CD40, CD45, CD80 and CD86 
to activate infiltrating T cells. 
 Hv1 expression correlates with NADPH 
oxidase activity and neuronal injury. 
Secrete MCP-1, MCP-5, MIP-2 and KC 
after IL-17 activation. 
 Secrete IL-1, IL-6, IL-12, IL-17, IL-23, 
TNF-. 




regulates cell death. 
Undergo intense proliferation 
orchestrated by CD36 
 Secrete IL-6, IL-12, TNF-, MMP-3 and 
MMP-9. 
After activation by IL-17 secrete high 
amounts of CXCL1, CXCL2, CXCL9, 
CXCL-12, IL-6, MMP-3, MMP-9, 
MCP-1, MCP-5, MIP-2  
bDCs 
bDCs migrate to the penumbra whereas 
peripherally recruited DCs migrate to 
the core. 
Activate infiltrating T cells. 
 May be involved in the activation of T
lymphocytes. 
Induce both Th1 and Th17 cells. 
Table 2. Features highlights the importance of separate features in stroke and EAE/MS. 
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1. Introduction 
Encephalitis may be defined as “An acute inflammatory global neurologic dysfunction”, 
characterized by altered mental status with protracted clinical course and high risk of 
significant morbidity. Timely therapeutic intervention is paramount to insure a good 
outcome”. The most common endemic infectious encephalitis in immune-competent hosts 
involves several types of herpes virus infections, frequently herpes simplex virus (HSV). We 
may add to this group the less common epidemic-regional, arbovirus encephalitis. In recent 
years however, identification of novel auto-antibodies lead to the classification of 
autoimmune encephalitis in two clinical settings: 1.A paraneoplastic disorder (PNS) with 
either an overt or an occult neoplasm driving the dysimmune response 2. Antibodies 
directed against specific neuronal receptor channels in patients without underlying 
malignancy. In both groups, the initial management involves search for a possible occult 
neoplasm as a trigger of the autoimmune response and the expeditious initiation of 
immunosuppressive therapy. Autoimmune non-paraneoplastic encephalitis is the focus in 
this chapter. We will discuss four cases with autoimmune encephalitis diagnosed on our 
service in recent years. The clinical phenotype, work up results and treatment will be 
reported. A management algorithm will also be proposed (Figure 1). All four patients were 
residents of either rural or small urban Illinois communities. These cases illustrate how 
familiarity with these disorders and increasing comfort with immune-suppression represent 
a needed skill in the practice of General Neurology. 
2. Case reports 
Case 1  
A 19 year old previously healthy right-handed Caucasian male presented with recent onset 
generalized tonic-clonic seizure on September, 2011. A few days later, he developed 
confusion, automatism, blepharospasm, orofacial dyskinesia and dysautonomia. His pulse 
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either an overt or an occult neoplasm driving the dysimmune response 2. Antibodies 
directed against specific neuronal receptor channels in patients without underlying 
malignancy. In both groups, the initial management involves search for a possible occult 
neoplasm as a trigger of the autoimmune response and the expeditious initiation of 
immunosuppressive therapy. Autoimmune non-paraneoplastic encephalitis is the focus in 
this chapter. We will discuss four cases with autoimmune encephalitis diagnosed on our 
service in recent years. The clinical phenotype, work up results and treatment will be 
reported. A management algorithm will also be proposed (Figure 1). All four patients were 
residents of either rural or small urban Illinois communities. These cases illustrate how 
familiarity with these disorders and increasing comfort with immune-suppression represent 
a needed skill in the practice of General Neurology. 
2. Case reports 
Case 1  
A 19 year old previously healthy right-handed Caucasian male presented with recent onset 
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rate would vary from 30 to 120 per minute throughout the day. He did not have fever, chills, 
neck stiffness, headache or viral-like prodrome. Neurological examination on admission was 
non-focal. Signs of meningeal irritation or increased intracranial pressure were not present. 
Other than sustained ankle clonus, we did not find additional abnormalities. Initial and 
serial follow-up brain computed tomography (CT) and magnetic resonance imaging (MRI) 
were unremarkable. Cerebrospinal fluid (CSF) findings were non-specific, with a 
lymphocytic pleocytosis (WBC 25, >90% lymphocytes) and negative bacterial, viral, fungal 
and protozoal cultures. Herpes simplex virus polymerase chain reaction (HSV-PCR) was 
negative. An electroencephalogram (EEG) showed slowing of background activity in the 
delta range, without epileptiform discharges. Work up for an occult malignancy 
was unrevealing. Computed tomography of the chest, abdomen and pelvis as well as a 
testicular ultrasound were all normal. Tumor markers including alpha 
fetoprotein (AFP) and beta human chorionic gonadotropin (B-hCG) were all negative. An 
autoimmune study performed by the Mayo Clinic laboratory was positive for anti-N-
methyl D-aspartate (NMDA) antibody and negative for other relevant auto-antibodies, in 
particular the anti-Ma antibody. Treatment with intravenous methylprednisolone (MP), 1 
gram (gm) daily for 5 days and a 5-day course of human immunoglobulin (Ig) at 0.4 gm/kg 
daily for 5 days was initiated. This was repeated once weekly for two months, along with 
tapering oral prednisone and a single dose of Rituximab. The patient also began 500 mg 
of mycofenolate twice daily with gradual and eventually complete neurological 
improvement. The patient returned to the spring semester in College and doing well.  
Case 2  
A 61 year old previously healthy right-handed Caucasian female presented with sudden 
episodic involuntary rapid irregular movements and posturing of the right upper extremity, 
facial grimacing and declining short term memory. Physical examination revealed 
intermittent involuntary facial grimacing and right hemiballismus but otherwise 
unremarkable neurologic examination. Her initial basic metabolic panel (BMP) 
demonstrated sodium (Na) of 127 (normal range 137-145 mmol/l) and Chloride (Cl) of 87 
(normal range 98-107 mmol/l) but was otherwise unrevealing. Thyroid stimulating hormone 
(TSH), Vitamin B12 (B12), antinuclear antibody (ANA) and Copper levels were all within 
normal limits. A CT of the head revealed a 3.5 mm right frontal gray and white 
matter hypodensity. Pre and post-contrast brain MRI showed abnormal signal and edema 
involving the right anterior caudate and lentiform nuclei (Figure 1), and the genu and 
anterior limb of the right internal capsule (Figure 1). Electroencephalogram showed diffuse 
background slowing in the theta and delta range without epileptiform discharges. Several 
involuntary hemibalismus events were video-captured and deemed non-epileptic in nature. 
Magnetic resonance angiography (MRA) of the head and neck and trans-thoracic 
echocardiography (TTE) were normal. Hyponatremia normalized with fluid restriction. 
Clinically, symptoms other than short term memory deficits appeared to spontaneously 
resolve. The initial presumed diagnosis was an atypical vascular event. Repeat brain 
imaging as her clinical course seemed to briefly stabilize, demonstrated no change in 
previously noted abnormality. Subsequently, she developed increased agitation, 
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disorientation, confusion, impulsivity, upper extremity chorea along with fecal and urinary 
incontinence. Her serum sodium dropped to 112 meq/ml, hence a 3 % NaCl therapy was 
initiated. Patient continued to decline clinically and required endotracheal intubation. 
Electroencephalogram showed asymmetric diffuse background slowing at the theta and 
delta frequency range, right hemisphere worse than left. A spinal tap showed normal 
opening pressure with normal glucose, protein, cell count, culture, venereal disease research 
laboratory (VDRL), Cryptococcus, IgG/Albumin ratio, myelin basic protein and oligoclonal 
bands. Patient appeared to improve clinically in relation to correction of her serum sodium 
status. She was extubated within a few days of her initial decline. In her case, hyponatremia 
was thought to be secondary to syndrome of inappropriate anti-diuretic hormone secretion 
(SIADH) and responded well to demeclocycline. Neuropsychiatric evaluation 
revealed deficits in concentration and constructional apraxia with delayed memory speed 
and processing. Patient’s behavioral presentation and scores on cognitive testing suggested 
primarily a subcortical dysfunction with relatively intact performance on tests related to 
cortical functioning. Frequent episodes of facial grimacing and automatisms were noted 
during clinical recovery. A repeat EEG captured multiple complex partial seizures 
emanating from the right temporal lobe, therefore anticonvulsant therapy was started. Two 
follow-up brain MRI studies showed resolution of previous lesions, consistent with a 
transient inflammatory process. 
 
Figure 1. Brain MRI in Autoimmune Encephalitis  
Axial T2 and FLAIR MRI of the brain in case 2. High signal intensity is present in the right caudate 
nucleus and adjacent anterior limb of the internal capsule. 
Autoimmune encephalitis was suspected and patient was started on a 7-day course of 
human Ig at 0.4g/kg/24hours and leviteracetam therapy. In the ensuing week, despite 
normal neuroimaging, she suffered from frequent falls, orthostasis, hypothermia and 
bradycardia. Clinical suspicion of autoimmune encephalitis was confirmed by the presence 
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normal neuroimaging, she suffered from frequent falls, orthostasis, hypothermia and 
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of anti-voltage gated potassium channel antibodies. Computed tomography of the chest, 
abdomen and pelvis were unremarkable for malignancy making the diagnosis autoimmune 
limbic encephalitis most likely etiology. A 5-day course of human Ig at 0.4g/kg/24 hours was 
administered along with 1 gram IV MP. This was later followed by a slow taper of 
prednisone at 60 mg daily. Neurological exam remained non-focal, except for abnormal 
upper extremity movements which were persistent throughout hospitalization. Her 
dysautonomia, cognition and memory improved significantly. She begun tapering oral 
prednisone upon discharge for eight months and is presently back to normal. 
Case 3 
A 65 year old right-handed Caucasian male was admitted for evaluation of brief intermittent 
episodes of dysarthria, emotional lability and bizarre behavior. According to his wife, 
“crying spells” in recent months were not his usual nature. He had been a very healthy 
individual up until a very recent diagnosis of prostate cancer. Neurological examination 
was remarkable for astereognosia without other focal deficits. Mental status examination 
was normal without evidence of previously reported emotional lability. Initial brain MRI 
without contrast was normal. A comprehensive metabolic panel (CMP) requested on 
admission was remarkable for hyponatremia at 130 mmol/l. An EEG demonstrated 
independent epileptiform discharges from bilateral temporal lobes consistent with 
electrographic partial seizures. Oxcarbamazepine therapy was initiated at an oral dose of 
300 mg twice daily with a recommendation to increase oral salt intake. Outpatient 
neuropsychological testing demonstrated prominent memory dysfunction characterized by 
global amnesia and semantic fluency deficiency consistent with left temporal lobe 
dysfunction. Generalized grand mal seizures and post-ictal confusion prompted 
readmission. Hyponatremia worsened at 126mmol/l, thus oxcarbamazepine was switched to 
leviteracetam. Despite the lack of clinical or electrographic seizure recurrence, the patient 
remained confused and disoriented. A repeat pre and post-contrast brain MRI demonstrated 
symmetric high T2 signal intensity involving bilateral mesial temporal lobes consistent with 
limbic encephalitis (Figure 2). Lumbar puncture (LP) revealed normal pressure, along with 
normal glucose and protein. Cells were not present and cytology was negative for malignant 
cells. Cerebrospinal fluid gram stain and cultures were negative. VDRL, HSV- PCR, 
cryptococcal antigen and lyme titers in the CSF were negative. Cerebrospinal fluid 
paraneoplastic panel was positive for neuronal voltage-gated potassium channel antibodies 
(0.60 nmol/l). Full body positron emission tomography (PET) scan was unremarkable for 
malignancy. Five days of MP at 1 gm/day and human Ig therapy at 0.4mg/kg/day were 
administered. Following these interventions, he demonstrated clinical improvement and 
was able to independently perform all activities of daily living. However, he continued to 
demonstrate severe long term memory impairment for nearly two months. He gradually 
improved on monthly human Ig and MP infusion therapy. In addition, he had episodic 
confusion and aphasia which required Video-EEG monitoring. No electrographic 
epileptiform activity was observed but lamotrigine therapy was initiated and maintained 
with successful outcome. Nearly 8 months from initial presentation, patient was noted to 
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have complete resolution of symptoms. EEG and brain MRI returned to normal. 
Simultaneously, prostate cancer was characterized as adenocarcinoma, with a Gleason score 
of 5. He was treated successfully with external beam irradiation with subsequent decrease in 
his prostate specific antigen (PSA) levels. Human Ig and MP therapy was completed within 
a year and later discontinued. Thereafter, neurological and psychiatric examination 
remained normal. 
 
Figure 2. Brain MRI in Limbic Encephalitis  
Axial FLAIR MRI of the brain in case 3.  Areas of increased signal intensity are noted in the hippocampi. 
The right side is slightly thickened.  CSF examination in this patient was normal and the Voltage-gated 
Potassium antibodies were present 
Case 4 
A 37 year old right-handed Caucasian female presented with an acute delirium associated 
with significant psychomotor agitation. Her past medical history was significant for acute 
polyendocrine autoimmune endocrine syndrome type 2 (APS 2) as well as Hashimoto’s 
thyroiditis diagnosed in her early 20’. A few years later, she developed an acute 
autoimmune adrenal failure secondary to anti-21 hydroxylase antibodies (Titer: 27.3 U/ml; 
Normal :< 1 U/ml). Ovarian failure later ensued in her 30’s. Her clinical and HLA picture 
(DR3 and DR4) were all diagnostic of an APS 2. Her neurologic examination was non-focal. 
A brain MRI and CSF were normal except for the presence of 6 white blood cells in the CSF. 
Herpes simplex virus-PCR was negative as well. An EEG demonstrated diffuse, generalized 
delta rhythm. Three years into her illness, a syndrome of recent memory loss occurred and a 
repeat MRI showed bilateral increased signal intensity involving the hippocampi. Anti-
voltage-gated potassium channel (VGPC) antibody titers and a paraneoplastic panel were 
both unremarkable, and thus a diagnosis of recurrent autoimmune limbic encephalitis was 
made. She improved on high-dose MP followed by tapering oral steroids. Patient has done 
well for the last decade on 20 mg of methotrexate weekly. To our knowledge, this is the first 
description of autoimmune encephalitis associated with APS 2. 
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have complete resolution of symptoms. EEG and brain MRI returned to normal. 
Simultaneously, prostate cancer was characterized as adenocarcinoma, with a Gleason score 
of 5. He was treated successfully with external beam irradiation with subsequent decrease in 
his prostate specific antigen (PSA) levels. Human Ig and MP therapy was completed within 
a year and later discontinued. Thereafter, neurological and psychiatric examination 
remained normal. 
 
Figure 2. Brain MRI in Limbic Encephalitis  
Axial FLAIR MRI of the brain in case 3.  Areas of increased signal intensity are noted in the hippocampi. 
The right side is slightly thickened.  CSF examination in this patient was normal and the Voltage-gated 
Potassium antibodies were present 
Case 4 
A 37 year old right-handed Caucasian female presented with an acute delirium associated 
with significant psychomotor agitation. Her past medical history was significant for acute 
polyendocrine autoimmune endocrine syndrome type 2 (APS 2) as well as Hashimoto’s 
thyroiditis diagnosed in her early 20’. A few years later, she developed an acute 
autoimmune adrenal failure secondary to anti-21 hydroxylase antibodies (Titer: 27.3 U/ml; 
Normal :< 1 U/ml). Ovarian failure later ensued in her 30’s. Her clinical and HLA picture 
(DR3 and DR4) were all diagnostic of an APS 2. Her neurologic examination was non-focal. 
A brain MRI and CSF were normal except for the presence of 6 white blood cells in the CSF. 
Herpes simplex virus-PCR was negative as well. An EEG demonstrated diffuse, generalized 
delta rhythm. Three years into her illness, a syndrome of recent memory loss occurred and a 
repeat MRI showed bilateral increased signal intensity involving the hippocampi. Anti-
voltage-gated potassium channel (VGPC) antibody titers and a paraneoplastic panel were 
both unremarkable, and thus a diagnosis of recurrent autoimmune limbic encephalitis was 
made. She improved on high-dose MP followed by tapering oral steroids. Patient has done 
well for the last decade on 20 mg of methotrexate weekly. To our knowledge, this is the first 
description of autoimmune encephalitis associated with APS 2. 
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3. Discussion 
The initial presentation of these patients consisted of an acute deterioration of mental status, 
agitation and sensorial changes with either a complex partial and or focal motor 
seizures. While initial dysfunction of the limbic system was seen in only one case, 
subsequent symptoms related to unilateral or bilateral medial temporal lobe dysfunction, 
complex partial seizures and memory loss developed in two additional patients, shortly 
after onset of symptoms. The term limbic was coined by Paul Broca from the Latin word 
meaning ”ring” [26] . He used the word limbic to define structures located within the medial 
temporal lobes and diencephalon, which are involved in the formation and consolidation of 
short term memory. In addition, neurologic findings localized to this area frequently 
involve movement disorders and automatisms. We will review key pathogenic causes of 
autoimmune encephalitis, describe common clinical characteristics and propose a 
management algorithm. 
4. Pathogenesis 
A practical classification of autoimmune encephalitis can be based on pathogenic 
mechanism. In some instances, autoimmunity is triggered by a known or occult neoplasm, 
however in the absence of malignancy, auto-antibodies are directed against intracellular or 
neural membrane receptors. The cause of autoimmunity in non-PNS cases is unclear. 
Antibodies may be directed against intracellular antigens: (anti-Hu and anti-Ma), or 
antibodies against neuronal antigens (VGKC, NMDA receptor and Gamma-amino butyric 
acid (GABA) type b receptors) (1-25). Identification of these antibodies may provide a clue as 
to the possible associated neoplasm. For instance, anti-NMDA encephalitis is frequently 
associated with germ-cell tumors of the ovary and may rarely be seen in men, as was the 
case we reported. Anti-Ma antibodies are often present among patients with germ cell 
tumors of the testis. The anti-Hu is frequently present in small cell lung carcinoma (SCLC). 
Recent autoimmune encephalitis with antibodies against the alpha-amino-3 hydroxi-
isoxazole propionic acid (AMPA) receptor have been reported reported [24]. Practically, the 
entire gamut of known auto-antibodies should be ordered in this group of patients as there 
is significant clinical overlap despite diverse neuronal antigenic targets. Once herpes virus 
encephalitis is ruled out, an investigation with auto-antibodies evaluation and 
immunosuppressive therapy can be initiated (Table 1). Given that reports from the 
immunologic testing usually take anywhere from two to three weeks, treatment should be 
initiated even before a diagnosis is confirmed. The initial therapy consists of high-dose 
intravenous Methyl-prednisolone, 1 gm daily for five days, followed by intravenous human 
Ig, usually at a dose of 0.4 gm/ kg per day for five additional days. Following a definitive 
diagnosis of autoimmune encephalitis, a plan of prolonged immunosuppressive treatment 
may be designed. 
Importantly, Dalmau, et al recently reported serum reactivity to the leucine-rich glioma 
inactivated 1 protein (LGI1) among patients with VGKC antibodies [11,12]. It is 
unclear however, if anti-VGKC antibodies can be used to screen for this syndrome in every 
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case. Hyponatremia is frequent and was found in two of our patients. We did not evaluate 
our patients for LGI1 antibodies because the above article by Dalmau et al was not in print 
when we evaluated these patients. 
The neuropathologic findings in patients with paraneoplastic (PNS) autoimmune 
encephalitis include perivascular and interstitial lymphocytic cuffing, microglial 
proliferation, gliosis and neuronal degeneration. It is likely that non-PNS autoimmune 
encephalitis is associated with similar findings. 
 
Table 1. Algorithm for autoimmune encephalitis 
Algorithm and work up
Autoimmune Encephalitis 



























Consider initiation of treatment with 
immunosuppression 
:Methlyprednisolone or iv IG until 




Search for occult 
neoplasm 




or iv IG until repeat 
of autoantibodies 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 198 
3. Discussion 
The initial presentation of these patients consisted of an acute deterioration of mental status, 
agitation and sensorial changes with either a complex partial and or focal motor 
seizures. While initial dysfunction of the limbic system was seen in only one case, 
subsequent symptoms related to unilateral or bilateral medial temporal lobe dysfunction, 
complex partial seizures and memory loss developed in two additional patients, shortly 
after onset of symptoms. The term limbic was coined by Paul Broca from the Latin word 
meaning ”ring” [26] . He used the word limbic to define structures located within the medial 
temporal lobes and diencephalon, which are involved in the formation and consolidation of 
short term memory. In addition, neurologic findings localized to this area frequently 
involve movement disorders and automatisms. We will review key pathogenic causes of 
autoimmune encephalitis, describe common clinical characteristics and propose a 
management algorithm. 
4. Pathogenesis 
A practical classification of autoimmune encephalitis can be based on pathogenic 
mechanism. In some instances, autoimmunity is triggered by a known or occult neoplasm, 
however in the absence of malignancy, auto-antibodies are directed against intracellular or 
neural membrane receptors. The cause of autoimmunity in non-PNS cases is unclear. 
Antibodies may be directed against intracellular antigens: (anti-Hu and anti-Ma), or 
antibodies against neuronal antigens (VGKC, NMDA receptor and Gamma-amino butyric 
acid (GABA) type b receptors) (1-25). Identification of these antibodies may provide a clue as 
to the possible associated neoplasm. For instance, anti-NMDA encephalitis is frequently 
associated with germ-cell tumors of the ovary and may rarely be seen in men, as was the 
case we reported. Anti-Ma antibodies are often present among patients with germ cell 
tumors of the testis. The anti-Hu is frequently present in small cell lung carcinoma (SCLC). 
Recent autoimmune encephalitis with antibodies against the alpha-amino-3 hydroxi-
isoxazole propionic acid (AMPA) receptor have been reported reported [24]. Practically, the 
entire gamut of known auto-antibodies should be ordered in this group of patients as there 
is significant clinical overlap despite diverse neuronal antigenic targets. Once herpes virus 
encephalitis is ruled out, an investigation with auto-antibodies evaluation and 
immunosuppressive therapy can be initiated (Table 1). Given that reports from the 
immunologic testing usually take anywhere from two to three weeks, treatment should be 
initiated even before a diagnosis is confirmed. The initial therapy consists of high-dose 
intravenous Methyl-prednisolone, 1 gm daily for five days, followed by intravenous human 
Ig, usually at a dose of 0.4 gm/ kg per day for five additional days. Following a definitive 
diagnosis of autoimmune encephalitis, a plan of prolonged immunosuppressive treatment 
may be designed. 
Importantly, Dalmau, et al recently reported serum reactivity to the leucine-rich glioma 
inactivated 1 protein (LGI1) among patients with VGKC antibodies [11,12]. It is 
unclear however, if anti-VGKC antibodies can be used to screen for this syndrome in every 
 
Autoimmune Encephalitis in Rural Central Illinois 199 
case. Hyponatremia is frequent and was found in two of our patients. We did not evaluate 
our patients for LGI1 antibodies because the above article by Dalmau et al was not in print 
when we evaluated these patients. 
The neuropathologic findings in patients with paraneoplastic (PNS) autoimmune 
encephalitis include perivascular and interstitial lymphocytic cuffing, microglial 
proliferation, gliosis and neuronal degeneration. It is likely that non-PNS autoimmune 
encephalitis is associated with similar findings. 
 
Table 1. Algorithm for autoimmune encephalitis 
Algorithm and work up
Autoimmune Encephalitis 



























Consider initiation of treatment with 
immunosuppression 
:Methlyprednisolone or iv IG until 




Search for occult 
neoplasm 




or iv IG until repeat 
of autoantibodies 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 200 
5. Clinical findings 
The initial clinical manifestations of these disorders may suggest compromise of limbic 
structures and often precede global cerebral dysfunction. This sequence was observed in 
three of our patients (Table 2, cases 2, 3, 4). At times, a more rapid onset of symptoms may 
be observed. (Table2, case 1). Complex partial and Grand mal seizures are both common. 
Focal signs are otherwise infrequent, however confusion, agitation and delirium are present 
and maybe the initial presentation, particularly in anti-NMDA antibody mediated 
encephalitis. HSV encephalitis should be excluded and initiation of acyclovir therapy should 
not be delayed until CSF HSV-PCR result is available. Lack of improvement or worsening 
clinical picture despite treatment with acyclovir may suggest autoimmune encephalitis. 
Nutritional deficiency with Korsakoff’s psychosis is usually evident from additional history 
and clinical findings. It is not possible from the clinical findings alone to determine if 
encephalitis represents a PNS. In fact, in greater than 65% of cases, PNS-related encephalitis 
is the first symptom of cancer. Occasionally, autoimmune encephalitis may mimic 
Creutzfeldt- Jacob disease (CJD) and both serum and CSF neuronal specific enolase, 14:3:3 
protein and tau levels can be elevated. Consequently, a diagnosis of autoimmune 
encephalitis should be considered among possible CJD patients. Brain MRI is often 
abnormal in autoimmune limbic encephalitis; however a normal brain MRI in NMDA-
associated encephalitis is not infrequent. 
6. Neuroimaging 
Brain MRI is generally abnormal. Unilateral or bilateral increased signal abnormalities 
involving mesial temporal lobes may be observed (Figure 2). Thickening of the hippocampi 
may be present without significant mass effect. Contrast enhancement is not frequent. Non-
limbic MRI lesions may be found as well. The presence of susceptibility artifact if found 
would be suggestive of HSV encephalitis. In cases of anti-NMDA receptor encephalitis, 
imaging may be normal, thus making the diagnostic process even a greater challenge. The 
imaging abnormalities described may improve after initiation of treatment. 
7. Additional testing 
A work-up summary for patients with presumed autoimmune encephalitis is suggested in 
table 1. Electroencephalography would be abnormal in most cases. Generalized or focal 
slowing, epileptiform discharges emanating from temporal or frontal lobes are both 
frequent. Status epilepticus would be an unusual finding. Lumbar puncture frequently 
reveals a normal pressure and may show moderate lymphocytosis, increased protein and 
possibly oligoclonal bands, increased IgG and increased CNS IgG synthesis rate. HSV titers 
and PCR should be negative and neuronal specific enolase levels may be increased. Auto-
antibodies may also be detected in CNS and titers can be monitored as a measure of 
treatment response. Comprehensive metabolic panels are generally normal with the 
exception perhaps of hyponatremia due to SIADH. Tumor markers may be present, 
suggesting PNS. We propose a work up algorithm that has been helpful in our experience. 
(table 1) A list of auto-antibodies, including PNS is listed in table 3 
 















































































































Table 2. Clinical presentation, pertinent work-up and management of four cases 
Neuronal Nuclear Antibodies 
Antineuronal Nuclear Antibody- Type 1 (ANNA-1) 
Antineuronal Nuclear Antibody- Type 2 (ANNA-2) 
Antineuronal Nuclear Antibody- Type 3 (ANNA-3) 
Neuronal and Muscle Cytoplasmic Antibodies 
Purkinke Cell Cytoplasmic Antibody- Type 1 (PCA-1) 
Purkinke Cell Cytoplasmic Antibody- Type 2 (PCA-2) 
Purkinke Cell Cytoplasmic Antibody- Type Tr (PCA-Tr) 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 200 
5. Clinical findings 
The initial clinical manifestations of these disorders may suggest compromise of limbic 
structures and often precede global cerebral dysfunction. This sequence was observed in 
three of our patients (Table 2, cases 2, 3, 4). At times, a more rapid onset of symptoms may 
be observed. (Table2, case 1). Complex partial and Grand mal seizures are both common. 
Focal signs are otherwise infrequent, however confusion, agitation and delirium are present 
and maybe the initial presentation, particularly in anti-NMDA antibody mediated 
encephalitis. HSV encephalitis should be excluded and initiation of acyclovir therapy should 
not be delayed until CSF HSV-PCR result is available. Lack of improvement or worsening 
clinical picture despite treatment with acyclovir may suggest autoimmune encephalitis. 
Nutritional deficiency with Korsakoff’s psychosis is usually evident from additional history 
and clinical findings. It is not possible from the clinical findings alone to determine if 
encephalitis represents a PNS. In fact, in greater than 65% of cases, PNS-related encephalitis 
is the first symptom of cancer. Occasionally, autoimmune encephalitis may mimic 
Creutzfeldt- Jacob disease (CJD) and both serum and CSF neuronal specific enolase, 14:3:3 
protein and tau levels can be elevated. Consequently, a diagnosis of autoimmune 
encephalitis should be considered among possible CJD patients. Brain MRI is often 
abnormal in autoimmune limbic encephalitis; however a normal brain MRI in NMDA-
associated encephalitis is not infrequent. 
6. Neuroimaging 
Brain MRI is generally abnormal. Unilateral or bilateral increased signal abnormalities 
involving mesial temporal lobes may be observed (Figure 2). Thickening of the hippocampi 
may be present without significant mass effect. Contrast enhancement is not frequent. Non-
limbic MRI lesions may be found as well. The presence of susceptibility artifact if found 
would be suggestive of HSV encephalitis. In cases of anti-NMDA receptor encephalitis, 
imaging may be normal, thus making the diagnostic process even a greater challenge. The 
imaging abnormalities described may improve after initiation of treatment. 
7. Additional testing 
A work-up summary for patients with presumed autoimmune encephalitis is suggested in 
table 1. Electroencephalography would be abnormal in most cases. Generalized or focal 
slowing, epileptiform discharges emanating from temporal or frontal lobes are both 
frequent. Status epilepticus would be an unusual finding. Lumbar puncture frequently 
reveals a normal pressure and may show moderate lymphocytosis, increased protein and 
possibly oligoclonal bands, increased IgG and increased CNS IgG synthesis rate. HSV titers 
and PCR should be negative and neuronal specific enolase levels may be increased. Auto-
antibodies may also be detected in CNS and titers can be monitored as a measure of 
treatment response. Comprehensive metabolic panels are generally normal with the 
exception perhaps of hyponatremia due to SIADH. Tumor markers may be present, 
suggesting PNS. We propose a work up algorithm that has been helpful in our experience. 
(table 1) A list of auto-antibodies, including PNS is listed in table 3 
 















































































































Table 2. Clinical presentation, pertinent work-up and management of four cases 
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Amphiphysin Antibody 
CRMP-5-IgG 
Cation Channel Antibodies 
N-Type Calcium Channel Antibody 
P/Q Type Calcium Channel Antibody 
Acetylcholine Receptor (Muscle) Binding Antibody 
Acetylcholine Receptor Ganglionic Neuronal Antibody 
Paraneoplastic Evaluation Algorithm 
Aliases: 
Acetylcholine Receptor (Muscle AChR) Binding Antibody 
AChR (Acetylcholine Receptor) 
AGNA 
Amphiphysin Antibody, serum 
ANNA (Antineuronal Nuclear Antibody) 
AntiCV2 
Anti-Enteric Neuronal Antibody 
Anti-GAD65 (Anti-Glutamic Acid decarboxylase) 
Anti-Glial Nuclear Antibody 
Anti-Purkinke Cell Cytoplasmic Antibody 
Anti-Ri 
Anti-Skeletal Muscle Antibody 
Anti-Yo 
Antineuronal 
APCA (Anti-Purkinke Cell Antibody 
Calcium Channel Blockers 
Cantoxin (Receptor Antibodies) 
Cerebellar Antibodies 
Syndrome and Antibody 
Chorea 
Collapsin Response-Mediator Protein 5 Antibody (CRMP-5), serum 
Cramp-Fasciculation 
CRMP-5-IgG 
Dorsal Root Ganglion Antibody 
Hu Antibody 
ICab (Islet Cell Cytoplasmic Antibody) 
 
Isaac’s disease 
Motor End-Plate Antibody 
Motor Nerve Terminal Antibodies 
Muscle Skeletal Antibodies 
Muscle Culture Antibodies 
Myoid Antibody 
N-Type Calcium Channel Antibody 
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Neuromuscular hyperexcitability 
Neuromyotonia 
Neuronal Ganglionic Acetylcholine Receptor Antibody 
Neuronal Nuclear Antibody 
Neuronal Nuclear Antibody Panel 
NMDA-Receptor Antibody (N-Methyl-D-Aspartate Receptor Antibodies) 
Ovarian Cancer-Related Antibodies 
P/Q Type Calcium Channel Antibody 
Paraneoplastic Antibodies 
Paraneoplastic Autoantibody Evaluation 
Paraneoplastic Neurological Autoimmunity 
Purkinke Cell Cytoplasmic Antibody- Type 1 (PCA-1) 
Purkinke Cell Cytoplasmic Antibody- Type 2 (PCA-2) 
Purkinke Cell Cytoplasmic Antibody- Type Tr (PCA-Tr) 
Potassium Channel Antibodies (specify) 
Ri, Antibody 
Stiff-man Syndrome 
Glutamic Acid Decarboxylase Antibody (Gad 65) 
Striational (Striated Muscle) Antibodies 
VGCC (Volatage Gated Calcium Channel Antibody) 
Eaton Lambert Syndrome 
Yo-Antibody 
Ovarian Cancer 
Table 3. Antibody testing among patients with autoimmune neurologic syndromes 
8. Treatment 
There is no evidence-based data to guide management of autoimmune encephalitis. Initially, a 
combination of intravenous high dose MP for 5 days and human Ig dose of 0.4 gm/kg for 5 
days can be the first line of treatment. This may be followed by monthly injection of MP and 
human Ig. Rituximab may be helpful with 4 to 6 monthly doses. In some cases, additional on-
going immunosuppression with mycofenolate or cyclophosphamide may be needed to treat 
either slow or non-improving cases. In addition, if the work up uncovers a neoplasm, surgical 
resection or chemotherapy should be initiated without delay. Considering that the initial 
identification of non-PNS autoimmune encephalitis is relatively recent, epidemiologic factors 
are now becoming apparent. Frequency and geographic distribution of these disorders will be 
available soon and this information could set the stage for future multicenter treatment trials.  
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1. Introduction 
Diabetes mellitus patients have a high blood sugar (glucose) level resulting either from the 
body’s failure to produce enough insulin (Diabetes Mellitus Type 1) or because body cells do 
not properly respond to the produced insulin (Diabetes Mellitus Type 2) [1,2]. During the 
digestion, carbohydrates, contained in food, are converted within a few hours to glucose. 
Insulin is a hormone produced in the pancreas that enables body cells (primarily muscle and fat 
cells) to absorb glucose which is in turn transformed into energy needed for daily life [3,4]. The 
insulin production is triggered by the increase of the glucose concentration in blood (Figure 1).  
 
Figure 1. By the decomposition of glucose, ATP is produced in the beta cells. The increase of the ATP 
concentration closes the K+ channel, leading to a depolarisation which in consequence opens the Ca2+ 
channel. Ca2+ activates the insulin gene expression via the Calcium Responsive Element Binding Protein 
(CREB). By exocytosis, the produced insulin is set free in the blood. 
 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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The regulatory function of insulin results in an instantly higher reception of glucose after the 
meals (Figure 2). Normally, insulin regulates the uptake of glucose from the blood during 
the course of a day (Figure 3). The inability of the body cells to absorb the glucose results in 
an accumulation (casual plasma glucose: 11.1 mmol/L) in the blood (hyperglycemia), 
leading to various potential medical complications and commonly leads to coma [5,6]. If the 
glucose concentration in the blood exceeds a certain amount it is discharged via the urine. 
Serious long-term complications of diabetes mellitus include cardiovascular disease, chronic 
renal failure and retinal damage [7-10]. Diabetes mellitus is currently a worldwide epidemic 
disease, sometimes referred as epidemic disease of the 21-th century [11,12]. Therefore an 
early diagnosis is desirable, enabling prevention at begin of this autoimmune disease. 
 
Figure 2. The hormone insulin induces the reception of glucose into the cells by a member of the 
transport protein GLUT. The binding of insulin at receptors, located at the cell surface, initiates the 
fusion of intracellular vesicles, containing GLUT, with the cell membrane. This increases instantly the 
number of the GLUT molecules at the cell surface, resulting in a higher reception of glucose. 
 
Figure 3. Qualitative view of the fluctuation of the blood sugar concentration in humans during the 
course of a day with 3 meals.  
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Diabetes mellitus type 1 result from the inability of the body to produce endogenous insulin; 
in consequence the patient must inject the required insulin, either manually or automatically 
via an insulin pump [13-14]. This is a major burden, because the insulin therapy, 
management and monitoring of diabetes is necessary for the rest of patient’s life [15]. Goal 
of the insulin therapy is not the healing of the patient, but the replacement of the lack of 
endogenous insulin. Diabetes mellitus type 1 includes childhood-onset diabetes, juvenile 
diabetes, and insulin-dependent diabetes mellitus (IDDM) [16]. The type 1 diabetes causes 
approximately 10% of diabetes mellitus cases worldwide and represents a majority of 
diabetes in children [17]. Recent publications show that a doubling of diabetes mellitus type 
1 in childhood (younger than 5 years) is expected by 2020, and in the juvenile age (younger 
than 15 years), the disease will rise by 70% [18]. Diabetes mellitus type 1 is characterized by 
a loss of the insulin-producing beta cells of the islets of Langerhans in the pancreas [19] 
(Figure 4). The majority of diabetes mellitus type 1 cases is of an immune-mediated nature, 
where the loss of beta cell results from a T-cell mediated autoimmune attack (antibodies: 
GADA, ICA, IA-2, IAA) [20]. After 80-90% of the beta cells are destroyed, the diabetes 
mellitus type 1 manifests. Therefore, at the start of the disease there is still a remaining 
insulin production. Mostly, at the onset of the disease, the affected people are otherwise 
healthy and of normal weight. In the early stages, the sensitivity and responsiveness to 
insulin are usually normal. The symptoms of diabetes mellitus are frequent urination 
(polyuria), increased thirst (polydipsia) and increased hunger (polyphagia) [21]. (Originally, 
the main symptom was excessive sweet urine, known as glycosuria). Diabetes mellitus type 
1 may also cause a rapid weight loss and irreducible mental fatigue.  
 
Figure 4. A) The cells of the islets of Langerhans (large object in the middle) in the pancrease produce 
insulin, which is secreted directly into the blood flow. Immune histochemistry with antibodies against: 
B) insulin (representation of the beta cells), C) glucagon (alpha cells), D) CD34 (capillaries). Picture 
provided by the Institute for Pathology of the Medical University of Graz (C. Lackner). 
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Whereas diabetes type 2 is mainly caused by lifestyle factors (such as smoking, elevated 
cholesterol levels, obesity, high blood pressure) and inheritance, diabetes type 1 seems to be 
only partly inherited, by mutations of the major histocompatibility complex (MHC) at 
chromosome 6, and requires an environmental trigger (possibly due to an infection). Certain 
infections, with some evidence pointing at Coxsackie B4 virus, rubella virus and others are 
considered risk factors [22-25]. Various nutritional risk factors, such as; the consumption of 
cow milk; early exposure to the protein gluten existing in some grass-related grains, notably 
wheat, rye, and barley, have been studied [26-28]. Bafilomycine, which is produced at 
decayed places in potatoes by streptomyces, leads to a glucose intolerance and damage to 
the islets of Langerhans in the pancreas. To explain the reaction of the autoimmune 
mechanism, it is assumed that certain bacteria and virus appears (from the point of view of 
the antibodies) similar to the cells of the pancreas (more precisely to a protein at the cell 
surface) and therefore the body destroys not only the infiltrated bacteria and virus but also 
attacks its own cells. Some sub structures of the antigens are similar to insulin and therefore 
trigger the autoimmune attack to the pancreas. Because insulitis, an inflammation of the 
islets of Langerhans of the pancreas, is considered to be a preliminary stage of diabetes 
mellitus type 1, an diminishing of the inflammation processes is considered to be a possible 
immune-therapeutically measure for the prevention of diabetes. The inflammation begins 
mostly in the childhood or at juvenile age.  
For diabetes mellitus type 1, islet cell auto-antibodies (ICA) could be detected in 80% of the 
cases [29]. Other auto-antibodies are insulin-antibodies (IAA) and tyrosinphosphatase-
antibodies (IA-2) [30]. The glutamic acid decarboxylase antibody (GADA) specifically 
attacks the enzyme glutamic acid decarboxylase (GAD 65) in the beta cells [31-34]. (65 refers 
to the molecular mass of 65kD). This antibody is an indication for diabetes type 1, although 
it is present in only 50-70% of the cases at the onset of the disease and at later stages 
successively more rarely. The GAD 65 gene is expressed in brain cells and in the beta cells of 
the pancreas. Inside the beta cells, the enzyme GAD 65 (EC 4.1.1.15) catalyzes the 
irreversible alpha-decarboxylation of L-glutamate into gamma-aminobutyrate (GABA) and 
carbon dioxide. (GABA is used as a neurotransmitter in the brain).  
 
GAD uses pyridoxal-phosphate (PLP) as a cofactor. GAD 65 is a homo dimer (it consists of 
two identical chains), characterized by successively 4 stranded β -sheets and 7 stranded β -
sheets (Figure 5). The enzyme that can provoke an autoimmune reaction against the beta 
cells of the pancreas progressing to type 1 diabetes mellitus [35]. The GAD 65 antigen was 
considered to be strictly located intra-cytoplasmatic in the beta cells of the pancreas. But this 
hypothesis can not explain the procedure of immunization and therefore the occurrence of 
GAD 65 antibodies in the blood.  
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Figure 5. The enzyme GAD 65 is a dimer. Each chain contains 4 stranded β -sheets (yellow) 
surrounded by three α -helices (red) and 7 stranded β -sheets surrounded by eight α -helices. Every 
chain has an own active centre. 
To understand the procedure and development of immunization, it was proposed that in an 
initial step the immune system is primed by the accessibility to GAD 65 [36,37]. The 
assumption is that the enzyme has to be in the human serum and should be found in higher 
concentrations before the onset of the disease. The proof and quantitative evaluation of 
GAD 65 in the human blood is done with the Fluorescence Correlation Spectroscopy (FCS), 
the Enzyme-Linked Immunosorbent Assay (ELISA) and the Surface enhanced laser 
desorption ionisation – time of flight (SELDI-TOF) system. 
To illustrate the mechanism of autoimmunization, the visualization of the GAD 65 tertiary 
structure, together with its antigenic determinants and the associated electrostatic field, is 
essential. The 3-D molecular surface, derived from space filling models, visualizes the fitting 
of the GAD 65 epitopes to the paratopes of the antibodies and quantitative values for the 
GAD 65 antigenic properties are obtained by dual models. The electrostatic potential and 
details of the electronic structure of the GAD 65 epitopes are calculated by quantum 
theoretical methods. Readers, not interested in theoretical and mathematical details, can 
omit the corresponding chapters as the figures enable a pictorial understanding of the 
principles.  
2. Measurement of GAD 65 in human sera 
The GAD 65 molecules are detected by the binding with their unique and specific 
antibodies, which enables it to pick out the GAD 65 molecules in a mixture of different 
molecules (Figure 6). All detection methods, used in this work, are based on this principle. 
The monoclonal antibodies Z1 and Z2, provided by Phadia, Sweden-Diagnostics, 
Freiburg/Breisgau, Germany, were used for the detection of GAD 65 in all the assays. 
Antibody Z1 and antibody Z2 are reacting with different epitopes of the GAD 65 molecule. 
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omit the corresponding chapters as the figures enable a pictorial understanding of the 
principles.  
2. Measurement of GAD 65 in human sera 
The GAD 65 molecules are detected by the binding with their unique and specific 
antibodies, which enables it to pick out the GAD 65 molecules in a mixture of different 
molecules (Figure 6). All detection methods, used in this work, are based on this principle. 
The monoclonal antibodies Z1 and Z2, provided by Phadia, Sweden-Diagnostics, 
Freiburg/Breisgau, Germany, were used for the detection of GAD 65 in all the assays. 
Antibody Z1 and antibody Z2 are reacting with different epitopes of the GAD 65 molecule. 
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Figure 6. Antigens, like GAD 65, are detected by specific capturing with their corresponding 
antibodies. This enables it to pick up the antigen GAD 65 from a mixture of molecules. 
Because very small concentrations of GAD 65 circulating in the human sera were expected, 
the ultra-sensitive fluorescence correlation spectroscopy (FCS) was used, at the beginning, 
for the search of free circulating GAD 65. 
2.1. Fluorescence Correlation Spectroscopy (FCS) 
FCS is a very sensitive analytical tool which enables the observation of a small number of 
molecules (up to picomolar concentrations) in a small volume element. By the FCS, the 
information about the molecules in the volume element is gained by evaluation of 
fluorescence fluctuations. FCS was developed by D. Magde, E. Elson, and W.W. Webb in 
1972 [38]. The development of sensitive detectors such as avalanche photodiodes makes it 
possible to detect fluorescence signals coming from individual molecules in highly diluted 
samples. Improvements in the measurement techniques, notably by the introduction of 
confocal microscopy, enable a more precise separation of the measurement volume from the 
background. This improved the signal-to-noise ratio and allowed single molecule detection. 
In the 1990’s began the practical application of FCS in molecular biology, ranging from the 
study of molecular dynamics, the determination of the size of proteins and the antigen-
antibody coupling to the study of biochemical pathways in living cells. 
2.1.1. Configuration and principle  
With the FCS method, the GAD 65 molecules and their interaction with the corresponding 
monoclonal antibodies are measured by determining their diffusion times in a tiny volume 
element [39-43]. For this purpose the antibody molecules are labelled with fluorescent 
markers and excited by laser light. Because fluorochromes come in a variety of colours and 
can be specifically bound to particular molecules it is possible to study the behavior of 
individual molecules.  
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The FCS setup consists of a laser, an inverted microscope, a beam splitter (dichroic mirror), 
several optical units, a spectrometer with photo diode and an evaluation unit (Figure 7). The 
laser beam is directed by the beam splitter through the inverted microscope and focussed 
into a small focal volume of the sample. The labelled molecules in the sample are excited 
and emit fluorescence light. The emitted fluorescence light passes through the inverted 
microscope and the beam splitter. The beam splitter separates the excitation light from the 
emitted fluorescence light by transmitting the fluorescence light to the spectrometer and 
reflecting the excitation light back to the microscope. The transmitted fluorescence light then 
passes through a pinhole which blocks scattered excitation light and fluorescence light from 
outside the focal spot. The intensity of the filtered light is measured by avalanche photo 
diodes. The evaluation of the FCS measurement results is based on auto-correlation and 
cross-correlation analysis of the fluorescence fluctuations. 
The optical unit of the FCS set up used in this study consists of a ConfoCor 2 (Zeiss) 
spectrometer and a confocal Zeiss Axiovert 100 microscope. An Argon ion-laser (458, 488, 
514 nm) and 2 Helium neon lasers (543, 633 nm) are used for the excitation of the fluorescent 
molecules. The laser-light is concentrated by a C-Apochromat objective (x 40/1.2 W corr.) on 
small spots (diameter: 0.5 μm ) in the sample solution. The GAD antibodies, were pipetted 
into a borosilicate chamber (Nalge Nunc, Lab Tek. chambered cover glass, German 
borosilicate cover glass, 8 chamber version), located on top of the inverted microscope. 
 
Figure 7. Set up and principle of the Fluorescence Correlation Spectroscopy (the radius 0r is 
approximately 0.5 μm ). 
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2.1.2. Evaluation of the fluorescence signal 
The fluorescence intensity is fluctuating due to the Brownian motion of the molecules 
through the focal volume element, defined by the optical system, whereby the concentration 
of the particles c(r,t)  is randomly fluctuating around the average concentration C :  
 δc(r ,t) c(r ,t) C   (1) 
The analysis gives the average number of fluorescent particles and average diffusion time, 
when the particle is passing through the volume. Since the relative fluctuations become 
smaller with increasing numbers of measured molecules, it is important to minimize the 
number of molecules in the focal volume. Changes in the diffusion times yield conclusions 
about the binding of GAD 65 to the corresponding antibody. The diffusion time of the 
labelled molecules depends on their size, therefore antigen-antibody compounds, which are 
bigger, show a slower diffusion time than the separated individual molecules. Modifications 
of the diffusion times give the required information on existence and concentration of GAD 
65 in the specimens.  
The fluorescence intensity fluctuations are recorded over time and quantified by temporally 
auto-correlation. From the auto-correlation and cross-correlation analysis of the fluorescence 
signal, results the characteristic diffusion times of the molecules. By the auto-correlation 
analysis, the measured fluorescence signal is compared with itself at some later time. The 
detected fluorescence signal intensity I(t) , at time step t , fluctuates around the mean 
intensity value I(t) . The fluctuations of the emitted fluorescence signal are defined as the 
deviations from the temporal average of the signal: 
 δI(t) I(t) I(t)   (2) 







   (3) 
The auto-correlation function G(τ) combines the average fluctuation of the molecule at time 
step t with its fluctuation shifted by time τ (correlation time). The normalized auto-







  (4) 
The auto-correlation amplitude 0G( ) is the normalized variance of the fluctuating 
fluorescence signal. If all fluctuations arise from changes in the local concentration of the 
molecules within the volume element of the focal spot, the variations in the fluorescence 
intensity can be written as: 
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δI(t) W(r)δc(r,t)dV   (5) 
The term δ(c(r ,t)) determines the dynamics of the molecules: δc(r,t) describes the 
fluctuations in the local molecule concentration at time t .The function W(r) describes the 
spatial distribution of the emitted fluorescence light. Substituting the expression for the 
intensity fluctuations into the auto-correlation function yields: 
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The auto-correlation function G(τ)  is characterized by the correlation time τ and the 
correlation amplitude 0G( ) . Every process, producing fluctuations in the fluorescence 
intensity, has a characteristic correlation time. The FCS output by itself only represents a 
time spectrum. Interpretations on physical phenomena have to be extracted from the auto-
correlation function by developing appropriate physical models. The parameters of interest 
are found after fitting the auto-correlation curve to modeled functional forms. 
2.1.3. Model of free diffusion 
If the model of free diffusion is used, the fluctuation signal is characterized by the diffusion 
time (in-out motion of the molecules in the volume element) and the average number  
of molecules in the volume element (Figure 8). The spatial and timely distribution of  
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 (7) 
This implies that the molecules are freely diffusing in three dimensions with the diffusion 
coefficient D . The larger the mass of the molecule, the larger is the diffusion time and in 
consequence the fluctuation is getting slower (Figure 8). The spatial distribution of the 
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With: 
 2 20 0 0r x y   (9) 
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Figure 8. Shown is the diffusion of the labelled antibodies and the antigen-antibody complexes through 
the volume element, formed by the laser beam. The diffusion of the molecules through the volume 
element, due to their Brownian motion, is measured as fluctuations of the emitted fluorescence light. 
The different diffusion velocities give rise to different fluctuations lengths.  
The function W(r) is decayed to 2e at 0r  in lateral direction and for 0z z  in axial 
direction. By assuming the three dimensional Gaussian distribution of the emitted 
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The dimensions 0r  and 0z  are determined by calibration measurements (Figure 7). 
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For the model of free diffusion, the auto-correlation function (formula 6) can be calculated 
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 (13) 
Dτ is the diffusion time. This is the mean transit time of the molecule in the volume element 
(reciprocal of the average diffusion speed of the molecules). The relationship between the 
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The auto-correlation amplitude 0G( ) is proportional to the reciprocal of the average number 
of molecules N  in the volume element: 
 10G( )
N
  (15) 
Then, the local concentration of the fluorescent molecules in the effective focal volume 
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Due to statistical averaging, the relative fluctuations of the fluorescent signal become 
weaker with an increasing concentration of molecules. Therefore it is important to minimize 
the concentration of molecules in the focal volume. The decay of the auto-correlation 
function is determined by the diffusion time (Figure 9). When the correlation time τ  equals 
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 
 (17) 
The diffusion time Dτ  is determined as fit parameter from the auto-correlation curve. Every 
augmentation of the mass of a biomolecule, resulting from the interaction with a second 
molecule, can be determined from the increase of the diffusion time. Molecular interactions 
are followed up by recording successive auto-correlation curves with shortest integration 
time. From those auto-correlation curves, changes in the diffusion time are determined 
(Figure 9). 
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Figure 9. The diffusion time Dτ  of the molecules is determined as fit parameter from the decay of the 
auto-correlation function G(τ) . The interaction of the GAD 65 molecule with its antibody can be 
determined from the increase of the diffusion time. 
2.1.4. Experiments 
The sensitivity of the FCS method for the detection of GAD 65 was determined in clean and 
spiking experiments. Alexa 647 and Alexa 488 were used as dyes. In order to avoid 
disturbing auto-fluorescence for standardization, the detection of GAD 65 was carried out in 
bi-distillate water. By step-wise dilution, a minimal precisely detectable amount of 2.65 
microgram/ml of GAD 65 was measured in such clean systems. To verify the minimal 
precisely detectable amount in sera, normal healthy controls were used, where the same 
amount of GAD 65 as to the clean systems was added (spiking experiment). Sera from 27 
juvenile patients were investigated. All the children between 5 and 12 years were diabetes 
mellitus type 1 patients in an early stage and already had auto-antibodies. 126 sera of adult 
persons from normal admissions to the clinic served as controls. The sera from the 
paediatric patients came from a serum bank (Department of Paediatrics of the Medical 
University of Graz), the adult sera were fresh.  
2.2. Enzyme-Linked ImmunoSorbent Assay (ELISA) 
The second assay for the detection of the antigen GAD 65 in sera is the enzyme-linked 
immunosorbent assay (ELISA). As a heterogeneous assay, ELISA separates specifically 
components in a mixture by adsorbing them onto a solid phase which is physically 
immobilized. Therefore, the linking and adsorption of proteins (for example antibodies and 
antigens) is necessary. The chemical linking of proteins was developed by S. Avrameas and 
G. B. Pierce. The adsorption of proteins at solid states was developed in 1966 by L Wide and 
J.Porath. Based on these results, ELISA was developed in 1971 independently by two 
working groups, namely by P. Perlmann and E. Engvall at Stockholm University in Sweden 
and A. Schuurs and B. van Weemen in the Netherlands [44,45]. There exist different types of 
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ELISA which differ in more or less steps: the ‘indirect’ ELISA, the ‘sandwich’ ELISA, the 
‘competitive’ ELISA and the ‘multiple’ ELISA. One of the most useful and common of  
the immunoassays for the detection of antigens is the two antibodies ‘sandwich’ ELISA.  
This assay enables it to determine fast and accurately the antigen concentration in biological 
sera [46-48].  
2.2.1. Principle and experimental setup 
The sandwich ELISA requires two monoclonal antibodies, the capture and the detection 
antibody, that bind to different epitopes on the antigen. A microtiter plate (with a size of 
127.76 mm×85.48 mm×14.35 mm) is a flat plate with multiple wells, arranged in a regular 
8x12 matrix array, which serve as small test tubes. Each well holds tens of nanolitres to 
several millilitres of liquid. The capture antibodies are fixed to the wells of the microtiter 
plate (Figure 10). In a first step, the serum is added to the capture antibodies and the 
corresponding antigen is picked up (Figure 10). The unbounded substances are washed 
away. In the next step, the detection antibodies are added and bind to the antigen. The 
detection antibodies are labelled with an enzyme. Again the enzyme-linked antibodies that 
do not bind are washed away. The remaining molecules form a “sandwich” consisting of 
layers of antibody/antigen/enzyme-linked antibody (Figure 10). In the last step, a 
colorimetric substrate is added, which is digested by the enzyme. This reaction results in a 
change of colour in the substrate, producing a visible signal, which indicates the quantity of 
antigen in the sample. Then, as result, the antigen is present in the sera if the substrate 
changes colour. The substrate concentration is measured by a photometer, whereby the 
concentration of the substrate is proportional to the antigen concentration in the serum. 
2.2.2. Evaluation of the results, calculation of the calibration curve 
For the evaluation of the ELISA output, the extinction is measured as a function of the 
concentration c  of the coloured substrate inside the wells. The extinction λE  is a measure 







    
 
 (18) 
0I  is the intensity of the incident light, I  is the light intensity after passing the medium. If 
the extinction values are applied on the y-axis and the logarithm of the concentration ln(c)  
on the x-axis, there results a sigmoid curve (mathematical function with an S-shape curve, 
including one turning-point and two asymptotes). Prior to the calculation of the calibration 
curve by a linear regression, the sigmoid curve must be transformed into a linear curve. The 
logit-function L is used for the linearization of sigmoid curves, which is of great importance 
for the evaluation of ELISA curves. From this operation results a linear curve. First, the 
measured extinction λE  values are normalized so that the resulting values lie in the range 
between 0 and 1. The normalized extinction values are then expressed as: 
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For the evaluation of the ELISA output, the extinction is measured as a function of the 
concentration c  of the coloured substrate inside the wells. The extinction λE  is a measure 
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0I  is the intensity of the incident light, I  is the light intensity after passing the medium. If 
the extinction values are applied on the y-axis and the logarithm of the concentration ln(c)  
on the x-axis, there results a sigmoid curve (mathematical function with an S-shape curve, 
including one turning-point and two asymptotes). Prior to the calculation of the calibration 
curve by a linear regression, the sigmoid curve must be transformed into a linear curve. The 
logit-function L is used for the linearization of sigmoid curves, which is of great importance 
for the evaluation of ELISA curves. From this operation results a linear curve. First, the 
measured extinction λE  values are normalized so that the resulting values lie in the range 
between 0 and 1. The normalized extinction values are then expressed as: 
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Figure 10. The capture antibodies are bound on a microtiter plate. The serum is added and the antigen 
GAD 65 is picked up. Then, the detection antibodies, labelled with an enzyme, are added and bind to 
the antigen. The enzyme catalyses a substrate reaction, whereby results a change of colour which is 
measured quantitatively by a photometer. 
The value pairs of the logit-log-plot (x-value is the logarithm of the substrate concentration 
and the y-value is the logit of the normalized extinction values) are used for the linear 
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regression. From the linear regression results the high (b) and ascent (a) of the linear 
calibration curve: 
 L aln(c) b   (21) 
Where: ln(c) is the x-value and L is the y-value (Figure 10). Then, the concentration c of the 
substrate is calculated out of the measured extinction values. The best accuracy is obtained 
in the neighborhood of the turning-point of the sigmoid curve, because in this range the 
ascent has a maximum value.  
2.2.3. Experiments 
In order to evaluate the stability of the GAD 65 molecule in sera, the concentration 
measurements in the samples were repeated after a time delay. Additionally the correlation 
between the GAD 65 concentrations from samples stored at different temperatures was 
determined. The correlation between the GAD 65 concentrations at different time steps is 
calculated by linear regression. Given a series of N measurements of the variables ny  and 
nx  (n=1,2,…,N), then the correlation coefficient R is applied to quantify the strength of their 


















The quantities x and y are the mean values of x and y and xσ and yσ are the respective 
standard deviations. If the coefficient equals 1, then the concentrations are completely 
linearly correlated. If the coefficient equals 0, then the variables are completely independent. 
Serum samples from 64 persons representing a cross-section of the samples in a blood bank 
(in Freiburg, Germany) were used. The specimens were randomly selected. Each sample 
was stored at room temperature and additionally in a refrigerator cooled at -80°C. 
2.3. Surface Enhanced Laser Desorption Ionisation – Time Of Flight  
(SELDI-TOF) 
Mass spectrometry is an analytical technique that measures the mass-to-charge ratio of 
charged particles. Based on preceding works of B. Goldstein and W. Wien, J.J. Thomson 
developed the first mass spectrograph [49]. End of the 1950’s the mass spectrometry was 
applied to the analysis of amino acids and peptides. K. Tanaka developed the laser 
desorption which was applied for the ionization of biological macromolecules, especially 
proteins [50]. In this study mass spectrometry was carried out according to the surface 
enhanced laser desorption ionisation – time of flight (SELDI-TOF) system. SELDI-TOF has 
been proven as suitable tool in the clinical laboratory for the profiling of biomarkers in 
complex biological specimens such as: serum, plasma, intestinal fluid and urine [51-56]. 
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SELDI–TOF consists of an aluminium carrier, called the array, a laser unit and a system 
which measures the time of flight (TOF) of the molecules (Figure 11). The TOF system 
includes an electric field, induced by the acceleration potential, and a detector. 
Photomultipliers, avalanche diodes etc. are used as detectors. 
 
Figure 11. Surface enhanced laser desorption ionisation– time of flight (SELDI-TOF). The proteins are 
“eluted” from the matrix array by laser desorption and ionization. The ionized proteins are accelerated 
in the electric field and enter the TOF tube, according to their mass to charge ratio, with different 
velocities and each detection signal is represented by a peak in the mass spectrum.  
2.3.1. Chip array 
Proteins are captured by adsorption, electrostatic interaction, or affinity chromatography on 
the solid-phase protein chip array. The different chip types have either: surfaces that bind 
many different proteins or surfaces with a specific biomolecular affinity. The chips of the fist 
type are composed of chemical surfaces, which have: hydrophobic, hydrophilic, anionic, 
cationic or metal affinity properties. The chips of the second type are composed of 
biochemically active surfaces, such as: immobilized antibodies, receptor proteins, DNA 
fragments or enzymes. The first type of surface binds many different proteins, whereas the 
second type binds only specific molecules, such as: antibodies, factors, DNA binding 
proteins and substrates. Therefore, the biochemically active surfaces are used to exploit 
specific molecular recognition mechanisms.  
After putting the sample on the chosen chip type, the weakly bound molecules are washed 
away. The remaining sample molecules are mixed with small photosensitive molecules. 
These molecules cause the sample to crystallize and form the matrix as it dries. (The matrix 
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is composed of the molecules in the sample mix which are not analyzed). The photosensitive 
molecules facilitate desorption and ionization of the proteins in the mixture.  
2.3.2. Laser desorption and ionization 
The chip with the samples is put into a vacuum chamber, the flight tube of the mass 
spectrometer (Figure 11). The laser pulse excites the photosensitive matrix molecules. The 
energy of the excited molecules is converted into thermal energy which heats up the sample 
spot. The overheated part of the sample mix explodes into a plume and the molecules are 
liberated from the array (Figure 12). The protein molecules in the plume collide with the 
excited matrix molecules, whereby the matrix molecules transfer protons to the proteins and 
create charged proteins. Due to repeated processes, the proteins can get multiple charges. 
 
Figure 12. The chip array (aluminium carrier) contains immobilized GAD 65 antibodies, enabling it to 
focus specially on the GAD 65 antigen. The sample molecules are mixed with small matrix molecules, 
facilitating desorption and ionization of the proteins in the mixture. The laser pulse excites the matrix 
molecules; the serum molecules are liberated from the array and protonized.  
2.3.3. TOF-measurement 
Inside the vacuum chamber, an electric field (along the direction r) is generated by an 
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The electric field is switched on synchronously with the end of the laser pulse. The 




Where z is the net charge of the ionized molecule and e is the elementary electron charge  
( 191 602 10.  C). The molecules are accelerated into a field-free region, the TOF tube (Figure 
11). Inside the TOF tube, the ionized molecules move toward the ion detector. The physical 
principle of the TOF analyser is that proteins, which have a different mass over charge ratio 
 m z  are accelerated differently and enter the TOF tube with different velocities. The ratio 
of each protein molecule is recorded on the basis of the time required to pass through the 
tube. A protein with a net charge z , which passes through a potential difference of U , 
acquires an energy of: 
 PotE zeU  (25) 
The net charge is always a multiple whole number of the elementary electron charge e . The 
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Where m is the protein mass and v  is its velocity. Then the velocity of the protein inside the 
TOF tube equals: 
 2zeUv
m
  (27) 
Because the molecules gain the same kinetic energy in the electric field, the velocity of the 
molecules with a small mass is bigger than the velocity of molecules with greater masses. If 
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The detector measures the time interval between the switch on of the electric field and the 
moment a charged molecule hits the detector. When the molecules strike the detector plates, 
the plates release a certain multiple of electrons. The release of electrons is generally 
amplified by a cascade of successive releases (avalanche effect). The detector signal is then 
defined by the ratio of released electrons and the number of molecules striking the detector 
plate. 
2.3.4. Mass spectrum and calibration 
The counted totals per time interval are displayed in the spectrum (Figure 11). The detection 
of molecules with the same molecular weight and the same electric charge produce a signal 
which is called a singleton peak. A peak in the spectrum is then the signal induced by 
neighbouring singleton peaks. The peak area is proportional to the number of detected 
molecules. The baseline of the spectrum is formed by the dark current inside the detector 
and the detected air molecules. In practice, linear deviations from the expected (theoretical) 
relation are observed. Therefore a calibration must be performed before the measurement. 
The calibration equation is given by: 
  20TOF
m αU t t β
z
 
   
 
 (31) 
The calibration equation considers the linear deviation in the spectrum by inserting the 









The factor a  is a temporary dummy variable. By measuring the time of flight TOFt  of 
molecules with well known masses, the calibration parameters α  and β  are determined. 
2.3.5. Experiments 
The sera were tested on a PS20 slide provided by Phadia, Sweden-Diagnostic, 
Freiburg/Breisgau, Germany. PS20 Protein chip arrays are 8 spot chips with 2 mm diameter 
spots, spatially compatible with one column of a standard 96-well microplate. The 
investigations were made with the Ciphergen system (Ciphergen Protein Chip Software 3.0) 
and the calibrations of the spectra were realized in point of view of the GAD 65. The serum 
was applied on the array and covered with the matrix from the laboratory of the Pasteur 
Institute in Paris. In a first experiment, sera without dilution were used and in a second 
experiment, the sera were diluted. To realize a diagnostic procedure, every serum was 
tested in duplicate with different successive dilutions (1:5, 1:10, 1:20.). Within the latter of 
“marker molecules” with known molecular weight such as Albumin and the analytical GAD 
65 molecule purisimum and in spiking experiments, the existence of GAD 65 can be 
estimated. The concentration of albumin in sera is of course tremendously higher than the 
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concentration of the expected GAD 65. By use of the protein chip PS20 with fixation by 
covalent bonds of the GAD 65 antibodies, the contamination of the exuberant albumin is less 
disturbing. The sera from 2 paediatric patients (also contained in the sample set of the FCS 
measurements) with early onset of diabetes mellitus type 1 were kindly provided from the 
serum bank of the Department of Paediatrics of the Medical University of Graz.  
3. Results 
3.1. FCS 
Clean and spiking experiments allowed a minimal precisely detectable amount of the GAD 
65 at the concentration of 2.65 microgram/ml. The measured diffusion times are shown in 
figure 9. This enabled a sufficient serum dilution and avoids interference by auto 
fluorescence and other proteins in the FCS system. With diffusion times of 985 resp. 630 
microseconds, GAD 65 could be found in 8 sera from patients with diabetes in an early 
onset. 4 of the patients were juvenile patients and 4 were adults, which were initially used as 
controls, who retrospectively showed signs of autoimmunity. 
3.2. ELISA 
GAD 65 was found in different concentrations, where the values range from 0.10-514.7 
ng/ml (1 ng/ml = 10-9 g/ml), in all the samples (Figure 13). This leads to an average 
concentration of 58.00 ng/ml. The correlation between the GAD 65 concentrations from 
samples stored at room temperature and the same samples stored in a refrigerator cooled at 




Figure 13. With the ELISA setup, GAD 65 was found in human sera from a blood bank, with values 
ranging from 0.10-514.7 ng/ml.  
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Figure 14. Correlation between the GAD 65 concentrations from samples stored at room temperature 
and cooled at -80°C.  
The high value of the correlation coefficient (0.9668) shows that there is practically no 
difference in the concentrations between samples at room temperature and the same 
samples at -80°C. Additionally, the correlation between the GAD 65 concentrations taken 
from samples stored at room temperature and taken from the same samples after a time 
delay of one week was calculated. During this week, the samples were stored at room 
temperature (Figure 15). The value of the correlation coefficient (0.9897) demonstrates that 




Figure 15. Correlation analysis between the GAD 65 concentrations taken from samples stored at room 
temperature and taken from the same samples after a time delay of one week. 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 226 
concentration of the expected GAD 65. By use of the protein chip PS20 with fixation by 
covalent bonds of the GAD 65 antibodies, the contamination of the exuberant albumin is less 
disturbing. The sera from 2 paediatric patients (also contained in the sample set of the FCS 
measurements) with early onset of diabetes mellitus type 1 were kindly provided from the 
serum bank of the Department of Paediatrics of the Medical University of Graz.  
3. Results 
3.1. FCS 
Clean and spiking experiments allowed a minimal precisely detectable amount of the GAD 
65 at the concentration of 2.65 microgram/ml. The measured diffusion times are shown in 
figure 9. This enabled a sufficient serum dilution and avoids interference by auto 
fluorescence and other proteins in the FCS system. With diffusion times of 985 resp. 630 
microseconds, GAD 65 could be found in 8 sera from patients with diabetes in an early 
onset. 4 of the patients were juvenile patients and 4 were adults, which were initially used as 
controls, who retrospectively showed signs of autoimmunity. 
3.2. ELISA 
GAD 65 was found in different concentrations, where the values range from 0.10-514.7 
ng/ml (1 ng/ml = 10-9 g/ml), in all the samples (Figure 13). This leads to an average 
concentration of 58.00 ng/ml. The correlation between the GAD 65 concentrations from 
samples stored at room temperature and the same samples stored in a refrigerator cooled at 




Figure 13. With the ELISA setup, GAD 65 was found in human sera from a blood bank, with values 
ranging from 0.10-514.7 ng/ml.  
 
The Role of the Antigen GAD 65 in Diabetes Mellitus Type 1: A Molecular Analysis 227 
 
 
Figure 14. Correlation between the GAD 65 concentrations from samples stored at room temperature 
and cooled at -80°C.  
The high value of the correlation coefficient (0.9668) shows that there is practically no 
difference in the concentrations between samples at room temperature and the same 
samples at -80°C. Additionally, the correlation between the GAD 65 concentrations taken 
from samples stored at room temperature and taken from the same samples after a time 
delay of one week was calculated. During this week, the samples were stored at room 
temperature (Figure 15). The value of the correlation coefficient (0.9897) demonstrates that 




Figure 15. Correlation analysis between the GAD 65 concentrations taken from samples stored at room 
temperature and taken from the same samples after a time delay of one week. 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 228 
3.3. SELDI-TOF 
Evidence for GAD 65 in one serum sample in the mass spectrum was found, giving a peak 
very close to albumin with a molecular weight of 65 kDa. This serum was from a juvenile 
patient with an early onset of diabetes mellitus type 1. Peak evaluation after spiking 
experiments was done to have comparable results as with FCS. The spectra always show the 
peaks of the antibodies at 50, 75 and 150 kDa. The spectra of the diluted sera (Figure 16) 
show a much diminished peak of the reference albumin. For the interpretation of the results, 
the peak intensity at 65 kDa was calibrated in proportion to the intensity of the albumin 
peak in the reference. The intensity of the appropriate peak in the spectrum is greater than 




Figure 16. The sera are diluted at 1:20. The spectrum of the diluted serum shows a peak at 65kDa which 
may results from GAD65. The intensity of the peak is greater, by a factor of 8.4, than the corresponding 
albumin peak. This serum is from a paediatric patient with diabetes mellitus type 1 at an early stage. 
4. Molecular analysis and visualization 
Functional specificity and biological function of a protein are linked to its structure. Due to 
the 3-D folding structure, the residues, which are responsible for the protein function, are 
brought into a precise geometric arrangement. The rest of the protein structure is mainly 
necessary to enable and maintain the correct spatial position between the amino acids on the 
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active site. Therefore, to understand a protein function, the 3-D structure of the protein 
reveals far more information than its sequence.  
For an analysis and planning of neutralization of GAD 65 with antibodies in the sera, the 
locations and shapes of the epitopes on the GAD 65 molecule are important. The structural 
visualization of the GAD 65 molecule and its epitope locations is illustrative and may help 
the reader to speculate on the antigenic sites of the molecule, enabling an understanding of 
the interaction with the immune-receptor, which is the basis for the development of active 
or passive immunotherapy in the near future. The epitopes are well known in literature and 
were identified by homolog-scanning mutagenesis, where segments of sequences from a 
homologous molecule (GAD 67) known not to bind to the specific antibodies are 
systematically substituted throughout the GAD 65 gene [57,58]. A complete or partial loss of 
antibody reactivity by the resulting mutated molecules (chimeras) suggests that GAD65 
specific sequences required for contact with the antibody has been exchanged by the point 
mutation. The quaternary structure of GAD 65 was determined experimentally by X-ray 
diffraction [59]. In this paper the visualization is done with the Swiss-Pdb Viewer 
(http://spdbv.vital-it.ch) [60].  
4.1. Visualisation of macromolecules 
Bioinformatics is an interdisciplinary discipline between computer science and molecular 
biology. On one side, bioinformatics is a science with interconnected data banks, connecting 
sequence information to structural, biomedical and clinical data. On the other side, 
bioinformatics is a science which provides mathematical algorithms and computational 
tools for: detecting sequence similarities and finding homologous sequences; prediction, 
analysis and visualization of protein 3-D structure etc.  
Structural information about proteins is available in the PDB structure database, an 
international repository for 3-D structure files [61]. Once a protein structure has been 
determined experimentally, either with crystallographic methods or by nuclear magnetic 
resonance spectroscopy, the structural information is deposited into the PDB. The 
structural information is stored in the PDB as data files, which contain mainly the 
Cartesian coordinates of all atoms involved in the protein (Figure 17). The entry point to 
the structural protein data is the PDB web site: http://www.rcsb.org/pdb. The database is 
accessed via Internet and the selected PDB data files, containing the atomic coordinates, 
are downloaded. The data files are used as input for protein visualization and the viewer 
software transforms the information in the PDB data file into an appropriate 
representation of the protein 3-D structure. Usually the molecules are visualized by 
“balls-and-sticks” models or by ribbons showing their secondary structures (Figure 5). 
The step from a molecule (set of connected atoms) to geometric shape is done by space 
filling diagrams. The theory of space filling diagrams is part of topology: the area of 
mathematics concerned with spatial properties that are preserved under continuous 
deformations of objects. 
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show a much diminished peak of the reference albumin. For the interpretation of the results, 
the peak intensity at 65 kDa was calibrated in proportion to the intensity of the albumin 
peak in the reference. The intensity of the appropriate peak in the spectrum is greater than 




Figure 16. The sera are diluted at 1:20. The spectrum of the diluted serum shows a peak at 65kDa which 
may results from GAD65. The intensity of the peak is greater, by a factor of 8.4, than the corresponding 
albumin peak. This serum is from a paediatric patient with diabetes mellitus type 1 at an early stage. 
4. Molecular analysis and visualization 
Functional specificity and biological function of a protein are linked to its structure. Due to 
the 3-D folding structure, the residues, which are responsible for the protein function, are 
brought into a precise geometric arrangement. The rest of the protein structure is mainly 
necessary to enable and maintain the correct spatial position between the amino acids on the 
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active site. Therefore, to understand a protein function, the 3-D structure of the protein 
reveals far more information than its sequence.  
For an analysis and planning of neutralization of GAD 65 with antibodies in the sera, the 
locations and shapes of the epitopes on the GAD 65 molecule are important. The structural 
visualization of the GAD 65 molecule and its epitope locations is illustrative and may help 
the reader to speculate on the antigenic sites of the molecule, enabling an understanding of 
the interaction with the immune-receptor, which is the basis for the development of active 
or passive immunotherapy in the near future. The epitopes are well known in literature and 
were identified by homolog-scanning mutagenesis, where segments of sequences from a 
homologous molecule (GAD 67) known not to bind to the specific antibodies are 
systematically substituted throughout the GAD 65 gene [57,58]. A complete or partial loss of 
antibody reactivity by the resulting mutated molecules (chimeras) suggests that GAD65 
specific sequences required for contact with the antibody has been exchanged by the point 
mutation. The quaternary structure of GAD 65 was determined experimentally by X-ray 
diffraction [59]. In this paper the visualization is done with the Swiss-Pdb Viewer 
(http://spdbv.vital-it.ch) [60].  
4.1. Visualisation of macromolecules 
Bioinformatics is an interdisciplinary discipline between computer science and molecular 
biology. On one side, bioinformatics is a science with interconnected data banks, connecting 
sequence information to structural, biomedical and clinical data. On the other side, 
bioinformatics is a science which provides mathematical algorithms and computational 
tools for: detecting sequence similarities and finding homologous sequences; prediction, 
analysis and visualization of protein 3-D structure etc.  
Structural information about proteins is available in the PDB structure database, an 
international repository for 3-D structure files [61]. Once a protein structure has been 
determined experimentally, either with crystallographic methods or by nuclear magnetic 
resonance spectroscopy, the structural information is deposited into the PDB. The 
structural information is stored in the PDB as data files, which contain mainly the 
Cartesian coordinates of all atoms involved in the protein (Figure 17). The entry point to 
the structural protein data is the PDB web site: http://www.rcsb.org/pdb. The database is 
accessed via Internet and the selected PDB data files, containing the atomic coordinates, 
are downloaded. The data files are used as input for protein visualization and the viewer 
software transforms the information in the PDB data file into an appropriate 
representation of the protein 3-D structure. Usually the molecules are visualized by 
“balls-and-sticks” models or by ribbons showing their secondary structures (Figure 5). 
The step from a molecule (set of connected atoms) to geometric shape is done by space 
filling diagrams. The theory of space filling diagrams is part of topology: the area of 
mathematics concerned with spatial properties that are preserved under continuous 
deformations of objects. 
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Figure 17. Protein structural information is available at the Protein Data Base (PDB). At the moment the 
database contains more than 80.700 experimentally determined structures. The PDB is contacted 
through the Internet. The structural information is stored in the PDB data files as atomic coordinates. 
The B-factor indicates the precision of each atom position. The requested PDB data files are downloaded 
and the protein structure visualized locally. 
4.2. Space filling models and molecular shapes 
Space filling diagrams are models that represent a molecule by the space it occupy [62-65]. 
They are embedded in the 3-D space ( 3 ) and show properties that make them suitable for 
molecular analysis. Each atom in a space filling diagram is represented by its location in 
space and a quantitative expression of influence on its surrounding. Most commonly, the 





  (33) 
The molecular boundary is defined as the envelope of the union of overlapping spheres. 
Three types are of special interest: the van der Waals model, the solvent accessible model 
and the molecular surface model.  
Van der Waals model (VW): Due to the movement of the electrons around the atomic 
nucleus, an atom can be considered as an electric dipole. The dipole of an atom polarises the 
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neighbour atom resulting in a transient attractive force between the atoms. Conversely, at 
short ranges a repulsive force between the electrons of both atoms arises. The radius at 
which the repulsive force begins to increase sharply is called the van der Waals radius. The 
van der Waals sphere iA of the i -th atom of a molecule is specified by its atom type and has 
a location in space: 3iz   and a radius ir  . This radius ir  is the same for all atoms of 
the same type i . The van der Waals model of a molecule is a union of balls: 
  3 1: ; ,...,i i iVW x x z r i N         (34) 
N  is the number of atoms in the molecule. That means: the van der Waals model is the set 
of points x  which are located inside the distance ir  from the centre of the van der Waals 
sphere iA . The van der Waals spheres of binding atoms overlap, whereas the spheres of 
non-binding atoms do not overlap (Figure 18). As the van der Waal model, the following 
space filling models depend on the atomic van der Waals radii and the coordinates of the 
atoms in the molecule. 
 
Figure 18. Van der Waals surface of GAD 65: The boundary of the space filling diagram is made up as 
envelope of the union of spheres with van der Waals radii.  
Solvent accessible model (SA): The interaction of the Van der Waals model and a solvent 
molecule, represented as sphere of radiusρ , is studied by increasing the radius ir  of every 
van der Waals sphere, associated to an atom iA , by ρ . That means: the radius of the van der 
Waals sphere is expanded by the radius of the solvent (Figure 19). The solvent accessible 
model is then defined (similar to the van der Waals model) as the union of the enlarged balls: 
  3 1: ; ,...,i i iSA x x z r ρ i N          (35) 
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Solvent accessible model (SA): The interaction of the Van der Waals model and a solvent 
molecule, represented as sphere of radiusρ , is studied by increasing the radius ir  of every 
van der Waals sphere, associated to an atom iA , by ρ . That means: the radius of the van der 
Waals sphere is expanded by the radius of the solvent (Figure 19). The solvent accessible 
model is then defined (similar to the van der Waals model) as the union of the enlarged balls: 
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Figure 19. Solvent accessible model of GAD 65: The boundary of the space filling diagram is made up as 
union of spheres which are grown by the radius of the sphere of a single solvent molecule. The accessible 
surface is the surface generated by the centre of the solvent sphere rolling of the van der Waal surface. 
The accessible surface is the surface generated by the centre of the solvent sphere rolling of 
the van der Waals surface. The radius ρ of the solvent sphere is usually set to 1.4 angstrom 
(the approximate radius of a water molecule).  
Molecular surface model (MS): A model that resembles in size the van der Waals model 
and in connectivity the solvent accessible model is the molecular surface model. It consists 
of all points 3x  that lie outside all solvent spheres disjoint from van der Waal modell: 
  3 :y SAMS x x y ρ      (36) 
The surface is generated by a sphere of radius ρ rolling about the van der Waals model. The 
molecular surface is the envelope generated by the rolling sphere. It differs from the van der 
Waal surface by covering portions of the volume inaccessible to the rolling sphere (Figure 
20). It consists of sphere and torus patches connected in a tangent continuous manner. The 
shape of a molecule is described by the molecular surface, which is the boundary of the 
molecule volume within which no other molecule can enter. The molecular shape of the 
antigen and the corresponding antibody is of special importance for the understanding of 
their intermolecular interaction. The interaction is usually described in terms of locks and 
keys: The shape of the lock (the antigen) must be complimentary to the shape of the key (the 
antibody) to initiate an immune response. The body develops antibodies with the right 
shape to attack specific antigens. The docking places for the antibodies are the epitopes of 
the antigen. The locations of the sequence fragments, constituting the epitopes, are 
highlighted on the GAD 65 3D structure (Figure 21). Molecular surfaces are suitable for the 
visualization of the epitope shapes, which enables a pictorial analysis of the local docking 
sites and their fitting. For the quantification of the epitope accessibility to the paratopes of 
the antibodies, dual models of the space filling diagrams are used. 
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Figure 20. Molecular surface of GAD 65: Boundary that is obtained by rolling the solvent sphere over 
the van der Waals surface. The molecular surface is the envelope generated by the rolling sphere. It 
consists of sphere and torus patches connected in a tangent continuous manner and filling up the 
inaccessible crevices and cusps.  
 
Figure 21. The GAD 65 molecule is represented by its molecular surface. The shapes of the GAD 65 
epitopes, enable a pictorial analysis of the local docking sites. The exposure values of the residues, 
constituting the epitopes, were calculated by Voronoi tessellation. These values (in %) indicate how much 
the epitopes are exposed to the surrounding solvent, indicating the accessibility to potential antibodies.  
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Figure 19. Solvent accessible model of GAD 65: The boundary of the space filling diagram is made up as 
union of spheres which are grown by the radius of the sphere of a single solvent molecule. The accessible 
surface is the surface generated by the centre of the solvent sphere rolling of the van der Waal surface. 
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Figure 20. Molecular surface of GAD 65: Boundary that is obtained by rolling the solvent sphere over 
the van der Waals surface. The molecular surface is the envelope generated by the rolling sphere. It 
consists of sphere and torus patches connected in a tangent continuous manner and filling up the 
inaccessible crevices and cusps.  
 
Figure 21. The GAD 65 molecule is represented by its molecular surface. The shapes of the GAD 65 
epitopes, enable a pictorial analysis of the local docking sites. The exposure values of the residues, 
constituting the epitopes, were calculated by Voronoi tessellation. These values (in %) indicate how much 
the epitopes are exposed to the surrounding solvent, indicating the accessibility to potential antibodies.  
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4.3. Dual models and exposure values 
The space filling models have a common dual counterpart. The dual counterpart is 
constructed by the Voronoi diagram that decomposes the union of balls (VW or SA model) 
into convex pieces [66-68]. 
 
The weighted distance of a point 3x  from iA is defined as: 
 2 2i i iπ (x) x z r    (37) 
The Voronoi cell iV of iA is the region of points whose weighted distance to iA is as least as 
small as to any other ball: 
  3 : ( ) ( )i j i jV x π x π x     (38) 
Each Voronoi cell is an intersection of closed half-spaces and therefore a convex polyhedron. 
Any two Voronoi cells overlap at most along some piece of their boundary and together the 
collection of cells covers the entire 3 . The common intersection of 1 1k   Voronoi cells is 
either empty or a common (3-k)-dimensional face. In Voronoi tessellation, the space, 
containing a set of discrete points lP , is subdivided into the non overlapping Voronoi cells 
[68]. Each cell lV  is associated with an element of the set of points lP  in that way, that every 
region contains space points x , which have the shortest distance to the associated point: 
  3| ,l l kV x P x P x l k       (39) 
This partition of the space is called Voronoi tessellation. In the definition, the Euclidean 







P x P x

    (40) 
For a given set of points the Voronoi decomposition is unique. The set of Voronoi cells is 
called a Voronoi diagram, which defines the topological relations of the set of discrete points 
(Figure 23A). The Voronoi tessellation describes the space filled by a packing of solid 
polyhedrons, connected by their faces, without empty space between them. The 
configuration of the cells provides information about the package of the associated set of 
points. Each cell in the diagram is characterized by its number of edges and faces (Figure 
22). All the values concerning the individual cells, such as: cell volume, cell surface, number 
Space-filling diagrams           Dual structures 
Van der Waals model                      Voronoi diagram 
Solvent accessible model                                    Delaunay triangulation 
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of sides, number of faces, area of contact faces and distances between the representative 
points, are derived from the geometry of the tessellation. 
 
Figure 22. Voronoi tessellation of the GAD 65 molecule. Each Voronoi cell lV  is a polyhedron which is 
uniquely associated with one of the residues. The αC  atoms are used as centre points. Each cell in the 
Voronoi diagram is characterized by its number of edges and faces. The common faces of the cells 
define the contacts with nearest residues.  
For completeness, let us shortly introduce the Delaunay triangulation. The Delaunay 
complex is a collection of simplices that records the overlap pattern among Voronoi cells. 
The complex contains the convex hull of 1k  ball centres if their corresponding Voronoi 
cells have a non-empty common intersection. Let B be a subset of 1k  atoms with 
 B i iZ z A B  and  B i iV V A B  . Then the Delaunay complex is: 
  conv B BD σ H (Z ) V     (41) 
Where ( conv BH (Z )  denotes the convex hull of the points in BZ . Figure 23A shows a Voronoi 
tessellation of a set of 4 points in the plane. In 2-D the Voronoi cell of a point is given by a 
polygon, where the intersection of the contact lines is build with aid of the lines joining the 
neighbour points. The set of segments joining the points two by two is called Delaunay 
triangulation, which is the dual of the Voronoi diagram (that means that it represents the 
same geometrical information about the set of points).  
A Voronoi tessellation can be used to quantify the contact areas of individual residues in 
proteins. The tessellations are mostly performed on the alpha carbon atoms (as point lP ) of 
the structure. The tetrahedron set, sharing a particular alpha carbon αC  as a vertex, defines 
its closest neighbourhood. The circumscribed sphere of each tetrahedron does not contain 
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any other alpha carbon (Figure 22). Two residues are in direct contact if their corresponding 
cells share a common face. To obtain quantitative values for the epitopes area, the exposure 
rate of the epitopes to the surrounding solvent was calculated. The contribution of an amino 
acid, at the epitope, to the exposure rate, is characterized by the number and size of the faces 
of its Voronoi cell exposed to the solvent. The total area of the Voronoi cell lV  of the l -te 
residue is denoted by lF . The area of the i -te common face to the solvent is: ia . aN  is the 
number of common faces. Thus a measure for the exposure of the l -te residue to the solvent 










   (42) 
The total area of the epitope can be quantified by summing up the areas for all the involved 











The relative exposure values (in %) of the epitope residues give hints about the 
accessibilities of the antibodies to the GAD 65 molecule and are shown in Figure 21. The 
Voro3D software was used for the Voronoi tessellations (http://www.lmcp.jussieu.fr/ 
~mornon/voronoi.html) [69]. 
4.4. Molecular electronic states and molecular recognition 
The structural visualization of the GAD 65 molecule and its epitopes, together with their 
electrostatic field, is illustrative and may help the clinical immunologist to better imagine 
the mechanisms of the GAD 65 antigenicity. The specific antigen-antibody recognition and 
the attraction of the two molecules are done by the electrostatic fields surrounding the 
molecules. The electrostatic potential can be studied locally at the epitopes or globally, 
surrounding the whole molecule at different distances. The local electrostatic potential 
generated by the epitope residues, at the epitope location play a role in the recognition and 
adjustment of the antibody at the docking place. The global electrostatic potential is 
extending in the surrounding solvent influencing other molecules.  
The electron behaviour in molecules is treated by methods based on quantum theoretical 
calculations. The Hamiltonian operator for the electronic Schrödinger equation describes the 
dynamic of the involved electrons [70-72]. For a molecule with N  electrons and K  nuclei, 
the Hamiltonian operator is given by: 
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Figure 23. A) Voronoi tessellation (red) of a set of 4 points in the plane together with the dual Delaunay 
triangulation (blue). B) The interactions between the electrons e and nuclei a, b of a molecule. C) The 
independent electron moves in the electrostatic field of the nuclei and the averaged field of all other 
electrons. D) The molecular orbital  is build as linear combination of atomic orbital.  





h is Planck’s constant 346 626 10.  Js) the interaction of the electrons with the K  nuclei 
(second term), the electron-electron interactions (third term). aZ  is the nuclear charge in 
atom a , air  is the distance between electron i and nucleus a , ijr  is the distance between 
electron i and electron j  (Figure 23B). Then the electronic properties are calculated with the 
nuclei coordinates as parameters which are provided by the corresponding PDB data files. 
The resulting major part of the further calculation remains in solving the electronic 
Schrödinger equation: 
 n n nH E    (45) 
The only possible values for the energy in quantum theory are the eigenvalues nE  of the 
Hamiltonian operator in the Schrödinger (eigenstate) equation with eigenfunctions n . A 
significant simplification can be obtained by introducing an independent-particle model 
where the dynamic of an electron is considered to be independent of all other electrons and 
the interaction is taken into account in an average fashion. That means that the electron 
moves independently in the electric field of the nuclei and the field of all other electrons 
(Figure 23C). In the independent-particle model, the total state function   of a molecule 
with N electrons is the product of the N single electron state functions k  ( 1,...,k N ). In 
quantum theory, the values of an observable are the expectation values of the corresponding 
operator in pure (eigenstates) or mixed states (linear combination of eigenstates). The energy 
of a molecular system, described by an appropriate state function, is therefore calculated as 
the expectation value of the Hamiltonian operator (in Dirac bra-ket notation): 
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The total area of the epitope can be quantified by summing up the areas for all the involved 











The relative exposure values (in %) of the epitope residues give hints about the 
accessibilities of the antibodies to the GAD 65 molecule and are shown in Figure 21. The 
Voro3D software was used for the Voronoi tessellations (http://www.lmcp.jussieu.fr/ 
~mornon/voronoi.html) [69]. 
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Figure 23. A) Voronoi tessellation (red) of a set of 4 points in the plane together with the dual Delaunay 
triangulation (blue). B) The interactions between the electrons e and nuclei a, b of a molecule. C) The 
independent electron moves in the electrostatic field of the nuclei and the averaged field of all other 
electrons. D) The molecular orbital  is build as linear combination of atomic orbital.  





h is Planck’s constant 346 626 10.  Js) the interaction of the electrons with the K  nuclei 
(second term), the electron-electron interactions (third term). aZ  is the nuclear charge in 
atom a , air  is the distance between electron i and nucleus a , ijr  is the distance between 
electron i and electron j  (Figure 23B). Then the electronic properties are calculated with the 
nuclei coordinates as parameters which are provided by the corresponding PDB data files. 
The resulting major part of the further calculation remains in solving the electronic 
Schrödinger equation: 
 n n nH E    (45) 
The only possible values for the energy in quantum theory are the eigenvalues nE  of the 
Hamiltonian operator in the Schrödinger (eigenstate) equation with eigenfunctions n . A 
significant simplification can be obtained by introducing an independent-particle model 
where the dynamic of an electron is considered to be independent of all other electrons and 
the interaction is taken into account in an average fashion. That means that the electron 
moves independently in the electric field of the nuclei and the field of all other electrons 
(Figure 23C). In the independent-particle model, the total state function   of a molecule 
with N electrons is the product of the N single electron state functions k  ( 1,...,k N ). In 
quantum theory, the values of an observable are the expectation values of the corresponding 
operator in pure (eigenstates) or mixed states (linear combination of eigenstates). The energy 
of a molecular system, described by an appropriate state function, is therefore calculated as 
the expectation value of the Hamiltonian operator (in Dirac bra-ket notation): 
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The first expression describes the mean kinetic energy of the electrons and the potential 
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The second term describes the Coulomb interaction between 2 electrons, where one electron 
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The third term describes the exchange interaction resulting from the indistinguishability of 
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Since molecular systems, involve the motions of a large number of electrons, their 
Schrödinger equations cannot be solved exactly and approximate solutions must be used. 
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This expansion is called “Linear Combination of Atomic Orbitals” (LCAO). μ i(r ) are the 
well known atomic orbitals: s-orbital, p-orbital, d-orbital. The coefficients nμc  define the 
contribution of the atomic orbital’s to the molecular orbitals and are the weight of the μ -the 
atomic orbital in the n-te molecular orbital (Figure 23D). These coefficients have to be 
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determined to find the molecular orbitals. Until now the molecules were considered as a 
system of electrons and nuclei, the expansion in atomic orbitals reflects the chemical view 
where molecules are building up of single atoms. The objective is now to find molecular 
orbitals that make the energy a minimum. This is done by determining a set of coefficients 











( *nμc  is the complex conjugate of nμc ). The variation procedure yields the HF-LCAO (HF: 
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This is the most important equation in the quantum theory of molecules. αβS  is the overlap 
matrix: 
 *αβ α i β i iS (r ) (r )dV    (54) 
The solutions of the HF-LCAO equation system are the energy 1nε ; (n ,...,M)  and the 
coefficients 1nβc ; (β ,...,M)  for the molecular orbitals 1n ; (n ,...,M)  . It is a linear 
equation system, of dimension MxM , where the solutions for larger molecules highly 
depend on computer power. The dimension of the equation system depends on the number 
of atoms and the involved atomic orbitals. In the simplest version only the p-orbital’s 
contributing to the delocalized π -bonds are considered (Hückel molecular orbitals), in a 
higher version all the valence orbitals contributing to the chemical bonds are used 
(Extended Hückel). In more sophisticated versions, beside the valence orbitals also inner 
atomic orbitals are used. The complexity of the equation system and the computational 
power depend on the evaluation of the integrals. The matrix elements of the Hamiltonian 
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A principal difficulty in solving the HF-LCAO equations is the large number ( 4M ) of two-
electron integrals. These integrals can involve up to four atomic centres. Therefore 
calculations for large molecules require enormous computer power. Semi-empirical 
methods reduce the computational cost by neglecting all three-centre and four-centre two-
electron integrals and the use of empirical parameters. 
 
Figure 24. A subset of the molecular orbitals from the epitope M5 is shown together with their energy 
levels. Positive values of the molecular orbitals are green encoded, negative values violet. The most 
important orbitals in organic chemistry are the highest occupied molecular orbital (HOMO: 104 A) and 
the lowest unoccupied molecular orbital (LUMO: 105 A). 
The molecular orbitals are arranged in order of increasing energy nε (Figure 24). Then the 
electrons are assigned to the orbitals beginning with the lowest energy. As a result, in a 
system with N electrons, the N/2 lowest molecular orbitals are occupied by respectively up 
to two electrons with opposite spins. The remaining M-N/2 (virtual) orbitals are unoccupied 
in the ground state and are occupied in excited electronic states (Figure 24). Physically, the 
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square of the orbitals represents the electron spatial density distribution or in other words: 
the probability for finding the electron in a certain space volume element. Because of the 
protein size, a full treatment on the quantum level is beyond the realm of the available 
computers. Therefore mixed quantum/classical (QM/MM) methods are chosen, whereby the 
GAD 65 molecule is divided into the epitopes, where a quantum description is required, and 
the rest of the molecule which is treated classically by molecular force fields (Figure 25). 
Once the molecular orbitals are known, a number of molecular properties can be calculated 
out of the molecular orbitals. The electron density is given by: 
 *n n
n
ρ(r) (r) (r)    (57) 
 
Figure 25. The electron density distribution at the residues of the epitope M5 is shown. The electron 
density in the visualisation is colour encoded according to its electrostatic potential. For large 
molecules, like GAD 65, the molecule is divided into a classical region and a quantum region. The 
epitope residues are treated by quantum mechanics and the rest of the molecule is treated classical by 
using molecular force fields. The spatial orientation of the dipole moment is shown (dotted lines). The 
surface shows electron density values of 5 308 10 /e a
 . 
It describes the distribution of the electrons in the molecule (Figure 25). The values of the 
electron density are expressed in units of 30e / a , where e is the electron charge and 0a  is the 
Bohr radius (0.5 angstrom).  
The electrostatic potential V(r) is expressed as an electrostatic potential map, showing 
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The first part of the equation results from the electrostatic potential of the atomic nuclei 
(point charge at position aR ) and the second part from the electron distribution (Figure 25). 
The values of the electrostatic field are expressed in units of 0e / a . The electrostatic field E

 
acts perpendicular on the potential surfaces. It is a measure of the force exerted between 
molecules. The electrostatic potential at the epitope location plays an important role in the 
specific antigen-antibody recognition e.g. the specific interaction of the antigen GAD 65 with 
antibodies (Figure 26). At greater distances, the charge distribution of the whole molecule is 
taken into consideration and the electrostatic potential attracts molecules in more extended 
ranges (Figure 27). The quantum mechanical calculations were done with HyperChem 
(http://www.hyper.com). 
 
Figure 26. The spatial distribution of the electrostatic potential surrounding the residues of the M5 
epitope. Negative values are red encode, positive values green. The surface shows where in 3D the 
electrostatic potential has a value of 03 8. e / a . 
 
Figure 27. The electrostatic potential surrounding the GAD 65 molecule plays an important role in the 
specific antibody recognition. The electrostatic potential map shows contours of constant values. 
Positive potential values are drawn in blue, negative values in red. Different constant electrostatic 
potential values, ranging from the neighbourhood (left) to more extended ranges (right) are shown. 
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5. Discussion 
The enzyme GAD 65 was generally considered to be strictly intracellular. But such a strictly 
intra-cytoplasmatic antigen would never have access to the immune system. With the 
ultrasensitive FCS technology, GAD 65 could be found to exist in peripheral blood of 
patients with diabetes mellitus type 1. It was measured with a sensitivity of 2.65 
microgram/ml in the sera of adult and paediatric patients. The antigen was not found in all 
the patients’ sera. The reason of the incidence is probably due to the complexed form 
(antigen-antibody complex) of GAD 65 at the time of investigation, hence hiding the antigen 
in the antibody excess. This could make it undetectable for FCS. 
To understand the procedure and development of immunization and therefore the 
occurrence of GAD 65 antibodies in the blood, it was proposed that in an initial step the 
immune system is primed by the accessibility to GAD 65. The assumption was that the 
enzyme has to be in the human serum and should be found in higher concentrations before 
the onset of the disease. FCS is a very sensitive method, but the technique requires a 
labelling of the antibodies with dyes, which is very difficult to achieve and makes the 
measurements with FCS time consuming and expensive. Furthermore, the method is very 
sensitive to disturbance, resulting from other proteins (like albumin) and free dye 
contamination. Therefore and encouraged by the relative high concentration of GAD 65 in 
the blood of patients with diabetes mellitus type 1, we used in the following an ELISA setup. 
In the ELISA setup, the antigen GAD 65 was detected, in the peripheral blood of persons 
representing a cross-section of 64 samples in a blood bank. The result from the ELISA 
experiments demonstrates that GAD 65 exists, in mostly small amounts, in the sera of the 
blood-donors. The average concentration of GAD 65, by taking all these samples into 
consideration, is 58.00 ng/ml. By assuming that the most blood-donors are healthy, it can be 
expected that GAD 65 exists in at least small concentrations in the human peripheral blood. 
(For the diabetes mellitus type 1 patients the concentrations are by factors 40-50 higher). The 
correlation analysis of the samples stored at -80°C and additionally at room temperature 
showed that the GAD 65 molecule in the sera is stable at room temperature. By determining 
the correlation between the GAD 65 concentrations, taken from samples stored at room 
temperature and taken from the same samples after a time delay of one week, it was found 
that he molecule GAD 65 is sufficiently stable in sera.  
By the use of SELDI-TOF and the study of some specimens used in the previous work with 
FCS we found some evidence for the diabetic antigen GAD 65 in a peak close to albumin. 
The albumin, produced in the liver, is the most abundant protein in human blood plasma. 
The reference range for albumin in blood is 35 to 53 mg/ml. Its concentration is therefore 
higher, by a factor above 10.000, than the expected value of GAD 65 (2.65 microgram/ml). 
The molecular weight of albumin is 66.47 kDa and therefore near the molecular weight of 
GAD (65 kDa). The weights differ only by 2.26%. Because of the tremendously higher 
concentration of albumin in the sera, a peak evaluation in regard of GAD 65 could not be 
achieved in a proper manner. Although an array with GAD 65 antibodies was used to pick 
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out the antigen of the sera, it seems that the omnipresent albumin could not be completely 
washed out, but remained partially on the chip bounded by van der Waals interactions. This 
leads to a superposition of the GAD 65 peak and the albumin peak at 65 kD , which 
complicate the proper detection of the antigen. The results of these first trials show that the 
application of SELDI-TOF for the detection of GAD 65 in human sera, in the manner 
presented here is not reliable for a routine procedure. In conclusion, the development of 
new techniques for the separation of GAD 65 from albumin is necessary for an accurate and 
reliable diction of the diabetes type 1 antigen. 
 
Figure 28. Interacting molecular surfaces. The major histocompatibility complex (MHC) protein (blue) 
I-Ag7 interacts with GAD 65.  
The source of GAD 65 in serum of normal healthy human is unknown. Numerous 
hydrophobic parts at the protein surface enable a potential interaction with the hydrophobic 
membrane lipids, leading to a reversible anchoring of the molecule to the cell membrane. 
Another source may be the normal turn-over of beta cells. To explain the mechanism of 
autoimmunization, the visualization of the GAD 65 tertiary structure, together with its 
antigenic determinants and the associated electrostatic field, is essential. Molecular 
modelling enables an imagination of the GAD 65-antibody interaction and understanding of 
antigenicity and binding sites, which is the basis for the development of an active or passive 
immunotherapy [73]. The 3-D molecular surface, derived from space filling models, 
illustrates the fitting of the GAD 65 epitopes to the paratopes of the antibodies (GADA) and 
other associated molecules (Figure 28). It enables a pictorial understanding of the interaction 
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with the antibody via complementary surfaces. Quantitative values for the GAD 65 
antigenic properties were obtained with Voronoi tessellation (dual model) by calculating the 
exposure rate of its epitopes to the surrounding solvent and the GAD antibodies. The 
electrostatic potential and details of the electronic structure of the GAD 65 epitopes were 
calculated by quantum theoretical methods. The specific antigen-antibody recognition and 
the attraction of the two molecules are done by the electrostatic fields surrounding the 
molecules. The local electrostatic field at the epitope location plays a crucial role in the 
antibody-antigen recognition.  
6. Conclusion 
Biomarkers are molecules which are associated with a particular disease, whereby he 
identification of specific biomarkers in the early stage of disease, improves the success of the 
therapy. However, a single value is not expressive for interpretation. Only the time 
progression of the biomarkers is interpretable. Due to its stability and its frequent existence 
in the human blood, it might be that GAD 65 could be a suitable candidate as biomarker for 
diabetes mellitus type 1. The results from the GAD 65 studies could also be important for 
the therapy of diabetes mellitus type 1 by passive administration of GAD 65 antibodies or 
even the application of GAD 65 for vaccination. First trials of injections with the antigen 
GAD 65 has been shown to preserve some insulin production for 30 months in humans with 
diabetes mellitus type 1. To gain more insight into the role of GAD 65 for early diagnosis 
and therapy, an additional screening of further samples, with corresponding case history, is 
planned. To use GAD 65 as a biomarker of diabetes mellitus type 1, a big longitudinal study 
will be necessary to follow children of high risk category by monitoring their GAD 65 serum 
level over time. By comparing to normal healthy subjects, a potential differentiator may be 
indentified. 
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out the antigen of the sera, it seems that the omnipresent albumin could not be completely 
washed out, but remained partially on the chip bounded by van der Waals interactions. This 
leads to a superposition of the GAD 65 peak and the albumin peak at 65 kD , which 
complicate the proper detection of the antigen. The results of these first trials show that the 
application of SELDI-TOF for the detection of GAD 65 in human sera, in the manner 
presented here is not reliable for a routine procedure. In conclusion, the development of 
new techniques for the separation of GAD 65 from albumin is necessary for an accurate and 
reliable diction of the diabetes type 1 antigen. 
 
Figure 28. Interacting molecular surfaces. The major histocompatibility complex (MHC) protein (blue) 
I-Ag7 interacts with GAD 65.  
The source of GAD 65 in serum of normal healthy human is unknown. Numerous 
hydrophobic parts at the protein surface enable a potential interaction with the hydrophobic 
membrane lipids, leading to a reversible anchoring of the molecule to the cell membrane. 
Another source may be the normal turn-over of beta cells. To explain the mechanism of 
autoimmunization, the visualization of the GAD 65 tertiary structure, together with its 
antigenic determinants and the associated electrostatic field, is essential. Molecular 
modelling enables an imagination of the GAD 65-antibody interaction and understanding of 
antigenicity and binding sites, which is the basis for the development of an active or passive 
immunotherapy [73]. The 3-D molecular surface, derived from space filling models, 
illustrates the fitting of the GAD 65 epitopes to the paratopes of the antibodies (GADA) and 
other associated molecules (Figure 28). It enables a pictorial understanding of the interaction 
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with the antibody via complementary surfaces. Quantitative values for the GAD 65 
antigenic properties were obtained with Voronoi tessellation (dual model) by calculating the 
exposure rate of its epitopes to the surrounding solvent and the GAD antibodies. The 
electrostatic potential and details of the electronic structure of the GAD 65 epitopes were 
calculated by quantum theoretical methods. The specific antigen-antibody recognition and 
the attraction of the two molecules are done by the electrostatic fields surrounding the 
molecules. The local electrostatic field at the epitope location plays a crucial role in the 
antibody-antigen recognition.  
6. Conclusion 
Biomarkers are molecules which are associated with a particular disease, whereby he 
identification of specific biomarkers in the early stage of disease, improves the success of the 
therapy. However, a single value is not expressive for interpretation. Only the time 
progression of the biomarkers is interpretable. Due to its stability and its frequent existence 
in the human blood, it might be that GAD 65 could be a suitable candidate as biomarker for 
diabetes mellitus type 1. The results from the GAD 65 studies could also be important for 
the therapy of diabetes mellitus type 1 by passive administration of GAD 65 antibodies or 
even the application of GAD 65 for vaccination. First trials of injections with the antigen 
GAD 65 has been shown to preserve some insulin production for 30 months in humans with 
diabetes mellitus type 1. To gain more insight into the role of GAD 65 for early diagnosis 
and therapy, an additional screening of further samples, with corresponding case history, is 
planned. To use GAD 65 as a biomarker of diabetes mellitus type 1, a big longitudinal study 
will be necessary to follow children of high risk category by monitoring their GAD 65 serum 
level over time. By comparing to normal healthy subjects, a potential differentiator may be 
indentified. 
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1. Introduction 
The immune system is the body’s main line of defense against invasion by infectious 
organisms, such as bacteria, virus, and fungi. In normal immune systems, an immune 
response does not occur against the self-antigen, and is called self-tolerance. Autoimmune 
diseases occur when body tissues are attacked by the body’s own immune system due to 
loss of tolerance to self-antigens (Dejaco et al., 2006). Under these conditions, body tissues 
are destroyed by antigen-specific cytotoxic T cells or auto-antibodies, and the accompanying 
inflammation can cause functional disability and morbidity. Autoimmune diseases are a 
heterogenous group of diseases with a wide spectrum of symptoms that affect 
approximately 6% of the population (Siatskas et al., 2006). They can be broadly classified as 
organ-specific or systemic depending on the location of the target antigen and clinical 
features (Sakaguchi, 2000). Common examples of systemic autoimmune diseases include 
systemic lupus erythematosus (SLE), rheumatoid arthritis, systemic sclerosis, ankylosing 
spondylitis, and polymyositis; examples of organ-specific autoimmune diseases include type 
1 diabetes, Addison’s disease, Hashimoto thyroiditis, Graves’ disease, Sjögren's syndrome, 
vitiligo, pernicious anemia, glomerulonephritis, myasthenia gravis, Goodpasture’s syndrome, 
autoimmune hemolytic anemia, idiopathic thrombocytopenia purpura, and pulmonary 
fibrosis. The clinical features of autoimmune diseases are very different, but immune-
mediated mechanisms are associated with the generation of an adaptive immune response 
toward the target antigen (Kuby, 1994; Siatskas et al., 2006).   
Conventional treatments, such as corticosteroids, cyclophosphamide, azathioprine, and 
methotrexate, are effective in some patients with autoimmune disease, but they are not 
uniformly effective and are associated with side effects and toxicity (Jantunen et al., 2000; 
Wiesik-Szewczyk et al., 2010).   
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With a better understanding of the pathophysiology of autoimmune diseases, many 
potential novel therapies focusing on cellular or molecular targets have been developed and 
evaluated (Nepom, 2002). This chapter provides a review of the pathophysiology and 
mechanisms underlying the induction of autoimmune diseases and the target sites and 
mechanisms of new therapies, and may help to understand the concept of new therapeutic 
trials that enhance or replace conventional therapies by reducing inflammatory immune 
responses and achieving immunological balance.  
2. Pathophysiology and mechanisms for the induction of autoimmune 
diseases 
The etiology of autoimmune diseases is unknown; however, autoimmune diseases may be 
caused by interplays between genetic factors, inappropriate immune regulation, and 
hormonal and environmental factors. Regarding immune regulation, lymphocytes and 
antigen-presenting cells play important roles in the generation of an effective immune 
response. Immune responses can be broadly divided into humoral and cell-mediated 
immune responses. The term “humoral” is derived from the Latin word “humor,” which 
means body fluid. The humoral immune response involves the interaction of B cells with an 
antigen and subsequent B-cell proliferation and differentiation into antibody-secreting 
plasma cells (Kuby, 1994). Apart from mediating the humoral response via antibody 
production in adaptive immunity, B cells function as antigen-presenting cells and have the 
ability to activate T cells. Furthermore, activated B cells may produce pro-inflammatory 
cytokines, which aggravate local inflammation (Mok MY, 2010). T cells regulate B-cell 
responses, and inflammatory T cells infiltrate target tissues, which can lead to tissue 
damage. Cells expressing major histocompatibility complex (MHC) class II molecules that 
can present peptides to CD4+ T helper (Th) cells are called antigen-presenting cells. Cells 
that constitutively express MHC class II molecules, such as B cells, dendritic cells, 
monocytes, macrophages, thymic dendritic cells, thymic epithelial cells, and human vascular 
endothelial cells, function as antigen-presenting cells (Kuby, 1994). However, inducible 
expression of MHC class II molecules can occur in fibroblasts, glial cells, pancreatic beta 
cells, thyroid epithelial cells, and non-human vascular endothelial cells during an 
inflammatory response (Kuby, 1994). 
In autoimmune disease, immune-mediated mechanisms are associated with the generation 
of an adaptive immune response against the target self-antigen (Siatskas et al., 2006). Many 
self-reactive lymphocytes are deleted during development or maturation, but not all self-
reactive lymphocytes are eliminated. In normal healthy individuals, the activity of mature, 
recirculating self-reactive lymphocytes are regulated by clonal anergy or clonal suppression. 
A breakdown in this regulation results in the activation of self-reactive T- or B-cell clones, 
inducing humoral or cell-mediated responses against the self-antigen.  
As described above, autoimmune diseases do not develop from a single event, but rather 
from many different events. Many mechanisms have been proposed for the induction of 
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autoimmune diseases. Some of the well-known mechanisms include release of sequestered 
antigens, molecular mimicry, inappropriate expression of MHC class II molecules, cytokine 
imbalance, dysfunction of idiotype network regulatory pathways, general regulatory T-cell 
defects, and polyclonal B-cell activation (Kuby, 1994). An overview of the “pathophysiology 
and mechanisms for the induction of autoimmune disease” is presented in Figure 1.  
 
Autoimmune diseases may be caused by interplays between genetic factors, inappropriate immune regulation, and 
hormonal and environmental factors. Immune-mediated mechanisms underlie the development of autoimmune 
diseases. (Ag: antigen, IL-2R: IL-2 receptor, Treg: regulatory T cell, MHC: major histocompatibility complex, APC: 
antigen presenting cell)  
Figure 1. Pathophysiology of autoimmune diseases  
2.1. Sequestered antigens 
Induction of tolerance in self-reactive T cells is thought to occur via exposure of immature 
lymphocytes to self-antigens during development. Thus, sequestered antigens not seen by 
the developing immune system will not induce self-tolerance. However, trauma to tissues 
following an accident or a viral or bacterial infection may release the sequestered self-
antigens into circulation, leading to auto-antibody formation on occasion (Kuby, 1994). 
Multiple sclerosis is the most common autoimmune disorder of the central nervous system 
(CNS). A study on multiple sclerosis revealed that CD8 T cells specific for protein 
sequestered in oligodendrocytes can mount a spontaneous lethal demyelinating attack on 
the CNS without help from other T- or B-cell subsets or signals from the innate immune 
system (Na et al., 2008).  
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2.2. Molecular mimicry 
A variety of bacteria and viruses possess antigenic determinants that are identical or similar 
to host cell components. This molecular mimicry between microbial antigens and host 
proteins can induce the production of activated T cells and antibodies that can cross-react 
with the host’s own cells and lead to autoimmune disease. For example, a recent study using 
bioinformatics tools revealed that some of the identified antigens have been detected in 
established autoimmune diseases associated with mycobacterial infection (Chodisetti et al., 
2012). 
2.3. Inappropriate expression of MHC class II molecules on non-antigen-
presenting cells & MHC molecules and susceptibility to autoimmune diseases 
Inappropriate MHC class II expression was first observed on thyroid cells derived from 
patients with Graves' disease (Hanafusa et al., 1983) and led to the hypothesis that such 
expression can lead to the presentation of thyroid autoantigens to T cells, thereby initiating 
an autoimmune response. Normally, MHC class II molecules are expressed only on antigen-
presenting cells. Healthy beta cells and thyroid acinar cells do not express MHC class II 
molecules. However, pancreatic beta cells in patients with type I diabetes mellitus (Bosi et 
al., 1987) and thyroid acinar cells in patients with Grave’s disease express high levels of 
MHC class II (Hanafusa et al., 1983). This inappropriate expression of MHC class II 
molecules may serve to sensitize Th cells to peptides derived from cells that inappropriately 
express MHC class II molecules, allowing activation of B cells and cytotoxic T (Tc) cells, or 
sensitization of TDTH cells against self-antigen.  
Individuals susceptible to autoimmunity must possess MHC molecules and T-cell receptors 
capable of binding self-antigens. Expression of certain MHC alleles causes susceptibility to 
autoimmune diseases, and the presence of certain domains in T-cell receptors has also been 
linked to many autoimmune diseases (Kuby, 1994). Indeed, several autoimmune diseases, 
including type I diabetes and rheumatoid arthritis, exhibit a strong association and linkage 
with specific sequence polymorphisms in MHC class II molecules (Castaño et al., 1990).  
Trauma or viral infection in an organ may induce localized inflammation. Increased levels 
of interferon (IFN)-γ can induce the expression of MHC class II molecules on a wide variety 
of non-antigen-presenting cells, thereby causing autoimmune disease (Todd et al., 1985). 
Further, the combination of IFN-γ with tumor necrosis factor (TNF)-α or interleukin (IL)-1β 
increases the expression of class I and II antigens in human thyroid follicular cells, 
compared with the effect of IFN-γ alone (Migita et al., 1990).  
2.4. Cytokine imbalance 
CD4+ Th cells can be subdivided into Th1, Th2, Th17, and regulatory T cells, on the basis of 
the cytokines they produce and the functions they perform (Cooke, 2006). Th1-type cytokines 
tend to produce the pro-inflammatory responses responsible for killing intracellular parasites 
such as viruses and certain bacteria, perpetuating autoimmune responses, and causing cell-
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mediated allergies. Preferential activation of Th1 cells plays a central role in the pathogenesis 
of many autoimmune diseases, including type 1 diabetes mellitus, multiple sclerosis, and 
rheumatoid arthritis (Emamaullee et al., 2009). The primary cytokines secreted from Th1 cells 
include IL-2, IFN-γ, and TNF-β. Overproduction of these cytokines from activated Th1 cells 
can induce excessive B-cell activation and autoantibody production (Kuby, 1994). In contrast, 
induction of Th2 populations results in a dominant protective effect against autoimmunity 
(Suarez-Pinzon and Rabinovitch, 2001; Sia, 2005). Th2-type cytokines include IL-4, IL-5, and 
IL-13, which are associated with the promotion of allergic responses, and IL-10, which 
produces anti-inflammatory responses. In fact, autoimmune diseases can be ameliorated by a 
reduced Th1 response or a shift toward Th2 responses in some cases, but there are exceptions.  
Th17 occurs at the sites of interaction between the internal and external environments of the 
body. Important cytokines of Th17 include IL-17, IL-12, and IL-23. IL-17 is a potent pro-
inflammatory cytokine that elicits the production of other inflammatory cytokines and 
chemokines such as TNF-α, IL-1ß, IL-6, IL-8, GM-CSF, and MCP-1 by endothelial cells, 
epithelial cells, and other cell types such as fibroblasts, keratinocytes, synoviocytes, and 
macrophages (Waite and Skokos, 2012). Thus, IL-17 can amplify ongoing inflammation. IL-
17 levels were elevated in many inflammatory autoimmune diseases, including systemic 
sclerosis, psoriasis, and rheumatoid arthritis (Chabaud et al., 1999). Furthermore, several 
autoimmune conditions that were previously assumed to be mediated by Th1 have now 
been shown to involve Th17 cells (Cooke, 2006). 
2.5. General regulatory T cell defects 
The CD4+ regulatory T cell subsets include IL-10–producing T regulatory cell type 1 (Tr1), 
transforming growth factor (TGF)-β–secreting T helper cell type 3 (Th3), and a 
subpopulation of naturally occurring regulatory T cells that express high levels of CD25 and 
the forkhead box P3 (FoxP3) (Dejaco et al., 2005). Lack of regulatory T cells that express CD4, 
CD25, and FoxP3 induces severe autoimmunity in both mice and humans (Buckner, 2010). 
General regulatory T-cell defects cause hyperactivity of both B and T cells. Thus, restoration 
of regulatory T cells can reverse autoimmunity. Studies on the functional assays revealed 
that regulatory T cells play a crucial role in the modulation of local immune responses (de 
kleer et al., 2004). Altered generation of regulatory T cells and insufficient suppression of 
inflammation are considered pivotal for the initiation and perpetuation of autoimmune 
diseases because imbalance between pro-inflammatory and regulatory T cells can lead to the 
breakdown of self-tolerance (Dejaco et al., 2005). In fact, reduced levels of circulating 
CD4+CD25high T cells were observed in patients with juvenile idiopathic arthritis (de kleer 
et al., 2004). Further, lower levels of circulating CD4+CD25high T cells also correlate with 
higher disease activity or poorer prognosis (de kleer et al., 2004). 
2.6. Dysfunction of the idiotype network regulatory pathways  
Production of anti-idiotype antibodies against self-proteins can contribute to autoimmune 
disease. For example, in Grave’s disease, antibodies produced against the thyroid-
stimulating hormone (TSH) receptor bind to the receptor and inappropriately stimulate the 
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17 levels were elevated in many inflammatory autoimmune diseases, including systemic 
sclerosis, psoriasis, and rheumatoid arthritis (Chabaud et al., 1999). Furthermore, several 
autoimmune conditions that were previously assumed to be mediated by Th1 have now 
been shown to involve Th17 cells (Cooke, 2006). 
2.5. General regulatory T cell defects 
The CD4+ regulatory T cell subsets include IL-10–producing T regulatory cell type 1 (Tr1), 
transforming growth factor (TGF)-β–secreting T helper cell type 3 (Th3), and a 
subpopulation of naturally occurring regulatory T cells that express high levels of CD25 and 
the forkhead box P3 (FoxP3) (Dejaco et al., 2005). Lack of regulatory T cells that express CD4, 
CD25, and FoxP3 induces severe autoimmunity in both mice and humans (Buckner, 2010). 
General regulatory T-cell defects cause hyperactivity of both B and T cells. Thus, restoration 
of regulatory T cells can reverse autoimmunity. Studies on the functional assays revealed 
that regulatory T cells play a crucial role in the modulation of local immune responses (de 
kleer et al., 2004). Altered generation of regulatory T cells and insufficient suppression of 
inflammation are considered pivotal for the initiation and perpetuation of autoimmune 
diseases because imbalance between pro-inflammatory and regulatory T cells can lead to the 
breakdown of self-tolerance (Dejaco et al., 2005). In fact, reduced levels of circulating 
CD4+CD25high T cells were observed in patients with juvenile idiopathic arthritis (de kleer 
et al., 2004). Further, lower levels of circulating CD4+CD25high T cells also correlate with 
higher disease activity or poorer prognosis (de kleer et al., 2004). 
2.6. Dysfunction of the idiotype network regulatory pathways  
Production of anti-idiotype antibodies against self-proteins can contribute to autoimmune 
disease. For example, in Grave’s disease, antibodies produced against the thyroid-
stimulating hormone (TSH) receptor bind to the receptor and inappropriately stimulate the 
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thyroid. Antibodies against the “TSH-specific antibody” (anti-idiotype antibody) can 
stimulate the TSH receptor. Anti-idiotype antibodies were found in patients with 
myasthenia gravis (Dwyer et al., 1983) and a patient with Grave’s disease (Kuby, 1994).  
2.7. Polyclonal B-cell activation 
Many bacteria and viruses, such as gram-negative bacteria, cytomegalovirus, and Epstein-
Barr virus, can induce nonspecific polyclonal B-cell activation without the help of Th cells. 
Lipopolysaccharide from gram-negative bacteria is sufficient to induce autoimmune disease 
in an immunologically normal host, suggesting that polyclonal B-cell activation plays a 
central role in the pathogenesis of systemic autoimmune diseases (Granholm, 1992). Indeed, 
autoimmune diseases can be arrested by suppressing excessive polyclonal B-cell activation, 
and autoimmune diseases can be exacerbated by enhancing polyclonal B-cell activation.   
3. Strategies to influence specific immune cells and molecules such as co-
stimulatory molecules, cytokines, and chemokines 
The immunity-related strategy for treating autoimmune diseases is to arrest ongoing 
inflammatory responses, prevent the adaptive memory response, and achieve antigen-
specific immunomodulation (Nepom GT, 2002). During the past several decades, strategies 
using agents that influence cytokines, hyperactivity of B cells, and B cell-T cell interaction 
have proven to be effective and safe therapies for autoimmune disease (Lacki JK, 2000). 
Overviews of the “Generation of adaptive immune response against the target self-antigen” 
and “Target sites of new therapies influencing specific immune cells, molecules, cytokines, 
and chemokines” are presented in Figure 2.  
3.1. B-cell-based therapy  
Strategies targeting B cells include B-cell depletion therapies, anti-cytokine therapies, B-cell 
tolerogens, and inhibition of co-stimulatory molecules (Mok MY, 2010).  
Potential targets for B-cell therapy include cell surface molecules and co-stimulatory 
molecules, such as CD20, CD22, B220, MHC class II molecules, CD35 (CR1), CD21 (CR2), 
CD32 (FcγRII), CD80 (B7-1), CD86 (B7-2), and CD40.  
3.1.1. B-cell depletion therapies  
CD20 is a B-cell-restricted surface molecule and an activated-glycosylated phosphoprotein 
that is expressed from pre-B to memory B cells (Mok MY, 2010). Anti-CD20 antibody (Ab) 
treatment results in B-cell depletion via antibody-dependent cell-mediated cytotoxicity, 
complement-mediated lysis, and stimulation of apoptosis (Pescovitz, 2006). Anti-CD20 Ab 
treatment was administered for B-cell depletion in human SLE (Anolik et al., 2007, Smith et 
al., 2006), autoimmune hemolytic anemia (Quartier et al., 2001; Perrotta et al., 2002), and 
rheumatoid arthritis (Furst et al., 2007). Clinical trials for SLE proved that anti-CD20 Ab 
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treatment has beneficial effects only on B-cell-driven SLE because beneficial effects were 
seen only in the African American and Hispanic subgroups, which are refractory to 
standard treatment and are more B-cell dependent (Isenberg et al., 2008). The main 
complication relating to anti-CD20 Ab treatment is an increased rate of serious infection, 
which terminated the clinical trials (Hutas et al., 2008).  
  
In autoimmune diseases, an adaptive immune response is mounted against the target self-antigen. The target sites of 
the new therapies are shown.  
3.1.1 B-cell depletion therapies  
3.1.2 B-cell-related anti-cytokine therapies 
3.1.3 Therapy using B-cell tolerogens  
3.2.1 Therapies targeting T-cell surface molecules 
3.2.2 Therapies targeting T-cell pathways related to trafficking and co-stimulation  
3.2.3 T-cell vaccination 
3.2.4 Therapies targeting MHC molecules or antigen-presenting cells in the first signal  
3.2.5 Therapies targeting antigens in the first signal  
3.2.6 Therapy using T-cell tolerogens 
3.3 Therapy targeting B cell-T cell interaction (inhibition of co-stimulatory molecules) 
3.4 Anti-cytokine therapy (prevention of ongoing inflammatory responses)  
(APC: antigen presenting cell, Tc: cytotoxic T cell, TCR: T cell receptor, MHC: major histocompatibility complex, Ag: 
antigen, LFA: lymphocyte function-associated antigen, CD: cluster of differentiation, VLA: very late antigen, ICAM: 
intercellular adhesion molecule, TACI: transmembrane activator and calcium modulator and cyclophilin ligand interactor, 
BCMA: B-cell maturation antigen, BAFF-R: B-cell-activating factor receptor, BLys: B-lymphocyte stimulator, IFN: 
interferon, IL: interleukin, GM-CSF: granulocyte-macrophage colony-stimulating factor, TNF: tumor necrosis factor) 
Figure 2. Target sites of new therapies influencing specific immune cells, molecules, cytokines, and 
chemokines 
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thyroid. Antibodies against the “TSH-specific antibody” (anti-idiotype antibody) can 
stimulate the TSH receptor. Anti-idiotype antibodies were found in patients with 
myasthenia gravis (Dwyer et al., 1983) and a patient with Grave’s disease (Kuby, 1994).  
2.7. Polyclonal B-cell activation 
Many bacteria and viruses, such as gram-negative bacteria, cytomegalovirus, and Epstein-
Barr virus, can induce nonspecific polyclonal B-cell activation without the help of Th cells. 
Lipopolysaccharide from gram-negative bacteria is sufficient to induce autoimmune disease 
in an immunologically normal host, suggesting that polyclonal B-cell activation plays a 
central role in the pathogenesis of systemic autoimmune diseases (Granholm, 1992). Indeed, 
autoimmune diseases can be arrested by suppressing excessive polyclonal B-cell activation, 
and autoimmune diseases can be exacerbated by enhancing polyclonal B-cell activation.   
3. Strategies to influence specific immune cells and molecules such as co-
stimulatory molecules, cytokines, and chemokines 
The immunity-related strategy for treating autoimmune diseases is to arrest ongoing 
inflammatory responses, prevent the adaptive memory response, and achieve antigen-
specific immunomodulation (Nepom GT, 2002). During the past several decades, strategies 
using agents that influence cytokines, hyperactivity of B cells, and B cell-T cell interaction 
have proven to be effective and safe therapies for autoimmune disease (Lacki JK, 2000). 
Overviews of the “Generation of adaptive immune response against the target self-antigen” 
and “Target sites of new therapies influencing specific immune cells, molecules, cytokines, 
and chemokines” are presented in Figure 2.  
3.1. B-cell-based therapy  
Strategies targeting B cells include B-cell depletion therapies, anti-cytokine therapies, B-cell 
tolerogens, and inhibition of co-stimulatory molecules (Mok MY, 2010).  
Potential targets for B-cell therapy include cell surface molecules and co-stimulatory 
molecules, such as CD20, CD22, B220, MHC class II molecules, CD35 (CR1), CD21 (CR2), 
CD32 (FcγRII), CD80 (B7-1), CD86 (B7-2), and CD40.  
3.1.1. B-cell depletion therapies  
CD20 is a B-cell-restricted surface molecule and an activated-glycosylated phosphoprotein 
that is expressed from pre-B to memory B cells (Mok MY, 2010). Anti-CD20 antibody (Ab) 
treatment results in B-cell depletion via antibody-dependent cell-mediated cytotoxicity, 
complement-mediated lysis, and stimulation of apoptosis (Pescovitz, 2006). Anti-CD20 Ab 
treatment was administered for B-cell depletion in human SLE (Anolik et al., 2007, Smith et 
al., 2006), autoimmune hemolytic anemia (Quartier et al., 2001; Perrotta et al., 2002), and 
rheumatoid arthritis (Furst et al., 2007). Clinical trials for SLE proved that anti-CD20 Ab 
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treatment has beneficial effects only on B-cell-driven SLE because beneficial effects were 
seen only in the African American and Hispanic subgroups, which are refractory to 
standard treatment and are more B-cell dependent (Isenberg et al., 2008). The main 
complication relating to anti-CD20 Ab treatment is an increased rate of serious infection, 
which terminated the clinical trials (Hutas et al., 2008).  
  
In autoimmune diseases, an adaptive immune response is mounted against the target self-antigen. The target sites of 
the new therapies are shown.  
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3.2.6 Therapy using T-cell tolerogens 
3.3 Therapy targeting B cell-T cell interaction (inhibition of co-stimulatory molecules) 
3.4 Anti-cytokine therapy (prevention of ongoing inflammatory responses)  
(APC: antigen presenting cell, Tc: cytotoxic T cell, TCR: T cell receptor, MHC: major histocompatibility complex, Ag: 
antigen, LFA: lymphocyte function-associated antigen, CD: cluster of differentiation, VLA: very late antigen, ICAM: 
intercellular adhesion molecule, TACI: transmembrane activator and calcium modulator and cyclophilin ligand interactor, 
BCMA: B-cell maturation antigen, BAFF-R: B-cell-activating factor receptor, BLys: B-lymphocyte stimulator, IFN: 
interferon, IL: interleukin, GM-CSF: granulocyte-macrophage colony-stimulating factor, TNF: tumor necrosis factor) 
Figure 2. Target sites of new therapies influencing specific immune cells, molecules, cytokines, and 
chemokines 
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CD22 is a B-cell surface glycoprotein and a specific adhesion molecule that regulates antigen 
receptor signaling, B-cell activation, and interaction with T cells (Tedder et al., 1997). Anti-
CD22 Ab treatment was tested in 14 SLE patients in an open-labeled study. No reduction in 
ANA or anti-dsDNA antibodies (Abs) was observed, but induction of B-cell modulation and 
evidence of clinical improvement were seen (Dörner et al., 2006; Carnahan et al., 2007). The 
action of anti-CD22 Abs is achieved by antibody-dependent cell cytotoxicity and induction 
of signal transduction via downmodulation of B-cell receptor signaling (Carnahan et al., 
2007).  
3.1.2. B-cell-related anti-cytokine therapies 
The B-lymphocyte stimulator (BLys), also called B-cell-activating factor (BAFF), is important 
in B-cell immunity (Moore et al., 1999). BLys is a TNF family ligand expressed on the cells of 
myeloid origin, such as monocytes, macrophages, and dendritic cells, and can bind to 3 
membrane receptors on B cells, including transmembrane activator and calcium modulator 
and cyclophilin ligand interactor (TACI), B-cell maturation antigen (BCMA), and BAFF 
receptor (BAFF-R). Anti-BLys Ab treatment decreased CD20+ B cells, reduced anti-dsDNA 
Abs and disease flares, and stabilized SLE, in particular, in serologically active SLE patients 
(Wallace et al., 2009; Wiglesworth et al., 2010).   
Treatment with BAFF-R linked to the Fc domain of human IgG1 ameliorated murine SLE, 
judging from the decrease in anti-dsDNA Abs and proteinuria and the improvement in 
glomerular lesions (Kayagaki et al., 2002).  
TACI-IgG can inhibit BLys and a proliferation-inducing ligand (APRIL), and TACI-IgG 
treatment decreased proteinuria and prolonged survival in murine lupus (Gross et al., 2000).  
3.1.3. Therapy using B-cell tolerogens  
Abetimus sodium is a synthetic compound of 4 deoxynucleotide sequences bound to a 
triethylene glycol backbone that can bind to anti-dsDNA Abs and crosslink B-cell receptors 
that recognize dsDNA. Thus, treatment with abetimus sodium induces deletion or anergy of 
anti-dsDNA Ab-producing B cells. Abetimus sodium was used as a B-cell tolerogen in SLE 
patients with lupus nephritis and it exhibited potential efficacy in some SLE patients with 
elevated anti-dsDNA Abs. However, a phase IV trial was prematurely terminated because 
of lack of clinical efficacy (Wiesik-Szewczyk et al., 2010).  
3.2. T-cell-based therapy and therapies targeting the first signal  
3.2.1. Therapies targeting T-cell surface molecules 
Monoclonal antibodies to T-cell surface molecules (CD3, CD4, and CD52) have been effectively 
used in clinical efficacy trials for autoimmune diseases, but all of them were associated with 
transient depression of circulating T cells. For example, treatment of New Zealand black × 
New Zealand white (NZB/W) F1 and the autoimmune disease-prone non-obese diabetic 
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(NOD) mice with anti-CD4 Abs blocked nonspecific overall immune responses (Phillips et al., 
2000). A clinical trial using anti-CD52 Abs revealed that profound lymphopenia, with recovery 
B cells and CD8+ cells and longer lasting CD4 cytopenia can occur (Willis et al., 2001). A 
monoclonal antibody directed against the α subunit of the high-affinity IL-2 receptor can more 
specifically block autoreactive Th cells in autoimmunity, because only activated Th cells 
express the high affinity IL-2R α subunit, CD25. Therapy with a monoclonal antibody to the 
IL-2 receptor CD25 led to downregulation of the receptor without depleting T cells. Egan et al. 
(2001) and Haufs and Haneke’s (2001) studies showed the efficacy of anti-CD25 Abs in 
epidermolysis bullosa acquista. In a study on multiple sclerosis, maintenance therapy with 
anti-CD25 Abs reduced the frequency of CD4+CD25+ regulatory T cells, but inflammatory 
activity in multiple sclerosis was substantially reduced with anti-CD25 Ab treatment despite 
reduction of circulating regulatory T cells (Oh et al., 2009).  
3.2.2. Therapies targeting T-cell pathways related to trafficking and co-stimulation  
Lymphocyte function-associated antigen-3 (LFA-3, CD58) is a cell-bound immunoglobulin 
superfamily receptor with only one known ligand, namely, CD2 (Springer et al., 1987). LFA-
3 is widely expressed on human hematopoietic and non-hematopoietic tissues, leukocytes, 
erythrocytes, endothelial and epithelial cells, and fibroblasts. The engagement of LFA-3 with 
CD2 optimizes immune recognition and initiates T-cell expansion and activation. These 
contact activities can occur between helper T cells and antigen-presenting cells and cytolytic 
effectors and target cells. The soluble LFA3/IgG1 fusion protein binds CD2 on T cells and Fc 
receptor on natural killer cells, macrophages, neutrophils, and mast cells. Thus, the soluble 
LFA3/IgG1 fusion protein can inhibit immune recognition as well as T-cell expansion and 
activation. 
LFA-1 is found on all T-cells and also on B-cells, macrophages and neutrophils and is 
involved in recruitment to the site of infection. It binds to ICAM-1 on antigen-presenting 
cells and functions as an adhesion molecule. Anti-LFA1 Ab treatment elicited an 
improvement in psoriasis (Papp et al., 2001; Tutrone et al., 2001). 
Very late antigen-4 (VLA-4) is an integrin dimer composed of CD49d (alpha) and CD29 
(beta). VCAM-1 (integrin receptor) binds to VLA-4 normally expressed on leukocyte plasma 
membrane, but does not adhere to the appropriate ligands until the leukocytes are activated 
by chemotactic agents or other stimuli. Treatment with the anti-α4 integrin Abs (VLA-4 
Abs), which targets T-cell trafficking pathways, also showed clinical benefit in Crohn’s 
disease and multiple sclerosis (Tubridy et al., 1999; Gordon et al., 2001).  
3.2.3. T-cell vaccination 
Cross-linked T cells apparently elicit regulatory T cells specific to T-cell receptor variable 
region determinants of the autoimmune clones, and it has been shown that a synthetic T-cell 
receptor variable region peptide can function as a vaccine and an effective therapy (Kuby, 
1994). For example, treatment with the IR501 therapeutic vaccine, which consists of a 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 260 
CD22 is a B-cell surface glycoprotein and a specific adhesion molecule that regulates antigen 
receptor signaling, B-cell activation, and interaction with T cells (Tedder et al., 1997). Anti-
CD22 Ab treatment was tested in 14 SLE patients in an open-labeled study. No reduction in 
ANA or anti-dsDNA antibodies (Abs) was observed, but induction of B-cell modulation and 
evidence of clinical improvement were seen (Dörner et al., 2006; Carnahan et al., 2007). The 
action of anti-CD22 Abs is achieved by antibody-dependent cell cytotoxicity and induction 
of signal transduction via downmodulation of B-cell receptor signaling (Carnahan et al., 
2007).  
3.1.2. B-cell-related anti-cytokine therapies 
The B-lymphocyte stimulator (BLys), also called B-cell-activating factor (BAFF), is important 
in B-cell immunity (Moore et al., 1999). BLys is a TNF family ligand expressed on the cells of 
myeloid origin, such as monocytes, macrophages, and dendritic cells, and can bind to 3 
membrane receptors on B cells, including transmembrane activator and calcium modulator 
and cyclophilin ligand interactor (TACI), B-cell maturation antigen (BCMA), and BAFF 
receptor (BAFF-R). Anti-BLys Ab treatment decreased CD20+ B cells, reduced anti-dsDNA 
Abs and disease flares, and stabilized SLE, in particular, in serologically active SLE patients 
(Wallace et al., 2009; Wiglesworth et al., 2010).   
Treatment with BAFF-R linked to the Fc domain of human IgG1 ameliorated murine SLE, 
judging from the decrease in anti-dsDNA Abs and proteinuria and the improvement in 
glomerular lesions (Kayagaki et al., 2002).  
TACI-IgG can inhibit BLys and a proliferation-inducing ligand (APRIL), and TACI-IgG 
treatment decreased proteinuria and prolonged survival in murine lupus (Gross et al., 2000).  
3.1.3. Therapy using B-cell tolerogens  
Abetimus sodium is a synthetic compound of 4 deoxynucleotide sequences bound to a 
triethylene glycol backbone that can bind to anti-dsDNA Abs and crosslink B-cell receptors 
that recognize dsDNA. Thus, treatment with abetimus sodium induces deletion or anergy of 
anti-dsDNA Ab-producing B cells. Abetimus sodium was used as a B-cell tolerogen in SLE 
patients with lupus nephritis and it exhibited potential efficacy in some SLE patients with 
elevated anti-dsDNA Abs. However, a phase IV trial was prematurely terminated because 
of lack of clinical efficacy (Wiesik-Szewczyk et al., 2010).  
3.2. T-cell-based therapy and therapies targeting the first signal  
3.2.1. Therapies targeting T-cell surface molecules 
Monoclonal antibodies to T-cell surface molecules (CD3, CD4, and CD52) have been effectively 
used in clinical efficacy trials for autoimmune diseases, but all of them were associated with 
transient depression of circulating T cells. For example, treatment of New Zealand black × 
New Zealand white (NZB/W) F1 and the autoimmune disease-prone non-obese diabetic 
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(NOD) mice with anti-CD4 Abs blocked nonspecific overall immune responses (Phillips et al., 
2000). A clinical trial using anti-CD52 Abs revealed that profound lymphopenia, with recovery 
B cells and CD8+ cells and longer lasting CD4 cytopenia can occur (Willis et al., 2001). A 
monoclonal antibody directed against the α subunit of the high-affinity IL-2 receptor can more 
specifically block autoreactive Th cells in autoimmunity, because only activated Th cells 
express the high affinity IL-2R α subunit, CD25. Therapy with a monoclonal antibody to the 
IL-2 receptor CD25 led to downregulation of the receptor without depleting T cells. Egan et al. 
(2001) and Haufs and Haneke’s (2001) studies showed the efficacy of anti-CD25 Abs in 
epidermolysis bullosa acquista. In a study on multiple sclerosis, maintenance therapy with 
anti-CD25 Abs reduced the frequency of CD4+CD25+ regulatory T cells, but inflammatory 
activity in multiple sclerosis was substantially reduced with anti-CD25 Ab treatment despite 
reduction of circulating regulatory T cells (Oh et al., 2009).  
3.2.2. Therapies targeting T-cell pathways related to trafficking and co-stimulation  
Lymphocyte function-associated antigen-3 (LFA-3, CD58) is a cell-bound immunoglobulin 
superfamily receptor with only one known ligand, namely, CD2 (Springer et al., 1987). LFA-
3 is widely expressed on human hematopoietic and non-hematopoietic tissues, leukocytes, 
erythrocytes, endothelial and epithelial cells, and fibroblasts. The engagement of LFA-3 with 
CD2 optimizes immune recognition and initiates T-cell expansion and activation. These 
contact activities can occur between helper T cells and antigen-presenting cells and cytolytic 
effectors and target cells. The soluble LFA3/IgG1 fusion protein binds CD2 on T cells and Fc 
receptor on natural killer cells, macrophages, neutrophils, and mast cells. Thus, the soluble 
LFA3/IgG1 fusion protein can inhibit immune recognition as well as T-cell expansion and 
activation. 
LFA-1 is found on all T-cells and also on B-cells, macrophages and neutrophils and is 
involved in recruitment to the site of infection. It binds to ICAM-1 on antigen-presenting 
cells and functions as an adhesion molecule. Anti-LFA1 Ab treatment elicited an 
improvement in psoriasis (Papp et al., 2001; Tutrone et al., 2001). 
Very late antigen-4 (VLA-4) is an integrin dimer composed of CD49d (alpha) and CD29 
(beta). VCAM-1 (integrin receptor) binds to VLA-4 normally expressed on leukocyte plasma 
membrane, but does not adhere to the appropriate ligands until the leukocytes are activated 
by chemotactic agents or other stimuli. Treatment with the anti-α4 integrin Abs (VLA-4 
Abs), which targets T-cell trafficking pathways, also showed clinical benefit in Crohn’s 
disease and multiple sclerosis (Tubridy et al., 1999; Gordon et al., 2001).  
3.2.3. T-cell vaccination 
Cross-linked T cells apparently elicit regulatory T cells specific to T-cell receptor variable 
region determinants of the autoimmune clones, and it has been shown that a synthetic T-cell 
receptor variable region peptide can function as a vaccine and an effective therapy (Kuby, 
1994). For example, treatment with the IR501 therapeutic vaccine, which consists of a 
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combination of 3 peptides derived from T cell receptors (Vβ3, Vβ14, and Vβ17) in Freund’s 
incomplete adjuvant, was safe and well tolerated, and showed clinical improvement in 
rheumatoid arthritis patients (Moreland et al., 1998).  
3.2.4. Therapies targeting MHC molecules or antigen-presenting cells in the first signal  
Expression of certain MHC alleles causes susceptibility to autoimmune diseases. Thus, 
selective inhibition of MHC molecules, which are associated with autoimmunity, by using 
monoclonal antibodies can delay and ameliorate autoimmune diseases (Kuby, 1994). For 
example, treatment with anti-MHC class II monoclonal Abs (monoclonal Abs to the murine 
I-E equivalent) prevented thyroidal and pancreatic autoimmunity in BioBreeding/Worcester 
(BB/W) rats (Boitard et al., 1985). Treatment of anti-I-A monoclonal Abs ameliorated many 
autoimmune diseases in animal models including lupus nephritis (NZB/W F1) (Adelman et 
al., 1983), experimental autoimmune uveoretinitis (Rao et al., 1989), and experimental 
autoimmune myasthenia gravis (Waldor et al., 1983). Engineered antigen-presenting cells 
have also been used for immunomodulation and tolerance induction. For example, FasL-
expressing antigen-presenting cells that specifically interact with Fas molecules on the 
surface of lymphocytes induce lymphocyte apoptosis (Zhang et al., 1999).  
3.2.5. Therapies targeting antigens in the first signal  
Oral presentation of T-cell-dependent antigens can lead to immunity or tolerance depending 
on the form of the antigen, dose, and number of feedings (Tomasi, 1980, Titus and Chiller, 
1981). Thus, parenteral administration of antigens or antigen analogs was evaluated as 
immunotherapy for autoimmune diseases. Myelin basic protein (MBP)-specific T cells and 
symptoms of multiple sclerosis were reduced in myelin-fed, HLA-DR2-negative patients 
(Weiner et al., 1993). Mice fed MBP do not develop experimental autoimmune 
encephalomyelitis (experimental allergic encephalomyelitis, EAE) following subsequent 
injection of MBP (Kuby, 1994). Type II collagen-induced arthritis is an animal model of 
polyarthritis induced in susceptible mice and rats by immunization with type II collagen, a 
major component of cartilage. Intragastric administration of soluble type II collagen, prior to 
immunization with type II collagen in adjuvant, suppressed the incidence of collagen-
induced arthritis (Nagler-Anderson C, 1986; Trentham et al., 1993).  
A synthetic polypeptide comprising a random mixture of alanine, glutamate, lysine, and 
tyrosine, which can bind MHC and elicit T-cell recognition, acts as an altered antigen ligand. 
Treatment using this synthetic polypeptide showed beneficial effects on multiple sclerosis 
(Fusco C, 2001).  
3.2.6. Therapy using T-cell tolerogens 
hCDR1 (TV-4710, Edratide) is a peptide derived from the immunoglobulin Vh region of 
human anti-dsDNA Abs. Treatment with hCDR1 as a T-cell tolerogen induced regulatory T 
cells and reduced proteinuria and immune complexes in the kidneys of SLE patients. In this 
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study on gene expression in peripheral blood mononuclear cells from SLE patients, 
treatment using hCDR1 increased in vivo gene expression of TGF-, FoxP3 and the anti 
apoptotic molecule Bcl-xL, but significantly decreased the gene expression of IL-1, TNF-, 
IFN-, IL-10, BLyS, caspase-3, and caspase-8. hCDR1 treatment also markedly decreased 
disease activity (Sthoeger et al., 2009).   
3.3. Therapy targeting B cell-T cell interaction (inhibition of co-stimulatory 
molecules) 
T-cell activation requires 2 signals and cytokines. The first signal is mediated via binding of 
the T-cell receptor to the antigen presented with MHC molecules on antigen-presenting 
cells. However, the first signal alone is not sufficient; a second co-stimulatory signal is also 
required. Thus, co-stimulation is important not only for normal immunity, but also for the 
pathogenesis of autoimmunity. Therapies targeting the 2 main co-stimulatory pathways B7-
CD28 and CD40-CD40L have been evaluated. Anti-CD40L Ab treatment reduced 
inflammation, vasculitis, and fibrosis in the kidney and increased survival in a murine lupus 
model, the SNF1 mouse (Kalled et al, 1998). Anti-CD40L Ab treatment also elicited clinical 
improvements such as decrease in anti-dsDNA Abs and hematuria and increase in C3 in 
some SLE patients. However, thromboembolism complications prevented continuation of 
the phase II study (Mok et al., 2010). CTLA4Ig is a fusion protein comprising the 
extracellular domain of CTLA4 and the constant region of immunoglobulin. CTLA4Ig 
competes with CD28 for binding to B7 thereby inhibiting the B7-CD28 co-stimulatory signal. 
CTLA4Ig treatment elicited improvements in murine SLE, judging from the decrease in 
proteinuria and increase in survival (Finck et al., 1994). CTLA4Ig gene therapy also had 
beneficial effects on canine SLE (Choi et al., 2005) and canine experimental autoimmune 
thyroiditis (Choi et al., 2008). A phase III clinical trial using CTLA4Ig in human SLE is 
currently underway (Mok, 2010).  
3.4. Anti-cytokine therapy (prevention of ongoing inflammatory responses) 
Inhibitors of inflammatory cytokines, such as a decoy receptor for inflammatory cytokines, 
have produced promising results in animal models of autoimmune diseases.  
TNF-α is an inflammatory cytokine produced by various cells such as monocytes, 
macrophages, T cells, and B cells. TNF-α stimulates the production of other cytokines such 
as IL-1, IL-6, IL-8, and GM-CSF. To prevent ongoing inflammatory responses, TNF-blocking 
agents were administered in patients with psoriasis, rheumatoid arthritis, or Crohn’s 
disease, and were shown to be efficacious (Chaudhari et al., 2001; Keating and Perry, 2002). 
However, ANA and anti-dsDNA Abs were observed in some rheumatoid arthritis or 
Crohn’s disease patients treated with TNF-blocking agents (De Bandt et al., 2005; Mohan et 
al., 2002). TNF-blocking agents were ineffective in multiple sclerosis (Skurkovish et al., 
2001). The diseases frequently recurred after discontinuation of TNF-blocking agent therapy. 
Further, Furst et al. recommend that caution should be exercised when using TNF-blocking 
agents. According to them, TNF-blocking agents should not be initiated or should be 
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combination of 3 peptides derived from T cell receptors (Vβ3, Vβ14, and Vβ17) in Freund’s 
incomplete adjuvant, was safe and well tolerated, and showed clinical improvement in 
rheumatoid arthritis patients (Moreland et al., 1998).  
3.2.4. Therapies targeting MHC molecules or antigen-presenting cells in the first signal  
Expression of certain MHC alleles causes susceptibility to autoimmune diseases. Thus, 
selective inhibition of MHC molecules, which are associated with autoimmunity, by using 
monoclonal antibodies can delay and ameliorate autoimmune diseases (Kuby, 1994). For 
example, treatment with anti-MHC class II monoclonal Abs (monoclonal Abs to the murine 
I-E equivalent) prevented thyroidal and pancreatic autoimmunity in BioBreeding/Worcester 
(BB/W) rats (Boitard et al., 1985). Treatment of anti-I-A monoclonal Abs ameliorated many 
autoimmune diseases in animal models including lupus nephritis (NZB/W F1) (Adelman et 
al., 1983), experimental autoimmune uveoretinitis (Rao et al., 1989), and experimental 
autoimmune myasthenia gravis (Waldor et al., 1983). Engineered antigen-presenting cells 
have also been used for immunomodulation and tolerance induction. For example, FasL-
expressing antigen-presenting cells that specifically interact with Fas molecules on the 
surface of lymphocytes induce lymphocyte apoptosis (Zhang et al., 1999).  
3.2.5. Therapies targeting antigens in the first signal  
Oral presentation of T-cell-dependent antigens can lead to immunity or tolerance depending 
on the form of the antigen, dose, and number of feedings (Tomasi, 1980, Titus and Chiller, 
1981). Thus, parenteral administration of antigens or antigen analogs was evaluated as 
immunotherapy for autoimmune diseases. Myelin basic protein (MBP)-specific T cells and 
symptoms of multiple sclerosis were reduced in myelin-fed, HLA-DR2-negative patients 
(Weiner et al., 1993). Mice fed MBP do not develop experimental autoimmune 
encephalomyelitis (experimental allergic encephalomyelitis, EAE) following subsequent 
injection of MBP (Kuby, 1994). Type II collagen-induced arthritis is an animal model of 
polyarthritis induced in susceptible mice and rats by immunization with type II collagen, a 
major component of cartilage. Intragastric administration of soluble type II collagen, prior to 
immunization with type II collagen in adjuvant, suppressed the incidence of collagen-
induced arthritis (Nagler-Anderson C, 1986; Trentham et al., 1993).  
A synthetic polypeptide comprising a random mixture of alanine, glutamate, lysine, and 
tyrosine, which can bind MHC and elicit T-cell recognition, acts as an altered antigen ligand. 
Treatment using this synthetic polypeptide showed beneficial effects on multiple sclerosis 
(Fusco C, 2001).  
3.2.6. Therapy using T-cell tolerogens 
hCDR1 (TV-4710, Edratide) is a peptide derived from the immunoglobulin Vh region of 
human anti-dsDNA Abs. Treatment with hCDR1 as a T-cell tolerogen induced regulatory T 
cells and reduced proteinuria and immune complexes in the kidneys of SLE patients. In this 
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study on gene expression in peripheral blood mononuclear cells from SLE patients, 
treatment using hCDR1 increased in vivo gene expression of TGF-, FoxP3 and the anti 
apoptotic molecule Bcl-xL, but significantly decreased the gene expression of IL-1, TNF-, 
IFN-, IL-10, BLyS, caspase-3, and caspase-8. hCDR1 treatment also markedly decreased 
disease activity (Sthoeger et al., 2009).   
3.3. Therapy targeting B cell-T cell interaction (inhibition of co-stimulatory 
molecules) 
T-cell activation requires 2 signals and cytokines. The first signal is mediated via binding of 
the T-cell receptor to the antigen presented with MHC molecules on antigen-presenting 
cells. However, the first signal alone is not sufficient; a second co-stimulatory signal is also 
required. Thus, co-stimulation is important not only for normal immunity, but also for the 
pathogenesis of autoimmunity. Therapies targeting the 2 main co-stimulatory pathways B7-
CD28 and CD40-CD40L have been evaluated. Anti-CD40L Ab treatment reduced 
inflammation, vasculitis, and fibrosis in the kidney and increased survival in a murine lupus 
model, the SNF1 mouse (Kalled et al, 1998). Anti-CD40L Ab treatment also elicited clinical 
improvements such as decrease in anti-dsDNA Abs and hematuria and increase in C3 in 
some SLE patients. However, thromboembolism complications prevented continuation of 
the phase II study (Mok et al., 2010). CTLA4Ig is a fusion protein comprising the 
extracellular domain of CTLA4 and the constant region of immunoglobulin. CTLA4Ig 
competes with CD28 for binding to B7 thereby inhibiting the B7-CD28 co-stimulatory signal. 
CTLA4Ig treatment elicited improvements in murine SLE, judging from the decrease in 
proteinuria and increase in survival (Finck et al., 1994). CTLA4Ig gene therapy also had 
beneficial effects on canine SLE (Choi et al., 2005) and canine experimental autoimmune 
thyroiditis (Choi et al., 2008). A phase III clinical trial using CTLA4Ig in human SLE is 
currently underway (Mok, 2010).  
3.4. Anti-cytokine therapy (prevention of ongoing inflammatory responses) 
Inhibitors of inflammatory cytokines, such as a decoy receptor for inflammatory cytokines, 
have produced promising results in animal models of autoimmune diseases.  
TNF-α is an inflammatory cytokine produced by various cells such as monocytes, 
macrophages, T cells, and B cells. TNF-α stimulates the production of other cytokines such 
as IL-1, IL-6, IL-8, and GM-CSF. To prevent ongoing inflammatory responses, TNF-blocking 
agents were administered in patients with psoriasis, rheumatoid arthritis, or Crohn’s 
disease, and were shown to be efficacious (Chaudhari et al., 2001; Keating and Perry, 2002). 
However, ANA and anti-dsDNA Abs were observed in some rheumatoid arthritis or 
Crohn’s disease patients treated with TNF-blocking agents (De Bandt et al., 2005; Mohan et 
al., 2002). TNF-blocking agents were ineffective in multiple sclerosis (Skurkovish et al., 
2001). The diseases frequently recurred after discontinuation of TNF-blocking agent therapy. 
Further, Furst et al. recommend that caution should be exercised when using TNF-blocking 
agents. According to them, TNF-blocking agents should not be initiated or should be 
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discontinued when serious infections occur (Furst et al., 2001). Instances of demyelinating-
like disorders, pancytopenia, and aplastic anemia have been reported in patients receiving 
TNF blockers (Furst et al., 2002). A recent study reported the association of TNF inhibitor 
treatment with the risk of elevated liver enzymes, such as ALT and AST in patients with 
rheumatoid arthritis (Sokolove et al., 2010). A TNF-blocking agent in conjunction with 
baseline immunosuppressive therapy significantly decreased proteinuria and attenuated 
arthritis in SLE patients (Aringer et al., 2004). A trial evaluating a TNF-blocking agent in 
membranous nephritis is currently underway (Wiesik-Szewczyk et al., 2010).  
IFN-γ is also a pleiotropic cytokine that is a key effector in the pathogenesis of various 
autoimmune diseases. Intramuscular injections of plasmids with cDNA encoding IFN-γR/Fc 
can retard lupus development and progression in MRL-Fas(lpr) mice. The therapy 
significantly reduced serum levels of IFN- and autoantibodies, lymphoid hyperplasia, and 
glomerulonephritis, and increased survival (Lawson et al., 2000).  
IL-12 is an inflammatory cytokine that plays a pivotal role in the development of 
autoimmune diseases, such as those in the NOD mouse. Gene transfer using a modified 
form of IL-12 into pancreatic beta islet cells decreased the activity of natural IL-12 and 
prevented the onset of diabetes in NOD mice (Yasuda et al., 1998).  
IL-6 is produced by monocytes, T cells, B cells, and mesangial cells. IL-6 stimulates B-cell 
maturation and immunoglobulin production. Combined with other cytokines, IL-6 also 
induces neutrophil activation, T-cell proliferation, and differentiation to cytotoxic T cells 
(Tackey et al., 2004). A monoclonal antibody against the IL-6 receptor α chain inhibits the 
binding of IL-6 to its receptor. Some SLE patients treated with this monoclonal antibody 
exhibited a significant decrease in acute phase reactant, activated B cells and memory B cells 
(Lacki et al., 1997). Furthermore, IL-6 receptor Ab treatment has been shown to be rapidly 
efficacious in patients with severe rheumatoid arthritis (Jones and Ding, 2010). However, 
complications relating to abnormalities in CBC and serum chemistry, such as neutropenia, 
increased concentrations of liver enzymes, cholesterol, and triglycerides, were observed in 
rheumatoid arthritis patients treated with anti-IL-6 receptor α chain monoclonal Abs (Iebba et 
al., 2012). The US Food and Drug Administration (FDA) approved the intravenous infusion 
of a monoclonal antibody against the IL-6 receptor α chain (tocilizumab) in adult patients 
with severely active rheumatoid arthritis who had an inadequate response to TNF antagonist 
therapies (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251572.htm).  
An IL-1-blocking agent (IL-1 receptor antagonist) has been approved for use in rheumatoid 
arthritis. However, its use also increased the incidence of serious bacterial infections. A 
recent meta-analysis study revealed that the IL-1 receptor antagonist is less effective than 
TNF-α inhibitors for the treatment of rheumatoid arthritis (Furst et al., 2010).  
As described in the previous section, IL-17 plays a central role in early inflammation and 
eosinophil recruitment. Therapeutic agents that target Th17, such as anti-IL-17 Ab and IL-25, 
showed promising results in animal models of autoimmunity. Anti-IL-17 Ab treatment 
reduced Th17 population, and prevented inflammation and bone erosion in experimental 
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rheumatoid arthritis by decreasing RANKL and IL-1 (Koenders et al., 2005). Multiple 
treatments with anti-IL-17 Abs dramatically reduced inflammatory lesions and neurological 
signs in experimental autoimmune encephalomyelitis (Hofsttter et al., 2005). IL-25 has 
shown to inhibit Th17 cells and promote the development of Th2 responses (Angkasekwinai 
et al., 2007). Further, a recent study showed that IL-25 regulates Th17 function in 
autoimmune inflammation (Kleinschek et al., 2007). Treatment with anti-IL-17 Abs or IL-25 
prevented progression to diabetes in pre-diabetic NOD mice, reduced islet inflammation, 
and prevented glutamic acid decarboxylase (GAD) 65 autoantibody formation (Emamaulle 
et al., 2009). Clinical trials of anti-IL-17 Abs in autoimmune diseases, including rheumatoid 
arthritis, psoriasis, and Crohn’s disease, are currently underway (www. clinicaltrials.gov). A 
recent study revealed that a small molecule, halofuginone (HF), selectively inhibits mouse 
and human Th17 differentiation by activating a cytoprotective signaling pathway, the amino 
acid starvation response (AAR) (Sundrud et al., 2009). Further, this study showed that HF 
prevented experimental autoimmune encephalomyelitis by inducing AAR. 
3.5. Protective cytokine gene therapy and induction or replacement of regulatory 
T cells  
Studies on cytokine gene therapy using viral or nonviral vectors have been conducted in 
animal models of autoimmune diseases, including type 1 diabetes mellitus, EAE, SLE, 
colitis, thyroiditis, and various forms of arthritis. The purpose of this therapy is to modify 
the inappropriate inflammatory immune responses in autoimmune disease. Genes encoding 
TGF-β, IL-4, and IL-10 are most frequently protective. For example, IL-10 gene therapy 
using replication-deficient adenovirus administered directly into the CNS prevented disease 
progression in murine EAE, whereas systemic administration of IL-10 gene therapy using 
adenovirus had little effect on EAE (Cua et al., 2001). Intramuscular injection of IL-10 gene 
therapy prevented diabetes induced by streptozotocin injections in mice (Zhang et al., 2003). 
IL-4 gene therapy using adenovirus administered directly into limb joints decreased 
inflammation and improved pathology in a rat model of adjuvant-induced arthritis (Woods 
et al., 2001). Monthly intramuscular injections of cDNA expression vectors encoding TGF-β1 
significantly elevated the serum levels of TGF-β, prolonged survival, and elicited beneficial 
effects in the MRL/lpr murine model of SLE (Raz et al., 1995). Systemic TGF-β1 gene therapy 
using an adenoviral system followed by syngeneic islet transplantation induced Foxp3+ 
regulatory cells, restored self-tolerance, and facilitated the survival of islet grafts and 
recovery of -cell function in overtly diabetic NOD mice (Luo et al., 2005). Chen et al. 
reported that TGF--induced Foxp3 gene expression has the ability to convert CD4+CD25- 
naive T cells to regulatory T cells with potent immunosuppressive potential (Chen et al., 
2003).  
The transfer of CD4+CD25+ regulatory T cells conferred significant protection against 
clinical EAE in a mouse model of multiple sclerosis (Kohm et al, 2002). Treatment with in 
vitro-expanded antigen-specific regulatory T cells from autoimmune-prone NOD mice also 
reversed diabetes after disease onset (Tang et al., 2004). Further, antigen-specific T cells 
transduced with FoxP3 using a retroviral system prevented diabetes in NOD mice (Jaeckel 
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discontinued when serious infections occur (Furst et al., 2001). Instances of demyelinating-
like disorders, pancytopenia, and aplastic anemia have been reported in patients receiving 
TNF blockers (Furst et al., 2002). A recent study reported the association of TNF inhibitor 
treatment with the risk of elevated liver enzymes, such as ALT and AST in patients with 
rheumatoid arthritis (Sokolove et al., 2010). A TNF-blocking agent in conjunction with 
baseline immunosuppressive therapy significantly decreased proteinuria and attenuated 
arthritis in SLE patients (Aringer et al., 2004). A trial evaluating a TNF-blocking agent in 
membranous nephritis is currently underway (Wiesik-Szewczyk et al., 2010).  
IFN-γ is also a pleiotropic cytokine that is a key effector in the pathogenesis of various 
autoimmune diseases. Intramuscular injections of plasmids with cDNA encoding IFN-γR/Fc 
can retard lupus development and progression in MRL-Fas(lpr) mice. The therapy 
significantly reduced serum levels of IFN- and autoantibodies, lymphoid hyperplasia, and 
glomerulonephritis, and increased survival (Lawson et al., 2000).  
IL-12 is an inflammatory cytokine that plays a pivotal role in the development of 
autoimmune diseases, such as those in the NOD mouse. Gene transfer using a modified 
form of IL-12 into pancreatic beta islet cells decreased the activity of natural IL-12 and 
prevented the onset of diabetes in NOD mice (Yasuda et al., 1998).  
IL-6 is produced by monocytes, T cells, B cells, and mesangial cells. IL-6 stimulates B-cell 
maturation and immunoglobulin production. Combined with other cytokines, IL-6 also 
induces neutrophil activation, T-cell proliferation, and differentiation to cytotoxic T cells 
(Tackey et al., 2004). A monoclonal antibody against the IL-6 receptor α chain inhibits the 
binding of IL-6 to its receptor. Some SLE patients treated with this monoclonal antibody 
exhibited a significant decrease in acute phase reactant, activated B cells and memory B cells 
(Lacki et al., 1997). Furthermore, IL-6 receptor Ab treatment has been shown to be rapidly 
efficacious in patients with severe rheumatoid arthritis (Jones and Ding, 2010). However, 
complications relating to abnormalities in CBC and serum chemistry, such as neutropenia, 
increased concentrations of liver enzymes, cholesterol, and triglycerides, were observed in 
rheumatoid arthritis patients treated with anti-IL-6 receptor α chain monoclonal Abs (Iebba et 
al., 2012). The US Food and Drug Administration (FDA) approved the intravenous infusion 
of a monoclonal antibody against the IL-6 receptor α chain (tocilizumab) in adult patients 
with severely active rheumatoid arthritis who had an inadequate response to TNF antagonist 
therapies (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251572.htm).  
An IL-1-blocking agent (IL-1 receptor antagonist) has been approved for use in rheumatoid 
arthritis. However, its use also increased the incidence of serious bacterial infections. A 
recent meta-analysis study revealed that the IL-1 receptor antagonist is less effective than 
TNF-α inhibitors for the treatment of rheumatoid arthritis (Furst et al., 2010).  
As described in the previous section, IL-17 plays a central role in early inflammation and 
eosinophil recruitment. Therapeutic agents that target Th17, such as anti-IL-17 Ab and IL-25, 
showed promising results in animal models of autoimmunity. Anti-IL-17 Ab treatment 
reduced Th17 population, and prevented inflammation and bone erosion in experimental 
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rheumatoid arthritis by decreasing RANKL and IL-1 (Koenders et al., 2005). Multiple 
treatments with anti-IL-17 Abs dramatically reduced inflammatory lesions and neurological 
signs in experimental autoimmune encephalomyelitis (Hofsttter et al., 2005). IL-25 has 
shown to inhibit Th17 cells and promote the development of Th2 responses (Angkasekwinai 
et al., 2007). Further, a recent study showed that IL-25 regulates Th17 function in 
autoimmune inflammation (Kleinschek et al., 2007). Treatment with anti-IL-17 Abs or IL-25 
prevented progression to diabetes in pre-diabetic NOD mice, reduced islet inflammation, 
and prevented glutamic acid decarboxylase (GAD) 65 autoantibody formation (Emamaulle 
et al., 2009). Clinical trials of anti-IL-17 Abs in autoimmune diseases, including rheumatoid 
arthritis, psoriasis, and Crohn’s disease, are currently underway (www. clinicaltrials.gov). A 
recent study revealed that a small molecule, halofuginone (HF), selectively inhibits mouse 
and human Th17 differentiation by activating a cytoprotective signaling pathway, the amino 
acid starvation response (AAR) (Sundrud et al., 2009). Further, this study showed that HF 
prevented experimental autoimmune encephalomyelitis by inducing AAR. 
3.5. Protective cytokine gene therapy and induction or replacement of regulatory 
T cells  
Studies on cytokine gene therapy using viral or nonviral vectors have been conducted in 
animal models of autoimmune diseases, including type 1 diabetes mellitus, EAE, SLE, 
colitis, thyroiditis, and various forms of arthritis. The purpose of this therapy is to modify 
the inappropriate inflammatory immune responses in autoimmune disease. Genes encoding 
TGF-β, IL-4, and IL-10 are most frequently protective. For example, IL-10 gene therapy 
using replication-deficient adenovirus administered directly into the CNS prevented disease 
progression in murine EAE, whereas systemic administration of IL-10 gene therapy using 
adenovirus had little effect on EAE (Cua et al., 2001). Intramuscular injection of IL-10 gene 
therapy prevented diabetes induced by streptozotocin injections in mice (Zhang et al., 2003). 
IL-4 gene therapy using adenovirus administered directly into limb joints decreased 
inflammation and improved pathology in a rat model of adjuvant-induced arthritis (Woods 
et al., 2001). Monthly intramuscular injections of cDNA expression vectors encoding TGF-β1 
significantly elevated the serum levels of TGF-β, prolonged survival, and elicited beneficial 
effects in the MRL/lpr murine model of SLE (Raz et al., 1995). Systemic TGF-β1 gene therapy 
using an adenoviral system followed by syngeneic islet transplantation induced Foxp3+ 
regulatory cells, restored self-tolerance, and facilitated the survival of islet grafts and 
recovery of -cell function in overtly diabetic NOD mice (Luo et al., 2005). Chen et al. 
reported that TGF--induced Foxp3 gene expression has the ability to convert CD4+CD25- 
naive T cells to regulatory T cells with potent immunosuppressive potential (Chen et al., 
2003).  
The transfer of CD4+CD25+ regulatory T cells conferred significant protection against 
clinical EAE in a mouse model of multiple sclerosis (Kohm et al, 2002). Treatment with in 
vitro-expanded antigen-specific regulatory T cells from autoimmune-prone NOD mice also 
reversed diabetes after disease onset (Tang et al., 2004). Further, antigen-specific T cells 
transduced with FoxP3 using a retroviral system prevented diabetes in NOD mice (Jaeckel 
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et al., 2005). These studies suggested that regulatory T cells act as main regulators of the 
immune system and provide a novel approach to cellular immunotherapy for autoimmune 
diseases.  
4. Stem cell therapy for autoimmune diseases  
4.1. Hematopoietic stem cell transplantation  
Non-disease prone animals that received bone marrow derived from diseased hosts 
developed autoimmune diseases (Berisso et al., 1999) and vice versa. This suggested that the 
hematopoietic compartment plays an important role in autoimmune disease susceptibility, 
and transplantation of autologous or allogeneic non-autoimmune disease-prone 
hematopoietic cells can attenuate autoimmune disease. Autologous, syngeneic, and 
allogeneic bone marrow (or hematopoietic stem cell) transplantations have been performed 
in animal models of human autoimmune diseases, including EAE (Burt et al., 1998; Karussis 
et al., 1993), experimental autoimmune myasthenia gravis (Pestronk et al., 1983), adjuvant-
induced arthritis (van Bekkum, 1989), collagen-induced arthritis (Kamiya et al., 1993), type 1 
diabetes (NOD mice) (Beilhack et al., 2003), and SLE-like autoimmune diseases (MLR/lpr 
mice and NZB/W F1 mice) (Ikehara, 2001; Smith-Berdan et al., 2007). The results from these 
animal studies suggested that myelo-ablative therapy supported by stem cell 
transplantation can result in remission of disease or induction of immune tolerance. The 
bone marrow was the initial source of hematopoietic stem cells, but peripheral blood is 
currently used following mobilization procedures comprising a combination of 
cyclophosphamide and G-CSF (Saccardi and Gualandi, 2008).  
The therapeutic concept of hematopoietic stem cell transplantation is to reset the immune 
system. Thus, patients receive aggressive immunosuppression to eliminate autoreactive 
lymphocytes (to ablate the immune system), and disease remission occurs via de novo 
regeneration of immunocytes from hematopoietic stem cells. Two mechanisms have been 
proposed. The first is re-education of the defective immune system by restoring diverse 
antigen-specific clones via reactivation of the thymic output and regenerating the adaptive 
immune system that had became apparently tolerant to self-antigens (Abrahamsson and 
Muraro, 2008). The second mechanism is reconstitution of the regulatory T-cell pool after 
stem cell transplantation. Regulatory T cells are important for preventing autoreactivity and 
control autoimmunity throughout life (Zhang et al., 2009). The rationale of allogeneic stem 
cell transplantation is substitution of the faulty immune system with a normal healthy one. 
However, the burden of higher mortality and morbidity due to graft versus host disease 
prevents its use in autoimmune disease except immune cytopenia. Allogeneic 
transplantation may be an option for selective patients who are not suitable for or have 
previously undergone autologous hematopoietic stem cell transplantation. 
Autologous BM transplantation for autoimmune diseases has no risk of graft-versus-host 
disease, but relapses are common (Chan et al., 2008). For example, a case report on 
autologous hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma concurrent 
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with Crohn’s disease discussed that autologous hematopoietic stem cell transplantation will 
not provide a long-term cure for Crohn’s disease (Anumakonda et al., 2007). In this case 
report, the authors postulated that autologous hematopoietic stem transplantation led to 
ablation of activated T cells for a prolonged period (8 years), but the genetic predisposition 
(positive family history) concurrent with other environmental factors such as smoking 
subsequently led to disease relapse. In case of genetically determined autoimmunity, an 
allogeneic source of stem cells is necessary to prevent a relapse of autoimmunity (Jorgensen 
et al., 2003). Patients with a refractory autoimmune disease that does not respond to current 
conventional treatments may be considered for stem cell transplantation. Pilot studies were 
conducted in systemic sclerosis (Tyndall et al., 1997; Martini et al., 1999), rheumatoid 
arthritis (Durez et al., 1998), SLE (Burt et al., 1997; Marmont et al., 1997), multiple sclerosis 
(Burt et al., 1998), and hematological autoimmune diseases, such as idiopathic 
thrombocytopenia (Lim et al., 1997), autoimmune hemolytic anemia, and Evans syndrome. 
Some promising results have been reported from phase I/II trial studies, and phase III 
randomized controlled trials are currently underway (http://clinicaltrials.gov/). Over one-
third of patients achieved durable remission and transplant-related mortality reached 12% 
in the initial “European group for Blood and Marrow Transplants” (EBMT) registry, which 
decreased to around 5% in a recent EBMT study (Farge et al., 2010). Susceptibility to 
bacterial, viral, and fungal infections increases until the immune system is reconstituted, 
which makes the hematopoietic stem cell transplantation a high-risk therapy. The major 
complications of hematopoietic stem cell transplantation include septicemia, pneumonia, 
increased risk of late infection, infertility, and secondary malignancies, such as acute 
leukemia and myelodysplastic syndrome.  
4.2. Mesenchymal stem cell transplantation  
Mesenchymal stem cells (MSCs) are multipotent adult stem cells that are the progenitors of 
multiple mesenchymal lineages (Pittenger et al., 1999). The therapeutic mechanisms of MSC 
transplantation include capacity for differentiation and transdifferentiation, paracrine 
effects, immunomodulatory properties, and capacity for directional migration. MSCs have 
immunoprivileges. MSCs can escape the immune system because they lack MHC class II or 
co-stimulatory molecules, such as B7, CD40, and CD40L, which leads to poor recognition by 
T cells (Deans et al., 2000). Moreover, a number of in vitro studies have revealed that MSCs 
exert immunosuppressive and immunomodulatory effects on MHC-mismatched 
lymphocyte proliferation by inhibiting naïve, memory, and activated T cells, B cells, NK 
cells, and dendritic cells (Bartholomew et al., 2002; Di Nicola et al., 2002). MSCs release 
paracrine factors, including trophic, chemoattractant, and immunomodulatory factors. 
Immunomodulatory factors secreted by human MSCs include TGF-β, HGF, PGE2, 
hemoxygenase-1, human leukocyte antigen-G5, and IL-10 (Wang et al., 2011). They are 
constitutively produced by MSCs or after cross-talk with target cells, and their production is 
also enhanced by cytokines secreted by target cells after cross-talk (Wang et al., 2011). MSCs 
exhibit immunomodulatory properties by direct cell-to-cell contact and/or release of soluble 
immunosuppressive factors (Uccelli et al., 2008). MSCs possess the capacity to home to 
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et al., 2005). These studies suggested that regulatory T cells act as main regulators of the 
immune system and provide a novel approach to cellular immunotherapy for autoimmune 
diseases.  
4. Stem cell therapy for autoimmune diseases  
4.1. Hematopoietic stem cell transplantation  
Non-disease prone animals that received bone marrow derived from diseased hosts 
developed autoimmune diseases (Berisso et al., 1999) and vice versa. This suggested that the 
hematopoietic compartment plays an important role in autoimmune disease susceptibility, 
and transplantation of autologous or allogeneic non-autoimmune disease-prone 
hematopoietic cells can attenuate autoimmune disease. Autologous, syngeneic, and 
allogeneic bone marrow (or hematopoietic stem cell) transplantations have been performed 
in animal models of human autoimmune diseases, including EAE (Burt et al., 1998; Karussis 
et al., 1993), experimental autoimmune myasthenia gravis (Pestronk et al., 1983), adjuvant-
induced arthritis (van Bekkum, 1989), collagen-induced arthritis (Kamiya et al., 1993), type 1 
diabetes (NOD mice) (Beilhack et al., 2003), and SLE-like autoimmune diseases (MLR/lpr 
mice and NZB/W F1 mice) (Ikehara, 2001; Smith-Berdan et al., 2007). The results from these 
animal studies suggested that myelo-ablative therapy supported by stem cell 
transplantation can result in remission of disease or induction of immune tolerance. The 
bone marrow was the initial source of hematopoietic stem cells, but peripheral blood is 
currently used following mobilization procedures comprising a combination of 
cyclophosphamide and G-CSF (Saccardi and Gualandi, 2008).  
The therapeutic concept of hematopoietic stem cell transplantation is to reset the immune 
system. Thus, patients receive aggressive immunosuppression to eliminate autoreactive 
lymphocytes (to ablate the immune system), and disease remission occurs via de novo 
regeneration of immunocytes from hematopoietic stem cells. Two mechanisms have been 
proposed. The first is re-education of the defective immune system by restoring diverse 
antigen-specific clones via reactivation of the thymic output and regenerating the adaptive 
immune system that had became apparently tolerant to self-antigens (Abrahamsson and 
Muraro, 2008). The second mechanism is reconstitution of the regulatory T-cell pool after 
stem cell transplantation. Regulatory T cells are important for preventing autoreactivity and 
control autoimmunity throughout life (Zhang et al., 2009). The rationale of allogeneic stem 
cell transplantation is substitution of the faulty immune system with a normal healthy one. 
However, the burden of higher mortality and morbidity due to graft versus host disease 
prevents its use in autoimmune disease except immune cytopenia. Allogeneic 
transplantation may be an option for selective patients who are not suitable for or have 
previously undergone autologous hematopoietic stem cell transplantation. 
Autologous BM transplantation for autoimmune diseases has no risk of graft-versus-host 
disease, but relapses are common (Chan et al., 2008). For example, a case report on 
autologous hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma concurrent 
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with Crohn’s disease discussed that autologous hematopoietic stem cell transplantation will 
not provide a long-term cure for Crohn’s disease (Anumakonda et al., 2007). In this case 
report, the authors postulated that autologous hematopoietic stem transplantation led to 
ablation of activated T cells for a prolonged period (8 years), but the genetic predisposition 
(positive family history) concurrent with other environmental factors such as smoking 
subsequently led to disease relapse. In case of genetically determined autoimmunity, an 
allogeneic source of stem cells is necessary to prevent a relapse of autoimmunity (Jorgensen 
et al., 2003). Patients with a refractory autoimmune disease that does not respond to current 
conventional treatments may be considered for stem cell transplantation. Pilot studies were 
conducted in systemic sclerosis (Tyndall et al., 1997; Martini et al., 1999), rheumatoid 
arthritis (Durez et al., 1998), SLE (Burt et al., 1997; Marmont et al., 1997), multiple sclerosis 
(Burt et al., 1998), and hematological autoimmune diseases, such as idiopathic 
thrombocytopenia (Lim et al., 1997), autoimmune hemolytic anemia, and Evans syndrome. 
Some promising results have been reported from phase I/II trial studies, and phase III 
randomized controlled trials are currently underway (http://clinicaltrials.gov/). Over one-
third of patients achieved durable remission and transplant-related mortality reached 12% 
in the initial “European group for Blood and Marrow Transplants” (EBMT) registry, which 
decreased to around 5% in a recent EBMT study (Farge et al., 2010). Susceptibility to 
bacterial, viral, and fungal infections increases until the immune system is reconstituted, 
which makes the hematopoietic stem cell transplantation a high-risk therapy. The major 
complications of hematopoietic stem cell transplantation include septicemia, pneumonia, 
increased risk of late infection, infertility, and secondary malignancies, such as acute 
leukemia and myelodysplastic syndrome.  
4.2. Mesenchymal stem cell transplantation  
Mesenchymal stem cells (MSCs) are multipotent adult stem cells that are the progenitors of 
multiple mesenchymal lineages (Pittenger et al., 1999). The therapeutic mechanisms of MSC 
transplantation include capacity for differentiation and transdifferentiation, paracrine 
effects, immunomodulatory properties, and capacity for directional migration. MSCs have 
immunoprivileges. MSCs can escape the immune system because they lack MHC class II or 
co-stimulatory molecules, such as B7, CD40, and CD40L, which leads to poor recognition by 
T cells (Deans et al., 2000). Moreover, a number of in vitro studies have revealed that MSCs 
exert immunosuppressive and immunomodulatory effects on MHC-mismatched 
lymphocyte proliferation by inhibiting naïve, memory, and activated T cells, B cells, NK 
cells, and dendritic cells (Bartholomew et al., 2002; Di Nicola et al., 2002). MSCs release 
paracrine factors, including trophic, chemoattractant, and immunomodulatory factors. 
Immunomodulatory factors secreted by human MSCs include TGF-β, HGF, PGE2, 
hemoxygenase-1, human leukocyte antigen-G5, and IL-10 (Wang et al., 2011). They are 
constitutively produced by MSCs or after cross-talk with target cells, and their production is 
also enhanced by cytokines secreted by target cells after cross-talk (Wang et al., 2011). MSCs 
exhibit immunomodulatory properties by direct cell-to-cell contact and/or release of soluble 
immunosuppressive factors (Uccelli et al., 2008). MSCs possess the capacity to home to 
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mesenchymal tissues, and injured sites in particular, which may also contribute to 
autoimmune disease treatment. According to the study by Ponte et al., human bone marrow 
MSCs (BMMSCs) express the following tyrosine kinase receptors: platelet-derived growth 
factor receptor (PDGF-R)α; PDGF-Rβ; and insulin-like growth factor receptor (IGF-R). MSCs 
also express ‘regulated upon activation, normal T-cell expressed, and secreted (RANTES) 
and macrophage-derived chemokine (MDC) receptors (CCR2, CCR3, and CCR4)’ and 
‘stromal-derived factor (SDF)-1 receptor (CXCR4)’ (Ponte et al., 2007). 
Survival results from an animal study comparing whole bone marrow cell transplantation 
with adherent cell (MSC)-removed bone marrow cell transplantation revealed that MSCs 
play a critical role in the treatment of lupus in the MLR/lpr mouse model. All mice treated 
with whole bone marrow cells survived more than 1 year, but 75% of mice treated with 
MSC-removed bone marrow cells died within 3 months (Ishida et al., 1994). Total bone 
marrow transplants consist of both hematopoietic stem cells and stromal cells, and MSCs 
play a pivotal role in tolerance induction (Jorgensen et al., 2003).  
Initially, MSCs were isolated from the bone marrow and later from various other tissues, 
including placenta, muscle, cartilage, and fat (da Silva Meirelles L et al., 2006).  
Recently, syngeneic, allogeneic, and xenogeneic MSC transplantations have been performed 
for autoimmune diseases in various animal models, including autoimmune encephalomyelitis 
(Zappia et al., 2005; Rafei et al., 2009; Constantin et al., 2009), type I diabetes (Fiorina et al., 
2009), inflammatory bowel disease (Gonzalez-Rey et al., 2009), rheumatoid arthritis (González 
et al., 2009), and SLE (Zhou et al., 2008; Sun et al., 2009; Choi et al., 2012). These studies yielded 
some promising results. For example, long-term serial administration of human adipose 
tissue-derived MSCs increased survival rates, improved serologic, immunologic, and 
histologic abnormalities, and decreased the incidence of severe proteinuria in NZB/W F1 mice, 
a murine SLE model. The levels of IL-4 and IL-10 in the serum and the proportion of 
CD4+FoxP3+ regulatory T cells in the spleen were increased in NZB/W F1 mice treated with 
MSCs, compared to control NZB/W F1 mice treated with saline (Choi et al., 2012). Clinical 
studies using allogeneic MSC transplantation in refractory SLE patients revealed 
improvements in serologic parameters and renal function (Sun et al., 2009; Liang J et al., 2010). 
Furthermore, pilot studies using autologous BMMSC transplantation in patients with 
refractory Crohn’s disease also yielded promising results (Duijvestein et al., 2010; Ciccocioppo 
R et al., 2011). Clinical trials using MSCs for diabetes and lupus nephritis are underway 
(http://clinicaltrials.gov/).  
4.3. Genetically modified stem cell therapy (Stem cell-based gene therapy) 
Gene therapy-assisted stem cell transplantation has become one of the most attractive 
therapies in clinical immunology (Marmont, 2011). The use of genetically selected or 
genetically engineered cell types can further control the possibility of disease progression or 
relapse. Hematopoietic stem cells engineered to express autoantigens in resting antigen-
presenting cells can be used to prevent autoimmune diseases. For example, syngeneic 
transplantation of hematopoietic stem cells encoding proinsulin transgenically targeted to 
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antigen-presenting cells completely prevents the development of spontaneous autoimmune 
diabetes in NOD mice (Steptoe et al., 2003). Transplantation of BM genetically engineered to 
express myelin oligodendrocyte glycoprotein (MOG) led to the deletion of MOG-specific 
thymocytes and prevented the induction and progression of EAE (Chan et al., 2008).  
Transplantation of genetically engineered autologous BM cells expressing diabetes-resistant 
MHC class II molecules (I-Ab) into NOD mice prevented the development of autoreactive T 
cells via negative selection and prevented the progression of diabetes (Tian et al., 2004).  
Genetic modification of stem cells or differentiated tissue cells with a decoy receptor for 
inflammatory cytokines can be used to treat autoimmune diseases. For example, NOD/SCID 
mice administered with MSCs genetically modified to secrete the soluble TNF receptor II 
exhibit decreased concentration of serum TNF-α.  
My previous study revealed that transplantation of adipose tissue-derived MSCs 
transduced with the CTLA4Ig gene by using a lentiviral vector reduces the inflammatory 
immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis 
(Choi EW et al., 2011). This study showed that MSCs can be efficiently transduced using 
lentiviral vectors to express therapeutic proteins and can retain their immunophenotype 
even after genetic manipulation. Moreover, the concentration of murine CTLA4Ig in the 
culture supernatants of CTLA4Ig-transduced MSCs was sustained at higher passages, 
indicating that MSCs genetically modified using the lentiviral system provide durable 
expression of therapeutic genes. Similarly, insertion of inducible regulatory genes into the 
stem cell compartment is expected to alter disease activity. Genetically modified stem cells 
that secrete immunomodulatory factors (e.g., IL-10, IDO, PGE2, TGF-β) and home to injured 
targets have great potential for treating various diseases, including autoimmune diseases.  
5. Conclusion 
During the past several decades, strategies using agents that influence cytokines, 
hyperactivity of B cells, and B cell-T cell interaction have been developed and some of these 
agents have proven to be effective and well tolerated therapies for autoimmune diseases. 
Although some of these treatments have yielded encouraging and promising results, 
prospective well-planned studies and international cooperation are required to collect 
experiences and clarify further details on safety and clinical efficacy depending on the 
disease states and the condition of patients.  
Hematopoietic stem cell therapy removes misguided inappropriate immune cells, restores 
immune cells, and resets or re-educates the immune system. Promising results have been 
reported from clinical trial studies. Some patients achieved durable remission, and transplant-
related mortality has decreased. MSCs are easily available, possess extensive capacity for in 
vitro expansion, and exhibit homing effects and immunomodulatory functions. Thus, MSCs 
have been targeted by researchers as an alternative source of treatment for autoimmune 
diseases. Stem cell therapy may be integrated with other therapeutic agents, including 
biologics and new intelligent molecules, for greater immunomodulation. 
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hyperactivity of B cells, and B cell-T cell interaction have been developed and some of these 
agents have proven to be effective and well tolerated therapies for autoimmune diseases. 
Although some of these treatments have yielded encouraging and promising results, 
prospective well-planned studies and international cooperation are required to collect 
experiences and clarify further details on safety and clinical efficacy depending on the 
disease states and the condition of patients.  
Hematopoietic stem cell therapy removes misguided inappropriate immune cells, restores 
immune cells, and resets or re-educates the immune system. Promising results have been 
reported from clinical trial studies. Some patients achieved durable remission, and transplant-
related mortality has decreased. MSCs are easily available, possess extensive capacity for in 
vitro expansion, and exhibit homing effects and immunomodulatory functions. Thus, MSCs 
have been targeted by researchers as an alternative source of treatment for autoimmune 
diseases. Stem cell therapy may be integrated with other therapeutic agents, including 
biologics and new intelligent molecules, for greater immunomodulation. 
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Stem cell-based gene therapy has great potential as a novel method for immunomodulation 
in autoimmune diseases. By identifying the correct gene for autoimmune disease treatment, 
stem cell-based gene therapy will be able to produce a synergic effect of gene therapy and 
stem cell therapy. Before they are put to clinical use, genetically engineered cells should be 
carefully tested at the genetic, molecular, and cellular levels.  
Selection and application of the appropriate therapy from among the various new 
therapeutic agents should be based on the risk-benefit analysis for each patient, because 
patients with autoimmune diseases exhibit different symptoms and severities and different 
responses to each treatment. Further studies are warranted to identify new specific targets 
and determine regimens to optimize the clinical response depending on the disease states. 
The development of non-toxic and effective novel gene transfer systems and clinical trials to 
evaluate combination therapies using agents that achieve immunomodulation or induce 
immune tolerance via different targets are also needed.  
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1. Introduction 
Diabetes mellitus is a chronic metabolic disease that results in high levels of glucose in the 
blood. Normally, glucose is transported into cells from the blood for energy, and this transport 
is initiated in response to the hormone, insulin. In diabetic patients, cellular glucose uptake is 
defective, in part due to the inability of cells to respond to insulin, or the inability of the body 
to produce the insulin itself. According to the International Diabetes Foundation, 366 million 
people worldwide had been diagnosed with diabetes in 2011, and this number is continuing to 
increase in every country (http://www.idf.org/). It is an especially challenging health problem, 
as treatments to both control hyperglycemia as well as the debilitating side effects of diabetes, 
such as injury to the blood vessels and nerves, must be addressed. Amongst the three types of 
diabetes (Type I - autoimmune, gestational and Type II – adult onset), Type II diabetes is the 
most prevalent, in which hyperglycemia is uncontrolled due to the body’s inability to produce 
enough insulin or due to the body’s inability to respond appropriately to lower the blood 
glucose level. In contrast, in patients with Type I diabetes (TID), insulin-producing beta (β) 
cells are destroyed by the immune system. Studies of TID by many groups have provided 
extensive insight to the fields of immunological tolerance and pancreatic developmental 
biology. In this chapter, we will briefly describe TID, provide a synopsis of pancreatic β cell 
development in mice as compared to humans, review of some of the medical treatments 
currently available for TID, and discuss current studies that have explored the use of stem cells 
as alternative possible therapies for TID.  
2. Type I diabetes in humans and mice 
2.1. TID in humans 
A fully comprehensive comparison of TID in humans and mice has recently been published, 
so we will only highlight certain areas (van Belle, Coppieters et al. 2011). TID is a multigenic 
disease, and several candidates have been discovered that implicate disruptions in the 
 The Author(s). L censee InTech. his chapter is distributed under the terms of the Creative Com ons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 280 
Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, 
Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A 
phase II, randomized, double-blind, placebo-controlled, dose-ranging study of 
belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 
2009;61(9):1168-78. 
Wang J, Liao L, Tan J. Mesenchymal-stem-cell-based experimental and clinical trials: current 
status and open questions. Expert Opin Biol Ther. 2011;11(7):893-909.  
Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA. Double-
blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 
1993;259(5099):1321-4. 
Wiesik-Szewczyk E, Lacki JK, Feleszko W, Olesinska M. Target therapies in systemic lupus 
erythematosus: current state of the art. Mini Rev Med Chem. 2010;10(10):956-65.  
Wiglesworth AK, Ennis KM, Kockler DR. Belimumab: a BLyS-specific inhibitor for systemic 
lupus erythematosus. Ann Pharmacother. 2010;44(12):1955-61.  
Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, 
Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients 
with autoimmune cytopenias. Br J Haematol. 2001;114(4):891-8. 
Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, Connors MA, Kurata 
H, Arai K, Haines GK, Kumar P, Koch AE. IL-4 adenoviral gene therapy reduces 
inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat 
adjuvant-induced arthritis. J Immunol. 2001;166(2):1214-22. 
Yasuda H, Nagata M, Arisawa K, Yoshida R, Fujihira K, Okamoto N, Moriyama H, Miki M, 
Saito I, Hamada H, Yokono K, Kasuga M. Local expression of immunoregulatory IL-
12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest. 
1998;102(10):1807-14.  
Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo 
A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate 
experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 
2005;106(5):1755-1761. 
Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regulatory T cell (Treg) 
subsets return in patients with refractory lupus following stem cell transplantation, and 
TGF-beta-producing CD8+ Treg cells are associated with immunological remission of 
lupus. J Immunol. 2009;183(10):6346-58.  
Zhang ZL, Shen SX, Lin B, Yu LY, Zhu LH, Wang WP, Luo FH, Guo LH. Intramuscular 
injection of interleukin-10 plasmid DNA prevented autoimmune diabetes in mice. Acta 
Pharmacol Sin. 2003;24(8):751-6. 
Zhang HG, Su X, Liu D, Liu W, Yang P, Wang Z, Edwards CK, Bluethmann H, Mountz JD, 
Zhou T. Induction of specific T cell tolerance by Fas ligand-expressing antigen-
presenting cells. J Immunol. 1999;162(3):1423-30. 
Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L. Transplantation of human bone 
marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr 






© 2012 Ciriza and Manilay, licensee InTech. This is an open access chapter distributed under the terms of 
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Stem Cell Therapies for Type I Diabetes 
Jesus Ciriza and Jennifer O. Manilay 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/47803 
1. Introduction 
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blood. Normally, glucose is transported into cells from the blood for energy, and this transport 
is initiated in response to the hormone, insulin. In diabetic patients, cellular glucose uptake is 
defective, in part due to the inability of cells to respond to insulin, or the inability of the body 
to produce the insulin itself. According to the International Diabetes Foundation, 366 million 
people worldwide had been diagnosed with diabetes in 2011, and this number is continuing to 
increase in every country (http://www.idf.org/). It is an especially challenging health problem, 
as treatments to both control hyperglycemia as well as the debilitating side effects of diabetes, 
such as injury to the blood vessels and nerves, must be addressed. Amongst the three types of 
diabetes (Type I - autoimmune, gestational and Type II – adult onset), Type II diabetes is the 
most prevalent, in which hyperglycemia is uncontrolled due to the body’s inability to produce 
enough insulin or due to the body’s inability to respond appropriately to lower the blood 
glucose level. In contrast, in patients with Type I diabetes (TID), insulin-producing beta (β) 
cells are destroyed by the immune system. Studies of TID by many groups have provided 
extensive insight to the fields of immunological tolerance and pancreatic developmental 
biology. In this chapter, we will briefly describe TID, provide a synopsis of pancreatic β cell 
development in mice as compared to humans, review of some of the medical treatments 
currently available for TID, and discuss current studies that have explored the use of stem cells 
as alternative possible therapies for TID.  
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normal process of negative selection of autoreactive T cells during thymic development, 
genetic association with specific major histocompatibility complex (MHC) genes in the 
human leukocyte antigen (HLA) locus, as well as dysregulation of mature T lymphocyte 
responses. For example, patients with mutations in the FoxP3 or Aire genes, which are 
important for the development and function of regulatory T cells (Tregs) and expression of 
“self-antigens” by medullary thymic epithelial cells, often present with autoimmune 
diabetes, as well as other autoimmune disorders (Michels and Gottlieb 2010). On the other 
end of the spectrum, the inability to downregulate or prevent mature T cell responses due to 
mutations in cytokine receptor expression (Garg, Tyler et al. 2012) or low surface expression 
of CTLA-4 (Haseda, Imagawa et al. 2011) can also result in sustained T cell cytotoxicity or 
lack of Treg response towards diabetes-related antigens. Environmental insults, such as viral 
infections, molecular mimicry between some viral proteins and diabetes-related 
autoantigens, changes in gut flora and the intestinal microenvironment, have also been 
linked with the onset of TID in humans. 
2.2. TID in mice 
The identification of the mechanisms underlying the autoimmunity of TID in humans has 
been facilitated by the use of rodent models of the disease (Van Belle, Taylor et al. 2009; von 
Herrath and Nepom 2009). Despite the fact that TID is a multigenic disease with 
heterogeneous etiologies, there is overall consensus that TID is caused by the destruction of 
pancreatic β cells by sets of immune cells that recognize many potential autoantigens (such 
as insulin, glutamate decarboxylase (GAD), islet antigens, and heat shock proteins-60 and -
70) and that the disease can be transferred by the transplantation of autoreactive T 
lymphocytes that are specific for these antigens (Mallone, Brezar et al. 2011). Several 
spontaneous, induced and transgenic mouse models currently exist, which have provided 
important insights into the genetics, cellular mechanisms and immunological aspects of TID. 
However, the non-obese diabetic (NOD) mouse strain remains the primary animal strain for 
studies of TID. The utility of the NOD mouse and comparison of the TID in the NOD mouse 
with human TID have been extensively reviewed and debated, and we direct the reader to 
these excellent reviews for further reference (Anderson and Bluestone 2005; Roep and 
Peakman 2011). The NOD mouse strain, when housed in specific-pathogen free conditions, 
displays the onset of diabetes after 12 weeks of age in both sexes. Insulitis is observed as 
mononuclear infiltration in the islets before full blown diabetes is evident, and this cellular 
infiltrate is comprised of primary T lymphocytes, but other lymphoid and myeloid cells are 
also present. The insulitis results in the destruction of the pancreatic islets and the insulin-
producing β cells. The NOD mouse also displays defects in functional macrophages and 
natural killer cells, NKT cells and regulatory T cells and complement. The NOD mouse, 
therefore, has allowed for the investigation of numerous immune mechanisms that 
contribute to the development of TID. The peripheral neuropathy that accompanies TID in 
humans is also evident in the NOD mouse, which has allowed for analysis and management 
of the side effects of TID (Anderson and Bluestone 2005; Roep and Peakman 2011). Similar 
to human diabetes, the MHC of the NOD mouse contains several loci that are linked to 
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increased susceptibility to TID. The NOD mouse background has also been used to derive 
the NOD/scid/γc-/- (NSG) immunocompromised strain, into which human cells can be 
transplanted (Shultz, Saito et al. 2010).  
Many studies in mice have focused on mechanisms to control the aberrant autoimmune 
response in TID, as well as strategies to replace dysfunctional β cells, using simple insulin 
replacement or rescue/regeneration of the β cells. Despite the similarities between TID in 
humans and in the NOD mouse, clear differences have been noted. TID in the NOD mouse 
appears to be a more aggressive disease compared than that in humans, so the NOD mouse 
may be more beneficial for studies of therapies for long-term TID than for discovery of pre-
susceptibility markers of TID. β cells in the NOD mouse may also be more proliferative and 
could possibly regenerate better than other strains (Sherry, Kushner et al. 2006), and 
evidence that pancreatic development is altered in the NOD mouse also exists (Homo-
Delarche 2001). Therefore, in addition to its clear autoimmune etiology, TID may also result 
from defects in pancreatic development.  
2.3. Pancreatic development in the mouse and human 
The adult pancreas organ is comprised of many cell types, including exocrine and endocrine 
cells, and is highly vascularized. Although TID is a disease that occurs in the fully formed 
pancreas, strategies to treat or cure TID via β cell regeneration or β cell differentiation from 
embryonic stem cells (ESCs) or induced pluripotent cells (iPSCs) have relied on the current 
knowledge of pancreatic development during the fetal period. Here, we briefly review the 
development of pancreas in the mouse and human, and then move to a description of 
development of β cells only.  
In the mouse, pancreas formation occurs in three phases (Jorgenson, Ahnfelt-Ronne et al. 
2007). In the first phase, pancreatic formation from the endodermal gut tube begins at 
embryonic day (e) 8.5. Patterning of the gut tube in the pancreatic region is reliant on 
retinoic acid (RA) signaling from the mesoderm. The dorsal and ventral pancreas buds form 
from the pancreatic epithelium in the primitive gut tube. Recently, the critical role of the 
Wnt signaling in the pancreatic mesenchyme in the differentiation of pancreatic epithelial 
cells was shown in vivo (Landsman, Nijagal et al. 2011). Eventually, the ventral pancreas 
rotates toward the dorsal pancreas, and they fuse into one organ by e12.5. At this stage, the 
pancreas organ undergoes significant cell proliferation and branching. In the second phase 
(e13.5), the cells within the immature pancreas begin to differentiate into exocrine cells that 
are required for the production of digestive enzymes, and endocrine cells that secrete 
hormones into the blood, such as glucagon, insulin, somatostatin, pancreatic polypeptide 
and ghrelin. Each of these hormones is produced by a distinct endocrine cell type (with 
insulin produced by the β cells) (Figure 1). The third phase of pancreatic development 
occurs after birth, and is associated with the ability of the pancreas to respond to dietary 
intake and maintain glucose homeostasis. 
Islet development in humans occurs at a slower rate compared to what is observed in mice, 
but the reasons for this are not understood. The size of the human islet is comparable to that 
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displays the onset of diabetes after 12 weeks of age in both sexes. Insulitis is observed as 
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also present. The insulitis results in the destruction of the pancreatic islets and the insulin-
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increased susceptibility to TID. The NOD mouse background has also been used to derive 
the NOD/scid/γc-/- (NSG) immunocompromised strain, into which human cells can be 
transplanted (Shultz, Saito et al. 2010).  
Many studies in mice have focused on mechanisms to control the aberrant autoimmune 
response in TID, as well as strategies to replace dysfunctional β cells, using simple insulin 
replacement or rescue/regeneration of the β cells. Despite the similarities between TID in 
humans and in the NOD mouse, clear differences have been noted. TID in the NOD mouse 
appears to be a more aggressive disease compared than that in humans, so the NOD mouse 
may be more beneficial for studies of therapies for long-term TID than for discovery of pre-
susceptibility markers of TID. β cells in the NOD mouse may also be more proliferative and 
could possibly regenerate better than other strains (Sherry, Kushner et al. 2006), and 
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cells, and is highly vascularized. Although TID is a disease that occurs in the fully formed 
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knowledge of pancreatic development during the fetal period. Here, we briefly review the 
development of pancreas in the mouse and human, and then move to a description of 
development of β cells only.  
In the mouse, pancreas formation occurs in three phases (Jorgenson, Ahnfelt-Ronne et al. 
2007). In the first phase, pancreatic formation from the endodermal gut tube begins at 
embryonic day (e) 8.5. Patterning of the gut tube in the pancreatic region is reliant on 
retinoic acid (RA) signaling from the mesoderm. The dorsal and ventral pancreas buds form 
from the pancreatic epithelium in the primitive gut tube. Recently, the critical role of the 
Wnt signaling in the pancreatic mesenchyme in the differentiation of pancreatic epithelial 
cells was shown in vivo (Landsman, Nijagal et al. 2011). Eventually, the ventral pancreas 
rotates toward the dorsal pancreas, and they fuse into one organ by e12.5. At this stage, the 
pancreas organ undergoes significant cell proliferation and branching. In the second phase 
(e13.5), the cells within the immature pancreas begin to differentiate into exocrine cells that 
are required for the production of digestive enzymes, and endocrine cells that secrete 
hormones into the blood, such as glucagon, insulin, somatostatin, pancreatic polypeptide 
and ghrelin. Each of these hormones is produced by a distinct endocrine cell type (with 
insulin produced by the β cells) (Figure 1). The third phase of pancreatic development 
occurs after birth, and is associated with the ability of the pancreas to respond to dietary 
intake and maintain glucose homeostasis. 
Islet development in humans occurs at a slower rate compared to what is observed in mice, 
but the reasons for this are not understood. The size of the human islet is comparable to that 
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of the mouse, but in the mouse, the mean area ratio of β cells is higher than observed in the 
human (Kim, Miller et al. 2009). Fetal antigen-1 is a protein expressed exclusively in human 
endodermal tissue and pancreatic epithelial cells before islet formation (Tornehave, Jansen 
et al. 1993). Islets can be located in the human fetus as early as 12-13 weeks post coitus 
(Piper, Brickwood et al. 2004), although functional β cells that are insulin-positive can be 
detected as early as 8 weeks.  
 
Figure 1. An overview of pancreatic endocrine cell development. The development of pancreatic endocrine 
cells starts with an early endocrine progenitor and ends with mature hormone-producing islet cell 
types. Cell surface markers (noted above the cell types) and gene expression (in italics) in distinct 
pancreatic cell lineages are shown. The existence of the self-renewing pancreatic stem cell is still 
controversial. 
An overview of pancreatic endocrine cell development is shown in Figure 1. Definitive 
endodermal progenitor cells can differentiate into pancreatic progenitor cells, which have 
been identified by the expression of two critical transcriptional factors: Pdx1 and neurogenin 
3 (Ngn3). Experiments with conditional Pdx1 transgenic reporter mice (inducible Cre-ERTM-
LoxP system to mark the progeny of cells that express Pdx1) demonstrated that Pdx1+ cells 
give rise to all three types of pancreatic tissue: exocrine, endocrine and duct (Gu, 
Dubauskaite et al. 2002). In line with this, Pdx1 deficiency in mouse and humans leads to a 
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complete pancreas agenesis at birth (Ahlgren, Jonsson et al. 1996). Pdx1 is also a critical 
transcriptional activator of insulin and somatostatin in adult islet cells (Ohlsson, Thor et al. 
1991; Leonard, Peers et al. 1993). Similar to Pdx1, Ngn3+ cells give rise to all islet lineage cells 
during embryogenesis (Gradwohl, Dierich et al. 2000), with peak Ngn3 expression at 15.5 
days post-coitus. Although some have reported that Ngn3 is undetectable in adult pancreas 
(Gradwohl, Dierich et al. 2000; Johansson, Dursun et al. 2007), Ngn3+ cells in duct-ligated 
adult pancreas were detected and observed to differentiate into islet cells (Gu, Dubauskaite 
et al. 2002; Xu, D'Hoker et al. 2008). Beta cells in the human, like in the mouse, are derived 
from a heterogeneous population of pancreatic progenitor cells (Scharfmann, Xiao et al. 
2008). Whether or not the pancreatic progenitors are derived from a self-renewing 
pancreatic stem cell is still under debate (Jiang and Morahan 2011), and is discussed further 
in Section 3.1. 
For β cell development, the essential role of three key transcription factors, Pax4, Nkx6.1, 
Nkx2.2, in the mouse and their relationships to the human β cell development is clear. Pax4 
(paired box 4) is required for the commitment to the pancreatic lineages (Wang, Elghazi et 
al. 2004), as well as for the regulation of β cell mass size, proliferation and survival in mice 
(Brun and Gauthier 2008), and mutations in the Pax4 gene have been linked to susceptibility 
to both Type I and Type II diabetes in humans (Yokoi, Kanamori et al. 2006; Chavali, 
Mahajan et al. 2011). In addition, both human and mice insulinoma cells overexpress Pax4 in 
comparison to mature β cells, suggesting that Pax4 may also play a role in β cell 
proliferation and resistance to apoptosis. Nkx2.2 is expressed early during embryonic 
pancreatic development (Doyle, Loomis et al. 2007), whereas Nkx6.1 is expressed later and 
restricted to the β cells. Nkx2.2 and Nkx6.1 knockout mice die in the neonatal period due to 
the lack of IPCs (Sussel, Kalamaras et al. 1998). Nkx2.2 has both activator and repressor 
functions; the repressor function is important for regulation of β cell function postnatally 
(Doyle and Sussel 2007). Nkx6.1 functions exclusively in β cells and is required for β cell 
development and specification, control of insulin secretion after glucose challenge, and can 
also induce human and rat β cell proliferation (Schisler, Fueger et al. 2008). However, in vivo 
overexpression of Nkx6.1 does not have any effect on β cells in the mouse (Schaffer, Yang et 
al. 2011). 
2.4. Current therapies for TID 
A fully mature, functional β cell produces and appropriately secretes the mature form of 
insulin (i.e. proteolytic processing of pro-insulin to form C-peptide is evident), in response 
to glucose to maintain normal glycemic levels in the blood. The current treatment for TID is 
long-term insulin replacement therapy that is delivered via injection, insulin pens or pumps, 
and has been quite successful for control of hyperglycemia. However, insulin replacement 
therapy is not considered a cure for TID, as patients receiving insulin long-term still 
manifest abnormalities in metabolism, as measured by above-normal levels of glycated 
hemoglobin (HbA1c). Furthermore, for children, the daily requirement for insulin 
replacement can limit their day-to-day activities, and TID-related complications, such as 
vascular disease, retinopathy and neuropathy, still persist even with insulin therapy. 
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endodermal tissue and pancreatic epithelial cells before islet formation (Tornehave, Jansen 
et al. 1993). Islets can be located in the human fetus as early as 12-13 weeks post coitus 
(Piper, Brickwood et al. 2004), although functional β cells that are insulin-positive can be 
detected as early as 8 weeks.  
 
Figure 1. An overview of pancreatic endocrine cell development. The development of pancreatic endocrine 
cells starts with an early endocrine progenitor and ends with mature hormone-producing islet cell 
types. Cell surface markers (noted above the cell types) and gene expression (in italics) in distinct 
pancreatic cell lineages are shown. The existence of the self-renewing pancreatic stem cell is still 
controversial. 
An overview of pancreatic endocrine cell development is shown in Figure 1. Definitive 
endodermal progenitor cells can differentiate into pancreatic progenitor cells, which have 
been identified by the expression of two critical transcriptional factors: Pdx1 and neurogenin 
3 (Ngn3). Experiments with conditional Pdx1 transgenic reporter mice (inducible Cre-ERTM-
LoxP system to mark the progeny of cells that express Pdx1) demonstrated that Pdx1+ cells 
give rise to all three types of pancreatic tissue: exocrine, endocrine and duct (Gu, 
Dubauskaite et al. 2002). In line with this, Pdx1 deficiency in mouse and humans leads to a 
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complete pancreas agenesis at birth (Ahlgren, Jonsson et al. 1996). Pdx1 is also a critical 
transcriptional activator of insulin and somatostatin in adult islet cells (Ohlsson, Thor et al. 
1991; Leonard, Peers et al. 1993). Similar to Pdx1, Ngn3+ cells give rise to all islet lineage cells 
during embryogenesis (Gradwohl, Dierich et al. 2000), with peak Ngn3 expression at 15.5 
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(Gradwohl, Dierich et al. 2000; Johansson, Dursun et al. 2007), Ngn3+ cells in duct-ligated 
adult pancreas were detected and observed to differentiate into islet cells (Gu, Dubauskaite 
et al. 2002; Xu, D'Hoker et al. 2008). Beta cells in the human, like in the mouse, are derived 
from a heterogeneous population of pancreatic progenitor cells (Scharfmann, Xiao et al. 
2008). Whether or not the pancreatic progenitors are derived from a self-renewing 
pancreatic stem cell is still under debate (Jiang and Morahan 2011), and is discussed further 
in Section 3.1. 
For β cell development, the essential role of three key transcription factors, Pax4, Nkx6.1, 
Nkx2.2, in the mouse and their relationships to the human β cell development is clear. Pax4 
(paired box 4) is required for the commitment to the pancreatic lineages (Wang, Elghazi et 
al. 2004), as well as for the regulation of β cell mass size, proliferation and survival in mice 
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2.4. Current therapies for TID 
A fully mature, functional β cell produces and appropriately secretes the mature form of 
insulin (i.e. proteolytic processing of pro-insulin to form C-peptide is evident), in response 
to glucose to maintain normal glycemic levels in the blood. The current treatment for TID is 
long-term insulin replacement therapy that is delivered via injection, insulin pens or pumps, 
and has been quite successful for control of hyperglycemia. However, insulin replacement 
therapy is not considered a cure for TID, as patients receiving insulin long-term still 
manifest abnormalities in metabolism, as measured by above-normal levels of glycated 
hemoglobin (HbA1c). Furthermore, for children, the daily requirement for insulin 
replacement can limit their day-to-day activities, and TID-related complications, such as 
vascular disease, retinopathy and neuropathy, still persist even with insulin therapy. 
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Pancreatic transplantation has been performed for TID patients with success, but the main 
limitations of this strategy are the low number of suitable donors required for transplant 
and the decision if the risks of surgery and transplantation outweigh the benefits 
(Jahansouz, Kumer et al. 2011). Furthermore, even with insulin replacement therapy or 
pancreatic transplantation, autoreactive immune cells that can attack and destroy any 
residual β cells in the patient can still remain. For this reason, therapies that modulate the 
immune response to β cells and β cell antigens also exist, and their safety and efficacy have 
been or are currently being tested in clinical trials (Bluestone, Herold et al. 2010; Waldron-
Lynch and Herold 2011). GAD65 specific-antigen-based immunotherapy with alum 
adjuvant demonstrated preservation of C-peptide fasting levels in younger new-onset 
patients four years after treatment (Ludvigsson, Hjorth et al. 2011), but this was not 
supported in the larger Phase III trial (Ludvigsson, Krisky et al. 2012). Humanized anti-CD3 
antibody (in which human Fc immunoglobulin domains are engineered to mouse CD3-
binding portions of the antibody) therapy given in a single dose reduced the decline of 
insulin production and the amount of exogenous insulin required in the patients (Herold, 
Gitelman et al. 2009). Interestingly, the anti-CD3 antibodies reduced the numbers of 
circulating T lymphocytes, but whether or not autoreactive T cells are specifically depleted 
is unclear. There is evidence that the anti-CD3 antibody acts as a weak TCR agonist and 
stimulates the production of regulatory T cells (Tregs) in humans. B lymphocytes in TID have 
been postulated to act as antigen-presenting cells and also to produce autoantibodies that 
can result in β cell destruction (Bluestone, Herold et al. 2010). Anti-CD20 antibodies target 
and deplete B lymphocytes, and lead to a preservation of β cell function in patients, as 
measured by C-peptide production and reduction of HbA1c levels compared to controls. 
However, the level of autoantibodies in these TID patients was not determined, so the 
mechanism by which anti-CD20 therapy works in TID patients is still uncertain. As we will 
explain further below, these immune modulation therapies may also be important for the 
future success of β cell regeneration and transplantation.  
3. Experimental alternative treatments for TID: Stem cells 
Pancreas transplantation has succeeded as a replacement for insulin-secreting β cells for TID 
patients, but this relies on a limited source of cadaveric pancreatic tissue (Danovitch, Cohen 
et al. 2005). Early studies demonstrated that isolated human islets did not proliferate in 
suspension culture, and that adherent islet cells showed limited replication of β cells 
(Nielsen, Brunstedt et al. 1979; Nielsen, Galsgaard et al. 2001). Therefore, alternative sources 
of IPCs are needed, and stem cells have been suggested as this source. Stem cells are 
undifferentiated cells that are capable of self-renewal and differentiation into any cell type. 
They can be classified depending on their origin. Embryonic stem cells (ESCs) are derived 
from the inner cell mass of implanted embryos (Evans and Kaufman 1981), induced 
pluripotent stem cells (iPSCs) are adult or fetal cells that have been “reprogrammed” to an 
ESC-like state (Takahashi and Yamanaka 2006), adult stem cells are isolated from adult 
tissues (Becker, Mc et al. 1963) and germline-derived stem cells are generated from 
embryonic or adult gonads (Shamblott, Axelman et al. 1998). In this section, we will discuss 
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the state-of-the-art technologies in which the different types of stem cells are generated and 
differentiated and their possible clinical applications as cellular replacement therapies for 
TID. 
3.1. Tissue-specific pancreatic stem cells 
The existence of pancreatic stem cells was proposed in the last decade (Ramiya, Maraist et 
al. 2000), and is still a topic of debate (Dor, Brown et al. 2004; Smukler, Arntfield et al. 2011) 
(Figure 1). When defining a “stem cell” by function, the standard tests are to examine the 
ability of a putative stem cell to self-renew, often using proliferation assays; and 
differentiate, measured by changes in function, cell surface marker and/or gene expression. 
Evidence from fetal and adult pancreas biology in physiological as well as pathological 
conditions support the hypothesis of the existence of pancreatic adult stem cells based on 
proliferation assays. For example, pancreas from pregnant rats and mice displayed an 
uptake of bromodeoxyuridine (BrdU) during pregnancy, suggesting the proliferation of 
islets (Parsons, Brelje et al. 1992; Karnik, Chen et al. 2007). This proliferation was stimulated 
by prolactin (Nielsen, Svensson et al. 1999; Rieck and Kaestner) that reduced expression of 
multiple endocrine neoplasia type 1 (MEN1), a tumor suppressor (Karnik, Chen et al. 2007), and 
enhanced expression of tryptophan hydroxylase 1 (Tph1), which allows for incorporation of 
BrdU in the cell (Kim, Toyofuku et al. 2010). In addition, expression of Ki-67 (a marker 
associated with proliferation) and β-cell mass increase has been described in the pancreas of 
obese mice, perhaps as a response to insulin resistance (Butler, Janson et al. 2003; Butler, 
Janson et al. 2003). Other authors have shown that mature β cells are capable of self-
replication (Figure 2), and that this is the mechanism by which new beta cells in the adult 
are generated. Young diabetic rats are able to regenerate β cells after streptozotocin (STZ)-
induced β cell destruction, but this capacity for regeneration declines rapidly during the first 
days of life (Wang, Bouwens et al. 1996). β cell regeneration is also detected after 
pancreatectomies, but the regeneration response is different between species, with a higher 
rate of regeneration in rodents than in larger mammals (Stagner and Samols 1991; Bonner-
Weir and Sharma 2002; Robertson, Lanz et al. 2002; Matveyenko, Veldhuis et al. 2006). More 
recently, human islet precursor cells were identified from IPCs that underwent an epithelial-
to-mesenchymal transition, demonstrating that, in vitro, human IPCs from the islets of 
cadaveric pancreas donors could spontaneously produce highly proliferative “de-
differentiated” fibroblast-like cells that could then possibly be expanded and later re-
induced into insulin-producing, β-like cells (Gershengorn, Hardikar et al. 2004; Russ, Bar et 
al. 2008; Russ, Sintov et al. 2011).  
As mentioned previously, Pdx1 and Ngn3 are two transcription factors which are essential 
for endocrine cell differentiation during pancreas development, and have been targets in the 
search of pancreatic stem cells. However, it has not been demonstrated if Pdx1+ cells can self-
renew (Jiang and Morahan 2011), a requirement for stem cell definition. Ngn3+ cells from 
duct-ligated adult pancreas can develop into islet cells (Xu, D'Hoker et al. 2008), satisfying 
the stem cell differentiation requirement. However, Ngn3 expression in the embryo inhibits 
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the state-of-the-art technologies in which the different types of stem cells are generated and 
differentiated and their possible clinical applications as cellular replacement therapies for 
TID. 
3.1. Tissue-specific pancreatic stem cells 
The existence of pancreatic stem cells was proposed in the last decade (Ramiya, Maraist et 
al. 2000), and is still a topic of debate (Dor, Brown et al. 2004; Smukler, Arntfield et al. 2011) 
(Figure 1). When defining a “stem cell” by function, the standard tests are to examine the 
ability of a putative stem cell to self-renew, often using proliferation assays; and 
differentiate, measured by changes in function, cell surface marker and/or gene expression. 
Evidence from fetal and adult pancreas biology in physiological as well as pathological 
conditions support the hypothesis of the existence of pancreatic adult stem cells based on 
proliferation assays. For example, pancreas from pregnant rats and mice displayed an 
uptake of bromodeoxyuridine (BrdU) during pregnancy, suggesting the proliferation of 
islets (Parsons, Brelje et al. 1992; Karnik, Chen et al. 2007). This proliferation was stimulated 
by prolactin (Nielsen, Svensson et al. 1999; Rieck and Kaestner) that reduced expression of 
multiple endocrine neoplasia type 1 (MEN1), a tumor suppressor (Karnik, Chen et al. 2007), and 
enhanced expression of tryptophan hydroxylase 1 (Tph1), which allows for incorporation of 
BrdU in the cell (Kim, Toyofuku et al. 2010). In addition, expression of Ki-67 (a marker 
associated with proliferation) and β-cell mass increase has been described in the pancreas of 
obese mice, perhaps as a response to insulin resistance (Butler, Janson et al. 2003; Butler, 
Janson et al. 2003). Other authors have shown that mature β cells are capable of self-
replication (Figure 2), and that this is the mechanism by which new beta cells in the adult 
are generated. Young diabetic rats are able to regenerate β cells after streptozotocin (STZ)-
induced β cell destruction, but this capacity for regeneration declines rapidly during the first 
days of life (Wang, Bouwens et al. 1996). β cell regeneration is also detected after 
pancreatectomies, but the regeneration response is different between species, with a higher 
rate of regeneration in rodents than in larger mammals (Stagner and Samols 1991; Bonner-
Weir and Sharma 2002; Robertson, Lanz et al. 2002; Matveyenko, Veldhuis et al. 2006). More 
recently, human islet precursor cells were identified from IPCs that underwent an epithelial-
to-mesenchymal transition, demonstrating that, in vitro, human IPCs from the islets of 
cadaveric pancreas donors could spontaneously produce highly proliferative “de-
differentiated” fibroblast-like cells that could then possibly be expanded and later re-
induced into insulin-producing, β-like cells (Gershengorn, Hardikar et al. 2004; Russ, Bar et 
al. 2008; Russ, Sintov et al. 2011).  
As mentioned previously, Pdx1 and Ngn3 are two transcription factors which are essential 
for endocrine cell differentiation during pancreas development, and have been targets in the 
search of pancreatic stem cells. However, it has not been demonstrated if Pdx1+ cells can self-
renew (Jiang and Morahan 2011), a requirement for stem cell definition. Ngn3+ cells from 
duct-ligated adult pancreas can develop into islet cells (Xu, D'Hoker et al. 2008), satisfying 
the stem cell differentiation requirement. However, Ngn3 expression in the embryo inhibits 
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proliferation by inducing cyclin-dependent kinase inhibitor 1a (Cdkn1a) (Miyatsuka, Kosaka et 
al. 2011), resulting in limited mitotic potential of Ngn3+ cells (Gradwohl, Dierich et al. 2000; 
Johansson, Dursun et al. 2007), which is evidence against self-renewal.  
 
Figure 2. Different mechanisms for β cell regeneration based on β cell mass. Differentiation from pancreatic 
stem cells and transdifferentiation from β cells would occur when less than 30% of the normal β cell 
mass is present, whereas self-replication of residual β cells would occur if 30-50% of the normal β cell 
mass is present. 
To test whether β cells can self-replicate in the adult, transgenic mice in which pre-existing β 
cells were specifically labeled were utilized (Dor, Brown et al. 2004). In the absence of 
pancreatic injury, these labeled cells were not replaced by new IPCs, arguing against the 
existence of an adult pancreatic stem cell. However, the labeled IPCs were able to uptake 
BrdU after pancreatectomy, indicating that adult β cells contain regenerative ability (Dor, 
Brown et al. 2004). A different model in which apoptosis was induced specifically in β cells 
using a diphtheria toxin receptor (DTR) transgenic mouse model showed β cell recovery, 
restoration to euglycemia, and that the surviving β cells were involved in their own 
regeneration (Nir, Melton et al. 2007). These studies assumed that insulin expression was 
limited exclusively to cells, but it has been shown that in certain circumstances, other cells 
and tissues can express insulin (Kojima, Fujimiya et al. 2004). In support of this, rare 
multipotent stem cells which express insulin have been described in both embryonic and 
adult mouse and human pancreas that are distinct from mature β cells (Smukler, Arntfield 
et al. 2011). Importantly, these cells were shown to self-renew, expressed Pdx1, Nkx6.1, Ngn3 
and insulin, and differentiate into IPCs that could alleviate diabetes in mice. Therefore, it 
appears that adult pancreatic stem cells do indeed exist, and the assumption that insulin is 
not expressed in β cell progenitors is incorrect. These findings can now be used to model 
additional cellular alternatives for β cell replacement in TID. 
Questions regarding the existence and location of pancreatic stem cells and progenitors 
outside of the pancreas are still an area of investigation. Hepatic and pancreatic cells are 
derived from a common endodermal progenitor during embryogenesis, and this has led to 
the hypothesis that cells from fetal liver tissue could be used as an alternative β cell source. 
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Pancreatic duct cells and liver cells can be induced to express certain β cell gene products in 
culture (Heremans, Van De Casteele et al. 2002; Sapir, Shternhall et al. 2005). In support of 
this, CD45- Ter119- c-kit- hepatic stem cells were isolated from mouse fetal liver and 
differentiated into IPCs in vitro. These differentiated cells were then transplanted into drug-
induced diabetic mice, which showed a significant reduction of their blood glucose levels 
(Feng, Du et al. 2005). Bone marrow has also been proposed as another possible source of 
IPCs. For example, human fetal bone marrow-derived CD45- Glycophorin A- mesodermal 
progenitor cells generated insulin secreting islet-like clusters when injected into human fetal 
pancreatic tissues that were implanted in STZ-treated NOD/severe combined 
immunodeficiency (SCID) mice (Ai, Todorov et al. 2007). In the mouse, progeny of Mac-1- 
Sca+ bone marrow cells cultured with cytokines such as IL-3, IL-6, IL-11 and stem cell factor 
(SCF) migrate into the pancreas islets and have been reported to convert into CD45- CD34+ 
insulin-expressing cells (Luo, Luo et al. 2009). The mechanisms involved in the conversion of 
these bone marrow cells into IPCs were not investigated. 
3.2. Transdifferentiated cells as heterologous sources of β cells 
Transdifferentiation is defined as a process by which a “terminally” differentiated cell 
changes into another type of differentiated cell. Transdifferentiation of pancreatic α cells 
into β cells has been suggested as a source of β cell replacement for TID. Transdifferentiation 
of α cells into β cells has been observed in vivo (Thorel, Nepote et al. 2010). Mice in which 
more than 99% of β cells were ablated eventually recovered β cell mass, due to 
transdifferentiated α cells. The rates of recovery from α cells ranged between 32 to 81% 
among individuals. These data have led to a model in which several β cell regenerative 
mechanisms can occur, but each mechanism is used under different pathological conditions 
(Figure 2). For example, in this model, pancreatic stem cells and progenitors, as well as 
transdifferentiated cells, naturally replace β cells when β cell mass is extremely depleted 
(less than 30% of normal), but β cell mass is regenerated by self-replication of β cells when 
the loss is 30 - 50% of normal (Thorel, Nepote et al. 2010). Interestingly, during 
transdifferentiation from the α to β phenotype, cells that express both insulin and glucagon 
can be temporally detected (Thorel, Nepote et al. 2010). These “bi-hormonal” cells have been 
described during pancreas development by immunohistochemistry or single cell gene 
expression analysis (Chiang and Melton 2003). Their existence is controversial and more 
studies are required before they can be accepted to be true endocrine progenitor cells, such 
as clear isolation of the population and definitive evidence that they can give rise to α or β 
cells in vitro or in vivo (Alpert, Hanahan et al. 1988; Teitelman, Alpert et al. 1993; Herrera, 
Huarte et al. 1994; Herrera 2000; Jensen, Heller et al. 2000). 
One important question that has not yet been answered pertains to the location of the cells 
that can undergo transdifferentiation into β cells in vivo. Two major pancreas compartments 
contain cells with the potential of generating new β cells via transdifferentiation in vivo: 
ductal epithelium and acinar tissue. Islet-like clusters of human ductal epithelium cells 
reverse diabetes after transplantation (Bonner-Weir, Taneja et al. 2000; Ramiya, Maraist et al. 
2000). After pancreatic duct ligation, ductal cells that express Ngn3 (a marker of pancreatic 
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proliferation by inducing cyclin-dependent kinase inhibitor 1a (Cdkn1a) (Miyatsuka, Kosaka et 
al. 2011), resulting in limited mitotic potential of Ngn3+ cells (Gradwohl, Dierich et al. 2000; 
Johansson, Dursun et al. 2007), which is evidence against self-renewal.  
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changes into another type of differentiated cell. Transdifferentiation of pancreatic α cells 
into β cells has been suggested as a source of β cell replacement for TID. Transdifferentiation 
of α cells into β cells has been observed in vivo (Thorel, Nepote et al. 2010). Mice in which 
more than 99% of β cells were ablated eventually recovered β cell mass, due to 
transdifferentiated α cells. The rates of recovery from α cells ranged between 32 to 81% 
among individuals. These data have led to a model in which several β cell regenerative 
mechanisms can occur, but each mechanism is used under different pathological conditions 
(Figure 2). For example, in this model, pancreatic stem cells and progenitors, as well as 
transdifferentiated cells, naturally replace β cells when β cell mass is extremely depleted 
(less than 30% of normal), but β cell mass is regenerated by self-replication of β cells when 
the loss is 30 - 50% of normal (Thorel, Nepote et al. 2010). Interestingly, during 
transdifferentiation from the α to β phenotype, cells that express both insulin and glucagon 
can be temporally detected (Thorel, Nepote et al. 2010). These “bi-hormonal” cells have been 
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expression analysis (Chiang and Melton 2003). Their existence is controversial and more 
studies are required before they can be accepted to be true endocrine progenitor cells, such 
as clear isolation of the population and definitive evidence that they can give rise to α or β 
cells in vitro or in vivo (Alpert, Hanahan et al. 1988; Teitelman, Alpert et al. 1993; Herrera, 
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One important question that has not yet been answered pertains to the location of the cells 
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contain cells with the potential of generating new β cells via transdifferentiation in vivo: 
ductal epithelium and acinar tissue. Islet-like clusters of human ductal epithelium cells 
reverse diabetes after transplantation (Bonner-Weir, Taneja et al. 2000; Ramiya, Maraist et al. 
2000). After pancreatic duct ligation, ductal cells that express Ngn3 (a marker of pancreatic 
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progenitors, see Section 2.3) differentiate into β cells if transplanted into fetal pancreas (Xu, 
D'Hoker et al. 2008). Experiments using ductal cell lineage tracing with the carbonic 
anydrase II (CA2, an enzyme specific for ductal cells) promoter showed CA2 expression in 
islet cells under normal conditions or after pancreatic duct ligation, adding more evidence of 
ductal epithelial cells’ ability to differentiate into islet cells. Some authors have suggested 
that these pancreatic ductal cells are mesenchymal stem cells (MSC) (Seeberger, Dufour et al. 
2006). Whether these MSC differentiate directly into pancreatic stem cells or 
transdifferentiate from epithelial cells to pancreatic stem cells still remains unclear (Bonner-
Weir, Inada et al. 2008; Inada, Nienaber et al. 2008). The exocrine tissue, in particular acinar 
cells, could provide a new alternative β cell replacement source for the treatment of 
diabetes. Acinar cells are usually discarded after islet purification from donated pancreas for 
transplantation, but could be reprogrammed in vivo to β cells by introducing a combination 
of the transcription factors Ngn3, Pdx1 and Mafa by means of adenovirus. These 
transcription factors are required only transiently and they are not detectable after two 
months of transfection (Zhou, Martin et al. 2008). Epithelial cells that were purified from 
non-endocrine islet cells were co-transplanted with fetal pancreatic cells and differentiated 
into endocrine cells (Hao, Tyrberg et al. 2006). Moreover, cells which express amylase/elastase, 
specific markers of acinar cells, differentiated into insulin expressing cells, as measured by 
cell tracing (Minami, Okuno et al. 2005). 
Taken together, the studies cited in this section demonstrate that there are many possible 
pluripotent and even terminally differentiated cells in vivo that could be used to derive new 
IPCs that can alleviate hyperglycemia in diabetic mouse models. However, the alternative 
source that been most exhaustively researched is the totipotent embryonic stem cell (ESC). 
In the next section, we review studies of ESC differentiation into IPCs.  
3.3. Differentiation of embryonic stem cells into insulin producing cells 
The use of ESCs for cell replacement therapies has great promise, due to the potentially 
unlimited self-renewal of ESC in their undifferentiated state, and the potential of ESC to 
differentiate into any type of cellular derivatives. Many groups have used diverse 
methodologies to differentiate human or murine ESCs into IPCs for β cell replacement in 
diabetes (Figure 3). The most common obstacles amongst the different protocols are the 
inability of ESC-derived IPCs (ESC-IPCs) to secrete insulin after glucose-stimulation, the risk 
of teratoma formation due to undifferentiated ESC that remain in the ESC-IPC culture, and 
immune rejection of the ESC-IPC after transplantation in vivo. Moreover, murine and human 
ESC lines do not behave similarly when they are differentiated into IPCs, which has led to 
species-distinct protocols (Figure 3).  
The efficiency of ESC-IPC differentiation in vitro between murine and human ESC cells is 
clearly different. One reason for this appears to be the manner by which the endodermal 
germ layer is initiated in ESC culture. The embryoid body (EB) is a three-dimensional cluster 
of ESC that induces the differentiation of the endoderm, mesoderm, and ectoderm germ 
layers. In contrast to the EB method, ESCs can also differentiate in two-dimensional 
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monolayers. For ESC-IPC differentiation, murine ESCs have been observed to differentiate 
very efficiently to endodermal cells via EB formation, with approximately 50% of the cells 
expressing Foxa2. In contrast, production of definitive endoderm cells in human EBs is less 
efficient, ranging from 5% to 19% of cells expressing Foxa2 or Sox17 (Shim, Kim et al. 2007). 
Instead, when cultured in monolayers, human ESCs show an efficiency of definitive 
endoderm differentiation over 80%, as measured by co-expression of Foxa2 and Sox17 
(D'Amour, Agulnick et al. 2005; McLean, D'Amour et al. 2007), but murine ESCs are not 
efficiently differentiated into endoderm with this method (Kim, Hoffman et al. 2010). 
Consequently, most methods described for murine ESCs utilize EB formation, whereas 
human ESC methods use monolayers. Finding a common consensus protocol is one future 
challenge to the improvement of ESC-IPC differentiation and function. A summary of some 
murine and human IPC differentiation studies that includes a comparison of the IPC 
functional tests performed is presented in Table 1 and Table 2, respectively. 
 
Figure 3. Comparison of murine versus human ESC differentiation protocols to insulin-producing cells. The 
schematic shows the differences in culture methods to produce IPCs from murine ESC (top) and human 
ESC (bottom). Please see the main text for more details. 
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progenitors, see Section 2.3) differentiate into β cells if transplanted into fetal pancreas (Xu, 
D'Hoker et al. 2008). Experiments using ductal cell lineage tracing with the carbonic 
anydrase II (CA2, an enzyme specific for ductal cells) promoter showed CA2 expression in 
islet cells under normal conditions or after pancreatic duct ligation, adding more evidence of 
ductal epithelial cells’ ability to differentiate into islet cells. Some authors have suggested 
that these pancreatic ductal cells are mesenchymal stem cells (MSC) (Seeberger, Dufour et al. 
2006). Whether these MSC differentiate directly into pancreatic stem cells or 
transdifferentiate from epithelial cells to pancreatic stem cells still remains unclear (Bonner-
Weir, Inada et al. 2008; Inada, Nienaber et al. 2008). The exocrine tissue, in particular acinar 
cells, could provide a new alternative β cell replacement source for the treatment of 
diabetes. Acinar cells are usually discarded after islet purification from donated pancreas for 
transplantation, but could be reprogrammed in vivo to β cells by introducing a combination 
of the transcription factors Ngn3, Pdx1 and Mafa by means of adenovirus. These 
transcription factors are required only transiently and they are not detectable after two 
months of transfection (Zhou, Martin et al. 2008). Epithelial cells that were purified from 
non-endocrine islet cells were co-transplanted with fetal pancreatic cells and differentiated 
into endocrine cells (Hao, Tyrberg et al. 2006). Moreover, cells which express amylase/elastase, 
specific markers of acinar cells, differentiated into insulin expressing cells, as measured by 
cell tracing (Minami, Okuno et al. 2005). 
Taken together, the studies cited in this section demonstrate that there are many possible 
pluripotent and even terminally differentiated cells in vivo that could be used to derive new 
IPCs that can alleviate hyperglycemia in diabetic mouse models. However, the alternative 
source that been most exhaustively researched is the totipotent embryonic stem cell (ESC). 
In the next section, we review studies of ESC differentiation into IPCs.  
3.3. Differentiation of embryonic stem cells into insulin producing cells 
The use of ESCs for cell replacement therapies has great promise, due to the potentially 
unlimited self-renewal of ESC in their undifferentiated state, and the potential of ESC to 
differentiate into any type of cellular derivatives. Many groups have used diverse 
methodologies to differentiate human or murine ESCs into IPCs for β cell replacement in 
diabetes (Figure 3). The most common obstacles amongst the different protocols are the 
inability of ESC-derived IPCs (ESC-IPCs) to secrete insulin after glucose-stimulation, the risk 
of teratoma formation due to undifferentiated ESC that remain in the ESC-IPC culture, and 
immune rejection of the ESC-IPC after transplantation in vivo. Moreover, murine and human 
ESC lines do not behave similarly when they are differentiated into IPCs, which has led to 
species-distinct protocols (Figure 3).  
The efficiency of ESC-IPC differentiation in vitro between murine and human ESC cells is 
clearly different. One reason for this appears to be the manner by which the endodermal 
germ layer is initiated in ESC culture. The embryoid body (EB) is a three-dimensional cluster 
of ESC that induces the differentiation of the endoderm, mesoderm, and ectoderm germ 
layers. In contrast to the EB method, ESCs can also differentiate in two-dimensional 
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monolayers. For ESC-IPC differentiation, murine ESCs have been observed to differentiate 
very efficiently to endodermal cells via EB formation, with approximately 50% of the cells 
expressing Foxa2. In contrast, production of definitive endoderm cells in human EBs is less 
efficient, ranging from 5% to 19% of cells expressing Foxa2 or Sox17 (Shim, Kim et al. 2007). 
Instead, when cultured in monolayers, human ESCs show an efficiency of definitive 
endoderm differentiation over 80%, as measured by co-expression of Foxa2 and Sox17 
(D'Amour, Agulnick et al. 2005; McLean, D'Amour et al. 2007), but murine ESCs are not 
efficiently differentiated into endoderm with this method (Kim, Hoffman et al. 2010). 
Consequently, most methods described for murine ESCs utilize EB formation, whereas 
human ESC methods use monolayers. Finding a common consensus protocol is one future 
challenge to the improvement of ESC-IPC differentiation and function. A summary of some 
murine and human IPC differentiation studies that includes a comparison of the IPC 
functional tests performed is presented in Table 1 and Table 2, respectively. 
 
Figure 3. Comparison of murine versus human ESC differentiation protocols to insulin-producing cells. The 
schematic shows the differences in culture methods to produce IPCs from murine ESC (top) and human 
ESC (bottom). Please see the main text for more details. 
 






In vitro glucose 
response 




R1 Not done Not done Yes Yes (Soria, Roche et al. 2000) 





Oh et al. 2005) 
(Lumelsky, Blondel 
et al. 2001) 
JM1, ROSA, 
and ESF122 Yes Yes Yes Yes 
(Hori, Rulifson et al. 
2002) 
R1 and 
ESF122 Yes Yes Yes 
Yes with Pax4 
transfection 
(Blyszczuk, Asbrand 
et al. 2004) 
D3 Yes Not done Not done Not done 
(McKiernan, 
O'Driscoll et al. 
2007) 
D3 Yes Not done Yes Not done (Wang and Ye 2009) 
B6 Yes Yes Yes Not done (Kim, Hoffman et al. 2010) 
EB3 Yes Yes Yes Not done (Miyazaki, Yamato et al. 2004) 
R1 Yes Yes Yes Not done (Banerjee, Sharma et al.) 
Table 1. Murine ESC-IPC differentiation protocols 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 292 















Yes Yes Yes Yes 
(D'Amour, Bang et 
al. 2006; Kroon, 
Martinson et al. 
2008) 
H1and H9 Yes Yes Yes Yes (Jiang, Shi et al. 2007) 
H1, H7 and 
H9 Yes Yes Yes Not done 
(Jiang, Au et al. 
2007) 
Hes3 Yes Yes Yes No (Phillips, Hentze et al. 2007) 
Table 2. Human ESC-IPC differentiation protocols 
The first successful approach differentiating ESCs into functional IPCs utilized murine ESCs 
that were transfected with a neomycin selection gene under the control of the human insulin 
promoter (Soria, Roche et al. 2000). IPCs from EBs were selected with neomycin and 
nicotinamide, and no teratoma formation was described after transplantation. These ESC-
IPCs normalized blood glycemia in diabetic mice during the first 4 weeks after transplant; 
however, 40% of the mice became hyperglycemic 12 weeks after implantation, suggesting 
that the ESC-IPCs function or lifespan was diminished (Soria, Roche et al. 2000). Since this 
initial report, numerous other approaches for differentiating ES cells into IPCs have been 
described, but three protocols by Lumelsky et al., Hori et al., and Blyszczuk et al. appear to 
be the most referenced (Lumelsky, Blondel et al. 2001; Hori, Rulifson et al. 2002; Blyszczuk, 
Asbrand et al. 2004). Non-transgenic ESCs were differentiated into IPCs by means of a five-
step protocol: 1) expansion of ES cells, 2) formation of EBs, 3) selection of nestin-expressing 
cells with a serum-free medium containing insulin, transferrin, selenium and fibronectin 
(ITSFn), 4) expansion of pancreatic endocrine progenitor cells with a N2 medium containing 
B27 and the mitogenic basic fibroblast growth factor (bFGF) and 5) induction of 
differentiation of IPCs by withdrawal of bFGF in presence of nicotinamide (Lumelsky, 
Blondel et al. 2001). ESC-IPCs expressed insulin-1 and insulin-2 (murine isoforms) as 
detected by immunohistochemistry and PCR, and secreted insulin after glucose challenge 
(Lumelsky, Blondel et al. 2001). However, two years later, ESC-IPCs produced by this 
method became controversial, as it was reported that they were incapable of de novo insulin 
synthesis, and instead acquired insulin from the culture medium (Rajagopal, Anderson et al. 
2003). This controversy currently is still unresolved, as some groups suggest that the insulin 
released by the ESC-IPCs is a mixture of insulin produced de novo, as well as insulin uptake 
from the medium (Paek, Morgan et al. 2005), and other groups state that the insulin 
expression by ESC-IPCs is an artifact due to apoptotic or necrotic cells (Hansson, Tonning et 
al. 2004).  
To settle this controversy, the detection of C-peptide, a by-product of endogenous insulin 
synthesis, will be needed in order to prove that ESC-IPCs produce insulin de novo. ESC-IPCs 
produced with the Lumelsky protocol have been shown to express C-peptide, but they 
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failed to alleviate diabetes in mice, due to teratoma formation (indicating that not all of the 
ESCs were completely differentiated) (Fujikawa, Oh et al. 2005). Hori et al. provided an 
alternative methodology, using the selection of nestin+ cells, a marker for mitotically active 
cells. Nestin is a neuronal marker, and it is not surprising that the Lumelsky and the Hori 
protocols would also generate neuronal cells when differentiating ES cells into IPCs 
(Lumelsky, Blondel et al. 2001; Hori, Rulifson et al. 2002). Moreover, Hori et al. added 
LY294002, an inhibitor of phosphoinositide 3-kinase, an essential intracellular signaling 
regulator, to the culture media at the IPC induction step (Hori, Rulifson et al. 2002). ESC-
IPCs produced via the Hori protocol were smaller, with a reduced cytoplasmic volume 
compared to pancreatic β cells, probably due to the ability of LY294002 to reduce cell size 
(Vanhaesebroeck, Leevers et al. 2001). Compared to the Lumelsky protocol, IPCs produced 
by the Hori protocol were able to release more insulin and rescue glycemic blood levels after 
3 weeks of transplantation in diabetic mice (Hori, Rulifson et al. 2002). However, these 
results could not been reproduced by other authors (Boyd, Wu et al. 2008).  
Blyszczuk et al. described a third ESC-IPC differentiation protocol (Blyszczuk, Asbrand et 
al. 2004). This protocol consisted of three steps: 1) formation of EBs, 2) spontaneous 
differentiation of EBs into cells of ectodermal, mesodermal and endodermal lineages by 
transferring EBs into gelatin-coated plates, and 3) induction of differentiation into IPCs by 
culturing the gelatin-plated EB cell suspension with culture media containing progesterone, 
laminin, putrescine, selenium, nicotinamide, insulin, transferrin and B27 (Blyszczuk, 
Asbrand et al. 2004; Schroeder, Kania et al. 2006; Schroeder, Rolletschek et al. 2006). ESC-
IPCs generated by the Blyszczuk protocol released insulin in vitro after glucose challenge, 
but they did not succeed in rescuing diabetic mice in vivo. The generation of ESC-IPC via the 
activation of differentiation genes such as Pax4 was also studied. When Pax4-transduced 
ESCs differentiated into IPCs and transplanted to diabetic mice, blood glucose levels were 
reduced for at least 4 weeks. Similar reduced blood glucose levels were detected in diabetic 
mice transplanted with IPCs transfected with Pax4 by nucleofection (Lin, Kao et al. 2007). 
However, mice treated either with unmodified or Pax4-modified ESC-IPCs developed 
teratomas (Blyszczuk, Asbrand et al. 2004). Exhaustive microarray studies have compared 
gene expression in ESC-IPC derived from wild type and Pax4+ ESC at different stages of in 
vitro differentiation in order to attempt understand the mechanisms and factors required to 
produce fully functional ESC-IPC. The authors conclude that murine ESC-derived 
pancreatic cells are unable to complete pancreatic differentiation in vitro, as they appear to 
be blocked at the embryonic/fetal stage of development, as deduced by their gene 
expression profiles (Rolletschek, Schroeder et al. 2010). To date, murine ESC-IPCs are only 
able to acquire full functional β cell characteristics in vivo, but not in vitro, so the challenge to 
identify the missing factors to induce complete maturation of ESC-IPC in vitro remains. 
Solving the ESC-IPC differentiation problem is complicated, as individual ESC lines do not 
behave similarly before and after differentiation, which also makes direct cross-comparison 
of the published ESC-IPC differentiation protocols difficult (Osafune, Caron et al. 2008). The 
three ESC-IPC differentiation protocols described above were compared using three 
different ESC cell lines, with the ES122 ESC line providing the best results (Boyd, Wu et al. 
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expression by ESC-IPCs is an artifact due to apoptotic or necrotic cells (Hansson, Tonning et 
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failed to alleviate diabetes in mice, due to teratoma formation (indicating that not all of the 
ESCs were completely differentiated) (Fujikawa, Oh et al. 2005). Hori et al. provided an 
alternative methodology, using the selection of nestin+ cells, a marker for mitotically active 
cells. Nestin is a neuronal marker, and it is not surprising that the Lumelsky and the Hori 
protocols would also generate neuronal cells when differentiating ES cells into IPCs 
(Lumelsky, Blondel et al. 2001; Hori, Rulifson et al. 2002). Moreover, Hori et al. added 
LY294002, an inhibitor of phosphoinositide 3-kinase, an essential intracellular signaling 
regulator, to the culture media at the IPC induction step (Hori, Rulifson et al. 2002). ESC-
IPCs produced via the Hori protocol were smaller, with a reduced cytoplasmic volume 
compared to pancreatic β cells, probably due to the ability of LY294002 to reduce cell size 
(Vanhaesebroeck, Leevers et al. 2001). Compared to the Lumelsky protocol, IPCs produced 
by the Hori protocol were able to release more insulin and rescue glycemic blood levels after 
3 weeks of transplantation in diabetic mice (Hori, Rulifson et al. 2002). However, these 
results could not been reproduced by other authors (Boyd, Wu et al. 2008).  
Blyszczuk et al. described a third ESC-IPC differentiation protocol (Blyszczuk, Asbrand et 
al. 2004). This protocol consisted of three steps: 1) formation of EBs, 2) spontaneous 
differentiation of EBs into cells of ectodermal, mesodermal and endodermal lineages by 
transferring EBs into gelatin-coated plates, and 3) induction of differentiation into IPCs by 
culturing the gelatin-plated EB cell suspension with culture media containing progesterone, 
laminin, putrescine, selenium, nicotinamide, insulin, transferrin and B27 (Blyszczuk, 
Asbrand et al. 2004; Schroeder, Kania et al. 2006; Schroeder, Rolletschek et al. 2006). ESC-
IPCs generated by the Blyszczuk protocol released insulin in vitro after glucose challenge, 
but they did not succeed in rescuing diabetic mice in vivo. The generation of ESC-IPC via the 
activation of differentiation genes such as Pax4 was also studied. When Pax4-transduced 
ESCs differentiated into IPCs and transplanted to diabetic mice, blood glucose levels were 
reduced for at least 4 weeks. Similar reduced blood glucose levels were detected in diabetic 
mice transplanted with IPCs transfected with Pax4 by nucleofection (Lin, Kao et al. 2007). 
However, mice treated either with unmodified or Pax4-modified ESC-IPCs developed 
teratomas (Blyszczuk, Asbrand et al. 2004). Exhaustive microarray studies have compared 
gene expression in ESC-IPC derived from wild type and Pax4+ ESC at different stages of in 
vitro differentiation in order to attempt understand the mechanisms and factors required to 
produce fully functional ESC-IPC. The authors conclude that murine ESC-derived 
pancreatic cells are unable to complete pancreatic differentiation in vitro, as they appear to 
be blocked at the embryonic/fetal stage of development, as deduced by their gene 
expression profiles (Rolletschek, Schroeder et al. 2010). To date, murine ESC-IPCs are only 
able to acquire full functional β cell characteristics in vivo, but not in vitro, so the challenge to 
identify the missing factors to induce complete maturation of ESC-IPC in vitro remains. 
Solving the ESC-IPC differentiation problem is complicated, as individual ESC lines do not 
behave similarly before and after differentiation, which also makes direct cross-comparison 
of the published ESC-IPC differentiation protocols difficult (Osafune, Caron et al. 2008). The 
three ESC-IPC differentiation protocols described above were compared using three 
different ESC cell lines, with the ES122 ESC line providing the best results (Boyd, Wu et al. 
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2008). When the ES122 ESC line was differentiated using the Lumelsky, Hori or Blyszczuk 
protocols, the Blyszczuk protocol proved to be superior: higher insulin-1 and insulin-2 gene 
and protein expression, greater increase in insulin secretion after glucose challenge in vitro 
and longer duration of normoglycemic blood level in diabetic mice after transplantation 
were achieved. However, consistent with previous reports, IPCs formed teratomas after 
three weeks of transplantation (Boyd, Wu et al. 2008). Therefore, in order for ESC-IPCs to be 
used in the clinic, it is clear that additional measures must included in the ESC-IPC 
protocols before transplantation, such as: the depletion of undifferentiated cells, using 
markers like stage-specific embryonic antigen 1 (SSEA-1) in order to avoid teratoma 
formation, methods to efficiently scale-up cell numbers before transplantation in order to 
reach similar blood glycemia levels as with healthy β cells, and/or the identification and 
addition of factors that can induce ESC-IPC to more mature, functional status when cultured 
in vitro.  
More differentiation protocols to generate ESC-IPCs from murine ESCs have been described, 
but all of the known assays to test function of ESC-IPC have not been performed (Table 1). 
A comparative analysis in which the murine ESC D3 line was differentiated through the 
formation of EBs in the presence of retinoic acid showed how the subsequent exposure to 
sodium butyrate produced IPCs that expressed insulin-1 and insulin-2. However, C-peptide 
was not expressed and in vitro glucose response assays or transplantation in diabetic mice 
were not performed (McKiernan, O'Driscoll et al. 2007). Another approach, using a three-
dimensional (3D) system with a Type I rat tail collagen solution, generated IPCs from the 
murine ESC D3 line that secreted more insulin after in vitro glucose challenge than IPCs 
generated in a two-dimensional (2D) system (Wang and Ye 2009); however, no in vivo 
functional analysis of these IPCs was performed. Comparing the 3D system with the 
differentiation protocols described by Blyszczuk et al., Lumelsky et al. or Hori et al. using 
the same cell line would be interesting. In another protocol that omitted EB formation, ESC-
IPCs were generated by following a four step protocol: 1) treatment of ES cells with all-trans-
retinoic acid (ATRA) and fibroblast growth factor (bFGF), 2) withdrawal of ATRA, 3) 
induction of formation of cell cluster by growth in presence of N2 and B27 supplements and 
4) culture of clusters in dibutyryl cAMP and nicotinamide (Kim, Hoffman et al. 2010). These 
ESC-IPCs expressed insulin and responded to glucose challenge, but transplantation into 
diabetic mice was not performed, so the functionality of these cells in vivo is unknown. As 
transgenesis of ESCs with Pax4 seemed to influence ESC-IPC differentiation, other groups 
have attempted to control the expression of pancreatic genes during ESC-IPC 
differentiation. For instance, regulation of Pdx1 expression via the “Tet-off” system 
generated IPCs that increased insulin-2 and Ngn3 expression and secreted more insulin after 
glucose challenge in vitro (Miyazaki, Yamato et al. 2004). The co-culture of ESCs with other 
cell types has also successfully generated IPCs that express insulin and C-peptide, and 
respond to glucose. Banerjee et al. used 3 co-culture steps: 1) induction toward endoderm-
like cells by co-culturing with primary hepatocytes, 2) inhibition of Sonic hedgehog by 
culturing in presence of KAAD-cyclopamine on Matrigel and retinoid induction, and 3) 
maturation to islet cells by co-culture with endothelial cells in medium containing 
nicotinamide, insulin, selenium, transferring and B27 (Banerjee, Sharma et al.). These studies 
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are all examples of the diverse approaches that have been explored to produce ESC-IPCs; 
however, none of the ESC-IPCs generated by these protocols have shown regulation of 
blood glucose levels after transplantation, as has been shown by Lumelsky et al., Hori et al. 
and Blyszczuk et al.  
For human ESCs, differentiation into IPCs through monolayers, without EB formation, is the 
methodology most commonly followed. The protocol by D’Amour et al., in which the in vivo 
differentiation steps from the definitive endoderm to endocrine pancreatic islets are 
mimicked in vitro, is currently considered the reference protocol for differentiating human 
ESC to IPC (D'Amour, Bang et al. 2006; Kroon, Martinson et al. 2008). Endodermal 
intermediates can be identified at each step: 1) definitive endoderm markers (Sox17, FoxA2 
and Cxcr4) are detected after the addition of activin A and Wnt3a in a medium with low 
serum concentration, 2) primitive gut tube markers (Hnf1b and Hnf4a) are induced by 
addition of FGF1- and KAAD-cyclopamine , 3) posterior foregut markers (Pdx1, Hnf6 or 
Sox9) are observed by induction with ATRA, KAAD-cyclopamine, FGF10 and B27, 4) 
pancreatic endoderm and endocrine precursor gene and protein expression (Nkx6-1, Ngn3, 
Pax4 or Nkx2-2) can be detected by induction with exendin-4, and 5) hormone-expressing 
endocrine cell markers (insulin, glucagon, somatostatin or poly-peptide Y) are induced by 
exposure of cells to IGF1 and HGF. Human ESC-IPCs generated via this protocol release C-
peptide at levels similar to β cells from islets in response to multiple secretory stimuli, but 
unfortunately, not to glucose (D'Amour, Bang et al. 2006). Interestingly, cells that co-express 
insulin and glucagon are observed, indicating that IPCs generated by the D’Amour protocol 
may still be immature β cell progenitors. A slight modification of the D’Amour protocol 
generated pancreatic endodermal cells from human ESCs, which protected diabetic 
immunocompromised SCID-Bg mice from hyperglycemia after transplant (Kroon, 
Martinson et al. 2008). 
Further modifications to the D’Amour protocol have shown some improvements in IPC 
properties. For example, human ESC-IPC that secrete insulin and respond to glucose were 
generated by combining activin A and ATRA in a chemically defined medium, and other 
maturation factors, such as bFGF and nicotinamide in DMEM/F12. ESC-IPCs differentiated 
by this system were able to rescue 30% of diabetic nu/nu mice from hyperglycemia for at 
least 6 weeks, with no teratoma formation observed for three months post-transplantation 
(Jiang, Shi et al. 2007). Other modifications, such as increasing the time of suspension 
cultures and different growth factor combinations have succeeded in producing ESC-IPCs. 
Those suspension cultures contained ductal, exocrine and endocrine-like cells and secreted 
insulin in response to glucose challenge, but their therapeutic potential for diabetes was not 
tested in vivo (Jiang, Au et al. 2007). 
Human ESC-IPCs have been also generated through the formation of EBs. Human EBs in a 
3D matrix were induced to differentiate into definitive endoderm by the presence of activin 
A and Bmp4, and then into IPCs via the addition of growth factors such as FGF18, EGF, 
TGF-α, IGF-1, IGF-1 and VEGF. In contrast with other reports, these ESC-IPCs expressed 
only insulin and no other pancreatic hormones; however, they did not rescue diabetic mice 
and formed teratomas instead. When Pdx1 gene expression was quantified among six 
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2008). When the ES122 ESC line was differentiated using the Lumelsky, Hori or Blyszczuk 
protocols, the Blyszczuk protocol proved to be superior: higher insulin-1 and insulin-2 gene 
and protein expression, greater increase in insulin secretion after glucose challenge in vitro 
and longer duration of normoglycemic blood level in diabetic mice after transplantation 
were achieved. However, consistent with previous reports, IPCs formed teratomas after 
three weeks of transplantation (Boyd, Wu et al. 2008). Therefore, in order for ESC-IPCs to be 
used in the clinic, it is clear that additional measures must included in the ESC-IPC 
protocols before transplantation, such as: the depletion of undifferentiated cells, using 
markers like stage-specific embryonic antigen 1 (SSEA-1) in order to avoid teratoma 
formation, methods to efficiently scale-up cell numbers before transplantation in order to 
reach similar blood glycemia levels as with healthy β cells, and/or the identification and 
addition of factors that can induce ESC-IPC to more mature, functional status when cultured 
in vitro.  
More differentiation protocols to generate ESC-IPCs from murine ESCs have been described, 
but all of the known assays to test function of ESC-IPC have not been performed (Table 1). 
A comparative analysis in which the murine ESC D3 line was differentiated through the 
formation of EBs in the presence of retinoic acid showed how the subsequent exposure to 
sodium butyrate produced IPCs that expressed insulin-1 and insulin-2. However, C-peptide 
was not expressed and in vitro glucose response assays or transplantation in diabetic mice 
were not performed (McKiernan, O'Driscoll et al. 2007). Another approach, using a three-
dimensional (3D) system with a Type I rat tail collagen solution, generated IPCs from the 
murine ESC D3 line that secreted more insulin after in vitro glucose challenge than IPCs 
generated in a two-dimensional (2D) system (Wang and Ye 2009); however, no in vivo 
functional analysis of these IPCs was performed. Comparing the 3D system with the 
differentiation protocols described by Blyszczuk et al., Lumelsky et al. or Hori et al. using 
the same cell line would be interesting. In another protocol that omitted EB formation, ESC-
IPCs were generated by following a four step protocol: 1) treatment of ES cells with all-trans-
retinoic acid (ATRA) and fibroblast growth factor (bFGF), 2) withdrawal of ATRA, 3) 
induction of formation of cell cluster by growth in presence of N2 and B27 supplements and 
4) culture of clusters in dibutyryl cAMP and nicotinamide (Kim, Hoffman et al. 2010). These 
ESC-IPCs expressed insulin and responded to glucose challenge, but transplantation into 
diabetic mice was not performed, so the functionality of these cells in vivo is unknown. As 
transgenesis of ESCs with Pax4 seemed to influence ESC-IPC differentiation, other groups 
have attempted to control the expression of pancreatic genes during ESC-IPC 
differentiation. For instance, regulation of Pdx1 expression via the “Tet-off” system 
generated IPCs that increased insulin-2 and Ngn3 expression and secreted more insulin after 
glucose challenge in vitro (Miyazaki, Yamato et al. 2004). The co-culture of ESCs with other 
cell types has also successfully generated IPCs that express insulin and C-peptide, and 
respond to glucose. Banerjee et al. used 3 co-culture steps: 1) induction toward endoderm-
like cells by co-culturing with primary hepatocytes, 2) inhibition of Sonic hedgehog by 
culturing in presence of KAAD-cyclopamine on Matrigel and retinoid induction, and 3) 
maturation to islet cells by co-culture with endothelial cells in medium containing 
nicotinamide, insulin, selenium, transferring and B27 (Banerjee, Sharma et al.). These studies 
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are all examples of the diverse approaches that have been explored to produce ESC-IPCs; 
however, none of the ESC-IPCs generated by these protocols have shown regulation of 
blood glucose levels after transplantation, as has been shown by Lumelsky et al., Hori et al. 
and Blyszczuk et al.  
For human ESCs, differentiation into IPCs through monolayers, without EB formation, is the 
methodology most commonly followed. The protocol by D’Amour et al., in which the in vivo 
differentiation steps from the definitive endoderm to endocrine pancreatic islets are 
mimicked in vitro, is currently considered the reference protocol for differentiating human 
ESC to IPC (D'Amour, Bang et al. 2006; Kroon, Martinson et al. 2008). Endodermal 
intermediates can be identified at each step: 1) definitive endoderm markers (Sox17, FoxA2 
and Cxcr4) are detected after the addition of activin A and Wnt3a in a medium with low 
serum concentration, 2) primitive gut tube markers (Hnf1b and Hnf4a) are induced by 
addition of FGF1- and KAAD-cyclopamine , 3) posterior foregut markers (Pdx1, Hnf6 or 
Sox9) are observed by induction with ATRA, KAAD-cyclopamine, FGF10 and B27, 4) 
pancreatic endoderm and endocrine precursor gene and protein expression (Nkx6-1, Ngn3, 
Pax4 or Nkx2-2) can be detected by induction with exendin-4, and 5) hormone-expressing 
endocrine cell markers (insulin, glucagon, somatostatin or poly-peptide Y) are induced by 
exposure of cells to IGF1 and HGF. Human ESC-IPCs generated via this protocol release C-
peptide at levels similar to β cells from islets in response to multiple secretory stimuli, but 
unfortunately, not to glucose (D'Amour, Bang et al. 2006). Interestingly, cells that co-express 
insulin and glucagon are observed, indicating that IPCs generated by the D’Amour protocol 
may still be immature β cell progenitors. A slight modification of the D’Amour protocol 
generated pancreatic endodermal cells from human ESCs, which protected diabetic 
immunocompromised SCID-Bg mice from hyperglycemia after transplant (Kroon, 
Martinson et al. 2008). 
Further modifications to the D’Amour protocol have shown some improvements in IPC 
properties. For example, human ESC-IPC that secrete insulin and respond to glucose were 
generated by combining activin A and ATRA in a chemically defined medium, and other 
maturation factors, such as bFGF and nicotinamide in DMEM/F12. ESC-IPCs differentiated 
by this system were able to rescue 30% of diabetic nu/nu mice from hyperglycemia for at 
least 6 weeks, with no teratoma formation observed for three months post-transplantation 
(Jiang, Shi et al. 2007). Other modifications, such as increasing the time of suspension 
cultures and different growth factor combinations have succeeded in producing ESC-IPCs. 
Those suspension cultures contained ductal, exocrine and endocrine-like cells and secreted 
insulin in response to glucose challenge, but their therapeutic potential for diabetes was not 
tested in vivo (Jiang, Au et al. 2007). 
Human ESC-IPCs have been also generated through the formation of EBs. Human EBs in a 
3D matrix were induced to differentiate into definitive endoderm by the presence of activin 
A and Bmp4, and then into IPCs via the addition of growth factors such as FGF18, EGF, 
TGF-α, IGF-1, IGF-1 and VEGF. In contrast with other reports, these ESC-IPCs expressed 
only insulin and no other pancreatic hormones; however, they did not rescue diabetic mice 
and formed teratomas instead. When Pdx1 gene expression was quantified among six 
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human ESC lines following this protocol, different levels of expression were detected 
(Phillips, Hentze et al. 2007). This result is not surprising, since distinct cell behaviors and 
differentiation potentials have been observed amongst independent stem cell lines (Osafune, 
Caron et al. 2008).  
Therefore, for human and murine ESC-IPC differentiation, no “standard” protocol currently 
exists, as the results appear to be dependent on the ESC line utilized. In addition, there is no 
consensus on the composition of the differentiation culture mediums to guide cells from 
definitive endoderm to the IPC fate. However, some compounds appear to be key factors for 
the success of ESC-IPC differentiation. Activin A, a member of the transforming growth 
factor-beta (TGF-β) family, is involved in cellular proliferation and differentiation, and 
seems to be essential at the first steps of differentiation of human ESC into definitive 
endodermal cells (D'Amour, Bang et al. 2006; Kroon, Martinson et al. 2008). Nicotinamide, 
the amide of vitamin B3, is a well-known inducer of endocrine differentiation (Otonkoski, 
Beattie et al. 1993), and has been used in the differentiation of human and murine ESCs into 
IPCs (Jiang, Shi et al. 2007; Boyd, Wu et al. 2008). Epidermal Growth Factor (EGF) and Basic 
Fibroblast Growth Factor (bFGF) have been also applied in human and murine ESC-IPC 
differentiation, as both factors induce cell proliferation and differentiation (Lumelsky, 
Blondel et al. 2001; Jiang, Au et al. 2007). However, EGF, but not bFGF, needs to be removed 
from the cultures during the last stages of the differentiation protocols in order to allow the 
formation of islet-like cell aggregates (Cras-Meneur, Elghazi et al. 2001; Hardikar, Marcus-
Samuels et al. 2003). Hepatocyte Growth Factor (HGF) is an inducer of cell proliferation that 
is secreted by mesenchymal cells, and has been used for human ESC-IPC differentiation 
(Otonkoski, Cirulli et al. 1996; D'Amour, Bang et al. 2006; Phillips, Hentze et al. 2007) as well 
as murine fetal liver differentiation into IPCs (Feng, Du et al. 2005). Exendin-4 stimulates β 
cell proliferation (Xu, Stoffers et al. 1999) and it has been used for murine and human ESC-
IPC differentiation (Tang, Cao et al. 2004; Wu, Liu et al. 2007; Gabr, Sobh et al. 2008; Gao, 
Wu et al. 2008; Li, Lam et al.). A combination of insulin, transferrin, selenium and 
fibronectin (ITSFn) has been a common cocktail in murine ESC-IPC differentiation, although 
the presence of insulin in the medium brought some controversy about the endogenous 
insulin production of IPCs (Lumelsky, Blondel et al. 2001; Hori, Rulifson et al. 2002; 
Blyszczuk, Asbrand et al. 2004; Hansson, Tonning et al. 2004). The concentration of glucose 
in the culture media can also influence ESC-IPC differentiation and their properties. Low 
glucose concentrations (5mM) increase the content of insulin in islet-like clusters, whereas 
higher concentrations (20-30 mM) induce their replication (Bonner-Weir, Deery et al. 1989; 
Guillemain, Filhoulaud et al. 2007). Importantly, the presence or absence of serum has a 
clear effect on ESC-IPC differentiation. It is widely accepted by all cell culture professionals 
that lot-to-lot variation of serum sources can affect the success of in vitro cell culture and 
assays. The most referenced protocols for murine or human ESC-IPC use serum-free 
medium, as they claim serum inhibits differentiation; however, the specific component in 
the serum has not been identified (Blyszczuk, Asbrand et al. 2004; Jiang, Au et al. 2007; 
Jiang, Shi et al. 2007). The inhibitory role of serum is somewhat controversial, as other 
reports have described how reduced serum concentrations (0-10%) are permissive for 
murine ESC-IPC differentiation (Vincent and Odorico 2009), yet other authors produced 
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ESC-IPC successfully with relatively high 15% serum concentrations (Ibii, Shimada et al. 
2007). Inherent variability in the behavior of individual ESC lines, in conjunction with these 
responses in the absence or presence of serum, could explain these results. Studies that 
identify the molecules released by developing pancreas could help to determine the main 
factors needed in ESC-IPC differentiation in vitro (Vaca, Martin et al. 2006). These studies 
could also be applied in the development of synthetic molecules, such as indolactam V, 
IDE1 or IDE2, for easier production and control of murine and human ESC-IPC 
differentiation (Borowiak, Maehr et al. 2009; Chen, Borowiak et al. 2009). 
In summary, despite the progress made to date, investigation must continue to optimize 
ESC-IPC differentiation before their clinical use is possible. ESC-IPC cultures contain 
heterogeneous cell populations, and have not been well-identified. Moreover, the ESC-IPCs 
do not always respond to glucose challenge and do not release insulin, limiting their use as 
a pancreatic β cell replacement in TID. Identification of novel factors to induce maturation of 
ESC-IPC phenotypes may help to achieve full functional status. However, perhaps a better 
strategy would be to identify and transplant the immature pancreatic progenitor cells within 
the ESC-IPC cultures, as they may mature and respond more appropriately in vivo.  
3.4. Identifying markers of endoderm and pancreatic progenitor cells in ESC-IPC 
cultures 
ESC-IPCs to date have not recapitulated pancreatic mature β cell phenotypes. Pancreatic 
progenitors that are generated within the heterogeneous ESC-IPCs may be suitable for 
cellular replacement therapy in TID. The pancreatic progenitors may not self-renew as stem 
cells do, but could differentiate into endocrine cells after transplantation, including β cells. 
The identification of specific cell surface markers on pancreatic progenitors would allow for 
their isolation and for the transplantation of a homogenous population of ESC-derived 
pancreatic progenitors. We will discuss some current advances in the identification of 
pancreatic progenitors in vivo that could be applied to the detection and isolation of ESC-
derived pancreatic progenitors from ESC-IPC cultures. 
3.4.1. Definitive endoderm progenitors 
In mice, putative definitive endodermal cells that co-express E-cadherin and Decay 
Accelerating Factor (DAF1/CD55) cell surface markers also express Pdx1 (Shiraki, Harada et 
al. 2010). Discoidin domain receptor tyrosine kinase 1 (DDR1) and delta/notch-like EGF 
related receptor (DNER) have been also indicated as possible murine pancreatic progenitor 
surface markers with bioinformatics studies confirmed by immunohistochemistry (Hald, 
Galbo et al. 2011). Murine ESCs bearing the GFP reporter gene and human IL2Rα (CD25) 
marker genes in the goosecoid (GSc) and Soc17 loci have allowed for the identification of 
seven surface markers that are differentially expressed between definitive and visceral 
endoderm cells: Amn (Amnionless), Sdc4 (Syndecan-4), Pthr1 (Parathyroid hormone 
receptor 1), Tmprss2 (Transmembrane protease, serine 2), Tm4sf2 (Transmembrane 4 
superfamily 2), Cxcr4 and Gpc1 (Glypican 1). Cxcr4, in combination with E-cadherin, 
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human ESC lines following this protocol, different levels of expression were detected 
(Phillips, Hentze et al. 2007). This result is not surprising, since distinct cell behaviors and 
differentiation potentials have been observed amongst independent stem cell lines (Osafune, 
Caron et al. 2008).  
Therefore, for human and murine ESC-IPC differentiation, no “standard” protocol currently 
exists, as the results appear to be dependent on the ESC line utilized. In addition, there is no 
consensus on the composition of the differentiation culture mediums to guide cells from 
definitive endoderm to the IPC fate. However, some compounds appear to be key factors for 
the success of ESC-IPC differentiation. Activin A, a member of the transforming growth 
factor-beta (TGF-β) family, is involved in cellular proliferation and differentiation, and 
seems to be essential at the first steps of differentiation of human ESC into definitive 
endodermal cells (D'Amour, Bang et al. 2006; Kroon, Martinson et al. 2008). Nicotinamide, 
the amide of vitamin B3, is a well-known inducer of endocrine differentiation (Otonkoski, 
Beattie et al. 1993), and has been used in the differentiation of human and murine ESCs into 
IPCs (Jiang, Shi et al. 2007; Boyd, Wu et al. 2008). Epidermal Growth Factor (EGF) and Basic 
Fibroblast Growth Factor (bFGF) have been also applied in human and murine ESC-IPC 
differentiation, as both factors induce cell proliferation and differentiation (Lumelsky, 
Blondel et al. 2001; Jiang, Au et al. 2007). However, EGF, but not bFGF, needs to be removed 
from the cultures during the last stages of the differentiation protocols in order to allow the 
formation of islet-like cell aggregates (Cras-Meneur, Elghazi et al. 2001; Hardikar, Marcus-
Samuels et al. 2003). Hepatocyte Growth Factor (HGF) is an inducer of cell proliferation that 
is secreted by mesenchymal cells, and has been used for human ESC-IPC differentiation 
(Otonkoski, Cirulli et al. 1996; D'Amour, Bang et al. 2006; Phillips, Hentze et al. 2007) as well 
as murine fetal liver differentiation into IPCs (Feng, Du et al. 2005). Exendin-4 stimulates β 
cell proliferation (Xu, Stoffers et al. 1999) and it has been used for murine and human ESC-
IPC differentiation (Tang, Cao et al. 2004; Wu, Liu et al. 2007; Gabr, Sobh et al. 2008; Gao, 
Wu et al. 2008; Li, Lam et al.). A combination of insulin, transferrin, selenium and 
fibronectin (ITSFn) has been a common cocktail in murine ESC-IPC differentiation, although 
the presence of insulin in the medium brought some controversy about the endogenous 
insulin production of IPCs (Lumelsky, Blondel et al. 2001; Hori, Rulifson et al. 2002; 
Blyszczuk, Asbrand et al. 2004; Hansson, Tonning et al. 2004). The concentration of glucose 
in the culture media can also influence ESC-IPC differentiation and their properties. Low 
glucose concentrations (5mM) increase the content of insulin in islet-like clusters, whereas 
higher concentrations (20-30 mM) induce their replication (Bonner-Weir, Deery et al. 1989; 
Guillemain, Filhoulaud et al. 2007). Importantly, the presence or absence of serum has a 
clear effect on ESC-IPC differentiation. It is widely accepted by all cell culture professionals 
that lot-to-lot variation of serum sources can affect the success of in vitro cell culture and 
assays. The most referenced protocols for murine or human ESC-IPC use serum-free 
medium, as they claim serum inhibits differentiation; however, the specific component in 
the serum has not been identified (Blyszczuk, Asbrand et al. 2004; Jiang, Au et al. 2007; 
Jiang, Shi et al. 2007). The inhibitory role of serum is somewhat controversial, as other 
reports have described how reduced serum concentrations (0-10%) are permissive for 
murine ESC-IPC differentiation (Vincent and Odorico 2009), yet other authors produced 
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ESC-IPC successfully with relatively high 15% serum concentrations (Ibii, Shimada et al. 
2007). Inherent variability in the behavior of individual ESC lines, in conjunction with these 
responses in the absence or presence of serum, could explain these results. Studies that 
identify the molecules released by developing pancreas could help to determine the main 
factors needed in ESC-IPC differentiation in vitro (Vaca, Martin et al. 2006). These studies 
could also be applied in the development of synthetic molecules, such as indolactam V, 
IDE1 or IDE2, for easier production and control of murine and human ESC-IPC 
differentiation (Borowiak, Maehr et al. 2009; Chen, Borowiak et al. 2009). 
In summary, despite the progress made to date, investigation must continue to optimize 
ESC-IPC differentiation before their clinical use is possible. ESC-IPC cultures contain 
heterogeneous cell populations, and have not been well-identified. Moreover, the ESC-IPCs 
do not always respond to glucose challenge and do not release insulin, limiting their use as 
a pancreatic β cell replacement in TID. Identification of novel factors to induce maturation of 
ESC-IPC phenotypes may help to achieve full functional status. However, perhaps a better 
strategy would be to identify and transplant the immature pancreatic progenitor cells within 
the ESC-IPC cultures, as they may mature and respond more appropriately in vivo.  
3.4. Identifying markers of endoderm and pancreatic progenitor cells in ESC-IPC 
cultures 
ESC-IPCs to date have not recapitulated pancreatic mature β cell phenotypes. Pancreatic 
progenitors that are generated within the heterogeneous ESC-IPCs may be suitable for 
cellular replacement therapy in TID. The pancreatic progenitors may not self-renew as stem 
cells do, but could differentiate into endocrine cells after transplantation, including β cells. 
The identification of specific cell surface markers on pancreatic progenitors would allow for 
their isolation and for the transplantation of a homogenous population of ESC-derived 
pancreatic progenitors. We will discuss some current advances in the identification of 
pancreatic progenitors in vivo that could be applied to the detection and isolation of ESC-
derived pancreatic progenitors from ESC-IPC cultures. 
3.4.1. Definitive endoderm progenitors 
In mice, putative definitive endodermal cells that co-express E-cadherin and Decay 
Accelerating Factor (DAF1/CD55) cell surface markers also express Pdx1 (Shiraki, Harada et 
al. 2010). Discoidin domain receptor tyrosine kinase 1 (DDR1) and delta/notch-like EGF 
related receptor (DNER) have been also indicated as possible murine pancreatic progenitor 
surface markers with bioinformatics studies confirmed by immunohistochemistry (Hald, 
Galbo et al. 2011). Murine ESCs bearing the GFP reporter gene and human IL2Rα (CD25) 
marker genes in the goosecoid (GSc) and Soc17 loci have allowed for the identification of 
seven surface markers that are differentially expressed between definitive and visceral 
endoderm cells: Amn (Amnionless), Sdc4 (Syndecan-4), Pthr1 (Parathyroid hormone 
receptor 1), Tmprss2 (Transmembrane protease, serine 2), Tm4sf2 (Transmembrane 4 
superfamily 2), Cxcr4 and Gpc1 (Glypican 1). Cxcr4, in combination with E-cadherin, 
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proved to be appropriate extracellular markers for the identification and isolation of 
definitive endoderm cells (E-cadherin+ Cxcr4+) from unmanipulated ES-derived cells 
(Yasunaga, Tada et al. 2005). Thus, Cxcr4 permits the isolation of definitive endoderm cells 
from human ES cells after 5 days of differentiation to nearly 100% purity, eliminating 
undifferentiated ESCs (D'Amour, Agulnick et al. 2005). However, Cxcr4 expression 
decreases during development, making the isolation of late definitive endoderm cells 
difficult. The combination of E-cadherin with CD55 has circumvented this problem by 
identifying early and late definitive endoderm cells in the embryo, and in ESC-derived cell 
cultures where GFP is expressed under the promoter of Pdx1 (Shiraki, Harada et al. 2010). 
Our group has also observed the presence of E-cadherin+ CD55+ cells in our ESC-IPC 
cultures (Figure 4B). Pdx1+Cxcr4+ ESC-derived cells spontaneously undergo differentiation 
into IPCs in vivo, and lead to a sustained correction of hyperglycemia in diabetic mice 
(Raikwar and Zavazava 2011).  
 
Figure 4. Identification of putative pancreatic progenitor from murine ESC-IPC cultures. ESC-IPCs were 
stained for markers of pancreatic progenitors found in the mouse embryo. A) CD133+CD49flow/+ cells. B) 
E-cadherin+CD55+ cells. The differentiation potential and properties of these in vitro-derived putative 
pancreatic progenitors requires further study.  
3.4.2. Pancreatic progenitors 
First isolated using Ngn3-fluorescent reporter mice (Gu, Wells et al. 2004; Mellitzer, Martin 
et al. 2004), Ngn3+ cells have been suggested as possible pancreatic progenitors. In later 
studies, CD133 (prominin 1) was described as an extracellular marker that identified cells 
which expressed Ngn3 in fetal and adult pancreas (Oshima, Suzuki et al. 2007; Sugiyama, 
Rodriguez et al. 2007). Mouse ductal cells with the phenotype CD133+CD34-CD45-Ter119- 
CD49flow/+ were isolated from fetal and adult murine tissues by flow cytometry. 
CD133+CD49flow/+ cells expressed Ngn3, increasing their isolation purity 1.4 fold when co-
stained for CD24. Moreover, CD133+CD49flow/+ cells expressed insulin-1, glucagon, 
somatostatin and pancreatic polypeptide after culturing them with mitomycin C-treated mouse 
embryonic fibroblast (MEFs) for 2 days (Sugiyama, Rodriguez et al. 2007). Pancreatic 
progenitors isolated from neonatal, but not from adult, pancreases were able to differentiate 
into endocrine cells when cultured in vitro with HGF and EGF (Oshima, Suzuki et al. 2007). 
A newer study confirmed CD133 as well as platelet-derived growth factor receptor β 
(PDFGRβ) as markers of pancreatic progenitors in murine fetal pancreas (Hori, Fukumoto et 
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al. 2008). CD133+ PDFGRβ - cells were CD49flow/+ and expressed Ngn3 and Pdx1. In vitro co-
culture of CD133+ PDFGRβ - cells with MEFs or their in vivo transplantation induced the 
formation of IPCs that expressed C-peptide in 7 days. Moreover, serial transplantation of 
these CD133+ PDFGRβ - cells demonstrated self-renewal properties and suggested they 
might be true pancreatic stem cells (Hori, Fukumoto et al. 2008). Inclusion of CD24 as a 
positive marker with CD133 and CD49f during cell isolation increases the yield of Ngn3+ 
cells after sorting from mouse embryos (Sugiyama, Rodriguez et al. 2007).  
Murine Ngn3-GFP ESC lines have been differentiated and Ngn3+ cells were detected and 
isolated from EBs. Ngn3+ cells were then sorted and differentiated in vitro into cells that 
expressed insulin, glucagon and Pdx1, among other pancreatic markers (Ku, Chai et al. 2007). 
Inducible Ngn3 expression in ESCs enhances expression of glucagon, somatostatin and 
insulin when they are differentiated into endocrine lineages, which reinforces the idea that 
Ngn3 is an intermediate gene during IPCs differentiation (Serafimidis, Rakatzi et al. 2008). 
However, the description of non-transgenic Ngn3-expressing-pancreatic progenitor cells 
identified by cell surface markers in ESC-differentiation cultures has not been reported in 
the primary literature. Our group has analyzed the percentage of CD133+CD49flow/+ cells 
during ESC-IPC differentiation following the Blyszczuk protocol, and we have detected an 
increase in the number of CD133+CD49flow/+ cells in our cultures (Figure 4A). CD24, has been 
cited as a marker of murine pancreatic progenitors, and CD24+ cells isolated from human 
ESC-IPC express Pdx1, and express insulin after 1 week in vitro (Jiang, Sui et al. 2011). 
Studies in vivo will confirm the differentiation potential of CD24+ cells in ESC-IPC cultures. 
The CD142 protein is expressed in the human fetal pancreatic epithelium at 8 weeks of 
gestation, and has been implicated in human ESC-IPC differentiation. Isolation of CD142+ 
cells allowed for the enrichment of pancreatic endoderm cells, and after transplantation into 
SCID/Bg mice, CD142+ cells differentiated to all pancreatic cell lineages, including IPCs that 
responded to glucose stimulation in vivo and did not form teratomas (Kelly, Chan et al. 
2011). However, these recipients were not diabetic, so future studies are required to 
demonstrate if they can rescue hyperglycemia in diabetic mice. 
The establishment of intermediate lineage-restricted progenitor cell lines (similar to the 
pancreatic progenitor cells) that generate homogeneous IPCs could be useful for scalable 
IPC production. Several clones were isolated from differentiation protocols into IPCs with 
the E-RoSH cell line (an endothelial lineage-restricted clonal murine ES cell derived line). 
The eight clones that were isolated could be frozen and thawed for months, and when 
cultured, they displayed properties of pancreatic β cells, such as expression of insulin-1, 
insulin-2, Pdx1, Nkx2.2, Nkx6.1, Isl1, and Foxa2, no expression of Ngn3, and expression of C-
peptide. Moreover, the clones were able to rescue diabetic mice and did not form teratomas, 
demonstrating the absence of undifferentiated ESC. However, these cells continued 
proliferating after transplantation and showed an abnormal karyotype, suggesting an 
insulinoma phenotype, that may be responsible for the hyperinsulinemia and hypoglycemia 
observed in the animals (Li, Luo et al. 2009). 
In summary, isolation and characterization of pancreatic progenitors from embryonic 
development and ESC-IPCs could provide another possible β cell replacement source for the 
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proved to be appropriate extracellular markers for the identification and isolation of 
definitive endoderm cells (E-cadherin+ Cxcr4+) from unmanipulated ES-derived cells 
(Yasunaga, Tada et al. 2005). Thus, Cxcr4 permits the isolation of definitive endoderm cells 
from human ES cells after 5 days of differentiation to nearly 100% purity, eliminating 
undifferentiated ESCs (D'Amour, Agulnick et al. 2005). However, Cxcr4 expression 
decreases during development, making the isolation of late definitive endoderm cells 
difficult. The combination of E-cadherin with CD55 has circumvented this problem by 
identifying early and late definitive endoderm cells in the embryo, and in ESC-derived cell 
cultures where GFP is expressed under the promoter of Pdx1 (Shiraki, Harada et al. 2010). 
Our group has also observed the presence of E-cadherin+ CD55+ cells in our ESC-IPC 
cultures (Figure 4B). Pdx1+Cxcr4+ ESC-derived cells spontaneously undergo differentiation 
into IPCs in vivo, and lead to a sustained correction of hyperglycemia in diabetic mice 
(Raikwar and Zavazava 2011).  
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et al. 2004), Ngn3+ cells have been suggested as possible pancreatic progenitors. In later 
studies, CD133 (prominin 1) was described as an extracellular marker that identified cells 
which expressed Ngn3 in fetal and adult pancreas (Oshima, Suzuki et al. 2007; Sugiyama, 
Rodriguez et al. 2007). Mouse ductal cells with the phenotype CD133+CD34-CD45-Ter119- 
CD49flow/+ were isolated from fetal and adult murine tissues by flow cytometry. 
CD133+CD49flow/+ cells expressed Ngn3, increasing their isolation purity 1.4 fold when co-
stained for CD24. Moreover, CD133+CD49flow/+ cells expressed insulin-1, glucagon, 
somatostatin and pancreatic polypeptide after culturing them with mitomycin C-treated mouse 
embryonic fibroblast (MEFs) for 2 days (Sugiyama, Rodriguez et al. 2007). Pancreatic 
progenitors isolated from neonatal, but not from adult, pancreases were able to differentiate 
into endocrine cells when cultured in vitro with HGF and EGF (Oshima, Suzuki et al. 2007). 
A newer study confirmed CD133 as well as platelet-derived growth factor receptor β 
(PDFGRβ) as markers of pancreatic progenitors in murine fetal pancreas (Hori, Fukumoto et 
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al. 2008). CD133+ PDFGRβ - cells were CD49flow/+ and expressed Ngn3 and Pdx1. In vitro co-
culture of CD133+ PDFGRβ - cells with MEFs or their in vivo transplantation induced the 
formation of IPCs that expressed C-peptide in 7 days. Moreover, serial transplantation of 
these CD133+ PDFGRβ - cells demonstrated self-renewal properties and suggested they 
might be true pancreatic stem cells (Hori, Fukumoto et al. 2008). Inclusion of CD24 as a 
positive marker with CD133 and CD49f during cell isolation increases the yield of Ngn3+ 
cells after sorting from mouse embryos (Sugiyama, Rodriguez et al. 2007).  
Murine Ngn3-GFP ESC lines have been differentiated and Ngn3+ cells were detected and 
isolated from EBs. Ngn3+ cells were then sorted and differentiated in vitro into cells that 
expressed insulin, glucagon and Pdx1, among other pancreatic markers (Ku, Chai et al. 2007). 
Inducible Ngn3 expression in ESCs enhances expression of glucagon, somatostatin and 
insulin when they are differentiated into endocrine lineages, which reinforces the idea that 
Ngn3 is an intermediate gene during IPCs differentiation (Serafimidis, Rakatzi et al. 2008). 
However, the description of non-transgenic Ngn3-expressing-pancreatic progenitor cells 
identified by cell surface markers in ESC-differentiation cultures has not been reported in 
the primary literature. Our group has analyzed the percentage of CD133+CD49flow/+ cells 
during ESC-IPC differentiation following the Blyszczuk protocol, and we have detected an 
increase in the number of CD133+CD49flow/+ cells in our cultures (Figure 4A). CD24, has been 
cited as a marker of murine pancreatic progenitors, and CD24+ cells isolated from human 
ESC-IPC express Pdx1, and express insulin after 1 week in vitro (Jiang, Sui et al. 2011). 
Studies in vivo will confirm the differentiation potential of CD24+ cells in ESC-IPC cultures. 
The CD142 protein is expressed in the human fetal pancreatic epithelium at 8 weeks of 
gestation, and has been implicated in human ESC-IPC differentiation. Isolation of CD142+ 
cells allowed for the enrichment of pancreatic endoderm cells, and after transplantation into 
SCID/Bg mice, CD142+ cells differentiated to all pancreatic cell lineages, including IPCs that 
responded to glucose stimulation in vivo and did not form teratomas (Kelly, Chan et al. 
2011). However, these recipients were not diabetic, so future studies are required to 
demonstrate if they can rescue hyperglycemia in diabetic mice. 
The establishment of intermediate lineage-restricted progenitor cell lines (similar to the 
pancreatic progenitor cells) that generate homogeneous IPCs could be useful for scalable 
IPC production. Several clones were isolated from differentiation protocols into IPCs with 
the E-RoSH cell line (an endothelial lineage-restricted clonal murine ES cell derived line). 
The eight clones that were isolated could be frozen and thawed for months, and when 
cultured, they displayed properties of pancreatic β cells, such as expression of insulin-1, 
insulin-2, Pdx1, Nkx2.2, Nkx6.1, Isl1, and Foxa2, no expression of Ngn3, and expression of C-
peptide. Moreover, the clones were able to rescue diabetic mice and did not form teratomas, 
demonstrating the absence of undifferentiated ESC. However, these cells continued 
proliferating after transplantation and showed an abnormal karyotype, suggesting an 
insulinoma phenotype, that may be responsible for the hyperinsulinemia and hypoglycemia 
observed in the animals (Li, Luo et al. 2009). 
In summary, isolation and characterization of pancreatic progenitors from embryonic 
development and ESC-IPCs could provide another possible β cell replacement source for the 
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treatment of diabetes. These multipotent cells are not teratoma-forming, and can 
differentiate into IPCs and other hormone expressing cells, and have been shown to reverse 
hyperglycemic blood levels after transplantation. However, the isolation of pure or enriched 
pancreatic progenitors using cell-specific surface markers from ESC-IPCs cell differentiation 
cultures that are able to cure diabetic mice still has not been demonstrated. More studies to 
assess the efficiency of human ESC-IPC differentiation and optimization of sorting methods 
to remove any undifferentiated teratoma-forming cells are necessary before clinical 
translation. Nevertheless, even if fully functional, teratoma-free ESC-IPCs are derived, they 
must circumvent another possible barrier after transplantation: the host immune system (see 
Section 3.6). For this reason, induced pluripotent stem cells have been proposed as an 
autologous alternative to ESCs. 
3.5. Differentiation of induced pluripotent stem cells into insulin-producing 
cells 
Induced pluripotent stem cells (iPSCs) are reprogrammed somatic cells that behave like 
ESCs and can be re-differentiated into all three germ layers and potentially, any terminally 
differentiated cell type (Takahashi and Yamanaka 2006). The generation of iPSCs was firstly 
achieved by the viral delivery of reprogramming factors (Takahashi and Yamanaka 2006) in 
murine cells, and later by non-viral methods (Yu, Hu et al. 2009). Human iPSCs have also 
been generated (Yu, Hu et al. 2009). iPSC are envisioned as the future of “personalized” 
medicine since they could be used to generate autologous therapies that will not require 
pharmacologic immune suppression after transplantation (Okita, Ichisaka et al. 2007). 
However, the immunogenicity of syngeneic iPSC, which was unexpected by the stem cell 
biology field, demonstrated that this is not the case (Zhao, Zhang et al. 2011). Moreover, 
autologous iPSC generated from patients with genetic diseases likely will retain the 
propensity to develop disease following re-differentiation, unless they are modified (Raya, 
Rodriguez-Piza et al. 2009). The use of allogeneic iPSC could alleviate this possibility, but 
would have the disadvantage of possible immune rejection. iPSCs differ from ESCs in gene 
expression profiles (Chin, Mason et al. 2009), persistence of donor-cell gene expression 
(Marchetto, Yeo et al. 2009; Ghosh, Wilson et al. 2010), differentiation abilities (Feng, Lu et 
al. 2010; Hu, Weick et al. 2010) and genetic stability (Mayshar, Ben-David et al. 2010; 
Laurent, Ulitsky et al. 2011).  
Currently, there is no standard iPSC to IPC differentiation protocol, but scientists have 
followed strategies similar to ESC to IPC differentiation (Table 3). Murine skin fibroblasts 
reprogrammed into iPSCs were differentiated into IPCs that were glucose responsive in vitro 
and normalized hyperglycemia in syngeneic mice with Type I and Type II diabetes. 
Teratoma formation was prevented by sorting out SSEA1+ IPCs before transplantation, and 
no immune rejection was detected (Alipio, Liao et al. 2010). Human iPSC to IPC 
differentiation has been performed using a four-stage protocol: 1) endoderm induction by 
activin A and wortmannin, 2) pancreatic differentiation with retinoic acid, Noggin and 
FGF7, 3) expansion of pancreatic endoderm cells with EGF and 4) maturation of IPCs with 
nicotinamide, bFGF, exendin-4 and BMP4 (Zhang, Jiang et al. 2009), and another method 
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following a human ESC-IPC protocol (Maehr, Chen et al. 2009; Thatava, Nelson et al. 2010). 
These IPCs expressed and released C-peptide after glucose challenge in vitro. Differentiation 
of distinct human iPSC lines also produced IPC that expressed C-peptide and insulin, but at 
lower levels than ESC-IPCs (Zhang, Jiang et al. 2009). Interestingly, iPSC-IPC generated 
from TID patients also appear to be responsive to glucose challenge in vitro (Maehr, Chen et 
al. 2009). iPSC generated from human β-cells (BiPSCs) appear to be predisposed to re-
differentiation into IPCs, as shown by the epigenetics of Pdx1 and insulin promoters. BiPSC 
express more insulin and C-peptide than ESC-IPCs after transplantation into SCID mice 
(Bar-Nur, Russ et al. 2011; Russ, Sintov et al. 2011). Human iPSC-IPCs have not yet been 
transplanted into diabetic humanized mouse models, so their therapeutic potential to 
normalize blood glucose levels and their safety in vivo still requires further investigation.  
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2010) 
Human 
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Table 3. iPS to IPC differentiation protocols  
3.6. Addressing the immunogenicity of ESC-IPCs and iPSC-IPCs 
Inflammation, due to local tissue damage, is a regular occurrence during transplantation of 
cells or organs, even in a syngeneic setting (Turvey, Gonzalez-Nicolini et al. 2000; Carvalho-
Gaspar, Billing et al. 2005). For instance, cellular infiltrates are evident in rat islet β cell 
allografts within one week post-transplant, and are completely destroyed within 2 weeks. 
Depletion of major histocompatibility complex class II (MHC II)-positive islet cells (which 
presumably are antigen-presenting cells) delays β cell rejection up to 5 weeks, while re-
aggregation of islet β cells after islet dissociation and β cell purification promotes allograft 
survival up to 20 weeks (Pipeleers, Pipeleers-Marichal et al. 1991). Embryonic tissue has not 
been considered to be highly immunogenic, mainly based on the “immune privileged” status 
of the fetus during gestation, which protects it from the maternal immune system. However, 
this immune privileged status is not generally observed outside the womb. For example, 
transplanted human β cells from fetal pancreas, which have a greater proliferative capacity 
than adult tissue (Hayek and Beattie 1997; Castaing, Peault et al. 2001), normalize blood 
glucose levels in diabetic immunoincompetent rodents (Hullett, Falany et al. 1987; Tuch, 
Osgerby et al. 1988; Tuch and Monk 1991; Castaing, Peault et al. 2001), but are rejected when 
transplanted into humanized SCID mice (immune reconstituted with human fetal liver and 
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treatment of diabetes. These multipotent cells are not teratoma-forming, and can 
differentiate into IPCs and other hormone expressing cells, and have been shown to reverse 
hyperglycemic blood levels after transplantation. However, the isolation of pure or enriched 
pancreatic progenitors using cell-specific surface markers from ESC-IPCs cell differentiation 
cultures that are able to cure diabetic mice still has not been demonstrated. More studies to 
assess the efficiency of human ESC-IPC differentiation and optimization of sorting methods 
to remove any undifferentiated teratoma-forming cells are necessary before clinical 
translation. Nevertheless, even if fully functional, teratoma-free ESC-IPCs are derived, they 
must circumvent another possible barrier after transplantation: the host immune system (see 
Section 3.6). For this reason, induced pluripotent stem cells have been proposed as an 
autologous alternative to ESCs. 
3.5. Differentiation of induced pluripotent stem cells into insulin-producing 
cells 
Induced pluripotent stem cells (iPSCs) are reprogrammed somatic cells that behave like 
ESCs and can be re-differentiated into all three germ layers and potentially, any terminally 
differentiated cell type (Takahashi and Yamanaka 2006). The generation of iPSCs was firstly 
achieved by the viral delivery of reprogramming factors (Takahashi and Yamanaka 2006) in 
murine cells, and later by non-viral methods (Yu, Hu et al. 2009). Human iPSCs have also 
been generated (Yu, Hu et al. 2009). iPSC are envisioned as the future of “personalized” 
medicine since they could be used to generate autologous therapies that will not require 
pharmacologic immune suppression after transplantation (Okita, Ichisaka et al. 2007). 
However, the immunogenicity of syngeneic iPSC, which was unexpected by the stem cell 
biology field, demonstrated that this is not the case (Zhao, Zhang et al. 2011). Moreover, 
autologous iPSC generated from patients with genetic diseases likely will retain the 
propensity to develop disease following re-differentiation, unless they are modified (Raya, 
Rodriguez-Piza et al. 2009). The use of allogeneic iPSC could alleviate this possibility, but 
would have the disadvantage of possible immune rejection. iPSCs differ from ESCs in gene 
expression profiles (Chin, Mason et al. 2009), persistence of donor-cell gene expression 
(Marchetto, Yeo et al. 2009; Ghosh, Wilson et al. 2010), differentiation abilities (Feng, Lu et 
al. 2010; Hu, Weick et al. 2010) and genetic stability (Mayshar, Ben-David et al. 2010; 
Laurent, Ulitsky et al. 2011).  
Currently, there is no standard iPSC to IPC differentiation protocol, but scientists have 
followed strategies similar to ESC to IPC differentiation (Table 3). Murine skin fibroblasts 
reprogrammed into iPSCs were differentiated into IPCs that were glucose responsive in vitro 
and normalized hyperglycemia in syngeneic mice with Type I and Type II diabetes. 
Teratoma formation was prevented by sorting out SSEA1+ IPCs before transplantation, and 
no immune rejection was detected (Alipio, Liao et al. 2010). Human iPSC to IPC 
differentiation has been performed using a four-stage protocol: 1) endoderm induction by 
activin A and wortmannin, 2) pancreatic differentiation with retinoic acid, Noggin and 
FGF7, 3) expansion of pancreatic endoderm cells with EGF and 4) maturation of IPCs with 
nicotinamide, bFGF, exendin-4 and BMP4 (Zhang, Jiang et al. 2009), and another method 
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following a human ESC-IPC protocol (Maehr, Chen et al. 2009; Thatava, Nelson et al. 2010). 
These IPCs expressed and released C-peptide after glucose challenge in vitro. Differentiation 
of distinct human iPSC lines also produced IPC that expressed C-peptide and insulin, but at 
lower levels than ESC-IPCs (Zhang, Jiang et al. 2009). Interestingly, iPSC-IPC generated 
from TID patients also appear to be responsive to glucose challenge in vitro (Maehr, Chen et 
al. 2009). iPSC generated from human β-cells (BiPSCs) appear to be predisposed to re-
differentiation into IPCs, as shown by the epigenetics of Pdx1 and insulin promoters. BiPSC 
express more insulin and C-peptide than ESC-IPCs after transplantation into SCID mice 
(Bar-Nur, Russ et al. 2011; Russ, Sintov et al. 2011). Human iPSC-IPCs have not yet been 
transplanted into diabetic humanized mouse models, so their therapeutic potential to 
normalize blood glucose levels and their safety in vivo still requires further investigation.  
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3.6. Addressing the immunogenicity of ESC-IPCs and iPSC-IPCs 
Inflammation, due to local tissue damage, is a regular occurrence during transplantation of 
cells or organs, even in a syngeneic setting (Turvey, Gonzalez-Nicolini et al. 2000; Carvalho-
Gaspar, Billing et al. 2005). For instance, cellular infiltrates are evident in rat islet β cell 
allografts within one week post-transplant, and are completely destroyed within 2 weeks. 
Depletion of major histocompatibility complex class II (MHC II)-positive islet cells (which 
presumably are antigen-presenting cells) delays β cell rejection up to 5 weeks, while re-
aggregation of islet β cells after islet dissociation and β cell purification promotes allograft 
survival up to 20 weeks (Pipeleers, Pipeleers-Marichal et al. 1991). Embryonic tissue has not 
been considered to be highly immunogenic, mainly based on the “immune privileged” status 
of the fetus during gestation, which protects it from the maternal immune system. However, 
this immune privileged status is not generally observed outside the womb. For example, 
transplanted human β cells from fetal pancreas, which have a greater proliferative capacity 
than adult tissue (Hayek and Beattie 1997; Castaing, Peault et al. 2001), normalize blood 
glucose levels in diabetic immunoincompetent rodents (Hullett, Falany et al. 1987; Tuch, 
Osgerby et al. 1988; Tuch and Monk 1991; Castaing, Peault et al. 2001), but are rejected when 
transplanted into humanized SCID mice (immune reconstituted with human fetal liver and 
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thymus tissue) (Rouleau, Namikawa et al. 1996). Human pancreas obtained from first 
trimester fetus are less immunogenic that pancreas from the second trimester of gestation, as 
indicated by cellular infiltrates that contain high levels of host CD45+ cells. This is consistent 
with an upregulation of T cell activating molecules, such as MHC II, the chemokine ligand 19 
(CCL19), complement component 3 (C3) and tumour necrosis factor superfamily 10 (TNFSF10, 
also known as TNF-related apoptosis-inducing ligand, TRAIL), in second trimester human 
fetal pancreas compared to first trimester tissue (Brands, Colvin et al. 2008). 
ESCs and iPSCs were also considered to be non-immunogenic, until recently. Murine ESCs 
do not express MHC I or MHC II, but increase MHC I expression when they differentiate 
spontaneously (Wu, Boyd et al. 2008). Despite of the lack of MHC I expression, ESCs are not 
deleted by natural killer (NK) cells (Koch, Geraldes et al. 2008). Interestingly, MHC I-
positive murine ESCs are not recognized by cytotoxic CD8+ T cells, even when antigen 
presenting cells (APCs) are used to prime T cells, suggesting that ES cells have some 
immune privilege. Nevertheless, this immune privilege is fragile and the addition of CD4+ 
helper T cells can induce ESC rejection in vivo (Wu, Boyd et al. 2008). In immunocompetent 
mice, ESC allografts contain infiltrates of CD11b+ macrophages, CD4+ and CD8+ T cells as 
early as 10 days post-transplantation (Wu, Boyd et al. 2008). In line with this, allogeneic EBs 
are not rejected if the CD4 and CD8 co-receptors are blocked, suggesting that ESC-derived 
tissues could be tolerated in allogeneic host (Lui, Boyd et al. 2010). In the absence of 
blocking, rejection of allogeneic EBs is mediated by CD8+ T cells and active F4/80+ MHC II+ 
mannose receptor-negative macrophages. IL-10, a cytokine that downregulates immune 
responses, is expressed in syngeneic and allogeneic EBs grafts that are not rejected (Lui, 
Boyd et al. 2010). This tolerance is completely eliminated when host CD4+ FoxP3+ regulatory 
T cells (Treg) are ablated. Tregs seem to protect EBs by keeping F4/80+ macrophages in a low 
activation state by preventing their upregulation of MHC II, as well as by suppressing 
cytotoxic CD8+ T cell responses by downregulating their expression of granzyme B (Lui, 
Boyd et al. 2010). It remains to be seen whether or not these mechanisms will apply 
universally to all ESC-derived tissues. 
To date, there have been few descriptions of the immunogenicity of ESC-IPCs, but the 
existing data indicate that both innate and adaptive arms of the host immune system could 
be activated after ESC-IPC transplantation. ESC-IPCs can normalize blood glucose levels of 
diabetic immune compromised mice short-term, but when transplanted into 
immunocompetent hosts, their functionality is impaired, even under syngeneic conditions 
(Wu, Boyd et al. 2008). One explanation for the immune rejection of ESC-IPCs is that they 
express higher levels of MHC I than ES cells, and express higher levels of both MHC I and 
MHC II after exposure with IFNγ in vitro. Incidentally, IFNγ is up-regulated within both 
syngeneic and allogeneic ESC-IPC grafts three days after transplantation (Boyd and Wood 
2009). However, the level of cellular infiltration differs between syngeneic and allogeneic 
ESC-IPC grafts. For example, Gr1+ leukocytes can be observed in allogeneic, but not 
syngeneic, ESC-IPC grafts, within the first 24 hours post-transplantation. CD11b+ 
macrophages can be detected in both syngeneic and allogeneic grafts by three days after 
transplantation, indicating a general response to local injury (Boyd and Wood 2010). In 
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addition, early inflammatory molecules that activate macrophages and granulocytes, such 
as IL-6, Gro-β (CXCL2 or macrophage inflammatory protein 2), Lix (CXCL5 or epithelial-
derived neutrophil-activating peptide 78), MIP-1α (CCL3 or macrophage inflammatory 
protein 1-alpha) and MIP-1β (CCL4 or macrophage inflammatory protein 1-beta, IP-10 
(Interferon gamma-induced protein 10 or CXCL10) and Mig (monokine induced by gamma 
interferon or CXCL9), are induced within both syngeneic and allogeneic ESC-IPC grafts 
within three days post-transplantation. Of these cytokines, IP-10, and Mig are associated 
with acute graft rejection (Burns, Wang et al. 2005). The adaptive immune system, as 
expected, is slower to respond, and infiltrates of reactive CD8+ T cells are observed in 
allogeneic ESC-IPCs 10 days post-transplantation. In all cases, the immune response to 
allogeneic ESC-IPC observed was lower than the response to transplanted allogeneic 
pancreatic islets (Boyd and Wood 2010). These studies suggest that IPCs are suitable for 
transplantation, but some immune response by macrophages and T cells should be 
expected, so it is likely that immunosuppressive drugs to prevent graft rejection will have to 
be administered with ESC-IPC grafts.  
Strategies to circumvent the immune system barrier to ESC-IPCs will be needed if they will 
be used for the treatment of diabetic patients. For instance, a short term immunosuppression 
approach blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), CD40 ligand 
(CD40L) or lymphocyte function-associated antigen 1(LFA-1) for 6 days, has shown to allow 
for the engraftment of murine and human ESCs (Pearl, Lee et al. 2011). Since CTLA4Ig 
treatment has previously induced long-term survival of xenogeneic pancreatic islet grafts 
(Lenschow, Zeng et al. 1992; Eventov-Friedman, Tchorsh et al. 2006), it is possible that 
similar pre-conditioning treatments in recipients will allow for the acceptance of ESC-IPC 
grafts. An alternative strategy is the co-culture of ESC-IPC with bone marrow-derived 
mesenchymal stem cells, since co-culture of β cells with bone marrow-derived mesenchymal 
stem cells induces the expression of protective molecules such as IL6 (in a paradoxically 
anti-inflammatory role) and TGFβ1, an immunosuppressive cytokine, and anti-apoptotic 
genes like Mapkapk2, Tnip1 or Bcl3 (Karaoz, Genc et al. 2010). Another interesting strategy to 
prevent immune rejection of pancreatic progenitors is their encapsulation in alginate 
capsules with pores that allow for the passage of nutrients and insulin, but not immune cells 
(Tuch, Hughes et al. 2011). The use of autologous iPSC, instead of ESCs, was thought to 
avoid these immune rejection issues, but new evidence has demonstrated that syngeneic 
iPS-derived tissues can in fact, be rejected, as shown by T cell infiltration in the grafts (Zhao, 
Zhang et al. 2011). This rejection appears to involve minor histocompatibility antigens. 
Candidate genes, such as Hormad1 (Horma Domain-Containing 1) or Zg16 (zymogen 
granule protein 16), were shown to be directly involved in the activation of antigen-specific 
T cells, as shown by IFN-γ release. Based on this evidence, it is clear that the potential of 
immune rejection of both ESC- and iPSC-derived tissues will be an obstacle to be overcome 
before they can be applied in the clinic. Moreover, a detailed understanding of the 
immunogenicity profiles of ESC- and iPSC-derived tissues of any type (i.e. not only IPCs) 
could provide important information about the type of potential immune response(s) to 
expect and prevent before transplantation and helping to identify alternative strategies to 
facilitate their acceptance.  
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thymus tissue) (Rouleau, Namikawa et al. 1996). Human pancreas obtained from first 
trimester fetus are less immunogenic that pancreas from the second trimester of gestation, as 
indicated by cellular infiltrates that contain high levels of host CD45+ cells. This is consistent 
with an upregulation of T cell activating molecules, such as MHC II, the chemokine ligand 19 
(CCL19), complement component 3 (C3) and tumour necrosis factor superfamily 10 (TNFSF10, 
also known as TNF-related apoptosis-inducing ligand, TRAIL), in second trimester human 
fetal pancreas compared to first trimester tissue (Brands, Colvin et al. 2008). 
ESCs and iPSCs were also considered to be non-immunogenic, until recently. Murine ESCs 
do not express MHC I or MHC II, but increase MHC I expression when they differentiate 
spontaneously (Wu, Boyd et al. 2008). Despite of the lack of MHC I expression, ESCs are not 
deleted by natural killer (NK) cells (Koch, Geraldes et al. 2008). Interestingly, MHC I-
positive murine ESCs are not recognized by cytotoxic CD8+ T cells, even when antigen 
presenting cells (APCs) are used to prime T cells, suggesting that ES cells have some 
immune privilege. Nevertheless, this immune privilege is fragile and the addition of CD4+ 
helper T cells can induce ESC rejection in vivo (Wu, Boyd et al. 2008). In immunocompetent 
mice, ESC allografts contain infiltrates of CD11b+ macrophages, CD4+ and CD8+ T cells as 
early as 10 days post-transplantation (Wu, Boyd et al. 2008). In line with this, allogeneic EBs 
are not rejected if the CD4 and CD8 co-receptors are blocked, suggesting that ESC-derived 
tissues could be tolerated in allogeneic host (Lui, Boyd et al. 2010). In the absence of 
blocking, rejection of allogeneic EBs is mediated by CD8+ T cells and active F4/80+ MHC II+ 
mannose receptor-negative macrophages. IL-10, a cytokine that downregulates immune 
responses, is expressed in syngeneic and allogeneic EBs grafts that are not rejected (Lui, 
Boyd et al. 2010). This tolerance is completely eliminated when host CD4+ FoxP3+ regulatory 
T cells (Treg) are ablated. Tregs seem to protect EBs by keeping F4/80+ macrophages in a low 
activation state by preventing their upregulation of MHC II, as well as by suppressing 
cytotoxic CD8+ T cell responses by downregulating their expression of granzyme B (Lui, 
Boyd et al. 2010). It remains to be seen whether or not these mechanisms will apply 
universally to all ESC-derived tissues. 
To date, there have been few descriptions of the immunogenicity of ESC-IPCs, but the 
existing data indicate that both innate and adaptive arms of the host immune system could 
be activated after ESC-IPC transplantation. ESC-IPCs can normalize blood glucose levels of 
diabetic immune compromised mice short-term, but when transplanted into 
immunocompetent hosts, their functionality is impaired, even under syngeneic conditions 
(Wu, Boyd et al. 2008). One explanation for the immune rejection of ESC-IPCs is that they 
express higher levels of MHC I than ES cells, and express higher levels of both MHC I and 
MHC II after exposure with IFNγ in vitro. Incidentally, IFNγ is up-regulated within both 
syngeneic and allogeneic ESC-IPC grafts three days after transplantation (Boyd and Wood 
2009). However, the level of cellular infiltration differs between syngeneic and allogeneic 
ESC-IPC grafts. For example, Gr1+ leukocytes can be observed in allogeneic, but not 
syngeneic, ESC-IPC grafts, within the first 24 hours post-transplantation. CD11b+ 
macrophages can be detected in both syngeneic and allogeneic grafts by three days after 
transplantation, indicating a general response to local injury (Boyd and Wood 2010). In 
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addition, early inflammatory molecules that activate macrophages and granulocytes, such 
as IL-6, Gro-β (CXCL2 or macrophage inflammatory protein 2), Lix (CXCL5 or epithelial-
derived neutrophil-activating peptide 78), MIP-1α (CCL3 or macrophage inflammatory 
protein 1-alpha) and MIP-1β (CCL4 or macrophage inflammatory protein 1-beta, IP-10 
(Interferon gamma-induced protein 10 or CXCL10) and Mig (monokine induced by gamma 
interferon or CXCL9), are induced within both syngeneic and allogeneic ESC-IPC grafts 
within three days post-transplantation. Of these cytokines, IP-10, and Mig are associated 
with acute graft rejection (Burns, Wang et al. 2005). The adaptive immune system, as 
expected, is slower to respond, and infiltrates of reactive CD8+ T cells are observed in 
allogeneic ESC-IPCs 10 days post-transplantation. In all cases, the immune response to 
allogeneic ESC-IPC observed was lower than the response to transplanted allogeneic 
pancreatic islets (Boyd and Wood 2010). These studies suggest that IPCs are suitable for 
transplantation, but some immune response by macrophages and T cells should be 
expected, so it is likely that immunosuppressive drugs to prevent graft rejection will have to 
be administered with ESC-IPC grafts.  
Strategies to circumvent the immune system barrier to ESC-IPCs will be needed if they will 
be used for the treatment of diabetic patients. For instance, a short term immunosuppression 
approach blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), CD40 ligand 
(CD40L) or lymphocyte function-associated antigen 1(LFA-1) for 6 days, has shown to allow 
for the engraftment of murine and human ESCs (Pearl, Lee et al. 2011). Since CTLA4Ig 
treatment has previously induced long-term survival of xenogeneic pancreatic islet grafts 
(Lenschow, Zeng et al. 1992; Eventov-Friedman, Tchorsh et al. 2006), it is possible that 
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3.7. Hematopoietic stem cell transplantation to induce immune tolerance for type 
I diabetes 
The autoimmune nature of TID provides two main targets in which hematopoietic stem cell 
transplantation (HSCT) could be used to ameliorate disease: the replacement of 
autoimmune T cells to prevent the onset of TID, and the induction of immunological 
tolerance to islet replacements via a previous HSCT or HSC co-transplantation. In both 
cases, induction of immunological tolerance to donor antigens is required for long-term 
survival of a transplanted organ. This is more easily achieved with autologous bone marrow 
transplantation, but can also occur when allogeneic bone marrow donors are used. In 
allogeneic bone marrow transplantation, induction of central and peripheral tolerance to 
donor antigens has been accomplished by creating mixed hematopoietic chimerism using 
non-myeloablative conditioning regimens (Sykes 2007; Sykes 2009). An important 
component to the induction of this tolerance is the education of donor and host T cells to 
recognize each other as “self” to avoid graft-versus-host disease (GVHD) and well as host-
versus-graft reactions. 
HSCT has been used to induce immune tolerance to TID antigens. Gene therapy approaches 
in which transplantation of syngeneic HSCs that were engineered to express pro-insulin 
under the MHC-II promoter transferred protection against insulitis and the development of 
spontaneous autoimmune diabetes (Steptoe, Ritchie et al. 2003; Chan, Clements et al. 2006). 
Transplant of fully allogeneic purified adult hematopoietic stem cells into lethally irradiated 
NOD mice (Beilhack, Scheffold et al. 2003) and the induction of mixed allogeneic 
hematopoietic chimerism using a non-myeloablative conditioning regimen cured diabetes in 
NOD mice and established clear immunological tolerance to both host and donor MHC as 
well as to insulin (Nikolic, Takeuchi et al. 2004). Recently, it has been shown that mixed 
chimerism across MHC mismatches is superior than mixed chimerism amongst MHC 
matched hematopoietic cells for prevention of insulitis in TID (Racine, Wang et al. 2011). 
Moreover, mesenchymal stem cells (MSC) co-transplanted with hematopoietic stem cells 
without islets prevented the onset of TID in allogeneic recipients, and co-transplantation of 
MSC with allogeneic hematopoietic stem cells and islets have been used to prevent the onset 
of TID in rodent models (Itakura, Asari et al. 2007; Asari, Itakura et al. 2011). 
The results of the first human clinical trial of the use of autologous HSC transplant to treat 
early-stage TID patients were excellent (Voltarelli, Couri et al. 2007). Importantly, in these 
studies TID was alleviated using hematopoietic grafts alone (i.e. without co-transplantation 
of islets). However, patients with late-stage TID can only currently be cured by islet 
transplantation protocols which require islets from multiple matched donors, exceeding 
donor availability (Shapiro, Ricordi et al. 2006), or other insulin producing cell sources (such 
as ESC-IPC and iPS-IPC), which will also require induction of immune tolerance. Combined 
islet and HSC allotransplantation using an 'Edmonton-like' immunosuppression, (i.e. 
without ablative conditioning) in which high doses of donor HSCs (4.3 + 1.9 x 106 HSCs/kg) 
were transplanted after 5 and 11days of islet transplantation, has not resulted in stable 
hematopoietic chimerism or graft tolerance after 1 year post-transplantation (Mineo, Ricordi 
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et al. 2008). Whether prior transplantation of HSCs could improve the engraftment of later 
islet transplantation is not clear, and is not easily tested in the clinic.  
The induction of immunological tolerance to ESC-derived tissues is an active and emerging 
area of investigation. Recent studies have provided proof-of-principle that the induction of 
immunological tolerance to ESC-derived tissues can be achieved, but the mechanisms of 
tolerance induction to ESC-derived hematopoietic-progenitors (ES-HP), as well as the ability 
of ES-HP themselves to induce immunological tolerance across allogeneic barriers, are still 
not well understood (reviewed in (Thompson and Manilay 2011)). Transplantation of 
HoxB4-transduced ES-HP resulted in mixed hematopoietic chimersm and the induction of 
specific transplantation tolerance to allogeneic cardiac grafts (Bonde and Zavazava 2006; 
Bonde, Chan et al. 2008). It appears that HoxB4-ES-HP-derived T cells are actively 
“tolerized” to donor antigens in the thymus, and that if not, they can cause lethal GVHD 
(Kim, Stultz et al. 2011). In line with this, recipients of allogeneic ES-HP lacked evidence of 
GVHD (Burt, Verda et al. 2004; Bonde and Zavazava 2006; Bonde, Chan et al. 2008). Finally, 
another study has shown that non-HoxB4 transduced ES-HP can prevent onset of TID in 
mice (Verda, Kim et al. 2008), but the method of ES-HP production in this study is quite 
different from the other more recent protocols. Therefore, it appears that ES-HP are similar 
to bone-marrow derived hematopoietic progenitors, and that they could be used to induce 
tolerance of allogeneic tissues that are derived from the same ESC line, or that share MHC 
antigens. The same theory could apply to hematopoietic progenitors that are derived from 
iPSC (Niwa, Umeda et al. 2009). 
4. Conclusion 
The replacement of β cells is a promising therapy for diabetic patients, but the process 
depends on the discovery and detailed study of sources other than cadaveric pancreas. 
Pancreatic stem cells would be an ideal source for β cell replacement, since they are 
committed to differentiate into pancreatic cells. However, their cellular marker phenotype, 
as well as their anatomic location, has not yet been identified. If these questions are 
resolved, the conditions for their expansion and differentiation will require further 
optimization, such as emulating the properties of the pancreatic stem cell niche, improving 
their expansion, and perfecting the composition of culture media to induce their 
differentiation into endocrine cells. In addition, as pancreatic stem cells will likely be 
isolated from healthy patients, the immune system barrier to allogeneic transplants will also 
need to be addressed.  
Another alternative to pancreatic stem cells is the differentiation of IPCs from ESC or iPSC, 
but this first requires the development and acceptance of a standard methodology to 
generate them. IPCs differentiated by this standard methodology will have to be completely 
mature and functional (i.e. respond appropriately when blood glucose level are altered, and 
have absolutely no teratoma-forming potential). The generation of a well-defined 
homogenous population of transplantable pancreatic progenitors that can be identified with 
extracellular markers would be an alternative to IPCs. Although they are not completely 
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mature, pancreatic progenitors could perhaps differentiate more readily into mature 
endocrine cells in response to the signals in their in vivo microenvironment. Studies to 
demonstrate that pancreatic progenitors can be isolated and differentiated from human 
ESCs, and can normalize blood glucose levels in humanized diabetic animal models still 
have not been reported. Perhaps a more complete comprehension of normal pancreas 
development can shed light into the processes that lead to the complete maturation of β-
cells in vivo, which can be translated to differentiation protocols from ESC and iPSC. iPSC 
that are reprogrammed from human β cells can be more efficiently differentiated into IPCs 
than ESCs, and would avoid the ethical issues related to the use of ESCs. However, 
optimization of non-viral strategies for reprogramming iPS cells would be preferable before 
clinical translation (Yu, Hu et al. 2009). Finally, independently of the type of cell 
transplanted (ESC-IPC, iPSC-IPC, or pancreatic progenitors), the immunogenicity of these 
cells will have to be considered and determined to predict the potential and type of immune 
response to block before and after transplantation. The data collected from such analyses 
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1. Introduction 
1.1. Potential mechanisms of pathogenesis of RA 
Rheumatoid arthritis (RA) is a chronically systemic inflammatory disorder that ultimately 
leads to the destruction of joint architecture. RA affects more than two million people in 
America and about 1% of the world’s population, women are three times more prone to RA 
than men (1, 2). About 58 million people suffer from RA all over the world. The disease has 
a variable course, from a mild, occasionally symptomatic illness requiring only symptomatic 
therapy to a fully onset requiring aggressive immunosuppressive therapy, surgery or both. 
The hallmarks of RA is the systemic loss of regulation of immune system characterized by 
either acute or chronic inflammation, in which the immune system primarily attacks the 
joints of the body leading to tissue pathology and clinical disease. The etiological factor 
causes the immune reaction is still unknown. The pathological insult starts with 
inflammation of the synovium (sinovita), which then takes the form of proliferative nature 
(pannus) with the damage of cartilage and bones. Plasmatic cells of joint produce antibody 
that form aggregates of IgG. In turn, IgG aggregates have been recognized by the immune 
system as foreign antigens and plasmatic cells (B cells, dendritic cells, T cells, and 
macrophages formed lymphoid follicle-like structures within the synovial membrane) begin 
to produce autoantibodies against those structures known as rheumatoid factors (RF). 
Autoantibodies directed against the Fc fragment of IgG. (3, 4). The most important type of 
RF is the IgM class, which appears in 70-80% of patients with RA. In the course of the 
disease, the normal, relatively avascular synovium then becomes heavily infiltrated by a 
wide variety of cells, including B cells, macrophages, fibroblasts, neutrophil granulocytes, 
dendritic cells, and many other cells (5). Because of the autoimmune inflammatory process, 
which leads to formation of pannus - granulation tissue that occurs from in the inflamed 
synovium, which is consists of actively proliferating fibroblasts, lymphocytes, macrophages 
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and rich with vessels. The synovial lining increases to a thickness of up to 30 cell layers, 
presumably through influx of macrophages, and by expansion of synovial fibroblasts. 
Pannus grows intensively, percolates from the synovial tissue to the cartilage and destroys it 
by the influence of enzymes, which are induced by the production of high amount of 
proinflammatory cytokines mainly tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6 
within the pannus. Furthermore, many other cytokines such as IL-17, IL-18, IL-15, 
chemokines, and angiogenic molecules are present in the inflamed synovial membrane and 
drive the development of the disease. Subsequently, these proinflammatory cytokines 
activate signal transduction pathways and transcription factors, which, in turn, control the 
production of cytokines (6). Gradually, intrasynovial cartilage disappears, it is replaced by 
granulation tissue and ankylosis develops. Chronic inflammation of periarthric tissues, joint 
capsule, ligaments and tendons lead to deformation of joints, semiluxations, and 
contractures. Currently, there is a large body of literature which suggests that autoimmune 
processes play a central role in the early stages of RA, and in later stages non-immune 
mechanisms (i.e., the ability of pannus for growth, invasion and destruction of joint 
cartilage) are more important. However, the crucial triggers for the onset of diseases that 
lead to pathogenic events in RA are still not fully understood. It is generally believed that 
RA is the result of interactions amongst genetic, environmental, biomechanical factors, 
neuroimmunological interactions and altered articular microvascular function (7). Several 
genetic loci have been proposed based on the genome wide association studies to have an 
association with the susceptibility and severity of RA (8-12). A disease association with 
HLA-DR4 alleles (which contain the shared epitope) is well established (13). However, apart 
from the major histocompatibility complex, genetic factors associated with RA severity have 
not yet been convincingly proved. However, other loci, including PTPN22 (protein tyrosine 
phosphatase, non-receptor type 22), PADI4 (peptidyl arginine deiminase, type IV), CTLA4 
(cytotoxic T-lymphocyte antigen 4), Fc�Rs (Fc receptors for IgG), CD40 and CDK6 were 
identified that involved in susceptibility and higher rate of joint destruction (14-17). Various 
cytokines and cytokine-receptor loci, such as those encoding TNF, IL-1, IL-10, and IL-18, 
have been implicated in disease association to various degrees in distinct populations (12). 
The area of identification of susceptible gene loci in RA is currently under intense 
investigation. The frequencies of bone marrow and circulating CD34+ HPC (hematopoietic 
progenitor cells) in RA patient are reduced (18-20), the median apoptotic index of early bone 
marrow myeloid precursors is significantly higher than in controls (21, 22) and their 
proliferative activity is impaired (18, 19). Reduced colony formation by highly purified RA 
CD34+ cells may be linked to an intrinsic defect in the clonogenic potential of RA 
progenitors. However, the molecular pathways responsible for this abnormality remain 
undetermined. HPC isolated from RA patients are hyporesponsive to hematopoietic growth 
factors and fail to expand appropriately. This defect appears specifically connected to the 
extracellular signal-regulated protein kinase (ERK) signaling pathway, a signaling cascade 
critically involved in cell cycle entry and progression of progenitor cells (23). The molecular 
defect causing RA has not been fully characterized although it is reported that many cell 
population have aberrant function, including monocytes, macrophages, B cells, T cells, 
endothelial cells, and fibroblasts, participate in the ongoing inflammatory process. Multiple 
 
Stem Cell-Based Cellular Therapy in Rheumatoid Arthritis 321 
inflammatory pathways contribute to the persistent chronic inflammation in RA (24). Recent 
advances in our understanding of the key cells (i.e., T cells, B cells) and inflammatory 
cytokines (TNF and IL-6) have provided therapeutic opportunities, which are now directly 
targeted by biologic agents approved by the US Food and Drug Administration (FDA) for 
the treatment of RA. 
2. Current biological therapies for RA 
Biologic therapies have brought improved efficacy in the treatment of RA. However, these 
therapies sometimes fail or produce only partial responses, because of the lack of reliable 
predictive biomarkers of prognosis, therapeutic response, and toxicity data. Sustained 
remission is rarely achieved and requires ongoing pharmacological intervention. Although 
RA often responds to immunosuppressive medication including corticosteroids, 
methotrexate, azathioprine and cyclophosphamide, or non-steroidal anti-inflammatory 
drugs, none of these drugs showed a curative effect (25). Synthetic disease-modifying 
antirheumatic drugs (DMARDs), such as methotrexate, leflunomide, and sulfasalazine, have 
evidently improved clinical symptoms and reduced joint damage in RA patients. However, 
despite the effectiveness of synthetic DMARDs, many patients who have been taking those 
drugs continue to have clinical symptoms of inflammation and progressive joint 
destruction. Recently, FDA approved many TNF-α inhibitors including infliximab, 
etanercept, adalimumab, golimumab, and certolizumab pegol in the RA treatment. In 
randomized clinical trials, all of these agents have been shown effective in reducing clinical 
symptom of inflammation in RA patients who have failed synthetic DMARDs (26). Multiple 
studies have demonstrated significant benefits of early treatment with TNF-α inhibitors 
combined with methotrexate (27-29). Other FDA-approved biologic agents for treating 
moderate-to- severe RA include abatacept, rituximab, and tocilizumab (30-33). However, all 
biologic agents carry an increased risk of infections. 
3. Current concept of stem cell therapy in RA 
The natural healing process for RA requires a combination of stem cells, growth factors, and 
matrix to optimize tissue repair and regeneration. The use of these bioactive cells to 
supplement and hasten the natural healing process is considered by many to be a new era of 
clinical treatment. This ideal cell population for the treatment of RA should have a series of 
properties, namely a high osteogenic and chondrogenic potential, and at the same time, it 
should be easily expanded, i.e., capable of self replicating and can be maintained in cultures 
for a long period of time. Due to their natural and intrinsic properties, stem cells are one of 
the best available cell types. There are mainly four types of stem cells undergoing current 
study. They are embryonic stem cells (ESCs), allogeneic (donor) stem cells (SCs), induced 
pluripotential adult stem cells (iPSCs), and last but not least autologous stem cells. Of these 
four, only two, donor SCs and autologous SCs have been used to treat arthritis in human at 
present. The multipotent autologous stem cells also know as mesenchyme stem cell (MSC) 
are sufficient to be used to treat disorders involving connective tissue, such as blood, 
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remission is rarely achieved and requires ongoing pharmacological intervention. Although 
RA often responds to immunosuppressive medication including corticosteroids, 
methotrexate, azathioprine and cyclophosphamide, or non-steroidal anti-inflammatory 
drugs, none of these drugs showed a curative effect (25). Synthetic disease-modifying 
antirheumatic drugs (DMARDs), such as methotrexate, leflunomide, and sulfasalazine, have 
evidently improved clinical symptoms and reduced joint damage in RA patients. However, 
despite the effectiveness of synthetic DMARDs, many patients who have been taking those 
drugs continue to have clinical symptoms of inflammation and progressive joint 
destruction. Recently, FDA approved many TNF-α inhibitors including infliximab, 
etanercept, adalimumab, golimumab, and certolizumab pegol in the RA treatment. In 
randomized clinical trials, all of these agents have been shown effective in reducing clinical 
symptom of inflammation in RA patients who have failed synthetic DMARDs (26). Multiple 
studies have demonstrated significant benefits of early treatment with TNF-α inhibitors 
combined with methotrexate (27-29). Other FDA-approved biologic agents for treating 
moderate-to- severe RA include abatacept, rituximab, and tocilizumab (30-33). However, all 
biologic agents carry an increased risk of infections. 
3. Current concept of stem cell therapy in RA 
The natural healing process for RA requires a combination of stem cells, growth factors, and 
matrix to optimize tissue repair and regeneration. The use of these bioactive cells to 
supplement and hasten the natural healing process is considered by many to be a new era of 
clinical treatment. This ideal cell population for the treatment of RA should have a series of 
properties, namely a high osteogenic and chondrogenic potential, and at the same time, it 
should be easily expanded, i.e., capable of self replicating and can be maintained in cultures 
for a long period of time. Due to their natural and intrinsic properties, stem cells are one of 
the best available cell types. There are mainly four types of stem cells undergoing current 
study. They are embryonic stem cells (ESCs), allogeneic (donor) stem cells (SCs), induced 
pluripotential adult stem cells (iPSCs), and last but not least autologous stem cells. Of these 
four, only two, donor SCs and autologous SCs have been used to treat arthritis in human at 
present. The multipotent autologous stem cells also know as mesenchyme stem cell (MSC) 
are sufficient to be used to treat disorders involving connective tissue, such as blood, 
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tendon, ligament, cartilage, bone, nerve, muscle, and liver. During the last 1-2 decades, the 
scientific community witnessed and reported the appearance of several sources of stem cells 
with both osteogenic and chondrogenic potential. There are many different sources of adult 
stem cells (e.g., bone marrow, periosteum, adipose tissue, skeletal muscle and umbilical 
cord) for bone and cartilage regenerative medicine, namely those focusing on the 
differentiation potential of the latter, as well as in vivo proof of concept of their applicability.  
4. MSC based stem cell therapy in RA 
MSCs are the non-hematopoietic progenitor cells found in various adult tissues. MSCs have 
been characterized by the ease of isolation and rapid growth in vitro while maintaining their 
differentiation potential, allowing for extensive culture expansion to obtain large quantities 
suitable for therapeutic use. MSCs are characterized by the capacity to adhere to plastic 
surface, the phenotype (CD90+, CD73+, CD105+ and absence of hematopoietic markers 
including CD45−, CD34, CD11b−, CD14− CD79α or CD19 and HLA-DR−), the ability to 
differentiate into at least three distinct lineages including adipocytes, chondrocytes, 
osteoblasts, and the capacity for self-renewal (34, 35). MSCs are hypoimmunogenic and are 
able to evade the host immune surveillance. MSCs express low (fetal) to intermediate (adult) 
level of major histocompatibility complex (MHC) class I molecules and do not express MHC 
class II molecules on the cell surface, although an intracellular pool of MHC class II molecules 
can be stimulated to express on the cell surface by interferon-gamma (IFN-γ) (36). However, 
because MSC do not express any costimulatory molecules, including B7-1 (CD80), B7-2 
(CD86), or CD40, MSCs do not activate alloreative T cells (37). After differentiation into 
adipocytes, osteoblasts, and chondrocytes, MSCs continue to express MHC class I but not class 
II molecules on the cell surface, even under stimulation, and continue to be non-immunogenic 
(36, 38). However, the immune privilege of MSCs seem to be limited. A few studies in mouse 
system have reported that allogeneic mismatched MSCs were rejected by the host and could 
not form ectopic bone in vivo, while syngeneic recipient allowed ectopic bone formation 
despite the fact that, the MSCs showed immunosuppressive activity in vitro (39, 40). Recently, 
MSCs have been shown to possess several immunomodulatory properties. These include 
suppression of T cell proliferation, influencing dendritic cell maturation and function, 
suppression of B cell proliferation and terminal differentiation, and immune modulation of 
other immune cells such as NK cells and macrophages (41-44). Meanwhile, MSCs also express 
the Toll-like receptors (TLR)-2 -8. The addition of polyI:C (TLR3 ligand), Pam3Cys (TLR2 
ligand) or LPS (TLR4 ligand) inhibited the differentiation potential of MSCs, but spared their 
immunosuppressive function (45). MSCs also inhibit the maturation and decrease the 
expression of antigen presentation molecules and costimulatory molecules on the surface of 
antigen-presenting cells (APCs) (42). Furthermore, MSCs not only have a direct inhibitory 
effect on T cells but also affect the first critical step of immune response in which they can 
inhibit the differentiation and maturation of the APCs and cause the dendritic cells to switch 
cytokine secretion profile to decrease the secretion of proinflammatory cytokines such as TNF-
α, IFN-γ, and IL-12, and importantly, increase the production of IL-10, which is a suppressive, 
tolerogenic and potent inducer of regulatory T cells (Tregs) (42, 46, 47). An additional study, 
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however, reported that TLR3 or -4 ligation resulted in a strong down-regulation of the Notch 
ligand Jagged-1, leading to the down-regulation of suppressive capacities (48). Thus, in the 
context of an inflammatory process, MSCs may lose the immunosuppressive function. MSCs 
have been shown in recent studies to have significant effects on a variety of conditions 
including both RA and osteoarthritis (49). MSCs are shown to have significant effects on a 
variety of autoimmune type of problems such as rheumatoid arthritis, osteoarthritis, lupus, 
colitis, mixed connective tissue disease, and scleroderma. The mechanism of the 
immunomodulatory effects of MSCs is not completely understood, although both direct and 
indirect actions have been suggested through either cell-cell interaction or soluble factors that 
create a local immunosuppressive environment. MSCs also alter the cytokine secretion profiles 
of dendritic cells, naive and effector T cells, and NK cells to induce a more profound anti-
inflammatory or tolerant phenotype. Secretion of the proinflammatory cytokines, TNF-α and 
IFN-γ, is decreased whereas that of the suppressive IL-4 and IL-10 is strongly stimulated (46). 
Other factors involved in the immunosuppression have been shown to include hepatocyte 
growth factor, TGF-β1, IL-10, IL-6, prostaglandin E2, nitric oxide, and possibly indoleamine 
2,3-dioxygnease. Although the precise mechanism has yet to be clarified (38, 50), a large body 
of evidences suggests that MSCs are immunosuppressive and anti-inflammatory and can be 
transplanted between MHC-incompatible individuals. Single injection of primary murine 
MSCs could prevent the occurrence of severe arthritis, associated with a decreased pro-
inflammatory cytokines in serum (51). Recently, the systemic injection of MSCs engineered to 
overexpress IL-10 significantly reduces the arthritic symptoms contrary to the injection of 
naïve MSCs (52). Several other studies have indicated the limitation of MSC based therapy due 
to its limited regeneration potentials, unidentified homing mechanism as well as long-term 
culture may leads to unstable culture and the possibility of malignancy. The first study on the 
use of MSCs in CIA (collagen induced arthritis) showed that the allogeneic C3H10T1/2 cells 
were unable to decrease the clinical signs of arthritis and even worsen the disease in a murine 
model (53). One of the groups suggested that the systemic injection of allogeneic, as well as 
autologous BM-derived primary MSCs could prevent the disease, but did not have any 
curative effects (54). Overall, the effect of MSCs on the immune cells is to tip off the immune 
response toward a tolerant and anti-inflammatory phenotype. These immunomodulatory 
effects appear not to be limited to MSCs themselves but also are shared by other mesenchymal 
cells. MSC- differentiated cells as well as various stromal cells from different tissues, including 
chondrocytes and fibroblasts, have also been shown to have immunosuppressive effects under 
certain conditions (36, 55). MSCs have been shown to decrease the severity of CIA, but so far 
very few clinical trials is going on despite the convincing evidence that primary MSCs could 
inhibit human T-cell proliferation by in vitro (56). Similar results have been recently obtained 
with human adipose-derived stem cells (ADSCs), which share similar properties with MSCs. 
The authors concluded that ADSCs suppressed T-cell response through the 
generation/activation of antigen-specific Tregs (57). The immunomodulatory role of MSCs is 
dose dependent, and two injections of bone marrow (BM)-MSCs on days 18 and 24 
significantly improved arthritic symptoms (58). The mechanisms involved are suggested as to 
be through CD4+CD25+Foxp3+ Treg cell induction as well as T-cell anergy or Treg activation 
(59, 60). MSCs treatment in immunized mice induced the proliferation of antigen-specific 
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tendon, ligament, cartilage, bone, nerve, muscle, and liver. During the last 1-2 decades, the 
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surface, the phenotype (CD90+, CD73+, CD105+ and absence of hematopoietic markers 
including CD45−, CD34, CD11b−, CD14− CD79α or CD19 and HLA-DR−), the ability to 
differentiate into at least three distinct lineages including adipocytes, chondrocytes, 
osteoblasts, and the capacity for self-renewal (34, 35). MSCs are hypoimmunogenic and are 
able to evade the host immune surveillance. MSCs express low (fetal) to intermediate (adult) 
level of major histocompatibility complex (MHC) class I molecules and do not express MHC 
class II molecules on the cell surface, although an intracellular pool of MHC class II molecules 
can be stimulated to express on the cell surface by interferon-gamma (IFN-γ) (36). However, 
because MSC do not express any costimulatory molecules, including B7-1 (CD80), B7-2 
(CD86), or CD40, MSCs do not activate alloreative T cells (37). After differentiation into 
adipocytes, osteoblasts, and chondrocytes, MSCs continue to express MHC class I but not class 
II molecules on the cell surface, even under stimulation, and continue to be non-immunogenic 
(36, 38). However, the immune privilege of MSCs seem to be limited. A few studies in mouse 
system have reported that allogeneic mismatched MSCs were rejected by the host and could 
not form ectopic bone in vivo, while syngeneic recipient allowed ectopic bone formation 
despite the fact that, the MSCs showed immunosuppressive activity in vitro (39, 40). Recently, 
MSCs have been shown to possess several immunomodulatory properties. These include 
suppression of T cell proliferation, influencing dendritic cell maturation and function, 
suppression of B cell proliferation and terminal differentiation, and immune modulation of 
other immune cells such as NK cells and macrophages (41-44). Meanwhile, MSCs also express 
the Toll-like receptors (TLR)-2 -8. The addition of polyI:C (TLR3 ligand), Pam3Cys (TLR2 
ligand) or LPS (TLR4 ligand) inhibited the differentiation potential of MSCs, but spared their 
immunosuppressive function (45). MSCs also inhibit the maturation and decrease the 
expression of antigen presentation molecules and costimulatory molecules on the surface of 
antigen-presenting cells (APCs) (42). Furthermore, MSCs not only have a direct inhibitory 
effect on T cells but also affect the first critical step of immune response in which they can 
inhibit the differentiation and maturation of the APCs and cause the dendritic cells to switch 
cytokine secretion profile to decrease the secretion of proinflammatory cytokines such as TNF-
α, IFN-γ, and IL-12, and importantly, increase the production of IL-10, which is a suppressive, 
tolerogenic and potent inducer of regulatory T cells (Tregs) (42, 46, 47). An additional study, 
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however, reported that TLR3 or -4 ligation resulted in a strong down-regulation of the Notch 
ligand Jagged-1, leading to the down-regulation of suppressive capacities (48). Thus, in the 
context of an inflammatory process, MSCs may lose the immunosuppressive function. MSCs 
have been shown in recent studies to have significant effects on a variety of conditions 
including both RA and osteoarthritis (49). MSCs are shown to have significant effects on a 
variety of autoimmune type of problems such as rheumatoid arthritis, osteoarthritis, lupus, 
colitis, mixed connective tissue disease, and scleroderma. The mechanism of the 
immunomodulatory effects of MSCs is not completely understood, although both direct and 
indirect actions have been suggested through either cell-cell interaction or soluble factors that 
create a local immunosuppressive environment. MSCs also alter the cytokine secretion profiles 
of dendritic cells, naive and effector T cells, and NK cells to induce a more profound anti-
inflammatory or tolerant phenotype. Secretion of the proinflammatory cytokines, TNF-α and 
IFN-γ, is decreased whereas that of the suppressive IL-4 and IL-10 is strongly stimulated (46). 
Other factors involved in the immunosuppression have been shown to include hepatocyte 
growth factor, TGF-β1, IL-10, IL-6, prostaglandin E2, nitric oxide, and possibly indoleamine 
2,3-dioxygnease. Although the precise mechanism has yet to be clarified (38, 50), a large body 
of evidences suggests that MSCs are immunosuppressive and anti-inflammatory and can be 
transplanted between MHC-incompatible individuals. Single injection of primary murine 
MSCs could prevent the occurrence of severe arthritis, associated with a decreased pro-
inflammatory cytokines in serum (51). Recently, the systemic injection of MSCs engineered to 
overexpress IL-10 significantly reduces the arthritic symptoms contrary to the injection of 
naïve MSCs (52). Several other studies have indicated the limitation of MSC based therapy due 
to its limited regeneration potentials, unidentified homing mechanism as well as long-term 
culture may leads to unstable culture and the possibility of malignancy. The first study on the 
use of MSCs in CIA (collagen induced arthritis) showed that the allogeneic C3H10T1/2 cells 
were unable to decrease the clinical signs of arthritis and even worsen the disease in a murine 
model (53). One of the groups suggested that the systemic injection of allogeneic, as well as 
autologous BM-derived primary MSCs could prevent the disease, but did not have any 
curative effects (54). Overall, the effect of MSCs on the immune cells is to tip off the immune 
response toward a tolerant and anti-inflammatory phenotype. These immunomodulatory 
effects appear not to be limited to MSCs themselves but also are shared by other mesenchymal 
cells. MSC- differentiated cells as well as various stromal cells from different tissues, including 
chondrocytes and fibroblasts, have also been shown to have immunosuppressive effects under 
certain conditions (36, 55). MSCs have been shown to decrease the severity of CIA, but so far 
very few clinical trials is going on despite the convincing evidence that primary MSCs could 
inhibit human T-cell proliferation by in vitro (56). Similar results have been recently obtained 
with human adipose-derived stem cells (ADSCs), which share similar properties with MSCs. 
The authors concluded that ADSCs suppressed T-cell response through the 
generation/activation of antigen-specific Tregs (57). The immunomodulatory role of MSCs is 
dose dependent, and two injections of bone marrow (BM)-MSCs on days 18 and 24 
significantly improved arthritic symptoms (58). The mechanisms involved are suggested as to 
be through CD4+CD25+Foxp3+ Treg cell induction as well as T-cell anergy or Treg activation 
(59, 60). MSCs treatment in immunized mice induced the proliferation of antigen-specific 
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clones of Tregs with a CD4+CD25+CD27+Foxp3+ phenotype, suggesting that the 
immunosuppressive activity of MSCs could be prolonged by the action of Treg clones that is 
activated by an antigen-specific stimulus (51). A recent result showed that ADSCs both 
prevented and treated CIA by significantly reducing the incidence and severity of 
experimental arthritis (61). In this study, treatment with ADSCs inhibited the production of 
various inflammatory mediators, decreased the expansion of antigen-specific Th1/Th17 cell, 
and induced the production of anti-inflammatory cytokine interleukin-10. Moreover, ADSCs 
could induce the generation of antigen-specific Tregs with the capacity to suppress collagen-
specific T cell responses. Currently, a clinical trial based on MSC transplantation has been 
initiated to treat RA; clinicians are trying to asses the safety and efficacy of umbilical cord-
derived MSCs for RA at phase I/II levels (NCT01547091, www.Clinical.Trials.gov).  
5. HSC (hematopoietic stem cell)-based therapy in RA 
Out of several advantages of HSC-based therapy, one potential of using HSC lines for 
transplantation in patients with autoimmune diseases is that these cells can be recovered 
from unaffected individuals. Thus, genetic makeup is defined and will not be affected by 
genetic influence whereas ESCs will be affected by genetic influences (62). In addition, by 
using genetically selected or engineered cell types may further limit the possibility of disease 
progression or re-emergence. There are several studies in the past that used cell-based 
approaches to treat active, destructive, refractory and inflammatory arthritis that involved 
HSC transplantation (HSCT) (62-65) and juvenile idiopathic arthritis (66, 67). Although this 
treatment was curative for some patients, prolonged immunosuppression after HSCT was 
associated with a significant risk of infection, which limited the potential of this therapy (68, 
69). One other potential problem of using non-self HSCs is the possible immune rejection of 
the transplanted cells. Under these circumstances, ESC-derived HSCs or other blood cells 
may offer distinct advantages over cord blood and BM-derived HSC lines in avoiding 
rejection of the transplant. In future, there is a hope for the development of deposit banks of 
ESCs expressing various combinations of the three most critical MHC molecules that can be 
utilized to allow close matching to the recipient's MHC composition. However, data from 
these trials implicated that Tregs, as a critical component of the regulatory state, will be 
functioning in the newly reconstituted immune system after transplant. In patients with 
juvenile idiopathic arthritis treated with HSCT, post-transplant reconstitution of 
CD4+CD25high Treg was more rapid than that of CD4+CD25– cells. This preferential recovery of 
Tregs could result from the relative resistance of Tregs to apoptosis after genotoxic stress (70). 
These results imply that there are other approaches to shift the balance of the immune system 
away from inflammation and toward regulation, e.g., those that selectively bolster Treg 
numbers or function, may prove to be successful and less risky than HSCT.  
6. Regulatory T cell-based therapy in RA 
Tregs play an important role in the prevention of autoimmunity, and have ability to 
modulate the severity of CIA (71, 72). Deficiencies in Treg function have been identified in a 
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wide variety of human autoimmune disorders, including RA (73-76). The majority of the 
reports suggested that biological or stem cells therapy will induce a potent population of 
Tregs in patients with RA (57, 59, 60), but the natural Treg defect will persist in responding 
patients after anti-TNF treatment (77). A few studies suggested that Tregs isolated from 
patients with active RA were competent at suppressing conventional T cell proliferation but 
not cytokine production (73). A recent report suggested that reduced expression and 
functional abnormalities in Tregs associated with cytotoxic T lymphocyte-associated antigen 
4 (CTLA-4) could account for the Treg defect in patients with RA (78). 
Tregs comprise about 5-10% of the mature CD4+ T helper cell subpopulation in mice and 
about 1-2% of CD4+ T cells in human. Tregs are composed of thymus-derived, naturally 
occurring CD4+CD25+Foxp3+ Tregs (nTregs) as well as adaptive (also called ‘induced’) Tregs 
(iTregs) that are generated from CD4+CD25−Foxp3− naive T cells in the periphery. Unlike other 
cell-surface markers used to identify Tregs, Foxp3 is not up-regulated upon activation, and 
discriminates Tregs from activated effectors T cells. On the other hand, Foxp3 is also expressed 
in T cells without conferring any regulatory functions. nTregs are characterized by the 
expression of CD25, CD45RB, CD62L, CD103, CD95 (Fas), MHC class II, CD127, neuropiln-1 
lymphocyt activation gene-3 (LAG-3), CTLA-4, glucocorticoid-induced TNFR family related 
gene (GITR), and Foxp3. iTreg cells are also characterized as expressing the same markers as 
nTreg cells but arise from CD4+D25+FoxP3- precursor cells. iTreg cells are further classified into 
two subgroups on the basis of TGF-β or IL-10 production. Recently, it was reported that 
human CD4+FoxP3+ T cells have three distinct populations with precise phenotypes and fates 
which includes, CD25++ CD45RA+ (Foxp3lo) resting Tregs (rTreg cells), CD25+++ CD45RA- 
(Foxp3hi) activated Tregs (aTregs), and CD25++ CD45RA- (Foxp3hi) cytokines-secreting T cells 
which lack suppressive activity (79). The first two groups of phenotypes represent different 
stages of Treg cell differentiation and are both playing suppressive function in vitro. However, 
the new and exclusive cell surface marker of Tregs is still an area of intense research.  
One critical factor in Treg cell-based therapy is the survival of Tregs. Tregs are highly 
susceptible to apoptosis in the absence of common gamma chain (γc) cytokines (i.e., IL-2, IL-
4, IL-7, IL-9, IL-15, and IL-21) because Tregs do not produce these cytokines and depend on 
other cells (80, 81). Tregs are also susceptible to apoptosis due to the low expression of the 
anti-apoptotic bcl-2 family members (82). Bcl-xL is an anti-apoptotic factor that is able to 
prolong the life span of apoptosis-prone lymphocytes. ß-catenin enhances the survival of 
CD4+CD25+ Tregs in vitro without altering their anergic state or suppressive function by 
modulating the antiapoptotic bcl-xl gene expression in Tregs (83). Recent reports (84) 
suggest that bcl-xL is involved in the development and function of Tregs by inducing the 
expression of Foxp3, CTLA-4, TGF-β, and repressing the programmed death receptor-1 (PD-
I) expression. Additionally, Foxp3 and bcl-xL could cooperatively promote Treg cell 
survival and prevention of arthritis development due to the increased life span of Tregs (85). 
These approaches promote Treg cell differentiation and long-term survival thus results in 
the long-lasting Treg cell persistence. 
Several studies have shown improvement of inflammation, e.g., that seen in murine antigen-
induced arthritis, by transfusion of functional Tregs (86-89). It has ignited some debates 
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associated with a significant risk of infection, which limited the potential of this therapy (68, 
69). One other potential problem of using non-self HSCs is the possible immune rejection of 
the transplanted cells. Under these circumstances, ESC-derived HSCs or other blood cells 
may offer distinct advantages over cord blood and BM-derived HSC lines in avoiding 
rejection of the transplant. In future, there is a hope for the development of deposit banks of 
ESCs expressing various combinations of the three most critical MHC molecules that can be 
utilized to allow close matching to the recipient's MHC composition. However, data from 
these trials implicated that Tregs, as a critical component of the regulatory state, will be 
functioning in the newly reconstituted immune system after transplant. In patients with 
juvenile idiopathic arthritis treated with HSCT, post-transplant reconstitution of 
CD4+CD25high Treg was more rapid than that of CD4+CD25– cells. This preferential recovery of 
Tregs could result from the relative resistance of Tregs to apoptosis after genotoxic stress (70). 
These results imply that there are other approaches to shift the balance of the immune system 
away from inflammation and toward regulation, e.g., those that selectively bolster Treg 
numbers or function, may prove to be successful and less risky than HSCT.  
6. Regulatory T cell-based therapy in RA 
Tregs play an important role in the prevention of autoimmunity, and have ability to 
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wide variety of human autoimmune disorders, including RA (73-76). The majority of the 
reports suggested that biological or stem cells therapy will induce a potent population of 
Tregs in patients with RA (57, 59, 60), but the natural Treg defect will persist in responding 
patients after anti-TNF treatment (77). A few studies suggested that Tregs isolated from 
patients with active RA were competent at suppressing conventional T cell proliferation but 
not cytokine production (73). A recent report suggested that reduced expression and 
functional abnormalities in Tregs associated with cytotoxic T lymphocyte-associated antigen 
4 (CTLA-4) could account for the Treg defect in patients with RA (78). 
Tregs comprise about 5-10% of the mature CD4+ T helper cell subpopulation in mice and 
about 1-2% of CD4+ T cells in human. Tregs are composed of thymus-derived, naturally 
occurring CD4+CD25+Foxp3+ Tregs (nTregs) as well as adaptive (also called ‘induced’) Tregs 
(iTregs) that are generated from CD4+CD25−Foxp3− naive T cells in the periphery. Unlike other 
cell-surface markers used to identify Tregs, Foxp3 is not up-regulated upon activation, and 
discriminates Tregs from activated effectors T cells. On the other hand, Foxp3 is also expressed 
in T cells without conferring any regulatory functions. nTregs are characterized by the 
expression of CD25, CD45RB, CD62L, CD103, CD95 (Fas), MHC class II, CD127, neuropiln-1 
lymphocyt activation gene-3 (LAG-3), CTLA-4, glucocorticoid-induced TNFR family related 
gene (GITR), and Foxp3. iTreg cells are also characterized as expressing the same markers as 
nTreg cells but arise from CD4+D25+FoxP3- precursor cells. iTreg cells are further classified into 
two subgroups on the basis of TGF-β or IL-10 production. Recently, it was reported that 
human CD4+FoxP3+ T cells have three distinct populations with precise phenotypes and fates 
which includes, CD25++ CD45RA+ (Foxp3lo) resting Tregs (rTreg cells), CD25+++ CD45RA- 
(Foxp3hi) activated Tregs (aTregs), and CD25++ CD45RA- (Foxp3hi) cytokines-secreting T cells 
which lack suppressive activity (79). The first two groups of phenotypes represent different 
stages of Treg cell differentiation and are both playing suppressive function in vitro. However, 
the new and exclusive cell surface marker of Tregs is still an area of intense research.  
One critical factor in Treg cell-based therapy is the survival of Tregs. Tregs are highly 
susceptible to apoptosis in the absence of common gamma chain (γc) cytokines (i.e., IL-2, IL-
4, IL-7, IL-9, IL-15, and IL-21) because Tregs do not produce these cytokines and depend on 
other cells (80, 81). Tregs are also susceptible to apoptosis due to the low expression of the 
anti-apoptotic bcl-2 family members (82). Bcl-xL is an anti-apoptotic factor that is able to 
prolong the life span of apoptosis-prone lymphocytes. ß-catenin enhances the survival of 
CD4+CD25+ Tregs in vitro without altering their anergic state or suppressive function by 
modulating the antiapoptotic bcl-xl gene expression in Tregs (83). Recent reports (84) 
suggest that bcl-xL is involved in the development and function of Tregs by inducing the 
expression of Foxp3, CTLA-4, TGF-β, and repressing the programmed death receptor-1 (PD-
I) expression. Additionally, Foxp3 and bcl-xL could cooperatively promote Treg cell 
survival and prevention of arthritis development due to the increased life span of Tregs (85). 
These approaches promote Treg cell differentiation and long-term survival thus results in 
the long-lasting Treg cell persistence. 
Several studies have shown improvement of inflammation, e.g., that seen in murine antigen-
induced arthritis, by transfusion of functional Tregs (86-89). It has ignited some debates 
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regarding the potential use in cellular therapy for RA. One approach to boost number of 
Tregs without myeloablative conditioning is to isolate Tregs from patients, expand them in 
culture, and then re-infuse the cells (90). Expansion of pre-existing Treg cell subsets ex vivo 
and transfuse back into patients in carefully controlled conditions to ensure the preservation 
of the regulatory capacity may be helpful, but could require large numbers of Tregs to be 
effective (91, 92). Ex vivo Treg cell expansion and re-infusion has successfully prevented or 
reversed a number of autoimmune diseases in mouse models, including models of 
inflammatory arthritis (93-97). There are several limitations and pitfalls in the treatment of 
patients with Tregs. Incomplete lineage commitment enables some human Tregs to express 
nuclear factor ROR-γt and to develop into IL-17-producing effector cells (98-100). It is also 
possible that cells become unstable after transfusion, particularly in an inflammatory 
environment, pathogenic responses might be exacerbated. Contamination of therapeutic 
Tregs with these unstable Tregs, or even with true autoreactive effector T cells, could lead to 
deterioration rather than attenuation of the autoimmune process. Tregs may be less effective 
in suppressing effector T cells in an autoimmune setting, and may even augment IL-17 
production in vitro (100-102). The ability to generate iTreg cells in vitro by culturing CD4+ T 
cells in the presence of TGF-β provides a mechanism by which large numbers of functional 
iTreg cells could be generated for adoptive transfer into patients with RA, however, TGF-β-
induced Tregs are potentially unstable and would pose a risk of converting into pathogenic 
responder T cells (103, 104). There are also several other disadvantages of the in vitro 
expansion or generation of Tregs for transfer back to patients, which include the risk of 
contamination from pathogenic responder T cells that could exacerbate the disease, and the 
generation of polyclonal Tregs that could initiate a generalized immunosuppression. In spite 
of these potential concerns, however, clinical trials are underway to test the therapeutic 
potential of Tregs in graft-versus-host diseases. Ectopic expression of the regulatory 
transcription factor, Foxp3, has been used to convert conventional CD4+ T cells into Tregs 
with regulatory function (87, 105). A powerful approach to generating large numbers of 
antigen-specific Tregs has been demontrated by the introduction of T cell receptor (TCR) 
gene into purified CD4+CD25+ T cells as well as co-transfer of Foxp3 and TCR genes to 
convert conventional CD4+ T cells into antigen-specific Tregs (88). However, important 
safety concerns remained for the application of this approach. TCR-transduced Tregs as well 
as Foxp3+TCR-transduced CD4+ T cells selectively accumulated in the draining lymph 
nodes of the antigen-challenged knee, indicating that both were able to respond to the 
antigen stimulation in vivo compared to PBS-treated control mice. There was no increase in 
Th17 cells in the T cell-treated mice, indicating that in the in vivo environment of 
inflammatory arthritis neither the engineered Tregs nor the engineered CD4+ T cells 
converted into Th17 cells. In a series of studies, both populations displayed characteristic 
markers of nTregs (CD25, CTLA-4, and GITR) and demonstrated suppressive activity. These 
studies open the possibility to target Tregs to tissue-specific antigens for the treatment of 
autoimmune tissue damage. Recent strategies have used the foot-and-mouth disease virus 
2A or 2A-like elements to create multicistronic vectors capable of generating multiple 
proteins from the same transcript. A single 2A peptide-linked retroviral vector has been 
used successfully to generate reliable and versatile gene therapy vectors that can be used in 
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biomedical research (106). In addition, co-expression of Foxp3 and bcl-xL linked by a 2A 
sequence in CD4+ cells is critical for augmenting the differentiation and persistence of Tregs. 
Most significantly, the co-introduction of these molecules into CD4+ T cells resulted in their 
ability to significantly block the development of arthritis in a murine model (87). These data 
provide new insights toward the generation of highly reactive Tregs for adoptive 
immunotherapy of autoimmune disease. However, adoptive cell transfer did not cure 
established arthritis, which could be explained by the absence of specificity that directs the 
movement of Tregs to the inflamed paw. Thus, generation of antigen-specific highly reactive 
Tregs may be a promising approach for the treatment of established autoimmune diseases. 
7. Concept of stem cell-derived Treg-based therapy in RA 
Because of the intrinsic resistance of Tregs to exogenous expansion and a high number of 
Tregs are required to perform the Treg-based immunotherapy, it becomes imminent to isolate 
a larger Treg cell subset for exogenous expansion and adoptive transfer, as discussed above, 
there are number problem and limitations to generate a large number of Tregs regardless of 
an increasing number of protocols for isolating subsets of Tregs, no approach to date has been 
confirmed the capacity to isolate the entire Treg cell population with 100 percent specificity. 
ESCs or iPSCs have the remarkable potential to develop into many different cell types in the 
body during early life and growth. ES or iPSC can give rise to all the blood cell types 
including myeloide (e.g., monocytes and macrophages, neutrophiles, basophiles, 
eosinophiles, erythrocytes, megakaryocytes/platelets, dendritic cells) and lymphiode lineage 
(e.g., T cells, B cells, NK cells). Whether ESCs or iPSCs will provide advantages over cord 
blood or adult BM-derived HSC remains to be determined. However, HSCs or MSCs, have 
limited potentials for self-renewal and the differentiation decline in response to 
differentiation signals with with each cycle compared to pluripotent ESCs or iPSCs (107). 
HSCs are present in differentiated cultures from human ESCs and from human fetal-derived 
embryonic germ stem cells (108-112). In contrast, iPSCs could be generated from mouse and 
human somatic cells by introducing Oct3/4 and Sox2 with either Klf4 and c-Myc or Nanog 
and Lin28 by using retroviruses or lentiviruses-mediated transduction (113-116). In addition, 
iPSCs are similar to natural pluripotent stem cells (e.g., ESCs) in many respects, such as the 
expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling 
time, embryoid body formation, teratoma formation, viable chimera formation, and potency 
and differentiability, but the full extent of the relations to natural pluripotent stem cells are 
still being assessed (117, 118). The use of iPSCs can bypass ethical and feasibility issues 
related to the use of ESCs and HSCs. The iPS technology continues to progress rapidly, and 
clinically applicable iPSCs can be generated from patients with noninvasive medical 
procedures. Collectively, iPSCs have a greater potential to be used in adoptive cell transfer 
(ACT)-based immunotherapy for autoimmune diseases compared to ESCs and HSCs.  
Previously, pluripotent stem cells (e.g., ESCs, HSCs) have been shown to differentiate into T 
cells in vitro, and recently iPSCs have been demonstrated to have the ability to differentiate 
into T cells (123) and antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) (124). In these 
studies, murine iPSCs were genetically modified with ovalbumin (OVA)-specific MHC I-
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biomedical research (106). In addition, co-expression of Foxp3 and bcl-xL linked by a 2A 
sequence in CD4+ cells is critical for augmenting the differentiation and persistence of Tregs. 
Most significantly, the co-introduction of these molecules into CD4+ T cells resulted in their 
ability to significantly block the development of arthritis in a murine model (87). These data 
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Tregs are required to perform the Treg-based immunotherapy, it becomes imminent to isolate 
a larger Treg cell subset for exogenous expansion and adoptive transfer, as discussed above, 
there are number problem and limitations to generate a large number of Tregs regardless of 
an increasing number of protocols for isolating subsets of Tregs, no approach to date has been 
confirmed the capacity to isolate the entire Treg cell population with 100 percent specificity. 
ESCs or iPSCs have the remarkable potential to develop into many different cell types in the 
body during early life and growth. ES or iPSC can give rise to all the blood cell types 
including myeloide (e.g., monocytes and macrophages, neutrophiles, basophiles, 
eosinophiles, erythrocytes, megakaryocytes/platelets, dendritic cells) and lymphiode lineage 
(e.g., T cells, B cells, NK cells). Whether ESCs or iPSCs will provide advantages over cord 
blood or adult BM-derived HSC remains to be determined. However, HSCs or MSCs, have 
limited potentials for self-renewal and the differentiation decline in response to 
differentiation signals with with each cycle compared to pluripotent ESCs or iPSCs (107). 
HSCs are present in differentiated cultures from human ESCs and from human fetal-derived 
embryonic germ stem cells (108-112). In contrast, iPSCs could be generated from mouse and 
human somatic cells by introducing Oct3/4 and Sox2 with either Klf4 and c-Myc or Nanog 
and Lin28 by using retroviruses or lentiviruses-mediated transduction (113-116). In addition, 
iPSCs are similar to natural pluripotent stem cells (e.g., ESCs) in many respects, such as the 
expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling 
time, embryoid body formation, teratoma formation, viable chimera formation, and potency 
and differentiability, but the full extent of the relations to natural pluripotent stem cells are 
still being assessed (117, 118). The use of iPSCs can bypass ethical and feasibility issues 
related to the use of ESCs and HSCs. The iPS technology continues to progress rapidly, and 
clinically applicable iPSCs can be generated from patients with noninvasive medical 
procedures. Collectively, iPSCs have a greater potential to be used in adoptive cell transfer 
(ACT)-based immunotherapy for autoimmune diseases compared to ESCs and HSCs.  
Previously, pluripotent stem cells (e.g., ESCs, HSCs) have been shown to differentiate into T 
cells in vitro, and recently iPSCs have been demonstrated to have the ability to differentiate 
into T cells (123) and antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) (124). In these 
studies, murine iPSCs were genetically modified with ovalbumin (OVA)-specific MHC I-
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 328 
restricted TCR (OT-I) by retrovirus-mediated transduction. These iPSCs differentiated into 
functional antigen-specific CTLs in vivo and significantly protected the hosts from a tumor 
challenge (124). Thus, a new approach to generate a high number of functional Tregs from 
ESCs or iPSCs may be used for the treatment of autoimmune diseases (Figures 1-3). ESCs 
and iPSCs can be induced to differentiate into antigen specific or naïve Tregs in vitro 
through a Notch-mediated signaling. Genetic modification of iPSCs or ESCs with the Foxp3 
gene and antigen specific TCR as well as stimulation with an in vitro Notch ligand will direct 







Figure 1. Generation of muticistronic construct for antigen-specific Tregs. (A) Mouse ES cells & iPS cells 
were maintained on feeder layers of irradiated SNL76/7 cells in 6-well culture plates and were passaged 
every 3 days. In brief, iPSCs were maintained in DMEM culture medium supplemented with 15% fetal 
calf serum (FCS), 0.1 mmol/L nonessential amino acids, 1 mmol/L l-glutamine, and 0.1 mmol/L β-
mercaptoethanol. (B) Schematic representation of the retrovirus construct based on MiDR vector contain 
bcl-xL, or Foxp3, or Foxp3 + bcl-xL or TCRα + TCRβ + FoxP3, ψ, packaging signal; 2A, picornavirus self-
cleaving 2A sequence; LTR, long terminal repeats; DsRed and IRES bidirectional promoter.  
 







Figure 2. Retroviral transduction of stem cells. (A) Schematic representation of retroviral transduction. 
Retroviral transduction was performed as described before (124). 5 × 104 iPSCs were cultured in the 
presence of stem cell factor (SCF), IL-6 and IL-3 for 48 hours in 24 well plate coated with 1% gelatin. At 
the same time virus producing packaging cells line were transfected with retroviral construct containing 
gene of interests. After 2 days, the supernatant was replaced with 1 ml viral supernatant containing 10 
μg/ml Polybrene, and the cells were spun for 1 h at 32°C and incubated at 32°C for 8 h. This was 
repeated the following day. Viral supernatant was removed and replaced with fresh medium, and 
iPSCs were re-cultured on fresh feeder layer. Expression of DsRed was determined by flow cytometry 
by gating on double positive (GFP + DsRed) iPSCs. DsRed-expressing iPSCs can be enriched and 
purified by cell sorting using a high-speed cell sorter and can be further use for differentiation and 
characterization. (B) Gene-transduced iPSCs were visualized by fluorescence microscopy. 
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Figure 3. In vivo & in vitro differentiations of transduced iPSCs. (A) Schematic representation of in vitro 
stem cells differentiation. Monolayers of OP9-DL1/OP9DL-1-MHC-II cells were cultured in α-MEM 
medium supplemented with 20% FCS and 2.2 g/L sodium bicarbonate. Gene-transduced, sorted and 
purified iPSCs were washed once in OP9-DL1 medium before plating onto subconfluent OP9-DL1 
monolayers for Treg lineage differentiation in the presence of murine recombinant 5 ng/ml Flt-3 ligand 
and 1 ng/ml murine rIL-7 after day 7. (B). Morphology of Treg cell differentiation on days 0, 7, 14, and 
28. (C) Foxp3-transduced iPSCs were co-cultured on OP9-DL1 cells for 7 days, and adoptively 
transferred into Rag1-/- mice that had no mature T cells or B cells. After 6 weeks, antigen-specific Treg 
cell development can be determined (e.g., we observed CD4+ CD25+ Foxp3+ Tregs in the lymph nodes 
(LN) and spleen and the cells had the ability to produce TGF-β and IL-10). Thus, Foxp3-tranduced 
iPSCs are capable of differentiating into functional Tregs both in vitro and in vivo. 
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other immune cell activities. In addition, gene transduction of antigen-specific TCR will 
result in iPSC or ESC-derived Tregs exhibiting a uniform expression of antigen-specific TCR 
following in vitro or in vivo development. This approach will help generate large numbers of 
functional antigen-specific Tregs. Therefore, gene transduction of iPSC or ESCs followed by 
T lineage differentiation through an in vitro Notch signaling or an in vivo approach will 
generate large numbers of monoclonal antigen-specific Tregs, which can be used for Treg-
based immunotherapy. These cells could be able to persist in vivo, unlike cells generated via 
the current therapeutic regimen, and will likely contribute toward the treatment of 
autoimmune diseases (such as type I diabetes, RA, and system lupus erythematosus). The 
use of iPSCs as a mean to develop disease-specific immune cells for immunotherapy has a 
great potential in the prevention of many diseases. Collectively, iPSCs have a greater 
potential to be used in Treg-based immunotherapy for autoimmune diseases compared to 
ESCs and HSCs.  
8. Conclusion 
Biologic agents have revolutionized the treatment of RA by reducing the signs and 
symptoms and improving physical function and quality of life in affected patients, and also 
showed promising data to treat many diseases. However, question remains for their side 
effects. Improved knowledge of the pathophysiology will lead to the recognition of more 
reliable and practical predictors of the disease course and treatment response. Stem cell-
based therapies offer many exciting opportunities for the development of novel treatment 
and cure for autoimmune diseases. The multipotent autologous stem cells have potential to 
treat disorders involving connective tissue because of their differentiation potential. In 
addition, the multipotent autologous stem cells have significant effects on a variety of 
autoimmune diseases because of their immunomodulatory immune response. Despite of the 
great potential and convincing evidence that primary MSCs inhibit human T-cell 
proliferation in vitro and decrease the severity of CIA in mouse models, there are very few 
clinical trials are going on worldwide and recent trials have produced mixed results. The 
results of clinical trails question the efficacy of MSCs in disease conditions in part due to 
incomplete understanding of the fate of MSC after infusion despite of the positive safety 
aspects. Because of the plasticity and potentially unlimited capacity for self-renewal, iPSC-
derived Tregs may be applied for Treg cell adoptive immunotherapy, such as cancer, 
autoimmune disorders, and infectious or aging-related diseases. A challenging research 
effort remains to fully examine this potential and to address several remaining questions, 
which include how to direct the differentiation of specific cell types, generate large number 
of differentiated cells in the best possible ways and determine which particular type of stem 
cell will be optimal for each therapeutic approach. However, stem cells or their progeny 
may provide one of several better roads for future delivery of immune cell-based therapies. 
The approaches for generation of antigen-specific Tregs from iPSCs provide an important 
foundation for the ultimate generation of patient- and/or disease-specific Treg-based 
therapies. However, to explore the potential to alleviate these devastating chronic diseases 
with the use of stem cell-based technologies is still enormous. 
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other immune cell activities. In addition, gene transduction of antigen-specific TCR will 
result in iPSC or ESC-derived Tregs exhibiting a uniform expression of antigen-specific TCR 
following in vitro or in vivo development. This approach will help generate large numbers of 
functional antigen-specific Tregs. Therefore, gene transduction of iPSC or ESCs followed by 
T lineage differentiation through an in vitro Notch signaling or an in vivo approach will 
generate large numbers of monoclonal antigen-specific Tregs, which can be used for Treg-
based immunotherapy. These cells could be able to persist in vivo, unlike cells generated via 
the current therapeutic regimen, and will likely contribute toward the treatment of 
autoimmune diseases (such as type I diabetes, RA, and system lupus erythematosus). The 
use of iPSCs as a mean to develop disease-specific immune cells for immunotherapy has a 
great potential in the prevention of many diseases. Collectively, iPSCs have a greater 
potential to be used in Treg-based immunotherapy for autoimmune diseases compared to 
ESCs and HSCs.  
8. Conclusion 
Biologic agents have revolutionized the treatment of RA by reducing the signs and 
symptoms and improving physical function and quality of life in affected patients, and also 
showed promising data to treat many diseases. However, question remains for their side 
effects. Improved knowledge of the pathophysiology will lead to the recognition of more 
reliable and practical predictors of the disease course and treatment response. Stem cell-
based therapies offer many exciting opportunities for the development of novel treatment 
and cure for autoimmune diseases. The multipotent autologous stem cells have potential to 
treat disorders involving connective tissue because of their differentiation potential. In 
addition, the multipotent autologous stem cells have significant effects on a variety of 
autoimmune diseases because of their immunomodulatory immune response. Despite of the 
great potential and convincing evidence that primary MSCs inhibit human T-cell 
proliferation in vitro and decrease the severity of CIA in mouse models, there are very few 
clinical trials are going on worldwide and recent trials have produced mixed results. The 
results of clinical trails question the efficacy of MSCs in disease conditions in part due to 
incomplete understanding of the fate of MSC after infusion despite of the positive safety 
aspects. Because of the plasticity and potentially unlimited capacity for self-renewal, iPSC-
derived Tregs may be applied for Treg cell adoptive immunotherapy, such as cancer, 
autoimmune disorders, and infectious or aging-related diseases. A challenging research 
effort remains to fully examine this potential and to address several remaining questions, 
which include how to direct the differentiation of specific cell types, generate large number 
of differentiated cells in the best possible ways and determine which particular type of stem 
cell will be optimal for each therapeutic approach. However, stem cells or their progeny 
may provide one of several better roads for future delivery of immune cell-based therapies. 
The approaches for generation of antigen-specific Tregs from iPSCs provide an important 
foundation for the ultimate generation of patient- and/or disease-specific Treg-based 
therapies. However, to explore the potential to alleviate these devastating chronic diseases 
with the use of stem cell-based technologies is still enormous. 
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1. Introduction 
Rheumatoid arthritis (RA) is a common, chronic, inflammatory disease. It affects around 1% 
of the adult population in all age groups, although the incidence peaks during the fifth 
decade of life. The aetiology of RA is unknown, but it is considered to be autoimmune in 
nature. Inflammation in the synovial tissues of the joints is the hallmark of RA, causing pain, 
stiffness, loss of function and progressive destruction of the cartilage and bone in the 
inflamed joints in the majority of patients. Early diagnosis and appropriate treatment is 
crucial for the amelioration of symptoms, improvement of function and prevention of 
structural damage.  
Traditionally, treatment of RA has been based on the use of a group of disease-modifying 
antirheumatic drugs (DMARDs), of which methotrexate (MTX) is the most widely used, 
often in combination with corticosteroids and/or NSAIDs (non-steroid anti-inflammatory 
drugs). Leflunomide, sulphasalazine, azathioprine, are examples of other synthetic 
DMARDs. The landscape of RA treatment has changed dramatically during the last decade 
due to the introduction of biologic DMARDs, small molecules that target small molecules 
(like cytokines) and cells of the immune system, important mediators of the immunological 
mechanisms in RA. To date, nine biologic agents have been approved for the treatment of 
RA and more molecules with distinct mechanisms of action are currently being tested in 
laboratories and in clinical trials. The good efficacy and general safety of these agents is well 
established from both clinical and epidemiological trials, but there are still several issues 
that remain unclear or need further study, such as long-term safety, more individualized 
treatment by finding predictors of response, cost-effectiveness, when to introduce biologic 
treatment and the feasibility of discontinuation after achieving low disease activity or 
remission.  
 The Author( ). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 342 
[122] Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S, Taghon 
T, et al. Generation of T cells from human embryonic stem cell-derived hematopoietic 
zones. J Immunol. [Research Support, Non-U.S. Gov't]. 2009 Jun 1;182(11):6879-88. 
[123] Lei F, Haque R, Weiler L, Vrana KE, Song J. T lineage differentiation from induced 
pluripotent stem cells. Cell Immunol. [Research Support, Non-U.S. Gov't]. 
2009;260(1):1-5. 
[124] Lei F, Zhao B, Haque R, Xiong X, Budgeon L, Christensen ND, et al. In vivo 
programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to 






© 2012 Chatzidionysiou, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Biologic Treatment in  
Rheumatoid Arthritis 
Katerina Chatzidionysiou 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/50745 
1. Introduction 
Rheumatoid arthritis (RA) is a common, chronic, inflammatory disease. It affects around 1% 
of the adult population in all age groups, although the incidence peaks during the fifth 
decade of life. The aetiology of RA is unknown, but it is considered to be autoimmune in 
nature. Inflammation in the synovial tissues of the joints is the hallmark of RA, causing pain, 
stiffness, loss of function and progressive destruction of the cartilage and bone in the 
inflamed joints in the majority of patients. Early diagnosis and appropriate treatment is 
crucial for the amelioration of symptoms, improvement of function and prevention of 
structural damage.  
Traditionally, treatment of RA has been based on the use of a group of disease-modifying 
antirheumatic drugs (DMARDs), of which methotrexate (MTX) is the most widely used, 
often in combination with corticosteroids and/or NSAIDs (non-steroid anti-inflammatory 
drugs). Leflunomide, sulphasalazine, azathioprine, are examples of other synthetic 
DMARDs. The landscape of RA treatment has changed dramatically during the last decade 
due to the introduction of biologic DMARDs, small molecules that target small molecules 
(like cytokines) and cells of the immune system, important mediators of the immunological 
mechanisms in RA. To date, nine biologic agents have been approved for the treatment of 
RA and more molecules with distinct mechanisms of action are currently being tested in 
laboratories and in clinical trials. The good efficacy and general safety of these agents is well 
established from both clinical and epidemiological trials, but there are still several issues 
that remain unclear or need further study, such as long-term safety, more individualized 
treatment by finding predictors of response, cost-effectiveness, when to introduce biologic 
treatment and the feasibility of discontinuation after achieving low disease activity or 
remission.  
 The Author( ). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Autoimmune Diseases –  





Etanercept Golimumab Infliximab 


























40 mg 200 mg 50 mg 50 mg 3 mg/kg 
Approved 
interval 




Subcutaneous Subcutaneous Subcutaneous Subcutaneous Intravenous 
Biologic 
(generic name) 
Abatacept Anakinra Rituximab Tocilizumab  
































500–1000 mg 100 mg 1000 mg x 2 










Intravenous Subcutaneous Intravenous Intravenous 
Table 1. Biologic agents approved for the treatment of rheumatoid arthritis (RA).  
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2. Biologic agents 
TNF (tumor necrosis factor) is a key cytokine of the immune response. Analysis of cytokine 
mRNA and protein in rheumatoid arthritis tissue revealed that many proinflammatory 
cytokines such as TNF alpha, IL-1 and IL-6 are abundant in all patients regardless of 
therapy1. These cytokines are of major importance in rheumatoid arthritis and are 
therapeutic targets. Five TNF inhibitors have been approved for the treatment of RA: the 
monoclonal antibodies infliximab (chimeric), adalimumab and golimumab (fully human), 
the TNF receptor etanercept, and the PEGylated Fab fragment of a fully human anti-TNF 
monoclonal antibody certolizumab pegol. There are several differences in 
pharmacodynamics and pharmacokinetics between these agents (table 1). Apart from the 
TNF inhibitors, biologics with different mechanism of action have been increasingly used in 
the clinical practice. Rituximab targets CD20 on the surface of B-cells and have been widely 
used in hematology for lymphoma treatment; Tocilizumab is an IL-6 (interleukin 6) inhibitor 
while anakinra blocks IL-1. Finally, abatacept inhibits costimulation of T-cell by binding B7 
(table 1). 
3. Efficacy of biological DMARDs 
Numerous randomized clinical trials provide clear evidence on the efficacy of biologic 
agents in RA, both in early disease (short disease duration) in biologic-naïve population and 
in late RA (longer disease duration) after failure of traditional DMARDs. These trials show 
the superiority of combination treatment of a biologic agent with methotrexate versus 
methotrexate monotherapy in both early and late disease2-18. In figure 1 and 2 the ACR 20, 50 
and 70 responses* of TNF inhibitors and other biologics from the largest clinical trials in 
methotrexate naïve patients and after inadequate response to methotrexate, are shown. The 
data demonstrate also clearly, especially in the MTX-naïve population, that a considerable 
proportion of patients respond to the simpler and less expensive monotherapy with 
methotrexate (MTX). Thus, one should keep in mind that in the combination groups, there 
are patients who would have responded to MTX monotherapy as well. 
In figure 2, the clinical responses of other biologic agents plus MTX versus placebo plus 
MTX are summarized. Again efficacy in early and in late disease is evident. Superiority of 
rituximab over placebo was observed in the IMAGE and SERENE trials9,10. Abatacept 
demonstrated acceptable safety and clinically meaningful efficacy in methotrexate naïve 
patients and methotrexate non responders7,11. Additionally, in the TOWARD trial17, 
tocilizumab-treated patients achieved significantly better results than those who received 
placebo during the first 6 months of therapy, after inadequate response to traditional 
                                                                                    
* ACR responses is a validate tool for the evaluation of efficacy of treatment in RA. ACR 20/50/70 response is defined as 
at least 20, 50 or 70%, respectively, improvement in both swollen joint count (SJC) and tender joint count (TJC), and at 
least 20, 50 and 70% improvement in 3 of the 5 following measures: pain VAS (visual analogue scale), Patient global 
assessment, Physician global assessment, ESR (erythrocyte sedimentation rate) or CRP (C-reactive protein) and 
functional questionnaire.  
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DMARDs. A large trial on the efficacy of tocilizumab in early RA is currently conducted. All 
these biologic agents seem to have comparable efficacy and significantly greater efficacy 
than placebo.  
 
Figure 1. A and B. Efficacy of TNF inhibitors (infliximab INF, etanercept ETA, adalimumab ADA, 
golimumab GLM, certolizumab pegol (CER) in combination with methotrexate (MTX) versus MTX 
monotherapy in MTX-naïve RA patients (1A) and RA patients with an inadequate response to MTX 
(1B). Efficacy is assessed by ACR 20, 50 and 70 responses.  
4. Safety of biological DMARDs 
Extension phase of clinical trials as well as data from registry studies provide us with 
important information about the safety of biologic DMARDs. The safety profile is generally 
acceptable, with a small increase risk for infections being the most common adverse event2-
22. Reactivation of latent tuberculosis is a well known risk during treatment with TNF 
inhibitors, therefore screening for tuberculosis is recommended before initiation of a TNF 
inhibitor. Infusion reaction is a common adverse event for rituximab and infliximab. Anti-
TNF induced SLE and demyelinating disease are rare complications of TNF inhibitors. 
Regarding risk for malignancies, data so far have not shown any clear increase in risk for 
malignancies. A meta-analysis of clinical registries and prospective observational studies 
showed no increase in malignancies other than skin cancers, including lymphoma, 
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associated with the use of TNF inhibitors23. However, longer follow up especially from large 
cohorts of patients, is needed.  
 
Figure 2. A and B. Efficacy of rituximab (RTX), abatacept (ABA) and tocilizumab (TOC) in combination 
with methotrexate (MTX) versus MTX monotherapy in MTX-naïve RA patients (2A) and RA patients 
with an inadequate response to MTX (2B). Efficacy is assessed by ACR 20, 50 and 70 responses.  
5. When to start biologic agents 
The effectiveness of biologic agents is well established in the above large, randomized clinical 
trials. These results do not, however, answer the question of when a biologic DMARD should 
be initiated. Traditional DMARDs, and most often methotrexate, unless contraindicated) is the 
first line treatment. However, about two third of patients who start treatment with 
methotrexate will discontinue treatment for reasons of either inefficacy or intolerance. The next 
step is either a combination of synthetic DMARDs (e.g. sulphasalazine and  
hydroxychloroquine) or introduction of a biologic agent. So far, only a few clinical trials have 
made a direct comparison of these two treatment options. In the SWEFOT trial, patients with 
early RA with an inadequate response to MTX after 3 months, defined as lack of achievement 
of low disease activity, were randomly allocated to addition of either sulphasalazine and 
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DMARDs. A large trial on the efficacy of tocilizumab in early RA is currently conducted. All 
these biologic agents seem to have comparable efficacy and significantly greater efficacy 
than placebo.  
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golimumab GLM, certolizumab pegol (CER) in combination with methotrexate (MTX) versus MTX 
monotherapy in MTX-naïve RA patients (1A) and RA patients with an inadequate response to MTX 
(1B). Efficacy is assessed by ACR 20, 50 and 70 responses.  
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hydroxychloroquine or infliximab. The latter group had significantly greater responses after 12 
months of therapy, with 39% of patients achieving the primary endpoint (European League 
Against Rheumatism (EULAR) good response†, which is a widely used validated outcome) 
compared to 25% in the former group (p=0.016)24. However, at the 2-year follow-up 
assessment, the clinical difference was no longer present (EULAR Good response was 38% in 
infliximab group vs. 31% in the conventional DMARDs group (p=0.2), but radiological disease 
progression was significantly greater in the latter group than the former25.  
Similar results were established in the BeSt trial26,27. In the BeSt trial three treatment groups 
were formed: sequential DMARD monotherapy (group 1), step-up combination therapy 
(group 2), initial combination therapy with tapered high-dose prednisolone (group 3) and 
infliximab (group 4). It was shown that a more aggressive treatment strategy as in group 3 
and 4 provided earlier clinical improvement than a less aggressive strategy as in groups 1 
and 2. Low disease activity (defined by DAS44 ≤ 2.4) was reached by 53%, 64%, 71% and 74% 
of patients in group 1, 2, 3 and 4, respectively (p=0.0004 for group 1 vs. 3, p=0.001 for group 
1 vs. 4). After 2 years, patients in all four treatment groups had approximately the same 
improvement in disease activity and functional status irrespective of initial treatment, 
probably because of tight control and frequent treatment adjustments. However, the more 
aggressively treated patients had less radiological progression of joint damage, and during 
the second year more of them could be treated successfully with monotherapy, suggesting 
that the initial aggressive therapy did result in some long-term gains.  
6. When to stop biologic agents 
A significant number of patients who receive biological treatment achieve low disease activity 
or remission. It is often difficult to define these terms, and there are today several definitions of 
both low disease activity and remission. According to the 2011 ACR (American College of 
Rheumatology) / EULAR (EUropean League Against Rheumatism) criteria, remission of 
rheumatoid arthritis is defined as tender joint count ≤ 1 AND swollen joint count ≤ 1 AND C-
reactive protein ≤ 1 mg/dl AND patient global assessment ≤ 1 (on a 0-10 scale) (boolean-based 
definition) or a Simplified Disease Activity Index score of ≤ 3.3 (Index-based definition)28. 
Other definitions of low disease activity and remission are also frequently used, as for example 
DAS28 score ≤ 3.2 (low disease activity) and DAS28 ≤ 2.6 (remission).  
When a patient is in state of low disease activity or remission for a sufficiently long period 
of time (usually at least 6 months) the next step is to assess the feasibility of discontinuation 
of the biologic agent with the aim of maintaining the good clinical response. This is a 
                                                                                    
† Definition of EULAR responses:  
 Improvement in DAS28 from baseline
DAS28 at endpoint ≥1.2 >0.6 and <1.2 ≤0.6 
≤3.2 GOOD MODERATE NO 
>3,2  and ≤5.1 MODERATE MODERATE NO 
>5.1 MODERATE NO NO 
DAS28=Disease Activity Score (based on 28 joint status) 
DAS28= 0.56*  + 0.28* + 0.70*ln (ESR) + 0.014* (General Health) 
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question of importance for reasons of safety and health economics. In various settings, the 
possibility has been investigated of discontinuing the biologic agent while maintaining the 
patient in remission on a conventional DMARD.  
In the ATTRACT study 17 patients in a single centre in the UK received infliximab and all 17 
experienced flare-ups after discontinuation of the biologic therapy after 2 years, with a mean 
time of 13.5–15.0 weeks after the end of therapy29. Of importance, re-introduction of infliximab 
after disease flare was associated with comparable responses without any safety issues. In 
another study Quinn et al. addressed the same question in a randomized, double-blind, 
placebo-controlled trial in a population of patients with early RA, with symptom duration of 
<12 months2. Induction of remission with infliximab plus MTX in early, poor prognosis RA 
provided not only significant reduction in synovitis and erosions at 1 year (shown by magnetic 
resonance imaging), but also sustained functional and quality-of-life benefits for 70% of the 
patients at 2 years despite infliximab withdrawal. These two studies tested the same question 
in different populations of RA patients; the former one in patients with longstanding disease 
(mean disease duration, 11 years), and the latter in patients with early RA. More recently, 
Tanaka et al. determined the possibility of discontinuing infliximab after attaining DAS-
guided low disease activity in patients with RA in the remission induction by Remicade in RA 
(RRR) study30. Of 102 patients, 56 (55%) maintained DAS28<3.2 and 44 (43%) reached 
remission (DAS28<2.6) 1 year after the discontinuation of infliximab. The mean disease 
duration in this study was 5.9 years which suggests that discontinuation of infliximab would 
be possible not only in patients with early RA but also in patients with more established 
disease. In a post hoc analysis from the BeSt study, it was shown that significantly more 
patients who received initial combination therapy with infliximab and MTX achieved 
sustained DAS44≤2.4 and were able to discontinue infliximab, compared with those with 
delayed introduction of the biologic agent (56% vs. 29%, p=0.008)31,32. It was also shown in the 
BeSt study that the shorter the symptom duration, the higher the likelihood of a biologic-free, 
and even a drug-free, remission. A systematic review and meta-analysis showed that patients 
with established RA who stopped treatment with traditional DMARDs had a significantly 
higher risk of disease flare or deterioration than those who continued treatment33. In this 
analysis, however, patients had RA of more than 2 years duration. Larger randomized, 
controlled, double-blind trials are needed in order to better approach this important issue.  
Several conclusions can be drawn from the information that exists today about 
discontinuation of biologic DMARDs:  
- Discontinuation of biologic treatment and sustained remission or low disease activity is 
the long-term therapeutic goal, important for matters of long-term safety and health 
economics.  
- Biologic-free remission may be possible after achieving remission or low disease 
activity in a considerable proportion of patients.  
- The duration of disease until the introduction of the biologic treatment may be 
negatively associated with the risk of deterioration after discontinuation of treatment, 
thus suggesting that earlier initiation of biologic treatment leads not only to better 
results, but also increases the possibility of withdrawal of biologic agents with 
maintenance of remission.  
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question of importance for reasons of safety and health economics. In various settings, the 
possibility has been investigated of discontinuing the biologic agent while maintaining the 
patient in remission on a conventional DMARD.  
In the ATTRACT study 17 patients in a single centre in the UK received infliximab and all 17 
experienced flare-ups after discontinuation of the biologic therapy after 2 years, with a mean 
time of 13.5–15.0 weeks after the end of therapy29. Of importance, re-introduction of infliximab 
after disease flare was associated with comparable responses without any safety issues. In 
another study Quinn et al. addressed the same question in a randomized, double-blind, 
placebo-controlled trial in a population of patients with early RA, with symptom duration of 
<12 months2. Induction of remission with infliximab plus MTX in early, poor prognosis RA 
provided not only significant reduction in synovitis and erosions at 1 year (shown by magnetic 
resonance imaging), but also sustained functional and quality-of-life benefits for 70% of the 
patients at 2 years despite infliximab withdrawal. These two studies tested the same question 
in different populations of RA patients; the former one in patients with longstanding disease 
(mean disease duration, 11 years), and the latter in patients with early RA. More recently, 
Tanaka et al. determined the possibility of discontinuing infliximab after attaining DAS-
guided low disease activity in patients with RA in the remission induction by Remicade in RA 
(RRR) study30. Of 102 patients, 56 (55%) maintained DAS28<3.2 and 44 (43%) reached 
remission (DAS28<2.6) 1 year after the discontinuation of infliximab. The mean disease 
duration in this study was 5.9 years which suggests that discontinuation of infliximab would 
be possible not only in patients with early RA but also in patients with more established 
disease. In a post hoc analysis from the BeSt study, it was shown that significantly more 
patients who received initial combination therapy with infliximab and MTX achieved 
sustained DAS44≤2.4 and were able to discontinue infliximab, compared with those with 
delayed introduction of the biologic agent (56% vs. 29%, p=0.008)31,32. It was also shown in the 
BeSt study that the shorter the symptom duration, the higher the likelihood of a biologic-free, 
and even a drug-free, remission. A systematic review and meta-analysis showed that patients 
with established RA who stopped treatment with traditional DMARDs had a significantly 
higher risk of disease flare or deterioration than those who continued treatment33. In this 
analysis, however, patients had RA of more than 2 years duration. Larger randomized, 
controlled, double-blind trials are needed in order to better approach this important issue.  
Several conclusions can be drawn from the information that exists today about 
discontinuation of biologic DMARDs:  
- Discontinuation of biologic treatment and sustained remission or low disease activity is 
the long-term therapeutic goal, important for matters of long-term safety and health 
economics.  
- Biologic-free remission may be possible after achieving remission or low disease 
activity in a considerable proportion of patients.  
- The duration of disease until the introduction of the biologic treatment may be 
negatively associated with the risk of deterioration after discontinuation of treatment, 
thus suggesting that earlier initiation of biologic treatment leads not only to better 
results, but also increases the possibility of withdrawal of biologic agents with 
maintenance of remission.  
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- More data about the feasibility of dose reduction or discontinuation of biological 
DMARDs are needed.  
7. Principles for use of biologic treatment in rheumatoid arthritis 
The rapid progress and advances in the field of biologic treatment in RA, combined with the 
high cost of these drugs and the potential long-term safety issues, makes it necessary to 
define clear rules that will guide the use of these agents in clinical practice.  
The rheumatologist should always keep in mind that the goal of RA treatment today is 
remission or low disease activity, if remission cannot be achieved. Treatment efficacy should 
be assessed in tight time intervals and changes in treatment should be considered if the goal 
has not been reached34.  
As soon as the diagnosis of RA is established a synthetic DMARD (most often Methotrexate) is 
started with or without concomitant corticosteroids. If the goal of treatment is not achieved 
after 3 months, an additional DMARD can be added or a biologic agent can be introduced. As 
it was analyzed above, data have shown superiority of the latter choice. Especially for patients 
with multiple negative prognostic factors, such as seropositivity, radiographic progression and 
high disease activity, early aggressive treatment is strongly indicated. In the absence of these 
unfavorable factors one could consider testing switching of synthetic DMARD or combination 
of synthetic DMARD +/- corticosteroids before biologics. In patients with active RA who have 
not yet been treated with DMARDs there is strong evidence that biologics provide better 
results at the group level, but not widely used in practice based on various considerations 
(safety, high cost, possibility of very good effect of methotrexate).  
The first biologic agent is most often a TNF inhibitor, unless contraindicated. If possible, 
TNF inhibitors should be combined with MTX; the clinical efficacy particularly the 
radiological efficacy of the combination is clearly superior to TNF inhibitor monotherapy. In 
case of a contraindication to TNF inhibitor therapy, a biologic agent with a different 
mechanism of action (rituximab, abatacept or tocilizumab) can be chosen.  
About one third of patients will discontinue the first TNF inhibitor for reasons of either 
intolerance or inefficacy (lack of efficacy or loss of efficacy). Since the goal is still remission, 
even patients with moderate responses (‘partial responders’) should eventually be 
candidates for an alternative treatment.  
After the failure of one biologic agent for the reasons described above, and after having 
perhaps tried to modify the dose of the concomitant DMARDs and/or corticosteroids with 
no effect, three main treatment options are available: a) optimize the dose of biologic drug; 
b) switch between TNF inhibitors; or c) switch to a biologic agent with a different 
mechanism of action. 
7.1. Optimize dose of biologic 
As it is shown in table 1, the TNF inhibitors have different dose intervals, ranging from once 
weekly (etanercept) to once every 8 weeks (infliximab). Concerning optimization of the 
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infliximab dose, controversial data are available. In the ATTRACT trial, four different 
treatment regimens of infliximab were studied:  infliximab 3 mg kg−1 every 4 and 8 weeks 
and 10 mg kg−1 every 4 and 8 weeks. At 24 weeks similar American College of 
Rheumatology (ACR) responses were observed. At 48 weeks, however, there was a 
tendency for the lowest dosage of infliximab to be less effective than the higher ones, but 
this difference was only significant with respect to the ACR50 responses29.  
An important question is whether dose increase or change of treatment interval can yield 
better results in patients with secondary loss of efficacy to infliximab. Results from 
uncontrolled observational studies have suggested that this might be true35. On the other 
hand, in a double-blind randomized trial, Pavelka et al. showed no significant difference in 
efficacy of two dosages of infliximab (3 and 5 mg/kg) after initial failure of the lower dosage 
to lead to remission36. Moreover, the higher dosage had a poorer safety profile. In an 
observational study conducted in our centre, patients in whom the dose of infliximab was 
increased in clinical practice appeared to have a benefit, as defined by reduction in the 
disease activity score (DAS28)37. However, patients in the control groups (i.e. patients with 
no change in infliximab dose and those receiving a stable dose of etanercept) also showed an 
improvement in DAS28. This observation suggests that the improvements were most 
probably attributable to regression to the mean and that no important benefit is gained from 
dose increases of infliximab. Finally, van den Bemt et al. found that 17 of 18 patients who 
were in clinical practice treated with infliximab at dosages higher than 3 mg/kg showed no 
deterioration of their RA if the dosage was reduced to 3 mg/kg38. In conclusion, the evidence 
suggests that increasing the dose of infliximab might result in loss of time, higher cost and 
potentially more side effects with no significant efficacy gain in most patients. Therefore, it 
would clearly be useful to be able to identify, using relevant biomarkers, a smaller subset of 
patients who might truly benefit from dose increases. Studies to investigate this possibility 
are currently underway. 
7.2. Switching to an alternative TNF inhibitor 
As it is shown in table 1, there are substantial differences between the five TNF inhibitors 
available today (in molecular structure, immunological actions and in pharmacokinetics). This 
is the reason why switching from one TNF inhibitor to another does make sense and is often 
used in the clinical practice, although these agents target the same cytokine. Observational 
studies support this argument, as a significant proportion of patients benefit from this 
switching. In the randomized double-blinded GO-AFTER study, patients who received 
golimumab after failure of a prior TNF inhibitor, showed significantly greater responses than 
those who received placebo39. However, cohort study data have shown a gradual loss of 
efficacy after a greater number of switches40-44. Thus, a first switch might provide significant 
improvement, whereas the effect is much less profound at the second or third switch. 
7.3. Switch to a biologic with different mechanism of action 
It might sound more reasonable, after the failure of TNF inhibition the next step to be 
change of mechanism, rather than switching between agents of the same drug class. There is 
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- More data about the feasibility of dose reduction or discontinuation of biological 
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infliximab dose, controversial data are available. In the ATTRACT trial, four different 
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efficacy of two dosages of infliximab (3 and 5 mg/kg) after initial failure of the lower dosage 
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disease activity score (DAS28)37. However, patients in the control groups (i.e. patients with 
no change in infliximab dose and those receiving a stable dose of etanercept) also showed an 
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suggests that increasing the dose of infliximab might result in loss of time, higher cost and 
potentially more side effects with no significant efficacy gain in most patients. Therefore, it 
would clearly be useful to be able to identify, using relevant biomarkers, a smaller subset of 
patients who might truly benefit from dose increases. Studies to investigate this possibility 
are currently underway. 
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As it is shown in table 1, there are substantial differences between the five TNF inhibitors 
available today (in molecular structure, immunological actions and in pharmacokinetics). This 
is the reason why switching from one TNF inhibitor to another does make sense and is often 
used in the clinical practice, although these agents target the same cytokine. Observational 
studies support this argument, as a significant proportion of patients benefit from this 
switching. In the randomized double-blinded GO-AFTER study, patients who received 
golimumab after failure of a prior TNF inhibitor, showed significantly greater responses than 
those who received placebo39. However, cohort study data have shown a gradual loss of 
efficacy after a greater number of switches40-44. Thus, a first switch might provide significant 
improvement, whereas the effect is much less profound at the second or third switch. 
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It might sound more reasonable, after the failure of TNF inhibition the next step to be 
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strong evidence about the efficacy of rituximab, abatacept and tocilizumab after TNF 
treatment (figure 2). However, there is no randomized clinical trial comparing head to head 
these two treatment options, but there are some observational studies from national 
registries. In the Swiss Clinical Quality Management program for RA (SCQM-RA) registry, 
patients with inadequate response to TNF inhibitor treatment achieved greater reductions in 
DAS28 when switching to rituximab than to an alternative TNF blocker45. This was 
especially obvious when the reason for discontinuation of the previous TNF inhibitor was 
secondary inefficacy46. A small observational study by Venkatachalam et al. provided similar 
results, whilst a study reported by Buch et al. also demonstrated comparable results of 
rituximab and alternative TNF inhibitors47,48. Our data have shown slightly better overall 
results for patients who had failed TNF inhibitor therapy when treated with rituximab than 
with another TNF blocker, but both options provided clinical benefits49.  
In figure 3 an algorithm of biologic treatment in RA is presented50.  
 
Failure*: primary or secondary loss of efficacy, intolerance or a partial, inadequate response.  
(After optimizing DMARD dose and/or trying combination of DMARDs). 
Figure 3. Algorithm of biologic treatment in RA.  
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8. Conclusions 
The field of RA treatment has changed dramatically after the introduction of biologic 
DMARDs. Despite the advances though, several issues remain to be further studied and 
clarified. On the one hand treatment algorithms are needed of the choice and time of 
introduction of biologics. On the other hand a more individualized treatment might be 
possible in the future. Such an approach is crucial, taking into consideration the increasing 
number of biologic agents, their high cost and the importance of choosing the right 
treatment from the beginning. These are some of the important challenges of clinical, 
epidemiological and basic rheumatologic research.  
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strong evidence about the efficacy of rituximab, abatacept and tocilizumab after TNF 
treatment (figure 2). However, there is no randomized clinical trial comparing head to head 
these two treatment options, but there are some observational studies from national 
registries. In the Swiss Clinical Quality Management program for RA (SCQM-RA) registry, 
patients with inadequate response to TNF inhibitor treatment achieved greater reductions in 
DAS28 when switching to rituximab than to an alternative TNF blocker45. This was 
especially obvious when the reason for discontinuation of the previous TNF inhibitor was 
secondary inefficacy46. A small observational study by Venkatachalam et al. provided similar 
results, whilst a study reported by Buch et al. also demonstrated comparable results of 
rituximab and alternative TNF inhibitors47,48. Our data have shown slightly better overall 
results for patients who had failed TNF inhibitor therapy when treated with rituximab than 
with another TNF blocker, but both options provided clinical benefits49.  
In figure 3 an algorithm of biologic treatment in RA is presented50.  
 
Failure*: primary or secondary loss of efficacy, intolerance or a partial, inadequate response.  
(After optimizing DMARD dose and/or trying combination of DMARDs). 
Figure 3. Algorithm of biologic treatment in RA.  
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1. Introduction 
In 10-20% of children with JIA, a wide range of extra-articular manifestations such as 
spiking febrile fever, carditis, pneumonitis and serositis were noted [1]. Despite the 
advances in modern medicine, treatment of the systemic JIA variant with glucocorticoids 
and immunosuppressants has not always proved effective [1,2,3]. In 50% of patients, 
progressively destructive changes in the joints, with recurring extra-articular manifestations, 
have been steadily increasing the disability level. Most children with systemic JIA take oral, 
intravenous or intra-articular corticosteroids. However, glucocorticoids do not control the 
disease, prevent the progression of cartilage bone destruction or reduce disability in 
patients, and their prolonged use leads to severe irreversible effects, particularly, short 
stature, delayed puberty, adrenal insufficiency, osteoporosis and corticosteroid dependence 
[1,2, 3].  
Interleukin 6 (IL-6), one of the central cytokines, has been discovered to play a leading role 
in development of systemic JIA. When excess IL-6 is produced, extra-articular 
manifestations such as fever and thrombocytosis are noted [4,5]. IL-6 stimulates the 
production of inflammatory proteins by hepatocytes (CRP, amyloid A, haptoglobin, 
 The Author(s). L I ec . This chapter is distributed under the terms of th  Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction 
In 10-20% of children with JIA, a wide range of extra-articular manifestations such as 
spiking febrile fever, carditis, pneumonitis and serositis were noted [1]. Despite the 
advances in modern medicine, treatment of the systemic JIA variant with glucocorticoids 
and immunosuppressants has not always proved effective [1,2,3]. In 50% of patients, 
progressively destructive changes in the joints, with recurring extra-articular manifestations, 
have been steadily increasing the disability level. Most children with systemic JIA take oral, 
intravenous or intra-articular corticosteroids. However, glucocorticoids do not control the 
disease, prevent the progression of cartilage bone destruction or reduce disability in 
patients, and their prolonged use leads to severe irreversible effects, particularly, short 
stature, delayed puberty, adrenal insufficiency, osteoporosis and corticosteroid dependence 
[1,2, 3].  
Interleukin 6 (IL-6), one of the central cytokines, has been discovered to play a leading role 
in development of systemic JIA. When excess IL-6 is produced, extra-articular 
manifestations such as fever and thrombocytosis are noted [4,5]. IL-6 stimulates the 
production of inflammatory proteins by hepatocytes (CRP, amyloid A, haptoglobin, 
 The Author(s). L I ec . This chapter is distributed under the terms of th  Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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fibrinogen), and competitively inhibits synthesis of albumin and transferrin [6]. Anemia is 
one of extra-articular manifestations of systemic JIA. It develops during IL-6 stimulated 
secretion of hepcidin by the hepatocytes [7-10]. In normal concentrations, IL-6 enhances the 
synthesis of the adrenocorticotropic hormone and cortisol, as well as the production of the 
growth hormone and procalcitonin [10,11]. However, at higher concentrations, IL-6 blocks 
the production of these hormones, which leads to fatigue, sleepiness, depression, cognitive 
disorders and retarded growth in children with systemic JIA [10,11,12], as the activity of IL-6 
is also connected with the development of amyloidosis associated JIA. Thus, inhibition of IL-
6 is very important in treatment of systemic JIA. Tocilizumab was synthesized for this 
purpose. Tocilizumab is a humanized monoclonal antibody to IL-6 receptor [13]. Based on 
the positive results of clinical studies on the efficacy and safety of Tocilizumab therapy, the 
drug has been registered for treatment of systemic JIA [16-23]. 
The purpose of this study is to evaluate the efficacy and safety of Tocilizumab treatment in 
children with the severe refractory systemic JIA.  
2. Patients and methods  
In a retrospective observational study, patients with the systemic JIA, treated with 
Tocilizumab between June 2009 and October 2011 in the Rheumatology Department, Science 
Center for Children’s Health of RAMS were followed. The use of Tocilizumab in all the 
cases was approved by the local ethics committee. Prior to treatment, written consent was 
taken from the parents of the children, children aged 14 and older gave written informed 
consent themselves.  
The results of treatment of 60 children (30 girls and 30 boys) aged 6.5 (4.5; 9) years (Me (25, 
75)) were given in this analysis. The mean disease duration before beginning Tocilizumab 
therapy was 4.5 (2.2; 6.5) years. Diagnosis of systemic JIA was made based on diagnostic 
ILAR criteria (International League of Associations for Rheumatology). All patients 
underwent standard clinical and laboratory examination. Control of hemoglobin level, the 
number of erythrocytes, platelets, leukocytes, ESR, serum concentration of urea, creatinine, 
uric acid, bilirubin, transaminases, and clinical urinalysis was performed once every two 
weeks. Blood pressure (BP) was checked on a daily basis.  
Number of systemic manifestations, swollen, painful joints, joints with limitation of 
function, serum CRP level were determined on a monthly basis. Therapy efficacy was 
evaluated according to the ACR pedi criteria ACR30, ACR50, ACR70. The criteria included a 
parent’s assessment of pain, parent’s global evaluation, physician’s global assessment of 
disease status using VAS, the functional ability by CHAQ, number of joints with active 
arthritis, number of joints with limitation of function and ESR.  
The main target of therapy was status of inactive disease and remission. Inactive phase 
of disease was established in the absence of active synovitis, systemic manifestations, 
normal ESR and serum CRP level, as well as absence of disease activity on the 
physician’s global assessment (on VAS). At the time of therapy initiation most children 
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had active polyarthritis (Table 1). All patients revealed extra-articular manifestations of 
disease: spiking fever in 90% (54), carditis in 3% (2), lymphadenopathy in 86% (36), 
maculopapular rash in 35% (21), spleno- and hepatomegaly in 45% (27) of the patients. 
The number of systemic manifestations per patient was 2.5 (Table 1, Fig. 1). High clinical 
disease activity was accompanied by a general inflammatory reaction: hypochromic 
anemia in 90% (54), leukocytosis in 75% (45) and thrombocytosis in 80% (48) of patients. 
The median ESR was more than twice the normal value and serum CRP level increased 
up to 10 times (Table 1).  
 
Index Value (Me (25; 75)
number of active joints 8 (4;14) 
number of joints with limitation of function 9(3;14) 
number of systemic manifestations per 
patient 2.5 (1.5; 3.5) 
ESR, mm/h 28 (18; 55) 
platelets, х109/ 490 (480; 640) 
hemoglobin, g/L 92 (86; 98) 
CRP, mg% 14 (7; 26) 
Table 1. Clinical characteristic of patients with the systemic JIA included in the study. 
Thus, at the beginning of therapy all patients with systemic JIA had active arthritis, severe 
systemic manifestations and high laboratory parameters of the disease activity with 
increasing disability.  
Previous therapy: Prior to the Tocilizumab treatment all patients were treated with 
antirheumatic drugs, in various modes. In the initial stages of the disease (based on the 
place of residence in the territorial health care facility) 60% (36) children were prescribed 
oral prednisolone at a dose of 10 to 30 mg / day. All children received methylprednisolone 
pulse therapy at a dose of 10-30 mg / kg initially, 47 (78%) - local glucocorticoid therapy 
from 1 to 10 times a year, 10 (17%) were treated with TNF-blockers and 22 (37%) with anti-B 
cell therapy with rituximab. All children were treated with antiinflammatory drugs 
(NSAIDs).  
Background therapy: Tocilizumab was administered in patients receiving immunosuppressive 
drugs (Table 2). Doses of antirheumatic drugs were stable within 3 months before 
Tocilizumab therapy. 
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Drug Dose(Me (25; 75)) Number of children 
methotrexate, mg/m2/week 18 (15; 25) 60 
cyclosporine, mg/kg/day 4 (4; 4) 46 
prednisolone, mg/day  10.5 (7; 12)  36 
NSAIDs - 60 
Table 2. Background therapy in patients with the systemic JIA included in the study. 
Tocilizumab treatment: Tocilizumab was administered intravenously, once every two or four 
weeks at a dose of 8-10 mg / kg per infusion. All the children within one or two months of 
receiving the drug every two weeks had the interval increased to four weeks between doses. 
Infusions were performed for one hour, at the rate of 10 ml / h for the first 15 minutes, and 
then increased to 130 ml / hour.  
Analysis of the efficacy was done after one month. The results indicated improvement in 52 
children by 1 month, in 50 children by 3 months, in 40 children by 6 months, in 32 children 
by 9 months and in 24 children by the end of a year.  
Statistical data processing was performed using the program STATISTICA 6.0 (StatSoft Inc., 
USA). Quantitative characters are shown as median (25, 75 percentiles). Changes in the 
quantitative traits during the treatment were evaluated using the Wilcoxon test conjugate 
pairs. Statistically significant differences were considered at p <0.05.  
2.1. Results  
Tocilizumab treatment ensured reliability and marked improvement of the systemic 
manifestations, as well as clinical and laboratory parameters of disease activity.  
Within one month after initiation of therapy, patients showed a significant decrease in 
number of systemic manifestations (Fig. 1). Carditis one of the serious extra-articular 
manifestations of systemic JIA, disappeared in all the patients. Frequency of skin rash also 
significantly reduced, from 21 (35%) to 13 (25%) of the cases. After the first infusion of 
Tocilizumab, no spikers of fever were observed in all patients (Fig. 1).  
After observation of 24 patients over a year, lymphadenopathy persisted in 3 patients, rash 
in 2 cases and hepato / splenomegaly in 1 patient. At the end of one year of observation, the 
number of systemic manifestations per patient was 0.25 (Figs. 1).  
In the fourth week of treatment the number of active joints significantly decreased from 8 (4, 
14) to 4 (1, 14), p <0.01. By the 12th month the rate was 0 ((0, 3), p <0.001) (Fig. 2).  
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Figure 1. Dynamics of Systemic Features in children with systemic JIA treated with Tocilizumab. 
Hereinafter: * p<0.001 – statistically significant difference compared to baseline 
 
Figure 2. Dynamics in number of active joints in children with systemic JIA treated with Tocilizumab. 
Hereinafter: * p<0.001, ** p<0.01 – statistically significant difference compared to baseline 
The same trend was observed in the joints with limitation of function. That parameter too 
significantly dropped after four weeks of treatment (Fig. 3). By the end of one year’s observation 
the median number of joints with limitation of function decreased 9 times (p <0.001).  
Along with the decrease in the number of joints with active arthritis, as well as joints with 
limitation of function, a significant improvement in functional ability of the affected joints was 
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noted (Fig. 4). After four weeks of Tocilizumab treatment the index of functional disability by 
CHAQ questionnaire decreased significantly from 2.0 (1.35, 2.7) to 1,3 (0.9; 1.3), p <0.001).  
 
Figure 3. Dynamics in number of joints with limitation of function in children with systemic  
JIA treated with Tocilizumab.  
Hereinafter: * p<0.001, ** p<0.01 – statistically significant difference compared to baseline 
 
Figure 4. Dynamics in index of functional disability in children with systemic  
JIA treated with Tocilizumab. 
Hereinafter: * p<0.001 – statistically significant difference compared to baseline 
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Tocilizumab therapy also influenced the laboratory parameters of the disease activity, showing 
significant increase in hemoglobin level (Fig. 5), decrease platelet counts, ESR, serum CRP level 
and normalization of these parameters by the first month of treatment (Fig. 6, 7, 8).  
 
Figure 5. Dynamics in hemoglobin level in children with systemic JIA treated with Tocilizumab. 
Hereinafter: * p<0.001 – statistically significant difference compared to baseline 
 
Figure 6. Dynamics in the platelets count in children with systemic JIA treated with Tocilizumab. 
Hereinafter: * p<0.001 – statistically significant difference compared to baseline 
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Figure 7. Dynamics in the ESR in children with systemic JIA treated with Tocilizumab. 
Hereinafter: * p<0.001 – statistically significant difference compared to baseline 
 
Figure 8. Dynamics in the serum CRP level in children with systemic JIA treated with Tocilizumab. 
Hereinafter: * p<0.001 – statistically significant difference compared to baseline 
Assessment of efficacy of Tocilizumab therapy according ACRpedi criteria by one month of 
Tocilizumab therapy showed 30% improvement in 82% of the patients, 50% improvement in 
47% of cases and 70% improvement in 29% of patients. After six months of treatment, all the 
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children maintained improvement criteria ACR30 while 65% recorded a rate of ACR70. 
After a year of therapy, 50% and 70% improvement, respectively, was observed in 100% and 
75% of patients (Fig. 9). In general, the efficacy of Tocilizumab after more than six months of 
treatment was characterized by the achievement of inactive disease status in 43% (17 of 40) 
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Figure 9. Response according to ACR pedi criteria in children with systemic JIA treated with 
Tocilizumab. 
Safety assessment of Tocilizumab treatment was performed by registered adverse events 
(AE), laboratory parameters, based on the results of the physical examination (BP, HR), and 
EKG. AE were evaluated in all the patients enrolled in the study, who received at least one 
infusion. Tocilizumab treatment was well tolerated and most AE were mild or moderate, 
reversible, not limiting the course of the treatment. Infusion reactions were noted. 
Registered AE were differentiated into two groups, namely infectious disorders and 
laboratory parameters (Table 3). 
 
Adverse events Patients n (%) 
Laboratory parameters: 
Neutropenia 25 (41%) 
Thrombocytopenia 1 (2%) 
Increase in alkaline phosphatase 1 (2%) 
Infectious disorders:  
Cellulitis 3 (5%) 
Herpes infection 4 (8%) 
Acute focal pneumonia 2 (3%) 
Table 3. Adverse events in patients on Tocilizumab therapy 
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Among the infectious AE reported, cellulitis was seen in 3 patients, exacerbation of herpes 
infection in 4 cases and acute focal pneumonia in 2 patients. Antibiotic therapy provided 
complete relief of cellulitis and pneumonia without complications. Aggravation of herpetic 
infection (4 cases) was not considered serious AE. Among the AE with the laboratory 
parameters, neutropenia was most frequently observed in the first few days after 
administration of the Tocilizumab, in 41% (25) of the patients. In 15 patients, the absolute 
neutrophil count decreased <1.000 in 1 μL, whereas in 2 patients it was 500 per 1μL. On 
identifying neutropenia, daily monitoring was conducted until neutrophil recovery 
occurred within weeks after the infusion. By reducing the number of neutrophils <1.0 x109 
/L patients received the colony-stimulating factor (G-CSF) filgrastim, at a dose of 5 mg / kg, 
with a positive effect. All cases of neutropenia were associated with Tocilizumab infusion. 
None of them were accompanied by infection and it was not a cause of treatment 
discontinuation.  
Mild thrombocytopenia was observed in one patient after 11 months of therapy. Two 
weeks after the regular drug administration, the platelet count decreased to 156 x109 /L. 
Concomitant therapy included glucocorticoids, cyclosporine, methotrexate, and NSAIDs. 
Thrombocytopenia was not considered serious AE, and unlikely to be the result of 
Tocilizumab therapy. Platelet count returned to normal within a week, without reducing 
the dose or interrupting the treatment. One patient reported a one-time increase in 
alkaline phosphatase activity to 6200 IU / L after the first injection of Tocilizumab while 
concomitant therapy included methotrexate and methylprednisolone. This rate returned 
to normal after eight days without changing the Tocilizumab treatment regimen. The AE 
were considered to be of no significance, and unlikely to be the result of Tocilizumab 
therapy.  
While observing clinically significant changes in the vital functions namely, BP and HR, the 
EKG parameters were also observed. Treatment was discontinued in 9 patients (table 4). 
 
Index Patients n 
Remission of disease 1 
Inefficacy 1 
Relapse of disease 6 
Parents’ refusal  1 
Table 4. Causes of discontinuation of Tocilizumab treatment. 
Normally, the safety profile of Tocilizumab in children is quite similar to the safety profile 
described earlier in adults with rheumatoid arthritis. It was within the expected range for a 
population of patients receiving immunosuppressive drugs. AE were manifested as mild to 
moderately severe infections, as well as changes in the laboratory parameters. Deaths did 
not occur during the period of Tocilizumab treatment. No case of discontinuation of therapy 
was registered due to AE development.  
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3. Clinical case 
Patient's data: female. Age: 9 years old (born in 2002) 
Diagnosis: Systemic JIA 
3.1. Medical history 
The girl has been sick since 2007 when she was 5 years old. Febrile fever, lymphadenopathy, 
inflammatory changes in the knees and ankles, high laboratory parameters of activity (ESR – 
52 mm/h) were observed during the onset. The following diagnosis was set at the local in-
patient facility: systemic-onset juvenile arthritis. Treatment with antibiotics, NSAIDs, oral 
methylprednisolone at a dose of 16 mg/day (1 mg/kg of body weight) was conducted. Fever 
subsided and inflammatory changes in joints resolved with treatment. Gradual reduction of 
methylprednisolone dose was initiated. In 6 months the dose was 4 mg per day. However, 
disease exacerbated again after the insolation, which manifested in febrile fever, high 
laboratory parameters of disease activity (ESR – 45 mm/h), swelling and pain in the elbows, 
metacarpophalangeal, interphalangeal joints of hands, knees and ankles. 
Methylprednisolone pulse therapy at a dose of 500 mg per administration was conducted 3 
times at the local in-patient facility; methotrexate at a dose of 10 mg/m2 of standard body 
surface area per week and NSAIDs were prescribed. Condition improved, the dose of 
methyprednisolone was decreased to 2 mg per day. In 6 months condition worsened again: 
febrile fever, exudative changes in the wrists, knees and ankles appeared. Due to persisting 
disease activity in 1.5 years from the disease onset, the girl was referred to the rheumatology 
department of Scientific Center for Children Health, RAMS. On admission to the 
department the child’s condition was assessed as severe. The girl experienced daily febrile 
fevers; the joint syndrome was polyarticular, affecting wrists, knees, ankles; motions were 
limited and painful. The child was bothered by morning stiffness for up to 60 minutes. On 
admission to the department pale skin, “shadows” under the eyes, generalized 
lymphadenopathy also came under notice. Leukocytosis, thrombocytosis, ESR elevation, 
hypochromic anemia, increased serum CRP concentration (Table 5) were observed in 
hematology during examination. Periarticular osteoporosis and single erosions of articular 
surfaces were revealed according to X-ray examination of the knees. Diagnosis systemic JIA 
was undoubtful. 
Methotrexate dose was increased up to 25 mg/m2 of standard body surface area per week 
intramuscularly. 2 injections were conducted with positive effect: fever subsided, intensity 
of pain syndrome and exudative changes in joints reduced. The child was discharged with 
recommendations to continue methotrexate treatment at the place of residence. For 6 
months the girl’s condition remained stable. 
In 6 months of methotrexate treatment at a dose of 25 mg/m2 of standard body surface 
area per week, the girl started experiencing febrile fever again, duration of morning 
stiffness increased up to 120 minutes, exudative changes in the wrists, elbows and ankles 
increased (Figure 10a-d). The child fell behind in physical development, height and 
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Among the infectious AE reported, cellulitis was seen in 3 patients, exacerbation of herpes 
infection in 4 cases and acute focal pneumonia in 2 patients. Antibiotic therapy provided 
complete relief of cellulitis and pneumonia without complications. Aggravation of herpetic 
infection (4 cases) was not considered serious AE. Among the AE with the laboratory 
parameters, neutropenia was most frequently observed in the first few days after 
administration of the Tocilizumab, in 41% (25) of the patients. In 15 patients, the absolute 
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the dose or interrupting the treatment. One patient reported a one-time increase in 
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to normal after eight days without changing the Tocilizumab treatment regimen. The AE 
were considered to be of no significance, and unlikely to be the result of Tocilizumab 
therapy.  
While observing clinically significant changes in the vital functions namely, BP and HR, the 
EKG parameters were also observed. Treatment was discontinued in 9 patients (table 4). 
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weight scores were below the 10th percentile (Table 5). According to hematology and 
immunologic blood test, activity of rheumatoid process persisted (Table 5). Based on the 
signs of aggressive disease course (polyarthritis, high immunologic activity, 
ineffectiveness of methotrexate therapy at a high dose, hormonal dependency, falling 
behind in physical development), the patient was prescribed treatment with genetically 
engineered biologic agent – Tocilizumab. 
 
 
Figure 10.  
3.2. Treatment with Tocilizumab 
The drug was administered intravenously at a dose of 8 mg/kg of body weight once in 4 
weeks. Drug prescription was approved by the Academic Board, Local Ethics Committee 
and Formulary Committees of Scientific Center for Children Health, RAMS. Child’s parents 
have signed an informed consent for drug use. 
a. Functional capabilities of the wrist 
joints prior to Tocilizumab therapy. 
b. Functional capabilities of the wrist 
joints prior to Tocilizumab therapy 
c. Functional capabilities of the elbow 
joints prior to Tocilizumab therapy 
d. The swelling ankle joints prior to Tocilizumab 
therapy. 
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3.3. Results of treatment 
Analysis of development rate of Tocilizumab therapeutic effect has revealed that right after 
the first administration the fever subsided, the girl became more active, after 2 week of 
treatment the morning stiffness resolved (Table 5); exudative changes in the affected joints 
had completely resolved by the 8th week, the range of motions restored (Figure 11 a-e); 
laboratory parameters of disease activity normalized in 4 weeks (Table 5). Tocilizumab 
treatment also positively affected patient’s quality of life, improved physical activity and 
emotional condition (Figure 11 a-e). Inactive disease status was observed in the patient in 2 
months of treatment, and in 8 months the patient entered systemic JIA remission, which has 
been maintained for 2 years of Tocilizumab treatment. 
 
Figure 11.  
a. Functional capabilities of the 
wrist joints with Tocilizumab 
therapy at week 104.
b. Functional capabilities of the 
wrist joints with Tocilizumab 
therapy at week 104
c and d. Functional capabilities of the elbow joints with Tocilizumab therapy at 
e. The absence of swelling in the ankle joints with Tocilizumab therapy at week 
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The girl continues receiving intravenous Tocilizumab infusions at a dose of 8 mg/kg of body 
weight once in 4 weeks in combination with methotrexate (due to height and weight 
increase, a dose is 18 mg/m2 of body surface area per week) and methylprednisolone at a 
dose of 2 mg/day. Child’s physical development parameters significantly improved with 
Tocilizumab therapy: in 2 years the girl has grown by1 cm and weight gain was 6 kg, height 
and weight were in the 10th – 25th percentile range. 
3.4. Adverse events 
No serious adverse events were observed during the follow-up. 
 
Parameters 




Duration of Tocilizumab therapy 
Background Day 1 4 weeks 26 weeks 52 weeks 104 weeks 




60 120 no no no no no 
The number of 
active joints 6 6 6 2 0 0 0 
CHAQ index of 
functional 
disability, score 
1.7 1.9 1.7 0.5 0 0 0 
ESR (mm/h) 25 70 45 2 7 2 4 
Hemoglobin 
(g/L) 88 110 110 118 120 125 128 
Erythrocytes 
(х1012/L) 3.8 4.7 4.8 5.2 5.25 5.4 5.5 
Platelets (х109/L) 840 654 622 328 335 270 290 
Leukocytes 
(х109/L) 17 22.7 17.8 7.96 6.7 8?4 7.8 
CRP (mg%), 
normal level up 
to 0.8 
3.85 26 16 <0.8 <0.8 <0.8 <0.8 
IgG (g/L), normal 
range 
(5.72-14.74) 
12.1 17.8 9.0 7.35 6.66 8.67 7.5 
Height, cm 112 114 114 115 116 119 125 














Table 5. Clinical and laboratory parameters of systemic JIA activity with Tocilizumab treatment in 
patient, 9 years old girl, over time. 
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4. Efficacy and safety of monoclonal human antibodies to TNFα in 
children with juvenile idiopathic arthritis and uveitis 
4.1. Introduction  
Juvenile idiopathic arthritis is a severe disabling disease associated with development of 
destructive arthritis and uveitis – in some patients.  
Treatment with methotrexate (15 mg/m2 of standard body surface area) provided disease 
control in many patients with juvenile idiopathic arthritis [26]. However, standard anti-
rheumatic treatment is unlikely to provide stable remission in some patients [27-30]. Due to 
insufficient efficacy of methotrexate, the progression of the disease continues. Treatment of 
uveitis is the most complicated, because its activity is usually independent on the activity of 
arthritis. 
Biologic drugs produced by the methods of gene engineering provide a good perspective for 
patients with methotrexate inefficacy. Adalimumab is one of these drugs.  
Adalimumab is the recombinant IgG1 human monoclonal antibodies consisting of 1330 
amino acids. The drug is manufactured by recombinant DNA technology. It binds to p55 
and p75 receptors of soluble and membrane – associated TNFα. Adalimumab can activate 
the complement system that results in lysis of cells with superficially located TNFα. The 
drug has no ability to bind to or inhibit the lymphotoxin (TNF); it alters the levels of 
adhesion molecules that contribute to leukocytes migration (ELAM-1, VSAM-1, and ICAM-
1). Adalimumab is administered subcutaneously once per 2 weeks; the elimination half-life 
of the drug is 2 weeks [31-34]. 
The results of controlled clinical trials and open studies demonstrated that subcutaneous 
administration every two weeks of the drug is safe and effective in adult patients with 
rheumatoid and psoriatic arthritis [34-48], as well as in children with juvenile idiopathic 
arthritis and uveitis [49-59]. 
The purpose of this study was to evaluate safety and efficacy of Adalimumab treatment in 
children with severe refractory juvenile idiopathic arthritis and uveitis. 
4.2. Patients and methods 
Enrolled: 104 patients (74 girls and 30 boys) age 10 (3; 17) years (Median (25; 75)) with 
oligoarticular, polyarticular, enthesitic, sistemic arthritis without active systemic 
manifestation no less within 1 year enthesitic types of juvenile idiopathic arthritis; in 48 
patients arthritis was associated with uveitis (Table 6). Mean disease duration prior to 
Adalimumab administration – was 6 (2; 16) years. The diagnosis of JIA based on ILAR 
(International League of Associations for Rheumatology) criteria [60]. 
At baseline, all patients had active arthritis (Table 7). Mean number of joints with active 
arthritis - 5 (2; 8), mean number of joints with limitation of function – 5 (1; 7.5). High level of 
clinical activity of the disease was associated with general inflammation reaction. Median 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 370 
The girl continues receiving intravenous Tocilizumab infusions at a dose of 8 mg/kg of body 
weight once in 4 weeks in combination with methotrexate (due to height and weight 
increase, a dose is 18 mg/m2 of body surface area per week) and methylprednisolone at a 
dose of 2 mg/day. Child’s physical development parameters significantly improved with 
Tocilizumab therapy: in 2 years the girl has grown by1 cm and weight gain was 6 kg, height 
and weight were in the 10th – 25th percentile range. 
3.4. Adverse events 
No serious adverse events were observed during the follow-up. 
 
Parameters 




Duration of Tocilizumab therapy 
Background Day 1 4 weeks 26 weeks 52 weeks 104 weeks 




60 120 no no no no no 
The number of 
active joints 6 6 6 2 0 0 0 
CHAQ index of 
functional 
disability, score 
1.7 1.9 1.7 0.5 0 0 0 
ESR (mm/h) 25 70 45 2 7 2 4 
Hemoglobin 
(g/L) 88 110 110 118 120 125 128 
Erythrocytes 
(х1012/L) 3.8 4.7 4.8 5.2 5.25 5.4 5.5 
Platelets (х109/L) 840 654 622 328 335 270 290 
Leukocytes 
(х109/L) 17 22.7 17.8 7.96 6.7 8?4 7.8 
CRP (mg%), 
normal level up 
to 0.8 
3.85 26 16 <0.8 <0.8 <0.8 <0.8 
IgG (g/L), normal 
range 
(5.72-14.74) 
12.1 17.8 9.0 7.35 6.66 8.67 7.5 
Height, cm 112 114 114 115 116 119 125 














Table 5. Clinical and laboratory parameters of systemic JIA activity with Tocilizumab treatment in 
patient, 9 years old girl, over time. 
Biologic Therapy in Patients with Juvenile Idiopathic Arthritis –  
A Unique Single Centre Experience at the Scientific-Research Pediatric Centre in the Russian Federation 371 
4. Efficacy and safety of monoclonal human antibodies to TNFα in 
children with juvenile idiopathic arthritis and uveitis 
4.1. Introduction  
Juvenile idiopathic arthritis is a severe disabling disease associated with development of 
destructive arthritis and uveitis – in some patients.  
Treatment with methotrexate (15 mg/m2 of standard body surface area) provided disease 
control in many patients with juvenile idiopathic arthritis [26]. However, standard anti-
rheumatic treatment is unlikely to provide stable remission in some patients [27-30]. Due to 
insufficient efficacy of methotrexate, the progression of the disease continues. Treatment of 
uveitis is the most complicated, because its activity is usually independent on the activity of 
arthritis. 
Biologic drugs produced by the methods of gene engineering provide a good perspective for 
patients with methotrexate inefficacy. Adalimumab is one of these drugs.  
Adalimumab is the recombinant IgG1 human monoclonal antibodies consisting of 1330 
amino acids. The drug is manufactured by recombinant DNA technology. It binds to p55 
and p75 receptors of soluble and membrane – associated TNFα. Adalimumab can activate 
the complement system that results in lysis of cells with superficially located TNFα. The 
drug has no ability to bind to or inhibit the lymphotoxin (TNF); it alters the levels of 
adhesion molecules that contribute to leukocytes migration (ELAM-1, VSAM-1, and ICAM-
1). Adalimumab is administered subcutaneously once per 2 weeks; the elimination half-life 
of the drug is 2 weeks [31-34]. 
The results of controlled clinical trials and open studies demonstrated that subcutaneous 
administration every two weeks of the drug is safe and effective in adult patients with 
rheumatoid and psoriatic arthritis [34-48], as well as in children with juvenile idiopathic 
arthritis and uveitis [49-59]. 
The purpose of this study was to evaluate safety and efficacy of Adalimumab treatment in 
children with severe refractory juvenile idiopathic arthritis and uveitis. 
4.2. Patients and methods 
Enrolled: 104 patients (74 girls and 30 boys) age 10 (3; 17) years (Median (25; 75)) with 
oligoarticular, polyarticular, enthesitic, sistemic arthritis without active systemic 
manifestation no less within 1 year enthesitic types of juvenile idiopathic arthritis; in 48 
patients arthritis was associated with uveitis (Table 6). Mean disease duration prior to 
Adalimumab administration – was 6 (2; 16) years. The diagnosis of JIA based on ILAR 
(International League of Associations for Rheumatology) criteria [60]. 
At baseline, all patients had active arthritis (Table 7). Mean number of joints with active 
arthritis - 5 (2; 8), mean number of joints with limitation of function – 5 (1; 7.5). High level of 
clinical activity of the disease was associated with general inflammation reaction. Median 
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 372 
ESR level was 3-fold higher compared to normal; C-reactive protein serum level was 9-fold 
higher compared to normal (Table 7). 
Parameter Number of patients (n=104) 
Boys/girls 74/30 
Age, years 10 (3; 17) 
Age group 3-13 years 80(73%) 
Age group 14-18 years 30(27%) 
Duration of the disease, years 5.8 (2; 16) 
Table 6. Demographic characteristics of patients with JIA and uveitis, included in the study 
 
Parameter – CHAQ and number of patients – 2.0(1.3; 2.75) Number of patients 
Juvenile idiopathic arthritis 
Oligoarticular  
Polyarticular (RF-) 
Polyarticular (RF+)  
Enthesitic  







Number of joints with active joints 
Median (25%;75%) 
5(2;8) 
Number of joints with limitation of function 
Me (25%;75%) 
5(1;7.5) 
Duration of the anti-rheumatic treatment, years 2,7 (1.1;2.9) 






Number of affected eyes 80 
ESR mm/hour 30 (23; 55) 
C-reactive protein, mg/l 9.5 (5; 23) 
Table 7. Clinical characteristics of patients with JIA included in the study. 
Uveitis was reported in 48 (44%) of patients, bilateral – in 32 (67%); unilateral uveitis – in 16 
(33%) patients (Table 8). 
Previous therapy. Prior to Adalimumab treatment all patients received various regimens of anti-
rheumatic treatment. Due to active arthritis and uveitis development at the onset of the 
disease, 66 (58%) of patients had a history of prednisolone treatment (10-20 mg/day); all 
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patients received pulse-therapy with methylprednisolone (10-20 mg/kg per administration); 86 
(83%) – intra-articular (1-10 times per year), 46 (44%) – cyclosporine, 49 patients were treated 
with TNFα blockers: 47 (45%) with Infliximab, 2 (1.9%) with Etanercept; 5 (4.8%) children 
received antiB-cells therapy with Rituximab, 1 (1%) patient inhibitor of T-cells co-stimulation 
Abatacept. All patients were treated with non-steroid anti-inflammation drugs (NSAIDs); 48 
(46%) patients with uveitis received local treatment with eye drops containing NSAIDs and 
glucocorticosteroids, 32(31%) - para-bulbar glucocorticoid injection (1-5 times per year) 
Despite treatment, all patients experienced disease progression. At the time of enrollment 
they had active arthritis, elevated laboratory parameters and progressing disability. 
Continuous recurrent uveitis was diagnosed in 48 children. 
Inclusion criteria: Ineffective treatment with methotrexate (15-25 mg/m2 of standard body 
surface area, once per week, intramuscular injections; within 3 month and more) and with 
other immunosuppressive drugs (leflunomide, sulfasalazine, cyclosporine), progression of 
arthritis, vision acuity decrease, continuous recurrence of uveitis, high laboratory 
parameters (ESR, CRP level), and increasing functional disability.  
Normal serum levels of urea, creatinine, bilirubin, ALT, AST; no significant acute or chronic 
infections. Patients with infections were treated with antibiotics. Prior to Adalimumab 
treatment all patients were examined for presence of tuberculosis – including tuberculin test 
(PPD test) and the chest CT. Treatment with TNFα antagonists has been recognized as a risk 
for active tuberculosis; some cases of latent tuberculosis could reactivate soon after treatment 
initiation. For this reason, worldwide health authorities recommend screening patients for 
latent tuberculosis and treating them before initiating anti-TNFα treatment [61]. Patients with 
positive or controversial PPD test (hyperemia, papule size ≥5 mm) were consulted by the 
phthisiatrician; and the test with tuberculin dilution was conducted (0.1, 0.1, 0.01 TU). If the 
tuberculosis infection was excluded, the patients received Adalimumab treatment.  
The control of hemogram and serum levels of urea, creatinine, bilirubin, ALT, AST, as well 
as urinalysis were conducted each 2 weeks.  
The following parameters were evaluated during the study: number of Active joints, 
number of joints with limited function, ESR and serum level of C-reactive protein; the 
activity of uveitis was evaluated according to criteria developed by M.J. Hogan [36]. 
Physician's Global Assessment of disease activity (using the 100 mm VAS scale), Parent's 
global evaluation of well being (using the VAS scale); evaluation of functional abilities 
using the CHAQ questionnaire. The effect of Adalimumab treatment was evaluated after 
4, 12, 24, 36 and 52 weeks of treatment. The efficacy was evaluated according to American 
College of Rheumatology pediatric criteria (ACRpedi) [62].  
The main target of therapy was status of inactive disease and remission [63].  
Evaluation of Adalimumab treatment safety was based on the registration of adverse 
events and regular control of serum levels of urea, creatinine, bilirubin, ALT, AST and 
hemogram.  
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(33%) patients (Table 8). 
Previous therapy. Prior to Adalimumab treatment all patients received various regimens of anti-
rheumatic treatment. Due to active arthritis and uveitis development at the onset of the 
disease, 66 (58%) of patients had a history of prednisolone treatment (10-20 mg/day); all 
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patients received pulse-therapy with methylprednisolone (10-20 mg/kg per administration); 86 
(83%) – intra-articular (1-10 times per year), 46 (44%) – cyclosporine, 49 patients were treated 
with TNFα blockers: 47 (45%) with Infliximab, 2 (1.9%) with Etanercept; 5 (4.8%) children 
received antiB-cells therapy with Rituximab, 1 (1%) patient inhibitor of T-cells co-stimulation 
Abatacept. All patients were treated with non-steroid anti-inflammation drugs (NSAIDs); 48 
(46%) patients with uveitis received local treatment with eye drops containing NSAIDs and 
glucocorticosteroids, 32(31%) - para-bulbar glucocorticoid injection (1-5 times per year) 
Despite treatment, all patients experienced disease progression. At the time of enrollment 
they had active arthritis, elevated laboratory parameters and progressing disability. 
Continuous recurrent uveitis was diagnosed in 48 children. 
Inclusion criteria: Ineffective treatment with methotrexate (15-25 mg/m2 of standard body 
surface area, once per week, intramuscular injections; within 3 month and more) and with 
other immunosuppressive drugs (leflunomide, sulfasalazine, cyclosporine), progression of 
arthritis, vision acuity decrease, continuous recurrence of uveitis, high laboratory 
parameters (ESR, CRP level), and increasing functional disability.  
Normal serum levels of urea, creatinine, bilirubin, ALT, AST; no significant acute or chronic 
infections. Patients with infections were treated with antibiotics. Prior to Adalimumab 
treatment all patients were examined for presence of tuberculosis – including tuberculin test 
(PPD test) and the chest CT. Treatment with TNFα antagonists has been recognized as a risk 
for active tuberculosis; some cases of latent tuberculosis could reactivate soon after treatment 
initiation. For this reason, worldwide health authorities recommend screening patients for 
latent tuberculosis and treating them before initiating anti-TNFα treatment [61]. Patients with 
positive or controversial PPD test (hyperemia, papule size ≥5 mm) were consulted by the 
phthisiatrician; and the test with tuberculin dilution was conducted (0.1, 0.1, 0.01 TU). If the 
tuberculosis infection was excluded, the patients received Adalimumab treatment.  
The control of hemogram and serum levels of urea, creatinine, bilirubin, ALT, AST, as well 
as urinalysis were conducted each 2 weeks.  
The following parameters were evaluated during the study: number of Active joints, 
number of joints with limited function, ESR and serum level of C-reactive protein; the 
activity of uveitis was evaluated according to criteria developed by M.J. Hogan [36]. 
Physician's Global Assessment of disease activity (using the 100 mm VAS scale), Parent's 
global evaluation of well being (using the VAS scale); evaluation of functional abilities 
using the CHAQ questionnaire. The effect of Adalimumab treatment was evaluated after 
4, 12, 24, 36 and 52 weeks of treatment. The efficacy was evaluated according to American 
College of Rheumatology pediatric criteria (ACRpedi) [62].  
The main target of therapy was status of inactive disease and remission [63].  
Evaluation of Adalimumab treatment safety was based on the registration of adverse 
events and regular control of serum levels of urea, creatinine, bilirubin, ALT, AST and 
hemogram.  
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 374 
All cases of Adalimumab treatment were approved by Local Ethics Committee of the 
Scientific Center of children's of RAMS. Prior to treatment, children older than 14 years and 
children’s parents were providing the written informed consent. 
Background therapy. Adalimumab was administered subcutaneously once per 2 weeks; 
dose – 40 mg per administration; in combination with background immunosuppressive 
therapy (Table 8). The dose of immunosuppressive drugs remained stable for at least 3 
months. 
 
Drug DoseMe (25;75) 
Number of patients 
n=104 
Methotrexate mg/m2/week 20 (15; 25) 64 
Cyclosporine, mg/kg/day + Methotrexate 
mg/m2/week 4 (4; 4) 38 
Prednisolone, mg/day 10 (5; 12) 54 
NSAIDs - 104 
Para-bulbar glucocorticoid injections - 32 - 48 
Local treatment of uveitis with drops - 48 
Table 8. Background therapy in patients with JIA and uveitis included in the study. 
The analysis of treatment efficacy was conducted after 4, 12, 24, 36, 52 weeks of treatment – 
in 104 of patients, accordingly. 
Statistical processing of data was conducted using the STATISTICA 6.0 (StatSoft Inc., USA) 
program. The quantification parameters were presented as medians (25; 75 percentiles); in 
some cases data were presented as means ± SD. Wilcoxon’s criterion was used for paired 
comparison. Statistically significant difference was considered to be р<0,05. 
4.3. Results 
By week 12 of treatment the statistically significant decrease in number of active joints was 
reported (5 (2; 8); 3 (0; 4) prior to treatment and after 12 weeks of treatment, respectively; p< 0.05), 
by week 52 there were no joints active (Figure 12). 
Similar changes were reported for joints with limitation of function – statistically significant 
decrease in their number was observed by week 12 (5 (1; 7.5); 3 (1; 5) prior to treatment and 
after 12 weeks of treatment, respectively; p< 0.05), by week 52 the 9-fold decrease of the 
median parameter was reported (p<0.05) (Figure 13). 
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Figure 12.  Dynamics in number of active joints in children with JIA treated with Adalimumab (n=104) 
Hereinafter:  
p<0.001, ** p<0.05 – statistically significant difference compared to baseline 
by week 52 there were no joints with active arthritis 
 
 
Figure 13. Dynamics in number of joints with limitation of function in children with JIA treated with 
Adalimumab (n=104) 
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The improvement of functional activity of joints after 4 weeks of Adalimumab treatment 
was associated with improvement of quality of life; that improvement was confirmed by the 
decrease in index of functional disability evaluated by CHAQ questionnaire - from 2.0 (1.3; 
2.75) to 1.0 (0.6; 1.4), p<0,001. 
Treatment with Adalimumab affected the laboratory parameters of disease activity.  
After 4 weeks of treatment the trend to decrease in ESR was reported. By week 12 the 
median significantly decreased; by week 52 the median was normal in the most of patients 
(Figure 14).  
 
Figure 14. Dynamics in ESR in children with JIA treated with Adalimumab (n=104) 
Significant decrease in the serum C-reactive protein level in all patients was observed after 8 
weeks of treatment; the median parameter normalized after 12 weeks of treatment (Figure 
15). 
Assessment of Adalimumab efficacy according ACRpedi demonstrated that after 4 weeks of 
treatment the 30% improvement was achieved in 100% of patients, 50% improvement – in 
80% (83), 70% improvement – in 55%(57) of patients. After 24 weeks 30% improvement was 
reported in 100% (104) of patients, 50% improvement – in 91% (95), 70% - in 74% (77) of 
patients; inactive disease was diagnosed in 55 % (58) of children. Within a year, JIA 
remission was diagnosed in 55% (58) of patients (Figure 16).  
Prior to administration of Adalimumab, injection of conjunctiva, edema of iris, corneal 
precipitations, areas of inflammation in lens and optical nerve disk edema were found in all 
children with uveitis (Table 9). 
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Figure 16. Response according to ACR pedi criteria in children with JIA treated with Adalimumab 
(n=104) 
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Parameter Number of the affected eyes (n=80) 
Injections of conjunctiva 85% (68/80) 
Edema of iris 46% (37/80) 
Corneal precipitations 40% (32/80) 
Areas of inflammation in lens 21% (17/80) 
Optical nerve disk edema 30% (24/80) 
Table 9. Clinical manifestations of uveitis in patients with JIA included into the study 
After 8 weeks of treatment complete management of conjunctiva injection, iris edema and 
optical nerve disk edema were reported in 55% (44/80) of the affected eyes - corneal 
precipitations disappeared in 45% (36/80); inflammation-associated changes of lens – in 18% 
(14/80) of eyes. Treatment-associated improvement of vision was found in 63 of 80 of the 
affected eyes; no changes of vision acuity were reported in 33 (41%) of the affected eyes. 
Dexamethazone eye drops were discontinued in 45% (22/48) of patients, NSAIDs eye drops 
– in 49% (24/48) of children; the dose of dexamethazone eye drops was reduced in 86% 
(41/48) of patients. The exacerbation of uveitis was persisting in 10% (8/80) of the affected 
eyes, subacute uveitis – in 25% (20/80); remission was found in 65% (52/80) of the affected 
eyes. After 24 weeks of treatment the cases of uveitis were not reported; subacute disease 
was observed in 22% (18/80) of eyes; remission was diagnosed in 78% (62/80) of the affected 
eyes. After 52 weeks of treatment remission was diagnosed in 83% of the affected eyes (66/80) 
(Figure 17). 
 
Figure 17. Efficacy of Adalimumab treatment in rheumatoid uveitis  
(n=48, number of affected eyes = 80) 
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4.4. Adverse events related to immunosuppressive therapy 
Safety evaluation was based on reported adverse events, laboratory parameters, and 
physical examination (evaluation of vital functions – BP, HR), and the ECG.  
Adverse events were evaluated in all enrolled patients that received at least one injection of 
the study drug. 
In general Adalimumab treatment was well-tolerated; most AE’s were mild, reversible and 
would not result in treatment limitations. Injection reactions (occurring during the drug 
administration or during 24 hours after) included pain at the injection site – in 72.1 % (75) of 
patients; hyperemia at the injection site was reported in 48 % (50) of patients.  
No cases of AE’s associated with laboratory values alterations were reported. 
No changes of vital functions (diastolic and systolic blood pressure, heart rate) or ECG 
changes were reported during the treatment course. Cases of Adalimumab discontinuation 
due to poor therapeutic response were not reported.  
Therefore, safety profile of Adalimumab in study patients was satisfactory. Adverse events 
included local skin reactions at the injection sites. Adalimumab treatment was not 
associated with any fatal outcomes or cases of drug withdrawal due to adverse events.  
One case of treatment discontinuation due to adverse events was reported in patient with 
suspected regional pulmonary tuberculosis. The patient was admitted to specialized 
hospital for further examination and development of treatment strategy. However, the 
diagnosis was not confirmed; the changes in lungs CT were considered to be the post-
infection changes. Treatment with Adalimumab was restarted. 
5. Clinical case 
Patient's data: female. Age: 15 years old  
Diagnosis: polyarticular JIA associated uveitis 
5.1. Case history 
Acute respiratory infections 3-4 times per year, rubella. Parents – practically healthy. Family 
history: no rheumatoid diseases reported.  
Disease onset – February 1997 (age 1.5 years); swelling of the left ankle joint, walk 
disorders, pain associated with movements in left knee and ankle joints. The local surgeon 
excluded the diagnosis of acute surgical disease. Local treatment of the affected joints 
(ointments containing NSAIDs) was prescribed. April 1997, consultation of 
rheumatologist: diagnosis – juvenile rheumatoid arthritis, oligoarticular type; diclofenac-
based treatment was prescribed. Treatment did not result in any decrease in swelling and 
pain.  
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4.4. Adverse events related to immunosuppressive therapy 
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Adverse events were evaluated in all enrolled patients that received at least one injection of 
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included local skin reactions at the injection sites. Adalimumab treatment was not 
associated with any fatal outcomes or cases of drug withdrawal due to adverse events.  
One case of treatment discontinuation due to adverse events was reported in patient with 
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hospital for further examination and development of treatment strategy. However, the 
diagnosis was not confirmed; the changes in lungs CT were considered to be the post-
infection changes. Treatment with Adalimumab was restarted. 
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Disease onset – February 1997 (age 1.5 years); swelling of the left ankle joint, walk 
disorders, pain associated with movements in left knee and ankle joints. The local surgeon 
excluded the diagnosis of acute surgical disease. Local treatment of the affected joints 
(ointments containing NSAIDs) was prescribed. April 1997, consultation of 
rheumatologist: diagnosis – juvenile rheumatoid arthritis, oligoarticular type; diclofenac-
based treatment was prescribed. Treatment did not result in any decrease in swelling and 
pain.  
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Since May 1997, the patient was followed at the Rheumatology Department of one of clinics 
in Moscow. Disease severity was considered to be moderate. Swelling of knee and ankle 
joints with pain and limited mobility was reported. Blood analysis: leukocytosis (17 × 109/l), 
ESR increase (up to 62 mm/hour). Blood immunology analysis: positive C-reactive protein 
test and positive anti-nuclear factor test. Treatment: diclofenac sodium, intra-articular 
administration of glucocorticoids. Since January 1998 the patient was treated with 
methotrexate (dose 7.5 mg/m2 of body surface/week). Methotrexate treatment was 
associated with mild improvements; the exacerbations of arthritis became less frequent. The 
intra-articular administration of glucocorticoids was conducted once per 1-2 months.  
2001, spring: rheumatoid uveitis was diagnosed. Local treatment (dexamethasone eye drops, 
diclofenac eye drops) resulted in management of its manifestations.  
Since October 2001, limited mobility of cervical part of the spine was reported; swelling of knee 
and ankle joints became more severe. The patient started complaining on severe morning 
stiffness. Only intra-articular administration of glucocorticoids resulted in certain 
improvements. Methotrexate dose was increased up to 10 mg/m2 of body surface per week. July 
2004: exposure to sunlight resulted in exacerbation of uveitis; combined immunosuppressive 
treatment (methotrexate plus cyclosporine, 3 mg/kg/day) was initiated. Combined treatment 
resulted in management of clinical manifestations of uveitis. Urine analysis: permanent 
macrohematuria was detected; therefore the immunosuppressive drugs were discontinued. 
Throughout a year the girl was receiving NSAIDs, with monthly intra-articular administrations 
of glucocorticosteroids. The treatment was ineffective. By November 2005, the number of joints 
affected by active arthritis increased; the polyarticular syndrome developed – elbow and radio-
metacarpal joints, as well as knee and ankle joints and small joints of palms were involved. The 
disability was progressing. Oral prednisolone (5 mg/day) with leflunomide (10 mg/day, with 
gradual dose increase up to 20 mg/day) were prescribed. Despite the intra-articular 
administration of glucocorticoids into knee and ankle joints, complete management of the 
arthritis was not achieved. February 2007: prednisolone was discontinued.  
Ineffective treatment with leflunomide, NSAIDs and monthly intra-articular injections of 
glucocorticoids were the basis for the prescription (January 2008) of anti-cytokine treatment 
with chimeric monoclonal antibodies to tumor necrosis factor (TNF) α (Infliximab, dose – 4.5 
mg/kg). The first three infusions of Infliximab resulted in improvement; swelling of joints 
decreased, the duration of morning stiffness was shorter; the laboratory parameters 
reflecting the disease activity were decreasing. March 2008: metabolic nephropathy was 
diagnosed. Development of renal calculi was considered the side effect of leflunomide 
treatment; therefore, the drug was discontinued. March 2008: methotrexate (7.5 mg/m2 of 
body surface area per week) was restarted. However, after the 4-th administration of 
Infliximab (same dose) resulted in exacerbation of swelling in the affected joints. The dose of 
Infliximab was increased up to 6.6 mg/kg. This dose of Infliximab was administered 5 times 
(total number of infliximab infusions – 9). Despite the dose increase, the therapy was not 
effective; the activity of arthritis was not changed. Therefore, intra-articular betamethasone 
injections (once per 1-1.5 months) were continued.  
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In order to develop the treatment strategy, the patient was admitted to the Rheumatology 
Department of the Scientific Center of Children’s Health of RAMS (March 2009). It was 11 
years after the onset of the disease. Disease was considered to be severe. Polyarthritis with 
affection of cervical spine, right shoulder joint, right elbow joint, femoral joints, knee joints, 
ankle joints, small joints of palms was diagnosed. The patient was unable to perform the full 
flexion of fingers; the movements in affected joints were limited and associated with pain. 
The patient complained on morning stiffness lasting up to 120 minutes. Paleness, blackness 
under the eyes, manifestations of hyper-corticism, associated with continuous intra-articular 
administration of exogenous glucocorticoids were found. The girl was in emotional 
depression. Blood analysis: elevated ESR (up to 57 mm/hour); serum level of C-reactive 
protein (up to 7.6%; normal level – up to 0.8 mg%, see Table). Computer tomography of 
knee joints: peri-articular osteoporosis, single erosions of bone tissue. Ophthalmologist’s 
consultation: slowly progressing binocular rheumatoid uveitis was diagnosed.  
The effect of intra-articular administration of glucocorticoids, associated with complications, 
and uncontrolled hormone dependency resulted in the decision to discontinue the hormone-
based therapy. Analysis of health status demonstrated secondary inefficacy of the treatment 
with chimeric monoclonal antibodies to TNFα in combination with methotrexate. Infliximab 
was discontinued due to development of resistance. Despite the severe swelling of joints, 
glucocorticoids were not administered due to hormone dependency and growth retardation 
(height of the 13-years old adolescent girl was 146 cm – as of the 11-years old child).  
According to the protocol of severe juvenile arthritis treatment, developed by the Scientific 
Center of Children’s Health of RAMS, the girl was treated with pulse-therapy with 
methotrexate (50 mg/m2 of body surface area) in combination with cyclosporine (4.4 
mg/kg/day) . 
The patient received 7 doses of methotrexate intravenously. The treatment resulted in 
certain improvement: the morning stiffness duration became shorter, and the girl became 
more active. However, the swelling of knee and ankle joints (Figure 18), limited mobility of 
the right shoulder joint (Figure 19), right elbow joint (Figure 20), knee joints (Figure 21), 
femoral joints (Figure 22) and ankle joints remained. Control blood analysis: the laboratory 
values reflecting the disease activity remained high (Table 10). Repeated ophthalmologic 
examination: manifestations of slowly progressing uveitis were found. The girl poorly 
tolerated methotrexate – severe headache and nausea were reported during 3 days after the 
drug administration. Within 1 month after the last intra-articular administration of 
betamethasone the withdrawal syndrome developed. It was manifested by myalgia, 
arthralgia, nausea, vomiting, and depression. Despite the development of the withdrawal 
syndrome, glucocorticoids were not restarted; active anti-rheumatic treatment was 
continued. The withdrawal syndrome resolved within 3 weeks.  
The inefficacy of combined treatment with methotrexate (50 mg/m2 of body surface area per 
week) and cyclosporine (4.4 mg/kg/day) as well as the good initial response to chimeric 
monoclonal antibodies to TNFα were the basis to prescribe the human antibodies to TNFα – 
Adalimumab. 
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injections (once per 1-1.5 months) were continued.  
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In order to develop the treatment strategy, the patient was admitted to the Rheumatology 
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Center of Children’s Health of RAMS, the girl was treated with pulse-therapy with 
methotrexate (50 mg/m2 of body surface area) in combination with cyclosporine (4.4 
mg/kg/day) . 
The patient received 7 doses of methotrexate intravenously. The treatment resulted in 
certain improvement: the morning stiffness duration became shorter, and the girl became 
more active. However, the swelling of knee and ankle joints (Figure 18), limited mobility of 
the right shoulder joint (Figure 19), right elbow joint (Figure 20), knee joints (Figure 21), 
femoral joints (Figure 22) and ankle joints remained. Control blood analysis: the laboratory 
values reflecting the disease activity remained high (Table 10). Repeated ophthalmologic 
examination: manifestations of slowly progressing uveitis were found. The girl poorly 
tolerated methotrexate – severe headache and nausea were reported during 3 days after the 
drug administration. Within 1 month after the last intra-articular administration of 
betamethasone the withdrawal syndrome developed. It was manifested by myalgia, 
arthralgia, nausea, vomiting, and depression. Despite the development of the withdrawal 
syndrome, glucocorticoids were not restarted; active anti-rheumatic treatment was 
continued. The withdrawal syndrome resolved within 3 weeks.  
The inefficacy of combined treatment with methotrexate (50 mg/m2 of body surface area per 
week) and cyclosporine (4.4 mg/kg/day) as well as the good initial response to chimeric 
monoclonal antibodies to TNFα were the basis to prescribe the human antibodies to TNFα – 
Adalimumab. 
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5.2. Treatment with Adalimumab 
Taking into considerations the facts mentioned above, it was decided to prescribe 
Adalimumab (dose – 40 mg once per 2 weeks) to patient A. The prescription was 
approved by the Scientific Council and the Ethics and Formulary Committees of Scientific 
Center for Children Health, RAMS. The parents signed the informed consent form, 
permitting the administration of drug. In order to exclude the diagnosis of tuberculosis 
prior to administration of Adalimumab, chest CT and dia-skin test (intra-cutaneous 
diagnostic test based on intra-cutaneous administration of 2 recombinant proteins of 
Mycobacterium tuberculosis) were conducted. No regional or infiltration changes were 
found during CT. 
5.3. Results of treatment 
After the exclusion of tuberculosis, Adalimumab treatment was initiated. The girl’s activity 
improved after the first administration of the drug. Morning stiffness resolved within 2 
weeks of treatment (Table 10). By the 4-th treatment week, swelling of the affected joints was 
completely managed; the volume of mobility has improved significantly. Within 6 weeks of 
Adalimumab treatment, laboratory values reflecting the disease activity returned to normal 
(Table 10). Control ophthalmological examination: remission of the slowly progressing 
uveitis was found. The girl continues receiving cyclosporine (total daily dose 4 mg/kg) and 
methotrexate (25 mg/m2/week). At present, the girl has already received 10 doses of 
Adalimumab (40 mg); treatment was not associated with any adverse events. Treatment is 
associated with remission of the disease, as evaluated by clinical and laboratory values 
(Figure 18-22) 
Therefore, this clinical report demonstrates a case of long-term juvenile idiopathic 
arthritis with continuous recurrence, characterized by rapid development of disability, 
high index of functional failure, poor quality of life, resistant to anti-rheumatic therapy, 
and secondary inefficacy of the chimeric monoclonal antibodies to TNFα. The 
Adalimumab treatment managed to overcome the resistance to chimeric antibodies and 
induced remission of arthritis, restoration of function of the affected joints, normalization 
of the laboratory values reflecting the activity of the disease. Positive effect of 
Adalimumab enabled the patient to overcome the severe corticosteroid dependency; the 
ability to decline the proposed oral prednisolone treatment strategy was achieved. 
Treatment results demonstrate that Adalimumab is highly effective in children with long-
term polyarthritis and uveitis, resistant to various dosage regimens of methotrexate and 
in combination with cyclosporine, as well as with secondary resistance to chimeric 
antibodies to TNFα. 
5.4. Adverse events 
No serious adverse events were observed during the follow-up. 
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Figure 19. Functional ability of shoulder joints prior (A) and during (B) the Adalimumab treatment 
course 
 
Figure 20. Functional ability of elbow joints prior (A) and during (B) Adalimumab treatment course 
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Figure 22. Functional ability of femoral joints prior (A) and during Adalimumab treatment course 
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Figure 19. Functional ability of shoulder joints prior (A) and during (B) the Adalimumab treatment 
course 
 
Figure 20. Functional ability of elbow joints prior (A) and during (B) Adalimumab treatment course 
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Figure 22. Functional ability of femoral joints prior (A) and during Adalimumab treatment course 
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Duration of Adalimumab therapy 








120 100 0 0 0 0 
Number of 
active joints 





19 15 7 4 0 0 
CHAQ index of 
functional 
disability, score 
1.6 1.7 1.1 0.6 0.5 0.5 
Red blood cells 
×1012/l 
3.98 3.67 4.01 4.33 4.70 4.67 
Hemoglobin, g/l 114 102 112 129 140 130 
Leukocytes 
(×109/l) 
8. 7.4 6.4 5.6 6.4 4.8 
Platelets (×109/l) 308 426 378 313 359 287 
ESR, (mm/h) 57 38 25 3 5 4 
C-reactive 
protein, mg% 
7.6 7.25 2.4 0.17 0.1 0.12 
Height, cm 146 146 147 148 149 149 
Table 10. Changes of clinical and laboratory parameters reflecting the activity of disease in association 
with Adalimumab treatment in patient a 
6. Conclusion 
Thus, the results of 1-year retrospective, observational trials showed high efficacy of 
Tocilizumab and Adalimumab in children with JIA. 
Tocilizumab is effective in patients with the most severe form of juvenile idiopathic arthritis 
refractory to treatment with glucocorticoids, methotrexate, cyclosporine, combined 
immunosuppressive therapy and to TNF-α antagonists treatment. The drug induced 
remission of extra-articular manifestations, arthritis and normalized laboratory parameters 
of the disease activity without treatment with oral prednisolone, thus avoiding severe 
irreversible complications of glucocorticoid therapy. Tocilizumab induced disease remission 
in 43% of patients. 
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Adalimumab is effective in patients with polyarthritis associated with uveitis. The drug 
induced disease remission and improved functional activity and quality of life in 55% of 
patients. Reduction in uveitis activity and remission were reported in 83% of affected eyes. 
The high efficacy of Adalimumab allowed to avoid oral prednisolone and discontinue 
topical glucocorticoid therapy in patients with uveitis. 
Both agents were well tolerated by patients; no severe serious adverse events were reported 
throughout the period of observation. 
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Autoimmune disease represents a group of more than 60 different chronic autoimmune 
diseases that affect approximately 6% of the population. Autoimmune diseases 
arise when ones immune system actively targets and destroys self tissue resulting in 
clinical disease with prime examples such as Lupus and Type 1 diabetes. The immune 
system is designed to protect us from foreign pathogens such as viruses and bacteria. 
However, during the process of generating immune cells for this purpose, as a negative 
consequence, self-reactive immune cells are also generated. This book aims to present 
the latest knowledge and insights regarding the different contributing factors and 
their interplay, discussions on several autoimmune diseases and their case studies, and 
therapeutic treatments, including stem cell, for autoimmune diseases.
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